<SEC-DOCUMENT>0001776985-26-000055.txt : 20260804
<SEC-HEADER>0001776985-26-000055.hdr.sgml : 20260804
<ACCEPTANCE-DATETIME>20260804070136
ACCESSION NUMBER:		0001776985-26-000055
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20260630
FILED AS OF DATE:		20260804
DATE AS OF CHANGE:		20260804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		261235398

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190840

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-kq22026quarterlyrepo.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="iaf38ecbe53f34a5bb80825157a1b3446_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:700;line-height:120%">FORM 6-K</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a&#8209;16 OR 15d&#8209;16</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">FOR THE MONTH OF AUGUST 2026</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER 001-39081 </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:700;line-height:120%">BioNTech SE<br></font><font style="color:#333333;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">An der Goldgrube 12</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">D-55131 Mainz</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Germany</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">+49 6131-9084-0<br></font><font style="color:#333333;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20&#8209;F or Form 40&#8209;F&#58; Form 20&#8209;F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Form 40&#8209;F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(1)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(7)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">On August 4, 2026, BioNTech SE (the &#8220;Company&#8221;) provided a development update and reported its financial results for the three and six months ended June 30, 2026. The interim condensed consolidated financial statements as well as the operating and financial review and prospects of the Company for the three and six months ended June 30, 2026 are attached hereto as Exhibit 99.1 and shall be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and incorporated by reference herein.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:3.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:1.5pt 1pt 1.5pt 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:125%">BioNTech SE</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt 1.5pt 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:1.5pt 1pt 1.5pt 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Ram&#243;n Zapata-Gomez</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt 1.5pt 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:1.5pt 1pt 1.5pt 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Dr. Sierk Poetting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Ram&#243;n Zapata-Gomez</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:1.5pt 1pt 1.5pt 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Dr. Sierk Poetting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt 1.5pt 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;   Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt 1.5pt 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;   Chief Operating Officer</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; August 4, 2026</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT INDEX </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.905%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt 1.5pt 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Exhibit</font></td><td colspan="3" style="padding:1.5pt 1pt 1.5pt 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Description of Exhibit</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt 1.5pt 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">99.1</font></td><td colspan="3" style="background-color:#ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:124%;text-decoration:underline"><a href="bntxq22026ex991quarterlyre.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:124%;text-decoration:underline">Quarterly Report for the Three and Six Months Ended June 30, 2026</a></font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>bntxq22026ex991quarterlyre.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i58ee89399d9d45f4ac20dcae213591ea_156680406961166"></div><div style="min-height:0pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><font><br></font></div></div><div style="margin-top:6pt;text-align:justify"><img alt="a260407_coverxq2a.jpg" src="a260407_coverxq2a.jpg" style="height:1122px;margin-bottom:5pt;vertical-align:text-bottom;width:794px"></div><div style="height:0pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:justify"><font><br></font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2476"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">                                                                                                                                                                                                             Exhibit 99.1</font></div></div><div style="margin-bottom:15pt;margin-top:12pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that can be accessed through, our website is not part of this document. Our agent for service solely for the purpose of notices and communications from the Securities and Exchange Commission in the United States is c&#47;o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139, +1 (617) 337-4701.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:justify"><font><br></font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_320"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">                                                                                                                                                                                                             Exhibit 99.1</font></div></div><div style="margin-bottom:56pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:20pt;font-weight:700;letter-spacing:0.02em;line-height:120%">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:15pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.683%"><tr><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Interim <a href="#i58ee89399d9d45f4ac20dcae213591ea_315" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Condensed Consolidated Statements of Profit or Loss</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_315" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="6" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Interim Condensed Consolidated Statements of Comprehensive Income</font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_158879430216628" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">2</a></font></div></td></tr><tr><td colspan="6" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Interim <a href="#i58ee89399d9d45f4ac20dcae213591ea_305" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Condensed Consolidated Statements of Financial Position</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_305" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="6" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Interim Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity</font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_2948" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="6" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Interim <a href="#i58ee89399d9d45f4ac20dcae213591ea_295" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Condensed Consolidated Statements of Cash Flows</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_295" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="6" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Selected Explanatory <a href="#i58ee89399d9d45f4ac20dcae213591ea_366" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Notes to the Unaudited Interim Condensed Consolidated </a></font></div><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_366" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Financial Statements</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_366" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;text-indent:14.17pt;vertical-align:top"><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">1</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_433" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Corporate Information</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_433" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;text-indent:14.17pt;vertical-align:top"><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">2</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_438" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Basis of Preparation, Significant Accounting Policies</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_438" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;text-indent:14.17pt;vertical-align:top"><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">3</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_446" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Revenue</a><a href="#i58ee89399d9d45f4ac20dcae213591ea_446" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">s</a> from Contracts with Customers</font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_446" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;text-indent:14.17pt;vertical-align:top"><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">4</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_882" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Income and Expenses</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_882" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">10</a></font></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;text-indent:14.17pt;vertical-align:top"><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">5</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_484" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">I</a><a href="#i58ee89399d9d45f4ac20dcae213591ea_484" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">ncome Tax</a>es</font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_484" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">12</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;text-indent:14.17pt;vertical-align:top"><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">6</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Other Intangible Assets</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_549755815327" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">13</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;text-indent:14.17pt;vertical-align:top"><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">7</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Property, Plant and Equipment</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_156680406961856" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">14</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;text-indent:14.17pt;vertical-align:top"><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">8</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_490" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Financial Assets and Financial Liabilities</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_490" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">14</a></font></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;text-indent:14.17pt;vertical-align:top"><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">9</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_738" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Issued Capital and Reserves</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_738" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">19</a></font></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;text-indent:14.17pt;vertical-align:top"><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">10</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_2599" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Provisions</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_2599" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">19</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;text-indent:14.17pt;vertical-align:top"><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">11</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_530" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Contingen</a><a href="#i58ee89399d9d45f4ac20dcae213591ea_530" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">t Liabilities</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_530" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">20</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;text-indent:14.17pt;vertical-align:top"><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">12</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_536" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Related Party Disclosures</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_536" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">25</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;text-indent:14.17pt;vertical-align:top"><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">13</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Events after the Reporting Period</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_542" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">26</a></font></div></td></tr></table></div><div style="margin-bottom:15pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:56pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:20pt;font-weight:700;letter-spacing:0.02em;line-height:120%">OPERATING AND FINANCIAL REVIEW <br>AND PROSPECTS</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.683%"><tr><td style="width:1.0%"></td><td style="width:94.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_3705" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Corporate Developments</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_3705" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">27</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_547" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Operating Results</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_547" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">28</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_632" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">Liquidity and Capital Resources</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_632" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">58</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Risk Factors</font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_549755815136" style="color:#000000;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">63</a></font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:justify"><font><br></font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_673"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:56pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:20pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_315"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Interim Condensed Consolidated Statements of Profit or Loss</font></div><div style="margin-bottom:15pt;text-align:justify"><font><br></font></div><div style="margin-bottom:15pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:33.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.389%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Three months ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Six months ended June 30,</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Note</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">105.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">260.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">223.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">443.6</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Cost of sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4.1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(97.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(76.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(168.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(160.2)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Research and development expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4.1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(551.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(509.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1,108.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1,034.7)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Sales and marketing expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4.1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(40.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(19.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(68.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(33.4)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">General and administrative expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4.1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(157.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(117.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(280.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(224.6)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4.2</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(248.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(117.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(281.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(165.7)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other operating income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4.2</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">40.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">78.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">57.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">139.8</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Operating loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(948.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(501.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,625.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,035.2)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Finance income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4.3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">97.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">105.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">217.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">228.0</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Finance expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4.3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(7.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(7.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(19.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(40.9)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Loss before tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(858.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(402.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,426.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(848.1)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Income taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">5</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">37.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">16.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">74.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">45.7</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Net loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(820.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(386.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,352.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(802.4)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Loss per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Basic and diluted loss per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(3.24)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1.60)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(5.34)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(3.33)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:15pt;text-align:center"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">1</font></div></td></tr></table></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_158879430216628"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Interim Condensed Consolidated Statements of <br>Comprehensive Income</font></div><div style="margin-bottom:15pt;text-align:justify"><font><br></font></div><div style="margin-bottom:15pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:35.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.389%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Three months ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Six months ended June 30,</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Note</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Net loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(820.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(386.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,352.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(802.4)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Other comprehensive income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">Other comprehensive income that may be reclassified to profit or loss in subsequent periods, net of tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Exchange differences on translation of foreign operations</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">8.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(63.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">21.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(94.1)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Net other comprehensive income &#47; (loss) that may be reclassified to profit or loss in subsequent periods</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">8.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(63.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">21.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(94.1)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods, net of tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Net gain &#47; (loss) on equity instruments designated at fair value through other comprehensive income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">8</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(2.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">24.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(20.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(7.2)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Net other comprehensive income &#47; (loss) that will not be reclassified to profit or loss in subsequent periods</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(2.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">24.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(20.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(7.2)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Other comprehensive income &#47; (loss), net of tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">6.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(38.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">1.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(101.3)</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Comprehensive loss, net of tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(814.8)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(425.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,351.7)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(903.7)</font></td></tr></table></div><div style="margin-bottom:10pt;margin-top:3pt;text-align:center"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">2</font></div></td></tr></table></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_305"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Interim Condensed Consolidated Statements of Financial Position</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:15pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.922%"><tr><td style="width:1.0%"></td><td style="width:46.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.880%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">June 30,</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">December&#160;31,</font></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Note</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Non-current assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Goodwill</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">373.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">367.9</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other intangible assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#160;6</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1,421.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1,606.0</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Property, plant and equipment </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">7</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1,036.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1,080.9</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Right-of-use assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">182.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">210.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Contract assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">2.0</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">8</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">2,006.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">2,554.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other non-financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">10.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">7.3</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Deferred tax assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">5</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">15.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">13.5</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total non-current assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">5,045.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">5,842.0</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Current assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Inventories </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">100.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">110.7</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Trade and other receivables </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">8</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">163.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">924.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Contract assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">10.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">8.1</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other financial assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">8</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">5,037.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">7,201.8</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other non-financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">172.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">173.8</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Income tax assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">5</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">70.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">52.6</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">8</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">9,741.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">7,675.4</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total current assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">15,297.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">16,146.6</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">20,342.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">21,988.6</font></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Equity and liabilities </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Equity </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Share capital</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">9</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">259.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">259.0</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Capital reserve</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">9</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">2,339.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">2,473.3</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Treasury shares</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(7.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(7.7)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Retained earnings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">16,609.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">17,961.9</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other reserves </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1,442.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1,462.3)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total equity </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">17,757.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">19,224.2</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Non-current liabilities </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Lease liabilities, loans and borrowings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">8</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">258.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">215.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other financial liabilities </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">8</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">90.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">94.9</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Provisions</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">10</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">58.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">35.5</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Contract liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">87.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">88.0</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other non-financial liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">107.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">104.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Deferred tax liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">5</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">33.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">84.3</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total non-current liabilities </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">635.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">622.1</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Current liabilities </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Lease liabilities, loans and borrowings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">8</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">57.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">52.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Trade payables and other payables</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">8</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">646.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">534.9</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other financial liabilities </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">8</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">78.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">351.7</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Income tax liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">5</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">21.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">65.6</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Provisions</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">10</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">234.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">145.3</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Contract liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">742.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">754.9</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other non-financial liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">168.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">237.7</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total current liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">1,949.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2,142.3</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total liabilities </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2,585.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2,764.4</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total equity and liabilities </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">20,342.6</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">21,988.6</font></td></tr></table></div><div style="margin-bottom:15pt;text-align:center"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">3</font></div></td></tr></table></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2948"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Interim Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity</font></div><div style="margin-bottom:15pt;text-align:justify"><font><br></font></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:25.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.959%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.959%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.959%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.959%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.959%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.959%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.959%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Equity attributable to equity holders of the parent</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Note</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Share capital</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Capital reserve</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Treasury shares</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Retained earnings</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Other reserves</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total equity</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">As of January 1, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">248.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">1,398.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(8.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">19,098.0</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,325.5)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">19,411.1</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Net loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(802.4)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(802.4)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other comprehensive loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(101.3)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(101.3)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total comprehensive loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(802.4)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(101.3)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(903.7)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Share-based payments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">49.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">0.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(52.0)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(2.3)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">As of June 30, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">248.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">1,447.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(8.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">18,295.6</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,478.8)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">18,505.1</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">As of January 1, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">259.0</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2,473.3</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(7.7)</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">17,961.9</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,462.3)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">19,224.2</font></td><td colspan="3" style="border-right:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Net loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1,352.7)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1,352.7)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other comprehensive profit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1.0</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1.0</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total comprehensive profit &#47; (loss)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,352.7)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">1.0</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,351.7)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Issuance of share capital, net of transaction costs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">9</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">127.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">128.6</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Obligation to issue share capital</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(132.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(132.6)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Share repurchase program</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">9</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(130.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(131.8)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Share-based payments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">19.3</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">20.8</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">As of June 30, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">259.0</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2,339.1</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(7.8)</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">16,609.2</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,442.0)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">17,757.5</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-right:1pt solid #bece33;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:15pt;text-align:center"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">4</font></div></td></tr></table></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_295"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Interim Condensed Consolidated Statements of Cash Flows</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.512%"><tr><td style="width:1.0%"></td><td style="width:46.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.022%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Three months ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Six months ended June 30,</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Note</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Operating activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Net loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(820.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(386.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1,352.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(802.4)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Income taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">5</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(37.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(16.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(74.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(45.7)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Loss before tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(858.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(402.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,426.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(848.1)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Adjustments to reconcile loss before tax to net cash flows&#58; </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Depreciation, amortization and impairment of property, plant, equipment, intangible assets and right-of-use assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">6, 7</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">266.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">51.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">387.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">93.8</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Share-based payment expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">20.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">32.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">43.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">54.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Net foreign exchange differences</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">17.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">12.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">17.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">60.5</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Gain on disposal of property, plant and equipment</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(0.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(0.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(0.4)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Finance income excluding foreign exchange differences</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(94.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(105.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(205.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(228.0)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Finance expense excluding foreign exchange differences</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">7.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">6.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">19.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">14.5</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Government and similar grants</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(14.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(18.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(32.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(33.0)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other non-cash income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(15.0)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Working capital adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Decrease &#47; (Increase) in trade and other receivables, contract assets and other assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">366.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(412.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">797.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">108.4</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Decrease in inventories</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">3.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">22.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">10.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">56.6</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(Decrease) &#47; Increase in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">224.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">909.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(147.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(72.4)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Interest received and realized gains from cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">70.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">73.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">157.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">191.7</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Interest paid and realized losses from cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(2.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(2.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(5.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(5.8)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Income tax paid, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(16.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(14.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(57.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(27.1)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Share-based payments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(13.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(11.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(15.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(15.1)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Government and similar grants received</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">33.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">7.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">48.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">31.0</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Net cash flows from &#47; (used in) operating activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">10.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">146.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(410.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(634.2)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Investing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Purchase of property, plant and equipment</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(54.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(27.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(111.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(76.0)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Proceeds from sale of property, plant and equipment</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">3.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">0.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">5.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1.0</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Purchase of intangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(0.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(3.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(22.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(572.3)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Acquisition of subsidiaries and businesses, net of cash acquired</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(78.5)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Investment in other financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(2,055.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1,670.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(3,606.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(4,177.7)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Proceeds from maturity of other financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">2,007.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1,635.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">6,285.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">6,085.9</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Net cash flows from &#47; (used in) investing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(100.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(64.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2,550.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">1,182.4</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Financing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Proceeds from loans and borrowings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">37.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">76.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Repayment of loans and borrowings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(5.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(3.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(5.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(8.2)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Payments related to lease liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(11.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(9.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(23.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(18.9)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Share repurchase program</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">9</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(129.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(129.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Net cash flows used in financing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(108.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(13.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(82.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(27.1)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Net increase &#47; (decrease) in cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(198.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">68.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">2,057.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">521.1</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Change in cash and cash equivalents resulting from exchange rate differences</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(3.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">9.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(6.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(6.9)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Change in cash and cash equivalents resulting from other valuation effects</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">3.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">6.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">14.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(6.6)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Cash and cash equivalents at the beginning of the period</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">9,939.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">10,184.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">7,675.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">9,761.9</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Cash and cash equivalents as of June 30</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">9,741.0</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">10,269.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">9,741.0</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">10,269.5</font></td></tr></table></div><div style="margin-bottom:16pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">Certain prior period lines were aggregated to conform to current period presentation and to improve readability.</font></div><div style="margin-bottom:15pt;margin-top:3pt;text-align:center"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">5</font></div></td></tr></table></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_366"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:56pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:20pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Selected Explanatory Notes to the Unaudited Interim Condensed Consolidated Financial Statements</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_433"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">1. Corporate Information</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">BioNTech SE is a limited company incorporated and domiciled in Germany. The registered office is located in Mainz, Germany (An der Goldgrube 12, 55131 Mainz). The accompanying unaudited interim condensed consolidated financial statements present the financial position and the results of operation of BioNTech&#160;SE and its subsidiaries and have been prepared on a going concern basis in accordance with the IFRS Accounting Standards as issued by the International Accounting Standards Board and as endorsed by the European Union. References to the &#8220;Company&#8221;, &#8220;BioNTech&#8221;, &#8220;Group&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to BioNTech SE and its consolidated subsidiaries.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are a global next-generation immunotherapy company aiming to pioneer novel medicines against cancer, infectious diseases and other serious diseases. Since our founding in 2008, we have focused on harnessing the power of the immune system to address human diseases with unmet medical needs and major global health burdens. Our fully integrated model combines decades of research in immunology with a multi-technology innovation engine, GMP manufacturing, translational drug discovery, clinical development, commercial capabilities, computational medicine, data science and artificial intelligence, or AI, and machine learning, or ML, capabilities to discover, develop and commercialize our marketed product and product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We have built a broad toolkit across multiple technology platforms, including a diverse range of potentially first-in-class therapeutic approaches. This includes investigational messenger ribonucleic acid, or mRNA immunotherapies and protein-based therapeutics (including targeted antibodies such as monoclonal, bispecific and antibody-drug conjugates, or ADCs).</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our multi-technology combination of platforms and product candidates aims to position us as pioneers in the field of individualized, patient-centric therapeutic approaches in oncology and infectious diseases. We believe that by combining complementary treatment modalities, we can leverage the potential of each technology to provide precise and personalized treatments to patients. Such treatments, if approved, could both increase the likelihood of therapeutic success and reduce the risk of therapeutic resistance.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our primary focus is oncology, where we endeavor to address the full continuum of cancer from early to late disease stages. The root causes of cancer treatment failure are cancer heterogeneity and interindividual variability. Driven by random sequential mutations, every patient&#8217;s cancer is different and within one patient&#8217;s tumor, every cell is different. Addressing these two challenges is the core of our strategy. To augment anti-tumor activity and to counteract resistance mechanisms, we seek to combine compounds with non-overlapping, potentially synergistic mechanisms of action.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">6</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In infectious diseases, our goal is to develop vaccines and therapeutics caused by respiratory viruses, latent viruses, bacteria and parasites. We believe our scientific approach and our mRNA technology have the potential to significantly contribute to the fight against global health threats caused by infectious diseases. We have pursued both strategic partnerships and corporate collaborations to partially fund our infectious disease global health programs and aim to continue to do so. Our infectious disease programs aim to contribute to equitable access to innovative vaccines for high medical need indications.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our approach has generated a robust and diversified product candidate pipeline across a range of technologies in oncology and infectious disease, and has led to the approval of our first marketed pharmaceutical product, </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Comirnaty</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">. Innovation is at the core of our company, and we see potential for our technologies to expand beyond oncology and infectious diseases.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our unaudited interim condensed consolidated financial statements as of and for the three and six months ended June 30, 2026 were authorized for issuance in accordance with a resolution of the Audit Committee of our Supervisory Board on August&#160;3, 2026.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_438"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">2. Basis of Preparation, Significant Accounting Policies </font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Basis of Preparation and Principles of Consolidation</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The accompanying unaudited interim condensed consolidated financial statements as of and for the three and six months ended June 30, 2026 have been prepared in accordance with IAS 34 Interim Financial Reporting.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The unaudited interim condensed consolidated financial statements do not include all the information and disclosures required in the audited consolidated financial statements, and should be read in conjunction with our audited consolidated financial statements and accompanying notes included in our Annual Report on Form 20-F as of and for the year ended December 31, 2025, as amended.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We prepare and present our unaudited interim condensed consolidated financial statements in Euros and round numbers to millions of Euros.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The unaudited interim condensed consolidated financial statements as of and for the three and six months ended June 30, 2026, include BioNTech SE and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Significant Accounting Judgments, Estimates and Assumptions and Accounting Policies</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The preparation of the unaudited interim condensed consolidated financial statements requires our management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities and contingent liabilities and the accompanying disclosures. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The significant accounting judgments, estimates and assumptions applied in the preparation of the unaudited interim condensed consolidated financial statements are consistent with those described in Note 3 and applied in the preparation of our audited consolidated financial statements as of and for the year ended December 31, 2025. Significant changes compared to the year ended December 31, 2025 are described below.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">7</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Judgment is required including, but not limited to, when accounting for the amortization of intangible assets. Generally, the straight-line method is used unless the expected consumption of the economic benefits is better reflected by applying, for example, the diminishing balance (degressive) method. Intangible assets are amortized over their useful lives. A summary of the useful lives applied to the Group&#8217;s intangible assets is as follows&#58;</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:75.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.952%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Intangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Useful life (years)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Intellectual property rights</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">8-42</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Licenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">3-20</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Software</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">3-8</font></div></td></tr></table></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Management bases its judgments and estimates on information available at the time when the unaudited interim condensed consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond our control. Such changes are reflected in the assumptions when they occur.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Judgment is also required in evaluating the potential application of IFRS 5 to certain non-current assets (or disposal groups). This includes assessing whether the criteria for classification as held for sale are met, including whether the non-current assets are available for immediate sale in their present condition and whether a sale is highly probable. Additionally, judgment is required in assessing if a component  of the group could qualify as a discontinued operation. These assessments are based on the relevant facts and circumstances, such as the status of disposal plans and the expected manner and timing of disposal.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Management also exercises judgment on an ongoing basis in the identification of objective evidence  of impairment indicators or their reversal for property, plant and equipment and, where relevant, in estimating recoverable amounts in accordance with IAS 36. These estimates include management&#8217;s assumptions, including expected future cash flows and disposal values. Future cash flows can be affected by a variety of factors, including, but not limited to changes in expected utilization including impacts from approved and ongoing restructuring activities. Disposal values are based on available data from similar transactions or observable market prices less incremental costs of disposing of an asset.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Assumptions and estimates are required in determining and reviewing the appropriate useful life in order to calculate the amount of depreciation on property, plant and equipment. In making these estimates, management considers the useful lives of the property, plant and equipment derived among other things, from past experience and ongoing and approved restructuring activities.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The accounting policies adopted in the preparation of the unaudited interim condensed consolidated financial statements are consistent with those followed in the preparation of our audited consolidated financial statements as of and for the year ended December 31, 2025, except for income taxes, which are accounted for using the expected annual tax rate in our unaudited interim condensed consolidated financial statements (see Note 5).</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">8</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Standards Applied for the First Time</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">IFRS Accounting Standards that were applied for the first time as of January 1, 2026, as disclosed in the notes to the audited consolidated financial statements as of and for the year ended December 31, 2025, had no impact on our unaudited interim condensed consolidated financial statements as of and for the three and six months ended June 30, 2026.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_446"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">3. Revenues from Contracts with Customers</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2004"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Disaggregated Information on Revenues</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Set forth below is the disaggregation of our revenues from contracts with customers&#58;</font></div><div style="margin-bottom:15pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:42.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.729%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Three months ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Six months ended June 30,</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">COVID-19 vaccine revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">51.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">153.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">118.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">286.3</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">53.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">107.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">104.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">157.3</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">105.6</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">260.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">223.7</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">443.6</font></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">COVID-19 Vaccine Revenues</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our COVID-19 vaccine revenues were recognized from the supply and sales of our COVID-19 vaccine worldwide during the three and six months ended June 30, 2026 and 2025, mainly comprising our share of the collaboration partner&#8217;s gross profit derived from sales in the collaboration partner&#8217;s territory. Overall, our COVID-19 vaccine revenues amounted to &#8364;51.9&#160;million and &#8364;118.8&#160;million during the three and six months ended June 30, 2026, respectively, compared to &#8364;153.3&#160;million and &#8364;286.3&#160;million in the same periods in the prior year, respectively. The decreases for the three and six months ended June 30, 2026, each compared with the corresponding prior&#8209;year period, were mainly driven by a lower volume of doses sold during the three and six months ended June 30, 2026. Our COVID-19 vaccine revenues are subject to seasonal effects in the fall and winter of the northern hemisphere. </font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Other Revenues</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our remaining other revenues were mainly derived from a pandemic preparedness contract with the German government, during the three and six months ended June 30, 2026 and 2025.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Revenues from contracts with customers were recognized as follows&#58;</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:47.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.363%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Three months ended <br>June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Six months ended <br>June 30,</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Timing of revenue recognition</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Goods and services transferred at a point in time</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">16.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">70.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">24.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">137.0</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Goods and services transferred over time</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">47.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">102.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">93.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">148.6</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;padding-left:14.17pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Revenue recognition applying the sales-based or usage-based royalty recognition constraint model </font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:5.2pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">42.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">87.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">105.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">158.0</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">105.6</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">260.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">223.7</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">443.6</font></td></tr></table></div><div style="margin-bottom:16pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Represents sales based on the share of the collaboration partners&#8217; gross profit.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">9</font></div></td></tr></table></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_882"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">4. Income and Expenses</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_454"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">4.1 General Expenses</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2017"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Cost of Sales</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our cost of sales increased by &#8364;20.6&#160;million, or 27%, from &#8364;76.4&#160;million during the three months ended June 30, 2025 to &#8364;97.0&#160;million during the three months ended June 30, 2026 and increased by &#8364;8.2&#160;million, or 5%, from &#8364;160.2&#160;million&#160;during the six months ended June 30, 2025 to &#8364;168.4&#160;million during the six months ended June 30, 2026. The increases for the three and six months ended June 30, 2026, each compared with the corresponding prior&#8209;year period, were mainly driven by the inclusion of degressive amortization charges related to assets acquired in connection with the acquisition of CureVac N.V., or CureVac, partially offset by lower expenses arising from inventory write-downs to net realizable value due to inventories expected to be unsellable, not fulfilling the specification defined by our quality standards, shelf-life expiry or destruction of inventory.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Research and Development Expenses</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our research and development expenses increased by &#8364;41.9&#160;million, or 8%, from &#8364;509.1&#160;million during the three months ended June 30, 2025 to &#8364;551.0&#160;million during the three months ended June 30, 2026 and increased by &#8364;73.3&#160;million, or 7%, from &#8364;1,034.7&#160;million&#160;during the six months ended June 30, 2025 to &#8364;1,108.0&#160;million during the six months ended June 30, 2026. The increases for the three and six months ended June 30, 2026, each compared with the corresponding prior&#8209;year period, were mainly driven by higher expenses for our immuno-oncology, or IO, and antibody-drug conjugate, or ADC, programs, in particular pumitamig and gotistobart, by impairments related to early clinical-stage product candidates recorded in June 2026 (see Note 6) as well as research and development costs from the inclusion of operations from CureVac, which was acquired in late 2025. The year-to-date period was also impacted by an impairment related to BNT331 recorded in March 2026 (see Note 6). The quarterly and year-to-date increases were partially offset by lower costs on non-focus programs and positive effects from cost shares with our collaboration partners. We do not track research and development expenses by product candidate and the costs that are directly attributable to individual product candidates represent only a portion of our research and development expenses, while almost half of our current research and development expenses consist of costs that support multiple programs. </font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Sales and Marketing Expenses</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our sales and marketing expenses increased by &#8364;20.4&#160;million, or 104%, from &#8364;19.7&#160;million during the three months ended June 30, 2025 to &#8364;40.1&#160;million during the three months ended June 30, 2026 and increased by &#8364;34.6&#160;million, or 104%, from &#8364;33.4&#160;million&#160;during the six months ended June 30, 2025 to &#8364;68.0&#160;million during the six months ended June 30, 2026. The increases for the three and six months ended June 30, 2026, each compared with the corresponding prior&#8209;year period, were mainly driven by pre&#8209;launch activities for late-stage programs as well as our ongoing commercial build&#8209;up, particularly in the United States.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">General and Administrative Expenses</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our general and administrative expenses increased by &#8364;40.0&#160;million, or 34%, from &#8364;117.7&#160;million during the three months ended June 30, 2025 to &#8364;157.7&#160;million during the three months ended June 30, 2026 and increased by &#8364;56.0&#160;million, or 25%, from &#8364;224.6&#160;million&#160;during the six months ended </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">10</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">June 30, 2025 to &#8364;280.6&#160;million during the six months ended June 30, 2026. The increases for the three and six months ended June 30, 2026, each compared with the corresponding prior&#8209;year period, were primarily driven by the inclusion of CureVac operations acquired in late 2025, as well as expenses associated with BioNTech&#8217;s global initiative on scaling processes and ERP infrastructure to strengthen operational execution. This was partly offset by cost reductions resulting from the execution of initiatives related to our pipeline prioritization and increased cost discipline. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_912"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">4.2 Other Operating Result</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2044"></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The other operating results recognized during the three and six months ended June 30, 2026 and 2025 are shown in the following table&#58;</font></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:47.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.363%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Three months ended <br>June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Six months ended <br>June 30,</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Other operating income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">40.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">78.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">57.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">139.8</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Government and similar grants</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">14.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">18.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">32.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">32.9</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Gain on derivative instruments at fair value through profit or loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">13.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">41.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">3.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">68.0</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Bargain purchase</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">15.0</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">12.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">18.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">21.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">23.9</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Other operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(248.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(117.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(281.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(165.7)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Pipeline prioritization costs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(221.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(43.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(240.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(43.6)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">External legal advice services</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(7.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(23.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(20.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(49.3)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Foreign exchange differences, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(15.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(41.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(11.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(54.8)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Impairment losses and reversals of impairment losses on financial assets (operating result), net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(6.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(0.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(6.5)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(4.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(2.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(9.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(11.5)</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total other operating result</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(207.9)</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(39.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(224.3)</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(25.9)</font></td></tr></table></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our total other operating result decreased by &#8364;168.9&#160;million from a negative result of &#8364;39.0&#160;million during the three months ended June 30, 2025 to a negative result of &#8364;207.9&#160;million during the three months ended June 30, 2026 and decreased by &#8364;198.4 million from a negative result of &#8364;25.9&#160;million during the six months ended June 30, 2025 to a negative result of &#8364;224.3&#160;million during the six months ended June 30, 2026.</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> Our expenses in connection with our pipeline prioritization included during the three months ended June 30, 2026 employee-related restructuring costs of &#8364;97.6&#160;million and impairment losses on property, plant and equipment as well as on other intangible assets </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">of &#8364;96.1&#160;million, </font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">of which &#8364;87.0&#160;million related to the sites in Marburg and Idar-Oberstein (see Note 7), compared to employee-related restructuring costs of &#8364;27.8&#160;million and impairment losses on property, plant and equipment outside of Europe of &#8364;10.0&#160;million, respectively, during the prior year quarter. Year-to-date, our pipeline prioritization costs included mainly employee-related restructuring costs of &#8364;105.0&#160;million and impairment losses </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">of &#8364;96.1&#160;million, </font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">with &#8364;87.0&#160;million related to the sites in Marburg and Idar-Oberstein.  Employee-related restructuring costs and impairment losses for the six months ended June 30, 2025 were the same as for the three months ended June 30, 2025.  </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">11</font></div></td></tr></table></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_477"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">4.3 Finance Result</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2087"></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The finance results recognized during the three and six months ended June 30, 2026 and 2025, are shown in the following table&#58; </font></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:47.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.363%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Three months ended <br>June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Six months ended <br>June 30,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total finance income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">97.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">105.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">217.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">228.0</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Interest income from effective interest method </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">66.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">68.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">128.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">145.9</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other gains</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">28.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">36.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">77.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">82.1</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 29.35pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Gains from financial assets or financial liabilities that are mandatorily measured at fair value through profit or loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">26.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">36.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">74.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">82.0</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 29.35pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other gains from financial assets subsequently measured at amortized cost</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">0.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">2.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">0.1</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Foreign exchange differences, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">2.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">12.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total finance expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(7.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(7.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(19.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(40.9)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Interest expenses from effective interest method and other interest expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(3.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(3.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(7.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(7.4)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Foreign exchange differences, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(0.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(26.4)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other losses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(4.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(2.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(11.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(7.1)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 29.35pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Losses from financial assets or financial liabilities that are mandatorily measured at fair value through profit or loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(4.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(10.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(4.4)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 29.35pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Fee expense from financial assets and financial liabilities that are not subsequently measured at fair value through profit or loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(0.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(0.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(2.7)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total finance result</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">89.4</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">98.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">198.8</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">187.1</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our finance result during the three and six months ended June 30, 2026 and 2025 was mainly derived from returns, such as interest, resulting from our security investments as well as fair value adjustments of our money market funds. Our total finance result decreased by </font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8364;9.0 million</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> from a positive finance result of </font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8364;98.4 million</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> during the three months ended June 30, 2025 to a positive finance result of </font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8364;89.4 million</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> during the three months ended June 30, 2026 and increased by </font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8364;11.7&#160;million</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> from a positive finance result of </font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8364;187.1 million</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> during the six months ended June 30, 2025 to a positive finance result of </font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8364;198.8&#160;million</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> during the six months ended June 30, 2026. The quarterly decrease was primarily driven by lower positive fair value effects of our money market funds, while the year-to-date increase was mainly due to positive impacts from foreign exchange differences, primarily derived from our security investments.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_484"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">5. Income Taxes</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">During the three and six months ended June 30, 2026 and 2025, income taxes were calculated based on the best estimate of the weighted average annual income tax rates expected for the full financial years (estimated annual effective income tax rates) on ordinary income before tax adjusted by the tax effect of any discrete items. During the six months ended June 30, 2026, our effective income tax rate was approximately 5.2%. During the six months ended June 30, 2025, our effective income tax rate was approximately 5.4%. </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">12</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The effective income tax rate was mainly driven by the expected negative result for 2026 and management&#8217;s assessment of the requirements in International Accounting Standards, or IAS, 12, including on the character and amounts of taxable future profits, the periods in which those profits are expected to occur, and the availability of tax planning opportunities. Thus, in countries where the requirements of IAS 12 were not fulfilled, no deferred tax asset was recognized. Such assessment takes into account the fact that there is an inherent risk of failure in pharmaceutical development and uncertainty of approvals that depend on external regulatory agencies&#8217; opinions. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We apply the mandatory exception to recognizing and disclosing information about deferred tax assets and liabilities arising from Pillar Two income taxes. Furthermore, we reviewed the corporate structure with regard to the Pillar Two Model Rules in various jurisdictions. Since the Group&#8217;s relevant effective tax rate for Pillar Two purposes is expected mainly above 15% in all jurisdictions in which it operates, it has been determined that the Group is not materially subject to Pillar Two &#8220;top-up&#8221; taxes. Therefore, the consolidated financial statements for the three and six months ended June 30, 2026 do not include further information otherwise required by paragraphs 88B and 88C of IAS 12.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2120"></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our income taxes recognized during the three and six months ended June 30, 2026 and 2025 are shown in the following table&#58; </font></div><div style="margin-bottom:15pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:38.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.575%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.575%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.575%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Three months ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Six months ended June 30,</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Current income taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(7.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(5.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">6.7</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Deferred taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(30.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(20.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(68.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(52.4)</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Income taxes income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(37.9)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(16.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(74.1)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(45.7)</font></td></tr></table></div><div id="i58ee89399d9d45f4ac20dcae213591ea_549755815327"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">6. Other Intangible Assets</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We identify indications of impairment of other intangible assets using various factors from external and internal information sources, including deviations from sales forecasts and the analysis of changes in medium-term planning.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">During the six months ended June 30, 2026, we recognized impairment losses related to other intangible assets of &#8364;126.9&#160;million, mainly recognized as research and development expenses in our unaudited interim condensed consolidated statements of profit or loss. Of this amount, &#8364;103.8&#160;million resulted from BNT331 and other early clinical-stage product candidates, which are outside our focus programs. The impairment loss related to BNT331 of &#8364;29.9&#160;million was identified following management&#8217;s decision to pause the program due to strategic considerations during the three months ended March 31, 2026. During the three months ended June 30, 2026, impairment losses of &#8364;73.9&#160;million related to non-focus in-process R&#38;D assets were identified since the likelihood of finalizing out-licensing agreements for these product candidates was considered unlikely and internal development is not foreseen as of June 30, 2026. The in-process R&#38;D assets were classified as intangible assets not yet available for use and, accordingly, were not designated useful lives and not amortized. In contrast, the intangible asset related to BNT331 was classified as an intangible asset with a definite useful life. The recoverable amounts of the intangible assets, calculated as their value in use, were determined to be zero and therefore the assets&#8217; carrying amounts were fully impaired as of June 30, 2026. </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">13</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The remaining impairment losses during the six months ended June 30, 2026 in the amount of &#8364;23.1&#160;million related to in-process R&#38;D, intellectual property rights, licenses, software and similar rights, and were made due to strategic considerations and reflected full impairments of the assets&#8217; carrying amounts. The corresponding recoverable amounts were mainly calculated as value in use and determined to be zero as of June 30, 2026.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_156680406961856"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">7. Property, Plant and Equipment</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">During the six months ended June 30, 2026, we recognized impairment losses related to property, plant and equipment of &#8364;96.1&#160;million, mainly recognized as other operating expenses in our unaudited interim condensed consolidated statements of profit or loss. These losses mainly related to our ongoing pipeline prioritization following our decision on our manufacturing footprint consolidation, in particular, to exit operations at several manufacturing sites.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">For the affected sites in Marburg and Idar-Oberstein, impairment losses of &#8364;68.9&#160;million were recorded related to the impairments of equipments, tools and installations as well as leasehold improvements. The recoverable amounts of the affected assets, based on their value in use, was determined to be zero and therefore the assets&#8217; were fully impaired as of June 30, 2026. In addition, an impairment loss of &#8364;14.5&#160;million was recorded related to the impairment of land and buildings. The recoverable amount of the affected asset, based on their fair value less cost of disposal, which was measured applying a multiple valuation method based on estimated annual market rents and therefore classified as a level 3 fair value measurement within the fair value hierarchy, was determined to be &#8364;6.8&#160;million. Following recognition of the impairment loss, the carrying amount of the asset was reduced to its recoverable amount.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">For the other affected sites, impairment losses of &#8364;12.7&#160;million were recorded mainly related to the impairment of construction in progress and advance payments. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_490"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">8. Financial Assets and Financial Liabilities</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Financial Assets and Liabilities at Amortized Cost and at Fair Value through OCI and Profit or Loss</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Set out below is an overview of financial assets and liabilities at amortized cost and at fair value through OCI and profit or loss, as of the dates indicated. Security investments are debt instruments under our asset management policy that generate a return individually and independently of our core operating activities.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">14</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:19.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.959%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="42" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">June 30, 2026</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Carrying amount</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Fair value</font></td><td colspan="3" style="border-right:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Security Investment</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">IFRS 9 Category</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Current</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Non-current</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Level 1</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Level 2</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Level 3</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Foreign exchange forward contracts</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">FVTPL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">0.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">0.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">0.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">0.6</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other funds</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Yes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">FVTPL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">199.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">199.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">199.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">199.9</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Deposits</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Yes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">510.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">157.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">667.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">667.9</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Commercial Paper</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Yes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">447.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">447.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">447.9</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Bonds</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Yes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">2,762.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1,700.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">4,463.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4,446.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">4,446.7</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Repos</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Yes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1,114.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">1,114.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">1,114.4</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Non-listed equity investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">FVTOCI</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">0.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">0.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">0.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">0.6</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Listed equity investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">FVTOCI</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">61.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">61.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">61.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">61.3</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Trade and other receivables </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">163.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">163.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">163.9</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">2.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">22.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">24.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">24.8</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">FVTPL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">63.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">63.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">63.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">63.4</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Subtotal</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">5,201.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2,006.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">7,207.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">4,508.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">200.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">64.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">7,191.4</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Cash at banks and on hand</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Yes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">546.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">546.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">546.7</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Money market funds</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Yes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">FVTPL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4,804.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">4,804.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4,804.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">4,804.3</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Deposits, Commercial Paper, Repos (&#60; 3 months)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Yes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4,390.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">4,390.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">4,390.0</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Subtotal</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">9,741.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">9,741.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">4,804.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">9,741.0</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Financial liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Foreign exchange forward contracts</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">FVTPL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">6.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">6.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">6.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">6.5</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Contingent consideration</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">FVTPL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">40.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">76.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">116.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">116.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">116.4</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Loans and borrowings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">10.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">102.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">112.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">112.9</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Trade payables and other payables</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">646.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">646.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">646.7</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other financial liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">31.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">13.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">45.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">45.4</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Lease liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">n&#47;a</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">46.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">156.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">203.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">203.2</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Subtotal</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">782.2</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">348.9</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">1,131.1</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">6.5</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">116.4</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">1,131.1</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-right:1pt solid #becd32;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:16pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Fair values for financial assets and liabilities at amortized costs are not disclosed when the book values represent a reasonable approximation. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Additional developments in our financial assets during the six months ended June 30, 2026 mainly resulted from a reallocation of existing capital and spending for our operations as disclosed in our </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">unaudited interim condensed consolidated </font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">statements of cash flows.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As of June&#160;30, 2026, we had cash and cash equivalents of &#8364;9,741.0&#160;million, current security investments disclosed as financial assets of &#8364;5,035.1&#160;million and non-current security investments disclosed as financial assets of &#8364;1,858.1&#160;million totaling &#8364;16,634.2&#160;million in cash, cash equivalents and security investments, a decrease of &#8364;601.4&#160;million compared to December 31, 2025. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our other financial liabilities decreased by &#8364;280.2&#160;million during the </font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">six months ended June 30, 2026</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> . The decrease mainly resulted from payments to our licensors resulting from our COVID-19 vaccine business.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">15</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.171%"><tr><td style="width:1.0%"></td><td style="width:19.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.301%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.301%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.301%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.301%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.301%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.301%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.310%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">December 31, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Carrying amount</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Fair value</font></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Security Investment</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">IFRS 9 Category</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Current</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Non-current</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Level 1</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Level 2</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Level 3</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Foreign exchange forward contracts</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">FVTPL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">6.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">6.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">6.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">6.3</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other funds</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Yes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">FVTPL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">199.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">199.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">199.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">199.9</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Deposits</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Yes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">3,358.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">3,458.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">3,458.5</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Commercial Paper</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Yes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">570.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">570.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">570.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Bonds</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Yes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">2,135.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">2,301.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">4,437.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">4,437.4</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Repos</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Yes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">894.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">894.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">894.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Non-listed equity investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">FVTOCI</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">0.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">0.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">0.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">0.6</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Listed equity investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">FVTOCI</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">82.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">82.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">82.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">82.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Trade and other receivables</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">924.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">924.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">924.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Reimbursement asset</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">36.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">36.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">36.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">0.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">23.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">23.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">23.9</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">FVTPL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">46.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">46.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">46.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">46.6</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Subtotal</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">8,126.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2,554.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">10,680.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">82.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">206.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">47.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">10,680.2</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Cash at banks and on hand</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Yes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">827.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">827.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">827.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Money market funds</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Yes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">FVTPL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">5,063.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">5,063.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">5,063.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">5,063.3</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Deposits, Commercial Paper, Repos (&#60; 3 months)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Yes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1,784.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">1,784.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">1,784.9</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Subtotal</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">7,675.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">7,675.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">5,063.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">7,675.4</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Financial liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Foreign exchange forward contracts</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">FVTPL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">0.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">0.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">0.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">0.4</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Contingent consideration</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">FVTPL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">43.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">77.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">120.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">120.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">120.6</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Loans and borrowings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">7.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">29.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">37.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">37.1</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Trade payables and other payables</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">534.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">534.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">534.9</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other financial liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">AC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.22pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">307.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">17.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">325.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">325.6</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Lease liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">No</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">n&#47;a</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">45.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">185.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">230.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">230.3</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Subtotal</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">938.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">310.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">1,248.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">0.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">120.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">1,248.9</font></td></tr></table></div><div style="margin-bottom:16pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">Fair values for financial assets and liabilities at amortized costs are not disclosed when the book values represent a reasonable approximation.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Equity Investments Designated at Fair Value through OCI</font></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:59.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.195%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Fair value as of June&#160;30, 2026</font></div></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Fair value as of December&#160;31, 2025</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Investment in Autolus Therapeutics plc</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">46.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">56.5</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Investment in Ryvu Therapeutics S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">6.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">12.3</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Investment in Duality Biologics Co. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">8.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">13.4</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other investments </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">0.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">0.6</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">61.9</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">82.8</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">16</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Financial investments in equity instruments measured at fair value through other comprehensive income comprise the following effects&#58;</font></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:47.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.363%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Three months ended <br>June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Six months ended <br>June 30,</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Net gain &#47; (loss) on equity instruments designated at fair value through other comprehensive income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(2.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">24.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(20.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(7.2)</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(2.3)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">24.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(20.9)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(7.2)</font></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Measurement of Fair Values</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The following table shows the valuation techniques used in measuring fair values for financial instruments in our unaudited interim condensed consolidated statements of financial position, as well as the significant unobservable inputs used. </font></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:21.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.355%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Type</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Valuation technique</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Significant unobservable inputs</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Forward exchange contracts</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Discounted cash flow using par method. Expected future cash flows based on foreign exchange forwards discounted over the respective remaining term of the contracts using the respective deposit interest rates and spot rates.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">n&#47;a</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Non-listed equity investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Quantitative and qualitative factors such as actual and forecasted results, cash position and financing round valuations.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt;padding-left:7.09pt;text-indent:-7.09pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8211;</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%;padding-left:3.09pt">Actual and forecasted results</font></div><div style="margin-bottom:4pt;padding-left:7.09pt;text-indent:-7.09pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8211;</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%;padding-left:3.09pt">Net asset value</font></div><div style="margin-bottom:4pt;padding-left:7.09pt;text-indent:-7.09pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8211;</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%;padding-left:3.09pt">Cash position</font></div><div style="margin-bottom:4pt;padding-left:7.09pt;text-indent:-7.09pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8211;</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%;padding-left:3.09pt">Nature and pricing indication of latest financing round</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Listed equity investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Stock prices of the listed companies and applicable exchange rates, if the listing is in a foreign currency.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">n&#47;a</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Money market funds</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Quoted prices on an active market.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">n&#47;a</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other funds</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Quoted prices for OTC transactions</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">n&#47;a</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Contingent consideration</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Present value of expected future payments and reflecting changes in expected achievement of underlying performance parameters and compounding effects. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt;padding-left:7.09pt;text-indent:-7.09pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8211;</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%;padding-left:3.09pt">Expected future payments based on performance-based contingent payments (upper limit of &#8364;268.9 million)</font></div><div style="margin-bottom:4pt;padding-left:7.09pt;text-indent:-7.09pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8211;</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%;padding-left:3.09pt">Applied cost of capital</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Royalty assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Present value of expected future cash flows.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt;padding-left:7.09pt;text-indent:-7.09pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8211;</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%;padding-left:3.09pt">Expected future cash flows based on a low-to-mid one-digit royalty rate on net sales. </font></div><div style="margin-bottom:4pt;padding-left:7.09pt;text-indent:-7.09pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8211;</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%;padding-left:3.09pt">Applied cost of capital</font></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Recurring Fair Values (Level 3)</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The following table shows the recurring fair value measurement of contingent consideration and royalty assets included in other financial assets subsequently measured at fair value through profit or </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">17</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">loss as well as the effect of the measurements on our unaudited interim condensed consolidated statements of profit or loss for the current period.</font></div><div style="margin-bottom:15pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:50.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.487%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Financial assets</font></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Financial liabilities</font></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Other financial assets</font></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Contingent consideration</font></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">As of January 1, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">39.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(47.8)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Additions</font></td><td colspan="3" style="padding:0 1pt 0 15.17pt"></td><td colspan="3" style="padding:0 1pt 0 15.17pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(79.6)</font></td><td colspan="3" style="padding:0 1pt 0 15.17pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Net effect on profit or loss &#8211; Other operating income &#47; (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Net change in fair value</font></td><td colspan="3" style="padding:0 1pt 0 15.17pt"></td><td colspan="3" style="padding:0 1pt 0 15.17pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">4.3</font></td><td colspan="3" style="padding:0 1pt 0 15.17pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Net effect on profit or loss &#8211; Finance income &#47; (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Net change in fair value</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(6.4)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Net effect on other comprehensive income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Net change in fair value</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">0.1</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">As of June 30, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">38.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(129.4)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">As of January 1, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">46.6</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(120.6)</font></td><td colspan="3" style="border-right:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Net effect on profit or loss &#8211; Other operating income &#47; (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Net change in fair value</font></td><td colspan="3" style="padding:0 1pt 0 15.17pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt 0 15.17pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">10.0</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt 0 15.17pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Net effect on profit or loss &#8211; Finance income &#47; (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Net change in fair value</font></td><td colspan="3" style="padding:0 1pt 0 15.17pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt 0 15.17pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">16.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(5.8)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">As of June 30, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">63.4</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(116.4)</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-right:1pt solid #bece33;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The sensitivity of the fair values of royalty assets to the significant, unobservable, variable input factors, with all other factors remaining constant, is shown in the following table&#58;</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Other Financial Assets</font></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:24.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.968%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.915%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Input factor</font></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Change in assumptions</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Change in fair value with increasing input factor <br>(in millions &#8364;)</font></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Change in fair value with decreasing input factor <br>(in millions &#8364;)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Cash flow projections</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">10</font></td><td style="border-top:1pt solid #005a64;padding:1.5pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">7.2</font></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(7.2)</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Discount rate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #a8c7ca;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1</font></td><td style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">%</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(5.3)</font></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">5.8</font></td></tr></table></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The sensitivity of the fair values of contingent consideration to the significant, unobservable, variable input factors, with all other factors remaining constant, is shown in the following table&#58;</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Contingent Consideration</font></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:24.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.968%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.915%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Input factor</font></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Change in assumptions</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Change in fair value with increasing input factor <br>(in millions &#8364;)</font></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Change in fair value with decreasing input factor <br>(in millions &#8364;)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Cash flow projections</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">10</font></td><td style="border-top:1pt solid #005a64;padding:1.5pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">11.0</font></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(11.0)</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Discount rate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #a8c7ca;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1</font></td><td style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">%</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(2.6)</font></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">2.7</font></td></tr></table></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">18</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Risk Management Activities</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">No changes have occurred regarding our risk management activities as disclosed in the notes to our audited consolidated financial statements included in our Annual Report on Form 20-F as of and for the year ended December 31, 2025, as amended. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_738"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">9. Issued Capital and Reserves</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As of June&#160;30, 2026, the number of shares outstanding was 251,204,366, with a notional value of &#8364;1 per share. This amount excludes 7,823,121&#160;shares held in treasury. As of December&#160;31, 2025, the number of shares outstanding was 251,325,340, excluding 7,702,147 shares held in treasury. As described in Note 5 to our audited consolidated financial statements included in our Annual Report on Form 20-F as of and for the year ended December 31, 2025, as amended, we completed the acquisition of the remaining CureVac shares at the beginning of January 2026 as part of the previously announced post-offer reorganization (back-end measures), resulting in a transfer within share capital as disclosed in our unaudited interim condensed consolidated statements of changes in stockholders&#8217; equity.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">On May 7, 2026, our Management Board and Supervisory Board authorized a new share repurchase program pursuant to which we may purchase American Depositary Shares, or ADSs, each representing one ordinary share, in the amount of up to $1.0&#160;billion until and including May 6, 2027. During the three and six months ended June 30, 2026, we repurchased 1,693,056 ADSs under the program at an average price of $89.50 (&#8364;77.85), for a total consideration of $151.6&#160;million (&#8364;131.8&#160;million).</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2599"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">10. Provisions</font></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:53.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.101%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">June 30, 2026</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">December 31, 2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Restructuring</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">133.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">39.1</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Contractual disputes &#47; settlements</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">58.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">58.6</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Obligations from onerous contracts</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">63.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">51.8</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">38.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">31.3</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">293.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">180.8</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Total current</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">234.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">145.3</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Total non-current</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">58.6</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">35.5</font></td></tr></table></div><div style="margin-bottom:15pt;margin-top:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As of June&#160;30, 2026, our provisions included &#8364;133.3 million of obligations from restructuring due to pipeline prioritization, of which &#8364;95.6&#160;million are classified as current and &#8364;37.7&#160;million as non-current. Compared to December&#160;31, 2025, the additions (see Note 4.2) exceed the usage of the provisions.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As of June&#160;30, 2026, our current provisions included &#8364;58.6&#160;million in contractual disputes mainly relating to collaborators regarding, among other things, the interpretation of each party&#8217;s obligations or the amounts payable under the respective agreements. There were no changes compared to December&#160;31, 2025.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As of June&#160;30, 2026, our current provisions included &#8364;63.4&#160;million&#160;of obligations from onerous contracts, mainly relating to production capacities derived from contracts with contract </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">19</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">manufacturing organizations, or CMOs, that became redundant. The changes compared to December&#160;31, 2025 relate to additions from contracts that became onerous related to restructuring.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As of June&#160;30, 2026, our current and non-current provisions included &#8364;38.2&#160;million in other obligations mainly comprising employee-related obligations such as social security costs related to share-based payment programs as well as inventor remunerations and obligations for dismantling&#47;removing. The change compared to December&#160;31, 2025, related mainly to additions.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_530"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">11. Contingent Liabilities</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our contingent liabilities include, but are not limited to, intellectual property disputes and contractual disputes regarding, among other things, the interpretation of each party&#8217;s obligations or the amounts payable under the respective agreements, product-related disputes, and actions by or on behalf of our shareholders. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">From time to time, in the normal course and conduct of our business, we may be involved in proceedings with third parties, including proceedings regarding, for example, the use and&#47;or remuneration for use of such third party&#8217;s intellectual property. As of June&#160;30, 2026, none of the intellectual property-related considerations outlined below, of which we have either been notified, or for which potential claims could be brought against us or our subsidiaries in the future, fulfill the criteria for recording a provision. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are subject to an increasing number of product-related disputes. Our product liability claims often involve highly complex issues related to medical causation, correctness and completeness of product information (Summary of Product Characteristics&#47;package leaflet) as well as label warnings and reliance thereon, scientific evidence and findings, actual and provable defectiveness and injury, and other matters. These complexities vary from matter to matter. As of June&#160;30, 2026, none of these claims fulfill the criteria for recording a provision. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Substantially all of our contingent liabilities are subject to significant uncertainties and, therefore, determining the likelihood of a loss and&#47;or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We currently do not believe that any of these matters will have a material adverse effect on our financial position, and will continue to monitor the status of these and other claims that may arise. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and&#47;or our cash flows in the period in which the amounts are accrued or paid. We will continue to evaluate whether, if circumstances were to change in the future, the recording of a provision may be needed and whether potential indemnification entitlements exist against any such claim.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Certain pending matters to which we are a party are discussed below.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">20</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Moderna Proceedings</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Germany</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%"> </font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Infringement Proceedings &#8211; EP&#8217;949 and EP&#8217;565</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In August 2022, Moderna filed a lawsuit against us and Pfizer and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, Pfizer Manufacturing Belgium NV, Pfizer Ireland Pharmaceuticals and Pfizer Inc. in the D&#252;sseldorf Regional Court alleging Comirnaty&#8217;s infringement of two European patents, 3590949B1, or EP&#8217;949, and 3718565B1, or EP&#8217;565. With respect to EP&#8217;565, on November 7, 2023, the Opposition Division of the EPO revoked EP&#8217;565 after a one-day oral hearing held in the co-pending opposition proceeding, and on December 7, 2023, it issued the written decision for revoking EP&#8217;565. On February 7, 2024, Moderna appealed the Opposition Division&#8217;s revocation decision on EP&#8217;565. On September 17, 2025, the EPO Technical Board of Appeal issued a preliminary opinion noting that it believes EP&#8217;565 is likely invalid. An oral hearing took place on January 27, 2026, at the conclusion of which the  Technical Board of Appeal affirmed the revocation of EP&#8217;565.  On April 29, 2026, the EPO Technical Board of Appeal issued a written decision finally revoking EP&#8217;565. On May 7, 2026, Moderna withdrew its infringement proceedings with respect to EP&#8217;565. On May 22, 2026, Pfizer and BioNTech consented to the withdrawal and the proceedings were dismissed. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">With respect to EP&#8217;949, on December 8, 2023, the Opposition Division issued a preliminary opinion noting that it believes EP&#8217;949 is likely invalid. As a result of those developments in the EPO proceedings, the D&#252;sseldorf Regional Court postponed its hearing on infringement with respect to EP&#8217;949, originally scheduled for December 12, 2023, to January 21, 2025. On May 16, 2024, the EPO Opposition Division decided that EP&#8217;949 is valid, in amended form, and issued its written decision regarding the same on July 8, 2024. We appealed this decision, and the appeal is currently pending. The D&#252;sseldorf Regional Court held an infringement hearing on January 21, 2025, and on March 5, 2025, it issued a first-instance decision declining to stay the infringement proceedings and finding infringement of EP&#8217;949 by us and Pfizer. We and Pfizer have appealed the D&#252;sseldorf Regional Court&#8217;s infringement decision, and the appeal is currently pending. The court has not ruled on the invalidity of EP&#8217;949, which will be decided in a next step by the EPO in the opposition appeal proceedings. On May 29, 2026, the EPO Technical Board of Appeal issued a preliminary opinion noting that it believes EP&#8217;949 is likely invalid. An oral hearing in this appeal has been scheduled for September 8-10, 2026. Moderna has not yet taken steps to enforce the D&#252;sseldorf Regional Court&#8217;s first-instance decision on infringement. </font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">United Kingdom</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In August 2022, Moderna filed a lawsuit asserting Comirnaty&#8217;s infringement of EP&#8217;949 and EP&#8217;565 against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, and Pfizer Limited, Pfizer Manufacturing Belgium NV and Pfizer Inc. in the Business and Property Courts of England and Wales, in the UK High Court. In September 2022, we and Pfizer filed a revocation action in the Business and Property Courts of England and Wales requesting revocation of EP&#8217;949 and EP&#8217;565.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The UK High Court held a trial between April 22, 2024, and May 21, 2024. On July 2, 2024, the UK High Court released two judgments. The first judgment concerns the validity of EP&#8217;949 and EP&#8217;565. In this first judgment, the UK High Court found that EP&#8217;565 is invalid and therefore not infringed, while EP&#8217;949 is valid and infringed. The second judgment concerns whether Moderna&#8217;s October 2020 commitment </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">21</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">not to &#8220;enforce &#91;its&#93; COVID-19 related patents against those making vaccines intended to combat the pandemic,&#8221; or the Patent Pledge, amounted to a consent under UK law to carry out any acts that would otherwise amount to patent infringement. With respect to this judgment, the UK High Court found that Moderna&#8217;s Patent Pledge amounted to consent to carry out activities that might otherwise infringe its patents prior to March 2022, but not after March 2022. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The UK High Court held a hearing on September 25, 2024, during which the Court granted Pfizer and BioNTech permission to appeal its judgment regarding the validity of EP&#8217;949, and declined Moderna&#8217;s permission to appeal its judgment regarding validity of EP&#8217;565. On October 16, 2024, Moderna sought permission from the UK Appeals Court to appeal the EP&#8217;565 judgment. On November 11, 2024, the UK Appeals Court denied Moderna&#8217;s application to appeal&#59; accordingly, the UK designation of EP&#8217;565 is finally revoked with no further opportunity to appeal in UK. No party sought permission to appeal the UK High Court&#8217;s judgment on the patent pledge.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The UK Court of Appeal held an oral hearing on the appeal of EP&#8217;949 on July 10-11, 2025. On August 1, 2025, the UK Court of Appeal issued a judgment agreeing with the UK High Court that EP&#8216;949 is valid, and dismissed our appeal. We applied for permission to appeal this decision to the UK Supreme Court, and on December 8, 2025, the UK Supreme Court denied permission to appeal. Accordingly, the UK designation of EP&#8216;949 is valid and infringed. However, Moderna has not yet taken steps to enforce this final judgment on infringement. Additionally, EP&#8216;949 is currently subject to opposition proceedings at the EPO. The Opposition Division initially issued a preliminary opinion noting that EP&#8216;949 is invalid, but in May 2024, issued a first-instance decision finding EP&#8216;949 valid. BioNTech and Pfizer appealed this first-instance decision. On May 29, 2026, the EPO Technical Board of Appeal issued a preliminary opinion noting that it believes EP&#8217;949 is likely invalid. The oral hearing in this appeal is scheduled for September 8-10, 2026. </font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">United States</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">U.S. District Court Litigation </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In August 2022, Moderna filed a lawsuit in the U.S. District Court for the District of Massachusetts against us and our wholly owned subsidiaries BioNTech Manufacturing GmbH and BioNTech US Inc. and Pfizer Inc. alleging Comirnaty&#8217;s infringement of U.S. Patent Nos. 10,898,574&#59; 10,702,600 and 10,933,127 and seeking monetary relief. On April 12, 2024, the U.S. District Court for the District of Massachusetts stayed the litigation pending resolution of the inter partes review of U.S. Patent Nos. 10,702,600 and 10,933,127.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Inter Partes Review</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In August 2023, Pfizer and we filed petitions seeking inter partes review of U.S. Patent Nos. 10,702,600 and 10,933,127 before the United States Patent Trial and Appeal Board, or the PTAB. On March 6, 2024, the PTAB issued decisions instituting inter partes review proceedings on all challenged claims of U.S. Patent Nos. 10,702,600 and 10,933,127. An oral hearing on the merits occurred on December 10, 2024. On March 5, 2025, the PTAB found all challenged claims of Moderna&#8217;s U.S. Patent Nos. 10,933,127 and 10,702,600 to be unpatentable and thus invalid. Moderna appealed this decision, and the appeal is pending.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">22</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Netherlands</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In September 2022, Moderna filed a lawsuit against us and our wholly owned subsidiary BioNTech Manufacturing GmbH and Pfizer B.V., Pfizer Export B.V., C.P. Pharmaceuticals International C.V. and Pfizer Inc. in the District Court of The Hague alleging Comirnaty&#8217;s infringement of EP&#8217;949 and EP&#8217;565. The District Court of the Hague held a hearing on October 6, 2023, on infringement and validity with respect to EP&#8217;949. On December 6, 2023, the Court found EP&#8217;949 to be invalid. On March 5, 2024, Moderna appealed this decision, and the appeal is pending. A hearing on the EP&#8217;949 appeal occurred on September 22, 2025, with a decision expected around September 2026. The infringement proceedings with respect to EP&#8217;565 have been withdrawn and therefore dismissed, following the EPO&#8217;s final revocation of EP&#8217;565 in January 2026.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Ireland </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In May 2023, Moderna filed a lawsuit against us and our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Inc., Pfizer Healthcare Ireland, Pfizer Ireland Pharmaceuticals, and C.P. Pharmaceuticals International C.V. alleging Comirnaty&#8217;s infringement of EP&#8217;949 and EP&#8217;565 in the High Court of Ireland. On February 26, 2024, the High Court of Ireland stayed the lawsuit pending the final determination of the EPO opposition proceedings for EP&#8217;949 and EP&#8217;565 (in each case including any appeals). </font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Belgium</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In May 2023, Moderna filed a lawsuit against us, our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Inc. and Pfizer Manufacturing Belgium alleging Comirnaty&#8217;s infringement of EP&#8217;949 and EP&#8217;565 in the Brussels Dutch-speaking Enterprise Court. On May 29, 2024, the parties filed a joint request to stay the proceedings, which was entered by the Court. On June 30, 2026, the Brussels Court confirmed the withdrawal of Moderna&#8217;s infringement proceedings with respect to EP&#8217;565 following Moderna&#8217;s request to withdraw these proceedings. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of Moderna&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Arbutus and Genevant Proceedings</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In April 2023, Arbutus Biopharma Corp., or Arbutus, and Genevant Sciences GmbH, or Genevant, filed a lawsuit against Pfizer and us in the U.S. District Court for the District of New Jersey alleging that Pfizer and we have infringed the following patents owned by Arbutus&#58; U.S. Patent Nos. 9,504,651&#59; 8,492,359&#59; 11,141,378&#59; 11,298,320&#59; and 11,318,098, through the use of Genevant&#8217;s lipid nanoparticle technology and methods for producing such lipids in Comirnaty, and seeking monetary relief. This proceeding is currently pending.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the lawsuit mentioned above. However, our analysis of </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">23</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Arbutus&#8217; and Genevant&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">GlaxoSmithKline Proceedings</font></div><div style="margin-bottom:15pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">United States</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In April 2024, GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC, or GSK, filed a lawsuit against Pfizer and us and our wholly owned subsidiaries BioNTech Manufacturing GmbH and BioNTech US Inc. in the U.S. District Court for the District of Delaware alleging that the cationic lipid used in Comirnaty infringes U.S. Patent Nos. 11,638,693&#59; 11,638,694&#59; 11,666,534&#59; 11,766,401&#59; and 11,786,467&#59; and seeking monetary relief. On August 14, 2024, GSK filed an amended complaint to assert infringement of three additional patents, U.S. Patent Nos. 11,759,422&#59; 11,655,475&#59; and 11,851,660. A trial is scheduled to occur in June 2027. This proceeding is currently pending.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Ireland</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In July 2025, GlaxoSmithKline Biologicals SA filed a lawsuit against our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Ireland Pharmaceuticals Unlimited Company, and Pfizer Healthcare Ireland Unlimited Company, alleging Comirnaty&#8217;s infringement of European Patent Nos.&#8239;2,590,626, 4,066,856, and 4,226,941 in the High Court of Ireland. This proceeding is currently pending. </font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Unified Patent Court</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In July&#8239;2025, GlaxoSmithKline Biologicals SA filed two lawsuits against BioNTech SE, BioNTech Europe GmbH, BioNTech Manufacturing GmbH, and BioNTech Manufacturing Marburg GmbH, as well as 26 Pfizer entities, in the Unified Patent Court (Hague Division). In the first lawsuit, GSK alleges Comirnaty&#8217;s infringement of European Patent No. 2,590,626, or EP&#8217;626, and in the second lawsuit, GSK alleges Comirnaty&#8217;s infringement of European Patent Nos. 4,066,856, or EP&#8217;856, and 4,226,941, or EP&#8217;941. Oral hearings wherein the UPC will hear the parties&#8217; arguments regarding infringement and invalidity of EP&#8217;626, EP&#8217;856, and EP&#8217;941 have been scheduled for September 3, 2026 and September 30-October 3,  2026. These proceedings are currently pending. </font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">United Kingdom</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In September 2025, we and Pfizer filed a revocation action against GlaxoSmithKline Biologics S.A. in the Business and Property Courts of England and Wales, in the U.K. High Court, requesting revocation of European Patent Nos.&#8239;2,590,626, 4,066,856, and 4,226,941. On October 7, 2025, GSK filed a defense and counterclaim for infringement against BioNTech SE and BioNTech Manufacturing GmbH, alleging Comirnaty&#8217;s infringement of European Patent Nos.&#8239;2,590,626, 4,066,856, and 4,226,941. A trial has been scheduled for February 2027. This proceeding is currently pending. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the lawsuit mentioned above. However, our analysis of GlaxoSmithKline&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">24</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of June 30, 2026. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Promosome Proceedings</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In January 2025, Promosome LLC, or Promosome, filed a lawsuit against us and Pfizer in the Unified Patent Court, or UPC, Munich Division, alleging that Comirnaty infringes European Patent No. 2,401,365, or EP&#8217;365, and seeking monetary relief. An oral hearing wherein the UPC heard the parties&#8217; arguments regarding infringement and invalidity was held on May 12, 2026. On July 7, 2026, the UPC issued a written decision finding EP&#8217;365 to be invalid and not infringed. This decision is appealable by Promosome.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We believe we have strong defenses against the allegations claimed relative to the patent and intend to vigorously defend ourselves in the lawsuit mentioned above. However, our analysis of Promosome&#8217;s claim is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, this matter constitutes a contingent liability as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the contingent liability.  </font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Bayer&#47;Monsanto Proceedings</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In January 2026, Bayer CropScience LLC, Monsanto Company, and Monsanto Technology, LLC, or collectively, Bayer, filed a lawsuit against us and Pfizer in the United States District Court for the District of Delaware, alleging that Comirnaty infringes U.S. Patent No. 7,741,118 and seeking monetary relief. This proceeding is currently pending.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We believe we have strong defenses against the allegations claimed relative to the patent and intend to vigorously defend ourselves in the lawsuit mentioned above. However, our analysis of Bayer&#8217;s claim is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, this matter constitutes a contingent liability as of June 30, 2026. However, it is currently impractical for us to estimate with sufficient reliability the contingent liability.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_536"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">12. Related Party Disclosures</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">ATHOS KG, Holzkirchen, Germany is the sole shareholder of AT Impf GmbH, Munich, Germany and a beneficial owner of our ordinary shares. Entities controlled by ATHOS KG mainly provide rental and property management activities and sell property, plant and equipment to us. The total amount of transactions with ATHOS KG or entities controlled by them had no significant impact on our unaudited interim condensed consolidated financial statements as of and for the three and six months ended June 30, 2026, compared to the details disclosed in Note 21 to our audited consolidated financial statements included in our Annual Report on Form 20-F as of and for the year ended December&#160;31, 2025, as amended.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">25</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="text-align:center"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Members of the Management Board and the Supervisory Board of BioNTech SE are related parties as key management personnel having authority and responsibility for planning, directing, and controlling the activities of BioNTech SE directly or indirectly. The total amount of transactions with related parties had no significant impact on our unaudited interim condensed consolidated financial statements as of and for the three and six months ended June 30, 2026, compared to the details disclosed in Note 21 to our audited consolidated financial statements included in our Annual Report on Form 20-F as of and for the year ended December&#160;31, 2025, as amended.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_542"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">13. Events after the Reporting Period</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Appointment of Guido Oelkers to Management Board as Chief Executive Officer</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">On August 3, 2026, we announced that the Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer (&#8220;CEO&#8221;), who will take office by February 1, 2027, at the latest, succeeding Prof. Ugur Sahin, M.D. Guido Oelkers is a seasoned CEO and strategic leader with over 30 years of experience in the biotechnology and pharmaceutical industries. He has a strong track record of transforming and scaling global organizations, driving sustainable growth through disciplined execution, focused capital allocation, and operational excellence. Throughout his career, Guido Oelkers has successfully built, prioritized and strengthened complex and innovative product portfolios across multiple areas, including oncology and immunology, while driving global business operations in key markets, notably in the United States. He will join us from the global Nasdaq Stockholm-listed biopharmaceutical company Swedish Orphan Biovitrum AB (&#8220;Sobi&#8221;), where he has served as CEO since 2017.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Genevant&#47;Arbutus Proceedings</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Canada </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In July 2026, Arbutus and Genevant filed a lawsuit against Pfizer, BioNTech SE, and certain of their affiliates in the Federal Court of Canada, alleging that COMIRNATY</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">infringes Canadian Patent No. 2,721,333.  This proceeding is currently pending.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Unified Patent Court </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In July 2026, Arbutus and Genevant filed two lawsuits against Pfizer, BioNTech SE, and certain of their affiliates in the Unified Patent Court. In the first lawsuit, Arbutus and Genevant allege that COMIRNATY</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">infringes European Patent No. 4,241,767, and in the second lawsuit, Arbutus and Genevant allege that COMIRNATY</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">infringes European Patent No.  4,495,237. These proceedings are currently pending. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We believe we have strong defenses against the allegations claimed relative to the patents and intend to vigorously defend ourselves in the lawsuits mentioned above. However, our analysis of Arbutus&#8217; and Genevant&#8217;s claims is ongoing and complex, and we believe the outcomes of the suits remains substantially uncertain.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">26</font></div></td></tr></table></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1131"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:56pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:20pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Operating and Financial Review and Prospects</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In this report, unless stated or the context otherwise requires, references to the &#8220;Company&#8221;, &#8220;BioNTech&#8221;, &#8220;Group&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to BioNTech SE and its consolidated subsidiaries. The following &#8220;Operating and Financial Review and Prospects&#8221; should be read together with the unaudited interim condensed consolidated financial statements and related notes as presented above. The following discussion is based on our financial information prepared in accordance with the IFRS Accounting Standards, or IFRS, as issued by the International Accounting Standards Board, which may differ in material respects from generally accepted accounting principles in other jurisdictions, including U.S. GAAP. The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those described in the &#8220;Risk Factors&#8221; section further below. Please also see &#8220;Forward-Looking Statements&#8221; included elsewhere in this quarterly report for the three and six months ended June 30, 2026. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_3705"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Corporate Developments</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Appointment of Guido Oelkers to Management Board as Chief Executive Officer</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">On August 3, 2026, we announced that the Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer (&#8220;CEO&#8221;), who will take office by February 1, 2027, at the latest, succeeding Prof. Ugur Sahin, M.D. Guido Oelkers is a seasoned CEO and strategic leader with over 30 years of experience in the biotechnology and pharmaceutical industries. He has a strong track record of transforming and scaling global organizations, driving sustainable growth through disciplined execution, focused capital allocation, and operational excellence. Throughout his career, Guido Oelkers has successfully built, prioritized and strengthened complex and innovative product portfolios across multiple areas, including oncology and immunology, while driving global business operations in key markets, notably in the United States. He will join us from the global Nasdaq Stockholm-listed biopharmaceutical company Swedish Orphan Biovitrum AB (&#8220;Sobi&#8221;), where he has served as CEO since 2017.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Expansion of the Supervisory Board</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are strengthening our focus on our growing late-stage oncology pipeline, while continuing our discovery and early research aimed at long-term innovation. Consequently, at our Annual General Meeting, or AGM, which took place on May 15, 2026, our shareholders approved expanding the Supervisory Board from six to eight members and adding additional expertise&#58; Prof. Iris L&#246;w-Friedrich, M.D., Ph.D., and Susanne Schaffert, Ph.D., were elected as new members of the Supervisory Board.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Iris L&#246;w-Friedrich has many years of expertise in the field of clinical development and broad experience in the scientific and medical fields. She also possesses knowledge in the areas of sales and commercialization, management, innovation, and international markets relevant to the Company. She is an experienced Supervisory Board member and adjunct professor of internal medicine at the faculty of medicine at Goethe University in Frankfurt am Main, Germany.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">27</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Susanne Schaffert is a member of supervisory boards in the healthcare sector, including that of Merck KGaA. She possesses particular expertise in the field of oncology as well as in sales and commercialization with a focus on product launches. Her knowledge spans innovation, research and development, and organizational leadership and management. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Additionally, shareholders approved the extension of the mandates of our Supervisory Board members Helmut Jeggle, Prof. Anja Morawietz, Ph.D., and Prof. Rudolf Staudigl, Ph.D. At a meeting held following the AGM, the Supervisory Board elected Helmut Jeggle as its Chairman.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">All resolutions proposed on the agenda items put to the vote at our AGM were approved by a majority of the shareholders.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Update on Negotiations with Co-Founders-Led New Company</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In March 2026, we announced plans for an independent company to be established and led by BioNTech co-founders Prof. Ugur Sahin, M.D., and Prof. &#214;zlem T&#252;reci, M.D. As of August 2026, discussions regarding the new company and potential contributions by BioNTech are ongoing. BioNTech's guiding principle in the negotiations is to maximize value for both patients and shareholders.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_547"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Operating Results</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_581"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Overview</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are a global next-generation immunotherapy company aiming to pioneer novel medicines against cancer, infectious diseases and other serious diseases. Since our founding in 2008, we have focused on harnessing the power of the immune system to address human diseases with unmet medical needs and major global health burdens. Our fully integrated model combines decades of research in immunology with a multi-technology innovation engine, GMP manufacturing, translational drug discovery, clinical development, commercial capabilities, computational medicine, data science and artificial intelligence, or AI, and machine learning, or ML, capabilities to discover, develop and commercialize our marketed product and product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We have built a broad toolkit across multiple technology platforms, including a diverse range of potentially first-in-class therapeutic approaches. This includes investigational messenger ribonucleic acid, or mRNA immunotherapies and protein-based therapeutics (including targeted antibodies such as monoclonal, bispecific and antibody-drug conjugates, or ADCs).</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our multi-technology combination of platforms and product candidates aims to position us as pioneers in the field of individualized, patient-centric therapeutic approaches in oncology and infectious diseases. We believe that by combining complementary treatment modalities, we can leverage the potential of each technology to provide precise and personalized treatments to patients. Such treatments, if approved, could both increase the likelihood of therapeutic success and reduce the risk of therapeutic resistance.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our primary focus is oncology, where we endeavor to address the full continuum of cancer from early to late disease stages. The root causes of cancer treatment failure are cancer heterogeneity and interindividual variability. Driven by random sequential mutations, every patient&#8217;s cancer is different and within one patient&#8217;s tumor, every cell is different. Addressing these two challenges is the core of </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">28</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">our strategy. To augment anti-tumor activity and to counteract resistance mechanisms, we seek to combine compounds with non-overlapping, potentially synergistic mechanisms of action.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In infectious diseases, our goal is to develop vaccines and therapeutics caused by respiratory viruses, latent viruses, bacteria and parasites. We believe our scientific approach and our mRNA technology have the potential to significantly contribute to the fight against global health threats caused by infectious diseases. We have pursued both strategic partnerships and corporate collaborations to partially fund our infectious disease global health programs and aim to continue to do so. Our infectious disease programs aim to contribute to equitable access to innovative vaccines for high medical need indications.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our approach has generated a robust and diversified product candidate pipeline across a range of technologies in oncology and infectious disease, and has led to the approval of our first marketed pharmaceutical product, </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Comirnaty</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">. Innovation is at the core of our company, and we see potential for our technologies to expand beyond oncology and infectious diseases.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1509"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Environmental, Social, and Governance (ESG) </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">BioNTech was founded out of a responsibility to patients and to society and this is still the vision that drives the Company. It gives grounds for our enhanced responsibility&#58; for translating the Company&#8217;s science into the health of people worldwide and contributing to equitable access to vaccines, for environmental and climate protection, for respecting human rights and for fostering the full potential of all employees. We recognize our responsibility as a corporate citizen and are committed to supporting our local communities and beyond through donations, sponsorships and volunteer activities. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our performance on environmental, social, and governance matters is regularly assessed by external rating agencies. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We retained our &#8220;Prime&#8221; status from ISS ESG in the assessment for 2025. ISS ESG is a provider of ESG screening, ratings and analytics services and part of the Institutional Shareholder Services Group (ISS). Since 2022, ISS ESG has consistently awarded us &#8220;Prime&#8221; status, placing us in the top 10% of all companies rated in the Pharmaceuticals and Biotechnology sector. We maintained our overall rating of B in the overall Corporate Rating 2025 on a scale from D- (lowest rating) to A+ (highest rating). Following a revision to ISS ESG's rating methodology and weighting criteria, our overall Corporate Rating was updated to B- effective May 2026, a level subsequently confirmed in both June and July 2026. In the ISS ESG QualityScore, we achieved an Environment Score of 2 and a Social Score of 1. These scores indicate a company&#8217;s transparency with a focus on social and environmental matters on a scale from 1 (high disclosure) to 10 (low disclosure). Furthermore, we received a score of 5 in the &#34;Governance&#8221; dimension of the ISS Quality Score on a risk scale ranging from 1 (low risk) to 10 (high risk).</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We received 50 out of 100 possible points in the 2025 S&#38;P CSA</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> (2024&#58; 52&#47;100). Since 2022, we have been actively engaging in the comprehensive S&#38;P CSA rating process and has been listed as a participating company.</font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:198pt"></div><div style="margin-bottom:4pt;padding-left:7.37pt;text-align:justify;text-indent:-7.37pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:140%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:140%">&#160;&#160;&#160;&#160;BioNTech SE's last governance data profile update, Jun 11, 2026. Last E&#38;S data profile update, May 26, 2026</font></div><div style="margin-bottom:4pt;padding-left:7.37pt;text-align:justify;text-indent:-7.37pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:140%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:140%">&#160;&#160;&#160;&#160;Results were released on July 30, 2025. Last updated&#58; December 12, 2025.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">29</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In May 2025, we received an ESG Risk Rating of 21.4</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> by the rating agency Morningstar Sustainalytics and were assessed to be at medium risk of experiencing material financial impacts from ESG factors (2024&#58; 25.9, medium risk). The score corresponds to the third level of a five-level risk scale (negligible, low, medium, high and severe). BioNTech ranks among the top 10% of biotechnology companies in this rating. The rating measures the extent to which the economic value of a company is at risk due to ESG factors. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our Corporate Sustainability &#38; Responsibility, or CSR, Management, is presented in detail in the separate 2025 Sustainability Report and made available online at www.biontech.com. More information about our performance in selected ESG ratings, our Human Rights Statement as well as further relevant information and material can also be found on our website. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_560"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Marketed Product&#58; Comirnaty, our COVID-19 Vaccine Program (BNT162) </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">COVID-19 vaccination has played an important role in saving lives and livelihoods across the world. Our commercial product, developed in 2020, Comirnaty, was the first-ever approved mRNA-based product, and, to our knowledge, remains the fastest ever developed prophylactic vaccine from viral sampling to approval. Our efforts have resulted in over 5 billion doses shipped globally since first approval to date.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Under our collaboration with Pfizer, we are the Marketing Authorization Holder in the United States, the European Union, or EU, the UK, Canada and other countries. Pfizer has marketing and distribution rights worldwide apart from Greater China, Germany, and T&#252;rkiye. We have the marketing and distribution rights to Comirnaty in Germany and T&#252;rkiye.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Under our collaboration with Fosun Pharmaceutical Industrial Development, Co., Ltd, or Fosun Pharma, Fosun Pharma has marketing and distribution rights in Mainland China, Hong Kong Special Administrative Region, or SAR, Macau SAR and Taiwan region.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">A. Commercial Updates</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We expect that as SARS-CoV-2 continues to evolve, and the risk of severe COVID-19 disease and deaths persists, there will be continued demand for primary and seasonal vaccinations, especially for at-risk and immunocompromised populations. Studies have demonstrated that natural immunity acquired by SARS-CoV-2 infection is variable across individuals and wanes over time due to viral escape mutations and decreasing antibody titers. The risk of severe COVID-19 disease remains high in vulnerable populations. Vaccination not only reduces the risk of severe COVID-19 but may also mitigate the risk of health impairments related to COVID-19. Given this, and our current understanding of COVID-19&#8217;s burden on healthcare systems during the fall and winter season, along with its observed peaks at other times of the year, we anticipate the need for annual adapted vaccines to be a long-term component of COVID-19 vaccination practices.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In 2026, we have been, and expect to continue, preparing for COVID-19 vaccine adaptation and, pending regulatory approval, commercial launch ahead of the upcoming 2026-2027 fall and winter season.</font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:198pt"></div><div style="margin-bottom:4pt;padding-left:7.37pt;text-align:justify;text-indent:-7.37pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:140%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:140%">&#160;&#160;&#160;&#160;The latest update to the score was issued on September 23, 2025&#59; the full rating update was issued on May 29, 2025.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">30</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">B. Clinical Development, Regulatory and Manufacturing Updates</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In May 2026, the WHO, EMA and FDA each issued recommendations to update the antigenic composition of authorized COVID-19 vaccines for the 2026-2027 vaccination season. The WHO advised manufacturers that monovalent LP.8.1 is the recommended vaccine antigen, while other antigens (e.g. XFG, NB.1.8.1) or other approaches that demonstrate broad and robust neutralizing antibody responses or efficacy against currently circulating SARS-CoV-2 variants could also be used. The EMA recommended updating COVID-19 vaccines to target the XFG variant of the JN.1 family of Omicron subvariants for the 2026-2027 vaccination campaign, and that other JN.1 recent descendant viruses including LP.8.1 could also be considered. The FDA has advised the manufacturers of the approved COVID-19 vaccines that to more closely match currently circulating SARS-CoV-2 viruses, the COVID-19 vaccines (2026-2027 Formula) for use in the United States beginning in fall 2026 should be a monovalent JN.1 lineage XFG variant vaccine.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In June 2026, we submitted a marketing authorization application to the EMA and a supplemental Biologics License Application to FDA for our Omicron XFG variant-adapted monovalent COVID-19 vaccine.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In July 2026, BioNTech and Pfizer&#8217;s Omicron XFG variant-adapted monovalent COVID-19 vaccine was approved by the European Commission following recommendation for marketing authorization by the EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_255086697647393"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Pipeline of Product Candidates&#58; Second Quarter of 2026 and Post Period-End Updates</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Below is a summary of active clinical trials evaluating our product and clinical product candidates, organized by platform and indication.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">31</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Oncology</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.15pt;font-weight:400;letter-spacing:0.04em;line-height:110%;position:relative;top:-3.85pt;vertical-align:baseline">1,2</font></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.171%"><tr><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.04em;line-height:120%">Phase 1</font></td><td colspan="6" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.04em;line-height:120%">Phase 1&#47;2</font></td><td colspan="6" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.04em;line-height:120%">Phase 2</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.04em;line-height:120%">Phase 2&#47;3</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.04em;line-height:120%">Phase 3</font></td></tr><tr><td colspan="3" style="background-color:#dcddb2;border-left:1pt solid #ffffff;border-top:1pt solid #0f7f40;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT116<br>Adv. NSCLC</font></td><td colspan="3" style="background-color:#9dcab9;border-left:3pt solid #ffffff;border-top:1pt solid #0f7f40;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT3214<br>Multiple solid tumors</font></td><td colspan="3" style="background-color:#cddee1;border-left:1pt solid #ffffff;border-top:1pt solid #0f7f40;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%"> + BNT314&#47;GEN1059</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">9</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Met. CRC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">4</font></div></td><td colspan="3" style="background-color:#dcddb2;border-left:3pt solid #ffffff;border-top:1pt solid #0f7f40;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Autogene cevumeran</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">6</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Adj. CRC</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:1pt solid #ffffff;border-top:1pt solid #0f7f40;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">2L+ EGFRm NSCLC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">11</font></div></td><td colspan="3" style="background-color:#dcddb2;border-left:3pt solid #ffffff;border-top:1pt solid #0f7f40;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT113<br>1L HPV16+ HNSCC</font></td><td colspan="3" style="background-color:#9dcab9;border-left:3pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #0f7f40;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Elfetabart drozuntecan</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">5</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L met. CRPC</font></div></td></tr><tr><td colspan="3" style="background-color:#9dcab9;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT211<br>Multiple solid tumors</font></td><td colspan="3" style="background-color:#9dcab9;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Elfetabart drozuntecan</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">5</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Multiple solid tumors</font></div></td><td colspan="3" style="background-color:#cddee1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%"> + BNT3212</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Multiple solid tumors</font></div></td><td colspan="3" style="background-color:#dcddb2;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Autogene cevumeran</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">6</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Adj. PDAC</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">2L Glioblastoma</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">11</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L met. CRC</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Gotistobart</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">7</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Met. NSCLC</font></div></td></tr><tr><td colspan="3" style="background-color:#99bdc1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT314&#47;GEN1059</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">9</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Multiple solid tumors</font></div></td><td colspan="3" style="background-color:#9dcab9;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Sacituzumab drozuntecan</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">5</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Multiple solid tumors</font></div></td><td colspan="3" style="background-color:#cddee1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%"> + BNT3213</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L HCC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">4,11</font></div></td><td colspan="3" style="background-color:#dcddb2;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT116</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">10</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L adv. NSCLC</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L HCC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">11</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L adv.&#47;met. Gastric</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L ES-SCLC</font></div></td></tr><tr><td colspan="3" style="background-color:#99bdc1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT317<br>Multiple solid tumors</font></td><td colspan="3" style="background-color:#9dcab9;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT329<br>Multiple solid tumors</font></td><td colspan="3" style="background-color:#cddee1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%"> + Elfetabart drozuntecan</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">5</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Adv.&#47;met. NSCLC and SCLC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">4</font></div></td><td colspan="3" style="background-color:#9dcab9;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT326&#47;YL202</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">8</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Multiple solid tumors</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">11</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L MPM</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">11</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L NSCLC</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L adv. NSCLC</font></div></td></tr><tr><td colspan="3" style="background-color:#9dcab9;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT326&#47;YL202</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">8</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Multiple solid tumors</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Gotistobart</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">7</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Met. CRPC</font></div></td><td colspan="3" style="background-color:#cddee1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%"> + Sacituzumab drozuntecan</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">5</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Multiple solid tumors</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">4</font></div></td><td colspan="3" style="background-color:#9dcab9;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT326&#47;YL202</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">8</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Adv.&#47;met. BC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">.11</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">2L NEN</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">11</font></div></td><td colspan="3" style="border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Unresectable Stage III NSCLC</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Gotistobart</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">7</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Multiple solid tumors</font></div></td><td colspan="3" style="background-color:#cddee1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%"> +</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT326&#47;YL202</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">8</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Multiple solid tumors</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Gotistobart</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">7</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">PROC</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">2L adv.&#47;met. NSCLC</font></div></td><td colspan="3" style="border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">2L SCLC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">11</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L adv. HCC</font></div></td><td colspan="3" style="background-color:#cddee1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%"> +</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT326&#47;YL202</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">8</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Adv. NSCLC</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L met. CRC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">11</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L met. PDAC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">11</font></div></td><td colspan="3" style="border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L TNBC</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Adv. RCC</font></div></td><td colspan="3" style="background-color:#cddee1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%"> + Trastuzumab pamirtecan</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">5</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Adv.&#47;met. BC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">4</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L ES-SCLC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">11</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L&#47;2L adv.&#47;met. TNBC</font></div></td><td colspan="3" style="border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L adv.&#47;met.TNBC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">11</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Multiple solid tumors</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">11</font></div></td><td colspan="3" style="background-color:#9dcab9;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Trastuzumab pamirtecan</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">5</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Multiple solid tumors</font></div></td><td colspan="3" style="background-color:#99bdc1;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L&#47;2L+ ES-SCLC</font></div></td><td colspan="3" style="background-color:#cddee1;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%"> or Sacituzumab drozuntecan</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">5</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%"> + Elfetabart drozuntecan</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">5</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Multiple solid tumors</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">4</font></div></td><td colspan="3" style="border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#9dcab9;border-left:3pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Trastuzumab pamirtecan</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">5</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Met. BC</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#99bdc1;border-bottom:1pt solid #ffffff;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">1L adv.&#47;met. TNBC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">11</font></div></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#99bdc1;border-bottom:1pt solid #ffffff;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Pumitamig</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">3</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">2L ES-SCLC</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">11</font></div></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#9dcab9;border-bottom:1pt solid #ffffff;border-left:3pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Trastuzumab pamirtecan</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">5</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">2L EC</font></div></td></tr></table></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.076%"><tr><td style="width:1.0%"></td><td style="width:15.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.302%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Next generation immunomodulator</font></td><td colspan="3" style="background-color:#99bdc1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Targeted therapy</font></td><td colspan="3" style="background-color:#9dcab9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">mRNA cancer immunotherapy</font></td><td colspan="3" style="background-color:#dcddb2;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Novel-novel combination</font></td><td colspan="3" style="background-color:#cddee1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Infectious Diseases</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.15pt;font-weight:400;letter-spacing:0.04em;line-height:110%;position:relative;top:-3.85pt;vertical-align:baseline">1,2</font></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.179%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.04em;line-height:120%">Phase 1</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.04em;line-height:120%">Phase 1&#47;2</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.04em;line-height:120%">Phase 2</font></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.04em;line-height:120%">Commercial</font></td></tr><tr><td colspan="3" style="background-color:#dcddb2;border-top:1pt solid #0f7f40;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT163</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">12</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">HSV</font></div></td><td colspan="3" style="background-color:#dcddb2;border-left:3pt solid #ffffff;border-top:1pt solid #0f7f40;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT162 + BNT161</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">13</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">COVID-19 - Influenza combination</font></div></td><td colspan="3" style="background-color:#dcddb2;border-left:3pt solid #ffffff;border-top:1pt solid #0f7f40;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT166</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">16</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Mpox</font></div></td><td colspan="3" style="background-color:#dcddb2;border-left:3pt solid #ffffff;border-top:1pt solid #0f7f40;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT162</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">13,14</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">COVID-19</font></div></td></tr><tr><td colspan="3" style="background-color:#9dcab9;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT351<br>HIV</font></td><td colspan="3" style="background-color:#dcddb2;border-left:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">BNT164</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:3.9pt;font-weight:400;letter-spacing:0.02em;line-height:140%;position:relative;top:-2.1pt;vertical-align:baseline">15</font></div><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Tuberculosis</font></div></td><td colspan="3" style="border-left:3pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:3pt solid #ffffff;border-right:3pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.919%"><tr><td style="width:1.0%"></td><td style="width:20.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">Antibody</font></td><td colspan="3" style="background-color:#9dcab9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6pt;font-weight:400;letter-spacing:0.02em;line-height:140%">mRNA</font></td><td colspan="3" style="background-color:#dcddb2;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;For further details about BioNTech&#8217;s rights, see elsewhere in this Quarterly Report.</font></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Abbreviations are defined in the corresponding trial descriptions.</font></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Partnered with Bristol Myers Squibb.</font></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Trial is currently being conducted by or on behalf of BioNTech. Bristol Myers Squibb holds co-exclusive rights to pumitamig.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">32</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(5)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Partnered with DualityBio.</font></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(6)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Partnered with Genentech, a member of the Roche Group.</font></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(7)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Partnered with OncoC4.</font></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(8)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Partnered with MediLink Therapeutics.</font></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(9)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Partnered with Genmab.</font></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(10)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;In collaboration with Regeneron.</font></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(11)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Trial ongoing in China only.</font></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(12)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Partnered with University of Pennsylvania.</font></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(13)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Partnered with Pfizer.</font></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(14)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Partnered with Fosun Pharma.</font></div><div style="margin-bottom:4pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(15)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Funded by the Gates Foundation.</font></div><div style="margin-bottom:16pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(16)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Funded by the Coalition for Epidemic Preparedness Innovations (CEPI).</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">A. Oncology Programs </font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">1. Pumitamig (BNT327&#47;BMS986545), a Bispecific Immunomodulator Candidate Targeting PD-L1 and VEGF-A</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Pumitamig is a bispecific immunomodulator candidate targeting both PD-L1 and VEGF-A. Pumitamig is currently being evaluated in multiple Phase 2 and Phase 3 global and China-only clinical trials to assess its efficacy and safety as monotherapy or in combination with chemotherapy, ADCs, other immunomodulators or mRNA-based cancer immunotherapies in various indications. We and our partner, BMS, currently have seven global registrational trials for pumitamig ongoing. Pumitamig is also being evaluated in combination with next-generation ADC candidates trastuzumab pamirtecan (BNT323&#47;DB-1303), elfetabart drozuntecan (BNT324&#47;DB-1311), sacituzumab drozuntecan (BNT325&#47;DB-1305), BNT326&#47;YL202, BNT3212, and in combination with bispecific antibody candidates BNT314&#47;GEN1059 and BNT3213. In addition, Pumitamig is being evaluated in a growing number of third-party-led combination trials alongside both approved and investigational agents, including a BMS-led clinical trial evaluating the combination of pumitamig and BMS' partnered asset izalontamab brengitecan (iza-bren).</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">ROSETTA Lung-01 Phase 3 Clinical Trial in First-Line Extensive-Stage Small Cell Lung Cancer, or ES-SCLC </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A global Phase 3 clinical trial (NCT06712355) is being conducted to evaluate pumitamig in combination with chemotherapy compared to atezolizumab in combination with chemotherapy as a first-line treatment for patients with ES-SCLC.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 3 Clinical Trial in Second-Line Small-Cell Lung Cancer, or SCLC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 3 clinical trial (NCT06616532) is being conducted in China to evaluate pumitamig in combination with chemotherapy compared to investigator&#8217;s choice chemotherapy as a second-line treatment for patients with SCLC. Enrollment has been terminated and follow-up of patients will continue.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 2 Clinical Trial in ES-SCLC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A global Phase 2 clinical trial (NCT06449209) is being conducted to evaluate pumitamig in combination with chemotherapy in patients with untreated ES-SCLC and in patients with SCLC that progressed after first- or second-line treatment. The trial is fully enrolled and treatment is ongoing.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">A subgroup analysis in patients with brain metastases from this trial is expected to be presented at the European Society for Medical Oncology, or ESMO, Congress 2026 in Madrid, Spain.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">33</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 2 Clinical Trial in First-Line ES-SCLC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 2 clinical trial (NCT05844150) is being conducted in China to evaluate pumitamig in combination with chemotherapy as a first-line treatment for patients with ES-SCLC.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 2 Clinical Trial in Second-Line SCLC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 2 clinical trial (NCT05879068) is being conducted in China to evaluate pumitamig in combination with chemotherapy as a second-line treatment for patients with SCLC.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">ROSETTA Lung-02 Phase 2&#47;3 Clinical Trial in First-Line Non-Small Cell Lung Cancer, or NSCLC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A global Phase 2&#47;3 clinical trial (NCT06712316) is being conducted to evaluate pumitamig in combination with chemotherapy compared to pembrolizumab and chemotherapy as a first-line treatment for patients with NSCLC. The global Phase 3 portion of the trial is underway following completion of the global Phase 2 portion of the trial.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">In May 2026, interim data from the Phase 2 part of the trial were presented at the American Society of Clinical Oncology, or  ASCO, Annual Meeting 2026. The data showed encouraging anti-tumor activity, with high response rates observed in both non-squamous and squamous NSCLC and across PD-L1 expression levels.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">ROSETTA Lung-201 Phase 3 Clinical Trial in Unresectable Stage III  NSCLC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A global Phase 3 clinical trial (NCT07361497) is being conducted to evaluate pumitamig compared to durvalumab following concurrent chemoradiation therapy in patients with unresectable stage III NSCLC.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">ROSETTA Lung-202 Phase 3 Clinical Trial in First-Line NSCLC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A global Phase 3 clinical trial (NCT07361510) is being conducted to evaluate pumitamig compared to pembrolizumab as a first-line treatment for patients with advanced PD-L1 &#8805; 50% NSCLC.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">ROSETTA Lung-107 Phase 2 Clinical Trial in Second-Line NSCLC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A global Phase 2 clinical trial (NCT06841055) is being conducted to evaluate pumitamig in combination with docetaxel as a second-line treatment for patients with NSCLC.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 2 Clinical Trial in EGFR-mutant Non-Squamous NSCLC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 2 clinical trial (NCT05756972) is being conducted in China to evaluate pumitamig in combination with chemotherapy in patients with EGFR-mutant non-squamous NSCLC who progressed after EGFR-tyrosine kinase inhibitor treatment.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">ROSETTA Breast-01 Phase 3 Clinical Trial in Locally Advanced or Metastatic First-Line Triple-Negative Breast Cancer, or TNBC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A global Phase 3 clinical trial (NCT07173751) is being conducted to evaluate pumitamig in combination with chemotherapy compared to chemotherapy alone as a first-line treatment for patients with locally advanced or metastatic PD-L1 negative TNBC.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">34</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 3 Clinical Trial in Locally Advanced or Metastatic First-Line TNBC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 3 clinical trial (NCT06419621) is being conducted in China to evaluate pumitamig in combination with chemotherapy compared to chemotherapy alone as a first-line treatment for patients with locally advanced or metastatic TNBC.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">In July 2026, the trial completed enrollment.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Based on current event accrual projections, the expected timing of the first interim data from this trial has been updated from 2026 to 2027.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 2 Clinical Trial in Locally Advanced or Metastatic TNBC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A global Phase 2 clinical trial (NCT06449222) is being conducted to evaluate pumitamig in combination with chemotherapy as a first- and second-line treatment for patients with locally advanced or metastatic TNBC.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">A subgroup analysis in patients with brain metastases from this trial is expected to be presented at the ESMO Congress 2026.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 1&#47;2 Clinical Trial in Locally Advanced or Metastatic TNBC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT05918133) is being conducted in China to evaluate pumitamig in combination with chemotherapy in patients with locally advanced or metastatic TNBC without previous systematic treatment.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">ROSETTA CRC-203 Phase 2&#47;3 Clinical Trial in Metastatic First-Line MSS Colorectal Cancer, or CRC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A global Phase 2&#47;3 clinical trial (NCT07221357) is being conducted to evaluate pumitamig as a first-line treatment for patients with microsatellite stable, or MSS, in combination with different CT regimens compared to standard of care or microsatellite instability-low and proficient mismatch repair, or MSI-L&#47;pMMR, metastatic colorectal cancer.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">A trial-in-progress poster was presented at the ASCO Annual Meeting 2026.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 2 Clinical Trial in Metastatic First-Line CRC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 2 clinical trial (NCT07133750) is being conducted in China to evaluate pumitamig in combination with chemotherapy as a first-line treatment in patients with MSS or MSI-L&#47;pMMR metastatic colorectal cancer.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">The expected timing of data from this trial has been updated from 2026 to 2027.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">ROSETTA Gastric-204 Phase 2&#47;3 Clinical Trial in Metastatic First-Line Gastric Cancer</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A global Phase 2&#47;3 clinical trial (NCT07221149) is being conducted to evaluate pumitamig in combination with chemotherapy compared to nivolumab in combination with chemotherapy as a first-line treatment for patients with metastatic gastric cancer.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">35</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 2 Clinical Trial in First-Line Hepatocellular Carcinoma, or HCC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 2 clinical trial (NCT05864105) is being conducted in China to evaluate pumitamig in combination with chemotherapy as a first-line treatment for patients with unresectable HCC.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">We expect data from this trial in 2026.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">ROSETTA HCC-206 Phase 1&#47;2 Clinical Trial in First-Line HCC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT07291076) is being conducted to evaluate pumitamig alone or in combination with ipilimumab as a first-line treatment for patients with advanced or unresectable HCC.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 2 Clinical Trial in First-Line Malignant Mesothelioma</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 2 clinical trial (NCT05918107) is being conducted in China to evaluate pumitamig in combination with chemotherapy as a first-line treatment for patients with malignant mesothelioma.</font></div><div style="padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="background-color:#ffffff;color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Data from this trial are expected to be presented at the IASLC 2026 World Conference on Lung Cancer, or WCLC 2026, in Seoul, South Korea.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 2 Clinical Trial in Second-Line Neuroendocrine Neoplasm, or NEN</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 2 clinical trial (NCT05879055) is being conducted in China to evaluate pumitamig in combination with chemotherapy as a second-line treatment for patients with NEN.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Data from this trial are expected to be presented at the ESMO Congress 2026.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 2 Clinical Trial in First-Line Pancreatic Ductal Adenocarcinoma, or PDAC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 2 clinical trial (NCT07255404) is being conducted in China to evaluate pumitamig in combination with chemotherapy as a first-line treatment for patients with metastatic PDAC.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 2 Clinical Trial in Second-Line Glioblastoma</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 2 clinical trial (NCT07297212) is being conducted in China to evaluate pumitamig alone or in combination with temozolomide as a second-line treatment for patients with recurrent glioblastoma.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">ROSETTA RCC-208 Phase 1&#47;2 Clinical Trial in Renal Cell Carcinoma, or RCC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT07293351) is being conducted to evaluate pumitamig alone or in combination with ipilimumab or cabozantinib in patients with advanced RCC.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 1&#47;2 Clinical Trial in Advanced Solid Tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT05918445) is being conducted in China to evaluate pumitamig as a monotherapy in patients with advanced solid tumors.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We have initiated several signal-seeking clinical trials to evaluate pumitamig in combination with some of our proprietary, novel assets in our portfolio&#58;</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Combination with Trastuzumab Pamirtecan (BNT323&#47;DB-1303) Phase 1&#47;2 Clinical Trial in Advanced&#47;Metastatic Breast Cancer</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT06827236) is being conducted to evaluate trastuzumab pamirtecan in combination with pumitamig in patients with hormone receptor-positive (HR+) or hormone receptor-</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">36</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">negative (HR-), human epidermal growth factor (HER)2-low, ultra-low, or null advanced metastatic breast cancer or TNBC.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Preliminary data from this trial are expected to be presented at the ESMO Congress 2026.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Combination with Elfetabart Drozuntecan (BNT324&#47;DB-1311) Phase 1&#47;2 Clinical Trial in Advanced Lung Cancers</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT06892548) is being conducted to evaluate elfetabart drozuntecan (BNT324&#47;DB-1311) in combination with pumitamig in patients with advanced lung cancers.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">We expect data from this trial in 2026.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Combination with Elfetabart Drozuntecan (BNT324&#47;DB-1311) Phase 2 Clinical Trial in Advanced&#47;Metastatic Solid Tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 2 clinical trial (NCT06953089) is being conducted to evaluate elfetabart drozuntecan (BNT324&#47;DB-1311) in combination with pumitamig or the TROP2 ADC candidate sacituzumab drozuntecan (BNT325&#47;DB-1305) in patients with advanced solid tumors.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Data from this trial are expected to be presented at the ESMO Congress 2026.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Combination with Sacituzumab Drozuntecan (BNT325&#47;DB-1305) Phase 1&#47;2 Clinical Trial in Advanced Solid Tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT05438329) is being conducted to evaluate sacituzumab drozuntecan in patients with advanced solid tumors. As part of this clinical trial, pumitamig is being evaluated in combination with sacituzumab drozuntecan in various solid tumor indications. </font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Data from the Phase 2 part of this trial in patients with TNBC were presented at the ESMO Breast Cancer Annual Congress 2026. Pumitamig in combination with sacituzumab drozuntecan was observed to result in encouraging clinical activity, while being well tolerated with a manageable safety profile.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Combination with BNT326&#47;YL202 Phase 1&#47;2 Clinical Trial in Advanced Solid Tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT07070232) is being conducted to evaluate BNT326&#47;YL202 as monotherapy and in combination with pumitamig in advanced solid tumors.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">A trial-in-progress poster was presented at the ASCO Annual Meeting 2026.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Combination with BNT326&#47;YL202 Phase 1&#47;2 Clinical Trial in Advanced NSCLC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT07111520) is being conducted to evaluate BNT326&#47;YL202 in combination with pumitamig in advanced NSCLC.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">The expected timing of data from this trial in patients with NSCLC or 2L+ EGFRm NSCLC has been updated from 2026 to 2027.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Combination with BNT314&#47;GEN1059 Phase 1&#47;2 Clinical Trial in Advanced&#47;Metastatic CRC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT07079631) is being conducted to evaluate BNT314&#47;GEN1059 in combination with pumitamig and chemotherapy in patients with advanced CRC.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">37</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Combination with BNT3212 Phase 1&#47;2 Clinical Trial in Advanced Solid Tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT07147348) is being conducted to evaluate BNT3212, a novel bispecific antibody-drug conjugate candidate targeting EGFR and HER3, for use as monotherapy and in combination with pumitamig in patients with advanced solid tumors.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Combination with BNT3213 Phase 1&#47;2 Clinical Trial in First-Line HCC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT06584071) is being conducted in China to evaluate pumitamig in combination with BNT3213, a novel bispecific antibody candidate targeting TIGIT and PVRIG, as a first-line treatment for patients with locally advanced or metastatic HCC.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 1b&#47;2 Clinical Trial in ES-SCLC in Collaboration with Boehringer Ingelheim</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1b&#47;2 clinical trial to evaluate the safety, tolerability and early clinical activity of pumitamig in combination with obrixtamig (BI 764532), Boehringer Ingelheim&#8217;s investigational DLL3&#47;CD3 T&#8209;cell engager, in ES-SCLC is planned to start in 2026.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We, together with our partner BMS, are initiating other Phase 1 signal-seeking, novel-novel trials of pumitamig with internal or BMS proprietary assets, and various Medical Evidence Generation studies with key opinion leaders are being planned. </font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">2. iNeST and FixVac</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">a) Autogene Cevumeran (RO7198457&#47;BNT122), an Individualized Neoantigen Specific Immunotherapy, or iNeST</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Autogene cevumeran is an investigational individualized mRNA cancer immunotherapy based on specific neoantigens that are present on a patient&#8217;s tumor.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">BNT122-01 Phase 2 Clinical Trial in Adjuvant CRC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A randomized Phase 2 clinical trial (NCT04486378) is being conducted to evaluate autogene cevumeran as an adjuvant treatment of circulating tumor DNA, or ctDNA, positive, surgically resected Stage II (high risk)&#47;Stage III CRC compared to watchful waiting after surgery and chemotherapy, which is the current standard of care for these high-risk patients. The primary endpoint for the trial is disease-free survival, or DFS. Secondary objectives include overall survival, or OS, and safety.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">In April 2026, the trial completed enrollment.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">In June 2026, a pre-specified interim analysis based on the primary endpoint of DFS (centrally assessed) was performed and the independent Data Safety Monitoring Board, or DSMB, recommended continuing the trial without modification. Thus, the clinical trial is expected to continue as planned per protocol and we expect to remain masked to the data until the final analysis. The data read-out from the final analysis of this trial is event-driven and currently expected in 2027.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">IMCODE003 Phase 2 Clinical Trial in Adjuvant PDAC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 2 clinical trial (NCT05968326) is being conducted to evaluate autogene cevumeran in combination with atezolizumab followed by chemotherapy compared to chemotherapy alone as an adjuvant treatment for patients with resected PDAC who have not received prior systemic anti-</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">38</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">cancer treatment and showed no evidence of disease after surgery. The trial is expected to enroll 260 patients. The primary endpoint is DFS. Secondary endpoints include OS and safety.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">b) FixVac</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">FixVac</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> is our fully owned, systemic, off-the-shelf mRNA-based cancer immunotherapy approach. </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">FixVac</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> candidates are designed to target shared antigens that have been identified to be frequently expressed across patients with a specific cancer type.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">BNT113</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">BNT113 contains two different RNAs encoding the two HPV16 oncoproteins E6 and E7, which are exclusively expressed in pre-malignant and malignant tissue.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">AHEAD-MERIT Phase 2&#47;3 Clinical Trial in Unresectable Recurrent or Metastatic, PD-L1+, HPV16+ HNSCC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 2&#47;3 clinical trial (AHEAD-MERIT&#59; NCT04534205) is being conducted to evaluate BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first-line treatment for patients with unresectable recurrent or metastatic, PD-L1+, HPV16+ HNSCC.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Based on current event accrual projections, we expect data from the first interim analysis from the Phase 3 part of this trial in 2026.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">BNT116</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">BNT116 is comprised of six different NSCLC-associated tumor-associated antigens. BNT116 is being evaluated in two clinical trials as monotherapy and in combination with other immunotherapies, ADCs and chemotherapies in patients with advanced or metastasized NSCLC. </font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">EMPOWERVAX Lung 1 Phase 2 Clinical Trial in PD-L1 &#8805; 50% Advanced NSCLC </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 2 clinical trial (NCT05557591) is being conducted in collaboration with Regeneron to evaluate BNT116 in combination with cemiplimab versus cemiplimab alone as a first-line treatment for patients with advanced NSCLC whose tumors express PD-L1 in &#8805; 50% of their tumor cells. The primary objective of the Phase 2 trial is to assess the objective response rate, or ORR, per blinded-independent review committee.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">LuCa-MERIT-1 Phase 1 Clinical Trial in NSCLC </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1 clinical trial (NCT05142189) is being conducted to evaluate the safety, tolerability and preliminary efficacy of BNT116 as monotherapy and in several combinations including with chemotherapy, cemiplimab, and some of our proprietary assets across various treatment lines and clinical settings in patients with NSCLC.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">In April 2026, at the 2026 Annual Meeting of the American Association for Cancer Research, or AACR, clinical and ctDNA data from three cohorts evaluating BNT116 in combination with cemiplimab from the Phase 1 trial described above were presented. BNT116 in combination with cemiplimab demonstrated clinical activity in patients with advanced NSCLC</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> and molecular responses were associated with clinical outcomes.</font></div><div style="padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="background-color:#ffffff;color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Data from this trial are expected to be presented at WCLC 2026.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">39</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">3. Antibody-Drug Conjugates</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">i. Trastuzumab Pamirtecan (BNT323&#47;DB-1303), an ADC in Development in Collaboration with DualityBio</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Trastuzumab pamirtecan is a topoisomerase-1 inhibitor-based ADC directed against Human Epidermal Growth Factor Receptor 2, or HER2, a target that is over-expressed in a variety of cancers and contributes to the aggressive growth and spread of cancer cells. The program received Fast Track Designation and Breakthrough Therapy designation from the FDA for advanced endometrial cancer.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">DYNASTY-Breast02 Phase 3 Clinical Trial in Advanced or Metastatic HR+, HER2-low Breast Cancer</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 3 clinical trial (NCT06018337) is being conducted to evaluate trastuzumab pamirtecan compared to investigator&#8217;s choice of chemotherapy in advanced or metastatic HR+, HER2-low breast cancer subjects whose disease has progressed on at least two lines of prior endocrine therapy or within six months of first-line endocrine therapy and cyclin-dependent 4&#47;6, or CDK4&#47;6, inhibitor and no prior chemotherapy. The trial has enrolled 541 patients. The primary endpoint is progression-free survival, or PFS. Secondary endpoints include OS, ORR, duration of response, or DOR, and safety, as well as patient-reported outcomes.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Based on current event accrual projections, we expect interim data from this trial in the fourth quarter of 2026.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">FERN-EC-01 Phase 3 Clinical Trial in Advanced Endometrial Cancer</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 3 clinical trial (NCT06340568) is being conducted to evaluate trastuzumab pamirtecan compared to investigator&#8217;s choice of chemotherapy in patients with advanced and HER2-expessing recurrent endometrial cancer. The trial is expected to enroll approximately 480 patients. The primary endpoints are PFS and ORR. Secondary endpoints include OS, DOR and safety.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">A trial-in-progress poster was presented  at the ASCO Annual Meeting 2026.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 1&#47;2 Clinical Trial in Advanced&#47;Unresectable, Recurrent, or Metastatic HER2-Expressing Solid Tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT05150691) is being conducted to evaluate trastuzumab pamirtecan in patients with advanced&#47;unresectable, recurrent, or metastatic HER2-expressing solid tumors.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">A potentially registrational cohort with HER2-expressing (IHC3+, 2+, 1+) patients with advanced&#47;recurrent endometrial cancer has completed enrollment.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">In April 2026, updated data from this cohort of patients with pretreated advanced or metastatic endometrial cancer were presented at the Society of Gynecologic Oncology, or SGO, Annual Meeting 2026. Trastuzumab pamirtecan demonstrated encouraging clinical activity across all HER2 expression levels and regardless of prior immunotherapy treatment. The safety profile was manageable and generally consistent with that of ADCs and HER2-targeted biologics.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">In June 2026, additional data were presented from Phase 2 portion of the trial at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen, Denmark. Trastuzumab pamirtecan was observed to result in encouraging and durable anti-tumor activity and meaningful survival in </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">40</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">patients with advanced HER2-expressing endometrial cancer. The safety profile was observed to be manageable and consistent with the known class effects of anti-HER2 ADCs.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">We and DualityBio plan to file a biologics license application (&#8220;BLA&#8221;) in 2026. The companies will determine the optimal regulatory path for trastuzumab pamirtecan based on the totality of clinical data in endometrial cancer and breast cancer. This approach is in line with companies&#8217; value-optimization strategy for the asset in an evolving treatment landscape and focuses on prioritizing opportunities where they can deliver significant benefit for patients.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">ii. Elfetabart Drozuntecan (BNT324&#47;DB-1311), an ADC in Development in Collaboration with DualityBio</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Elfetabart drozuntecan is a topoisomerase-1 inhibitor-based ADC directed against B7-H3. It has received Fast Track Designation from the FDA for the treatment of patients with advanced&#47;unresectable, or metastatic castration-resistant prostate cancer, or mCRPC, who have progressed on or after standard systemic regimens. It has also received Orphan Drug Designation from the FDA for the treatment of patients with advanced or metastatic esophageal squamous cell carcinoma and SCLC.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 3 Clinical Trial in mCRPC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 3 clinical trial (NCT07365995) is being conducted to evaluate elfetabart drozuntecan compared to docetaxel in patients with mCRPC.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">In May 2026, the first patient in the trial was dosed.</font></div><div style="padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">A trial-in-progress poster was presented  at the ASCO Annual Meeting 2026.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 1&#47;2 Clinical Trial in Advanced Solid Tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT05914116) is being conducted to evaluate elfetabart drozuntecan in patients with advanced solid tumors.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">In April 2026, updated data from this trial were presented at SGO 2026. Elfetabart drozuntecan showed encouraging clinical activity in previously treated cervical cancer, particularly in the second-line setting as well as in platinum resistant ovarian cancer, or PROC. The safety profile in gynecologic malignancies was consistent with previous reports, and no new safety signals were observed.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Data from this trial in patients with PROC are expected to be presented at the ESMO Congress 2026.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">iii. Sacituzumab Drozuntecan (BNT325&#47;DB-1305), an ADC in Development in Collaboration with DualityBio</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Sacituzumab drozuntecan is a topoisomerase-1 inhibitor-based ADC directed against TROP2.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 1&#47;2 Clinical Trial in Advanced Solid Tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT05438329) is being conducted to evaluate sacituzumab drozuntecan in patients with advanced solid tumors. As part of this clinical trial, sacituzumab drozuntecan is being studied in combination with pumitamig in various solid tumor indications.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">41</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">iv. BNT326&#47;YL202, an ADC in Development in Collaboration with MediLink Therapeutics</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">BNT326&#47;YL202 is a topoisomerase-1 inhibitor-based ADC directed against HER3. </font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 1 Clinical Trial in Advanced or Metastatic EGFR-Mutated NSCLC or HR+ and HER2-Negative Breast Cancer</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1 clinical trial (NCT05653752) is being conducted to evaluate BNT326&#47;YL202 as a later-line treatment in patients with locally advanced or metastatic EGFR-mutated NSCLC or HR+ and HER2-negative breast cancer.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 2 Clinical Trial in Advanced Solid Tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 2 clinical trial (NCT06107686) is being conducted in China to evaluate BNT326&#47;YL202 in patients with advanced solid tumors.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 2 Clinical Trial in Multiple Breast Cancers</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 2 clinical trial (NCT06439771) is being conducted in China to evaluate BNT326&#47;YL202 in patients with locally advanced or metastatic breast cancer with TNBC, HR+, HER2-zero-expression or HER2-low-expression.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Data from this trial are expected to be presented at the ESMO Congress 2026.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">v. BNT329, an ADC for the Treatment of Advanced Solid Tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">BNT329 is a fully owned carbohydrate antigen 19-9, or CA19-9, targeting ADC. CA19-9 is expressed in pancreatic cancers and other solid tumors, plays a role in tumor adhesion and metastasis formation, and is a marker of an aggressive cancer phenotype.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 1&#47;2 Clinical Trial in Advanced Solid Tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT07186842) is being conducted to evaluate BNT329 in patients with advanced solid tumors.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">vi. BNT3214, an ADC for the Treatment of Advanced Solid Tumors</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 1&#47;2 Clinical Trial in Advanced Solid Tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT07455734) is being conducted to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of BNT3214 in participants with advanced solid tumors.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">4. Other Antibody Product Candidates</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">i. Gotistobart (BNT316&#47;ONC-392), a Selective Treg-Depleting Antibody Candidate in Development in Collaboration with OncoC4</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Gotistobart (BNT316&#47;ONC-392) is an investigational regulatory T cell-depleting antibody that binds to cytotoxic T-lymphocyte associated protein 4, or CTLA-4, on the surface of Tregs, but CTLA-4 is recycled to the cell surface once internalized, preserving and enriching CTLA-4 on the surface of tumor infiltrating Tregs. This results in enhanced Treg depletion in the tumor microenvironment, which drives tumor cell death. Gotistobart (BNT316&#47;ONC-392) is being developed in collaboration with OncoC4.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">42</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">PRESERVE-003 Phase 3 Clinical Trial in NSCLC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A two-stage global Phase 3 trial (NCT05671510) is being conducted to evaluate the efficacy and safety of gotistobart as monotherapy compared to docetaxel in patients with metastatic NSCLC that progressed on previous platinum-based chemotherapy and PD-(L)1-inhibitor treatment. </font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Updated data from the Stage 1 of this trial are expected to be presented at WCLC 2026.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Based on current event accrual projections, we expect interim data from Stage 2 of the two-stage Phase 3 trial in 2026. This will be assessed by the Independent Data Monitoring Committee, or IDMC, to recommend whether to unblind the trial or continue to the next pre-planned interim analysis.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">PRESERVE-004 Phase 2 Clinical Trial in PROC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 2 clinical trial (NCT05446298) is being conducted to evaluate gotistobart in combination with pembrolizumab in patients with PROC. The clinical trial is designed to evaluate multiple doses of gotistobart in combination with a fixed dose of pembrolizumab in participants with ovarian cancer who are resistant to platinum-based chemotherapy. The primary endpoints are ORR and safety. Secondary endpoints include DOR, diseases control rate, or DCR, PFS and OS.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">In May 2026, data from  the trial were presented at the ASCO Annual Meeting 2026. Gotistobart in combination with pembrolizumab demonstrated encouraging and durable antitumor activity in heavily pretreated patients with PROC.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">PRESERVE-006 Phase 1&#47;2 Clinical Trial in mCRPC</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT05682443) is being conducted to evaluate the safety and efficacy of gotistobart in combination with lutetium Lu-177 vipivotide tetraxetan in patients with mCRPC who have disease progressed on androgen receptor pathway inhibition. The primary endpoints are safety and PSA50 and rPFS as dual primary efficacy endpoints.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">The expected timing of data from this trial has been updated from 2026 to 2027.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">PRESERVE-001 Phase 1&#47;2 Clinical Trial in Advanced or Metastatic Solid Tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 dose escalation and cohort expansion clinical trial (NCT04140526) is being conducted to evaluate gotistobart as a single agent and in combination with pembrolizumab in patients with advanced or metastatic solid tumors.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">An update of patients with advanced melanoma refractory or resistant to prior anti-CTLA-4 and anti-PD-(L)1 therapies is expected to be presented at the ESMO Congress 2026.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">ii. BNT314&#47;GEN1059 is being developed in collaboration with Genmab. BNT314&#47;GEN1059 is a potential first-in-class bispecific antibody product candidate designed to boost antitumor immune responses through epithelial cell adhesion molecule-, or EpCAM-, dependent 4-1BB agonistic activity.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 1 Clinical Trial in Advanced or Metastatic Solid Tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1 clinical trial (NCT06150183) is being conducted to evaluate the safety and preliminary antitumor activity of BNT314&#47;GEN1059 in patients with advanced or metastatic solid tumors.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">43</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">iii. BNT317, an Antibody for the Treatment of Advanced Solid Tumors</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 1 Clinical Trial in Advanced Solid Tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1 clinical trial (NCT06750185) is being conducted to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of BNT317 in participants with advanced solid tumors.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">5. Oncology Cell Therapy Product Candidates</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">i. BNT211, a chimeric antigen receptor, or CAR, T-cell therapy &#8211; CAR-T - in multiple solid tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">BNT211 is a novel approach combining an autologous tumor-specific CAR-T cell therapy candidate targeting the oncofetal antigen Claudin-6, or CLDN6, with a CLDN6-encoding CAR-T cell amplifying RNA vaccine, or CARVac, that is based on BioNTech&#8217;s FixVac platform in one regimen.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Phase 1 Clinical Trial in CLDN6-Positive Relapsed or Refractory Solid Tumors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1 dose escalation clinical trial (NCT04503278) is being conducted to evaluate BNT211 as monotherapy or in combination with CARVac in patients with CLDN6-positive relapsed or refractory solid tumors, including NSCLC, gastric cancer, ovarian cancer and testicular germ cell tumors.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">B. Infectious Disease Programs</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">1. Next-Generation COVID-19 Vaccine</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In collaboration with Pfizer, we are aiming to develop a vaccine candidate that enhances and broadens SARS-CoV-2 immunogenicity responses.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">2. COVID-19 </font><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">&#8211; </font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Influenza Combination mRNA Vaccine Program </font><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">&#8211; </font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">BNT162 + BNT161</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In collaboration with Pfizer, Phase 1&#47;2 clinical trials are being conducted to evaluate the safety, tolerability and immunogenicity of the combination of the companies&#8217; mRNA vaccine candidates against influenza and COVID-19. We expect to provide updates as the program progresses.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">3. Herpes Simplex Virus Vaccine Program </font><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">&#8211; </font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">BNT163</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1 clinical trial (NCT05432583) is being conducted to evaluate the safety, tolerability, immunogenicity and preliminary efficacy of BNT163 for the prevention of genital lesions caused by HSV-2 and potentially HSV-1.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">4. Tuberculosis Vaccine Program </font><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">&#8211; </font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">BNT164</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1b&#47;2a clinical trial (NCT05547464) is being conducted to assess the safety, reactogenicity, and immunogenicity of mRNA vaccine candidates against tuberculosis disease.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">5. Malaria Vaccine Program </font><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">&#8211; </font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">BNT165</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 trial (NCT06069544) to evaluate the safety, tolerability, immunogenicity and efficacy of a second investigational RNA-based vaccine candidate has been completed. BioNTech is assessing next steps in the development of this vaccine candidate.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">6. Mpox Vaccine Program </font><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">&#8211; </font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">BNT166</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A randomized, placebo-controlled Phase 2 clinical trial (NCT07379580) is being conducted to evaluate the safety, reactogenicity, and immunogenicity of BNT166 in healthy participants.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">44</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">7. HIV Vaccine Program </font><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">&#8211; </font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">BNT168</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1&#47;2 clinical trial (NCT07698600) to evaluate the safety, immunogenicity, and impact on virological control of BNT168 in adults living with or without human immunodeficiency virus, or HIV, is planned to start in 2026.</font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">8. HIV Antibody Program </font><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">&#8211; </font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">BNT351</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A Phase 1 clinical trial (NCT07392372) is being conducted to evaluate the safety, pharmacokinetics, and antiviral activity of BNT351 in adults living with and without HIV.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_3654"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Financial Operations Overview</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2822"></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The following table shows our unaudited interim condensed consolidated statements of profit or loss for each period presented&#58;</font></div><div style="margin-bottom:15pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:43.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.387%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Three months ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Six months ended June 30,</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">105.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">260.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">223.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">443.6</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Cost of sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(97.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(76.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(168.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(160.2)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Research and development expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(551.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(509.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1,108.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1,034.7)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Sales and marketing expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(40.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(19.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(68.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(33.4)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">General and administrative expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(157.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(117.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(280.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(224.6)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(248.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(117.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(281.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(165.7)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other operating income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">40.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">78.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">57.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">139.8</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Operating loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(948.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(501.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,625.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,035.2)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Finance income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">97.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">105.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">217.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">228.0</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Finance expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(7.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(7.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(19.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(40.9)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Loss before tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(858.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(402.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,426.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(848.1)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Income taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">37.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">16.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">74.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">45.7</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Net loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(820.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(386.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,352.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(802.4)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Loss per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Basic and diluted loss per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(3.24)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1.60)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(5.34)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(3.33)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Important financial and operating terms and concepts are described in Item 5 of our Annual Report on Form 20-F as of and for the year ended December&#160;31, 2025, as amended.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_3547"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Non-IFRS Measures as Defined by BioNTech</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition to our results determined in accordance with IFRS Accounting Standards, or IFRS results, we report certain adjusted, non-IFRS, measures used internally as a supplemental measure of our business performance. We believe that reporting these adjustments, and the non-IFRS measures that result, together with our IFRS results provides helpful complementary information to better understand our business performance and to facilitate comparability of business performance across different periods. These non-IFRS measures are also used by management for financial forecast and internal reporting purposes. Non-IFRS measures are intended to and may also provide useful information in evaluating performance relative to peer companies, many of which use similar non-IFRS measures to supplement their IFRS results. </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">45</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">While non-IFRS measures may offer additional insights, our non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Non-IFRS adjustments include certain items that are associated with discrete events or matters and that management does not consider indicative of our performance for the period, and thus are excluded from the measures based on IFRS Accounting Standards. Non-IFRS measures are also aligned with the financial forecast of our management, which do not include these events or matters given their nature. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our non-IFRS measures exclude the following items in relation to our measures based on IFRS Accounting Standards&#58;</font></div><div style="margin-bottom:6pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Expenses and income from legal proceedings</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">, defined as&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Expenses (net of insurance recoveries) and income arising from certain legal proceedings (e.g., contractual-disputes, litigations, and government investigations), resulting from past events, that would result generally in a provision in accordance with IAS 37, an accrual, or outflow of resources (such as cash) recorded in our other operating result (other operating income or expense) in the period, which management does not consider indicative of the Company&#8217;s performance for the period and exceeds a minimum threshold of &#8364;10.0 million per matter. These expenses and income do not include expenses from obligations or income from receivables arising from agreements following the settlements or conclusions for future transactions and operations, or expenses for external legal advisory services or internal legal costs. The Company describes the key facts of the matter such as involved parties, dispute, jurisdiction, terms of a settlement or court-ordered judgment in the respective sections in the Notes to the Consolidated Financial Statements.</font></div><div style="margin-bottom:6pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Impairment and reversal</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">, defined as&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Expenses in accordance with IAS 36 impairment of goodwill and impairment and reversals of impairments of intangible assets (IAS 38), property, plant and equipment (IAS 16) and right-of-use assets (IFRS 16) that relate to matters which management does not consider indicative of the Company&#8217;s performance for the period and that exceed a minimum threshold of &#8364;10.0 million per asset or group of assets. Write-downs of inventories (IAS 2) or impairments of other assets not covered by IAS 16, IAS 38 and IFRS 16 are not adjusted.</font></div><div style="margin-bottom:6pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Employee-related expenses from restructuring</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">, defined as&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Major restructuring costs recognized in accordance with IAS 37 for streamlining operations and improving overall efficiency under specific Board approved programs that are of a significant scale and result in a structural change but do not relate to matters which management considers indicative of the Company&#8217;s performance for the period, where the costs of individual or related projects, including employee-related costs such as severance or outplacement, exceed a minimum threshold of &#8364;10.0 million. This does not include training or relocating continuing staff, marketing, investment in new systems and distribution networks, or consulting costs related to the restructuring.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">46</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Income from bargain purchase and income and expenses from divestiture related items</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">, defined as&#58; </font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Income from a bargain purchase resulting from a business combination according to IFRS 3&#47;IFRS 10 and income and expenses from valuation of non-current assets as held for sale according to IFRS 5, above a minimum threshold of &#8364;10.0 million per item are adjusted, where management does not consider such income or expenses to be indicative of the Company&#8217;s performance for the period. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">These non-IFRS adjustments result in the following adjusted measures based on IFRS Accounting Standards&#58; adjusted expenses, adjusted operating profit&#47;loss, adjusted profit&#47;loss before tax, adjusted net profit&#47;loss, and adjusted earnings&#47;loss per share on both a basic and diluted basis (each referred to with the prefix &#8220;Adjusted&#8221; or as a whole &#8220;Adjusted Results&#8221;). The calculation of these and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes the above described adjustments. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Due to their non-standardized nature, our adjusted results may not be directly comparable to those of other companies, unlike measures based on IFRS Accounting Standards. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The following tables provide a reconciliation of our adjusted results to our measures based on IFRS Accounting Standards for the three and six months ended June 30, 2026 and 2025&#58;</font></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:26.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.959%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.959%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="42" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Non-IFRS Reconciliation for the three months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:center"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">non-IFRS adjustments (unaudited)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr style="height:54pt"><td colspan="3" rowspan="2" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">IFRS <br>Results</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Expenses and income from legal proceedings</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Impairment and reversal</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Employee-related expenses from restructuring</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Income from bargain purchase and income and expenses from divestiture related items</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Adjusted <br>Results</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:4pt;text-align:right"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></div></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Research and development expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(551.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">73.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(477.1)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(248.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">87.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">97.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(63.5)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Operating loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(948.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">160.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">97.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(689.6)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Loss before tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(858.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">160.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">97.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(600.2)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Net loss</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:4.22pt;font-weight:700;letter-spacing:0.03em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(820.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">160.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">97.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(562.3)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Loss per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Basic and diluted loss per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(3.24)</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(2.22)</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:16pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Tax effects are not considered as part of our non-IFRS adjustments.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">47</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:26.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.959%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.653%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="42" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Non-IFRS Reconciliation for the three months ended June 30, 2025</font></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">non-IFRS adjustments (unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:54pt"><td colspan="3" rowspan="2" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">IFRS <br>Results</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Expenses and income from legal proceedings</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Impairment and reversal</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Employee-related expenses from restructuring</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Income from bargain purchase and income and expenses from divestiture related items</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Adjusted <br>Results</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(117.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">10.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">27.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(79.4)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Operating loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(501.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">10.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">27.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(463.3)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Loss before tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(402.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">10.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">27.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(364.9)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Net loss</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:4.22pt;font-weight:700;letter-spacing:0.03em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(386.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">10.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">27.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(348.8)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Loss per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Basic and diluted loss per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1.60)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1.45)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:16pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Tax effects are not considered as part of our non-IFRS adjustments.</font></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:26.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.959%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.959%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="42" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Non-IFRS Reconciliation for the six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="21" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt;text-align:center"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">non-IFRS adjustments (unaudited)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr style="height:54pt"><td colspan="3" rowspan="2" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">IFRS <br>Results</font></td><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Expenses and income from legal proceedings</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Impairment and reversal</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Employee-related expenses from restructuring</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Income from bargain purchase and income and expenses from divestiture related items</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Adjusted <br>Results</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Research and development expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1,108.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">103.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(1,004.2)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(281.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">87.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">105.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(89.3)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Operating loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,625.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">190.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">105.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,329.8)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Loss before tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,426.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">190.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">105.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,131.0)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Net loss</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:4.22pt;font-weight:700;letter-spacing:0.03em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,352.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">190.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">105.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,056.9)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Loss per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Basic and diluted loss per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(5.34)</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(4.17)</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:16pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Tax effects are not considered as part of our non-IFRS adjustments.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">48</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:26.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.959%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.653%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="42" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Non-IFRS Reconciliation for the six months ended June 30, 2025</font></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">non-IFRS adjustments (unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:54pt"><td colspan="3" rowspan="2" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">IFRS <br>Results</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Expenses and income from legal proceedings</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Impairment and reversal</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Employee-related expenses from restructuring</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Income from bargain purchase and income and expenses from divestiture related items</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Adjusted <br>Results</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(unaudited)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(165.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">10.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">27.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(127.9)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other operating income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">139.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(15.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">124.8</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Operating loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,035.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">10.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">27.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(15.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,012.4)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Loss before tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(848.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">10.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">27.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(15.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(825.3)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Net loss</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:4.22pt;font-weight:700;letter-spacing:0.03em;line-height:140%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(802.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">10.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">27.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(15.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(779.6)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:6.5pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Loss per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Basic and diluted loss per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(3.33)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(3.23)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:16pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Tax effects are not considered as part of our non-IFRS adjustments.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_608"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Comparison of the three and six months ended June 30, 2026 and 2025</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_923"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Revenues</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1576"></div><div style="margin-bottom:15pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:43.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.387%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Three months ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Change</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8364;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">%</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">COVID-19 vaccine revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">51.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">153.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(101.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(66)</font></td><td style="border-top:1pt solid #005a64;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">53.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">107.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(53.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(50)</font></td><td style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">105.6</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">260.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(155.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(60)</font></td><td style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">%</font></td></tr></table></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1542"></div><div style="margin-bottom:15pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:43.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.387%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Six months ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Change</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8364;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">%</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">COVID-19 vaccine revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">118.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">286.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(167.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(59)</font></td><td style="border-top:1pt solid #005a64;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">104.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">157.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(52.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(33)</font></td><td style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">223.7</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">443.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(219.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(50)</font></td><td style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">%</font></td></tr></table></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1549"></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">COVID-19 Vaccine Revenues</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our COVID-19 vaccine revenues decreased by &#8364;101.4&#160;million, or 66%, from &#8364;153.3&#160;million during the three months ended June 30, 2025, to &#8364;51.9&#160;million during the three months ended June 30, 2026, and decreased by &#8364;167.5&#160;million, or 59%, from &#8364;286.3&#160;million during the six months ended June 30, 2025, to &#8364;118.8&#160;million during the six months ended June 30, 2026. The decreases for the three and six months ended June 30, 2026, each compared with the corresponding prior&#8209;year period, were mainly driven by a lower volume of doses sold during the three and six months ended June 30, 2026. Our COVID-19 vaccine revenues are subject to seasonal effects in the fall and winter of the northern hemisphere. </font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Other Revenues</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our remaining other revenues decreased by &#8364;53.8&#160;million, or 50%, from &#8364;107.5&#160;million during the three months ended June 30, 2025, to &#8364;53.7&#160;million during the three months ended June 30, 2026, and decreased by &#8364;52.4&#160;million, or 33%, from &#8364;157.3&#160;million during the six months ended June 30, 2025, to </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">49</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8364;104.9&#160;million during the six months ended June 30, 2026, and primarily comprise revenues resulting from our pandemic preparedness contract with the German government. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_931"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Cost of Sales</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1566"></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our cost of sales increased by &#8364;20.6&#160;million, or 27%, from &#8364;76.4&#160;million during the three months ended June 30, 2025, to &#8364;97.0&#160;million during the three months ended June 30, 2026, and  increased by &#8364;8.2&#160;million, or 5%, from &#8364;160.2&#160;million during the six months ended June 30, 2025, to &#8364;168.4&#160;million during the six months ended June 30, 2026. The increases for the three and six months ended June 30, 2026, each compared with the corresponding prior&#8209;year period, were mainly driven by the inclusion of degressive amortization charges related to assets acquired in connection with the acquisition of CureVac N.V., or CureVac, partially offset by lower expenses arising from inventory write-downs to net realizable value due to inventories expected to be unsellable, not fulfilling the specification defined by our quality standards, shelf-life expiry or destruction of inventory.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_950"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Research and Development Expenses</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_360090058100458"></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:43.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.387%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Three months ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Change</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8364;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">%</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">External services</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(200.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(233.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">33.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(14)</font></td><td style="border-top:1pt solid #005a64;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">%</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Employee costs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(169.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(164.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(5.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">3&#160;</font></td><td style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">%</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Depreciation, amortization and impairment</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(108.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(23.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(85.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">366&#160;</font></td><td style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">%</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:5.2pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(72.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(87.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">14.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(17)</font></td><td style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total research and development expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(551.0)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(509.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(41.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">8</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:140%">&#160;</font></td><td style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">%</font></td></tr></table></div><div style="margin-bottom:16pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Includes cost allocations for services received from other functions as a bundle, comprising, among others, employee-related and other allocated costs that cannot be separately distinguished or assigned to the line items presented above.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_360090058100469"></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:43.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.387%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Six months ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Change</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">&#8364;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">%</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">External services</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(441.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(496.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">55.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #005a64;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(11)</font></td><td style="border-top:1pt solid #005a64;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">%</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Employee costs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(333.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(318.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(14.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">5&#160;</font></td><td style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">%</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Depreciation, amortization and impairment</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(174.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(48.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(126.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">262&#160;</font></td><td style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">%</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Other</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:5.2pt;font-weight:400;letter-spacing:0.04em;line-height:140%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(159.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(171.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">12.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(7)</font></td><td style="border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total research and development expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,108.0)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(1,034.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(73.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">7</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:140%">&#160;</font></td><td style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #a8c7ca;padding:1.5pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">%</font></td></tr></table></div><div style="margin-bottom:16pt;margin-top:3pt;padding-left:9.92pt;text-align:justify;text-indent:-9.92pt"><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:4.87pt;font-weight:400;letter-spacing:0.03em;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</font><font style="color:#107072;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:7.5pt;font-weight:400;letter-spacing:0.03em;line-height:120%">&#160;&#160;&#160;&#160;Includes cost allocations for services received from other functions as a bundle, comprising, among others, employee-related and other allocated costs that cannot be separately distinguished or assigned to the line items presented above.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1621"></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our research and development expenses increased by &#8364;41.9&#160;million, or 8%, from &#8364;509.1&#160;million during the three months ended June 30, 2025, to &#8364;551.0&#160;million during the three months ended June 30, 2026, and increased by &#8364;73.3&#160;million, or 7%, from &#8364;1,034.7&#160;million during the six months ended June 30, 2025, to &#8364;1,108.0&#160;million during the six months ended June 30, 2026.  The increases for the three and six months ended June 30, 2026, each compared with the corresponding prior&#8209;year period, were mainly driven by higher expenses for our immuno-oncology, or IO, and antibody-drug conjugate, or ADC, programs, in particular pumitamig and gotistobart, by impairments related to early clinical-stage product candidates recorded in June 2026 (see Note 6 to the unaudited interim condensed consolidated financial statements included elsewhere in this Quarterly Report) as well as research and development costs from the inclusion of operations from CureVac, which was acquired in late 2025. The year-to-date period was also impacted by an impairment related to BNT331 recorded in </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">50</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">March 2026 (see Note 6 to the unaudited interim condensed consolidated financial statements included elsewhere in this Quarterly Report). The quarterly and year-to-date increases were partially offset by lower costs on non-focus programs and positive effects from cost shares with our collaboration partners. We do not track research and development expenses by product candidate and the costs that are directly attributable to individual product candidates represent only a portion of our research and development expenses, while almost half of our current research and development expenses consist of costs that support multiple programs.  </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our adjusted research and development expenses decreased by &#8364;32.0&#160;million, or 6%, from &#8364;509.1&#160;million during the three months ended June 30, 2025, to &#8364;477.1&#160;million during the three months ended June 30, 2026, and decreased by &#8364;30.5&#160;million, or 3%, from &#8364;1,034.7&#160;million during the six months ended June 30, 2025, to &#8364;1,004.2&#160;million during the six months ended June 30, 2026. For the three months ended June 30, 2026, our adjusted research and development expenses exclude impairment losses of &#8364;73.9&#160;million related to early clinical-stage product candidates, which are outside our focus programs, since the likelihood of finalizing out-licensing agreements for these product candidates was considered unlikely as of June 30, 2026. For the six months ended June 30, 2026, our adjusted research and development expenses exclude impairment losses of &#8364;103.8&#160;million, including an additional impairment loss related to BNT331, recorded in March 2026, following management&#8217;s decision to pause the program. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_3627"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Sales and Marketing Expenses</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_3633"></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our sales and marketing expenses increased by &#8364;20.4&#160;million, or 104%, from &#8364;19.7&#160;million during the three months ended June 30, 2025, to &#8364;40.1&#160;million during the three months ended June 30, 2026, and increased by &#8364;34.6&#160;million, or 104%, from &#8364;33.4&#160;million&#160;during the six months ended June 30, 2025 to &#8364;68.0&#160;million during the six months ended June 30, 2026. The increases for the three and six months ended June 30, 2026, each compared with the corresponding prior&#8209;year period, were mainly driven by pre&#8209;launch activities for late-stage programs as well as our ongoing commercial build&#8209;up, particularly in the United States.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_942"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">General and Administrative Expenses</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1649"></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our general and administrative expenses increased by &#8364;40.0&#160;million, or 34%, from &#8364;117.7&#160;million during the three months ended June 30, 2025, to &#8364;157.7&#160;million during the three months ended June 30, 2026, and increased by &#8364;56.0&#160;million, or 25%, from &#8364;224.6&#160;million during the six months ended June 30, 2025, to &#8364;280.6&#160;million during the six months ended June 30, 2026. The increases for the three and six months ended June 30, 2026, each compared with the corresponding prior&#8209;year period, were primarily driven by the inclusion of CureVac operations acquired in late 2025, as well as expenses associated with BioNTech&#8217;s global initiative on scaling processes and ERP infrastructure to strengthen operational execution. This was partly offset by cost reductions resulting from the execution of initiatives related to our pipeline prioritization and increased cost discipline.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">51</font></div></td></tr></table></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_958"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Other Operating Result</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1676"></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our total other operating result decreased by &#8364;168.9 million from a negative result of &#8364;39.0 million during the three months ended June 30, 2025, to a negative result of &#8364;207.9 million during the three months ended June 30, 2026, and decreased by &#8364;198.4 million from a negative result of &#8364;25.9 million during the six months ended June 30, 2025, to a negative result of &#8364;224.3&#160;million during the six months ended June 30, 2026. The decreases for the three and six months ended June 30, 2026, each compared with the corresponding prior&#8209;year period, were mainly driven by pipeline prioritization costs, while other effects nearly offset each other. For the three and six months ended June 30, 2026, our pipeline prioritization costs amounted to &#8364;221.5 million and &#8364;240.2 million, respectively, compared to &#8364;43.6 million and &#8364;43.6&#160;million in the respective prior year periods.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">For the three months ended June 30, 2026, our adjusted other operating expenses exclude employee-related costs of &#8364;97.6&#160;million and impairment losses of &#8364;87.0&#160;million, compared to &#8364;27.8&#160;million and &#8364;10.0&#160;million, respectively, during the prior year quarter. For the six months ended June 30, 2026, our adjusted other operating expenses exclude employee-related costs of &#8364;105.0&#160;million and impairment losses of &#8364;87.0&#160;million, compared to &#8364;27.8&#160;million and &#8364;10.0&#160;million, respectively, during the prior year period. In addition, for the six months ended June 30, 2025 our adjusted other operating income excludes a bargain purchase of &#8364;15.0 million. As a result, our adjusted total other operating result decreased by &#8364;22.1 million from a negative adjusted other operating result of &#8364;1.2 million during the three months ended June 30, 2025, to a negative adjusted other operating result of &#8364;23.3 million during the three months ended June 30, 2026, and decreased by &#8364;29.2 million from a negative adjusted other operating result of &#8364;3.1 million&#160;during the six months ended June 30, 2025, to a negative adjusted other operating result of &#8364;32.3 million during the six months ended June 30, 2026. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_967"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Finance Result</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1703"></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our finance result during the three and six months ended June 30, 2026 and 2025 was mainly derived from returns, such as interest, resulting from our security investments as well as fair value adjustments of our money market funds. Our total finance result decreased by &#8364;9.0 million, or 9%, from a positive finance result of &#8364;98.4 million during the three months ended June 30, 2025, to a positive finance result of &#8364;89.4 million during the three months ended June 30, 2026, and increased by &#8364;11.7 million, or 6%, from a positive finance result of &#8364;187.1 million during the six months ended June 30, 2025, to a positive finance result of &#8364;198.8 million during the six months ended June 30, 2026. The quarterly decrease was primarily driven by lower positive fair value effects of our money market funds, while the year-to-date increase was mainly due to positive impacts from foreign exchange differences, primarily derived from our security investments.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_3075"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Income Taxes</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_975"></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our income taxes increased by &#8364;21.8 million from &#8364;16.1 million of tax income during the three months ended June 30, 2025, to &#8364;37.9 million of tax income during the three months ended June 30, 2026, and increased by &#8364;28.4 million from &#8364;45.7 million of tax income during the six months ended June 30, 2025, to &#8364;74.1 million of tax income during the six months ended June 30, 2026. The effective income tax rate for the six months ended June 30, 2026 was approximately 5.2% and approximately 5.4% for the six months ended June 30, 2025. </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">52</font></div></td></tr></table></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_614"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Related Party Transactions</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Related party transactions that occurred during the three and six months ended June 30, 2026 and 2025, are explained in Note 12 to the unaudited interim condensed consolidated financial statements included elsewhere in this Quarterly Report. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_619"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Critical Accounting Policies and Use of Estimates</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2026 and 2025 have been prepared in accordance with IAS 34 Interim Financial Reporting.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our critical accounting policies and the use of estimates are explained in Note 2 to the unaudited interim condensed consolidated financial statements included elsewhere in this Quarterly Report and further discussed in Note 3 to our audited consolidated financial statements of our Annual Report on Form 20-F as of and for the year ended December&#160;31, 2025, as amended.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_626"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Legal Proceedings</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are and may be involved in various legal proceedings, including patent litigation, product liability and other product-related litigation, as well as other legal proceedings that arise from time to time in the ordinary course of business, including, but not limited to, personal injury, consumer, off-label promotion, securities, antitrust, employment law, tax, environmental, and&#47;or other claims or investigations.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We currently do not believe that any of these matters will have a material adverse effect on our financial position, and will continue to monitor the status of these and other claims that may arise. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and&#47;or our cash flows in the period in which the amounts are accrued or paid. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Certain pending matters to which we are a party are discussed below.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">For a description of the risks relating to these and other legal proceedings we face and may in the future face and our assessments thereof, see &#8220;Risk Factors&#8221; in this Quarterly Report.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Moderna Proceedings</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Germany </font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Infringement Proceedings &#8211; EP&#8217;949 and EP&#8217;565</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In August 2022, Moderna filed a lawsuit against us and Pfizer and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, Pfizer Manufacturing Belgium NV, Pfizer Ireland Pharmaceuticals and Pfizer Inc. in the D&#252;sseldorf Regional Court alleging Comirnaty&#8217;s infringement of two European patents, 3590949B1, or EP&#8217;949, and 3718565B1, or EP&#8217;565. With respect to EP&#8217;565, on November 7, 2023, the Opposition </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">53</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Division of the EPO revoked EP&#8217;565 after a one-day oral hearing held in the co-pending opposition proceeding, and on December 7, 2023, it issued the written decision for revoking EP&#8217;565. On February 7, 2024, Moderna appealed the Opposition Division&#8217;s revocation decision on EP&#8217;565. On September 17, 2025, the EPO Technical Board of Appeal issued a preliminary opinion noting that it believes EP&#8217;565 is likely invalid. An oral hearing took place on January 27, 2026, at the conclusion of which the  Technical Board of Appeal affirmed the revocation of EP&#8217;565.  On April 29, 2026, the EPO Technical Board of Appeal issued a written decision finally revoking EP&#8217;565. On May 7, 2026, Moderna withdrew its infringement proceedings with respect to EP&#8217;565. On May 22, 2026, Pfizer and BioNTech consented to the withdrawal and the proceedings were dismissed. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">With respect to EP&#8217;949, on December 8, 2023, the Opposition Division issued a preliminary opinion noting that it believes EP&#8217;949 is likely invalid. As a result of those developments in the EPO proceedings, the D&#252;sseldorf Regional Court postponed its hearing on infringement with respect to EP&#8217;949, originally scheduled for December 12, 2023, to January 21, 2025. On May 16, 2024, the EPO Opposition Division decided that EP&#8217;949 is valid, in amended form, and issued its written decision regarding the same on July 8, 2024. We appealed this decision, and the appeal is currently pending. The D&#252;sseldorf Regional Court held an infringement hearing on January 21, 2025, and on March 5, 2025, it issued a first-instance decision declining to stay the infringement proceedings and finding infringement of EP&#8217;949 by us and Pfizer. We and Pfizer have appealed the D&#252;sseldorf Regional Court&#8217;s infringement decision, and the appeal is currently pending. The court has not ruled on the invalidity of EP&#8217;949, which will be decided in a next step by the EPO in the opposition appeal proceedings. On May 29, 2026, the EPO Technical Board of Appeal issued a preliminary opinion noting that it believes EP&#8217;949 is likely invalid. An oral hearing in this appeal has been scheduled for September 8-10, 2026. Moderna has not yet taken steps to enforce the D&#252;sseldorf Regional Court&#8217;s first-instance decision on infringement. </font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">United Kingdom</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In August 2022, Moderna filed a lawsuit asserting Comirnaty&#8217;s infringement of EP&#8217;949 and EP&#8217;565 against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, and Pfizer Limited, Pfizer Manufacturing Belgium NV and Pfizer Inc. in the Business and Property Courts of England and Wales, in the UK High Court. In September 2022, we and Pfizer filed a revocation action in the Business and Property Courts of England and Wales requesting revocation of EP&#8217;949 and EP&#8217;565.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The UK High Court held a trial between April 22, 2024, and May 21, 2024. On July 2, 2024, the UK High Court released two judgments. The first judgment concerns the validity of EP&#8217;949 and EP&#8217;565. In this first judgment, the UK High Court found that EP&#8217;565 is invalid and therefore not infringed, while EP&#8217;949 is valid and infringed. The second judgment concerns whether Moderna&#8217;s October 2020 commitment not to &#8220;enforce &#91;its&#93; COVID-19 related patents against those making vaccines intended to combat the pandemic,&#8221; or the Patent Pledge, amounted to a consent under UK law to carry out any acts that would otherwise amount to patent infringement. With respect to this judgment, the UK High Court found that Moderna&#8217;s Patent Pledge amounted to consent to carry out activities that might otherwise infringe its patents prior to March 2022, but not after March 2022. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The UK High Court held a hearing on September 25, 2024, during which the Court granted Pfizer and BioNTech permission to appeal its judgment regarding the validity of EP&#8217;949, and declined Moderna&#8217;s permission to appeal its judgment regarding validity of EP&#8217;565. On October 16, 2024, Moderna sought </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">54</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">permission from the UK Appeals Court to appeal the EP&#8217;565 judgment. On November 11, 2024, the UK Appeals Court denied Moderna&#8217;s application to appeal&#59; accordingly, the UK designation of EP&#8217;565 is finally revoked with no further opportunity to appeal in UK. No party sought permission to appeal the UK High Court&#8217;s judgment on the patent pledge.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The UK Court of Appeal held an oral hearing on the appeal of EP&#8217;949 on July 10-11, 2025. On August 1, 2025, the UK Court of Appeal issued a judgment agreeing with the UK High Court that EP&#8216;949 is valid, and dismissed our appeal. We applied for permission to appeal this decision to the UK Supreme Court, and on December 8, 2025, the UK Supreme Court denied permission to appeal. Accordingly, the UK designation of EP&#8216;949 is valid and infringed. However, Moderna has not yet taken steps to enforce this final judgment on infringement. Additionally, EP&#8216;949 is currently subject to opposition proceedings at the EPO. The Opposition Division initially issued a preliminary opinion noting that EP&#8216;949 is invalid, but in May 2024, issued a first-instance decision finding EP&#8216;949 valid. BioNTech and Pfizer appealed this first-instance decision. On May 29, 2026, the EPO Technical Board of Appeal issued a preliminary opinion noting that it believes EP&#8217;949 is likely invalid. The oral hearing in this appeal is scheduled for September 8-10, 2026. </font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">United States</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">U.S. District Court Litigation </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In August 2022, Moderna filed a lawsuit in the U.S. District Court for the District of Massachusetts against us and our wholly owned subsidiaries BioNTech Manufacturing GmbH and BioNTech US Inc. and Pfizer Inc. alleging Comirnaty&#8217;s infringement of U.S. Patent Nos. 10,898,574&#59; 10,702,600 and 10,933,127 and seeking monetary relief. On April 12, 2024, the U.S. District Court for the District of Massachusetts stayed the litigation pending resolution of the inter partes review of U.S. Patent Nos. 10,702,600 and 10,933,127.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Inter Partes Review</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In August 2023, Pfizer and we filed petitions seeking inter partes review of U.S. Patent Nos. 10,702,600 and 10,933,127 before the United States Patent Trial and Appeal Board, or the PTAB. On March 6, 2024, the PTAB issued decisions instituting inter partes review proceedings on all challenged claims of U.S. Patent Nos. 10,702,600 and 10,933,127. An oral hearing on the merits occurred on December 10, 2024. On March 5, 2025, the PTAB found all challenged claims of Moderna&#8217;s U.S. Patent Nos. 10,933,127 and 10,702,600 to be unpatentable and thus invalid. Moderna appealed this decision, and the appeal is pending.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Netherlands</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In September 2022, Moderna filed a lawsuit against us and our wholly owned subsidiary BioNTech Manufacturing GmbH and Pfizer B.V., Pfizer Export B.V., C.P. Pharmaceuticals International C.V. and Pfizer Inc. in the District Court of The Hague alleging Comirnaty&#8217;s infringement of EP&#8217;949 and EP&#8217;565. The District Court of the Hague held a hearing on October 6, 2023, on infringement and validity with respect to EP&#8217;949. On December 6, 2023, the Court found EP&#8217;949 to be invalid. On March 5, 2024, Moderna appealed this decision, and the appeal is pending. A hearing on the EP&#8217;949 appeal occurred on September 22, 2025, with a decision expected around September 2026. The infringement proceedings with respect to EP&#8217;565 have been withdrawn and therefore dismissed, following the EPO&#8217;s final revocation of EP&#8217;565 in January 2026.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">55</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Ireland</font><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%"> </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In May 2023, Moderna filed a lawsuit against us and our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Inc., Pfizer Healthcare Ireland, Pfizer Ireland Pharmaceuticals, and C.P. Pharmaceuticals International C.V. alleging Comirnaty&#8217;s infringement of EP&#8217;949 and EP&#8217;565 in the High Court of Ireland. On February 26, 2024, the High Court of Ireland stayed the lawsuit pending the final determination of the EPO opposition proceedings for EP&#8217;949 and EP&#8217;565 (in each case including any appeals). </font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Belgium</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In May 2023, Moderna filed a lawsuit against us, our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Inc. and Pfizer Manufacturing Belgium alleging Comirnaty&#8217;s infringement of EP&#8217;949 and EP&#8217;565 in the Brussels Dutch-speaking Enterprise Court. On May 29, 2024, the parties filed a joint request to stay the proceedings, which was entered by the Court. On June 30, 2026, the Brussels Court confirmed the withdrawal of Moderna&#8217;s infringement proceedings with respect to EP&#8217;565 following Moderna&#8217;s request to withdraw these proceedings. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of Moderna&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Arbutus and Genevant Proceedings</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In April 2023, Arbutus Biopharma Corp., or Arbutus, and Genevant Sciences GmbH, or Genevant, filed a lawsuit against Pfizer and us in the U.S. District Court for the District of New Jersey alleging that Pfizer and we have infringed the following patents owned by Arbutus&#58; U.S. Patent Nos. 9,504,651&#59; 8,492,359&#59; 11,141,378&#59; 11,298,320&#59; and 11,318,098, through the use of Genevant&#8217;s lipid nanoparticle technology and methods for producing such lipids in Comirnaty, and seeking monetary relief. This proceeding is currently pending.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the lawsuit mentioned above. However, our analysis of Arbutus&#8217; and Genevant&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">GlaxoSmithKline Proceedings</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">United States</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In April 2024, GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC, or GSK, filed a lawsuit against Pfizer and us and our wholly owned subsidiaries BioNTech Manufacturing GmbH and </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">56</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">BioNTech US Inc. in the U.S. District Court for the District of Delaware alleging that the cationic lipid used in Comirnaty infringes U.S. Patent Nos. 11,638,693&#59; 11,638,694&#59; 11,666,534&#59; 11,766,401&#59; and 11,786,467&#59; and seeking monetary relief. On August 14, 2024, GSK filed an amended complaint to assert infringement of three additional patents, U.S. Patent Nos. 11,759,422&#59; 11,655,475&#59; and 11,851,660. A trial is scheduled to occur in June 2027. This proceeding is currently pending.</font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Ireland</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In July 2025, GlaxoSmithKline Biologicals SA filed a lawsuit against our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Ireland Pharmaceuticals Unlimited Company, and Pfizer Healthcare Ireland Unlimited Company, alleging Comirnaty&#8217;s infringement of European Patent Nos.&#8239;2,590,626, 4,066,856, and 4,226,941 in the High Court of Ireland. This proceeding is currently pending. </font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Unified Patent Court</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In July&#8239;2025, GlaxoSmithKline Biologicals SA filed two lawsuits against BioNTech SE, BioNTech Europe GmbH, BioNTech Manufacturing GmbH, and BioNTech Manufacturing Marburg GmbH, as well as 26 Pfizer entities, in the Unified Patent Court (Hague Division). In the first lawsuit, GSK alleges Comirnaty&#8217;s infringement of European Patent No. 2,590,626, or EP&#8217;626, and in the second lawsuit, GSK alleges Comirnaty&#8217;s infringement of European Patent Nos. 4,066,856, or EP&#8217;856, and 4,226,941, or EP&#8217;941. Oral hearings wherein the UPC will hear the parties&#8217; arguments regarding infringement and invalidity of EP&#8217;626, EP&#8217;856, and EP&#8217;941 have been scheduled for September 3, 2026 and September 30-October 3,  2026. These proceedings are currently pending. </font></div><div style="margin-bottom:6pt;margin-top:10pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">United Kingdom</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In September 2025, we and Pfizer filed a revocation action against GlaxoSmithKline Biologics S.A. in the Business and Property Courts of England and Wales, in the U.K. High Court, requesting revocation of European Patent Nos.&#8239;2,590,626, 4,066,856, and 4,226,941. On October 7, 2025, GSK filed a defense and counterclaim for infringement against BioNTech SE and BioNTech Manufacturing GmbH, alleging Comirnaty&#8217;s infringement of European Patent Nos.&#8239;2,590,626, 4,066,856, and 4,226,941. A trial has been scheduled for February 2027. This proceeding is currently pending. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the lawsuit mentioned above. However, our analysis of GlaxoSmithKline&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of June 30, 2026. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Promosome Proceedings</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In January 2025, Promosome LLC, or Promosome, filed a lawsuit against us and Pfizer in the Unified Patent Court, or UPC, Munich Division, alleging that Comirnaty infringes European Patent No. 2,401,365, or EP&#8217;365, and seeking monetary relief. An oral hearing wherein the UPC heard the parties&#8217; arguments regarding infringement and invalidity was held on May 12, 2026. On July 7, 2026, the UPC issued a written decision finding EP&#8217;365 to be invalid and not infringed. This decision is appealable by Promosome.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">57</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We believe we have strong defenses against the allegations claimed relative to the patent and intend to vigorously defend ourselves in the lawsuit mentioned above. However, our analysis of Promosome&#8217;s claim is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, this matter constitutes a contingent liability as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the contingent liability. </font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Bayer&#47;Monsanto Proceedings</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In January 2026, Bayer CropScience LLC, Monsanto Company, and Monsanto Technology, LLC, or collectively, Bayer, filed a lawsuit against us and Pfizer in the United States District Court for the District of Delaware, alleging that Comirnaty infringes U.S. Patent No. 7,741,118 and seeking monetary relief. This proceeding is currently pending.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We believe we have strong defenses against the allegations claimed relative to the patent and intend to vigorously defend ourselves in the lawsuit mentioned above. However, our analysis of Bayer&#8217;s claim is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, this matter constitutes a contingent liability as of June 30, 2026. However, it is currently impractical for us to estimate with sufficient reliability the contingent liability.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_632"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Liquidity and Capital Resources</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_645"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Overview</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Given our strong financial, scientific and operational accomplishments, we believe we have the resources to diligently allocate our current capital to drive a multi-platform strategy and deliver a fully integrated global biotechnology company. We focus our research and development, or R&#38;D, on rapidly advancing our diversified clinical oncology pipeline with synergistic potential and maintaining leadership position in COVID-19 vaccine business. We plan to continue investing in the acceleration of late-stage trial execution for our immuno-oncology and antibody-drug-conjugates programs as well as our mRNA cancer immunotherapies. As a science and innovation driven company, we will continue to focus investments on R&#38;D and scaling the business for commercial readiness in oncology in 2026. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As of June&#160;30, 2026, we had cash and cash equivalents of &#8364;9,741.0&#160;million, current security investments disclosed as financial assets of &#8364;5,035.1&#160;million and non-current security investments disclosed as financial assets of &#8364;1,858.1&#160;million accumulating to &#8364;16,634.2&#160;million in cash, cash equivalents and security investments. In general, the aim is to protect and maximize the financial resources available for further research and development projects.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Cash and cash equivalents and financial securities are invested in accordance with our asset management and investment policy, primarily with a focus on liquidity and capital preservation, and consist primarily of cash in bank accounts and on hand as well as long- and short-term financial investments.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">58</font></div></td></tr></table></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_652"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Cash Flow</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2282"></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The following table summarizes the primary sources and uses of cash for each period presented&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 10.92pt 0 1pt;text-indent:-9.92pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Three months ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Six months ended June 30,</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2026</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2025</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:120%">Net cash flows from &#47; (used in)&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Operating activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">10.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">146.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(410.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(634.2)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Investing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(100.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(64.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">2,550.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">1,182.4</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt 1.5pt 15.17pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Financing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(108.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(13.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(82.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">(27.1)</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total cash inflow &#47; (outflow) before change in cash and cash equivalents resulting from exchange rate differences and other valuation effects</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">(198.1)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">68.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">2,057.9</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">521.1</font></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Operating Activities</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We derive cash flows from operations primarily from the sale of products and services rendered. Our cash flows from operating activities are significantly influenced by cash we generate from our COVID-19 vaccine collaboration under which we receive a share of our collaboration partner&#8217;s gross profit as well as cash we receive from out-licensing and our use of cash for operating expenses and working capital to support the business.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our net cash flows from operating activities for the three months ended June 30, 2026 were &#8364;10.5&#160;million. </font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Cash payments for our operating activities exceeded our cash received from our revenue streams for the</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> three months ended June 30, 2026, resulting in a cash outflow of &#8364;62.6&#160;million. On the other hand, we generated positive cash contributions from interest and other payments related to the security investments of &#8364;70.8&#160;million and grants of &#8364;33.7&#160;million, which were partly offset by tax payments of &#8364;16.1&#160;million and by share-based payment programs of &#8364;13.0&#160;million.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our net cash flows from operating activities for the three months ended June 30, 2025 were &#8364;146.5&#160;million. Cash received from our revenue streams exceeded payments for our operating activities for the three months ended June 30, 2025, resulting in a cash inflow of &#8364;94.7&#160;million. Additionally, we generated positive cash contributions from interest and other payments related to the security investments of &#8364;73.1&#160;million and grants of &#8364;7.8&#160;million, which were partly offset by tax payments of &#8364;14.9&#160;million and by share-based payment programs of &#8364;11.5&#160;million.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our net cash flows used in operating activities for the six months ended June 30, 2026 were &#8364;410.5&#160;million. </font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Cash payments for our operating activities exceeded our cash received from our revenue streams for the six months ended June 30, 2026, resulting in a cash outflow of &#8364;537.5&#160;million. On the other hand, we generated positive cash contributions from interest and other payments related to the security investments of &#8364;157.4&#160;million and grants of &#8364;48.0&#160;million, which were partly offset by tax payments of &#8364;57.7&#160;million </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">and by share-based payment programs of &#8364;15.1&#160;million.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our net cash flows used in operating activities for the six months ended June 30, 2025 were &#8364;634.2&#160;million. Cash payments for our operating activities exceeded our cash received from our revenue streams for the six months ended June 30, 2025, resulting in a cash outflow of &#8364;808.9&#160;million. On the other hand, we generated positive cash contributions from interest and other payments related to the security investments of &#8364;191.7&#160;million and grants of &#8364;31.0&#160;million, which were partly offset by tax payments of &#8364;27.1&#160;million and by share-based payment programs of &#8364;15.1&#160;million. </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">59</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Investing Activities</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our net cash flows used in investing activities for the three months ended June 30, 2026 were &#8364;100.1&#160;million</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">. The amount includes &#8364;48.1&#160;million mainly r</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">epresenting net payments</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> in security investments. The payments in property, plant and equipment of &#8364;54.6&#160;million related to investments in building our facilities in Mainz, Germany, China and elsewhere.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our net cash flows used in investing activities for the three months ended June 30, 2025 were &#8364;64.4&#160;million. The amount includes &#8364;34.7&#160;million mainly representing net payments in security investments. The net payments in property, plant and equipment and intangible assets of &#8364;29.7&#160;million are related to investments in building our laboratory and office facilities in Mainz, Germany and elsewhere. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our </font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">net cash flows from investing activities for the six months ended June 30, 2026 were &#8364;2,550.5&#160;million. The amount includes &#8364;2,679.8&#160;million, mainly representing net repayments from matured security investments. The payments in property, plant and equipment of &#8364;111.4&#160;million related to investments in building our facilities in Mainz, Germany, China  and elsewhere.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our net cash flows from investing activities for the six months ended June 30, 2025 were &#8364;1,182.4&#160;million. This amount includes &#8364;1,908.2&#160;million, mainly consisting of repayments from matured security investments offset by a payment of &#8364;565.1 million for the settlement of our pre-existing relationship in connection with the License and Collaboration Agreement with Biotheus Inc., or Biotheus, entered into in November 2023, which is separate from the remaining purchase price to be transferred for the acquired business of Biotheus. Other offsetting effects are the remaining net cash outflow for the Biotheus business combination of &#8364;78.5&#160;million and net payments in property, plant and equipment of &#8364;75.0 million related to investments in building our laboratory and office facilities in Mainz, Germany and elsewhere.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:110%">Financing Activities</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our net cash flows used in financing activities for the three months ended June 30, 2026 were &#8364;108.5&#160;million and mainly related to payments for the share repurchase program of &#8364;129.2 million and to lease payments of &#8364;11.3&#160;million. These payments were partly offset by proceeds from loans and borrowings of &#8364;37.8&#160;million. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our net cash flows used in financing activities for the three months ended June 30, 2025 were &#8364;13.3&#160;million and mainly related to our lease payments of &#8364;9.6&#160;million.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our net cash flows used in financing activities for the six months ended June 30, 2026 were &#8364;82.1&#160;million and mainly related to payments for the share repurchase program of &#8364;129.2 million and to lease payments of &#8364;23.2&#160;million. These payments were partly offset by proceeds from loans and borrowings of &#8364;76.2&#160;million.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our net cash flows used in financing activities for the six months ended June 30, 2025 were &#8364;27.1&#160;million and mainly related to our lease payments of &#8364;18.9&#160;million.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">60</font></div></td></tr></table></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_658"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Operation and Funding Requirements</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As part of our capital allocation strategy, we expect to continue to incur significant and increasing operating expenses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we and our collaborators&#58;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">continue or expand our research or development of our programs in preclinical development&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">continue or expand the scope of our clinical trials for our product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">initiate additional preclinical, clinical, or other trials for our product candidates, including under our collaboration agreements&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">continue to invest in our immunotherapy platforms to conduct research to identify novel technologies&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">change or increase our manufacturing capacity or capability&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">change or add additional suppliers&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">add additional infrastructure to our quality control, quality assurance, legal, compliance and other groups to support our operations as a public company and our product development and commercialization efforts, including new and expanded sites globally&#894; </font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">attract and retain skilled personnel&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">seek marketing approvals and reimbursement for our product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">enhance our commercial infrastructure for other product candidates for which we are seeking to obtain marketing approval&#59; </font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">seek to identify and validate additional product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">acquire or in-license other product candidates and technologies&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">acquire other companies&#59;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">make milestone or other payments under any in-license agreements&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">maintain, protect, defend, enforce and expand our intellectual property portfolio&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">experience any delays or encounter issues with any of the above.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are a party to license and research and development agreements with universities and other third parties, as well as patent assignment agreements, under which we have obtained rights to patents, patent applications and know-how. We enter into contracts in the normal course of business with CROs for clinical trials and clinical and commercial supply manufacturing, and with vendors for preclinical research studies and for other services and products for operating purposes. We work together with CMOs who manufacture our product candidates and products, and enter into lease agreements to lease laboratory, GMP manufacturing, storage and office spaces. Purchase obligations under our agreements, to the extent that they are quantifiable and not cancellable, have been </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">61</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">considered when defining our guidance for future cash commitments. The following table shows our significant committed cash outflow within one year and for the years 2027 and beyond.</font></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.854%"><tr><td style="width:1.0%"></td><td style="width:43.515%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">June 30, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:140%">(in millions &#8364;)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Less than 1 year</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">1 to 5 years</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">More than 5 years</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total</font></td><td colspan="3" style="border-right:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Commitments under purchase agreements for property, plant and equipment</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">74.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">5.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">80.6</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">Contractual obligation to acquire intangible assets</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">179.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">311.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.04em;line-height:140%">194.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">685.4</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">Total</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">254.6</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">317.0</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">194.4</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:8pt;font-weight:700;letter-spacing:0.03em;line-height:140%">766.0</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-right:1pt solid #bece33;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are subject to all of the risks related to the development and commercialization of pharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our future funding requirements, both near and long term, will depend on many factors, including, but not limited to&#58;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the initiation, progress, timing, costs, and results of preclinical or nonclinical studies and clinical trials for our product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the amount and timing of revenues and associated costs from sales of our COVID-19 vaccine&#59;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the results of research and our other platform activities&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the clinical development plans we establish for our product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the terms of any agreements with our current or future collaborators, and the achievement of any milestone payments under such agreements to be paid to us or our collaborators&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the number and characteristics of product candidates that we develop or may in-license&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA and other comparable regulatory authorities&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the cost of filing, prosecuting, obtaining, maintaining, protecting, defending and enforcing our patent claims and other intellectual property rights, including actions for patent and other intellectual property infringement, misappropriation and other violations brought by third parties against us regarding our product candidates or actions by us challenging the patent or intellectual property rights of others&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the effect of competing technological and market developments, including other products that may compete with one or more of our product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the cost and timing of completion and further expansion of clinical and commercial scale manufacturing activities sufficient to support all of our current and future programs&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">62</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the cost of establishing sales, marketing, and distribution capabilities for any product candidates for which we may receive marketing approval and reimbursement in regions where we choose to commercialize our products on our own&#59; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the terms of any ADS repurchases we make.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_549755815136"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Risk Factors</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our business is subject to various risks, including those described below. You should consider carefully the risks and uncertainties described below and in our future filings. If any such risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. Additionally, risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and&#47;or prospects.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1255"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Risk Factor Summary</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Our business is dependent on the successful development, regulatory approval and commercialization of new medicinal product candidates based on our technology platforms, particularly our oncology assets including pumitamig and our antibody-drug conjugate, or ADC, clinical assets. If we and our collaborators are unable to obtain approval for and effectively commercialize our product candidates for the treatment of patients in their intended indications, our business would be significantly harmed.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">We are developing product candidates and services, including our oncology pipeline and ADC product candidates, in an environment of rapid technological and scientific change, including evolving standards of care, and our failure to effectively compete would prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do and we may not be able to compete successfully.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Our product candidates may not work as intended, may cause undesirable effects or may have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control. Clinical trials of our product candidates may be delayed, and certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, and we may have difficulty recruiting patients to participate in clinical trials, any of which can affect our ability to fund our company and would have a material adverse impact on our business.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">If we are not successful in discovering, developing and commercializing additional product candidates beyond our current portfolio, our ability to expand our business and achieve our strategic objectives would be impaired.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Demand for our COVID-19 vaccine, though difficult to predict, is expected to continue to decrease in the near future. Changing market dynamics, including as a result of government policy and public </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">63</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">sentiment, will impact our revenue, which currently depends heavily on sales of our COVID-19 vaccine, and result in challenges relating to production of our COVID-19 vaccine. </font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Our reported revenue is partially based on preliminary estimates of COVID-19 vaccine sales and costs from Pfizer Inc., or Pfizer, that are likely to change in future periods, which may impact our reported financial results.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Other companies or organizations may challenge our intellectual property rights or may assert intellectual property rights that prevent us from developing and commercializing our COVID-19 vaccine or our product candidates and other technologies, or that negatively affect our results of operations.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Even if we obtain regulatory approval for our product candidates, the products may not gain the market acceptance among physicians, patients, hospitals, treatment centers and others in the medical community necessary for commercial success.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict. If our operating results fall below expectations, the price of the ADSs representing our shares could decline.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">If we identify material weaknesses in our internal control over financial reporting and fail to remediate such material weaknesses, we may not be able to report our financial results accurately or to prevent fraud.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">As a &#8220;foreign private issuer,&#8221; we are exempt from a number of rules under U.S. securities laws, as well as Nasdaq rules, and we are permitted to file less information with the Securities and Exchange Commission, or the SEC, than U.S. companies. This may limit the information available to holders of the ADSs and may make our ordinary shares and the ADSs less attractive to investors.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Our approved product and product candidates are based on novel technologies and they may be complex and difficult to manufacture. We may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping. If we or any of the third-party manufacturers we work with encounter such difficulties, our ability to supply materials for clinical trials or any approved product could be delayed or stopped.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">If our efforts to obtain, maintain, protect, defend and&#47;or enforce the intellectual property related to our COVID-19 vaccine or our product candidates and technologies are not adequate, we may not be able to compete effectively in our market.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">We have experienced and may continue to experience significant volatility in the market price of the ADSs representing our ordinary shares.</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Our principal shareholders and management own a significant percentage of our ordinary shares and will be able to exert significant control over matters subject to shareholder approval.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">64</font></div></td></tr></table></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1285"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Risks Related to our Business</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our business is dependent on the successful development, regulatory approval and commercialization of new medicinal product candidates based on our technology platforms, particularly our oncology assets including pumitamig and our antibody-drug conjugate, or ADC, clinical assets. If we and our collaborators are unable to obtain approval for and effectively commercialize our product candidates for the treatment of patients in their intended indications, our business would be significantly harmed.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain, and we may not be able to obtain full approvals, or may only obtain partial approvals, in the requested indication for the commercialization of product candidates we may develop. Any product candidates we may develop and the activities associated with their development and commercialization, including design, testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and by comparable global health authorities. To obtain the requisite regulatory approvals required to commercialize any of our product candidates, we and our collaborators must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective for their intended use in the relevant target population. Successful completion of clinical trials is a prerequisite to submitting a biologics license application, or BLA, or a new drug application, or NDA, to the FDA, a Marketing Authorization Application, or MAA, to the EMA, and similar marketing applications to comparable global regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. Although our COVID-19 vaccine has received emergency use authorization and&#47;or regulatory approvals in certain countries, it is possible that none of our other product candidates, or any product candidates we may seek to develop in the future, will ever obtain regulatory approval. We have limited experience in filing and supporting the applications necessary to gain marketing approvals and may need to rely on third-party contract research organizations, or CROs, regulatory consultants or collaborators to assist us in this process. We expect to submit initial BLAs&#47;MAAs for our product candidates in the United States, the European Union and in other countries globally. In some of these jurisdictions, mRNA-based medicinal products may be classified in different ways and may be subject to specific requirements. Securing regulatory approval requires the submission of extensive quality, preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Clinical benefit and risk are regularly assessed during development, and any new medicinal product we develop may turn out to be insufficiently, i.e., not clinically meaningfully, effective, or may prove to have unacceptable adverse effects, or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The process of obtaining marketing approvals in the United States, the European Union and elsewhere is expensive, and if additional clinical trials are required, may take many years. Timing can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies and standards of care during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application may cause delays in the approval or </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">65</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">rejection of an application. The FDA, EMA and comparable regulatory authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that the data are insufficient for approval and require additional preclinical, clinical or other trials. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. Additional delays or non-approval may result if an FDA panel of experts, referred to as an Advisory Committee, or other regulatory authority recommends non-approval or restrictions on approval. For example, the FDA&#8217;s approval of our LP.8.1-adapted monovalent COVID-19 vaccine is in a narrower population than our previous variant-adapted vaccines. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials, and the review process. Officials appointed by the U.S. presidential administration to oversee the agencies involved with approval of drugs and biologics may seek to change regulatory requirements for approval or the approach to reviewing applications. Together with changes of regulatory policy priorities and allocated resources, this could cause further delays, expense or non-approvals.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Regulatory agencies also may approve a product candidate for fewer or more limited indications or patient populations than requested or may grant approval subject to the conduct of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The FDA, EMA and other regulatory agencies review the Quality or Chemistry, Manufacturing and Controls, or CMC, section of regulatory filings. Any aspects found unsatisfactory by regulatory agencies may result in delays in clinical trials and commercialization. In addition, the regulatory agencies typically conduct pre-approval inspections at the time of a BLA, MAA or comparable filing. Any findings by regulatory agencies and failure to comply with requirements may lead to delay in approval and failure to commercialize the potential mRNA product candidate.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If we experience delays in obtaining, or if we fail to obtain, approval of any product candidates we may develop, the commercial prospects for those product candidates will be harmed, and our ability to generate revenues will be materially impaired. Additionally, even if we are successful in obtaining marketing approval for product candidates, because our preclinical studies and clinical trials have not been designed with specific commercialization considerations, the commercial prospects for those product candidates could be harmed, and our ability to generate revenues could be materially impaired.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We are developing product candidates and services, including our oncology pipeline and ADC product candidates, in an environment of rapid technological and scientific change, including evolving standards of care, and geopolitical uncertainties, and our failure to effectively compete would prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do and we may not be able to compete successfully.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The pharmaceutical market is intensely competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and other public and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to target. Many of our competitors have&#58;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">66</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and commercialization of products&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">more extensive experience in preclinical testing, conducting</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> clinical trials, obtaining regulatory approvals and manufacturing, marketing and selling drug products&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">product candidates that are based on previously tested or accepted technologies&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">products that have been approved or are in late stages of development&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">collaborative arrangements in our target markets with leading companies and research institutions.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We will continue to face intense competition from products that have already been approved and accepted by the medical community for the treatment of the conditions for which we may develop products in the future. We also expect to face competition from new products that enter the market. There are a number of products currently under development, which may become commercially available in the future, for the treatment of conditions for which we are trying, or may in the future try, to develop drugs. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively than any products we develop.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We anticipate competing with the largest pharmaceutical companies in the world, many of which are currently conducting research in the fields of infectious diseases, immuno-oncology, rare genetic diseases and cancer immunotherapies. Some of these companies have greater financial and human resources than we currently have. In addition to these large pharmaceutical companies, we may directly compete with fully-integrated biopharmaceutical companies and other immunotherapy-focused oncology companies, as well as a number of companies focused on immunotherapies or shared tumor antigen and neoantigen therapeutics, some of which have entered into collaboration and funding agreements with larger pharmaceutical or biotechnology companies. We also face competition from other companies and institutions that continue to invest in innovation in the ADC field.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If we successfully develop other product candidates, and obtain approval for them, we will face competition based on many different factors, including&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the safety and effectiveness of our products relative to alternative therapies, if any&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="background-color:#ffffff;color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="background-color:#ffffff;color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the timing and scope of regulatory approvals for these products&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="background-color:#ffffff;color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the availability and cost of manufacturing and commercialization capabilities&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="background-color:#ffffff;color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the price of any approved immunotherapy&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="background-color:#ffffff;color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">reimbursement coverage&#894; and</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">67</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="background-color:#ffffff;color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">intellectual property position.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We also face competition in the rapidly growing and developing artificial intelligence, or AI, industry. Our competitors may develop or commercialize products and services with significant advantages over any products we develop based on any of the factors listed above or on other factors. In addition, our competitors may develop collaborations with or receive funding from larger pharmaceutical, biotechnology or technology companies, providing them with an advantage over us. Our competitors therefore may be more successful in commercializing their products and services than we are, which could adversely affect our competitive position and business. Competitive products and services may make any products and services we develop obsolete or non-competitive before we can recover the expenses of developing and commercializing such products, if approved, and services.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our product candidates may not work as intended, may cause undesirable effects or may have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As with most medicinal products, use of our product candidates could be associated with undesirable effects or adverse events which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. The potential for adverse events is especially acute in the oncology setting, where patients may have advanced disease, impaired organ function, compromised immune and other systems and may be receiving numerous other therapies. Undesirable side effects or unacceptable toxicities caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA or comparable regulatory authorities. Results of our trials could reveal a high and unacceptable severity and prevalence of adverse reactions that negatively affect the benefit&#47;risk assessment.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If unacceptable side effects arise in the development of our product candidates, we, the FDA, competent authorities of EU member states, ethics committees, the institutional review boards, or IRBs, at the institutions in which our studies are conducted, or the Data Safety Monitoring Board, or DSMB, could suspend or terminate our clinical trials. The FDA or comparable regulatory authorities could also order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We are committed to training medical personnel using our product candidates to understand the side effect profiles for our clinical trials, as well as providing guidance to prescribers upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly. </font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Clinical trials are strictly regulated and monitored by sponsors, independent data and safety monitoring boards, ethics committees, and regulatory agencies. Despite adequate risk minimization measures, unexpected events may occur that could adversely impact patients&#8217; safety and&#47;or affect our ability to obtain regulatory approvals and, if approved, commercialize our product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In our ongoing and planned clinical trials, we have contracted, and are expected to continue to contract, with academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, these centers and hospitals may </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">68</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, inexperience, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA, the EMA or other comparable regulatory authority delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. The centers using our products, if and when approved, could also have difficulty managing any adverse effects of our products, or use medicines that do not adequately control such undesirable effects or that have a detrimental impact on the efficacy of the treatment. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, even if we successfully advance our product candidates into and through clinical trials, such trials will likely only include a limited number of patients and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of patients are exposed to the product candidate. Further, any clinical trials may not be sufficient to determine the effects and safety consequences of taking our product candidates over a multi-year period.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If any of our product candidates receives marketing approval and we or others later identify undesirable effects caused by such products, a number of potentially significant negative consequences could result, including&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">regulatory authorities may withdraw their approval of the product&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we may be required to recall a product or change the way such product is administered to patients&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a Medication Guide outlining the risks of such side effects for distribution to patients&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we could be sued and held liable for harm caused to patients&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the product may become less competitive&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our reputation may be negatively impacted.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our results of operations and business. In addition, if one or more of our product candidates or our immunotherapy approach generally prove to be unsafe, our technology platforms and pipeline could be affected, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">69</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all and would have an adverse effect on our business.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Much of our pipeline is in preclinical development and these programs could be delayed or not advance into the clinic. Before we can initiate clinical trials for product candidates, we must complete extensive preclinical studies, including IND-enabling Good Laboratory Practice toxicology testing, that support our planned Investigational New Drug applications, or INDs, in the United States or similar applications in other jurisdictions. We must also complete extensive work on CMC activities (including collecting yield, purity and stability data) to be included in the IND filing. CMC activities for a new category of medicines such as mRNA therapies require extensive manufacturing processes and analytical development, which are uncertain and lengthy. For instance, batch failures have occurred as we scale up our manufacturing and may occur in the future. In addition, we have had in the past, and may in the future have, difficulty identifying appropriate buffers and storage conditions to enable sufficient shelf life of batches of our preclinical or clinical product candidates. If we are required to produce new batches of our product candidates due to insufficient shelf life, it may delay the commencement or completion of preclinical or clinical trials of such product candidates. For example, we cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA or other regulatory authorities will accept the results of our preclinical testing or our proposed clinical programs or if the outcome of our preclinical testing, studies and CMC activities will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control. Clinical trials of our product candidates may be delayed, certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, and we may have difficulty recruiting patients to participate in clinical trials, any of which can affect our ability to fund our company and would have a material adverse impact on our business.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Clinical testing is expensive and complex and can take many years to complete. Its outcome is inherently uncertain. We may not be able to initiate, may experience delays in, or may have to discontinue clinical trials for our product candidates. We and our collaborators also may experience numerous unforeseen events during, or as a result of, any clinical trials that we or our collaborators conduct that could delay or prevent us or our collaborators from successfully developing our product candidates, including&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the FDA, other regulators, IRBs or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site for any number of reasons, including concerns regarding safety and aspects of the clinical trial design&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we may experience delays in reaching, or fail to reach, agreement on favorable terms with prospective trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we have optimized in the past and may in the future optimize our manufacturing processes, including through changes to the scale and site of manufacturing, which may lead to additional studies (including bridging and bioequivalence studies) or potentially significant changes in our </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">70</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">clinical trial designs, requiring additional cost and time, and, as a consequence, lead to a delay in plans for progressing one or more product candidates&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the outcome of our preclinical studies and our early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">in an effort to optimize product features, we have made in the past and may continue to make changes to our product candidates after we commence clinical trials of a medicine which may require us to repeat earlier stages of clinical testing or delay later-stage testing of the medicine&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">clinical trials of any product candidates may fail to show safety or efficacy, or may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional nonclinical studies or clinical trials, or we may decide to abandon product development programs&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">differences in trial design between early-stage clinical trials and later-stage clinical trials may make it difficult to extrapolate the results of earlier clinical trials to later clinical trials&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">preclinical and clinical data are often susceptible to varying interpretations and analyses, and many product candidates believed to have performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our product candidates may have undesirable effects or other unexpected characteristics. One or more of such effects or events could cause regulators to impose a clinical hold on the applicable trial, or cause us or our investigators, IRBs or ethics committees to suspend or terminate the trial of that product candidate or any other of our product candidates for which a clinical trial may be ongoing&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the number of trial participants required for clinical trials of any product candidates may be larger than we anticipate, identification of trial participants for such trials may be limited, enrollment in these clinical trials may be slower than we anticipate due to perceived adverse effects, limited patient populations, competitive trials, or other reasons, or participants may withdraw from clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">despite robust sponsor oversight, our and our collaborators&#8217; third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations in a timely manner, or at all, or may deviate from the clinical trial protocol or withdraw from the trial, which may require the addition of new clinical trial sites&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">regulators may elect to impose a clinical hold, or we, our investigators, IRBs or ethics committees may elect to suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to an unacceptable benefit-risk ratio&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">71</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">with respect to infectious disease vaccine trials in particular, we have to wait for a particular level of infection in the placebo arm in order to assess protection provided by vaccine, and we cannot control the rate of exposure or infection, which can make timing uncertain&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">patient characteristics, the rate of disease progression, and other external influences beyond our control can make the timing of analysis uncertain, particularly in the case of later-stage oncology trials&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the cost of preclinical or nonclinical testing and studies and clinical trials of any product candidates may be greater than we anticipate&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials may be insufficient or inadequate&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">safety or efficacy concerns regarding our product candidates may result from any concerns arising from nonclinical or clinical testing of other therapies targeting a similar disease state or other therapies, such as gene therapy, that are perceived as similar to ours&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the FDA or other regulatory authorities may require us to submit additional data, such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We could also encounter delays if a clinical trial is suspended or placed on hold by us, the FDA, or other regulatory authorities, ethics committees, or the IRBs of the institutions in which such trials are being conducted, or if such trial is recommended for suspension or termination by the DSMB. In the event a trial is suspended or placed on hold, it may, upon further analysis, be terminated altogether. If a pivotal trial is terminated, the relevant program may also be subject to delays or termination. We may in the future be delayed in gaining clearance from the FDA or other regulators to initiate clinical trials through, among other things, the imposition of a clinical hold in order to address comments from such regulators on our clinical trial design or other elements of our clinical trials. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols&#894; inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold&#894; unforeseen safety issues or adverse side effects&#894; failure to demonstrate a benefit, or adequate benefit-risk ratio, from using a product candidate&#894; failure to establish or achieve clinically meaningful trial endpoints&#894; changes in governmental regulations or administrative actions&#894; or lack of adequate funding to continue the clinical trial. Many of the factors that cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. We could also experience delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA and regulatory authorities in other jurisdictions have limited experience with commercial development of several of our technologies. The FDA may require an Advisory Committee to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">72</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">the FDA often adheres to the Advisory Committee&#8217;s recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be certain.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We must also complete extensive work on CMC activities that require extensive manufacturing processes and analytical development, which are uncertain and lengthy. The FDA and other regulatory authorities have indicated that, prior to commencing later stage clinical trials for our mRNA-based product candidates, we will need to scale up and further refine assays to measure and predict the potency of a given dose of these product candidates. Any delay in the scaling and refining of assays that are acceptable to the FDA or other regulatory authorities could delay the start of future clinical trials. Further, the FDA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data for our clinical trials or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Significant additional preclinical or nonclinical testing and studies or clinical trial delays for our product candidates also could allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in the development, or the suspension of development, of our product candidates may harm our business, financial condition and prospects significantly. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, on June 28, 2024, the Supreme Court overturned the </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Chevron</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> doctrine in the combined cases of </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Loper Bright Enterprises v. Raimondo</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> and </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Relentless Inc. v. Department of Commerce</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">. The </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Chevron</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> doctrine gave deference to regulatory agencies in litigation against the FDA and other agencies. In addition, the Supreme Court decided </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Corner Post, Inc. v. Board of Governors of the Federal Reserve System</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">, which lengthened the time in which some challenges to agency rules can be initiated. As a result of these cases, more plaintiffs may bring lawsuits against the FDA to challenge longstanding decisions and policies of the FDA, which could undermine the FDA&#8217;s authority, lead to uncertainties in the industry, and disrupt the FDA&#8217;s normal operations, which could delay the FDA&#8217;s review of our marketing applications.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">If we or our collaborators encounter difficulties enrolling participants in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We depend on enrollment of participants in our clinical trials for our product candidates. In the past, our collaborators have found, and we or our collaborators may in the future find, it difficult to enroll trial participants in our clinical studies, which could delay or prevent clinical studies of our product candidates. Identifying and qualifying trial participants to participate in clinical studies of our product candidates is critical to our success. The timing of our clinical studies depends on the speed at which we can recruit trial participants to participate in testing our product candidates. Delays in enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates. If trial participants are unwilling to participate in our studies because of negative publicity from adverse events in our trials or other trials of similar products, or those related to a specific therapeutic area, or for other reasons, including competitive clinical studies for similar patient populations, the timeline for recruiting trial participants, conducting studies, and obtaining regulatory approval of potential products may be delayed. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our product, or termination of the clinical studies altogether.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">73</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We may not be able to identify, recruit and enroll a sufficient number of trial participants, or those with required or desired characteristics to achieve diversity in a study, to complete our clinical trials in a timely manner. Patient and subject enrollment is affected by factors including&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">severity of the disease under investigation&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">complexity and design of the study protocol&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">size of the patient population&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">eligibility criteria for the study in question&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">proximity and availability of clinical study sites for prospective trial participants&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">availability of competing therapies and clinical trials, including between our own clinical trials&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">efforts to facilitate timely enrollment in clinical trials&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">patient referral practices of physicians&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">ability to monitor trial participants adequately during and after treatment&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">ability to recruit clinical trial investigators with the appropriate competencies and experience&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">clinicians&#8217; and trial participants&#8217; perceptions of the potential advantages and side effects of the product candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our ability to obtain and maintain participant informed consent&#894; </font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">major changes in the approval status of competitor investigational products during the clinical trial period&#59; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the risk that trial participants enrolled in clinical trials will not complete a clinical trial.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of trial participants available to us because some trial participants who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by a third party. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of trial participants who are available for our clinical trials at such clinical trial sites. Moreover, because in some cases our product candidates represent a therapeutic novelty in contrast to more traditional methods for disease treatment and prevention, potential trial participants and their doctors may be inclined to use conventional therapies or other investigational therapies rather than enroll trial participants in any future clinical trial involving more novel product candidates. Additionally, if new product candidates, such as gene editing therapies, show encouraging results, potential trial participants and their doctors </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">74</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">may be inclined to enroll trial participants in clinical trials using those product candidates. If such new product candidates show discouraging results or other adverse safety indications, potential trial participants and their doctors may be less inclined to enroll trial participants in our clinical trials. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In particular, certain conditions for which we plan to evaluate our current product candidates are rare diseases with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials will further limit the pool of available trial participants. Additionally, the process of finding and diagnosing patients may prove costly.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We, our collaborators, and other third parties on whom we rely conduct various activities, including research, clinical trials, manufacturing and, where approved, marketing, in jurisdictions across the globe. Such activities are subject to a variety of risks which could materially and adversely affect our business.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our activities increasingly span different jurisdictions. For example, clinical trials of our product candidates are currently being conducted in several countries, and we plan to commercialize our product candidates, if approved, globally. Accordingly, we are subject to additional risks related to operating in multiple countries, including&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">differing regulatory requirements in such countries&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">differences in the standard of care across jurisdictions, which complicates the choice of adequate comparator therapies in global trials&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in Germany and shipping the product candidate to the patient abroad&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">import and export requirements and restrictions&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">restrictions on transfers of information, including certain technologies and personal data&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">economic weakness, including inflation, or changes to the political climate, public sentiment, and government policy preferences in certain economies and markets&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">taxes, including withholding of payroll taxes&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">difficulties staffing and managing operations outside of Germany&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">workforce uncertainty in countries where labor unrest is more common&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">75</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">potential liability under the U.S. Foreign Corrupt Practices Act of 1977 or comparable regulations in other jurisdictions&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">challenges enforcing our contractual and intellectual property rights, especially in those countries that do not respect and protect intellectual property rights to the same extent as Germany and the United States&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">business interruptions resulting from geopolitical actions, including war and terrorism, or public health epidemics or pandemics.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As part of our global operations, we and our collaborators rely on relationships with entities based in various jurisdictions, including for clinical research and manufacturing activities and other regional operational needs. Such relationships may involve the use of our or others&#8217; intellectual property. We expect to continue to rely on such entities, which include locally-based contract manufacturing organizations, or CMOs, and CROs, in the future. For example, we and our collaborators rely on WuXi Biologics Co., Ltd. and its affiliates for outsourcing activities related to manufacturing and the supply chain, research and development, certain IP, and commercialization readiness for certain of our product candidates. Such entities are subject to evolving local regulatory requirements, and may also be subject to U.S. and EU legislation, including the recently enacted U.S. BIOSECURE Act, sanctions, trade restrictions, and&#47;or other regulations. Such requirements could increase the cost or reduce the supply of material available to us, delay or restrict the procurement or supply of such material, or have an adverse affect on our ability to secure significant commitments from governments to purchase our potential therapies.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Further, governments may turn, and have turned, to trade barriers to protect their domestic industries against foreign imports, thereby increasing our cost to operate globally. If significant tariffs or other restrictions are imposed on imports by the United States and related countermeasures are taken by impacted countries, our business, including operating results, cash flows, and financial condition, may be adversely affected. Recently, trade and tariff policies among the United States and other countries have been unsettled and are subject to frequent changes. The U.S. government has imposed tariffs and other trade restrictions on goods across a range of industries, and such actions have at times prompted retaliatory measures by affected countries such as China, Canada and the European Union. While tariffs with certain countries have been temporarily reduced or paused, the imposition of new tariffs will likely be met with further reciprocal tariffs, thus increasing the possibility of a global trade war. If further tariffs are imposed on a broader range of imports, or if retaliatory trade measures are enacted by affected countries, these factors could significantly increase the cost to our global clinical research and manufacturing activities, adversely affect the commercial sale of our COVID-19 vaccines, and harm our competitive position in key markets. Additionally, ongoing trade tensions and uncertainty regarding future trade policies could negatively impact global economic conditions and consumer confidence, further affecting our global operations.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">76</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As noted above, we and our partners have conducted and are expecting in the future to conduct clinical trials for our product candidates at clinical sites located outside of the United States. Although the FDA may accept data from clinical trials outside the United States that are not conducted under an IND, acceptance of this data in support of a marketing application or IND requires the clinical trial to have been conducted in accordance with GCPs, and that the FDA is able to validate the data from the clinical trial through an onsite inspection if it deems such inspection necessary. Where data from non-U.S. clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will not approve the application on the basis of non-U.S. data alone unless those data are considered applicable to the U.S. patient population and U.S. medical practice, the clinical trials were performed by clinical investigators of recognized competence, and the data is considered valid without the need for an onsite inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an onsite inspection or other appropriate means. There can be no assurance the FDA will accept data from clinical trials conducted outside of the United States in support of a marketing application. If the FDA does not accept data from our clinical trials of our product candidates, it would likely result in the need for additional clinical trials, which would be costly and time-consuming and delay or permanently halt our development of a product candidate.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">These and other risks associated with our international operations and our collaborations with our collaborators may materially adversely affect our ability to attain or maintain profitable operations.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Interim top-line and preliminary data from studies or trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">From time to time, we may publish interim top-line or preliminary data from preclinical studies or clinical trials. Interim data are subject to the risk that one or more of the outcomes may materially change as more data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Additionally, interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to disclose publicly regarding a particular study or clinical trial is based on what is typically extensive information, and our securityholders may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by our securityholders or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the top-line data that we report differ from actual </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">77</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Results of earlier studies and trials of our product candidates may not be predictive of future trial results.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Success in preclinical studies and early clinical trials does not ensure that later clinical trials will be successful. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after positive results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Notwithstanding any potential promising results in earlier studies and trials, we cannot be certain that we will not face similar setbacks. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. In addition, the results of our preclinical studies may not be predictive of the results of outcomes in human clinical trials. For example, our tumor-specific cancer immunotherapy candidates and any future product candidates may demonstrate different chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human biological systems in unforeseen or harmful ways. Product candidates in later stages of clinical trials may fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Even if we are able to initiate and complete clinical trials, the results may not be sufficient to obtain regulatory approval for our product candidates.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our planned clinical trials or those of our collaborators may be less efficacious or may reveal significant adverse events not seen in our preclinical or nonclinical studies and may result in a safety profile that could delay or terminate clinical trials, or delay or prevent regulatory approval or market acceptance of any of our product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">There is typically an extremely high rate of attrition for product candidates across categories of medicines proceeding through clinical trials.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">These product candidates may fail to show the desired safety and efficacy profile in later stages of clinical trials despite having progressed through nonclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in later-stage clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Many of our product candidates are being developed or are intended to be co-administered with other developmental therapies or approved medicines. For example, autogene cevumeran (BNT122&#47;RO7198457) is being developed to be co-administered with checkpoint inhibitors. Such combinations may have additional side effects, which may be difficult to predict in future clinical trials.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting trial participants to any of our clinical trials, trial participants may withdraw from trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. We, the FDA or other regulatory authorities, ethics </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">78</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">committees or an IRB may impose a clinical hold on, or suspend or terminate, clinical trials of a product candidate at any time for various reasons, including a belief that participants in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, an unfavorable benefit-risk ratio may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">If we are not successful in discovering, developing and commercializing additional product candidates beyond our current portfolio, our ability to expand our business and achieve our strategic objectives would be impaired.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Although a substantial amount of our efforts focus on the clinical trials and potential approval of our existing product candidates, a key element of our strategy is to discover, develop and potentially commercialize additional products beyond our current portfolio to treat various conditions and in a variety of therapeutic areas. We intend to do so by investing in our own drug and target discovery efforts, exploring potential collaborations for the development of new products, and in-licensing technologies. Identifying new product candidates requires substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Even if we identify product candidates that initially show promise, we may fail to develop and commercialize such products successfully for many reasons, including the following&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the research methodology used may not be successful in identifying potential product candidates&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">competitors may develop alternatives that render our product candidates obsolete&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we may discontinue the development of a product candidate&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">an approved product may not be accepted as safe and effective by trial participants, the medical community or third-party payors.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If we are unsuccessful in identifying and developing additional products, our potential for growth may be impaired.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">79</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">mRNA drug development carries substantial clinical development and regulatory risks due to limited regulatory experience with mRNA immunotherapies.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">To our knowledge, other than our, Moderna, Inc.&#8217;s and Arcturus Therapeutics&#8217; vaccines, no mRNA immunotherapies have been approved or received emergency use authorization or conditional marketing authorization to date by the FDA or the EMA. Successful discovery and development of mRNA-based (and other) immunotherapies by either us or our collaborators is highly uncertain and depends on numerous factors, many of which are beyond our or their control. Our product candidates that appear promising in the early phases of development may fail to advance, experience delays in the clinic or clinical holds, or fail to reach the market for many reasons, including&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">discovery efforts aimed at identifying potential immunotherapies may not be successful&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">nonclinical or preclinical study results may show product candidates to be less effective than desired or have harmful or problematic side effects&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">clinical trial results may show the product candidates to be less effective than expected, including a failure to meet one or more endpoints or have unacceptable side effects or toxicities&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">manufacturing or distribution failures or insufficient supply of GMP materials for clinical trials or higher than expected cost could delay or set back clinical trials, or make our product candidates commercially unattractive&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our improvements in the manufacturing processes may not be sufficient to satisfy the clinical or commercial demand of our product candidates or regulatory requirements for clinical trials&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">changes that we make to optimize our manufacturing, testing or formulating of GMP materials could impact the safety, tolerability and efficacy of our product candidates&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">pricing or reimbursement issues or other factors could delay clinical trials or make any immunotherapy uneconomical or noncompetitive with other therapies&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">changing social and political preferences regarding vaccines and mRNA therapies&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the failure to timely advance our programs or receive the necessary regulatory approvals, or a delay in receiving such approvals, due to, among other reasons, slow or failure to complete enrollment in clinical trials, withdrawal by trial participants from trials, failure to achieve trial endpoints, additional time requirements for data analysis, data integrity issues, BLA, MAA or the equivalent application, discussions with the FDA or the EMA, a regulatory request for additional nonclinical or clinical data, or safety formulation or manufacturing issues may lead to our inability to obtain sufficient funding&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the proprietary rights, products and technologies of our competitors may prevent our immunotherapies from being commercialized.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">For administrative purposes, some mRNA products may be classified together with gene therapy products by the FDA or other regulatory agencies. Unlike certain gene therapies that irreversibly alter cell DNA and may be subsequently subject to specific safety concerns, mRNA products are not </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">80</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">designed to localize to the cell nucleus or interact with the genome. Side effects observed in other gene therapies, however, could negatively impact the perception of immunotherapies despite the differences in mechanism. In addition, unclear or inconsistent regulatory classification of mRNA products may result in uncertainties regarding the regulatory requirements and pathways for marketing approval. On the other hand, mRNA-based vaccines for the prevention of infectious diseases, like our COVID-19 vaccine, are not currently classified as gene therapies in most regions. The regulatory pathway for an individualized therapy, such as our Individualized Neoantigen Specific Immunotherapy, or iNeST, an mRNA-based immunotherapy where each patient receives a different combination of mRNAs, remains undetermined. The number and design of the clinical and preclinical studies required for the approval of these types of medicines have not been established, may be different from those required for advanced medicinal therapy products or therapies that are not individualized or may require safety testing like gene therapy products. Moreover, the length of time necessary to complete clinical trials and submit an application for marketing approval by a regulatory authority varies significantly from one pharmaceutical product to the next and may be difficult to predict.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified senior management and scientific personnel.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent upon members of our management and scientific teams. We may not be able to retain these persons due to the competitive environment in the biotechnology industry, as well as a current global shortage of these highly qualified individuals. The loss of any of these persons&#8217; services may adversely impact the achievement of our research, development, financing and commercialization objectives. We are also aware of physical threats made against certain of these people. In response to these threats, we have deployed personal protection for such individuals and increased our security generally. We currently do not have &#8220;key person&#8221; insurance on any of our employees.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, we rely on consultants, contractors and advisors, including scientific and clinical advisors, to assist us in formulating our research and development, regulatory approval and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The loss of the services of one or more of our current employees or advisors might impede the achievement of our research, development, regulatory approval and commercialization objectives. In addition, we have flexibly grown our workforce through the use of contractors and part-time workers. We may not be able to retain the services of such personnel, which might result in delays in the operation of our business.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Recruiting and retaining other qualified employees, consultants and advisors for our business, including scientific and technical personnel, will be critical to our success as well. Competition for skilled personnel, including in mRNA research, clinical development, clinical operations, regulatory affairs, therapeutic area management, manufacturing, and AI, is intense and the turnover rate can be high. We may not be able to attract and retain personnel on favorable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for individuals with similar skill sets. In addition, adverse publicity, and the failure to succeed in preclinical studies or clinical trials or in applications for marketing approval may make it more challenging to </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">81</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">recruit and retain qualified personnel. The inability to recruit or loss of services of certain executives, key employees, consultants or advisors may impede the progress of our research, development and commercialization objectives and have a material adverse impact on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our employees, principal investigators and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could have an adverse effect on the results of our operations.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators and consultants, despite our robust efforts to prevent such misconduct through sponsor oversight. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, to provide accurate information to the FDA, the EMA and other regulatory authorities, to comply with healthcare fraud and abuse laws and regulations in the United States and abroad, to report financial information or data accurately or to disclose unauthorized activities to us. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Employment-related disputes, including employee litigation and unfavorable publicity, could negatively affect our future business.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">From time to time we may be subject to claims by our employees or regulatory authorities with respect to employment and workplace matters, including lawsuits or proceedings against us regarding injury, creating a hostile workplace, discrimination, wage and hour disputes, sexual harassment or other employment issues. In recent years, there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment- related lawsuits have had to terminate management or other key personnel, and have suffered reputational harm that has negatively impacted their business. If we were to face any employment-related claims, our business could be negatively affected.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">The illegal distribution and sale by third parties of counterfeit versions of our COVID-19 vaccine, or, if approved, our other product candidates, could have a negative impact on our financial performance or reputation.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Third parties have in the past and may continue to illegally distribute and sell counterfeit versions of COVID-19 vaccines. Counterfeit products are frequently unsafe or ineffective, and may even be life-threatening. Counterfeit medicines may contain harmful substances or the wrong dosage. However, </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">82</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">to distributors and users, counterfeit products may be visually indistinguishable from the authentic version.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Reports of adverse reactions to counterfeit products, increased levels of counterfeiting, or unsafe vaccines could materially affect public confidence in our COVID-19 vaccine or other product candidates. It is possible that adverse events caused by unsafe counterfeit vaccines will mistakenly be attributed to our COVID-19 vaccine, or, if approved, our other product candidates. In addition, thefts of inventory at warehouses, plants or while in-transit, which are subsequently improperly stored and which are sold through unauthorized channels, could adversely impact patient safety, our reputation, and our business. Public loss of confidence in the integrity of our COVID-19 vaccine or, if approved, our other product candidates, as a result of counterfeiting or theft could have a material adverse effect on our business, results of operations, and financial condition.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We and our collaborators or other contractors or consultants depend on information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our internal computer systems and those of our current and any future collaborators, vendors, and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, cybersecurity threats, war, and telecommunication and electrical failures. If any such material system failure, accident or security breach were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from one or more ongoing or completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, because of our approach of running multiple clinical trials in parallel, any breach of our computer systems may result in a loss of data or compromised data integrity across many of our programs in many stages of development. Any such breach, loss or compromise of clinical trial participant personal data may also subject us to civil fines and penalties, including under the EU General Data Protection Regulation, or the GDPR, relevant law of an EU member state, HIPAA, and other relevant state and federal privacy laws in the United States or in other jurisdictions. To the extent that any disruption or security breach were to result in a loss of, or damage to, data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of our product candidates could be delayed.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">While we have not experienced any material system failures, accidents or security breaches to date, in December 2020, we were informed by the EMA that the agency was subject to a cyberattack and that some documents relating to our regulatory submission for our COVID-19 vaccine candidate, which was stored on an EMA server, had been unlawfully accessed. None of our systems were breached in connection with this incident and we are unaware that any study participants were identified through the data being accessed.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We have put systems and procedures in place to minimize the likelihood of such incidents reoccurring&#894; however, we cannot guarantee that third parties will not be able to gain unauthorized </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">83</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">access to or otherwise breach our systems in the future. Any such unauthorized access or breach could adversely affect our business, results of operations and financial condition.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of our current or future product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We face an inherent risk of product liability exposure related to the testing of any of our current or future product candidates in clinical trials, and an even greater risk related to any commercialized products, such as our COVID-19 vaccine. We have received product liability claims against our COVID-19 vaccine, and expect to receive additional product liability claims in the future. If we cannot successfully defend ourselves against claims that our products and&#47;or our product candidates have caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">decreased demand for any product or product candidate that we may develop&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">loss of revenue&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">substantial monetary awards to patients, healthy volunteers or their children&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">significant time and costs to defend the related litigation&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">withdrawal of clinical trial participants&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the inability to commercialize any products or product candidates that we may develop&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">injury to our reputation and significant negative media attention.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We carry clinical trial insurance and product liability insurance, which we believe to be sufficient in light of our current clinical programs and commercial operations. However, the amount of coverage we have obtained may not be adequate, and we may seek to further increase insurance coverage limits as our pipeline moves towards commercialization. As we evolve, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause the price of the ADSs to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">If our products become subject to a product recall it could harm our reputation, business and financial results.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The FDA and similar governmental authorities in other jurisdictions have the authority to require the recall of certain commercialized products. In the case of the FDA, the authority to require a recall of a biologic product must be based on an FDA finding that a batch, lot or other quantity of the biologic product presents an imminent or substantial hazard to the public health. In addition, some governmental bodies outside the United States have the authority to require the recall of any product or product candidate in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative, recall a product if any material deficiency in a product is </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">84</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">found. A government-mandated or voluntary recall by us could occur as a result of manufacturing errors, design or labeling defects or other deficiencies and issues.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Recalls of any of our products or, if approved, our product candidates, would divert managerial and financial resources and have an adverse effect on our financial condition and results of operations. A recall announcement could harm our reputation with customers and negatively affect our sales, if any.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Issues in the development and use of AI, combined with an uncertain regulatory environment, may result in reputational harm, liability or other adverse consequences to our business.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are investing in AI technology systems, including through our acquisition of InstaDeep, and such systems are complex and rapidly changing. We face significant competition from other companies with respect to our AI and machine learning services, along with an evolving regulatory landscape. The introduction of AI into the development and manufacturing of our product candidates, or the provision of services relating to AI technologies and applications, may result in new or enhanced governmental or regulatory scrutiny, litigation, intellectual property risks, confidentiality or security risks, ethical concerns or other complications that could harm our business, reputation or financial condition.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Uncertainty around AI may require additional investment in the development and maintenance of proprietary datasets and development of appropriate protections and safeguards for handling the use of customer data with AI technologies, which may be costly and could impact our expenses. In addition, AI may create content that appears correct but is inaccurate or flawed, and if created by third parties, may be mistakenly attributed to us. Our customers or others may rely on or use this flawed content to their detriment, which may expose us to brand or reputational harm, competitive harm or legal liability. </font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our ability to effectively monitor and respond to the rapid and ongoing developments and expectations relating to environmental, social and governance, or ESG, matters, including related social expectations and concerns, may impose unexpected costs or result in reputational or other harm that could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the price of ADSs representing our ordinary shares to decline.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">There are rapid and ongoing developments and changing, sometimes conflicting, expectations relating to ESG matters and factors such as the environmental impact of our operations, access to our COVID-19 vaccine, corporate governance, our product stewardship practices, management of business ethics, human rights due diligence in our own operations and our supply chain, and workforce development. At the same time, ESG matters, including climate change, are the subject of increased politicization, particularly in the United States. These factors may result in increased regulatory, social or other scrutiny on us. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We believe we must address climate risks from our own contribution to climate change (inside-out perspective), risks to our own operations due to physical effects of climate change as well as transition risks (outside-in perspective), and interactions between both perspectives. To this end, we have set ourselves near-term scienced-based emissions reduction targets for our own operations (scope 1, 2) and for our supply chain (supplier engagement target for scope 3), validated by the Science Based Targets initiative, or SBTi, in early February 2024.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">85</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Additionally, we are addressing increasingly complex regulatory requirements with respect to human rights risks. These requirements include German legislation, such as the Act on Corporate Due Diligence Obligations for the Prevention of Human Rights Violations in Supply Chains (Lieferkettensorgfaltspflichtengesetz &#8211; LkSG), potential legislative planning by the European Union, and local or regional regulations. Regulatory frameworks require us to identify, prevent, mitigate and ideally end the extent of any potential adverse impacts or violations throughout our own operations and value chain.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Finally, we are faced with increasing ESG related transparency and reporting obligations. These requirements arise, for example, from the EU Corporate Sustainability Reporting Directive regulation, the European Sustainability Reporting Standards, and the respective German implementation law and other possible obligations. Should we fail to meet our climate protection targets or if we are unable to adequately recognize and respond to such developments and governmental, societal, investor and NGO expectations relating to such ESG matters, we may have to pay substantial fines, forego corporate opportunities, become subject to additional scrutiny, incur unexpected costs or experience damage to our reputation or our various brands. If any of these events were to occur, there may be a material adverse effect on our business, financial condition, cash flows and results of operations, and the price of ADSs representing our ordinary shares may decline.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We have observed that in addition to the importance of their financial performance, companies are increasingly being judged by their performance on ESG matters. A variety of organizations measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. We may fail to comply with standards or best practices put forth by such organizations or by governmental or regulatory bodies. There can be no certainty that we will manage such issues successfully, or that we will successfully meet society&#8217;s expectations as to our proper role. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, the price of ADSs representing our ordinary shares, financial condition, or results of operations, including the sustainability of our business over time.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1267"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Risks Related to our COVID-19 Vaccine and the Commercialization of our Pipeline</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Demand for our COVID-19 vaccine, though difficult to predict, is expected to continue to decrease in the near future. Changing market dynamics, including as a result of government policy and public sentiment, will impact our revenue, which currently depends heavily on sales of our COVID-19 vaccine, and result in challenges relating to production of our COVID-19 vaccine.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Prior to the commercialization of our COVID-19 vaccine, we had not sold or marketed any products in our pipeline. As a result, a majority of our total revenues to date are attributable to sales of our COVID-19 vaccine. However, we have experienced and we expect to continue to experience increasing reductions in demand for COVID-19 vaccination generally, including for our vaccine, now that the virus has entered an endemic stage and as a growing proportion of the population becomes vaccinated. We expect that future revenues from sales of our COVID-19 vaccine will decrease as demand for vaccination wanes. Such revenues will depend on numerous factors, including&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the extent to which a COVID-19 vaccine, including any booster shot, continues to be necessary while COVID-19 remains an endemic virus&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">competition from other COVID-19 vaccines, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">86</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our ability to successfully and timely develop effective vaccines targeting new variants and mutations of COVID-19&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the extent to which changes in local, national and state government policy preferences in the United States and other jurisdictions, including changes in vaccine recommendations, and evolving public sentiment affect demand for COVID-19 vaccines or mRNA therapeutics and our ability to successfully commercialize our product candidates, if approved&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our ability to receive full regulatory approvals where we currently have, or previously have had, emergency use authorizations or equivalents&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our ability to expand our geographic customer base&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our pricing and reimbursement negotiations with governmental authorities, private health insurers and other third-party payors after our initial sales to national governments, including the transition towards ordinary-course insurance coverage in the public and private sectors&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the ability of countries and jurisdictions to store and distribute doses of our COVID-19 vaccine to end users at cold temperatures&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the safety profile of our COVID-19 vaccine, including if previously unknown undesirable effects or increased incidence or severity of known undesirable effects are identified with our COVID-19 vaccine&#59; </font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">intellectual property litigation involving our COVID-19 vaccine and COVID-19 vaccines in general&#59; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our manufacturing and distribution capabilities for our COVID-19 vaccine.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We cannot accurately predict the revenues our COVID-19 vaccine will generate in future periods or for how long our COVID-19 vaccine will continue to generate material revenues, and we cannot ensure it will maintain its competitive position. Uncertainty in the demand for our COVID-19 vaccine and difficulties in targeting appropriate supply of our COVID-19 vaccines have in the past resulted, and may in the future result, in significant inventory write-downs and cancellations of contract manufacturing orders. Our business and financial condition could be materially affected by lowered COVID-19 vaccine revenues resulting from any of the above factors, or by production and supply chain difficulties. In addition, if our revenues or market share of, or other financial metrics relating to, our COVID-19 vaccine do not meet the expectations of investors or securities analysts, the market price of the ADSs representing our ordinary shares may decline.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our reported revenue is based in part on preliminary estimates of COVID-19 vaccine sales and costs from Pfizer that are likely to change in future periods, which may impact our reported financial results.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our reported revenue is based in part on preliminary estimates from Pfizer and other assumptions and judgments that we have made, which may be subject to significant uncertainties. Our revenue </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">87</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">includes preliminary estimates in part due to a difference in Pfizer&#8217;s financial quarter for subsidiaries outside the United States, which consequently creates an additional time lag between the recognition of revenues and the receipt of payment. Although our revenue recognition policy is based on facts and circumstances known to us and various other assumptions that we believe to be reasonable under the circumstances, our actual results may deviate from such reported revenue.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We depend on Pfizer to determine and provide estimates of the costs and profits to be shared with us in the countries where it is commercializing our COVID-19 vaccine under our collaboration agreement with Pfizer for our COVID-19 vaccine, which we refer to as the Pfizer Agreement. Because the information supplied by Pfizer is preliminary and subject to change, the revenue we report based on such information is also subject to finalization. This is particularly true for vaccine sales outside of the United States, where Pfizer has a different reporting cycle than ours. As a result, we may not have the complete sales and costs results outside of the United States for months not covered by the reporting period, but we are nonetheless required to report estimated figures.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Pfizer has historically provided us with profit figures for our COVID-19 vaccine sales in the United States using standard U.S. transfer prices and manufacturing and shipping cost variances (as far as those have been identified) that could be subject to adjustment (e.g., due to changes in manufacturing costs or the price of our COVID-19 vaccine). Pfizer has also provided estimated profits for COVID-19 vaccine sales outside of the United States that were preliminary in nature for the last month of a quarter, as Pfizer&#8217;s subsidiaries outside of the United States have a different reporting cycle than ours. These estimated figures have changed, and in the future such estimated figures are likely to change, as we receive final data from Pfizer for the applicable period in accordance with the reporting cycle of Pfizer&#8217;s ex-U.S. subsidiaries and as actual costs become known. Further, to the extent that Pfizer does not provide such preliminary information in the future, our provisional sales figures for territories outside of the United States will be subject to an even greater level of estimate and judgment. Any changes to the preliminary data we report herein may have an impact on our reported revenues and expenses, profitability or financial position.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We may be unsuccessful in adapting our COVID-19 vaccine or developing future versions of our COVID-19 vaccine to protect against variants of the SARS-CoV-2 virus, and even if we are successful, a market for vaccines against these variants may not develop and our ability to continue to generate income from sales of our COVID-19 vaccine is uncertain.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The COVID-19 disease itself is unpredictable and each variant comes with varying levels of transmissibility and severity. Consequently, the burden of the disease may wane or dissipate such that our and other COVID-19 vaccines may be considered less essential from individual and public health perspectives.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our COVID-19 vaccine was initially developed based upon the genetic sequence of the original SARS-CoV-2 virus that was first detected. The SARS-CoV-2 virus continues to evolve, and new strains of the virus or those that are already in circulation may prove more transmissible or cause more severe forms of COVID-19 disease than the predominant strains observed to date. Our vaccine may not be as effective in protecting against existing and future variant strains of the SARS-CoV-2 virus as it is against the original virus or currently known strains of the SARS-CoV-2 virus. We and Pfizer intend to continue to observe our COVID-19 vaccine, including variant-adapted vaccine candidates, in global clinical trials. It is possible that subsequent data from these clinical trials may not be as favorable as data we submitted to regulatory authorities to support our applications for emergency use authorization or marketing or conditional marketing approval or that concerns about the safety of our </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">88</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">variant-adapted COVID-19 vaccines will arise from widespread use outside of clinical trials. While we continue to monitor emerging SARS-CoV-2 strains, undertake investigations into the immunogenicity of our COVID-19 vaccine against new variants as they emerge and develop modified versions of our COVID-19 vaccine against new variants, these efforts may be unsuccessful, and failure to timely and successfully adapt our vaccine to variants of the SARS-CoV-2 virus could lead to significant reputational harm and adversely affect our financial results. Furthermore, variant-adapted COVID-19 vaccines may not receive approval or emergency use authorization in all jurisdictions, which could adversely affect our business prospects. It is also possible that we may expend significant resources adapting our COVID-19 vaccine to protect against certain variants of the SARS-CoV-2 virus, but that a market for adapted vaccines does not develop for one or more variants or that demand does not align with our projections or cost expenditures. Moreover, even if we are successful in developing an adapted vaccine and there is a market for the new vaccine, new variants continue to emerge and any adapted vaccine may not be as effective in protecting against such future variant strains.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">If we discover safety issues with our products, including our COVID-19 vaccine, that were not known at the time of approval, commercialization efforts for our products could be negatively affected, approved products could lose their approval or sales could be suspended, we could be subject to product liability claims and our business and reputation could be materially harmed. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our COVID-19 vaccine and any other product candidates for which we receive approval or emergency use authorization are subject to continuing regulatory oversight, including the review of additional safety information. Billions of doses of our COVID-19 vaccine have been delivered worldwide, and our COVID-19 vaccine is being more widely used by patients as an authorized product than it was used in clinical trials. As a result, undesirable effects and other problems may be observed that were not seen or anticipated, or were not as prevalent or severe, during clinical trials. We cannot provide assurance that newly discovered or developed safety issues will not arise, and we have received, and expect to continue to receive, product liability claims relating to our COVID-19 vaccine. With the use of any vaccine by a wide patient population, serious adverse events may occur from time to time that did not arise in clinical trials or that initially appeared to be unrelated to the vaccine itself and only with the collection of subsequent information were found to be causally related to the product. Safety events that arise outside of a clinical trial setting are difficult to monitor, and given the widespread use of our COVID-19 vaccine, we have experienced difficulty tracking potential treatment-related adverse events on a global basis. Any safety issues could cause us to suspend or cease marketing of our approved products, possibly subject us to substantial liabilities, and adversely affect our ability to generate revenue and our financial condition. The subsequent discovery of previously unknown problems with a product could negatively affect commercial sales of the product, result in restrictions on the product or lead to the withdrawal of the product from the market. The reporting of adverse safety events involving our products or public speculation about such events could cause the price of the ADSs representing our ordinary shares to decline or experience periods of volatility. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Unexpected safety issues, including any that we have not yet observed in our clinical trials or in real world data, could lead to significant reputational damage for us and our product development platforms going forward and other issues, including delays in our other programs, the need for re-design of our clinical trials and the need for significant additional financial resources. </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">89</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Failure to comply with continuing regulatory requirements by us or our collaboration partners could adversely impact regulatory approvals for our products, result in product recalls or suspensions, and&#47;or subject us to fines and&#47;or other types of liabilities. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If we or our collaborators fail to comply with applicable continuing regulatory requirements, including good industry practices, such as good manufacturing practices, or GMP, we or our collaborators may be subject to fines, suspension or withdrawal of regulatory approvals for specific drugs, product recalls and seizures, operating restrictions and&#47;or criminal prosecutions. We and the manufacturers we engage to make our products and the manufacturing facilities in which our products are made are subject to periodic review and inspection by the U.S. Food and Drug Administration, or the FDA, and other regulatory authorities. If problems are identified during a review or inspection, we or our collaborators may be the subject of adverse regulatory action, including the issuance of untitled or warning letters, which could result in our inability to use the facility to make our product or a determination that inventories are not safe for commercial sale. Any of these factors could adversely affect our business prospects and our financial position could be materially harmed.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities, private health insurers and other third-party payors provide coverage and adequate reimbursement levels and implement pricing policies favorable to our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, and&#47;or delayed payments from government authorities could limit our ability to market those products and decrease our ability to generate revenue.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford certain treatments, including our COVID-19 vaccine and other product candidates we may develop and sell. In addition, because our mRNA product candidates represent an entirely new therapeutic modality, we cannot accurately estimate how future products we may develop and sell would be priced, whether reimbursement could be obtained, or any potential revenue. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment in any of our products. Additionally, even if pricing terms with governmental authorities are agreed upon, there may be delayed or denied payments. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">There is significant uncertainty related to the insurance coverage and reimbursement for newly approved products in particular in the United States, including genetic medicines. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &#38; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel products such as ours. Reimbursement agencies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States but have not been approved for reimbursement in certain European countries.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Outside the United States, certain countries, including a number of member states of the European Union, set prices and reimbursement for pharmaceutical products, with limited participation from the </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">90</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">marketing authorization holders. We cannot be sure that such prices and reimbursement will be acceptable to us or our collaborators. If the regulatory authorities in these jurisdictions set prices or reimbursement levels that are not commercially attractive for us or our collaborators, our revenues from sales by us or our collaborators, and the potential profitability of our drug products, in those countries would be negatively affected. An increasing number of countries are taking initiatives to attempt to reduce large budget deficits by focusing cost-cutting efforts on pharmaceuticals for their state-run health care systems. These international price control efforts have impacted all regions of the world but have been most drastic in the European Union. Additionally, some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then may experience delays in the reimbursement approval of our product or be subject to price regulations that would delay our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of the product in that particular country.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. The Inflation Reduction Act, or IRA, enacted in August 2022 allows HHS to negotiate the price of certain drugs and biologics that CMS reimburses under Medicare Part B and Part D. The IRA&#8217;s negotiation program will apply to high-expenditure single-source drugs that have been approved for at least 7 years (11 years for biologics), among other negotiation selection criteria. The negotiated prices, which became effective in 2026 for the first round of selected drugs, are capped at a statutorily-determined ceiling price. The IRA also penalizes drug manufacturers that increase prices of Medicare Part B and Part D drugs at a rate greater than the rate of inflation. In addition, the law eliminates the &#8220;donut hole&#8221; under Medicare Part D beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program, once the out-of-pocket maximum has been reached. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. These IRA provisions have begun to take effect progressively starting in 2023, although the drug negotiation provisions of the IRA are currently the subject of legal challenges. The effects of the IRA on our business and the healthcare industry in general are not yet known. In addition, the Center for Medicare and Medicaid Innovation, or CMMI, has announced two new mandatory models that propose MFN pricing for certain products covered by Medicare and one new voluntary model that proposes MFN pricing for products covered by Medicaid. These models, or other models announced by CMMI, could result in significantly lower prices for our products. These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our products for which we may obtain regulatory approval or the frequency with which any such product is prescribed or used. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importing from other countries and bulk purchasing. Officials appointed by the current presidential administration to oversee the implementation of the IRA may take a different approach, and the </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">91</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">administration and Congress could also pursue statutory changes to the program, either of which could negatively affect our revenues.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products in the marketplace.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Government policies, including relating to manufacturing, export controls, or tariffs, and negative public perception regarding vaccines and mRNA-based therapeutics could severely and adversely impact the manufacturing and sales of our COVID-19 vaccine and other product candidates we may develop, if approved.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">There is a heightened risk that vaccines could be subject to export controls, adverse emergency actions or supply requirements by governmental and other authorities. In the past, the European Union and other regions have imposed, or threatened to impose, export controls that would limit or block the delivery of COVID-19 vaccines manufactured in or outside their territories in instances where manufacturers have been delayed or have not fully satisfied their delivery obligations to such governments, which could have prohibited us from delivering our COVID-19 vaccine to other jurisdictions. Recently, trade and tariff policies among the United States and other countries have been unsettled and are subject to frequent changes. The U.S. government has imposed tariffs and other trade restrictions on goods across a range of industries, and such actions have at times prompted retaliatory measures by affected countries such as China, Canada and the European Union. While tariffs with certain countries have been temporarily reduced or paused, the imposition of new tariffs will likely be met with further reciprocal tariffs, thus increasing the possibility of a global trade war. If trade restrictions or tariffs reduce global economic activity, potential impacts could include declining sales&#59; increased costs&#59; volatility in foreign exchange rates&#59; and a decline in the value of our financial assets. Issued or future executive orders or other new or changes in laws, regulations or policy regarding tariffs could have a material adverse effect on our business, earnings and financial guidance. The actual impact of the new tariffs on our business is subject to a number of factors including, but not limited to, restrictions on trade, the effective date and duration of such tariffs, countries included in the scope of tariffs, changes to amounts of tariffs, potential retaliatory tariffs imposed by other countries, and the extent to which tariffs are imposed on finished or unfinished pharmaceutical products. Vaccines are also at risk of being subject to adverse emergency actions taken by governmental entities in certain countries, including intellectual property expropriation, compulsory licenses, strict price controls or other actions, such as the requirement that specific quantities of vaccine doses be set aside for designated purposes or geographic areas. Additional changes in governmental policy preferences and regulatory decision-making may have an adverse effect on our ability to commercialize products or, if approved, product candidates. For example, the FDA&#8217;s approval of our LP.8.1-adapted monovalent COVID-19 vaccine is in a narrower population than our previous variant-adapted vaccines.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Furthermore, public sentiment regarding commercialization of vaccines, the safety and efficacy of our COVID-19 vaccine, other COVID-19 vaccines and treatments, and other public perceptions and misinformation relating to COVID-19, mRNA technology, and our and other COVID-19 vaccines may limit our ability to generate income from sales of our COVID-19 vaccine and other product candidates </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">92</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">we may develop and sell, including due to changes in local, national and state government policies in the U.S. and other jurisdictions, and cause reputational damage.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We face significant competition with other makers of COVID-19 vaccines and may be unable to maintain a competitive market share for our COVID-19 vaccine.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">A number of competitors currently have programs to develop COVID-19 vaccine candidates, including vaccines developed by Moderna, Inc. and Novavax, Inc. Our competitors pursuing vaccine candidates may have greater financial, product candidate development, manufacturing and marketing resources than we do. Larger pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for their products, and may have the resources to invest heavily to accelerate discovery and development of their vaccine candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our efforts to continue successful commercialization of our COVID-19 vaccine may fail if competitors develop and commercialize COVID-19 vaccines that are safer, more effective, produce longer immunity against COVID-19, require fewer administrations, have fewer or less severe undesirable effects, have broader market acceptance, are more convenient to administer or distribute or are less expensive than any vaccine candidate that we have developed or we may develop.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our COVID-19 vaccine is sensitive to temperature, shipping and storage conditions and could be subject to risk of loss or damage.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our COVID-19 vaccine is, and other product candidates we develop could be, sensitive to temperature, storage and handling conditions. In particular, while we have improved the required shipping and storage conditions of our COVID-19 vaccine, it must be shipped and stored at cold temperatures. Loss in supply of our COVID-19 vaccine and our product candidates could occur if the product or product intermediates are not stored or handled properly. Shelf life for our product candidates may vary by product, and it is possible that supply of our COVID-19 vaccine or our product candidates could be lost due to expiration prior to use. This has in the past led, and could in the future lead, to additional manufacturing costs and delays in our ability to supply required quantities for clinical trials or for commercial purposes. Such distribution challenges may make our COVID-19 vaccine a less attractive product than other COVID-19 vaccines that do not require as cold storage, and our COVID-19 vaccine may become increasingly less competitive as additional other vaccines become authorized for emergency use. If we, our partners and customers are unable to adequately manage these issues, we may be exposed to product liability claims and the market opportunity for our COVID-19 vaccine may be reduced, each of which could adversely affect our business prospects and materially harm our financial condition.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">The market opportunities for some of our product candidates may be small due to the rarity of the disease, or limited to those patients who are ineligible for or have failed prior treatments. As the target patient populations for some of our programs are small, we may be unable to achieve or maintain profitability in future periods without obtaining regulatory approval for additional indications.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The FDA often approves new cancer therapies initially only for use by patients with relapsed or refractory advanced cancer. We expect to seek approval initially for some of our product candidates in this context. Subsequently, for those products that prove to be sufficiently beneficial, we would expect to seek approval in earlier lines of treatment and potentially as a first-line therapy, but there is no guarantee that our product candidates, even if approved, would be approved for earlier lines of </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">93</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. We are also developing product candidates for the treatment of rare diseases.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our projections of the number of people who have or will have the diseases we may be targeting may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of trial participants may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we obtain significant market share for our products, if approved, because the potential target populations may be small, we may be unable to achieve or maintain profitability in future periods without obtaining regulatory approval for additional indications.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">If we are unable to continue to increase our marketing and sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates effectively in the United States and other jurisdictions, if approved, or generate sufficient product sales revenue.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">With respect to our COVID-19 vaccine, we rely heavily on the sales, distribution, and marketing capabilities of our partners except in Germany and T&#252;rkiye. To successfully commercialize any other products that may result from our development programs, several of which are undergoing pivotal clinical trials, we will need to continue developing sales and marketing capabilities in the United States, Europe and other regions, either on our own or with others. We may enter into collaborations with other entities to utilize their mature marketing and distribution capabilities, but we may be unable to enter into marketing agreements on favorable terms, if at all. If our current and future collaborators do not commit sufficient resources to further commercialize our COVID-19 vaccine and our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we may be unable to generate sufficient product sales revenue to sustain our business. We compete with many companies that currently have extensive and well-funded marketing and sales operations. Without continuing to grow our internal team or obtaining the support of third parties to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our ability to achieve or maintain profitability in future periods depends in part on our and our collaborators&#8217; ability to penetrate global markets, where we would be subject to additional regulatory burdens and other risks and uncertainties associated with international operations that could materially adversely affect our business.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our ability to achieve or maintain profitability in future periods will depend in part on our ability and the ability of our collaborators to commercialize any products that we or our collaborators may develop in markets throughout the world. Commercialization of products in various markets could subject us to risks and uncertainties, including&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">obtaining, on a country-by-country basis, the applicable marketing authorization from the competent regulatory authority&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the burden of complying with complex and changing regulatory, tax, accounting, labor and other legal requirements in each jurisdiction that we or our collaborators pursue&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">reduced protection for intellectual property rights&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">94</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">differing medical practices and customs affecting acceptance in the marketplace&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">import or export licensing requirements&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">governmental controls, trade restrictions or changes in tariffs&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">economic weakness, including inflation, or political instability&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">longer accounts receivable collection times&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">longer lead times for shipping&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">language barriers&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">foreign currency exchange rate fluctuations&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the impact of epidemics, pandemics and other public health developments, such as COVID-19, on employees and the global economy&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">reimbursement, pricing and insurance regimes&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the interpretation of contractual provisions governed by local laws in the event of a contract dispute.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We do not have prior experience in all of these areas, and the experience we do have in some of these areas is limited. Our collaborators may have limited experience in these areas as well. Failure to successfully navigate these risks and uncertainties may limit or prevent market penetration for any products that we or our collaborators may develop, which would limit their commercial potential and our revenues.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Even if we obtain regulatory approval for our product candidates, the products may not gain the market acceptance among physicians, patients, hospitals, treatment centers and others in the medical community necessary for commercial success.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Even with the requisite approvals, the commercial success of our products will depend in part on the medical community, patients, and third-party or governmental payors accepting immunotherapies in general, and our products in particular, as medically useful, cost-effective and safe.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Any product that we bring to the market may not gain market acceptance by physicians, trial participants, third-party payors, and others in the medical community. Additionally, ethical and legal concerns and social preferences about research involving mRNA could result in additional regulations restricting or prohibiting the products and processes we may use. If these products do not achieve an adequate level of acceptance, we may not generate significant product sales revenue and may not be able to achieve or maintain profitability in future periods. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including&#58;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">95</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the potential efficacy and potential advantages over alternative treatments&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the ability to offer our products, if approved, at competitive prices&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the prevalence and severity of any undesirable effects, including any limitations or warnings contained in a product&#8217;s approved labeling&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the prevalence and severity of any undesirable effects resulting from checkpoint inhibitors or other drugs or therapies with which our products are administered&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the relative convenience and ease of transportation, storage and administration&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">any restrictions on the use of our products, if approved, together with other medications&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the willingness of the target patient population to try new therapies, such as mRNA vaccines and therapies, and of physicians to prescribe these therapies&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the strength of marketing and distribution support and timing of market introduction of competitive products&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the extent to which changes in local, national and state government policy preferences in the United States and other jurisdictions resulting from new elected leadership and evolving public sentiment affect demand for COVID-19 vaccines or mRNA therapeutics and our ability to successfully commercialize our product candidates, if approved&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">publicity concerning our products or competing products and treatments&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">sufficient third-party insurance coverage or reimbursement, and patients&#8217; willingness to pay out-of-pocket in the absence of third-party coverage or adequate reimbursement.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be known until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of the products may require significant resources and may never be successful. Our efforts to educate the marketplace may require more resources than are required by the conventional technologies marketed by our competitors due to the complexity and uniqueness of our programs.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, for our products that are approved for marketing, we and&#47;or our collaborator are subject to significant regulatory obligations regarding the submission of safety and other post-marketing information and reports for such product, and will need to continue to comply (or ensure that our third-party providers comply) with current GMP and current good clinical practices, or GCP, for any clinical trials that we or a collaborator conduct post-approval. In addition, there is always the risk that we or a collaborator or regulatory authority might identify previously unknown problems with a product post-approval, such as adverse events of unanticipated severity or frequency. Compliance with these requirements is costly, and any such failure to comply or other issues with our product candidates identified post-approval could have a material adverse impact on our business, financial condition and results of operations.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">96</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid in the United States, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In addition, because certain of our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenue from our product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">a covered benefit under its health plan&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">safe, effective and medically necessary&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">appropriate for the specific patient&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">cost-effective&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">neither experimental nor investigational.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse healthcare providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payors rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payors, and reduce the willingness of physicians to use our product candidates.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">97</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We intend to seek approval to market our product candidates in the United States, the European Union and other selected jurisdictions. If we obtain approval for our product candidates in any particular jurisdiction, we will be subject to rules and regulations in that jurisdiction. In some countries, particularly those in Europe, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the marketplace. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">The advancement of healthcare reform legislation and changes to the regulatory environment in the United States, the European Union and elsewhere may increase the difficulty and cost for us to obtain marketing approval of and commercialize any product candidates we or our collaborators develop and may adversely affect the prices for such product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In August 2022, the IRA was enacted, which sets forth meaningful changes to drug product reimbursement by Medicare. The IRA is anticipated to have significant effects on the pharmaceutical industry and may reduce the prices we can charge and reimbursement we can receive for our products in the United States, among other effects. Any reduction in reimbursement from Medicare resulting from the IRA or other legislative or policy changes or from other government programs may result in a similar reduction in payments from private payers. On August 16, 2024, CMS announced the results of a first round of discounted prices effectively set by CMS under the IRA, applicable to ten products of other manufacturers&#59; those discounted prices, set to take effect for calendar year 2026, were as high as 79% from 2023 list prices. Additional products will be discounted in future years. We cannot be sure whether additional legislative changes will be enacted, or the effect of forthcoming guidance implementing the IRA, or what the impact of such changes on our products and product candidates may be. Officials appointed by the current presidential administration to oversee the implementation of the IRA or other statutes may take a different approach, and the administration and </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">98</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Congress could also pursue statutory changes to this or other programs, either of which could negatively affect our revenues.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability to commercialize any products for which we obtain marketing approval.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We expect that additional healthcare reform measures or proposals will be adopted in the future, any of which could limit the amounts that governments will pay for healthcare products and services, including public health measures, which could result in reduced demand for our products and product candidates or additional pricing pressures. In the event that the pricing structures for healthcare products, such as the product candidates we are developing, change materially and limit payments for such product candidates, our business will be adversely impacted as our products may no longer be commercially viable based on their expected net present value&#894; we may have invested significant resources in product candidates that cannot be commercially developed&#894; or we may determine that assets that have reached an early phase of development cannot or will not be taken into further development, notwithstanding their clinical viability. In addition, development assets or clinical programs that are part of our collaborations may no longer be deemed commercially viable to pursue based on our collaborators&#8217; assessments of the impact of any proposed, announced, or legislated pricing reforms.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We cannot predict what healthcare reform initiatives may be adopted in the future. Further legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from our approved products and from product candidates that we may successfully develop and for which we may obtain regulatory approval, and may affect our overall financial condition and ability to develop product candidates.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Drug marketing and reimbursement regulations in the European Union and elsewhere may materially affect our ability to market and receive coverage for our products in the member states of the European Union and elsewhere.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our COVID-19 vaccine is currently approved in the United States, the European Union, and other jurisdictions, and we intend to seek approval to market other product candidates in the United States, the European Union and other selected jurisdictions. If we obtain approval for our products or product candidates in a particular jurisdiction, we will be subject to rules and regulations in that jurisdiction. In some countries, particularly those in the European Union, the pricing of biologics is subject to governmental control and other market regulations that could put pressure on the pricing and usage of our products or product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">99</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, in most countries outside the United States, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and, generally, prices tend to be significantly lower in the European Union. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our collaborators and the potential profitability of any of our product candidates in those countries would be negatively affected.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1276"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Risks Related to our Financial Condition and Capital Requirements</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Long-term sustainable profitability is difficult to achieve and maintain over time and is highly dependent on various factors.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our ability to continue to generate revenues and achieve and maintain long-term sustainable profitability depends on our ability, alone or with collaborators, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our product candidates. We continue to generate revenues from sales of our COVID-19 vaccine and additional limited revenues from other transactions and contracts. While we expect to maintain revenue from ongoing COVID-19 vaccine sales, future demand for COVID-19 vaccination is subject to uncertainty. Variations driven by factors such as new virus variants, legal developments, policy changes, public health measures and public sentiment may impact long-term demand of our COVID-19 vaccine. Consequently, our revenue projections are influenced by this inherent unpredictability. The amount of long-term revenue from such sales, including the sales of our COVID-19 vaccine, is uncertain at this time. Our ability to generate future revenues from pharmaceutical product sales and sales of our other products and services depends heavily on our and our collaborators&#8217; success in&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">completing research and preclinical and clinical development of our product candidates&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">seeking and obtaining U.S. and non-U.S. marketing approvals for product candidates for which we complete clinical trials&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">seeking and obtaining market access and favorable pricing terms in the United States, the European Union, and other key geographies&#59;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">100</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">furthering the development of our own manufacturing capabilities and manufacturing relationships with third parties in order to provide adequate (in amount and quality) products and services to support clinical development and the market demand for our approved products and product candidates, if approved&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">obtaining market acceptance of our approved products and product candidates as a treatment option&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">launching and commercializing products for which we obtain marketing approval and reimbursement, either through collaborations or, if launched independently, by establishing a sales force, marketing and distribution infrastructure&#894; </font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">addressing any competing technological and market developments, in particular, declining demand for any of our approved products&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">implementing additional internal systems and infrastructure&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">managing our expenses&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">maintaining, defending, protecting, enforcing and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">attracting, hiring and retaining qualified personnel.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Additionally, we have incurred significant costs associated with the commercialization of our COVID-19 vaccine. Our expenses could increase beyond our expectations if we are required by the FDA, the European Medicines Agency, or EMA, or other regulatory agencies to perform clinical and other trials or make changes to our manufacturing or quality systems in addition to those that we currently anticipate. Accordingly, such costs could adversely affect our future ability to achieve and maintain profitability.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict. If our operating results fall below expectations, the price of the ADSs representing our ordinary shares could decline.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our financial condition and operating results have varied in the past and will continue to fluctuate from one financial period to the next due to a variety of factors, many of which are beyond our control. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Factors relating to our business that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this report&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the size and timing of orders for our COVID-19 vaccine&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">delays or failures in advancement of existing or future product candidates into the clinic or in clinical trials&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">101</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the occurrence of adverse events during our clinical trials or post marketing authorization&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our ability to develop and manufacture our product candidates and commercialize and manufacture our COVID-19 vaccine and, if approved, our product candidates, at commercial scale, including risks associated with quality compliance, such as product design, manufacturing processes, supply chain management, and compliance with regulatory requirements&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our ability to manage our growth and spending&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our ability to execute our corporate objectives&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">strategic decisions related to portfolio prioritization, which may result in certain potential one-time effects and charges and other material adverse effects on our financial condition and results of operations&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the outcomes of research programs, clinical trials, or other product development or approval processes conducted by us and our collaborators&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the ability of our collaborators to develop and successfully commercialize products developed from our suite of therapeutic classes&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our relationships, and any associated exclusivity terms, with collaborators&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our contractual or other obligations to provide resources to fund our product candidates, and to provide resources to our collaborators or to the collaborations themselves, including take-or-pay or similar obligations&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the extent to which we repurchase outstanding ADSs under any share repurchase plans we may enter into in the future&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">risks associated with the international aspects of our business, including the conduct of clinical trials in multiple locations, and the risks associated with potential international commercialization, including regulatory approval, market competition, public sentiment and consumer demand, supply chain disruptions, and changes to the law and regulatory policy, such as increases in tariffs, in different jurisdictions, such as the United States&#894; </font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our ability to minimize and manage product recalls or inventory losses caused by unforeseen events, cold chain interruption, testing difficulties or decreased demand, and our ability to write down certain inventory&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our ability to report our financial results accurately and in a timely manner&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our dependence on, and the need to attract and retain, key management and other personnel&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our ability to obtain, protect, maintain, defend and enforce our intellectual property rights&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">102</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our ability to prevent the theft or infringement, misappropriation or other violation of our intellectual property, trade secrets, know-how or technologies&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our and our collaborators&#8217; ability to defend against claims of infringement of the intellectual property rights of third parties&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">potential advantages that our competitors and potential competitors may have in securing funding, obtaining the rights to critical intellectual property or developing competing technologies or products&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our ability to obtain additional capital that may be necessary to expand our business&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our collaborators&#8217; ability to obtain and devote additional capital that may be necessary to develop and commercialize products under our collaboration agreements, including our COVID-19 vaccine&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our ability to minimize and manage product liability claims arising from the use of our COVID-19 vaccine and our product candidates and other future products, if approved&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">business interruptions such as power outages, strikes, acts of terrorism or natural disasters&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our ability to use our net operating loss carryforwards to offset future taxable income&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">risks of counterparty defaults within our asset management portfolio&#59; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">increased or unpredictable pricing for the commodities we rely on, including as a result of inflation.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Each of the factors listed above may be affected by the changing impact of COVID-19 on the global community and the global economy.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Due to the various factors mentioned above, and others, the results of any of our periods should not be relied upon as indications of our future operating performance. Our operating results may fluctuate significantly from one reporting period to the next, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In any particular period, our operating results could be below the expectations of securities analysts or investors, which could cause the price of the ADSs to decline. While as a general matter we intend to periodically report on the status of our product candidate pipeline, including articulating anticipated next steps in the form of development plans or potential data readouts, we may not always be able to provide forward-looking guidance on the timing of those next steps. In addition, we do not control the timing of disclosures of any milestones related to any of our programs that are managed by our collaborators. Any disclosure by a collaborator of data that are perceived as negative, whether or not such data are related to other data that we or others release, may have a material adverse impact on the price of the ADSs or our overall valuation. The price of the ADSs may decline as a result of unexpected clinical trial results in one or more of our programs, including adverse safety events reported for any of our programs.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">103</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We have incurred significant losses in the past and we may incur significant losses in the future. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Prior to the first full year of commercialization of our COVID-19 vaccine, and for the years ended December 31, 2024 and December 31, 2025, and for the six months ended June 30, 2026, we incurred significant losses from operations due to our significant research and development expenses and our investment in our manufacturing capabilities. Prior to commercialization of our COVID-19 vaccine, we funded our operations primarily from private placements or issuances of ordinary shares (including in the form of ADSs) in connection with our public offerings, generation of proceeds under our collaboration agreements, secured bank loans and issuance of a convertible note.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We have experienced, and we expect to continue to experience, increasing reductions in demand for COVID-19 vaccination generally, including for our vaccine. We expect that future revenues from sales of our COVID-19 vaccine will continue to decrease as demand for vaccination wanes. We plan to continue to invest heavily in research and development as we make a strong drive to build out our global development organization and diversify our therapeutic area footprint. Additionally, we plan to enhance capabilities through complementary acquisitions, technologies, infrastructure and manufacturing. Even for those products for which we have obtained or may obtain regulatory approval or emergency use authorization, our future revenues will depend upon the size of any markets in which such products have received approval or authorization to market, our ability to achieve sufficient market acceptance, reimbursement from third-party payors, and adequate market share in those markets.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If achieved, profitability is difficult to maintain over time and is highly dependent on various factors. Our future financial results will depend, in part, on the rate of our future expenditures, the extent to which we experience long-term success of our commercial products and our ability to obtain funding through revenue from commercial sales, equity or debt financings, sales of assets, collaborations or grants. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As part of our capital allocation strategy, we expect to continue to incur significant and increasing operating expenses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we and our collaborators&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">continue, expand, or modify the research or development of our programs in preclinical development&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">continue, expand, or modify the scope of our clinical trials for our product candidates&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">initiate additional preclinical, clinical, or other trials for our product candidates, including under our collaboration agreements&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">execute on our strategic decisions related to portfolio prioritization, which may result in certain potential one-time effects and charges and other material adverse effects on our financial condition and results of operations&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">continue to invest in our immunotherapy platforms to conduct research to identify novel technologies&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">change our manufacturing capacity or capability&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">104</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">change or add additional suppliers&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">make changes to our infrastructure in connection with our quality control, quality assurance, legal, compliance and other groups to support our operations as a public company and our product development and commercialization efforts, including changes to our sites globally&#894; </font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">attract and retain skilled personnel&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">seek marketing approvals and reimbursement for our product candidates&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">develop our sales, marketing, and distribution infrastructure for our COVID-19 vaccine and any other products for which we may obtain marketing approval or emergency use authorization&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">seek to identify and validate additional product candidates&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">acquire or in-license other product candidates and technologies&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">acquire other companies&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">make milestone or other payments under any in-license agreements&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">maintain, protect, defend, enforce and expand our intellectual property portfolio&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">experience any delays or encounter issues with any of the above.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">The amount of, and our ability to use, net operating losses and research and development credits to offset future taxable income may be subject to certain limitations and uncertainty. In addition, pending and future tax audits within our Group, disputes with tax authorities and changes in tax law or fiscal regulations could lead to additional tax liabilities. We are subject to routine tax audits by the respective local tax authorities. Any additional tax liability could have an adverse effect on our business, financial conditions, results of operations or prospects.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In Germany, we have unused German tax loss carryforwards for corporate taxes for German group entities with pre tax group losses, though we generally have not recognized deferred tax assets related to such loss carryforwards for International Financial Reporting Standards, or IFRS, reporting purposes as of December&#160;31, 2025. Deferred tax assets are recognized for unused tax losses only to the extent that it is probable that taxable profit will be available against which the losses can be utilized. In general, net operating loss, or NOL, carryforwards in Germany do not expire. Furthermore, under current German tax laws, certain substantial changes in the Company&#8217;s ownership and business may further limit the amount of NOL carryforwards that can be used annually to offset future taxable income.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">For the German tax group, we incurred tax losses up to and including December 31, 2020. Even though we recognized deferred tax assets on a majority of German tax loss carry forwards in 2020 which were fully utilized in 2021, they are, however, subject to review and possible adjustment by the German tax authorities. In addition, the incurred tax losses up to and including December 31, 2024 also remain subject to review.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">105</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, we have U.S. federal and state NOL carryforwards due to our subsidiaries in the United States, which may be subject to limitations on use after an ownership change. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We may not be able to utilize a material portion of our historic or current NOLs or credits in either Germany (resulting from our German tax group or non-tax group entities in Germany) or the United States until these have been finally assessed by the tax authorities or when the limitation period has passed. In addition, the rules regarding the timing of revenue and expense recognition for tax purposes in connection with various transactions are complex and uncertain in many respects, and, if challenged, our recognition may be subject to a revised assessment. In the event any such challenge is sustained, our NOLs could be materially reduced or we could be determined to be a material cash taxpayer for one or more years, which could have an adverse effect on our business, financial conditions, results of operations or prospects. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Furthermore, our ability to use our NOLs or credits is conditioned upon our attaining profitability and generating taxable income. Taxable income exceeding NOLs will be subject to taxation resulting in tax liabilities. As described above, we incurred significant net losses in every year since our inception other than 2018, 2021, 2022 and 2023 and anticipate that in the future, we may incur losses for the majority of the group entities. Our ability to utilize our NOL or credit carryforwards in the United States and for some other group entities is uncertain. Therefore, we do not recognize deferred tax assets on NOLs and tax credit carryforwards in the United States, as the requirements of IAS 12 are not fulfilled.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Under German tax laws, we are obligated to withhold a percentage of wage tax and social security contributions on personnel expenses if contract services providers are considered to be our internal employees and remit those withholdings to German tax authorities and social security institutions. Late payments may subject us to penalties and fees. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Under German tax and social security laws, we are obligated to withhold a percentage of payments we make to third parties in consideration of the services provided, in case these are considered employment payments, and remit those withholdings to German tax authorities and social security institutions. After a significant volume of service providers were engaged to assist with research, development, manufacturing and supply of our COVID-19 vaccine, we discovered after internal review that we and certain of our subsidiaries did not withhold, report and remit certain German wage taxes and social security contributions in connection with certain contract service providers engaged in a manner comparable to internal employees, which we notified tax authorities about. If we do not properly and timely make required payments in the future, we could be subjected to fees, administrative offenses or other proceedings or penalties. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">It is not possible to seek the refund of these wage taxes or social security contributions from either the German tax authorities or social security institutions after filing returns. In Germany, employers are considered secondarily liable for wage taxes. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, value added taxes, or VAT, on invoices received by contract services providers who are considered internal employees are considered non-deductible and must be repaid to the German tax authorities. It is possible to reclaim the VAT repaid to the German tax authorities from the service provider. There is a possibility that the relevant input VAT claims against the contract service providers may, in some instances, not be enforceable as a result of a contract service provider no longer existing, the lapse of time or any other facts preventing the enforcement of such claims.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">106</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We may require substantial additional financing to achieve our goals, and a failure to obtain this capital on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our operating plans may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, sales of assets, marketing and distribution arrangements, other collaborations and licensing arrangements, or a combination of these approaches. We may require additional capital to obtain regulatory approval for, and to commercialize, future product candidates. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. Our spending will vary based on new and ongoing development and corporate activities. Due to the high uncertainty of the length of time and activities associated with discovery and development of our product candidates, we are unable to estimate the actual funds we will require for development, marketing and commercialization activities.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our future funding requirements, both near and long term, will depend on many factors, including, but not limited to&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the initiation, progress, timing, costs, and results of preclinical or nonclinical studies and clinical trials for our product candidates&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the amount and timing of revenues and associated costs from sales of our COVID-19 vaccine&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the results of research and our other platform activities&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the clinical development plans we establish for our product candidates&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the terms of any agreements with our current or future collaborators, and the achievement of any milestone payments under such agreements to be paid to us or our collaborators&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the terms of any other strategic transactions, including relating to any acquisitions, into which we enter&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the number and characteristics of product candidates that we develop or may in-license&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA and other comparable regulatory authorities&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the cost of filing, prosecuting, obtaining, maintaining, protecting, defending and enforcing our patent claims and other intellectual property rights, including actions for patent and other intellectual property infringement, misappropriation and other violations brought by third parties against us regarding our products or product candidates or actions by us challenging the patent or intellectual property rights of others&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the effect of competing technological and market developments, including other products that may compete with one or more of our product candidates&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">107</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the cost and timing of completion and further expansion of clinical and commercial scale manufacturing activities sufficient to support all of our current and future programs, including the development of modular production and clinical facilities in various markets via our </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">BioNTainer</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> network&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the cost of establishing sales, marketing, and distribution capabilities for any product candidates for which we may receive marketing approval and reimbursement in regions where we choose to commercialize our products on our own.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">To date, we have financed our operations primarily through the sale of equity securities, revenue from collaborations, and revenue from sales of our COVID-19 vaccine. While we are currently generating product sales and royalty revenue to finance our operations, we cannot be certain that we will continue to generate sufficient revenue from product sales and royalties to finance our operations. If we were to seek financing from outside sources, that additional funding may not be available on favorable terms, or at all. Should our revenues sufficiently decrease in the future, we expect to finance our future cash needs through a combination of product sales, public or private equity offerings, debt financings, collaborations, licensing arrangements, and other marketing or distribution arrangements. Any fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts, at the right time, on favorable terms, or at all, including as a result of the impact that the shift of COVID-19 towards an endemic phase and other global events, such as political upheavals and economic downturns, may have on the capital markets.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Negative clinical trial data or setbacks, or perceived setbacks, in our programs or with respect to our technology could impair our ability to raise additional financing on favorable terms, or at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders, and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of the ADSs representing our ordinary shares to decline. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that may adversely affect our shareholders&#8217; rights.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Further, to the extent that we raise additional capital through the sale of ADSs, ordinary shares or securities convertible or exchangeable into ordinary shares or ADSs, share ownership interests will be diluted. If we raise additional capital through debt financing, we would be subject to fixed payment obligations and may be subject to security interests in our assets and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements, sales of assets, collaborations, or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs. We also could be required to seek collaborators for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or intellectual property that we otherwise would seek to develop or commercialize ourselves. If we are unable to raise additional capital in sufficient amounts, at the right time, on favorable terms, or at all, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our products or product candidates, or one or more of our other research and development initiatives. Any of the above events could significantly </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">108</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">harm our business, prospects, financial condition and results of operations, cause the price of the ADSs to decline, and negatively impact our ability to fund operations.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We may encounter difficulties in developing and expanding our company and managing such development and expansion, which could disrupt our operations.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">To manage our anticipated development and expansion, we must continue to implement and improve our managerial, operational, legal, compliance and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. This includes our acquisitions of Biotheus in January 2025 and CureVac in December 2025, as well as strategic initiatives more generally. In addition, our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing these development activities.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As an evolving biotechnology company, we are actively pursuing drug classes, platforms and product candidates in many therapeutic areas and across a wide range of diseases. Successfully developing products for, and fully understanding the regulatory and manufacturing pathways to, all of these therapeutic areas and disease states requires a significant depth of talent, resources and corporate processes in order to allow simultaneous execution across multiple areas. Due to our limited resources, we may not be able to effectively manage this simultaneous execution and the expansion of certain operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure and&#47;or give rise to operational mistakes, legal or regulatory compliance failures, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our product candidates. If our management is unable to effectively manage our expected development, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to effectively implement our business strategy. Our future financial performance and our ability to compete effectively and commercialize our COVID-19 vaccine and our product candidates, if approved, will depend in part on our ability to effectively manage the current and future development of our company.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives. We are subject to financial reporting and other requirements for which our accounting and other management systems and resources may not be adequately prepared. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm the business.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As a public company, we incur significant legal, accounting and other expenses. The U.S. federal securities laws, including the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and rules subsequently implemented by the SEC and the Nasdaq Stock Market LLC, or Nasdaq, have imposed various requirements on public companies, including requirements to file annual and event-driven reports with respect to our business and financial condition, and to establish and maintain effective disclosure and financial controls and corporate governance practices. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations result in substantial legal and financial compliance costs and have made some activities time-consuming and costly. We may not be able to produce reliable financial statements or file these financial statements as part of a periodic report in a timely manner with the </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">109</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">SEC or comply with Nasdaq listing requirements. In addition, we could make errors in our financial statements that could require us to restate our financial statements.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting, including the attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To maintain compliance with Section 404, we document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we have needed to continue to dedicate internal resources, have engaged outside consultants, and have adopted a detailed work plan to assess and document the adequacy of internal control over financial reporting. We will continue to implement steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that in the future neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Shareholder activism, the current political environment, and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. For example, effective March 18, 2026, pursuant to the Holding Foreign Insiders Accountable Act, directors and officers of foreign private issuers, including us, are required to comply with the beneficial ownership reporting requirements of Section 16(a) of the Exchange Act. In addition, the SEC issued a concept release in June 2025 soliciting comment on potential changes to the regulatory framework applicable to foreign private issuers, including potential modification or elimination of certain accommodations currently available to foreign private issuers. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">If we identify material weaknesses in our internal control over financial reporting and fail to remediate such material weaknesses, we may not be able to report our financial results accurately or to prevent fraud. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our management is responsible for establishing and maintaining internal control over financial reporting, disclosure controls, and compliance with the other requirements of the Sarbanes-Oxley Act and the rules promulgated by the SEC thereunder. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with international financial reporting standards. A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim financial statements will not be prevented or detected by the company&#8217;s internal controls on a timely basis.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If we fail to comply with the relevant rules and regulations or otherwise fail to prepare our financial statements in accordance with international financial reporting standards, a material weakness may arise. If we are unable to successfully remediate any material weaknesses, our financial statements could contain material misstatements discovered in the future that could cause us to fail to meet our future reporting obligations and cause the price of the ADSs to decline.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">110</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">If we fail to appropriately account for complex terms in our collaboration and licensing agreements, we could be required to restate our financial statements.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our collaboration and licensing agreements involve complex terms and significant judgment in determining the appropriate accounting treatment. The accounting for such agreements is often subject to interpretation and evolving guidance. If our accounting assessments are later determined to be incorrect, we may be required to restate previously issued financial statements, which could have a material adverse effect on our financial condition and results of operations.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We have various international trade obligations, including customs value calculation, customs tariff number classification and other related securities requirements. Late payments to customs authorities may subject us to penalties and fees.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our supply chain, production and distribution network across the globe creates an increasing level of complexity in customs and foreign trade processes. The requirements for internal control systems are increasing and must be developed simultaneously. The risk management system for customs and foreign trade, which we are continuously improving, determines which stakeholders, goods, and means of transport should be examined and to what extent. These risks include the potential for non-compliance with customs value calculation, customs tariff number classification, trade restrictions, security regulations as well as the potential failure to facilitate international trade. We have in the past discovered that certain of our and our subsidiaries&#8217; customs value calculations were not applied correctly, following which we notified the customs authorities of potential late payments.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are, and will likely continue to be, subject to various audits that arise from time to time, including customs and potential future foreign trade audits. If we do not properly address our international trade and customs requirements, we could be subjected to penalties and fees. </font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">As a &#8220;foreign private issuer,&#8221; we are exempt from a number of rules under the U.S. securities laws, as well as Nasdaq rules, and we are permitted to file less information with the SEC than U.S. companies. This may limit the information available to holders of the ADSs and may make our ordinary shares and the ADSs less attractive to investors.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are a &#8220;foreign private issuer,&#8221; as defined in the rules and regulations of the SEC, and, consequently, we are not subject to all of the disclosure requirements applicable to companies organized within the United States. Although the SEC in June 2025 issued a concept release soliciting public comment on the definition of &#8220;foreign private issuer&#8221; and has signaled interest in exploring other rules relating to foreign private status, we currently remain exempt from certain rules under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act. Effective March 18, 2026, pursuant to the Holding Foreign Insiders Accountable Act, directors and officers of foreign private issuers, including us, are required to comply with the beneficial ownership reporting requirements of Section 16(a) of the Exchange Act. However, our officers and directors are exempt from the &#8220;short-swing&#8221; profit recovery and short sale prohibition provisions of Section 16 of the Exchange Act. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies. Accordingly, there may be less publicly available information concerning our company than there is for U.S. public companies.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As a foreign private issuer, we file an Annual Report on Form 20-F within four months of the close of each financial year ending December 31 and reports on Form 6-K relating to certain material events promptly after we publicly announce these events. Additionally, we rely on a provision in Nasdaq&#8217;s </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">111</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Listed Company Manual that allows us to follow German company law and European law applicable to European stock corporations in general, the German Stock Corporation Act (Aktiengesetz), the Council Regulation (EC) No 2157&#47;2001 of October 8, 2001 on the Statute for a European company (SE), or the SE Regulation, and the German Act on the Implementation of Council Regulation (EC) No 2157&#47;2001 of October 8, 2001 on the Statute for a European company (SE) (Gesetz zur Ausf&#252;hrung der Verordnung (EG) NR. 2157&#47;2001 des Rates vom 8. Oktober 2001 &#252;ber das Statut der Europ&#228;ischen Gesellschaft (SE)) (SE-Ausf&#252;hrungsgesetz-SEAG), in particular with regard to certain aspects of corporate governance. This allows us to follow certain corporate governance practices that differ in significant respects from the corporate governance requirements applicable to U.S. companies listed on Nasdaq.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">For example, we are exempt from regulations of Nasdaq that require a listed U.S. company to&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">have a majority of the board of directors consist of independent directors&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">require non-management directors to meet on a regular basis without management present&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">adopt a code of conduct and promptly disclose any waivers of the code for directors or executive officers that should address certain specified items&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">have an independent compensation committee&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">have an independent nominating committee&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">solicit proxies and provide proxy statements for all shareholder meetings&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">review related party transactions&#59; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">seek shareholder approval for the implementation of certain equity compensation plans and issuances of ordinary shares.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As a foreign private issuer, we are permitted to follow home country practice in lieu of the above requirements. We therefore continue to follow German corporate governance practices in lieu of the corporate governance requirements of Nasdaq in certain respects. In particular, we follow German corporate governance practices in connection with the distribution of annual and interim reports to shareholders, the application of our code of conduct to our employees and the Supervisory Board, executive remuneration disclosure, proxy solicitation in connection with shareholders&#8217; meetings, and obtaining shareholder approval in connection with the establishment of, or material amendment to, certain equity-based compensation plans.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our audit committee is required to comply with the provisions of Section 301 of the Sarbanes-Oxley Act and Rule 10A-3 of the Exchange Act, both of which are also applicable to U.S. companies listed on Nasdaq. As we are a foreign private issuer, however, our audit committee is not subject to additional requirements of Nasdaq applicable to listed U.S. companies, including an affirmative determination that all members of the audit committee are &#8220;independent,&#8221; using more stringent criteria than those applicable to us as a foreign private issuer.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">112</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Due to the above exemptions for foreign private issuers, our shareholders will not be afforded the same protections or information generally available to investors holding shares in public companies organized in the United States, some investors may find the ADSs less attractive as a result, and there may be a less active trading market for the ADSs.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We face risks related to catastrophic global events including natural disasters, political crises, or public health epidemics and pandemics and other public health developments, that could adversely affect our operations.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our business could be adversely impacted by the effects of catastrophic global events, including natural disasters such as an earthquake, fire, hurricane, tornado, flood or significant power outage&#59; public health crises such as the COVID-19 pandemic&#59; political crises, such as terrorist attacks, war and other political instability, including the ongoing geopolitical conflicts in the Middle East and Ukraine, and resulting sanctions imposed and retaliatory actions taken in response to such sanctions&#59; or other catastrophic events.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">For example, prolonged or expanded conflicts, and political responses to global actions, could destabilize oil and gas supply and demand patterns, increase energy volatility and have severe adverse effects on regional and global supply chains and economies and our business. We also continue to evaluate the impacts that energy shortages may have on our partners, suppliers and service providers. Were any of these parties to experience significant impacts from any energy shortage, our business could be materially harmed. We cannot predict with certainty the impact that volatility in energy prices could have on our or their operations, including on the manufacturing of our COVID-19 vaccine and the manufacturing and testing of our product candidates. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Although we have generated revenues from sales of our COVID-19 vaccine, there remains uncertainty regarding other potential effects of COVID-19 on our business. For example, if a new variant of COVID-19 emerges for which existing vaccines, including our COVID-19 vaccine, are ineffective, infections may become even more widespread, negatively impact our ability to enroll patients in clinical studies and complete clinical trials on the timelines we currently anticipate, or result in an economic downturn that could affect demand for our products and services or our ability to raise capital, which could have a material adverse effect on our business, operating results and financial condition. Our suppliers, licensors or collaborators could also be disrupted by conditions related to COVID-19 or other pandemics and epidemics, possibly resulting in disruption to our supply chain, clinical trials, partnerships or operations.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We maintain insurance coverage that we believe is appropriate for our business&#59; however, such coverage involves significant costs, is increasingly expensive, and does not cover all potential risks, which may expose us to uninsured or underinsured liabilities. We do not carry insurance for all categories of risk that our business may encounter and insurance coverage is becoming increasingly expensive. We do not know if we will be able to maintain existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. We currently maintain insurance coverage for losses relating to property damage, business interruption, transportation, product liability, cyber matters, clinical trials, and several other areas of coverage.&#160;For example, attracting and retaining qualified individuals to serve on our Supervisory Board and our Management Board requires that we </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">113</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">obtain and maintain adequate director and officer liability insurance, which has increased in cost as our operations have evolved. We are dedicating resources to exploring additional avenues for more adequate coverage as our business evolves. However, the coverage or coverage limits of our insurance policies may not be adequate. If our losses exceed our insurance coverage, our financial condition would be adversely affected. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources. Clinical trials or regulatory approvals for any of our product candidates could be suspended, which could adversely affect our results of operations and business, including by preventing or limiting the development and commercialization of any product candidates that we or our collaborators may develop.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, such as actual events or concerns involving liquidity, defaults or non-performance, could adversely affect our operations and liquidity. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds, have in the past and may in the future lead to market-wide liquidity problems. There is no guarantee that the U.S. Department of Treasury, the Federal Deposit Insurance Corporation, and Federal Reserve Board will provide access to uninsured funds in a timely fashion, or at all, in the event of the closure of banks or financial institutions.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">While we maintain our cash and cash equivalents in multiple financial institutions worldwide, our access to our cash and cash equivalents in amounts adequate to finance our operations could be significantly impaired by the financial institutions with which we have arrangements directly facing liquidity constraints or failures. In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any material decline in available funding or our ability to access our cash and cash equivalents could adversely impact our ability to meet our operating expenses, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws, any of which could have material adverse impacts on our operations and liquidity.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1294"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Risks Related to the Manufacturing of our COVID-19 Vaccine, our Product Candidates and Future Pipeline</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our COVID-19 vaccine and product candidates are based on novel technologies and they may be complex and difficult to manufacture. We may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping. If we or any of the third-party manufacturers we work with encounter such difficulties, our ability to supply materials for clinical trials or any approved product could be delayed or stopped.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The manufacturing processes for our COVID-19 vaccine and our product candidates are novel and complex. Due to the novel nature of this technology and the recency of our experience at larger scale production, we may encounter difficulties in manufacturing, product release, shelf life, testing, storage and supply chain management, or shipping. These difficulties could be due to any number of reasons, including, but not limited to, complexities of producing batches at larger scale, equipment failure, choice and quality of raw materials and excipients, analytical testing technology, and product instability. In an effort to optimize product features, we have in the past and may in the future make changes to our product candidates in their manufacturing and stability formulation and conditions. </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">114</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">This has resulted in the past, and may in the future result, in our having to resupply batches for preclinical, clinical, or commercial activities when there is insufficient product stability during storage and insufficient supply. Insufficient stability or shelf life of our products or product candidates could materially delay our or our collaborators&#8217; ability to continue the clinical trial for that product candidate or require us to begin a new clinical trial with a newly formulated drug product, due to the need to manufacture additional preclinical, clinical or commercial supply.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our rate of innovation is high, which has resulted in, and will continue to cause a high degree of, technology change that can negatively impact product comparability during and after clinical development. Furthermore, technology changes may drive the need for changes in, modification to, or the sourcing of, new manufacturing infrastructure or may adversely affect third-party relationships.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The process to generate mRNA medicines is complex and, if not developed and manufactured under well-controlled conditions, can adversely impact pharmacological activity. We may encounter difficulties in scaling up our manufacturing process, thereby potentially impacting clinical and commercial supply. Additionally, for individualized therapies, we may encounter issues with our ability to timely and efficiently manufacture product given the on-demand requirements of such therapies, thereby potentially impacting clinical and commercial supply.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As we continue developing new manufacturing processes for our drug substance and drug product, the changes we implement to the manufacturing process may impact, in turn, specification and stability of the drug product. Changes in our manufacturing processes may lead to failure of lots and this could lead to a substantial delay in our clinical trials or an inability to supply sufficient commercial quantities of drug product. Our mRNA product candidates may prove to have a stability profile that leads to an unfavorable shelf life. This poses risk in supply requirements, wasted stock and higher cost of goods.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We are dependent on a number of equipment providers who are also implementing novel technology. Further, we have developed our own custom manufacturing equipment for certain of our product candidates. If such equipment malfunctions or we encounter unexpected performance issues, we could encounter delays or interruptions to clinical and commercial supply.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Due to the number of different programs, we may in the future have cross contamination of products inside of our factories, CROs, external CMOs, suppliers or in the clinic that affect the integrity of our products. Additionally, for some programs the manufacturing scale is extremely small compared to the standard volumes of supply, such that we run the risk of contaminating the process each time we reopen a container to use remaining supplies.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As we scale the manufacturing output for particular programs, we plan to continuously improve yield, purity and the pharmaceutical properties of our product candidates from IND-enabling studies through commercial launch, including shelf life stability and solubility properties of drug product and drug substance. Due to continuous improvement in manufacturing processes, we may switch processes for a particular program during development. However, after the change in process, more time is required for pharmaceutical property testing, such as six- or 12- month stability testing. That may require resupplying clinical or commercial material, or making additional GMP batches to keep up with clinical trial demand before such pharmaceutical property testing is completed.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">115</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are utilizing a number of raw materials and excipients that are either new to the pharmaceutical industry or are being employed in a novel manner. Some of these raw materials and excipients have not been scaled to a level to support commercial supply and could experience unexpected manufacturing or testing failures, or supply shortages. Such issues with raw materials and excipients could cause delays or interruptions to clinical and commercial supply of our COVID-19 vaccine and our product candidates. Further, now and in the future, one or more of our programs may have a single source of supply for raw materials and excipients. Some of our suppliers are located in countries different from our manufacturing sites. Export restrictions could lead to unplanned interruptions in manufacturing, thus impacting supply of both clinical and commercial material. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We have established a number of analytical assays, and may have to establish several more, to assess the quality of our mRNA products and product candidates. We may identify gaps in our analytical testing strategy that might prevent release of product or could require product withdrawal or recall. For example, we may discover new impurities that have an impact on product safety, efficacy or stability. This may lead to an inability to release mRNA products or product candidates until the manufacturing or testing process is rectified.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our product and product intermediates are extremely temperature sensitive, and we may learn that any or all of our products are less stable than desired. We may also find that transportation conditions negatively impact product quality. This may require changes to the formulation or manufacturing process for one or more of our products or product candidates and result in delays or interruptions to clinical or commercial supply. In addition, the cost associated with such transportation services and the limited pool of vendors may also add additional risks of supply disruptions. As we transport intermediate products with holding times in refrigeration (TIR) and allowed times out of refrigeration (TOR) across long distances and crossing borders, traffic issues and customs delays could lead to the loss of batches which would need to be replaced.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Certain of our product candidates are uniquely manufactured for each patient and we may encounter difficulties in production, particularly with respect to scaling our manufacturing capabilities. If we or any of the third-party manufacturers with whom we contract encounter these types of difficulties, our ability to provide such product candidates for clinical trials or, if approved, products for patients could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We custom design and manufacture certain product candidates that are unique and tailored specifically for each patient. Manufacturing unique lots of these product candidates is susceptible to product loss or failure due to issues with&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">logistics associated with the collection of a patient&#8217;s tumor, blood or other tissue sample&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">shipping such samples to a facility for genetic sequencing&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">next-generation sequencing of the tumor mRNA&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">biopsy of a sufficient quantity of cancerous tissue to allow for proper sequencing and identification of tumor-specific mutations&#894; </font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">identification of appropriate tumor-specific mutations&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">116</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the use of a software program, including proprietary and open source components, which is hosted in the cloud and a part of our product candidate, to assist with the design of the patient-specific mRNA, which software must be maintained and secured&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">effective design of the patient-specific mRNA that encodes for the required neoantigens&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">batch-specific manufacturing failures or issues that arise due to the uniqueness of each patient-specific batch that may not have been foreseen&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">quality control testing failures&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">unexpected failures of batches placed on stability&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">shortages or quality control issues with single-use assemblies, consumables or critical parts sourced from third-party vendors that must be changed out for each patient-specific batch&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">significant costs associated with individualized manufacturing that may adversely affect our ability to continue development&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">successful and timely manufacture and release of the patient-specific batch&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">shipment issues encountered during transport of the batch to the site of patient care&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the ability to define a consistent safety profile at a given dose when each participant receives a unique treatment&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our reliance on single source suppliers.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We also continue to evolve our own custom manufacturing equipment. This equipment may not function as designed, which may lead to deviations in the drug product being produced. This can lead to increased batch failure and the inability to supply patients enrolled in the clinical trial. If our clinical development plans are expanded, we may not be able to supply this expanded need reliably without significant investments due to the custom nature of the equipment and single-use assemblies. In addition, there will be considerable time to scale up our facilities or build new facilities before we can begin to meet any commercial demand if one or more of our individualized product candidates are approved. This expansion or addition of new facilities could also lead to product comparability issues, which can further delay introduction of new capacity.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">For those of our product candidates that are manufactured for each individual patient, we are required to maintain a chain of identity with respect to each patient&#8217;s tissue sample, the sequenced data derived from such tissue sample, the results of such patient&#8217;s genomic analysis and the custom manufactured product for such patient. Maintaining such a chain of identity is difficult and complex, and failure to do so could result in product mix-up, adverse patient outcomes, loss of product, or regulatory action, including withdrawal of any approved products from the market. Further, as our product candidates are developed through early-stage clinical studies to later-stage clinical trials towards approval and commercialization, we expect that multiple aspects of the complicated collection, analysis, manufacture and delivery processes will be modified in an effort to optimize </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">117</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">processes and results. These changes may not achieve the intended objectives, and any of these changes could cause our product candidates to perform differently than we expect, potentially affecting the results of clinical trials.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our inability to manufacture sufficient or appropriate quantities of our COVID-19 vaccine or any of our product candidates, or our failure to comply with applicable regulatory requirements, could materially and adversely affect our business.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Manufacturing is a vital component of our individualized immunotherapy approach, and we have invested significantly in our manufacturing facilities, including the construction of a novel modular manufacturing facility that we refer to as a &#8220;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">BioNTainer</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">,&#8221; and the construction of a facility to support manufacturing of our Individualized Vaccines Against Cancer candidates. All internal manufacturing is performed under GMP guidelines. We also rely on a network of CMOs for the manufacture of our COVID-19 vaccine. We do not rely on any external CMOs for the manufacture of our individualized product candidates and at this time, we have limited redundancy among our facilities. Due to the individualized nature of our product candidates, we do not maintain product reserves. If any of our or our external CMOs&#8217; manufacturing facilities, including our </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">BioNTainer</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> units, experience difficulties, including related to manufacturing, product release, shelf life, testing, storage and supply chain management or shipping, our clinical development programs may be delayed or suspended until we or our external CMOs can resume operations. We may also be required to incur significant expenditures to resolve such difficulties.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We and our collaboration partner also have experienced, and continue to face the risk of, inventory write-downs or redundant production capacities with respect to our COVID-19 vaccine. Planned new formulations of our COVID-19 vaccine, including versions that could protect against new variants of COVID-19, have resulted or may result in significant research and development expense that was not or may not be recouped. In addition, we have experienced in the past, and may experience in the future, redundant production capacities under our agreements with CMOs due to planned new formulations, adaptations of our COVID-19 vaccine and increased internal manufacturing capacities. Significant inventory write-downs or redundant manufacturing expenses would negatively impact our results of operations.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our facilities are subject to various regulatory requirements and may be subject to announced or unannounced inspections by the FDA or other regulatory authorities at any time during the development or commercialization phase. If we or our external CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, the EMA or comparable regulatory authorities in other jurisdictions, we may not be able to rely on our or our external CMOs&#8217; manufacturing facilities for the manufacture of our product candidates. If the FDA, the EMA or another comparable regulatory authority finds our or our external CMOs&#8217; facilities inadequate for the manufacture of our COVID-19 vaccine or our product candidates or otherwise deficient, including as a result of a site inspection, such facilities may be the subject of adverse regulatory action, including the issuance of untitled or warning letters. If such facilities are subject to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which would significantly delay or otherwise impact our ability to develop, obtain regulatory approval for or market our COVID-19 vaccine or our product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Additionally, we may experience manufacturing difficulties due to resource constraints, labor disputes or unstable political environments. If we were to encounter any of these difficulties, our ability to </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">118</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">provide our product candidates to patients in clinical trials, or to provide approved products for the treatment of patients, would be jeopardized.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We are subject to regulatory and operational risks associated with the physical and digital infrastructure at both our internal manufacturing facilities and at those of our external service providers.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The designs of our facilities are based on current standards for biotechnology facilities. They have been reviewed and approved by local authorities and have also received GMP manufacturing licenses. We have designed our facilities to incorporate a significant level of automation of equipment with integration of several digital systems to improve efficiency of operations. We have attempted to achieve a high level of digitization for clinical and commercial manufacturing facilities relative to industry standards. While this is meant to improve operational efficiency, this may pose additional risk of process equipment malfunction and even overall manufacturing system failure or shutdown due to internal or external factors including, but not limited to, design issues, system compatibility or potential cybersecurity breaches. This may lead to a delay in supply or shutdown of our facilities. Any disruption in our manufacturing capabilities could cause delays in our production capacity for our drug substances or drug products, impose additional costs, or require us to identify, qualify and establish an alternative manufacturing site, the occurrence of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As we expand our development and commercial capacity, we may continue to establish additional manufacturing capabilities in different jurisdictions, which may lead to regulatory delays or prove costly. If we fail to select the correct location, complete the construction in an efficient manner, recruit required personnel, and&#47;or generally manage our growth effectively, the development and production of our products or product candidates could be delayed or curtailed. Additional investments may be needed if changes in our manufacturing process lead to required changes in our infrastructure.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our COVID-19 vaccine and certain of our product candidates rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our product candidates require many specialty raw materials, some of which are manufactured by small companies with limited resources and experience to support a commercial product, and suppliers may not be able to deliver raw materials to our specifications. In addition, some such suppliers normally support blood-based hospital businesses and generally do not have the capacity to support commercial products manufactured under GMP by biopharmaceutical firms. These suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also do not have contracts with many of these suppliers, and we may not be able to contract with them on acceptable terms or at all. Accordingly, we have experienced and we may in the future experience delays in receiving key raw materials to support clinical or commercial manufacturing.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">119</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms or at all, which could have a material adverse impact on our business.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We are subject to significant regulatory oversight with respect to manufacturing our products and product candidates. Our manufacturing facilities or the manufacturing facilities of our third-party manufacturers or suppliers may not meet regulatory requirements. Failure to meet GMP requirements set forth in regulations promulgated by the FDA, the EMA and other comparable regulatory authorities could result in significant delays in and costs of our products.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The manufacturing of immunotherapies for clinical trials or commercial sale is subject to extensive regulation. GMP requirements govern manufacturing processes and procedures, including record-keeping, and the implementation and operation of quality systems to control and assure the quality of products and materials used in our products and product candidates. Poor control of the GMP production processes can lead to product quality failures that can impact our ability to supply product, resulting in loss of potential product sales revenue, cost overruns and delays to clinical timelines for our clinical programs, which could be extensive. Such production process issues include but are not limited to&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">critical deviations in the manufacturing process&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">facility and equipment failures&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">contamination of the product due to an ineffective quality control strategy&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">facility contamination as assessed by the facility and utility environmental monitoring program&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">ineffective process, equipment or analytical change management, resulting in failed lot release criteria&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">raw material failures due to ineffective supplier qualification or regulatory compliance issues at critical suppliers&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">ineffective product stability&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">failed lot release or facility and utility quality control testing&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">ineffective corrective actions or preventative actions taken to correct or avoid critical deviations due to our developing understanding of the manufacturing process as we scale&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">failed or defective components or consumables.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We must supply all necessary documentation in support of a BLA or other marketing authorization application on a timely basis and must adhere to the FDA&#8217;s, the EMA&#8217;s and other countries&#8217; GMP requirements, which are enforced, in the case of the FDA, in part through its facilities inspection program.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Regulatory authorities typically require representative manufacturing site inspections to assess adequate compliance with GMPs and manufacturing controls as described in the filing. If either we or </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">120</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">one of our third-party manufacturing sites fail to provide sufficient quality assurance or control, approval to continue delivery of our commercial product or to commercialize our product candidates may not be granted. Inspections by regulatory authorities may be announced or unannounced and may occur at any time during the development or commercialization phase. The inspections may be product-specific or facility-specific for broader GMP inspections, or as a follow up to market or development issues that the regulatory agency may identify. Deficient inspection outcomes may result in adverse regulatory action, including the issuance of untitled or warning letters, which could influence our ability, or the ability of our third-party manufacturers or suppliers, to fulfill supply obligations, impacting or delaying supply or delaying programs. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including, but not limited to, clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our products and product candidates (including those of our collaborators) and our overall business operations.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The manufacturing process for any product is subject to the FDA&#8217;s, the EMA&#8217;s and other regulatory authorities&#8217; approval processes, and we may need to contract with manufacturers whom we believe can meet applicable regulatory authority requirements on an ongoing basis. If we or our third-party manufacturers are unable to reliably manufacture to specifications acceptable to the FDA, the EMA or other regulatory authorities, we or our collaborators may not obtain or maintain the approvals we or they need to release and deliver such products. Even if we or our collaborators obtain regulatory approval for any of our immunotherapies, there is no assurance that either we or our CMOs will be able to manufacture our product candidates to specifications acceptable to the FDA, the EMA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, impair commercialization efforts or increase our cost of goods. The occurrence of any of the foregoing could have an adverse effect on our business, financial condition, results of operations and growth prospects.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, we may not have direct control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. Furthermore, all of our CMOs are engaged with other companies to supply or manufacture materials or products for such companies, which exposes our CMOs to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may generally affect the regulatory status of our CMOs&#8217; facilities, and could result in the sanctions and other adverse outcomes described above. Our potential future dependence upon others for the manufacture of our products, product candidates and raw materials may adversely affect our future operating results and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The FDA, the EMA and other regulatory authorities may require us to submit product samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA or other regulatory authorities may require that we do not distribute a lot or lots until the relevant agency authorizes such release. Deviations in the manufacturing process, including those affecting quality attributes and stability, may result in </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">121</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">unacceptable changes in the product that could result in lot failures or product recalls. Our CMOs have, in the past, experienced lot failures and some may have experienced product recalls. Lot failures or product recalls with respect to product produced by either our own facilities or those of our third-party manufacturers could cause us and our collaborators to delay clinical trials, product launches or product supply, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We also may encounter problems hiring and retaining the experienced scientific, quality-control and manufacturing personnel needed to operate our manufacturing processes and operations, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. While we train and qualify all personnel around the appropriate handling of our products and materials, we may not be able to control for or ultimately detect intentional sabotage or negligence by any employee or contractor.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1303"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Risks Related to our Reliance on Third Parties</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We rely on third parties in the conduct of significant aspects of our preclinical studies and clinical trials and intend to rely on third parties in the conduct of future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or fail to meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We currently rely, and expect to continue to rely, on third parties, such as CROs, clinical data management organizations, collaborators, medical institutions and clinical investigators, to conduct various and significant elements of our clinical trials. Furthermore, we currently rely, and expect to continue to rely, on third parties to conduct certain research and preclinical testing activities. In some cases, these third parties may terminate their engagements with us. If we need to enter into alternative arrangements, it would delay our discovery or product development activities.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our regulatory or contractual responsibilities. We are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Moreover, the FDA requires us to comply with GCP for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We are also required to register ongoing clinical trials and post the results of completed clinical trials on a U.S. government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions. For any violations of laws and regulations during the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We and our CROs are required to comply with regulations, including GCP, for conducting, monitoring, recording and reporting the results of preclinical studies and clinical trials to ensure that the data and results are scientifically credible and accurate and that the trial participants are adequately informed, among other things, of the potential risks of participating in clinical trials. We are also responsible for </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">122</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">ensuring that the rights of our clinical trial participants are protected. These regulations are enforced by the FDA, the regulatory authorities of the EU member states, and comparable regulatory authorities of other jurisdictions for any product candidates in clinical development. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we or our CROs fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable regulatory authorities of other jurisdictions may require us to perform additional clinical trials before approving our marketing applications. We cannot be sure that, upon inspection, the FDA will determine that any of our future clinical trials will comply with GCP. In addition, our clinical trials must be conducted with product candidates produced in accordance with the requirements of GMP regulations. Our failure or the failure of our CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Although we have designed, and in the future intend to design the clinical trials for certain of our product candidates, our collaborators will design the clinical trials that they are managing (in some cases, with our input) and in the case of clinical trials controlled by us, we expect that CROs will conduct all of the clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, are outside of our direct control. Our reliance on third parties to conduct future preclinical studies and clinical trials results in less direct control over the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also potentially lead to mistakes as well as difficulties in coordinating activities. Outside parties may&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">have staffing difficulties&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">fail to comply with contractual obligations&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">experience regulatory compliance issues&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">undergo changes in priorities or become financially distressed&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">form relationships with other entities, some of which may be our competitors&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">make human errors&#894; or</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">be subject to cyberattacks.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may subject us to unexpected cost increases that are beyond our control. If the CROs do not perform preclinical studies and clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates, or our development programs may be materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by our CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay commercialization and require significantly greater expenditures.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">123</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We also rely on other third parties to transport, store and distribute the required materials for our clinical trials. In the past, certain of our third-party vendors have mishandled our materials, resulting in loss of full or partial lots of material. Any further performance failure on the part of these third parties could result in damaged products and could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, if approved, producing additional losses and depriving us of potential product sales revenue, causing us to default on our contractual commitments, result in losses that are not covered by insurance, and damage our reputation and overall perception of our products in the marketplace.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our existing collaborations, or any future collaboration arrangements that we may enter into, may not be successful, which could significantly limit the likelihood of receiving the potential economic benefits of the collaboration and adversely affect our ability to develop and commercialize our products and product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We have entered into collaborations under which our collaborators have provided, and may in the future provide, funding and other resources for developing and commercializing our products and product candidates. We expect to enter into additional collaborations to access additional funding, capabilities and&#47;or expertise in the future. Our existing collaborations, and any future collaborations we enter into, may pose a number of risks, including the following&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">collaborators may not perform or prioritize their obligations as expected&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the clinical trials conducted as part of such collaborations may not be successful&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">collaborators may not pursue development and commercialization of any product candidates and products that achieve regulatory approval or may elect not to continue or renew development or commercialization of programs based on clinical trial results, changes in the collaborators&#8217; focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">collaborators may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">product candidates developed in collaborations with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the development or commercialization of our product candidates&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of any such product&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development of any product candidates, may cause </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">124</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">delays or termination of the research, development or commercialization of such product candidates, may lead to additional responsibilities for us with respect to such product candidates, or may result in litigation or arbitration, any of which would be time-consuming and expensive&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">collaborators may not properly maintain, protect, defend or enforce our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">collaborators may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, the development of our product candidates may be delayed, and we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">future relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing shareholders, or disrupt our management and business&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our international operations through any future collaborations, acquisitions or joint ventures may expose us to certain operating, legal and other risks not encountered in Germany or the United States.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If our collaborations do not result in the successful development and commercialization of programs, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone, earn-out, royalty or other contingent payments, or otherwise yield the expected benefits under the collaborations. As a result, our development of product candidates and commercialization efforts could be delayed and we may need additional resources to develop and commercialize our product candidates. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval and commercialization described in this report apply to the activities of our collaborators.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our research, development and commercialization plans.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our research and product development programs and the potential commercialization of any product candidates we develop alone or with collaborators will require substantial additional cash to fund expenses, and we expect that we will continue to seek collaborative arrangements with others in connection with the development and potential commercialization of current and future product </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">125</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">candidates or the development of ancillary technologies. We face significant competition in establishing relationships with appropriate collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Whether or not we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include, among other things and as applicable for the type of potential product or technology, an assessment of the opportunities and risks of our technology, the design or results of studies or trials, the likelihood of approval, if necessary, of the FDA or comparable regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products and technologies and industry and market conditions generally.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Current or future collaborators may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us. Additionally, we may be restricted under existing collaboration agreements from entering into future agreements on certain terms or for certain development activities with potential collaborators. For example, we have granted exclusive rights or options to Pfizer for certain targets, and under the terms of our respective collaboration agreements with them, we will be restricted from granting rights to other parties to use our mRNA technology to pursue potential products that address those targets. Similarly, our collaboration agreements have in the past and may in the future contain non-competition provisions that could limit our ability to enter into collaborations with future collaborators.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Collaborations are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we do enter into additional collaboration agreements, the negotiated terms may force us to relinquish rights that diminish our potential profitability from development and commercialization of the subject product candidates or others. If we are unable to enter into additional collaboration agreements, we may have to curtail the research and development of the product candidate or technology for which we are seeking to collaborate, reduce or delay research and development programs, delay potential commercialization timelines, reduce the scope of any sales or marketing activities or undertake research, development or commercialization activities at our own expense. If we elect to increase our expenditures to fund research, development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We have entered into in-licensing arrangements and may form or seek to enter into additional licensing arrangements in the future, and we may not realize the benefits of such licensing arrangements.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are a party to licenses that give us rights to third-party intellectual property, including patents and patent applications, that are necessary or useful for our business. For example, we have obtained licenses from Acuitas Therapeutics Inc., or Acuitas, CellScript LLC, or CellScript, and its affiliate, mRNA RiboTherapeutics, Inc., to patent rights claiming certain uses of modified RNA, as well as </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">126</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">licenses from certain other parties for intellectual property useful in pharmaceutical formulations. We may enter into additional licenses to third-party intellectual property in the future.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The success of products developed based on in-licensed technology will depend in part on the ability of our current and future licensors to prosecute, obtain, maintain, protect, enforce and defend patent protection for our in-licensed intellectual property. Our current and future licensors may not successfully prosecute the patent applications we license. Even if patents were issued in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, we sublicense our rights under various third-party licenses to our collaborators. Any impairment of these sublicensed rights could result in reduced revenues under our collaboration agreements or result in termination of an agreement by one or more of our collaborators.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the scope of rights granted under the license agreement and other interpretation-related issues&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate the intellectual property of the licensor that is not subject to the licensing agreement&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our right to sublicense patent and other intellectual property rights to third parties under collaborative relationships&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our diligence obligations with respect to the use of the licensed intellectual property and technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the ownership of inventions, trade secrets, know-how and other intellectual property resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the priority of invention of patented technology&#59; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the amounts to be paid pursuant to certain program milestones being achieved or to royalty obligations, including the triggering of royalty obligations and amounts to be paid pursuant thereto.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If disputes over intellectual property that we have in-licensed or other related contractual rights prevent or impair our ability to maintain our current licensing arrangements on favorable terms, we may be unable to successfully develop and commercialize the affected product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we, our </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">127</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">co-owners or our licensors fail to adequately protect, defend, maintain or enforce this intellectual property, our ability to commercialize products could suffer.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We and our collaborators rely on third parties to manufacture certain of our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Although we expect to continue using our own clinical manufacturing facilities where available, we also rely on outside vendors to manufacture supplies and process our product candidates. We only manufacture our COVID-19 vaccine on a commercial scale and may not be able to achieve commercial-scale manufacturing and processing for our other product candidates, if approved, and may be unable to create an inventory of mass-produced, off-the-shelf product to satisfy demands for our product candidates, if approved.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may not be able to develop commercially viable products other than our COVID-19 vaccine.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, our reliance on a limited number of CMOs exposes us to the following risks&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA or other regulatory authorities may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of regulatory authority questions, if any&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our CMOs might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">CMOs may not be able to execute our manufacturing procedures appropriately&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our future CMOs may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the U.S. Drug Enforcement Administration and corresponding state agencies and by regulatory authorities in other jurisdictions to ensure strict compliance with GMP and other government regulations and corresponding standards in other jurisdictions. We do not have control over CMOs&#8217; compliance with these regulations and standards&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we may not own, or may have to share, the intellectual property rights to any improvements made in the manufacturing process for our products&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our CMOs could breach or terminate their agreement with us&#894; and</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">128</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our CMOs would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Each of these risks could delay our clinical trials, the approval, if any, of our COVID-19 vaccine or product candidates by the FDA or regulatory authorities in other jurisdictions or the commercialization of our COVID-19 vaccine or product candidates, or result in higher costs or deprive us of potential product sales revenue. In addition, we will rely on third parties to perform release tests on our COVID-19 or our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We and certain of our collaborators currently rely on CMOs located outside of the United States to manufacture clinical materials. Such ex-U.S. CMOs may be subject to or affected by U.S. legislation, executive orders, regulations, or investigations, including but not limited to the recently enacted BIOSECURE Act, the Department of Justice&#8217;s Final Rule issued on January 8, 2025 implementing the Executive Order on Preventing Access to Americans&#8217; Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern, sanctions, trade restrictions and other U.S. and other regulatory requirements, which could increase the cost or reduce the supply of material available to us, delay or restrict the procurement or supply of such material, delay or impact clinical trials, have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies and adversely affect our financial condition and business prospects.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We are dependent on single source suppliers for some of the components and materials used in, and the processes required to develop, our COVID-19 vaccine and our product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We currently depend on single source suppliers for some of the components and materials used in, and manufacturing processes required to develop, our COVID-19 vaccine and our product candidates. We cannot ensure that these suppliers or service providers will remain in business, or have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single source suppliers of raw materials, components, key processes and finished goods exposes us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If we have to switch to a replacement supplier, the manufacture and delivery of our product candidates could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our COVID-19 vaccine and our product candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single source components and materials used in our COVID-19 vaccine and our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">129</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">prices in a timely manner, could impair our ability to meet the demand for our COVID-19 vaccine and product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, as part of the FDA&#8217;s approval of our product candidates, we will also require FDA review of the individual components of our process, which include the manufacturing processes and facilities of our single source suppliers.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our reliance on these suppliers, service providers and manufacturers subjects us to a number of risks that could harm our reputation, business and financial condition, including, among other things&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">delays to the development timelines for our product candidates&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">a lack of long-term supply arrangements for key components with our suppliers&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">production delays related to the evaluation and testing of components from alternative suppliers, and corresponding regulatory qualifications&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">delay in delivery due to our suppliers&#8217; prioritizing other customer orders over ours&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">damage to our reputation caused by defective components produced by our suppliers&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If any of these risks materialize, costs could significantly increase and our ability to meet demand for our products could be impacted.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1312"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Risks Related to Intellectual Property </font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">If our efforts to obtain, maintain, protect, defend and&#47;or enforce the intellectual property related to our COVID-19 vaccine or our product candidates and technologies are not adequate, we may not be able to compete effectively in our market.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our commercial success depends in part on our ability to obtain, maintain, protect, defend and enforce patent and other intellectual property, including trade secret and know-how, protection for our COVID-19 vaccine and for our product candidates, proprietary technologies and their uses, as well as our ability to operate, develop, manufacture and commercialize our COVID-19 vaccine or one or more of our product candidates without infringing, misappropriating or otherwise violating the intellectual property or other proprietary rights of our competitors or any other third parties, including </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">130</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">any non-practicing entities or patent assertion entities. We generally seek to protect our intellectual property position by filing and&#47;or licensing patent applications in the European Union, the United States and elsewhere related to our product candidates, proprietary technologies (including methods of manufacture) and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent that the issued claims cover third parties&#8217; activities in the countries in which they are performed. We cannot be certain that the claims in any of our patent applications will be considered patentable by the United States Patent and Trademark Office, or the USPTO, courts in the United States or the patent offices and courts in other jurisdictions, including Europe, nor can we be certain that any claim in our issued patents will not be found invalid or unenforceable if challenged. Accordingly, there can be no assurance that our patent applications or those of our licensors will result in additional patents being issued or that issued patents will adequately cover our COVID-19 vaccine or our product candidates, or otherwise afford sufficient protection against competitors with similar technology, nor can there be any assurance that issued patents will not be infringed, designed around, invalidated or held unenforceable. Furthermore, we may not be able to apply for patents on certain aspects of our current or future products or product candidates, proprietary technologies and their uses in a timely fashion, at a reasonable cost, in all jurisdictions, or at all, and any potential patent protection we obtain may not be sufficient to prevent substantial competition.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Even claims of issued patents may later be found invalid or unenforceable, or may be modified or revoked in proceedings before various patent offices or in courts in the United States, Europe or other jurisdictions. The degree of future protection for our intellectual property and other proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we do not adequately obtain, maintain, protect, defend and enforce our intellectual property and proprietary technology, competitors may be able to use our products, product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our current or future licensors or collaborators will be successful in prosecuting, obtaining, protecting, maintaining, enforcing or defending patents and patent applications necessary or useful to protect our products or product candidates, proprietary technologies (including methods of manufacture) and their uses. These risks and uncertainties include, from time to time, the following&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the USPTO and various other governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patenting process, the noncompliance with which can result in abandonment or lapse of a patent or patent application or a finding that a patent is unenforceable, and partial or complete loss of patent rights in the relevant jurisdiction&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">patent applications may not result in any patents being issued&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">131</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">claims of issued patents that we own (solely or jointly) or have in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">other parties may have designed around our patent claims or developed technologies that may be related or competitive to our COVID-19 vaccine or to our product candidates or other technologies, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent filings, either by claiming the same or overlapping methods, products, reagents, tools or devices or by claiming subject matter that could dominate one or more of our patent claims&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">any successful opposition to claims of any patents owned by or in-licensed to us could deprive us of rights necessary for the development and exploitation of our COVID-19 vaccine or our product candidates and other technologies, or the successful commercialization of any product candidates and other technologies that we may develop&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">because patent applications in the United States and most other jurisdictions are confidential for a period of time after filing, we cannot be certain that we, our co-owners or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">a court or patent office proceeding, such as a derivative action or interference, can be provoked or instituted by a third party or a patent office, and might determine that one or more of the inventions described in our patent filings, or in those we licensed, was first invented by someone else, so that we may lose rights to such invention(s)&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">a court or other patent proceeding, such as an inter partes review, post grant review or opposition, can be instituted by a third party to challenge the inventorship, scope, validity and&#47;or enforceability of our patent claims and might result in invalidation or revision of one or more of our patent claims, or in a determination that such claims are unenforceable&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns&#59; existing legislation (for example, in the United States, the Public Readiness and Emergency Preparedness Act, etc.) may be interpreted, and new legislation may be passed, to permit third-party use of patented technologies relating to a public health concern, with little or no compensation to the patent holder(s)&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing competitors a better opportunity to create, develop and market competing product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. The standards that the USPTO and its counterparts use to grant patents are not always applied predictably or uniformly and can change. Similarly, the ultimate degree of protection that will be afforded to </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">132</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">biotechnology inventions, including ours, in the United States and other countries, remains uncertain and is dependent upon the scope of the protection decided upon by patent offices, courts and lawmakers. Moreover, there are periodic changes in patent law, as well as discussions in the U.S. Congress and in other jurisdictions about modifying various aspects of patent law. There is no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. In certain countries, for example, methods for the medical treatment of humans are not patentable. More generally, the laws of some countries do not protect intellectual property rights to the same extent as U.S. or EU laws, and those countries may lack adequate rules and procedures for granting, maintaining, protecting, defending and enforcing our intellectual property rights.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Furthermore, the patent prosecution process is expensive and time-consuming, and we may not be able to file, prosecute, maintain, protect, defend, enforce or license all necessary or desirable patents or patent applications, as applicable, at a reasonable cost or in a timely manner. It is possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties, if any of these parties were to breach such agreements and improperly disclose such output before a patent application is filed, this could jeopardize our ability to seek patent protection. We also rely to a certain extent on trade secrets, know-how, and technology, which are not protected by patents, to maintain our competitive position. If any trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The issuance of a patent is not conclusive as to its inventorship, priority date, scope, term, validity or enforceability so that any patents that may issue or that we may license may be challenged in the courts or patent offices in the United States, Europe and other jurisdictions. Once granted, patents may remain open to a variety of challenges, including opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings, and furthermore, may be challenged as a defense in any enforcement action that we might bring. Such challenges may result in loss of exclusivity or in patent claims being narrowed, terminated, disclaimed, invalidated, assigned to others or held unenforceable, any or all of which could limit our ability to stop others from using or commercializing similar or identical products, or limit the scope and&#47;or term of patent protection of our products and product candidates and&#47; or eliminate it altogether, thus hindering or removing our ability to limit third parties from making, using or selling products or technologies that are similar or identical to ours, and&#47;or reduce or eliminate royalty payments to us from our licensees. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our pending and future patent applications may not result in patents being issued which protect our technology or our product(s) or product candidates, or which effectively prevent others from commercializing competitive technologies and products. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">133</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our ability to enforce our owned and in-licensed patent and other intellectual property rights depends on our ability to detect infringement, misappropriation and other violation of such patents and other intellectual property. It may be difficult to detect infringers, misappropriators and other violators who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement, misappropriation or other violation in a competitor&#8217;s or potential competitor&#8217;s product or service, and in some cases we may not be able to introduce obtained evidence into a proceeding or otherwise utilize it to successfully demonstrate infringement. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Furthermore, patents or other intellectual property rights that we may be able to secure for our COVID-19 vaccine or our other COVID-19 vaccine candidates could be restricted or preempted if governments determine that they will not enforce, or will require compulsory licensing of, technologies useful to address the spread of COVID-19.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, proceedings to enforce or defend our owned or in-licensed patents could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. If any of our owned or in-licensed patents covering our product candidates or other technologies are narrowed, invalidated or found unenforceable, or if a court found that valid, enforceable patents held by third parties covered one or more of our product candidates or other technologies, our competitive position could be harmed or we could be required to incur significant expenses to protect, enforce or defend our rights. If we initiate lawsuits to protect, defend or enforce our patents, or litigate against third-party claims, such proceedings would be expensive and would divert the attention of our management, technical personnel, and other employees even if the eventual outcome is favorable to us.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The degree of future protection for our intellectual property and other proprietary rights is uncertain, and we cannot ensure that&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product(s), our product candidates and other technologies&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">any of our pending patent applications or those of our licensors may issue as patents&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">others will not or may not be able to make, use, offer to sell or sell products that are the same as or similar to our own but that are not covered by the claims of the patents that we own or license&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we will be able to successfully commercialize our products on a substantial scale, if approved, before the relevant patents that we own or license expire&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">134</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we were the first to make the inventions covered by each of the patents and pending patent applications that we own or license&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we, our co-owners or our licensors were the first to file patent applications for these inventions&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">others will not develop similar or alternative products or technologies that do not infringe the patents we own or license&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">any of the claims of patents we own or license will be found to ultimately be valid and enforceable&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates and other technologies or will provide us with any competitive advantages&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">a third party may not challenge the claims of patents we own or license and, if challenged, a court would hold that such patent claims are valid, enforceable and infringed&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we may develop or in-license additional proprietary technologies that are patentable&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the patents of others will not have an adverse effect on our ability to issue patents, or otherwise on our business&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our competitors do not conduct research, development, testing or commercialization activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we will develop additional proprietary technologies, product(s) or product candidates that are separately patentable&#894; and </font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our, or our collaborators&#8217;, development and commercialization activities, including our manufacturing processes, or products will not infringe patents of our competitors or any other third parties, including any non-practicing entities or patent assertion entities.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Other companies or organizations may challenge our intellectual property rights or the intellectual property rights of our partners or may assert intellectual property rights that prevent us or our partners from developing and commercializing our COVID-19 vaccine or our product candidates and other technologies.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We practice in new and evolving scientific fields, the continued development and potential use of which has resulted in many different patents and patent applications from organizations and individuals seeking to obtain intellectual property protection in the fields. We own and in-license patent applications and issued patents that describe and&#47;or claim certain technologies, including products, reagents, formulations, tools and methods including uses and manufacturing methods, or features or aspects of any of these. These issued patents and pending patent applications claim certain compositions of matter and methods relating to the discovery, development, testing, manufacture and commercialization of therapeutic modalities and our delivery technologies, including lipid nanoparticles, or LNPs. If we, our co-owners or our licensors are unable to obtain, maintain, protect, defend or enforce patent protection with respect to our products, product candidates and </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">135</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">other technology and any other products, product candidates and technology that we may develop, our business, financial condition, results of operations and prospects could be materially harmed.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As the scientific fields mature, our known competitors and other third parties, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents, and they have filed and will continue to file patent applications claiming inventions in the fields in the United States and elsewhere. This may limit, interfere with or eliminate our and our partners&#8217; ability to make, use, sell, import or otherwise exploit our COVID-19 vaccine or our product candidates or other technologies. There is uncertainty about which patents will issue, and, if they do, as to when, to whom and with what claims. With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We, our co-owners, our partners or our licensors may in the future become a party to patent proceedings or priority disputes in the United States, Europe or other jurisdictions. In the United States, the Leahy-Smith America Invents Act, or the America Invents Act, includes a number of significant changes that affect the way patent applications are prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent through USPTO-administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. We expect that our competitors and other third parties will institute litigation and other proceedings, such as interference, reexamination and opposition proceedings, as well as inter partes and post-grant review proceedings against us and the patents and patent applications that we own and in-license. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Additionally, we face ongoing COVID-19 vaccine-related patent litigation. ModernaTX, Inc., or Moderna, has brought litigation against us and Pfizer regarding European patents 3590949B1, or EP&#8217;949, and 3718565B1, or EP&#8217;565, in Germany (only EP&#8217;949 currently at issue), England and Wales (only EP&#8217;949 currently at issue), the Netherlands (only EP&#8217;949 currently at issue), Ireland, and Belgium (only EP&#8217;949 currently at issue), and regarding U.S. Patent Nos. 10,898,574, 10,702,600, and 10,933,127 in the United States. BioNTech and Pfizer also initiated proceedings seeking the revocation of EP&#8217;949 in the Business and Property Courts of England and Wales and have filed opposition proceedings in the EPO seeking the revocation of EP&#8217;949. With respect to EP&#8217;565, the EPO confirmed the final revocation of this patent following oral proceedings on January 27, 2026. BioNTech and Pfizer have filed petitions for inter partes review before the Patent Trial and Appeal Board in the United States with respect to U.S. Patent Nos. 10,702,600 and 10,933,127. Arbutus Biopharma Corp., or Arbutus, and Genevant Sciences GmbH, or Genevant, have brought litigation against us and Pfizer in the United States regarding U.S. Patent Nos. 9,504,651&#59; 8,492,359&#59; 11,141,378&#59; 11,298,320&#59; and 11,318,098. Promosome LLC, or Promosome, has initiated litigation against us and Pfizer in the Unified Patent Court (Munich Division) regarding one European patent, EP 2 401 365. GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC, or collectively, GSK, have brought litigation against us and Pfizer in the United States regarding U.S. Patent Nos. 11,638,693, 11,638,694, 11,666,534, 11,766,401, 11,786,467, 11,759,422, 11,655,475, and 11,851,660, and in the High Court of Ireland, as well as the United Patent Court, regarding European Patent Nos. 2,590,626, 4,066,856, and 4,226,941. BioNTech and Pfizer also initiated proceedings seeking the revocation of EP&#8217;626, EP&#8217;856, </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">136</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">and EP&#8217;941 in the Business and Property Courts of England and Wales and have filed opposition proceedings in the EPO seeking the revocation of EP&#8217;856 and EP&#8217;941. Bayer CropScience LLC, or Bayer, Monsanto Company, and Monsanto Technology, LLC, or Monsanto, have initiated litigation against us and Pfizer in the United States District Court for the District of Delaware regarding  U.S. Patent No. 7,741,118. We cannot guarantee that we will not become subject to additional COVID-19 vaccine patent infringement lawsuits in the future. In addition, should Pfizer not prevail in any of the ongoing COVID-19 vaccine patent infringement lawsuits to which it is a party, Pfizer may seek to require us to indemnify Pfizer for losses suffered therefrom as well as any losses from future COVID-19 vaccine patent infringement lawsuits in which it does not prevail. We believe we have strong defenses against each of these claims and intend to vigorously defend ourselves in each proceeding, but we can make no assurances regarding the ultimate outcome of any of these matters. Additionally, as we continually evaluate these various proceedings, we may from time to time make strategic decisions to settle or otherwise resolve certain proceedings despite our continued belief in the strengths of our defenses.</font></div><div style="text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We expect that we will continue to be subject to similar proceedings or priority disputes, including oppositions, in Europe or other jurisdictions relating to patents and patent applications in our portfolio.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If we, our co-owners, our partners or our licensors are unsuccessful in any interference proceedings or other priority or validity disputes, including any derivations, post-grant review, inter partes review or oppositions, to which we or they are subject, we may lose valuable intellectual property rights through the narrowing or loss of one or more patents owned or in-licensed, or our owned or in-licensed patent claims may be narrowed, invalidated or held unenforceable. In many cases, the possibility of appeal exists for either us or our opponents, and it may be years before final, unappealable rulings are made with respect to these patents in certain jurisdictions. The timing and outcome of these and other proceedings is uncertain and may adversely affect our business if we are not successful in defending the patentability and scope of our pending and issued patent claims. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management, technical personnel and other employees and could have a material adverse impact on our business and our ability to successfully compete against our current and future competitors.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">There are many issued and pending patent filings that claim aspects of technologies that we may need for our mRNA products or product candidates, or other product candidates, including patent filings that relate to relevant delivery technologies. There are also many issued patents that claim targeting genes or portions of genes that may be relevant for immunotherapies we wish to develop. In addition, as evidenced by the lawsuits brought against Moderna, Pfizer and us, there may be additional issued and pending patent applications that may be asserted against us in a court proceeding or otherwise based upon the asserting party&#8217;s belief that we may need such patents for the development, manufacturing, testing and commercialization of our COVID-19 vaccine or of our product candidates. Thus, it is possible that one or more organizations, ranging from our competitors to non-practicing entities or patent assertion entities, has or will hold patent rights to which we may need a license, or hold patent rights which could be asserted against us. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If those organizations refuse to grant us a license to such patent rights on reasonable terms, if we fail to invalidate relevant patents, or if a court or other governing body determines that we need such patent rights that have been asserted against us and we are not able to obtain a license on reasonable terms or at all, we may </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">137</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">be unable to perform research and development or other activities or market products covered by such patents, and we may need to cease the development, manufacture, testing and commercialization of one or more of the product candidates we may develop. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations or prospects.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We may not be successful in obtaining, maintaining, protecting or defending the necessary intellectual property rights to allow us to identify and develop product candidates, and test product components and manufacturing processes for our development pipeline.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We currently have rights to certain intellectual property through our owned and in-licensed patents and other intellectual property rights relating to identification, development and testing of our product candidates or other technologies. As our activities may involve additional product candidates or services that could require the use of intellectual property and other proprietary rights held by third parties, the growth of our business could depend in part on our ability to acquire, in-license or use such intellectual property and proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these intellectual property and other proprietary rights may be held by others. We may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary, on reasonable terms, or at all, for product candidates and other technologies that we may develop. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We sometimes collaborate with academic institutions and&#47;or utilize services of CROs and CMOs in certain aspects of our research or development under written agreements with these parties. These agreements may not ensure protection of intellectual property rights in developed technology, or may fail to provide us with sufficient control of or access to such intellectual property rights. For example, agreements with these academic institutions typically provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. However, these institutions may not honor our option and right of first negotiation for intellectual property rights or we may otherwise be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program or otherwise continue to develop certain product candidates or other technologies. CROs and&#47;or CMOs may control certain technologies that were utilized in and&#47;or developed through work on our behalf, and may not pursue protection of such technologies, or may provide us with only non-exclusive rights in such technologies, so that relevant technologies may be shared with other parties including our competitors. In any relationship with a third party, there is a risk of disagreement over intellectual property rights (including inventorship or ownership of, rights to protect and&#47;or enforce, and&#47;or rights to use) in utilized or developed technologies.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Moreover, some of our owned patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain, or continue to maintain, exclusive rights to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">138</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">market competing products and technologies. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, third parties that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain, protect, defend or enforce the existing intellectual property rights we have, we may have to abandon the development and commercialization of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">The lifespans of our patents may not be sufficient to effectively protect our products or product candidates, technologies and business.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective non-provisional filing date, assuming maintenance fees are timely paid after the patent has issued. Most other jurisdictions also provide a 20-year nominal patent term, though many require payment of regular, often annual, annuities to maintain pendency of an application or viability of an issued patent. In some jurisdictions, one or more options for extension of a patent term may be available, but even with such extensions, the lifespan of a patent, and the protection it affords, is limited. Even if patents covering our product candidates, proprietary technologies and their uses are obtained, once the patent term has expired, we may be subject to competition from third parties that can then use the inventions included in such patents to create competing products and technologies. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. The USPTO can also require, in certain circumstances, that the expiration date of a subject patent be shortened by the filing of a terminal disclaimer over one or more patents that may expire sooner than the subject patent. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such candidates are commercialized. If any patents that we own or in-license expire, we would not be able to stop others from using or commercializing similar or identical technology and products, and our competitors could market competing products and technology. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process for a drug product subject to the provisions of the Hatch-Waxman Act. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">139</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. For example, we did not extend any patent for our COVID-19 vaccine. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">If we fail to comply, or are viewed to have failed to comply, with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors or other third parties, we could lose license rights that are important to our business or suffer monetary losses.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are heavily reliant upon licenses to certain intellectual property and other proprietary rights from third parties that are important or necessary to the development and commercialization of our technology and product(s) or product candidates, and we expect to enter into similar license agreements in the future. Licensing of intellectual property is important to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Our licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop, test, or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in any or all of our licenses.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Where we obtain licenses from, or collaborate with, third parties, in some circumstances we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license from, or that arises through collaboration with, such third parties, or such activities, if controlled by us, may require the input of such third parties. In some cases, patent prosecution (including preparation and filing) of our in-licensed intellectual property or of intellectual property developed through collaboration, is controlled solely by the licensor or collaborator. We may also require the agreement and&#47;or cooperation of our licensors and collaborators to protect, enforce, utilize, or defend any in-licensed patent rights, and such agreement and&#47;or cooperation may not be provided. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, protected, enforced or defended in a manner consistent with the best interests of our business. Any patents or patent applications that we in-license may be challenged, narrowed, circumvented, invalidated or held unenforceable, or our licensors may not properly maintain such patents or patent applications and they may expire. If our licensors fail to obtain, maintain, defend, protect or enforce the intellectual property we license from them, we could lose our rights to the intellectual property and our competitors could market competing products using the inventions in such intellectual property. In certain cases, we control the prosecution of patents included from in-licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our collaborators. If we and our licensors or collaborators disagree over IP protection strategies for relevant technologies, disputes may arise, and we could lose access to or control over protection of technologies important to our business. If so, we may not be able to adequately protect our product(s) or product candidates, including not being able to prevent a competitor or other third party from developing the same product(s) or product candidates for the same or a different use. Any of the </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">140</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Moreover, we may disagree from time to time with licensors or collaborators regarding, among other things, the interpretation of each party&#8217;s obligations or the amounts payable under our agreements. For example, on December 20, 2024, we entered into a Settlement Agreement with the National Institutes of Health, or NIH, pursuant to which we agreed, among other things, to pay $791.5 million to the NIH to settle disputes concerning royalties and other related amounts allegedly owed on sales of our COVID-19 vaccine since commercialization. Additionally, on March 27, 2025, we entered into a Settlement Agreement with the University of Pennsylvania, or UPenn, pursuant to which we agreed, among other things, to pay up to $467.0 million to UPenn to settle disputes concerning royalties and other related amounts allegedly owed on sales of our COVID-19 vaccine since commercialization. For more information regarding our settlements with the NIH and UPenn, see Note 12.2 of our consolidated financial statements included in our Annual Report on Form 20-F as of and for the year ended December 31, 2025, as amended.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If we are found to have failed to satisfy obligations or materially breached any of our agreements, such as licenses to third-party intellectual or any disagreements between us and our licensors, a licensor could potentially have the right or reason to terminate the license or to exercise the option of a non-exclusive license, which would allow our competitors to have access to the same intellectual property and technology licensed to us. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone and royalty payment, exclusivity and other obligations on us. If we fail to comply with our obligations under these agreements, including royalty payments, or we are subject to a bankruptcy, the licensor may have the right to terminate the license agreement, in which event we would not be able to develop, market and commercialize product(s) or product candidates covered by the license agreement. In spite of our best efforts and even if we disagree, our licensors might still conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop, test and commercialize the product(s) or product candidates covered by these license agreements. In the event that any of our license agreements were to be terminated by the licensor, we may need to negotiate new or reinstated agreements, which may not be available to us on equally favorable terms, or at all. If these license agreements are rightfully terminated, or if the underlying patents or other intellectual property fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market and commercialize, products similar or identical to ours, and our licensors may be able to seek additional judicial remedies. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing license agreements in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties (potentially including our competitors) to receive licenses to a portion of the intellectual property that is subject to our existing licenses. Failure to prevail with respect to any contractual disagreements could result in a material adverse effect on our competitive position, business, financial conditions, results of operations or prospects, particularly if discussions result in legal or other dispute resolution proceedings.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described in this section. If we, our co-owners or our licensors fail to adequately protect this intellectual property, our ability to </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">141</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">develop, test, market and commercialize our product(s) or product candidates could suffer. Moreover, if disputes over intellectual property that we have in-licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop, test, market and commercialize the affected product(s) or product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Some of our in-licensed intellectual property has been discovered through government-funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights and certain reporting requirements, and compliance with such regulations may limit our exclusive rights and our ability to contract with manufacturers.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Certain intellectual property rights that have been in-licensed, including patent applications and patents that we in-license from UPenn, the Louisiana State University, the Broad Institute, the NIH, Genevant, and CellScript, have been generated through the use of U.S. government funding and are therefore subject to certain federal regulations. The U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or the Bayh-Dole Act. These U.S. government rights may include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions covered by that Act for any governmental purpose. In addition, the U.S. government may have the right, under certain limited circumstances, to require the licensor to grant exclusive, partially exclusive or non-exclusive licenses to any of these inventions to a third party if it determines that (i) adequate steps have not been taken to commercialize the invention, (ii) government action is necessary to meet public health or safety needs or (iii) government action is necessary to meet requirements for public use under federal regulations (also collectively referred to as &#8220;march-in rights&#8221;). The U.S. government may also have the right to take title to these inventions if the licensor fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Any exercise by the government of such rights could harm our competitive position, business, financial condition, results of operations and prospects. Intellectual property generated under a government-funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, the U.S. government requires that any products embodying any such inventions or produced through the use of any such inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture the products substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. We may not be able to obtain a waiver of this preference for U.S. industry, and this preference may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our owned or in-licensed future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. If we or our licensors are unable to secure an exemption to these manufacturing requirements, if we comply with them, or if we are unable to comply with them, we may experience a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">142</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our current proprietary position for certain products and product candidates depends upon our owned or in-licensed patent filings covering components, manufacturing-related methods, formulations and&#47;or methods of use, which may not adequately prevent a competitor or other third party from using the same product candidate for the same or a different use.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Composition of matter patent protection is generally considered to be desirable because it provides protection without regard to any particular method of use or manufacture or formulation. While we have pursued or obtained patent protection covering components of certain product candidates and tests, manufacturing-related methods, formulations and&#47;or methods of use, we have not yet obtained patent protection for all components of certain product candidates and tests, manufacturing-related methods, formulations and&#47;or methods of use. For instance, we do not currently have any claims in our owned or in-licensed issued U.S. patents that cover the overall construct used in our iNeST product candidates. We also cannot be certain that claims in any future patents issuing from our pending owned or in-licensed patent applications or our future owned or in-licensed patent applications will cover the composition of matter, tests, manufacturing-related methods, formulations and&#47;or methods of use of our current or future product candidates. Method of use patents protect the use of a product for the specified method and formulation patents cover formulations to deliver therapeutics. These types of patents do not prevent a competitor or other third party from developing, testing, marketing or commercializing a similar or identical product for an indication that is outside the scope of the patented method or from developing a different formulation that is outside the scope of the patented formulation. Moreover, with respect to method of use patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method of use patents, the practice is common and this type of infringement is difficult to prevent or enforce. Consequently, we may not be able to prevent third parties from practicing our inventions in the United States or abroad. </font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Intellectual property rights of third parties could adversely affect our ability to commercialize our product(s) and product candidates, and we might be required to litigate or obtain licenses from third parties in order to develop, test or market our product(s) and product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Because our products and product candidates are still in early stages of development, testing or commercialization, and one or more features of the products or product candidates, or related technologies such as their manufacture, formulation, testing or use, may still change, we cannot be confident that we are aware of all third-party intellectual property that might be relevant to products that we eventually hope to commercialize. Furthermore, even if all aspects of our product(s) or product candidates, or of other technology, were known, it is possible that third-party intellectual property, which may or may not currently be public, could develop in a manner (for example, through issuance of additional patents) that could impede our ability to make or use relevant products or product candidates, or other technology. Various third-party competitors practice in relevant spaces, and may have issued patents, or patent applications that will issue as patents in the future, that will impede or preclude our ability to commercialize products. Furthermore, while U.S. patent laws provide a &#8220;safe harbor&#8221; to our clinical product candidates under 35 U.S.C. &#167; 271(e)(1), which exempts from patent infringement activities related to pursuing FDA approval for a drug product, that exemption expires when an NDA or BLA is submitted. Accordingly, after such submission (including for certain formulations of our COVID-19 vaccine), the 271(e)(1) safe harbor may no longer provide the same level of protection from third party patent infringement claims for that product. We may become exposed to lawsuits from third parties who consider our COVID-19 vaccine to infringe their patents. More generally, given the uncertainty of clinical trials, we cannot be certain of the timing of their completion </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">143</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">and it is possible that we might want to submit an NDA or BLA at a time when one or more relevant third-party patents is in force. Thus, it is possible that at the time that we commercialize our product candidates, one or more third parties may have issued patent claims that cover such products or critical features of their production, testing or use. We may not be able to commercialize our products if patents issued to third parties or other third-party intellectual property rights cover, or may be alleged to cover, our products or elements thereof, or their methods of manufacture, testing or use at the time that we seek to commercialize them. In such cases, we may not be in a position to develop, test or commercialize product candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, successfully design around their claims, or enter into a license agreement with the intellectual property right holder(s). Such litigation or licenses could be costly, licenses could not be available on commercially reasonable terms or at all, and design-around could be prohibitively expensive or impossible. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Additionally, with respect to our products, product candidates and related technologies that may play a role in addressing a pandemic or other public health emergency, it is unclear whether governments around the world will protect vaccine manufacturers for liability from infringement of third party intellectual property, at least during the period of such public health emergency. Thus, it is possible that third parties may assert intellectual property rights against us relating to our COVID-19 vaccine, and that we will not be successful in arguing that commercialization of our COVID-19 vaccine is exempted from infringement and&#47;or liability for infringement (for example, under 35 U.S.C. &#167; 271(e)(1), discussed above, or under the Public Readiness and Emergency Preparedness Act, or the PREP Act, etc.). Furthermore, even if such commercialization was deemed protected from infringement during the period of the pandemic crisis, now that various global and U.S. agencies have declared an end to the global COVID-19 public health emergency, any such exemption may be terminated so that continuing commercialization could expose us to liability, and might even be precluded if third party(ies) who hold relevant intellectual property rights are able to secure injunction(s) or are unwilling to license to us on commercially feasible terms.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">It is also possible that we have failed to identify relevant third-party patents that cover, or applications that will mature into patents that cover, one or more aspects of our platform or product(s) and product candidates. Given that, in most jurisdictions, a patent application is confidential when initially filed, and typically remains so until it is published about 18 months after the initial filing, it may not be possible for us to identify certain relevant filings in time to avoid using the technology that they claim. Additionally, the claims of pending patent applications can, subject to certain limitations, be amended over time, so that even patent applications whose claims did not cover our products or activities when published could be amended to cover one or more aspects of our platform or product candidates over time, and we might not be aware that such amendment had been made.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We may be involved in lawsuits or other legal proceedings to protect or enforce our intellectual property or the intellectual property of our licensors, or to defend against third-party claims that we infringe, misappropriate or otherwise violate such third party&#8217;s intellectual property, each of which could be expensive, time consuming and unsuccessful.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, ex parte reexaminations, post-grant review, and inter partes review proceedings before the USPTO and corresponding European and other non-U.S. patent offices.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">144</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Competitors and other third parties may infringe, misappropriate or otherwise violate our intellectual property rights or those of our licensors. To prevent infringement, misappropriation or other unauthorized use, we may be required to file claims, which can be expensive and time-consuming. In certain instances, we have instituted and may in the future institute inter partes review proceedings against issued U.S. patents and opposition proceedings against European patents owned by third parties. We have a number of opposition proceedings ongoing at the EPO against third-party patents related to mRNA technologies. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our products, product candidates and services may be subject to claims of infringement of the patent rights of third parties.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, in a patent infringement proceeding, our owned or in-licensed patents may be challenged and a court may decide that a patent we own or in-license is not valid, is unenforceable and&#47;or is not infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product(s) and&#47;or product candidates, the defendant could counterclaim that our patent is invalid and&#47;or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and&#47;or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including novelty, non-obviousness, enablement or written description. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. Similar mechanisms for challenging the validity and enforceability of a patent exist in ex-U.S. patent offices and may result in the revocation, cancellation or amendment of any ex-U.S. patents we hold in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and&#47;or unenforceability, we could lose at least part, and perhaps all, of the patent protection on a product and&#47;or product candidate. Such a loss of patent protection would have a material adverse impact on our competitive position, business, financial conditions, results of operations and prospects.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Third parties, including our competitors to non-practicing entities or patent assertion entities, may assert that we are employing their intellectual property and other proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, testing, methods of manufacture or methods for treatment related to the use, development, testing, manufacture or commercialization of our COVID-19 vaccine or product candidates. For example, BioNTech SE and certain of our wholly owned subsidiaries are or recently have been defendants in litigations initiated by Bayer&#47;Monsanto, Moderna, Arbutus, Genevant, GSK, and Promosome regarding </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Comirnaty</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">. See &#8220;Legal Proceedings.&#8221; As patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product(s) and&#47;or product candidates may infringe. In addition, third parties may obtain patents in the future and claim that our technologies infringe upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the testing or manufacturing processes of any of our product(s) and&#47;or product candidates, any molecules formed during the testing and manufacturing processes or any final product itself, the holders of any such patents may obtain injunctive or other equitable relief, which could effectively block our ability to develop, test and commercialize such product and&#47;or product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">145</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">held by a court of competent jurisdiction to cover aspects of our formulations, processes for testing or manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop, test and commercialize the applicable product and&#47;or product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms, or at all, or may be non-exclusive.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same intellectual property and technology. Our defense of litigation, interference, derivation or similar proceedings may fail and, even if successful, may result in substantial costs and distract our management, technical personnel and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds we need to continue our clinical trials and research programs, to license necessary technology from third parties or to enter into development or manufacturing collaborations that would help us bring our product(s) and&#47;or product candidates to market.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our management, technical personnel and other employees from their normal responsibilities. Such proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such proceedings adequately. Some of our competitors may be able to sustain the costs of such proceedings more effectively than we can because of their greater resources in one or more aspects, or for other reasons. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In the event of a successful claim of infringement, misappropriation or other violation against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products, or obtain one or more licenses from third parties, which may not be made available on commercially favorable terms, if at all, or may require substantial time and expense.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same intellectual property and technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and product(s) and&#47;or product candidates, which could limit our ability to generate revenues or achieve or maintain profitability and possibly prevent us from generating revenue sufficient to sustain our operations. Moreover, certain of our collaborations provide, and we expect additional collaborations to provide, that royalties payable to us for licenses to our intellectual property may be offset by amounts paid by our collaborators to third parties for licenses to such third parties&#8217; intellectual property in the relevant fields, which could result in significant reductions in our revenues from products developed through collaborations.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">146</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, in connection with certain license and collaboration agreements, we have agreed to indemnify certain third parties for certain costs incurred in connection with litigation relating to intellectual property rights or the subject matter of the agreements. The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments in any litigation or other intellectual property proceedings. If securities analysts or investors perceive these results to be negative, the price of the ADSs representing our ordinary shares could decline.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non- compliance with these requirements.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents and applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents or applications. We have systems in place to remind us to pay these fees and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies&#894; however, we cannot guarantee that we will successfully pay these fees. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our in-licensed intellectual property, and we cannot guarantee that they will do so. In such an event, our competitors might be able to enter the market with similar or identical products or technology, and this would have a material adverse impact on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Changes in patent law in the United States or in other countries could diminish the value of patents in general, thereby impairing our ability to protect our products.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As is the case with other biotechnology companies, our success is heavily dependent on our intellectual property rights, particularly patents that we own and in-license. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and therefore obtaining and enforcing biotechnology patents is costly, time-consuming and inherently uncertain. Moreover, there are periodic changes in patent law. For example, after March 2013, under the America Invents Act, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The America Invents Act also includes a number of significant changes that have affected the way patent applications are prosecuted and also affect patent litigation. Such legislation and its implementation could increase the uncertainties and costs surrounding the prosecution of our </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">147</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, decisions by courts and governmental bodies in the United States and other jurisdictions may affect the value of patent applications, issued patents or other intellectual property that we own or in-license. For example, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, the USPTO and other administrative agencies, and their equivalents in other jurisdictions, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to obtain, maintain, protect, defend or enforce our intellectual property in the future.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition to seeking patent protection for some of our technology, product(s) and product candidates, we also seek to rely on trade secret protection and confidentiality agreements to maintain our competitive position and protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery development, testing, manufacturing and commercialization processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets and know-how may be difficult to protect.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We seek to protect these trade secrets, know-how and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants and require all of our employees and key consultants who have access to our trade secrets, proprietary know-how, information or technology to enter into confidentiality agreements. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. To the extent we become involved in litigation that may require discovery of our trade secrets, know-how and other proprietary technology, we seek to secure protective orders from the court that bind the parties with access to the discovered information. Despite our best efforts, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Any of these parties who may have access to our trade secrets, know-how and other proprietary technology may breach such agreements or orders. For example, a former employee of our COVID-19 vaccine collaborator, Pfizer, has reportedly misappropriated trade secrets on our COVID-19 vaccine. We may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret or know-how is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets and know-how. In addition, we cannot be certain that our proprietary technical information and related confidential </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">148</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">documents that we have shared with our collaborators and&#47;or have submitted to governmental agencies, including regulatory agencies, for evaluation and supervision of pharmaceutical products will be kept confidential. For example, certain documents relating to our COVID-19 vaccine were unlawfully accessed after a cyberattack on the EMA in December 2020. If any of our trade secrets or know-how were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, financial condition and prospects.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We may be subject to claims that we have wrongfully hired an employee from a competitor, or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties, including alleged trade secrets of their former employers.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We have received confidential and proprietary information from third parties in the course of our research and other collaborations with others in the industry, academic institutions and other third parties. In addition, many of our employees, consultants and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, independent contractors and advisors do not use the confidential or proprietary information, trade secrets or know-how of others in their work for us, we may be subject to claims that we have inadvertently or otherwise used or disclosed confidential or proprietary information, trade secrets or know-how of these third parties, or that our employees, consultants, independent contractors or advisors have inadvertently or otherwise used or disclosed confidential information, trade secrets or know-how of such individual&#8217;s current or former employer. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management, technical personnel and other employees. Claims that we or our employees, consultants or advisors have misappropriated the confidential or proprietary information, trade secrets or know-how of third parties could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In the future, we may be subject to claims that current or former employees, consultants, independent contractors, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. While it is our policy to require our employees, consultants, independent contractors, collaborators and other third parties who may be involved in the conception, development or reduction to practice of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives, develops or reduces to practice such intellectual property that we regard as our own. In addition, certain such agreements, even if successfully executed may distribute ownership or control of intellectual property rights between or among parties, for example based on subject matter, relationship to other intellectual property, and&#47;or one or more aspects of development of the intellectual property&#59; after the agreements are in place disputes may arise over such distribution principles or over proper treatment of particular developed intellectual property in accordance with them. Disagreements may be difficult or impossible to resolve, may be expensive to address, and may </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">149</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">result in our failing to secure or maintain ownership in or control of intellectual property necessary or important to our business.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached. For example, we may have inventorship or ownership disputes arise from conflicting obligations of employees, consultants, independent contractors, collaborators or other third parties who are involved in developing and commercializing our product(s) and&#47;or product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business, operating results and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management, technical personnel and other employees.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Furthermore, the laws of some other countries do not protect intellectual property and other proprietary rights or establish ownership of inventions to the same extent or in the same manner as the U.S. laws. A majority of our employees work in Germany and are subject to German employment law. Ideas, developments, discoveries and inventions made by such employees are subject to the provisions of the German Act on Employees&#8217; Inventions, which regulates the ownership of, and compensation for, inventions made by employees. We face the risk that disputes can occur between us and our employees or former employees pertaining to alleged non-adherence to the provisions of this act that may be costly to defend and take up our management&#8217;s, technical personnel&#8217;s and other employees&#8217; time and efforts whether we prevail or fail in any such dispute. There is a risk that the compensation we provided to employees who assign patents to us may be deemed to be insufficient and we may be required under German law to increase the compensation due to such employees for the use of the patents. In those cases, where employees&#8217; rights have not been assigned to us, we may need to pay compensation for the use of those patents. If we are required to pay additional compensation or face other disputes under the German Act on Employees&#8217; Inventions, our business, results of operations and financial condition could be adversely affected.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We will not seek to protect our intellectual property rights in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Filing, prosecuting and defending patents on product(s) and&#47;or product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States, particularly those in Asia, including China, can be less extensive than those in the United States. In addition, the laws of some countries do not protect intellectual property rights to the same extent as laws in Germany and the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States to the same extent as within the United States, or from selling or importing products made using our inventions in and to the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own product candidates and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">150</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">may compete with our product(s) and&#47;or product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain jurisdictions, particularly outside of Europe and the United States. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement, misappropriation or other violation of our patents and other intellectual property or development, testing, marketing and commercialization of competing products in violation of our owned or in-licensed intellectual property and other proprietary rights generally. Proceedings to enforce our intellectual property rights in such jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or in-license. In particular, the validity, enforceability and scope of protection of intellectual property in China, where we derive net sales and maintain collaboration partnerships including licensing, are still evolving and historically, have not protected and may not protect in the future, intellectual property rights to the same extent as laws developed in Europe, including Germany, and the United States. Consequently, the time required to enforce our intellectual property rights in the legal regime of China may be lengthy and delay our recovery.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours or collaborators may fail to use our trade names or trademarks appropriately or at all, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors and collaborators. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">151</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">agreements or misuse or failure to use of our trademarks and trade names by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks, and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, know-how, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">others may be able to make COVID-19 vaccines or therapies, and&#47;or individualized cancer immunotherapies that are similar to our COVID-19 vaccine and&#47;or any product candidates we may develop and commercialize or utilize similar technologies that are not covered by the claims of the patents that we now or may in the future own or have exclusively in-licensed&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we, our co-owners or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or have exclusively in-licensed&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we, our co-owners or our licensors or future collaborators might not have been the first to file patent applications covering certain of our or their inventions&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">it is possible that our pending patent applications or those that we may own or in-license in the future will not lead to issued patents&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">claims of issued patents that we own or have exclusively in-licensed may be held invalid or unenforceable, including as a result of legal challenges by our competitors&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our competitors might conduct research, development, testing or commercialization activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we may not develop additional proprietary technologies that are patentable&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the patents of others may have an adverse effect on our business&#894; and </font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">152</font></div></td></tr></table></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1330"></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Risks Related to Government Regulation</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We may not be able to develop or obtain approval for companion diagnostics required for commercialization of some of our product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Administration of some of our product candidates may require the use of immuno-assays and bioinformatic tools in which patients are screened for optimal target antigens of our product candidates. If safe and effective use of a biologic product depends on an in vitro diagnostic, then the FDA generally requires approval or clearance of the diagnostic, known as a companion diagnostic, concurrently with approval of the therapeutic product. To date, the FDA has generally required in vitro companion diagnostics intended to select the patients who will respond to cancer treatment to obtain a pre-market approval, or PMA, for that diagnostic, which can take up to several years, simultaneously with approval of the biologic product. Similarly, in the European Union, an in vitro companion diagnostic may be placed on the market only if it conforms to certain &#8220;essential requirements&#8221; and bears the Conformit&#233; Europ&#233;ene Mark, or CE Mark. The conformity assessment process to obtain the CE Mark can be lengthy and we may fail to demonstrate such conformity. Further, the applicable regulatory framework for in vitro diagnostics in the EU changed in May 2022 when a new EU regulation with stricter regulatory requirements for in vitro diagnostics became applicable. Under the regulation, all new in vitro companion diagnostics must undergo conformity assessment by a notified body prior to obtaining their CE Mark.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">For our individualized immunotherapy candidates, the FDA and comparable regulatory authorities outside of the United States may require the development and regulatory approval of a companion diagnostic assay as a condition to approval. The FDA may require original or supplemental PMA approvals for use of that same companion diagnostic as a condition of approval of additional individualized therapeutic candidates. We do not have experience or capabilities in developing or commercializing companion diagnostics and plan to rely in large part on third parties to perform these functions. Companion diagnostic assays are subject to regulation by the FDA and other comparable regulatory authorities in other jurisdictions as medical devices and require separate regulatory approval prior to the use of such diagnostic assays with our individualized therapeutic candidates. If we, or any third parties that we engage to assist us, are unable to successfully develop companion diagnostic assays for use with our individualized therapeutic candidates, or are unable to obtain regulatory approval or experience delays in either development or obtaining regulatory approval, we may be unable to identify patients with the specific profile targeted by our product candidates for enrollment in our clinical trials. Accordingly, further investment may be required to further develop or obtain the required regulatory approval for the relevant companion diagnostic assay, which would delay or substantially impact our ability to conduct additional clinical trials or obtain regulatory approval.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Because we are developing some of our product candidates for the treatment of diseases in which there is little clinical experience and, in some cases, using new endpoints or methodologies, the FDA, the EMA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">There may not be pharmacologic therapies approved to treat the underlying causes of many diseases that we may address in the future. For instance, we and our collaborators are applying our technology to develop therapeutics in indications such as certain rare diseases, including some for which no or few clinical trials have been attempted. As a result, any future design and conduct of clinical trials of product candidates for the treatment of certain rare diseases may take longer, be more costly, or be less effective as part of the novelty of development in these diseases. Even if we decide to conduct </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">153</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">clinical trials and the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we or our collaborators may conduct for our programs. Further, even if we do achieve the pre-specified criteria, our trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA also could give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not being supportive of licensure. Other regulatory authorities in Europe and other jurisdictions may make similar findings with respect to these endpoints.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">The FDA, the EMA or other comparable regulatory authorities may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If the results of our clinical trials are sufficiently compelling, we or our collaborators intend to discuss with the FDA and regulatory authorities in other countries the submission of a BLA or respective applications in other countries for our product candidates. However, we do not have any agreement or guidance from the FDA that our regulatory development plans will be sufficient for submission of a BLA for any of our product candidates. The FDA, the EMA or other regulatory agencies may grant accelerated approval for our product candidates and, as a condition for accelerated approval, the FDA, the EMA or other regulatory agencies may require a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA, the EMA or other regulatory agencies that are more accelerated than those available for regular approvals. In addition, the standard of care may change with the approval of new products in the same indications that we are studying. This may result in the FDA, the EMA or other regulatory agencies requesting additional studies to show that our product candidate is superior to the new products.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the FDA, the EMA or comparable regulatory authorities may disagree with the design or implementation of our clinical trials&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we may be unable to demonstrate to the satisfaction of the FDA, the EMA or comparable regulatory authorities that our product candidates are safe and effective for any of their proposed indications&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA or comparable regulatory authorities for approval, including due to the heterogeneity of patient populations&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">154</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the FDA, the EMA or comparable regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA, the EMA or comparable regulatory authorities to support the submission of a BLA or other comparable submissions or to obtain regulatory approval in the United States or elsewhere&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the FDA, the EMA or comparable regulatory authorities will inspect our manufacturing facilities and may not approve our facilities or our manufacturing processes and controls&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the approval policies or regulations of the FDA, the EMA or comparable regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval&#59; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">appointees of the presidential administration in the United States may seek to change regulatory requirements for the approval of products or the approach to the review of product applications.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We may not be able to file INDs with the FDA, clinical trial applications with the competent authorities of the member states of the European Union or similar applications with other comparable regulatory authorities to commence additional clinical trials on the timelines we expect, and even if we are able to, one or more of these regulatory authorities may not permit us to proceed.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The timing of filing on our product candidates is dependent on further preclinical, clinical and manufacturing success. We cannot be sure that submission of an IND or IND amendment with the FDA, a clinical trial application with the regulatory authorities of the EU member states or similar application with other comparable regulatory authorities will result in the FDA, the regulatory authorities of the EU member states or any comparable regulatory authority allowing testing and clinical trials to begin, or that, once begun, issues will not arise that result in the suspension or termination of such clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, clinical trial application or similar applications, we cannot guarantee that such regulatory authorities will not change their requirements in the future.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We may seek Orphan Drug Designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with Orphan Drug Designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our strategy includes filing for Orphan Drug Designation where available for our product candidates. Under the U.S. Orphan Drug Act, the FDA may grant Orphan Drug Designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population of 200,000 or greater in the United States where there is no reasonable expectation that the cost of developing the drug or biologic will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives, such as opportunities for grant funding toward clinical trial costs, tax advantages, and user-fee waivers. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full new drug application or a BLA, to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">155</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">superiority to the product with orphan drug exclusivity or where the original manufacturer is unable to assure sufficient product quantity. Similar rules apply in the European Union with respect to drugs or biologics designated as orphan medicinal products.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not protect the product effectively from competition because different drugs with different active moieties may receive and be approved for the same condition, and only the first applicant to receive approval will receive the benefits of marketing exclusivity. Even after an orphan-designated product is approved, the FDA can subsequently approve a later drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior if it is shown to be safer, more effective, or makes a major contribution to patient care. Similar considerations apply in the European Union with respect to drugs or biologics designated as orphan medicinal products. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for our product candidates, we may never receive such designations.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We may seek Breakthrough Therapy or Fast Track designation for one or more of our product candidates, but we may not receive such designations. Even if we do, it may not lead to a faster development or regulatory review or approval process, and it may not increase the likelihood that such product candidates will receive marketing approval.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We may seek a Breakthrough Therapy Designation in the United States for one or more of our product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA. Although priority review shortens the goal date by which FDA intends to decide on an application, it does not guarantee any particular action by FDA, or even FDA action by that date.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy Designation for a drug may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We may also seek Fast Track Designation in the United States for some of our product candidates. If a therapy is intended for the treatment of a serious or life-threatening condition and the therapy </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">156</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">demonstrates the potential to address significant unmet medical needs for this condition, the drug sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, and even if we believe a particular product candidate is eligible for this designation, we cannot be sure that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track Designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We expect some of the product candidates we develop will be regulated as biologics in the United States and therefore they may be subject to competition from biosimilars approved through an abbreviated regulatory pathway.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the other company&#8217;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We believe that any of our product candidates approved as a biological product under a BLA should qualify for a 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">The regulatory landscape that will govern our product candidates is uncertain. Regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The regulatory requirements to which our product candidates will be subject are not entirely clear. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. Although the FDA decides whether individual gene therapy protocols may proceed, the </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">157</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee, a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the European Union, a special committee called the Committee for Advanced Therapies was established within the EMA in accordance with Regulation (EC) No 1394&#47;2007 on advanced-therapy medicinal products, or ATMPs, to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include gene therapy products as well as somatic cell therapy products and tissue engineered products.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As the regulatory landscape for our CAR-T-cell immunotherapy product candidates is new, we may face even more cumbersome and complex regulations than those emerging for gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product sales revenue to maintain our business.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We may be unable to obtain regulatory approval for our product candidates under applicable international regulatory requirements.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The denial or delay of such approval would delay commercialization of our product candidates and adversely impact our potential to generate revenue, our business and our results of operations.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Approval by the FDA in the United States, if obtained, does not ensure approval by regulatory authorities in other countries or jurisdictions. In order to market our products or product candidates in any other jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a jurisdiction-by-jurisdiction basis regarding safety and efficacy. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">158</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Seeking regulatory approval in other jurisdictions could result in difficulties and costs for us and require additional preclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. The European Union and other jurisdictions&#8217; regulatory approval processes involve all of the risks associated with the FDA approval. If we fail to comply with regulatory requirements in certain markets or to obtain and maintain required approvals, or if regulatory approvals in certain markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be unrealized.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Certain jurisdictions may have submission requirements for drug clinical trial and marketing applications that require us or our partners to submit substantial detailed materials related to non-clinical and clinical development and manufacturing and quality control to drug regulators or testing laboratories. This can include confidential standard operating procedures or executed batch records for the production of biological products or other records or documents that set forth detailed information about the manufacturing process and the manufacturing site. If these materials are disclosed in an unauthorized manner, lost, or otherwise diverted to third parties or competitors during the application preparation process, this could negatively affect our ability to protect our intellectual property.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our partners in different countries are subject to local regulatory requirements and standard on the manufacturing and distribution of drugs and the implementation of clinical and non-clinical research. These include but are not limited to good manufacturing, distribution, laboratory, clinical practice, and pharmacovigilance rules. If these companies do not comply with applicable standards, they could become the subjects of inspections, investigations and enforcement, including orders to cease the activities pending remediation that is acceptable to the government. Such an order or other similar enforcement could interfere with our clinical development and marketing activities both in that jurisdiction and others, if it impacts supply or the quality and transfer of data.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">A third-party investigational product candidate used in combination with our product candidates may be unable to obtain regulatory approval, which may delay commercialization of our product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are developing several of our product candidates to be used in combination with our and third-party product candidates. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing products, we would continue to be subject to the risks that the FDA, the EMA or comparable regulatory authorities in other jurisdictions could revoke approval of the product used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing products. If the products or product candidates we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA, the EMA or comparable regulatory authorities in other jurisdictions may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially. We also plan to evaluate current and future product candidates in combination with one or more product candidates that have not yet been approved for marketing by the FDA, the EMA or comparable regulatory authorities in other jurisdictions. We will not be able to market any product candidate we develop in combination with an unapproved product candidate if that unapproved product candidate does not ultimately obtain marketing approval. In addition, unapproved product candidates face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">159</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">for serious adverse effects, delay in their clinical trials and lack of FDA, EMA or comparable regulatory authority approval.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If the FDA, the EMA or comparable regulatory authorities in other jurisdictions do not approve these other product candidates or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the products or product candidates we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval of or market any product candidate we develop.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Some of our product candidates are classified as gene therapies by the FDA and the EMA, and the FDA has indicated that our product candidates will be reviewed within its Center for Biologics Evaluation and Research, or CBER. Even though our mRNA product candidates are designed to have a different mechanism of action from gene therapies, the association of our product candidates with gene therapies could result in increased regulatory burdens, impair the reputation of our product candidates, or negatively impact our platform or our business.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">There have been few approvals of gene therapy products in the United States and other jurisdictions, and there have been well-reported significant adverse events associated with their testing and use. Gene therapy products have the effect of introducing new DNA and potentially irreversibly changing the DNA in a cell. In contrast, mRNA is highly unlikely to localize to the nucleus, be reverse transcribed or integrated into the genome. Consequently, we expect that our products or product candidates will have a different potential side effect profile from gene therapies because they lack risks associated with altering cell DNA irreversibly. Further, we may avail ourselves of ways of mitigating side effects in developing our products and product candidates to address safety concerns that are not available to other products or product candidates classified as gene therapies, such as lowering the dose of our products or product candidates during repeat dosing or stopping treatment to potentially ameliorate undesirable side effects.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Regulatory requirements governing gene and cell therapy products have evolved and may continue to change in the future, and the implications for mRNA-based therapies is unknown. For example, the FDA has established the Office of Tissues and Advanced Therapies within CBER to consolidate the review of gene therapy and related products, and convenes the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. In the European Union, mRNA has been characterized as a gene therapy medicinal product. In certain countries, mRNA therapies have not yet been classified or any such classification is not known to us. Notwithstanding the differences between our mRNA product candidates and gene therapies, the classification of some of our mRNA product candidates as gene therapies in the United States, the European Union and potentially other counties could adversely impact our ability to develop our product candidates, and could negatively impact our platform and our business. For instance, a potential future clinical hold on gene therapy products across the field due to risks associated with altering cell DNA irreversibly could apply to our mRNA product candidates irrespective of the mechanistic differences between gene therapies and mRNA.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Adverse events reported with respect to gene therapies or genome editing therapies could adversely impact one or more of our programs. Although our mRNA product candidates are designed not to make any permanent changes to cell DNA, regulatory agencies or others could believe that adverse effects of gene therapy products caused by introducing new DNA and irreversibly changing the DNA in a cell could also be a risk for our approved mRNA products or investigational therapies, and as a result may delay one or more of our trials or impose additional testing for long-term side effects. Any new requirements and guidelines promulgated by regulatory review agencies may have a negative </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">160</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">effect on our business by lengthening the regulatory review process, requiring us to perform additional or larger studies, or increasing our development costs, any of which could lead to changes in regulatory positions and interpretations, delay or prevent advancement or approval and commercialization of our product candidates or lead to significant post-approval studies, limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory agencies and advisory committees and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of some or all of our product candidates.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our COVID-19 vaccine and any other product candidates for which we receive approval or emergency use authorization are subject to continuing regulatory oversight, and we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. We may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products or product candidates.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our COVID-19 vaccine and any other product candidates for which we receive approval or emergency use authorization are subject to continuing regulatory oversight, including the review of additional safety information, and the applicable regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Similar requirements apply to holders of (conditional) approvals in other countries. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. In other countries outside of the United States, advertising and promotional material may be subject to similar or more onerous rules. For example, direct-to-consumer advertising of prescription medicinal products is prohibited in many jurisdictions outside of the United States, including the European Union.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If we fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">issue adverse public statements about our business or products&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">issue a warning letter asserting that we are in violation of the law&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">seek an injunction or impose civil or criminal penalties or monetary fines&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">suspend or withdraw regulatory approval or revoke a license&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">suspend any ongoing clinical studies&#894; </font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">refuse to approve a pending BLA (or comparable approval) or supplements to a BLA (or comparable approval) submitted by us&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">seize product&#894; or</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">refuse to allow us to enter into supply contracts, including government contracts.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">161</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any approved products and generate revenues.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If any of our products or product candidates cause undesirable side effects, it could delay or prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences following any potential marketing approval. Products or product candidates we may develop may be associated with an adverse immune response or other serious adverse events, undesirable side effects or unexpected characteristics. In addition to serious adverse events or side effects caused by any of our products or product candidates, the administration process or related procedures also can cause undesirable side effects. If any such events occur, the clinical trials of any of our product candidates could be suspended or terminated.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If in the future we are unable to demonstrate that such adverse events were caused by factors other than our product candidate, the FDA, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, any of our product candidates for any or all targeted indications. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled trial participants to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of any of our product candidates, the commercial prospects of such product candidates, if approved, may be harmed and our ability to generate product sale revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to identify and develop product candidates, and may harm our business, financial condition, result of operations and prospects significantly.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Additionally, following regulatory approval of a product candidate, the FDA or other regulatory authority could require us to adopt a REMS or a risk management plan to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems and processes that are highly controlled, restrictive, and more costly than what is typical for the industry.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Furthermore, if we or others later identify undesirable side effects caused by any product that we develop, several potentially significant negative consequences could result, including&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">regulatory authorities may suspend or withdraw approvals or revoke licenses of such product&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">regulatory authorities may require additional warnings on the label&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">regulatory authorities may make unfavorable statements about the safety of our products&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we may be required to change the way a product is administered or conduct additional clinical trials&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">we could be sued and held liable for harm caused to patients and their children&#894; and</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">162</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our reputation may suffer.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Any of these events could prevent us from achieving or maintaining market acceptance of any products we may identify and develop and could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Upon the successful approval of a product candidate, we will continue to face significant regulatory oversight of its manufacturing and distribution. Product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with GMP and adherence to commitments made in the BLA or comparable approval. If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Governmental investigations and inquiries with respect to our COVID-19 vaccine and any other product candidates for which we receive approval or emergency use authorization may adversely affect our business, financial condition and results of operations.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In April 2025, we, along with several other pharmaceutical companies, received a letter from the Chairman of the Permanent Subcommittee on Investigations of the U.S. Senate Homeland Security and Governmental Affairs Committee, or the Subcommittee, that requested certain information and documents relating to the respective COVID-19 vaccines we developed (in our case, </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Comirnaty</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">). This and other governmental investigations or inquiries in which we may become involved may result in additional claims and lawsuits being brought against us by governmental agencies or private parties. It is not possible at this time to predict either the outcome or the potential financial impact of the congressional investigation mentioned above or any further investigations or inquiries of us that may result from such investigation. It is also not possible at this time to predict the additional expenses related to such investigation, which may be significant. The initiation of any additional investigation relating to us, the costs and expenses associated therewith, or any assertion, claim or finding of wrongdoing by us, could&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">adversely affect our business, financial condition and results of operations&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">result in reputational harm and reduced market acceptance and demand for our products&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">harm our ability and our commercial partners&#8217; ability to market our products&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">harm our ability to develop our product candidates&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">cause us to incur significant liabilities, costs and expenses&#59; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">cause our senior management to be distracted from execution of our business strategy.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Furthermore, the pending congressional investigation could negatively affect our ability to raise capital and impair our ability to engage in strategic transactions.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">163</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We may be subject to additional healthcare regulation and enforcement by the U.S. federal government and by authorities in the United States, the European Union and other jurisdictions in which we conduct our business. Our operations may be directly, or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without limitation, the federal Health Care Program Anti-Kickback Statute, the federal civil and criminal False Claims Act, and the Physician Payments Sunshine Act and regulations. Many states and other jurisdictions have similar laws and regulations, some of which may be broader in scope. These laws will impact, among other things, our proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws enacted by both the federal government and the states in which we conduct our business. The laws that will affect our operations include, but are not limited to the following&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">The U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers, and formulary managers on the other. The ACA amends the intent requirement of the federal Anti-Kickback Statute to provide that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">The U.S. federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment or approval from Medicare, Medicaid or other government payors. The ACA provides, and recent government cases against pharmaceutical and medical device manufacturers support, the view that federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may implicate the False Claims Act&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">The U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit a person from knowingly and willfully executing a scheme or making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (e.g., public or private)&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care providers&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">The U.S. Federal Food, Drug, and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">The U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product&#59;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">164</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Federal transparency laws, including the federal Physician Payment Sunshine Act, which require disclosure of payments and other transfers of value provided to physicians and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">U.S. state law equivalents of each of the above federal laws, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances which are also applicable to us, and many of them differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts in certain circumstances&#59;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">The U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents, as well as non-U.S. companies that are registered with the SEC, from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">Similar statutes, healthcare laws and regulations in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Due to the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of European Union member states and other jurisdictions, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Payments made to physicians in certain EU member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization or the regulatory authorities of the individual EU member states. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">165</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We are subject to certain anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Among other matters, anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as &#8220;trade laws,&#8221; prohibit companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors and other collaborators from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of trade laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We plan to engage third parties for clinical trials and&#47;or to obtain necessary permits, licenses, intellectual property (including patents) and other regulatory approvals, and we can be held liable for the corrupt or other illegal activities of our personnel, agents or collaborators, even if we do not explicitly authorize or have prior knowledge of such activities.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We are subject to stringent privacy laws, information security policies and contractual obligations governing the use, processing, and cross-border transfer of personal information and our data privacy and security practices.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We receive, generate and store significant and increasing volumes of sensitive information, such as employee, personal and patient data.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are subject to a variety of local, state, national and international laws, directives and regulations that apply to the collection, use, storage, retention, protection, disclosure, transfer and other processing of personal data, collectively referred to as &#8220;data processing&#8221;, in the different jurisdictions in which we operate, including comprehensive regulatory systems in the United States and Europe. Legal requirements relating to data processing continue to evolve and may result in ever-increasing public scrutiny and escalating levels of enforcement, sanctions and increased costs of compliance.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Compliance with U.S. and international data protection laws and regulations could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. Moreover, complying with these various laws could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and&#47;or adverse publicity and could negatively affect our operating results and business. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition and results of operations.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The collection and use of personal data in the European Union had previously been governed by the provisions of the EU Data Protection Directive, which EU member states were required to implement. While the Data Protection Directive did not apply to organizations based outside the European Union, the GDPR has expanded its reach to include any business, regardless of its location, that targets goods or services to residents in the European Union or that &#8220;monitors&#8221; their behavior in the European </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">166</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Union. The GDPR imposes strict requirements on controllers and processors of personal data, including special protections for &#8220;sensitive information&#8221; which includes health and genetic information of patients residing in the European Union. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Since we are located in the European Union, we are subject to the GDPR. Additionally, as the GDPR applies extraterritorially, we are also subject to the GDPR even where our data processing activities occur outside of the European Union if such activities involve the personal data of individuals located in the European Union and the above-mentioned applicable law triggers apply. GDPR regulations have imposed additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. This may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Other jurisdictions outside the European Union are similarly introducing or enhancing privacy and data security laws, rules and regulations, which could increase our compliance costs and the risks associated with non-compliance. In particular, in China, where some of our clinical data are originated, the cybersecurity, data privacy, data protection, or other data-related laws and regulations, including the Personal Information Protection Law, Regulations on Network Data Security Management, Provisions on Promoting and Regulating Cross-Border Data Flows, and Human Genetic Resources Regulation (which regulates the collection and transfer of human biospecimens and genetic data derived from them in clinical research to foreign or foreign controlled parties), may require approvals or filings prior to transferring those data to foreign-owned or controlled entities in China or overseas, and these regimes are continually evolving, meaning their interpretation and enforcement may be uncertain. These rules establish mechanisms such as governmental security assessment, certification, and standard contractual clauses for certain cross&#8209;border data transfers. Depending on the nature and volume of data processed in China, we or our partners may be required to complete one or more of these transfer mechanisms as a condition to exporting relevant data. Compliance with these requirements could affect our operations, including data flows necessary for clinical development, manufacturing, or other activities conducted in China. The scope and practical application of these rules continue to develop, and there is uncertainty regarding how regulators will apply them in specific circumstances. In the United States, we may be subject to restrictions and requirements under the Department of Justice&#8217;s Final Rule issued on December 27, 2024 implementing the Executive Order on Preventing Access to Americans&#8217; Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern, signed on February 28, 2024. Practices regarding the collection, use, storage, transmission and security of personal information by companies have also been subject to increasing regulatory focus. As such, we cannot assure you that we will be compliant with such new regulations in all respects, and we may be ordered to rectify and terminate any actions that are deemed illegal by the government authorities and become subject to fines and other government sanctions, which may materially and adversely affect our business, financial condition, and results of operations. In addition, the uncertainties regarding further interpretation and implementation of these laws and regulations may adversely affect the secure storage of documented work as well as the cross-border transfer of important data and personal information originated from our clinical trial activities, which are critical to the development of our pipelines.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">167</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We cannot guarantee that we are, or will be, in compliance with all applicable international regulations as they are enforced now or as they evolve. For example, our privacy policies may be insufficient to protect any personal information we collect, or may not comply with applicable laws, in which case we may be subject to regulatory enforcement actions, lawsuits or reputational damage, all of which may adversely affect our business. There is significant uncertainty related to the manner in which data protection authorities will seek to enforce compliance with the GDPR and other international data protection regulations, especially with regard to clinical trial activities. For example, it is not clear if the authorities will conduct random audits of companies doing business in the European Union, or if the authorities will wait for complaints to be filed by individuals who claim their rights have been violated, as enforcement practices vary from country to country. Enforcement uncertainty and the costs associated with ensuring GDPR compliance may be onerous and adversely affect our business, financial condition, results of operations and prospects. If we fail to comply with the GDPR and the applicable national data protection laws of the EU member states, or if regulators assert we have failed to comply with these laws, it may lead to regulatory enforcement actions, which can result in monetary penalties of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. If any of these events were to occur, our business and financial results could be significantly disrupted and adversely affected.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Although we take measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, manipulated, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings, and liability under federal or state laws that protect the privacy of personal information, as well as regulatory penalties. In many jurisdictions, there are legal requirements to provide notice of breaches to affected individuals and&#47;or regulators in certain circumstances. Such a notice could harm our reputation and our ability to compete. Regulators may also have the discretion to impose penalties without attempting to resolve violations through informal means. Although we have implemented security measures to prevent unauthorized access to patient data, such data is currently accessible through multiple channels, and there is no guarantee we can protect our data from breach. Unauthorized access, loss or dissemination could also damage our reputation or disrupt our operations, including our ability to conduct our analyses, deliver test results, process claims and appeals, provide customer assistance, conduct research and development activities, collect, process and prepare company financial information, provide information about our tests and other patient and physician education and outreach efforts through our website, and manage the administrative aspects of our business.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">If we or our third-party suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also may produce hazardous waste products. We generally anticipate contracting with third parties for the disposal of these materials and wastes. We will not be able to eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">168</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1321"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Risks Related to Ownership of the ADSs</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">We have experienced and may continue to experience significant volatility in the market price of the ADSs representing our ordinary shares.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Biopharmaceutical companies such as BioNTech SE that are developing potential therapeutics and vaccines to combat COVID-19, as well as conducting mRNA-based research in oncology and infectious disease more generally, have experienced significant volatility in the price of their securities upon publication of preclinical and clinical data as well as news about their development programs and commercialization activities. For example, during 2025, the closing sales price of the ADSs representing our ordinary shares on the Nasdaq Global Select Market ranged from $86.65 to $126.88. In addition, volatility in the overall market and in the market price of a particular company&#8217;s securities </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">169</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">can result in securities litigation, including shareholder class action lawsuits. Any securities litigation can result in substantial costs and a diversion of our management&#8217;s attention and resources.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Acquisitions, joint ventures and collaborations may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. We may not realize the benefits of these acquisitions, joint ventures or collaborations.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We may evaluate various acquisitions and collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition, joint venture or collaboration may entail numerous risks, including&#58;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">increased operating expenses and cash requirements&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the assumption of additional indebtedness or contingent liabilities&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships&#894;</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals, their quality control, quality assurance, internal controls, legal and compliance procedures&#894; and</font></div><div style="margin-bottom:15pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#bece33;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#8211;</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt;padding-left:6.34pt">our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</font></div><div style="text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">In addition, if we undertake acquisitions, we may utilize our cash, issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. For example, in July 2023, we acquired InstaDeep, a leading global technology company in the field of AI and machine learning, for upfront consideration of cash and BioNTech shares, and potential future milestone payments. Although we believe that AI and machine learning technology has the potential to accelerate the development of therapeutic programs and further optimize manufacturing and supply chain processes, it is possible that our use of the acquired technology will not achieve the desired results, and that we will not be able to retain and grow InstaDeep&#8217;s business around the world. If demand for the services developed by InstaDeep does not continue, or if we are unable to improve our AI and machine learning technology in a timely, effective and competitive manner, we may not be able realize the expected outcomes from the InstaDeep acquisition. In January 2025, we acquired Biotheus, a clinical-stage biotechnology company, for upfront consideration predominantly of cash, with a small portion in our ADSs, and potential future milestone payments. Although the Biotheus acquisition expands our operations in China, our expectations regarding the creation of long-term value for shareholders and potential future commercialization in oncology may not be realized. In December 2025, we acquired CureVac N.V., a biotechnology company focused on the development of mRNA therapeutics, through a public </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">170</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">exchange offer. While we believe the acquisition has the potential to enhance our capabilities in mRNA research, development, manufacturing and commercialization, there can be no assurance that we will realize the anticipated benefits from the transaction. There is no guarantee that we will realize any anticipated benefits of these or future acquisitions, or that the diversification of our business through acquired technology or products will be successful. </font></div><div><font><br></font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Moreover, we may not be able to locate suitable acquisition or collaboration opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Following the acquisition of CureVac, we may be required to repay monies received under the Advance Purchase Agreement with the European Commission for its first-generation COVID-19 vaccine candidate.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">On November 30, 2020, prior to our acquisition of CureVac, CureVac AG entered into an Advance Purchase Agreement, which we refer to as the APA, with the EU Commission, acting on behalf of all Member States of the European Union, for the supply of up to 405 million doses of its first-generation COVID-19 vaccine candidate, which we refer to as CVnCoV. Under the APA, CureVac AG received an upfront payment of &#8364;450 million for development and commercial supply activities of CVnCoV. In October 2021, CureVac AG notified the EU Commission of the withdrawal of its regulatory approval application for CVnCoV, which notification automatically terminated the APA. According to the APA, in such case of termination, CureVac AG would be required to return any unspent amount of the upfront payment. In the context of the APA, &#8220;spent&#8221; means either costs incurred, or commitments made in connection with the purposes set forth in the APA.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">On July 24, 2024, the EU Commission informed CureVac SE that it had engaged Deloitte, S.L., which we refer to as Deloitte, to conduct an audit of CureVac SE&#8217;s compliance with the APA. On September 17, 2025, the EU Commission provided CureVac SE with Deloitte&#8217;s draft audit report, which included preliminary findings alleging missing documentation, absence of project cost allocation, cost traceability and reconciliations, as well as inconsistencies between information submitted during the audit and financial information previously provided to the EU Commission. CureVac SE is cooperating fully with the EU Commission and Deloitte and submitted a detailed response and objections on October 17, 2025. The EU Commission subsequently issued its final audit report.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">CureVac SE contested the findings in Deloitte&#8217;s draft audit report and believes it can refute the issues raised.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">However, it remains uncertain to what extent Deloitte, the EU Commission, or any other governmental authorities will accept CureVac SE&#8217;s position. It is also unclear whether the EU Commission will rely on Deloitte&#8217;s final audit report to seek recovery of any portion or all of the &#8364;450 million upfront payment, or if regulators may undertake additional actions in connection with the allegations. As the successor to CureVac SE following the acquisition, we cannot exclude the possibility of being required to repay a portion or all of the &#8364;450 million upfront payment or being subject to additional actions from government authorities. Should we be unsuccessful in contesting any such claims, or the imposition of related penalties, this could materially affect our financial position, cash flows, and results of operations.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">171</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our Articles of Association designate specific courts in the United States as the exclusive forum for certain U.S. litigation that may be initiated by our shareholders, which could limit our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our Articles of Association provide that the United States District Court for the Southern District of New York shall be the competent court of jurisdiction for the resolution of any litigation on the grounds of or in connection with U.S. federal or state capital market laws. In the absence of these provisions, under the Securities Act of 1933, as amended, or the Securities Act, U.S. federal and state courts have been found to have concurrent jurisdiction over suits brought to enforce duties or liabilities created by the Securities Act. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The choice of forum provision contained in our Articles of Association may limit a shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our executive officers, directors, or other employees, or impose additional litigation costs on shareholders in pursuing any such claims, particularly if the shareholders do not reside in or near the state of New York, which may discourage such lawsuits. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other U.S. or German courts will enforce our choice of forum provision. The enforceability of similar choice of forum provisions in other companies&#8217; governing documents has been challenged in recent legal proceedings, and it is possible that a court in the relevant jurisdictions with respect to us could find the choice of forum provision contained our Articles of Association to be inapplicable or unenforceable. If the relevant court were to find the choice of forum provision contained in our articles of association to be inapplicable or unenforceable, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition and operating results. The choice of forum provision may also impose additional litigation costs on shareholders who assert that the provision is not enforceable or invalid. The United States District Court for the Southern District of New York may also reach different judgments or results than would other courts, including courts where a shareholder considering a U.S.-based action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our shareholders.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Holders of the ADSs may not be able to participate in any future preemptive subscription rights issues or elect to receive dividends in shares, which may cause additional dilution to their holdings.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Under German law, the existing shareholders of a company generally have a preemptive right in proportion to the amount of shares they hold in connection with any issuance of ordinary shares, convertible bonds, bonds with warrants, profit participation rights and participating bonds. However, our shareholders in a shareholders&#8217; meeting may vote, by a majority representing at least three-quarters of the share capital represented at the meeting, to waive this preemptive right provided that, from the company&#8217;s perspective, there exists good and objective cause for such waiver.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The deposit agreement provides that the depositary need not make rights available to you unless the distribution to ADS holders of both the rights and any related securities are either registered under the Securities Act or exempted from registration under the Securities Act. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to participate in our future rights offerings and may experience dilution in their holdings. For example, </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">172</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">ADS holders were unable to participate in our summer 2020 rights offering. In addition, if the depositary is unable to sell rights that are not exercised or not distributed or if the sale is not lawful or reasonably practicable, it will allow the rights to lapse, in which case you will receive no value for these rights.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">The amount and frequency of our dividends and ADS repurchases may fluctuate.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The amount, timing and execution of any ADS repurchase program we conduct in the future and the amount and timing of any dividends we pay may fluctuate based on our priorities for the use of cash for other purposes, and any ADS repurchases would be subject to the parameters contained in the applicable repurchase plan. These purposes may include operational spending, capital spending, acquisitions and repayment of debt. Additionally, we may choose to repurchase ADSs so that such ADSs may be used to settle outstanding and future equity awards granted to our employees. Changes in cash flows, tax laws and the price of the ADSs could also impact any ADS repurchase program. Additionally, we may enter into a Rule 10b5-1 trading plan governing the repurchases, and if we do, we would have no discretion over the particular purchases made and would only be able to set minimum price floors and maximum ADS count ceilings.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">Our principal shareholders and management own a significant percentage of our ordinary shares and will be able to exert significant control over matters subject to shareholder approval. </font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Our executive officers, directors, five percent shareholders, and their affiliates beneficially own a majority of our ordinary shares (including ordinary shares represented by ADSs) as of December 31, 2025, and will have the ability to influence us through their ownership positions. For example, these shareholders, acting together, may be able to exert significant influence over matters such as elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our ordinary shares that shareholders may believe are in their best interest. Such insiders may also act in concert to waive rights to participate in rights offerings, as was done in our summer 2020 rights offering, which would have the effect of permitting the ADSs or shares underlying such waived rights to be offered to the public in an underwritten offering without contravening German law pricing requirements.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">The large number of shares eligible for sale or subject to rights requiring us to register them for sale could cause the market price of the ADSs to drop significantly, even if our business is performing well.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">We have filed registration statements on Form S-8 under the Securities Act to register all ordinary shares issued or issuable under our equity plans. Such Form S-8 registration statements have become, and any other registration statements on Form S-8 we file in the future will become, effective upon filing, upon which shares registered under such registration statements become available for sale in the open market.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Additionally, certain sales of ADSs or our ordinary shares that we have made have included, and we may in the future make sales including, holding period restrictions or registration rights. Sales of ADSs or our ordinary shares as restrictions end or pursuant to registration rights may make it more difficult for us to finance our operations through the sale of equity securities in the future at a time and at a price that we deem appropriate. These sales also could cause the trading price of the ADSs to fall and make it more difficult to sell the ADSs on favorable terms.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">173</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">If we are a &#8220;passive foreign investment company&#8221; for U.S. federal income tax purposes, there may be adverse U.S. federal income tax consequences to U.S. investors.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Based on our income and assets, we believe that we should be treated as a &#8220;passive foreign investment company,&#8221; or PFIC, for the preceding taxable year. However, the determination of our PFIC status is made annually based on the factual tests described below. Consequently, while we may be a PFIC in future years, we cannot estimate with certainty at this stage whether or not we are likely to be treated as a PFIC in the current taxable year or any future taxable years. Generally, if, for any taxable year, at least 75 percent of our gross income is &#8220;passive income&#8221; or at least 50 percent of our gross assets during the taxable year (based on the average of the fair market values of the assets determined at the end of each quarterly period) are assets that produce or are held for the production of passive income, we will be characterized as a PFIC for U.S. federal income tax purposes. Passive income for this purpose generally includes, among other things, dividends, interest, rents, royalties, gains from commodities and securities transactions, and gains from assets that produce passive income. However, rents and royalties received from unrelated parties in connection with the active conduct of a trade or business should not be considered passive income for purposes of the PFIC test. For example, if we were to be characterized as a PFIC for U.S. federal income tax purposes in any taxable year during which a U.S. Holder (as defined in &#8220;Taxation &#8212;Material United States federal income tax considerations&#8221; in our Annual Report on Form 20-F as of and for the year ended December 31, 2025, as amended) holds ordinary shares or ADSs, such U.S. Holder could be subject to additional taxes and interest charges upon certain distributions by us and any gain recognized on a sale, exchange or other disposition of our shares, whether or not we continue to be characterized as a PFIC. Certain adverse consequences of PFIC status can be mitigated if a U.S. Holder makes a &#8220;mark to market&#8221; election or a &#8220;Qualified Electing Fund,&#8221; or QEF, election. We have made available to U.S. Holders the information necessary to make and maintain a QEF election for the year ended December 31, 2025, and intend to provide U.S. holders with the necessary information for any taxable year in which we are treated as a PFIC. See &#8220;Taxation &#8212;Material United States federal income tax considerations &#8212;Passive foreign investment company considerations&#8221; in our Annual Report on Form 20-F as of and for the year ended December 31, 2025, as amended.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Whether we are a PFIC for any taxable year will depend on the composition of our income and the composition and value of our assets from time to time. Each U.S. Holder is strongly urged to consult their tax advisor regarding these issues and any available elections to mitigate such tax consequences.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:10pt;font-weight:700;letter-spacing:0.02em;line-height:110%">The acquisition of a substantial interest in the Company by non-EU&#47;non-EFTA investors requires government approval, which may restrict certain investments and limit demand for the BioNTech ADSs.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">As the Company is considered an operator of &#8220;critical infrastructure&#8221; within the meaning of the Ordinance on the Designation of Critical Infrastructure pursuant to the BSI Act (Verordnung zur Bestimmung Kritischer Infrastrukturen nach dem BSI-Gesetz), it falls within the scope of the cross-sector review of the German foreign investment screening regime under the German Foreign Trade and Payments Ordinance (Au&#223;enwirtschaftsverordnung). As a result, non-EU&#47;non-EFTA investors intending to acquire, directly or indirectly, at least 10% of the voting rights in the Company or who already hold voting rights in the Company and will acquire further voting rights reaching or exceeding 20%, 25%, 40%, 50% or 75% of the voting rights in the Company must notify the planned acquisition to the German Federal Ministry for Economic Affairs and Energy (Bundesministerium f&#252;r Wirtschaft und Energie, or the BMWE). The BMWE will then assess whether the acquisition likely adversely </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">174</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">affects the public order or security of Germany or other EU member states or projects or programs of Union interest within the meaning of Article 8 of Regulation (EU) 2019&#47;452 of the European Parliament and of the Council of 19 March 2019 establishing a framework for the screening of foreign direct investments into the Union. Clearance by the BMWE qualifies as a closing condition for all over-the-counter transactions. If the acquisition has been made via the stock exchange, the acquirer is prohibited from exercising its voting rights until the transaction has been cleared or is deemed cleared. If the BMWE identifies likely adverse effects, the acquisition of voting rights in the Company could be restricted or prohibited or, if the acquisition has been made via the stock exchange, the BMWE may order a sell-down of the voting rights in the Company acquired via the stock exchange or a transfer to a trustee within a certain period of time and&#47;or prohibit the exercise of voting rights until such time as the acquisition is finally reversed.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1142"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:14pt;font-weight:400;letter-spacing:0.04em;line-height:120%">Disclaimer</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_553"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">Forward-Looking Statements</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">This quarterly report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning&#58; our expected revenues and net profit&#47;(loss) related to sales of our COVID-19 vaccine, referred to as </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Comirnaty</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> where approved for use under full or conditional marketing authorization, in territories controlled by our collaboration partners, particularly for those figures that are derived from preliminary estimates provided by our partners&#59; the rate and degree of market acceptance of our COVID-19 vaccine and, if approved, our investigational medicines&#59; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages&#59; the initiation, timing, progress, results, and cost of our research and development programs, including our current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations&#59; our expectations regarding potential future commercialization in oncology, including goals regarding timing and indications&#59; the targeted timing and number of potentially registrational trials, and the registrational potential of any trial we may initiate&#59; our expectations regarding the impact of changes to our manufacturing  operations&#59; discussions with regulatory agencies&#59; our expectations with respect to intellectual property&#59; the impact of our collaboration and licensing agreements</font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">&#59; our expectations with respect to developments in law, public policy, and international trade&#59; our expectations with respect to government investigations&#59; </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">and our expectations with respect to legal claims and proceedings. In some cases, forward-looking statements can be identified by terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.</font></div><div style="text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The forward-looking statements in this quarterly report are based on our current expectations and beliefs of future events, and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech&#8217;s control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to&#58; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">175</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:70.87pt;width:100%"><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.996%"><tr><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.787%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="padding-left:120pt"><img alt="fsridynmyoja6mda5mdg4zmfky.gif" src="fsridynmyoja6mda5mdg4zmfky.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#3c9673;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:6.5pt;font-weight:400;letter-spacing:0.04em;line-height:120%;text-decoration:none">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="padding-left:120pt"><img alt="fsridynmyoja6mzkwzmyyzjzkz.gif" src="fsridynmyoja6mzkwzmyyzjzkz.gif" style="height:8px;margin-bottom:5pt;vertical-align:text-bottom;width:26px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">commencement and&#47;or completion dates for clinical trials, </font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">projected data release timelines, </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">regulatory submission dates, regulatory approval dates and&#47;or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this report, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data&#59; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation&#59; our pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors&#59; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine&#59; the impact of tariffs and escalations in trade policy&#59; competition from other COVID-19 vaccines or related to our other product candidates&#59; the timing of and our ability to obtain and maintain regulatory approval for our product candidates&#59; the ability of our COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants&#59; our ability to identify research opportunities and discover and develop investigational medicines&#59; the ability and willingness of our third-party collaborators to continue research and development activities relating to our development candidates and investigational medicines&#59; unforeseen safety issues and claims for personal injury or death arising from the use of our COVID-19 vaccine and other products and product candidates developed or manufactured by us&#59; our ability and that of our collaborators to commercialize and market our product candidates, if approved&#59; our ability to manage our development and related expenses&#59; regulatory developments in the United States and other countries&#59; our ability to effectively scale our production capabilities and manufacture our products, including our target COVID-19 vaccine production levels, and our product candidates&#59; the expected timing of our manufacturing consolidation plans and our ability to enter into divestment sales&#59; </font><font style="background-color:#ffffff;color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">expected changes to BioNTech&#8217;s leadership and the transition of responsibilities at the Management Board, including identification and recruitment of successors&#59; </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">risks relating to the global financial system and markets&#59; and other factors not known to us at this time. You should review the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in this quarterly report for the three and six months ended June 30, 2026 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC&#8217;s website at https&#58;&#47;&#47;www.sec.gov&#47;. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this quarterly report in the event of new information, future developments or otherwise.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1526"></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#005a64;font-family:'Neue Haas Grotesk Display Pro 65 Medium',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">General Information</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">This quarterly report contains references to our trademarks and to trademarks belong to other entities. Solely for convenience, trademarks and trade names referred to, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">The BioNTech name, and certain other names used or intended to be used by our business, are protected by trademarks. Our trademark portfolio includes, but is not limited to, </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">BioNTech</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">, </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">Comirnaty</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">, </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">BioNTainer</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">, </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">FixVac</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">, </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">RiboCytokine</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt"> and </font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">RiboMab</font><font style="color:#080509;font-family:'Neue Haas Grotesk Display Pro 45 Light',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:15.00pt">, including logo versions of some of these trademarks. Brand names appearing in italics throughout this report, and the BioNTech name, are trademarks owned by BioNTech. All other trademarks are the property of their respective owners.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:15pt;text-align:center"><font><br></font></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.860%"><tr><td style="width:1.0%"></td><td style="width:67.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#929292;font-family:'Neue Haas Grotesk Display Pro 55 Roman',serif;font-size:8pt;font-weight:400;letter-spacing:0.03em;line-height:120%">BioNTech &#124; Quarterly Report for the three and six months ended June 30, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#c3c3c3;font-family:'Neue Haas Grotesk Display Pro 75 Bold',serif;font-size:12pt;font-weight:700;letter-spacing:0.02em;line-height:120%">176</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>a260407_coverxq2a.jpg
<TEXT>
begin 644 a260407_coverxq2a.jpg
M_]C_X@_P24-#7U!23T9)3$4  0$   _@87!P; (0  !M;G1R4D="(%A96B '
MZ@ !  4 "  Z "YA8W-P05!03     !!4%!,
M]M8  0    #3+6%P<&P
M                     !%D97-C   !4    &)D<V-M   !M   !+QC<')T
M   &<    "-W='!T   &E    !1R6%E:   &J    !1G6%E:   &O    !1B
M6%E:   &T    !1R5%)#   &Y   " QA87)G   .\    "!V8V=T   /$
M #!N9&EN   /0    #YM;6]D   /@    "AV8V=P   /J    #AB5%)#   &
MY   " QG5%)#   &Y   " QA86)G   .\    "!A86=G   .\    "!D97-C
M          A$:7-P;&%Y
M
M        ;6QU8P         G    #&AR2%(    4   !Y&MO2U(    ,   !
M^&YB3D\    2   "!&ED       2   "%FAU2%4    4   "*&-S0UH    6
M   "/'-L4TD    4   "4F1A1$L    <   "9FYL3DP    6   "@F9I1DD
M   0   "F&ET250    8   "J&5S15,    6   "P')O4D\    2   "UF9R
M0T$    6   "Z&%R       4   "_G5K54$    <   #$FAE24P    6   #
M+GIH5%<    *   #1'9I5DX    .   #3G-K4TL    6   #7'IH0TX    *
M   #1')U4E4    D   #<F5N1T(    4   #EF9R1E(    6   #JFUS
M   2   #P&AI24X    2   #TG1H5$@    ,   #Y&-A15,    8   #\&5N
M054    4   #EF5S6$P    2   "UF1E1$4    0   $"&5N55,    2   $
M&'!T0E(    8   $*G!L4$P    2   $0F5L1U(    B   $5'-V4T4    0
M   $=G1R5%(    4   $AG!T4%0    6   $FFIA2E     ,   $L !, $,
M1  @ '4 ( !B &\ :@!ISNRW[  @ $P 0P!$ $8 80!R &< 90 M $P 0P!$
M $P 0P!$ "  5P!A '( ;@!A %, >@#M &X 90!S "  3 !# $0 0@!A '(
M90!V &X _0 @ $P 0P!$ $( 80!R '8 ;@!I "  3 !# $0 3 !# $0 +0!F
M &$ <@!V &4 <P!K .8 <@!M $L ; !E '4 <@!E &X +0!, $, 1 !6 .0
M<@!I "T 3 !# $0 3 !# $0 ( !A "  8P!O &P ;P!R &D 3 !# $0 ( !A
M "  8P!O &P ;P!R $P 0P!$ "  8P!O &P ;P!R $$ 0P!, "  8P!O '4
M; !E '4 <B / $P 0P!$ " &109$!D@&1@8I!!H$/@0[!$P$/@1 !#X$,@0X
M!#D ( !, $, 1" / $P 0P!$ " %Y@71!>(%U07@!=E?:8)R $P 0P!$ $P
M0P!$ "  30#@ '4 1@!A '( 90!B &X _0 @ $P 0P!$!"8$,@0U!$($/00^
M!#D ( 06!!H +00T!#@$000_!#L$-00Y $, ;P!L &\ =0!R "  3 !# $0
M3 !# $0 ( !C &\ =0!L &4 =0!R %< 80!R &X 80 @ $P 0P!$"3 ) @D7
M"4 )*  @ $P 0P!$ $P 0P!$ " .*@XU $P 0P!$ "  90!N "  8P!O &P
M;P!R $8 80!R &( +0!, $, 1 !# &\ ; !O '( ( !, $, 1 !, $, 1  @
M $, ;P!L &\ <@!I &0 ;P!+ &\ ; !O '( ( !, $, 1 .( [,#QP/! \D#
MO .W " #OP.X \P#O0.W "  3 !# $0 1@#D '( 9P M $P 0P!$ %( 90!N
M &L ; !I "  3 !# $0 3 !# $0 ( !A "  8P!O '( 90!S,*LPZ3#\ $P
M0P!$=&5X=     !#;W!Y<FEG:'0@07!P;&4@26YC+BP@,C R-@  6%E:(
M     /-1  $    !%LQ865H@        @]\  #V_____NUA96B        !*
MOP  L3<   JY6%E:(        "@X   1"P  R+EC=7)V        !      %
M  H #P 4 !D '@ C "@ +0 R #8 .P!  $4 2@!/ %0 60!> &, : !M '(
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M6 5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP;
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MY_MW_ ?\F/TI_;K^2_[<_VW__W!A<F$       ,    "9F8  /*G   -60
M$]    I;=F-G=          !  $          0    $          0    $
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M  $" 0$@ 2   /_M "Q0:&]T;W-H;W @,RXP #A"24T#[0      $ $@
M 0 ! 2     !  '_VP"$  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,# P,# P,! 0$! 0$! @$!
M @(" 0(" P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# __=  0!*O_N  Y!9&]B90!DP     '_P  1" TH"4X# !$
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M:.KKE;,JJ1E( ;4 Y5S'I;K>U9[##%E+ @6(?ZUSRY>O*00/MUK,F:;S/C8
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MNMK+9>P8G)?2UAYTK@9P )5<M@N8AK$ @D!3E(N"/*DO(P$)8DJ .;*BA=;
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MVRG0:VY1F%M2+@=Z&TA<6&$#<HTS9K<VIR]A>YL!?TIO4CGD%3X<3.ZW',=
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M8E9';L?M_'VTM&'9>E:8EG8"M&)9'WE]OV'2MFT=AV]U:-G-KUHPY[?9^O\
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M:VO-V)T!]*WKF(,+QFRDH+'0: C32^FGOI-\[&6L%T\0%FY%)^IELPU%SK8
M$$VK=S AF3AR".R#ES%EL",VI#6TN&/G6D[FN)P#](I7E(*KFL;7*^U[Q6S
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M&+(Q8ZD:#4+S CI?4\K 5AIVM8Y>,NP" W N+ J<S>U<]"%%;L(W489M,I)
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M&RJK@BQ'4EAUMFT/>LMQ,!,(16(93=FU6.V6SWNP!UZH/44AK._ 7%@R)EU
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M W'GTK;?$T&F#F )4L2I5&-B51LA5K=R+6^-+4M$A28JL-BV9 Q(L2"EAF!
MTMDZ6]:*KO0WO<Q2X?%M;*25LH!7VM?[V]@#Y$$VHJ7$*F*6'$GZ[^5P+!;"
MUP/XH! M>W6E0G?)BXV0<Q37&9V%[DA;ZV U*D7N;404G[@Q24+>XOJ1H_\
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MP%:G<#,!V[M[-O('M;5M:W:YO5&5$%[D@@$WRCJ O6_<7':L41<<C*5RJ&S
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MV]VNAK+<C/ QE#:Q(.NB@6U[$=+6K#7>8NG;H?=]M;1HXS$$=+:G6]C?0CT
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MME\KYB0?>!W]]9HQ-TF82=0H'+U\R.NIZ'K6S>N8!E8D.IMH#?L?9!.I( S
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M V;E1<I%RKV]H$6Y1[^M9NK@)O9G"MF)D-^8G0KI8VN0+WLO2DRCR-G8, 2
M"C"Z@B_([$@7NUFY:184C&$;,H0AF+!5)T%@+'*=+@$UK34V?29U&4&XM9E[
MANA<GL6&@OY5O0PQYF943*2F4J;@YRT>MCW)-)XFSH 26.;*I2V4N2;#52+#
MKF[=:(M!+ C$*P6YO]4@V"\V6Y)UMITZTLRYT*$<[*0^89F36USE!L>E%X&N
M\PR/:9UN0<H.9KGZU]+?QA:MI7,,!RG(QL"6RLLE\C,5'+F%QUYAZ&B15@<K
M-F,JH8"U\CNIM<^TNAS="#1-1#.EI.5@@O[6JWL+ GWW;J:VU<TFD=<N9S(
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MLS?B<"*R(ZE7#:V6[6()O8Z&UO2M&MZ)W"L5U7D"C,MO7N!Y7%;N9OI<3L0
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M-B5[CO6F9IWG8964C(-;GNJC+J"!T!-)%>)B(+*" "!T %AIJ=38Z6K#+G4
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M9OJC+<6C[78^=!86.@+CC 0^V;D  *%NX #6!UT^%(;"*]WR#'*"ELVC&R$
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M^6]LOL, 0S9F4YB?,"L-9':Y?IE3)RLB#H2;<O:UJPPXX=I)$NPSV6U^ZD$
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MTBZXBHM(,$1D8J1&5)L"FJG,0+]CGMW[6H$O1"+4S(GU;E1;A_QGD-P;G-8
M"U^M-VFV&CR6H(42M<H ZVX9.0!^0VOYC0ZUJQMY'#PR.F8*,P?,JLILP"]2
M.A%Z&XIOM"1;9DRMF$C*&=@!]'&!E('OL#Z^5!<;NW$7<PR89V!<ZDJ3F<#0
M :7 NNAI#BDC=PMQ."8VY+6Y3J!>06NV7I8Z?;0&O.ST9IJ]N05XC# ,5R%#
M8AQ]4,-02+ZB])<7:YF[$)\5AD0$$,04D-UZ:!LPMU-K&D*]Q,]V*[0NDPQ4
MA2K(@&9,CZ=.I8V/ZJ5F] >]V9 , J276^6YC %R0-2A-P+O;UI5I)W:,OV
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M$A@#9E:RJ5:RJ.<BQU:W;K6TS2? "/'F'L\QR\0D<RH!S +W;TI:=C/$Q2Q
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MC&H(8,(]2".OM!CT-].4C7SK##N,MS=5)"FP ZF]^EM :PV89%)LVH.;*P#
M!U[H;6L%MYZUAHQ2+'[5VY3EZ@K[P#<Z7K3$/4+Y4RC^,H[%2#D[!2= <HUK
M$:X 26.YT"*C&ZA5LX/9>GEWM:MIV:9H4.YR6VOB6S"YV?*,G4J!B<*!?OT
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M&"-=M1=B<PT/#%^MU -[#RK+Y]H1,R&0<RKS*<S%C86NSY;$D$ @TI&&5"$
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M-PQ-NAO:]CZ$UI&'Q0A3>YN=!Y ]?OK39ELCKPUT) TU!^%C?[JR[,W3!DL
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M$<:278E"\@ OJJ!+C6UQ8&_VT)!5J&,2VY;@AK$E;LTIRJ=5Z  ?CR3+4)V
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M#ZM&SZM&'U;-'U;,/JT_J-G%:R,/OW:UEC1]6S#ZL1C.MAUUZ?;:L?U&+0X
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MWM-Y'%M>HZ_5!L3\;BD&+)G=@%:UK1DQEF'M#EO8#4=]?*MM/V!-Z.G ZJK
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MUQII6Q,H_>HYR+>0YLPL>&& ((%@QOJ0-=!VK5^(G=ER [88L3I?FRA;%B@
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M4@ ,;BQOF*CBW\Q:AFHJSN!\V>Z@H,^<6L<QM<@,=0"3Y:?"M6"I<>!SP]&
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MOVI/B88P1[("LH*MJ.G,5]KN;"XK'S-7]QDR \0:@Z9KWL#V ^%(-VUYG#W
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M"EI40E+JBD$E;ZC,1U-JVLA,HWS \B<K 1)D95)!0J75];KK<#+[J4G[@2?
M!R*J$&[,O(O*A>1G &:US>RCTHD'8VP'(L!0R,TBJQLA1#E<WMS"]]2:)J\D
M!EZ3 KQLK,KE!D&9N&MR&0<R>J+2X/("\M0O<-F#G*J:Y5/UBVF<]A#E(M>B
MQ=LWH)?,+L7#8@KE,;*K!4-R ^I-FU HL)*]T:8721Y;CG: 92J9N:]@;V<6
M\Z*FGH) LF;A.B6=BP09R+\)PQ"CM<LUJ5%V>?(T\P,(\T9>S%HQF""V=I.K
M&2Q]A;:]:)80=$"DA[*C YG)NXL1HP!T=">YU%98V?1*Q#NY#L'N<J@A[* H
M2VJD V!\JRU\S/$[DE0%6P2VEA=G9M<KA .&?=6_ P"0I([G,0SIF/#8'4$Z
MAB>H0=.]:69@(RC*<H"GV"YM]4YLY\LQ-NPI261AA161V9RZ\.Z KS,Q>W*O
M;)S"];66HEVT1W$8 8GAYE5N2_>,9@ -%-[^=;2MKJ:>>FAV+!\C$J+,M@#R
MJ"!8,3T)I0G0R2WC?4BRY; '.&8^V !?V#I6& A"H8YU)4*!= JEHS[ 46S9
MK>=9IF:!,226()*J<R$W#2CD'"5LI/*[<H]:')IVL;M?0.((CQBJ*8T2$CFT
M4F3.^8'5K!FM\:$Y(,ED@QPT; R,PC"*BJQ-RY:P[ZC7W"A5&FU84@ZBSDB5
M22L>KL"H8610;#07"VO323U2S"1U#%8CD-EL@RG7K(#HQ'2XO39]NH5)O0,L
M,V=_X.1'!0%2FFB9;:=4.6D]@1+S0Z@BR\[-H&#"U@+$ Z:@6O<>=#DTS%FU
M8%A.(^<,HBD-U!C)8VT + ]2120G$$A,E]+Y0192+*I-V'6X)))^-;,,)0LQ
M!YHB&+"_,,HNI';.O3KVK1@ D4%^4Y2%S*FCDYU"]>YTN?4U@JP$FC58G%R[
M*JJS@6LP-M1I8VK%>_8#DG>_ *)Q<@EK@L%4#6Y07-QH0+$401,+A$2J@L%9
MVA+1 %FS7.H8ZF,)8MY4I: S%* K+S!'.F0'ZQ:SNMM,ATK9AQER\CYKY0'>
M,D,'#-HH L;AA>M,P,(\CB.V7*H8921Q)8P;,+?QC(*08&L 66T07*67*%;V
M V@N.MC<A?>*4&09X<<6U@ "<FEK:(NO;K8T.6HN#S##AA3'D=LRIE(47%\P
M^M\*0]!=D#!$'MF+1C7.<N9G 8E0K7Z7)H!EK: Z%6:[.6*Z WMJ-0#ET[6K
M9I\CND,;,6 13&P4YDRWS&UM"/J@:UIRBLF;M)H[.@5B'2/E%E8"P4!KV[ZV
MK6_'FC:@S((V6V4 LYSH ;75M,W07R@=#6;\>9IP:/C ZRVS *5($WLYU]H#
M+U4AR1295+>C9F]QLSY N10#(+W*M>X)U)%CT I'6R%*"XF$QH0P*9V9@W#L
MQ7J;F1F.EDL=*UOR?$4HQ7 Z<%0(V)NHXEK,<RK_ !HQTS+V]*Q3D:<$SXQF
M,0J9%*JK$W6S6D5B.):XN=/MI6_(UU:.W :0EE5$S!"6\Q8 @#2Y-JTJDEJ9
MU:.3R *JZ\7*2%R\/H#<WN2S$5J3<M148[NA\078B-@3FRL+?Q-#UL-":3WB
MCN8NJK<?7SZ$'I<>E88=&#-8&RJ7*@BRL R^V2P-@2HMUK9IM+4R<+,B90&=
M%(9C8$6[L5L&N*S4TI)Z&/F8#AJ-%NP(&A]#T(8'X6K,C')+4Z,%5;,Q?VE)
ML3TMS@CL";:^58"G).U@/*@S7 -[H ZD@,ITOJ>Q-'@TU9:B OG3.6!D(*,[
M!CKFR#V 1?L#[Z+'7,QQN%$R*'+!<Q8H\8S66XYES= ,]&3X(%;=?: 9\K7D
M6ZLB>W&MH\S\^7M<KDHL7;)Z&Y9H+I1= %(9F7.R,=&-[EF]U_76EWT O0+G
M)"RMJ0&"\MU*V%R4;0@9K4Y@U>]\@06S%A(P)SB,)*#FZ9HV)=SIFL.].HYL
M2 '"(%).4,,[,06#/9M+D<@NM.#1CCY[7X8 ;*1;,5)!)*MH<RZ>FM;3S-/,
MZ22F*PC()C8-$Z@*K-?ZY%Q<:^\5MOWF62,J3%\S6C1AQ"Q9;C7F8FY U8K:
MMY(V"S,&02!K,RJ&4BXD9@4R)8W!YNO:AV]Q@-BF5B%M&RY'((7+PF! YGO=
MK_JI#[,Q:T!092T2ED)+)?*?KQW(((ZE@2+=36DWHU8V#\-,][D.F8$ !K:Y
MC="3>V4:D5JIE'L,!\4O#:]@4]#I:UB6(-^AZVH*8J+LK"A@D0A=0UU1F!/(
MO6QS"Y.EK"MNRS%AO%/Q+L#FY2 MN3EL#=NMQ099O+,79V0902C( S7T4::J
MNHZ\M(T%)\'J#)&89N4#V?9;/F7J"#T UZ5EPJ>61SG  &FE[]="%N3I;4!;
MTAQN\M!6\=FD":#*JDWY4O=@03K<GB4*4/>8VCNK*V=F!RE25#  &UCK8@BY
M%"TU"1:M;L,JL"KE441LI0,+FP#"W<C6]9<W<Z,R9F (M&HM?V3E',#W-JRY
MES!*A#"Z*>K@*"&/E8WMU I+5]30#=&90"V7BYFMWY>I^%JUNQ6:2N9F Y(K
M*3)S*$=00 2K%"5-NY[VH<X<4*U"O$889&4,&#7-F4+)E.4 */=Y^5-:D.1B
M$OC<.H615CCS."JGH2YY5XQ[-8W[UE.+U$3U0C=I8-R2+Q(\A =4YP GU2>@
MS#U[TN:;=TL@32>8A=JX !VN<RK%)?\ O=?J#J2NGE6Z;M9\+@9)W&_QD:"+
MB9G60(T;1%3<YC9KV.ME/F*=+-Y#9_6%QVFR:\J*V518^S'JJEE-F =%&MSH
M:5N-&MY^P4VS=KV?AKB"%#1F-F6R!; ,%).AN3;^-:B16>9MR:T''V5M@LD*
MR@9UDDRWL[(BH2LL;]4-];4MQ?!9!8YJ[Y"[V?M-I@5>2P4 ELPC'2^777(_
M5AUO6U&7()%K=%=@L?RHV<,2%L3RJMXR<LENUA8^M;ENZ+0)%VU%'A=H@F)L
M^4W92O5,GF+&_6LC"R[ B:!B8P+D+>1%_P#FG[16(+%JUF\PUBQ9 NP!1F5;
MA;',V;*_+>X"@&LN8VN8.BF(+S(;6LD@:]F/\8>^LN)C)Q=N!\<222",J\/E
M*6YO].= -:V$S.S2J#=C&Q!]KH$##TZFL-& 3VRG-=0@S _7+-D4#RNVE88=
MY,0K*68\-E -U4V4-T)UN,U%WH@]Z7!'43,G*7%C8D#J<W0][W-;\!-Y<&S&
M^(5^8V# %EO]0*;$G/<<I%J3O/D9>5]3&DKN,V4G+<F_M =21;0Z4G>J&\^8
M';%)9+GALY+9F8@LF<</I>Q8,*WO2Y&O$QMBC<+;+)>QS&W0=?9-+N:L<F8!
M<QR-&(V"DN;.2;E'Z'-GZ>E8;L8EQ)/M$@E7D+90 W,,Q'2^IK=I>PRR,8Q5
MCU&0BXR'4:7!/E<UHRP'.,*D9L[G,&:R^P\MW%_2QI:WK:(U9'3YW=B592Q&
M=LI!-N_%1K$*/2M;LN1NR]AC.-4QNH8AE:4%4T1BZD@>846-O=2<Q-XG1\0V
M@4W"VB:YY;BXTZZ$J:-'T5W&\M3$^-R95*@,N86#6S&VEB.EZ4:R YGD<.P9
M 4*C)>Y]5-[W(K3RU,\TP8C$*92+VD76,CE0 CI?I>MK-7$WMH+3PTF:7>+&
M7&HV/B;F]Q?Y]L^DST'6!E>NX\H_C1__TKV&T/\ /V-],3-_EFE#&IZ3[P)Y
M5M".!R.M:D;X&0=?A24)X';]E*,_(=JP4?5HP^K##ZMFSD?JK-3:YGU)-\3O
M_%_'37]!K9A];I[KUO@8<D=/(5I:LPY!O6=AIG-8:/NE9J8<UAM'PZ5C%+0Y
MK1CN?5AG8?5AC/JPQ'-8;/JPP[>>O06%M*WP$G)T';]_[:TC%J?+;WZ#[^M:
MD;/@;>7QUUOY?"MFS)IH;^ZM&:9''?R\OQ\*4;X'/W5HT=JVC#ZVM;:,1R.G
MPMZG7M6C#D][^_36UZQ&'VH7W&_[_=>L9K\AS;4CS'?L1VO6+F;/@+CRK30J
MY]I;UMK^.U;X&9\3D"X]/+N?CI67-/ZSX=/6^OX\JU(U?F=C?3I^.E:,/OUZ
M:#6MHP^ MT^^L,OS.IT&GF+_ +*V;S9VL/NK1H^'05AA]^RL,.?*L,/JT]##
MZMF'U88?5AH^K1A]6&SZL,/JV:/JPV?5K,P^K##ZL,/JPT=3Y^H^_2MLPY_'
M[_=2<C9U.FO;\7K8AZGUK]ATK1LY[ :>ZLX&9\3J1?\ F^[[ZQ&:=QU'E;UK
M9ASU&MK'\#XUHT<6TZWL"*V;XG']]ZZ^Z_I6"6<-KJ.QU]3YV]*PTM3J=.WV
MUK0V<'\?"L,.I%S<@BU[>1 K9AB:,'IV%S;L?*L-VN8B@\O7]8K$[B6C$5)^
M)[UC9JQC8>[U/?X5@DZ=+6]1Y&P)[]*VC.TZD&]NH\_7M6,P^\KGT]UJT8=2
M=38?N-;$GP[>O4GL/7UL:PVM#X'KTUMW_7TM6&CF]QKVU.NIYOOK#+G.;O?K
MJ?3T^RL,R,H8Z>H[:Z_LK1NY\#<#I?II[]:PU<^/LG330?N'OK+FEJ8SV8$Z
M#[/=YVI1C.-+6.I%_/J";#[+_"L-&)N]^MKV]/V5KO-<3&; 6 Z :#36S?=K
M6\_8;,?36UK:#RT]>M;$G0V(OWT)/2X.FI\JQ&.QTZ^?D;GMV^\4H2=+GJ+6
MTZ^7?TI!AU)';49BIMU)(S ];VL;5M&&(7!S6T]#UMV\A>M,PXU!O:Q:^;37
M\ @5AACZ,0O5M3V MYKWT[ULPX+WZD@GMV/<^7:L-:'Q92R@$Y@KD$Z &^GO
M2W>LNC#BQ-[W-CII:^G4_&E7,1TOH1H!:X%_@WIH16C39P0,O0V\_4BY/:^M
M89=<3&>QT)TUUO>PZ]KV-;9A\0>G<!K$:7%M"3W%88=4-N6UV&M[:>1O\*T:
M9V'* #;+9P3YYSI8:TD4FK'5;$V!Z@ZMU \_A6<#1V4%B=+6TU-BNE[@=P;U
MH4<-'FL";&Y)!/Z_6M&KYG5AT*WL$"J;=&S &WF3>MFF? (C9C=B2Q4@V["]
MR38ZBMZY&79P;-9E6WF#]8][]3:]8;1]S'5M!K8"Y4"_4$Z]2:V_J-,X-B,J
MDW)U]XZ6\S:L,[#XQBQSW%A<W&K$]V_BGTK$9VF#A)S6#O>]C?S /3WUEN9E
MD]0,X8 Z6Y21I[5LNAZZBL,.%0L%N+=P!ZZ]?(UG T^PQW+V*H%L2H[J0!S
MCL>]^U;!G)/*06'U5'D;][]^@%_*M,T?*"5!4$7M?2][&Y)OR^E8S1\0NJEK
MC,7L-0M^@MT/3M6<#.&9Q;70ADM>WF.ARCL+"MH5'7+0ZN(Q8$YB-5'7+F^L
M.YI60KNT,!  -[L+ !NK7/4FVE].E:<;FM3*@-BK*"Q)ZCV5O<$>0-(:L^P2
M876XL UC8'4C*;VUMV-:X&6/N4%<ZV+&P)N0"+BQOH#:U:LW<WV@6<1G,K:2
M: WT)/DK'II2K/AH: ,D0)5E5BC!2P#&V4-S%B58,-:UGQ$O()IF #918!GX
M:A<PT.F9B%L".GG2XY"6!) 94S,MF<E3J,V<I<64:V ![4H3IF%\K$6Y@!8<
MUB;I:V@7ZRN-*SO-!1CIS;*LEI'4@V0*TF4<K6Z@  _$TI+LS,8FL1B1>1BS
M&-6 5LH,@9NN9?JJU[^X47=5K,$W<P+C75B ZN/K,NA9%[OFT6W2DM6T1M L
MX_* O$*WR-D%LH1F"W+#NP:X\[4G.Y@-7' /<%5)!12C9U8MKE)U 8_"MVOD
M9O7!,6,C*DLEA$,C,#8-<\ZDZ#,%N1ZBM..9N]T&2XLDE)&"9B3G%BV0+U8'
M0*5RV/G>DVXBTT&F&D+)&L=@'D(SMJK:'0DZ"]:AF[BEFP_@D* H;AF5M%-T
M9EZ].U;FFUEJ8#XR,N0Y6+A5+@66,GI<=3J.O:AV?$T=UL+H2,V6]Q<$D6M;
MS#?JK7>8<L+>Y0!H-3IUM[Z5P[#1P1<$6))^[W_92C#@@BUFOG(#J!U';+ZD
MK]U:>8J&IR$!]H$6890&LMP=+MTT[BM-7R>@6QV9;J0#<:6<O8 ,?O+.!IW6
MAV1EV=I.1R-!T4M?E)ZJ4':_WUK=YF[V[S&V<$EK<Y#!>Y[9NVI%::21F?$R
M6S&P)N 19>JGN">UKUKP%>!BL 6&6Y%@">;6^F@TU6L-'0-TS+UN,M\MLP N
M;VMHPK'FK&I'8Y+", WU1CFS,01=6&ATMWO2'36[D\Q.:S. UE#*%"D?2DFX
MRC^)T!5I &!]*';*[61J[3.H35KYF+:7'*4MJ6'4:5JR-J69R0P6W,ZW"L52
MQ;/T-S8/I6MU"MXXS-(_/RC4G,,O8"PRZ6&A/OK35D8FVSJI8:CK=C]8V'GK
MVM212>5CHS*S9647"J>$@UOU#'N#661OO.Y*"X8 W4!+/=A>Q ([V;M6A;9U
MD<F104 ,:%#=3:]M,VFI K+";YG!C%[*2[N006!3,W8D=E4UEC=S[4*C(H!O
MPP#U#,MFDMY7.E:S,N=C94NQ4J" SJMPIMF6]KBY(T'>LN;NK:HQB^KNN5?K
M$C-&%ZW5>N8CK6&=K.K+E ,8"@-G#JO)K;*%'8G,;5AM]FAU$2#JS@%BQN&9
M;D:/F&BVOZUABM[#BQ4QQCZ]\RLP+:BS.AZFXUM>LL*OF=65; '.1:]_KL)+
MJ]^X "B_D*PV!P%!="AX88$V;.V8= 3Z@=*PPQRIQ"9<Q;.MBMK"U\JD#R*]
M*4N0*W$ ,C EE)"A (R;H 3=;D_PA)K9G@!Q JBYSME50PO<*X>Y+>O>E1D]
M!$H7 <JI'&N96>RL&8 D#-USGM1X/@-WS"V978Y$X6=TOF:S+9-%"$>G47HC
M$M/0 NJN"0JGA9ED:0D,5CZ$ >7G2HY(T%V)ODSO,6B+H$LH 1<MB6(^HO>C
MT_K$, 2ID 3-'(2K/Q<O(.&MUU'E:U+9HPKAR2?FX8*T=LQ"H%)OG%SY"E]9
MV"=V_$"O#($" 6.?@^R,SD\RCVS<FVG2XHG 3Q L:@H'0NI+R*&#!06#6$9U
MTS>=]*RUC+F?*SRJ05C)S%88R]W:/2W0W).E;-\#(0Q:U@Q62,W^L$9;D#NP
M5CUUK/$SQ,3AS(P;,%#!LO*K%2 P)+>TI4WMUM6S'V'*+_"$DQG-FR*MP\6=
M+,I:V@ OZ4I+,0WD?<,$(J(QS68NQ13S/PR5U:ZW%8:OVG$MEE +H8T"J0=4
M9N@8N  3>MB;F5(Y&;F5(48->1W 5<G4@C4*YZ5LP%QG*B3"P<9"RY6)D4CK
MQ&L /3K2)2R:%**?',%X6*,EF5+,&C86!50O$8DWOVH0N*:N@WB-GTCL\8S.
MC=60]2 18Y;^= >K[PB#**)68* ZERK%8VR%V&I#7]HVZ^E(D;0<Q!,YB"LA
M [C34\UCT-@;G3O3.4FLD+CJ&L08R"\O+8'4]5 OIT%M/MH62'$+W#K#QG,D
MX+W-ADR\J\K:,?,BQ]QI#U%AGAE)1"#&,I#E&&>X$:BV37,2P.O:@Z,R"!ZQ
MNJA50&^9F RE)&Z@EAJI-P +=JV*L<%(Q"&$*F0CG +J5;J5);1R/NK#=K]Q
MC,99.(;@*MF;)D%B.4?Q+^O>M&[ .5+*PR.76.,@@+=0;7S9=;$'[ZVC873A
MPI8$68D-&+D>DAOT(["MZ")Z!1*H7-:Y8Z7(-KJO6W8L-*7P!2T ; \O, +W
M4$K<YE%U OFY6:U*6@,#21E\^8VC18UL$8 NSZC,;F^E;,/HRG%*HQ +.SW.
M9@P)%B/JC*5-O6M,P&0IEE,B0*P!"]+R+G%F*+<WLVITI!M9AKA7#L2!E:X4
M=OX($DLIZ.S+^BE!0Z@C52&]KF.5!RJ+'*&S=,Q_10Y:BH^D&J'*Y4%0A4AN
MAO;ZR^9)/VTD(9X4)7*6Y4%WS6#1C,R@,#J.E-VC8.2-%.6Q.92;^1L+:'6Q
M\ZPPSHM@[_17&;*K:HI55%W;^,>@]U"FFW?@+CH? *;W(R(%:^6\;/(;</II
M<]&\Z'86=E/+="5*713,;M#K8YQH9;,>7RK##+ER !P'&MF9KLTFAS-V-E(]
MU88<@*9 .&5D*7SL^52#II?3V:PP#JH+'BF[#H23HURH493W5+]*V89;1NA5
M?I"2J9C?+])U*9@O*!W&E:L88W3(@5T+2)F52AY3S!1?[K5O7N-&%0P0=;KS
MG-S:=1J"1J#6[(PSPNO#=S8VS.0J^PRD, WD2>E::S-F)Y"59E/T1E.?-H&9
ME5@5/G&2=/6MVYFC(K,C*2B$6SW8C+;N>PS$=O2M61AUF<$DYU8GF!;E4WZ+
MV%UUMYUEC32>IP&  "\0YES/F%KK8<0GR2,6U[5C1BBEH=2R6O8!<UE*C,+>
M>8-;FK+"*B;L=W98QF!.4>VE\YL=#RV!7*>M*A'>$;KX@21BY-FC5%6Y:07Y
M"/*XL3V]:+&"B9NI!=,IY>?B$L  J\,J@LW$'=F 4K[VHB%6 ^(0?2!HFRJU
MN&P)9R?I+L>L;(#K6XNSNP,EF$L\;!K"[Q-HEC<*HM;06Y;L1?SH\7?N$W:>
M>@38HQ0AGNVA*, #<%AS:D')T%O4T7+1 0N,N5K%@L9"K$)+YK,"7XCGR"]*
M/'1 @GQ$JN9!8L#&Z(%-LPMH&/96 T\[4]C+D\Q(5RXG+F5F<1GEZJ25.87(
M/0*;:^5%@VW9\A,FD 'D7AJJNHD+!E<,1=2&N"?8[#KYTJWO$[Z.IQ*E2H#,
MK"S@D$D#5B I"Y?6]Z7%.^9F^=3C\I"DBQ/#!<?1C0$:VM8 :F_6E-&;_,$Q
MXK,X4G*R]#T! !91&.CAF46-8HF;P8)(BH4!<<UI&4_2=FRY>HSDVI-L[<!=
M\@?'B(4B9T8I(TT? 1CK]:Y-]06&HI+C9BT[@^/$$M=9;Y6S93JKE@"P![@=
M_*DN.\K&/M#2/%)D9U*@E;2%AE4@\N0>:@MH:#*"CQ-QM<-H,398R+*N<!<W
M< 7&O4J36E&7+((W9!Y'.RH"6',Z:(P&7,;L3U(%QK6Y0;6[S"*HGD]0VP^,
M;)8BY*L6=3F0 /8#3S'6FTJ;4A5DPPAQ2R*3F%FZV895L=2!>QS?=66:5VA<
M;)&8S6$ARYUBD5T"B]Q;FO;K= :U9,79/0Y24&190P*WE"C^*7MD)'4Y;??2
M)*[7(W96.8Y4+M&39BI+%QERA=;9?[[+:AN#3N;MQ0*$@2/,56->4Y5< -F'
M(66_UK7'G0I1SRT-J]^P^659G)8J; +'<V1I&T"L?+W4FW,6XV.V9@5691RL
M#E77,JZ@ ];5EC+ 9VC,CA8BJ<SAO(MU0=B;=J2;L BK ,"'OJP1='%N6X\B
M0:UX&P/*%D0B55ME&1$U8&_M,_UF\Q0903R1H)\5A,ZM'DN >6S#,3_INQU^
M%;C3RY(')9J^@EL9@F<%N"8PEKL4( )-CR'5GMWK'3LFKY6!RC9^:\A#X_!J
M'8*SYW!R.J96:]\Q)(*BS"W3K2>KNE81+5\AM=J8#+"90KJUK?296/.V5A(=
M"A*][:?"CTZ?W*&U1><-_M2.2*4(X0YCS#4K:0W2-'&A:(7N.U.HI1REF!=[
M6"K\YF-QRL BNKBULT,>K@::L03^.BU3B^.0+K6A:[/VZ 5X3@I%DT7^%++E
M+*Z]5=?+THL:--O)BHUFM1P-G[>1HXIW8EY,W%#->PO]&J :&4^5:J4I4]'D
M&C60O,#MKD5U?,"H55)Y2U\]CITRBQK'&V368;>5]1:X/:,;",$D9T5BZH>0
MMU5/,?JI3BE#M"J27<'\&)B,BLLMU# &^H#7L@/:[$:>=(LN0K?:#.#$Z@M;
M10>N@L#;1=.E#M<*F&"8L@M>1@I*$@WN 0.W>]$W8VT,N"5QHRR+)<G(;QB(
MV0=[Z7%KT+=D;,;8R,*')RA2 I9+6N=,W;F TO2]PU<Y;$+$&"$2 W#%]+YV
MXZE.A.0&YZ6%9N=IESHV*S*OTA&15S,?]& U ;N >WG2MR/(P#MBPQMQ0!]2
MZFRGV@"?,7TI5C1U^=W9ES7O&[6TYE9.();^9)T%89=<T8OG1(X@#%AH%5R@
M5<MLX.E[U@G?1B.(R@Y6S V8YC<C^"/7S# CWUAF^C"V.?)?JQ Y@PT+Z$'N
M-*PUUB.DF+5652Y5EU4 WMYV_C9KZ^59D:ZPQOM D "]PI4CVN5WUL.@!-+4
M["MY 5<>F@9G5AFT(L+7T)\A2&"<C&V.'+FXID+!2%.AAR] /XY(T]*(H/AH
M:WNTP/M#.8I "QLK@G(A53]&J7)YRP%_6LW'S-[W:8FQF;5FLI]O.1H568?5
M-^I'VUFXS.L[#%^<LI/"N=+AOJ*HL1J3>]G/7RK-V7-&]]O.]C"=H"Y(;*VI
M8A<X;U)&@T!HBR5F(<W[ ,^/ +R%F92 &'L#/W%].Y-:EH8Y,^.T2BB-@0)#
M=5?0^=HVZD4-1E:YK>?L''\)<5QMZ,<EU _,6)<*-388_98N3WOF^^E.ZC9C
MW9]G6?/=_&C_T[V&/_MACO\ ")?\MJ7P&,_3?>!!TK. A9HY[CWUDC? R#J*
M0A)WI1M\CFL-H^K1A]6&^!]6S#L.WX_&E:%(X-:,9E/L_96S2U.-.NEO=]GW
M"MHV?$=!ZUKB:3.U8:/JPP^ U)K+\#:.16&(Y'2M,4D<UAAQ6&(^K#.PYK#9
M]6^':8<BL>AHY';OW_?6&F<FUNO6_P"#]M8C2OJ?*/M\O3O[]*T\Q5_<=@+D
MG3T'W=/A6N!L[:>E;L8?6U&O3[_7T-;,.;5HPY[=/QTK:,.>U_2MO0P^\K]+
MGW_SUIFT=CT^ ^[MVZVK#6A\%Z7]_3[O6L,.Q'2PZ]?3]5:XF(X %[6M;7^?
MJ*V;X'(Z:#XZ:V_3>D\#.)\!<=;CI^^MF,^ L+7&GZ*QYFCXC2U[#OW]:UF9
M<[5AAQ^/7W>5;,."-+6OIWK#.UG-KC6L,T>1P/CY>?2MFSD&X%:-,YK##ZM&
M'U;-'U8;/JPP^K##ZM&'U88?5LT?5ALXK1AS6&'U;-'U88<?M[?CO6&'W7]H
M_56C#@]#;KTU_?6&F<:#J#6&(Y.M:,;NCJ;Z'KV]+>=89WZ'7O;I^G^:MF'Q
M%R1W_2/3RK1G@<Z>58:.C==._GW]U;1I\SXC[-.]_2Y&G4&]:,1TK##G\?CX
MULPXT-JQFC@@>>MK?O'J*T;S.F4>A';OZ'6L$LZ,NMK=>U8D;1A9.XT![?KK
M9I_48F3J"/Q_/6";6,#)T/ZOT]JVS1P1EU]]KC6WJ.E:,R.NG0]1< C[=?.M
MB3H?>0._E;T]:PVCBUKZV\B+=_U"L--G![>XCT)_18ULV=<UA8'I;MUT_;6C
M1VN3>PL!8]==?(]JQ&'*R 6)TS=+]_W6K&:N<\0FYO87&G7X7ZUI)"M,SG,.
MM]"&Z=;@?H(K9IG<D@CIT:_0@W/VZ@6K#1C8Z'0#OZ6\CWL:Q(UQ,;#1>K7/
MLCSO8? BE&SH2+D#S/74CTK8GL,(O9AKI[5[#7-UM[JPUH=;7L.IZ^HZ_J-8
M8=<MK#6X)!]23W]U:9HZD'6]@18C2VOFQ)M6(PZVT)T%^P (/>QMK?UK##$"
M#<Z^0'E?OYVK+&&-@+ZE3H;@#OY>7:L,.A"FP-A<BQL38_;W!K:-'35K&XU;
M2_KJVG\6]8C&<%LU\PMY91T_C#UN*QFCX>AL-+6ZV\F\Q6&CDGIK8<UR "3;
M0W]!6&F8CK]46M8D+H+=1;I>WI6&SL5/LW6Y ZCL.P%;M[S#'>UQRV]D&PL2
M>OII>M.YA];+TOK874^1M8DDCMY?OT:/K'U.NGF?B+ UG S0^+ KK>_,=-+]
M+W.I.O6M6]XI/+,[V7/?06L+7-KG0-8@ZJ?MK5C9]J18G,!FLX^LPUUTU%P*
MS3(2['-@;==0=1H;7\M-*S3,R[.K#I8#6X;2PT^-KD5@I.Z.I!M86%]5*ZD?
MLO6S.)P&()T!)[$VMV!\KULT=[ 957*&N!<:@@*;DG6Q)-K5ALZ @&UKCV1I
MHA ! >VMKDUAIZ'4@'E-B2QU&C%>^GE6:&=O #R(3J"$! LH U(8@=.][>^M
MF(#2(1;*6+93<I;*3FO[QIUK =N9\Q)L!EL";W4]Q>X]5M6"6=%;ADEA8/;4
M:D=A[LU:9H[%KEF*E=,MCHUKZ!;:\U^U8;6>AQ8] +@ VS9=#H,I/7, :4N0
MN.2."@N"QL  >IL!;2WJ:WXF/DCH3RD:D&YUZLN@O[@#6=QHR*% S  919"W
M5V)ME'70"AR3;--'0J ULP89<U@!T7N>O0MYUEF:U KELPMFNQNXZ9#;E Y>
MIK$G9FPOQ)YKI(R*PL222%!/,QTN.86Z=*)%>;F8!&ERYKA<A%KYLNH&ENI-
M[$UMI/43)/V!>[YG^D)RJ- H %_+3K85M*SR$!?,F0%B+MF)MEN;F]@'%RAL
M![Z2)86S+8-F6X?*S$   @>R+&]A;O2Q-@FQA7(V<E6)5U?F-@C E;^1'E1%
MNWLC;T$1BW^G=&LXD+!E5B 0X!(LRV%K^8HZ4=4 ?U!.Q567AR7=20P+,N8#
MI8_6%M"*RRL)[@3%B&=U21U4,&MW8@#15(L<P([FD.*1O>RS#5)7("V*Y0.;
M*N<$#J"<I  /?KVI"@KV$WY,S1R2HB7E=L@+9A8BQOFN /9%_?>E[BYF7=[A
MCA)@%T+J"2,W$8OJ02I%P+$D>ZD2CNYA(L6&#=<B2 !P>2S',VHZV[ 'N:%:
MP:,A28?AI8+E7DO(&4#);52'ZG.2#;TK!0-5K<M\K#6Z'*AE/U]2 1;RK32>
M3,,Z27&=;DHF9U[ +921_IRQ/PI$H)+S5F9W&4,G,P(95#7\@P.4C7KE-:LT
MNP2? D D6(%KB["_KIUM67]QAT!L,X6Y#: "UR-0"HN;:];UN_(5%I.[Y'=[
M<O4-U:W<@7 1="/72M!5)/(YXY[6RG0AAJ!TC)L"1?6DV,W;&,9LS+G"D,-
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M#/$[5H6?5AA]6&'U8:/JPV?5M&'(ZUF1HYU'IJ/Y_=6&LCM?]/O_ !TK1HY
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M@;'5KBX4'KJ*VC&!Y$:^@R6(ZF^35\]O345LU96,0'0D:JMFRZIIJK7]16O
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M7,Z_W_-:_P#&# #WUO=,T.-2!FU7+FRLU\VNN?RL>M:W7V&9G"@7#:\,D,0
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MB$"ARW7DV+3>@<Q8\2N6=UM'$!F/M:'VB=-">M:C!733N+WU:S:N&V&V@ K
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M:^4C;N[4:V7L#F.M Q,4J::MK^4F-BSWL3+Z-^,3_]6]CM ?V0QI_P"6)?\
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MB)$ ]V+<)/J.1D%K]&[5IV:%75CDM8H[%BJYWR@JQY5O;7F!-J3N1,.RR!B
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MN1WX[7=;DJ56[BP%R;V93S!K=JU<S=.IFB$A6YYK$V&A4"Q!SVOU[7K9K=,
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MEL\K(B1KJ\4;V1P;Y,I(ST%OS0\:L+VN*O9>\R%<T3%C?/&0X46F%R8LYRA
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MJG]=K:"DN[[C#LN8 W"G6XNUV(/8TDRYP<H!4#4VOI?UO<Z=16<>PVG='*V
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MU9IJ:WDLLC&TTC%Y/HR!>RFQS,Z@H4[7!8_&M61N]\T%AE9U6)&!"W#ES;B
M<P9+'4&XK-U<C3MQU DTZ9!JZ2"V9602(68G*$!T4G]-+C!O1")VT6H2RSWS
M,LEF5KRC*'9 O+9%(Y"2-?6CPA;-Z@9Y+M"Z>4&0,BH001PY3G6W=E^J)GZB
MBJ-W99@=X*),2S"-D/*,UES&%BJ M9LNC&XHUK3?*QE\S <0Y=TM9,ZQ^01+
MY6)?VK:*/*B;KY& I)YLS*S,.'DD<<6YY/J<UKZ:TEP6K1EPPPLD61)4.=@7
MXA*?2(W$<JT9[L0;?"AU(7S0I,.89P) JY!GC8MF)T+"Q"_W]P;BFTHVBTA<
M=Y]P;8>6)U5B[%2&17OE*.J@@*-"XTUH(OO!:8NR11LP#F)2UE+*49V"V((L
M3IZUIJYN+:TT!<>)<W5@59LX&A7+PPP&<,3S:_92-R_!A<@6N.)51?FD9AG)
M(E:TDC$*O2RJ0?C6G SS5Q.QQBA<KE4(6REV);,3FSN+$VLU:W#63>1\,5Q&
M"J2BWSV"6]D9'U&MF-:<7P";S,OSE7F.6<98QJ%S&UF((;.2=+5BB[=IF\SJ
M^*#,SLZ2!;9?HQ;37,!TT6D[N[H:<Y'88N)&=@&=23(&4#E;*+90>YK-V^J$
MMR9P,4DJA2R(PYB"I-^^;,++[[UFYV&7DCH<4J9FY65K!& 6Q*W,F7+KR Z^
M59NM:(R\@,N,AC=PS%E(T")FL38YB>V4$=?.MVD;WI(Z?/(UY>=6+Y^,&_C
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M&$@9G8EM%):P&76UB3VM;6_G6+4PYB%D-SS+*IS%<P",+D =<S*-/*MFCM,
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M,%L%RV2*&,,P(FO*V0A;Z$ &M7-;QT4@%B53.&3@FW#NU] 2O>M"3K+PF9R
ML:DE)(LK.6=QS$6UL#>]*R]AAU1M'"Z!DU-KYP>W?+I6UV&'V9" 0QZ@L VH
M/8  W.E88=I9&RRL Q1N&6B7*^EM3FZ6]+Z=*V8?(.#ED!^C>23*'*ZEBSD$
M ]422P]U;0M/(^Y7"NS2*W$DR+EL&41@ K<"XL*V:;1C+J3)QE8QL\MVR-RD
M(!J1H!FL+]*W<2['0R($N%,JR67*#;*0,K68:*JV'D#0)7WG82W9GQ=I%4J%
M#<!QE9%"S9GS1L2=+QQBBK029D+9K(0T;)<CAA6!S:^QS"UZWO"KY&>&1<Y8
M?22 W7.&( )/"X9\GDNIOV]*'*][\!2T,M]8S#%&2C%&8M9V(TS$-_HAM<UJ
M4,C#-Q6C25@&-AG?B:VRD#6_OI#AE84I6?8#L+-F?ADY<J9HR <I51KS="U[
M]^@H35G8,G?-:&88AK%H&!*R96[GACH[ =;^76ASBFL]12;0*BQ$LA"-(B@!
MWL^:P6ULQ0@$-Y=J XVR-W881331@DM(X5(FOE02/$;FUT]K1A;7I27&+S9E
MV&$&((7.VK!UC$DITM8N%>[6+ $"D.GGEH*35C N(S(28VMQAI');_0EN3FY
M2.^G:M*C?6QO>.K8DJJ'.%7B@,J)<@#F!X9N-<W7H:QT,^ G>87R8ZYF,;,6
MNPO(!&I!8VRKUZ$#WUJ-#/,UO !\5E!7.68C/%DN8X;!<]P+W)(-_*G$:$;9
MO,U=A;B9VS-(MLB,&>S95?,; J"%<D-J0#I2U22R1JX338E0KY9#]$S,2MR"
M;Y[W);0LWVT>$++/01.6=N 7&9V$W&R(>$CJUAD"LX 8E=+G,;T3/@#N<1%
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MN="16IPMFM ZE;4$),%9 #$XOE%OI$%N96#,"2J^@(H;AEVA(R5C*DA9LQR
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M$ X?^B+_ 'W2L,.S(5,TK\I%\EFXEF;.YR(#=<V0#XUA@')65"(U#,,EHP"
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ME#6^KK13+,ZE)&N2 LA1DD5&Y@6/*T)/UU[VZ5H6M#I*D3H5'M@B)T5E<QE
MO/G-]')ZGN:VC4@&H:$ L@2/.=$$;S7XQR@V!+.5D6X[7K8DQ,&!R2JR0*Q
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M_B *TW<$T=&L6%F7J5-E\O9%Q>P(%:1EF=)( 634KE"G+966Y;70:"E;S$M
M62&X54%R UCY\S7!]WW5E[]QJU@JEC86MIF)4!38=<AO?2VI(I=Q  DC9;E@
M2U@;DZIGM>P[ZM\+5OB8!3E%V!=SERY1H; V%AV -;6HE@9PUBU^4.;W(OF
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MF;,74@'0H^7B2@]GZ6%:W(F :0YF,;D6<JAC:50'6.RW1[C*0%%[=ZWYL<C
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M*RHN&V=O;L_'8[8JF1G"I\^; /(YRHC&P)(UH2RT9T3HSY:NA?2&K'"5JE3
MXV62C724)/E&K%N'=O[C;R2Y[)5(8!@0RD JP((*D @@C0@T4ZY=/-:'-8;-
M;WRX?R@W^T9[U;B[L_U(QXD?TY[O[1V]\^&_W])_YM^8;179_P T.&_I*WI^
M><6^?/Q(LO3*>M"J5>K:5KG(_*/Y4_YGV-PV#^ ?"_A%*4[]?U6[NRW;6ZFI
M>^M[KN&-^3;^5M_VH3QNW!\&_P#:?_Z4?Z>=H;0P'],?]5;\_P#YK^8;#VIM
MGB_F?^IOL7Y[Q?S;PLOSJ'+GS7-LI3"OORW;:]I6^B/ES_55TCPO1_\ 2OJ/
MA,Y1ZSX3O[MH2G?=^#PO?=MZ2UOV/<L/6P\OVT8] GW7ROK[SI6&,[B]A8=N
M_P *PT(K?SQ*\/O"[8DF\GB1OKNON-L**Z':N].V\!L7"2R@ C#863'SP'%X
MMRP"0Q!Y78@*I) ..26NA';3VOLO8V&>,VMB*.&PJ^ZJ3C!-\E=J[Y)7;X(U
MT^(7Y8'Y(&YD\V#W>QV_WB=/$9(A/N9ND<'LP3QW!1\=OOC]TI)(,XMQ</#B
M$8<R9U()$Z]-/BSE&U/+UT#V?-T\++%8V2XTJ5HW[ZTJ65^,5)/57(Q[9_+G
M;K0,XW>^3EM_:D8=!&VV?$K9VP6:,J>(SI@=S=XPCJ]@%#,&&MQT*'B%P13<
M1^B1P47]J[)JS7[O$1AX4J@0?[?7_P"_6O\ PMW_ (R&L^$=GU_R#7_5*?["
M_P"_/^909@ORZF!DFR[0^3%B\+A\C$2X+QBAQ\W$N,J\"?PQV:@0B]VXEQ;H
M;Z9\([/K"4_T2=-RM5V-*,>S%*3]SP\?$??<O\M3\F?;<T6%WNW-\5=QI96(
M?'MLG86\FQ<.G$RJ9L1LG;J[;+&,AB(]GN!9A<V&92Q$'K<LVSOT0W0_$-0Q
M^'QN&D^.["I!=[C/?]T'X7V%^#WRHOD_>/:+_4F\5MT][<:\+3ML"+&2;*WJ
MAAC#-)-B-TMNP[,WE@@C"&\C841V!YK42,XR]%YG5=@=,^BW2=+](\;0KU+7
MW+[M1+FZ4U&HEV[MA_//\7[THL^B..EM+C6WK6Q)];R\K_JK#!@_'7QQ_J*8
M3=O%?TL?TS'>#$;2@R?GK\S?,_S='@Y,^;\T;5^<<;YW:UDRY>IOIYQ_1#_H
M@?Y@N#V7B_TH_37],JM>%OA7P7J^IC2=[_!L1O[W66M:.[NZN^3W!X/X6Y+>
MW=VW"^OM7(CH/EX"ZW\*[ =2-^+GKV']* Z5Y>_Y\23UZ'Y?UU_[+1_^DO\
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M_P">?6_^?$O^J?\ ]>O_ &6FGL6_]%_O?^Q''^UV_P#?*_7^[CO_ -FA6O\
MGQ'_ *I__7K_ -EIGZ2?Z[_>_P#8C[_:[?\ OE8O_P ^_P#YZ%9_SXE_U3_^
MO7_LM,_23_7?[W_L1Q_M=O\ WRSO?^[C_P ]"M_\^)?]4_\ Z]?^RTS])/\
M7?[W_L0H=T?EH?TT[U[L;L?U-A@?Z8]X=B[!^??TX?.OF?YWVEAMG_.OFW]*
MV'^<?-_G&?)Q$SY;9EO<6;H5^CP_5?TRV3T2_4K\'_33:>%PG6_IGUG5?":\
M*/6;GZ7PW]S?WMS?AO6MO1O=#J['ZNE*KUE]V+=MW6RO]\3E\^GF+GM7T(XD
M*0+^7-\MP_(PV7X<[3_J9?U2?Z?]H;RX#@_TY_TG?FG^E[#;&GXO%_I3WI^?
M_//SM;+EAX?#O=LUE'4GU:65[G-/*1Y1/YGM#"5O@?PSX5*I&W6]5N]6H/\
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M9U&AM:[ _=6&,$%LIX2L"<JBYYF0ZDL"+ZD5NR>N@@ZYSE*L6D58VM:_$1=
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M==]T7;^ QOY03:>"Q0M'C-U<#X_X+8TP>1\1>&+=C"X39+$F>X*I<)E4<JJ
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M%*M2Q%*2HOJZ5/=JQ\ZUZ<(7WH*2SOYRBEF\[)HB=9F%[*"T0$B_2.647C+
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M_P!-7;G^Y*W^:(^&87]LA[T<?U$?%[_KF^^/_9"QW_5*L_F >6W_ *:NW?\
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MD8="?.Y[WZ^[IYUAHQWL+\I)-B+#3W5MF:F,FUPMKG4V-NW>^AK>1H^!(5@
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MBY/\7M^D+3]@EZF/*N1RC!Y3%Q(SS%KG4%OHK]"/>*2*/HRP'%=D;B#.YM_
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M.Z/R^O 7=+#8B7&X?=CY7_A;N[A\7.B)-BX=B^,^PMFQ8B:-/HUEG3#!F4:
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M=N;=K)<79%(7QR\8=ZO'OQ5WS\5]\<0\NU][=KS8R+"<0R8?8NR(K8?8F[^
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MB:UR-+D+>L,.XC-RRI[2O*[VL$4:VM;2]ZWH8=5S*'-P1FBCD%QJ&YE(&E[
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M;WFMKL$,PYGUO<VT-^NIO?2E"4DS$YSE>4ZG4 VSV#6M]E:R->!@=KH#T%@
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M+8-<!7TSR"VOI2E+DQ+CED%<V!F#N0;F,E4RBY7W@=012MY^PTXO4#&(H'8
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MCP]^7CX68+C8J+97B3LS>[PVVXF%N7Q6&VOL+$[<V-AI(Q828=M[]V]FL]R
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MT/!Q@WRO>&"48> *26)%@W]6NQ-@3;0^E2_3_P#Z*?[;_DRG_H<_^EG^U/\
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M/U_96&C0)M?^VNT_\88W_IYEK\V>VOGC%_A-7_#D7J/HKN-FOR)?^M5;P?\
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M]>]88:@_RL_CEXM^">[_ ()8GPIW\VYN-B-X=L[\P;:EV'+!$VT8=G8+=B3
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M.)4MR@9I#9KKH&U'M,0P1?0Z&L,U D^$$@?*G(<X8]0&6W1$ME8B]M-:-%9
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MZV).T4*QEB&222YS_1J0R$BS)<\H []ZPT8WCCS611*H^D+A-71>;*0- 2A
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M8D,G1G:79464]@#YU*=/YRC'"16C=1^[J_RE/_0YTXNIM>J_34<*EW-XAO\
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M$J+Y@=L$3$;KE)9B;(' (9= 3KDL+^5*ZSL%6*B/]$.PB'Y2W@>!U;P*5C8
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M'+WY;BW6M6[3#[YG",US(,KYF/*6DS=09.WVTLT=_F:1LS6Y5SL6)%XPRW1
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M^6XN&?1F&8W-^Y/0!?UUM&C,DH;,KV(RAKCIU[CM;[*UPS,N"!,?HRK(Q#V
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M120-;'W5S'(]7)K@=1@VXJQH;K,Q8R,Q!1 O*G:P)4UEKFGGF#42'/A\M^*
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M'H"JZ@!=>E_C6E%FDS,)QPULI)!/(AY]3U MT\ZS=9M.YGC=,R@.&8.A_A+
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M-A4F>V49;!\H_@&*=O[TDUEA&Z[ #$[.8,& 0-=[@MF+:<HD%M23T%;5T)L
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MRYT*7SK>X]%XNACL-:PPP\,2$+=WMF9@X"J(;ZV,=SE#=*PPZR+(8U4%CER
ME+KH &R9DY[0]-=36[B=UG4J2JL C6):_P#$X!XV8WN;V2L$G&?B++IDXFG$
MO$V7S<#0CB=>NE888SAC"?89L@S*P8*JR+':7,!RJ;&L,.JQ1\Z9/II7NA=Y
M"+ 7>VG32L,,)AX<(D18V"-<JERV4F]M==/MHBT,.&CCED,?#9"%4G.CO$$/
MLLMN7/F-888I82&LIS+G>\Q%C[7LD=B!]E888^%]"Z@.N=\J,+6+(=2/0FL,
M'B\$8T3>W:'#D#)_2[B@$_B$[1V.7^N2;N#V'[6V*^+7?^)DELKY0_4?BC__
MTKUNTO[88S_"9?0>V>I[TH85/3?> _Q>WZ!WK+B#L/Q^TUAM'/6L,U.:PVC(
M#?\ %KTD3H<^6M_+I2D;61V'W?CM6"CM6&D?5HP^K##ZMFSFM\##[[J2;X6X
MG(T/[KULQ'-^GZ_Q>L-\3GL/M-9IF:.#^/=Y^=:XFSD,?*_NZ_96S1W]1Y5H
MT5N/RW7_ %M_P6_Z#;:__;SXFFF)])=QY'_1&?/VSOP.7\(R"GY/G;NP]V?E
MC>!^W-Y-L[*W?V)L_;NW9,?MC;>T,'LK96!CDW-WD@CDQFT,?-A\)ADDGE5
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MCIF#\H/0?'Q4L/M; 7=K*=:%.3OIYM1QE?LM="X_VH?P _Z[GX._]I,W*_\
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MYHW^JKHO_5+ ?[HI?YYU_P!J%\ O^NX>#]O+^J7N7_XFJ5O1YHU^JKHO_5+
M?[HI?YYGP?CQX';1QF$P&S_&;PHQ^/Q^)AP6!P&#\1-S\5C,9B\5*D.&PF$P
MT.V))L1B<1-(J1QHK,[D  D@5MSCI=>\73Z3='*U2-*EM# RJR:2BJ])MMNR
M22G=MO))9MCK 7!]+Z'](]=*PF@CWGW<V-OANYM_=+>+!1;2W?WHV)M/=_;F
MSY<RQX[96V<#-L_:.#=D*NJ8G"8AU)!!%]->F-75GHQKC<)A]H82K@<7%3PM
M:G*$XOC&:<9+VIM%*GY3WR>M[/DR^+^\WACO-!B9,)@\3)C]T=ORPY,/O5NC
MBYI?S-MS#.JB%I9(4,6*C0D8?&12Q'5+F,J0=.6ZSYZ=,NBN.Z'[>K;'QB;I
MQ>]2FUE4I-O<FN%[922]&:E'@(/PH\6O$'P1WWV3XB>&>\>,W9WIV.SK#C,-
MDEP^,P<V7YWLO:N!G63![4V3C50"7#SH\;%5:P=59=1DXN\=2,V)MS:G1W:-
M/:NQZLJ.-IZ-9IIZQE%Y2B^,6FN.J36_;P)_++>&F\&#PFROE ;H;3W V\JI
M'B-Z=SL)BMY-S<6UT$F*EV1Q9MZMB7S$B&)=JZ*3Q02$IW'$Q?IY,]/]&OT0
M.R,53C0Z4T)X7%<:E).I2?;NW=2'<NLT]+@;"-UOEN?)'WRABGV+\H;PN@29
M%>*'>7>;![E8QLQC54^8;Y?F''+.S2 ",QB0ZZ:&Q55IO1HZG@O*-T%VA%2P
M^U<$K\*E147^]J[COV6OV9.SB_[4'X"?]=O\(>G_ %TG<S_Q-4O?AS7O)7]5
M71?^J6 _W12_SSC_ &H+P$Z?U;O"'K?_ *V5N8=.MC_9K2YK6_#FO>;72GHQ
M_5' ?[HI?YYT;Y07@+8?[F_PAZW(_JE;F=#K_P >NU9OPYKWFOU4]&+_ #C@
M/]T4O\\Z_P"U!> AO?QM\(>AZ>).YEOJ_P#8:U&M;WX<U[S/U4]&/ZI8#_=%
M+_/.A^4%X"6/^YN\(]>P\2=S?_$U6;\>:,_53T8_JC@/]T4O\\%[/\<?!/:^
M/P6RME>,'A;M+:FT\;AL!LW9VS_$#=+&;0Q^/QDZ8;!8' X3#;7DQ&+QF+Q$
MJI'%&K/([!5!) .;T>:"4NDG1VO5C0H8_!3K3DHQC&O2<I2;LDDI7;;R26;;
MLASVMJ?,^M[]Z63'$T7_ );:W]*_R>3K<[>\12;C_L'[H=*:8K1'FS]$9\BV
M5]+7_P &D:4/D_Z^/'@G_P!"YX;_ /;Y;&IK#TUWH\[=%OV3;._#\/\ PL"[
MVUN@.HN3[CT]U2I]&F83;L;Z:=_??I6&TCJ;ZV&E]?3]=M:V).IM87R"QZZZ
MV\^XO6C9U(Z:BQ-K#NHZ?=6Q)\; =V!O8 #H#8>H^VL-F$D  &^;I=C?H;V'
M:]8LS#1U^6M_N9^3[U_M]XB>5O[7[H_&FF+TC[3S;^B*^1[*^EK_ .#2--_R
M8_\ =D_D]_\ 0X>$_P#V_NP*:4_C(]Z\3S_T,_9ALK^N6%_AX%T\YKBP%ET)
M&EQ[(-^G:I?(^B)\0.@]K-WUMZ7Z&LN8=5.A! /-H#;FMJU[:^S29&,ZWL2+
MDV)L;'W]=2:2:.3H,PMTT!!T:WM:'4:UB-&,BXRG2W,/[ZVAM6S1URJ0+:WM
M:PU&NM^YO:M^!HQW4-;0J;@M8@CK8:Z#2DVN8<902<IL=1KY7*_JK>2,WG8P
ML6!"A0=&N;6NN53IW.M8DC=SL!?,+:L6.;N RBP';0WK3R,,=EO:PM:P!L2
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MJ<#CAIF CRA04C4E;!AS-E"'V2"=3>QK<S4,KW,F2R%S'DE9\J1D@I(JFQ+
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MK#!0[J[I;T;\[?V;NKN9N]MG>K>3;$XPVR]A; V=BMJ[5QTQ!8IAL%@HIIY
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MN6%_AX%U :$@WT4C2UBHT)L=.O>I<^B)P.7KIIIFUUM>Y/0UHPQ _6:][W!
ML5&8\P&E]>E;[$8?+<MUL+Z>8/FWIVI#U$GQ&MP20,P&;LUP3\!>L,9R2+J
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M5?*U889E+7 &9FS!KKRC*+Y1E86N+UAG:"XI6"@G*%NR$'(['3-;M:D3OO!
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MX&9UOQ,BY@ /XS,__8OW)%&8921,W*V4 E#KU%HP.]S6&GR1\KE!(7(S?2,
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MY)6D:P,@$@#65?J@7I:T%<CJ!$Q!4%'*2AF-PI"( I4=G('VUAIG8*TB))"
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M^?%X['\*ME^)H\6AN"N*7:>]>+W8&QAN+_3IPN#\UV%MKY]^<OZ<FS9N%PN
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M6_A%</8D7L2"I4Z:X(G<!Y/.@^S9*>$V7@U-:.=-5&NU.IOM/M3N2:PF$PF
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M."_*'49[:>T1U^MV!M:E6-'7/;*&!#9A($!]GEL2<O\ &N+7\JRQC1]SZC1
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M-ESWZ#-;0&MF D:,ZJ3D"B]P4D#6Z9S[2+6&'?(TKL$7,D@+Y7;,%:RMF)Z
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M3E)][;8L9HT&:$C,DO*!)<2,SJ=018%'RW\[K0X:CRIH< <X 1F81 RS(<I
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M&XZ*20.P%:,M[SLZVO<GZ0DBPN6 (TR]"!?K66S-<3$Z]5(4 "V1<Q=BIT
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M5#4XD4-')F 6-FC#K*270CG&4CZIS6M6D*GH8BDAT.0*&9T5E^C53K:_?/\
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M6L]1-T=!H!^K45HPZ,/7H3\+ZUAESJP!%P-&UT%B.WJ*PPX[6&GKU-88=#U
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MXPQ%60JR@$M[0(N5RMSVR]+,3ITOTTI1HYM;-EOF! +FRJ"6S7;I=1>WQK/
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M5L_(&&IDS:!O*L,.X<E>1XSJ!>UT#>07ZQM^WM6S#J0S,R@V90&8*;^EL_\
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MZS&[9G1I4*FRMESO]&VBDY3JATL;TKJY+/(1UD3%GS#*J\\@O8C-E5>IN+Z
M ^ZD6S,WT<F0<0N2"$7,@^D.=@A(:QT.M.-U:B'-M6R V<WS$6$1^D:^3@E?
MHT!'DQ/QI0@^=@5*9B,U[N?:_P"B_(??6& =;.;%F=2EC9/:7AG(_P!)=@ 8
MB=*PP[B35019$TS?WIT-NM[]*PP#O)+&^0-E5]83P_X,)T^ZL,.ID9;@DD1%
M182=;*5[CO6&'5I&1@2&RE;Q_1VXH_X7EUXMO.L,/HGXD>8+'R(T<B7?3Z;_
M $+B:7/:L,,+LX&5VR7^C8<,:VZ?<:PPX9AFC4L/9.3.9?\ 0[?&L,,<K-$J
M@!$1PAT?KGT-JPPQO(R,K9FMF"@1_P & PMKT%]*5$PZC$F*.5;<,A]%R<0R
M1R=1Q=.HK>ZC /F17CUSWC#LPN0&B/*/I"5N+ULT=Y&D4LP(#.2#P_90?QK?
M\-/>L,,3,_-*;.Y18W3)F$@-AQ0O^@V\ZPPQEIO:#V8(03GS64&UN'KEZ>U6
M&'09F.5EX9DD8*;YN)K8-F/6_#O?O6&&-<N>573*YD(=S)Q+<06&G0 VZ5AA
MAXT65Q$0QTN)(\ZRDZ',_P!0)V]*PPZ3/(%0$A+A5+ RE\JLRW!Z#B&L,,&;
M*$!)60+QAE!098OHQG/4M8:UAAA;$9F5%,+$LIMFD=PQ&K*!T'>L,.6<.BHT
MC%XXP6F+D'VVNLD1U9?XM88<-*2ZY6D8:<-V;*U_K73ZIOV[5AAQ*ZEN'(KM
M$67Z2][EN_VBL,'G\ ,O].FTKNYD7=C'A@QY2OYXV,%8#S"J!\:98_XE>M^)
MDML;Y5+Z-^,3_]>]1M,_V2QP_P"69?\ *-+X$?4OUCY7 58(.:T;1W7K6FA3
MS1WO6TLA%CB];L;L=JT:.U8+N<@5HT=A_-^/Q^W:Y&'8,#^/QI6,RWO_ #_/
M\\NXK1B/CZ?B];-]A]^/OK#1P.MK_N_GK#:.U88?5AA]6C9\#6S#GK[ZPP^K
M9A\/7\?JK7:8<_HL._X!K-3&?>[K^.E;,.]Q:UP;"WQK1M'VAM[M/A^RL,T.
MUM?Q;\7K1HX!M;30>?ZNW6MV]XHYO>QT M<WK#.)P1VN?CTMZ?CM67,>1R.V
MOIZ>>OPK##MT[UAC.!>YU\NU:9AV_5K]M;3-G8=O36MFF?=NUS]W[;UAG$^!
MZ^[0?CTK#+'-K $>6OD?=ZBLN;[#FX"Z:'UOU'7TK1A\#^BQ[=!6&F<+H+_:
M+?CSK#.)VN=?T?"L-'';]_EI]E89Q/N@TL1[^GNK1F?$YTL=0!Z>=CUK9LXN
M+=+_ '5EC-#GOU Z^NO3]-8:/LWK;K[CWU]YK#+' !([=[@BW3I[ZPWW' N"
M3:WIZV[ULPYUMZ_?6C61S\:PT?5HPXZ_I]UO332MFSXD=]/W5AHX)UM<?NK#
M:2. ;]=?(#[;V^%;-O(XUZBVFO7J!I>W8&M"3XVZ=!;IUN>VHZUOM,/CV-NU
M_B;?9TK3T-'3L1<VM\-:T8<^6OW^>O2L%'%S8^7>L-'U;3,.+VUO8@^_0_OK
M>IA]>M&CZMFFSC\?96V:U/KW[VOW/ZZTS#@]/+3\ >588?>6OX_ K##X]/Q]
MM88=3;W7![_9>MF/0X!Z #H.M^E_TWK&).;=#];I<_NK7@8="+#W7[:D_LK:
M-'!!\K4K4V<??6F8SH;Z#737K:U]*Q"4CGSZ7MJ>MCY6/I6&VSH=;@#H.X_1
M6&D=#U/3OIZ]ZV;.AUN/0Z^ENEJ2:[S@'33O?WFP0]*PT8["QY>I%C?4#R'G
M^NL,.MQI<'K;W#S^%;-G%C\?,Z7\_C6"7D<-8 ==-=!U]_E:M&(Z^GV7\_\
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MFM3#JHOS,KJ'9PBYCD+CHZKH0J7UOIK6C#O&T@!"$2JC<25 Y#)8V*6ZFYU
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MN>UA:["_UM>]ZQ&'#6O8WTO;MKZ]K:UC,.A&7*"!=B20&TL-!8'0 BL-:G#
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M*P(.OK6S6ZP$T!8W50TBH3EU.7U(;0:^5:TT,LPM;"1O*&=4-CDZZ9AH??\
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M8)CO<#.!89C8V.4]^]_Q\-NWM-),R-&)4S:%%:P8K:^87MTUZ>58FXFVKKM
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M!J>O>A2Q&X[3:"=5%H$3['979I),P4HJDE;&-@I)TUS7BU)I/PQ<+-F^I6O
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MEK&MF&*0.(S=V1LSVXI&L:I(,HRGKIU%:NC#H2&#,[MDB#MEBU4*S7CT.I<
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MU&T\SO<R6("KFMRVT2P!U']_2.(I&=&4LRJSLV>RH>1(RO(QMW#<,UO7(6"
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M<2%I+>T&":9W8BQ/U:CL2ZF(J_!J/H<1Y2IQA3ZVIZ7 )9',\C3R@\1F?CR
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M0#ZV3O;O1-WM8+??8=&#6#+99!]'YQC-JI)DOT'E6MU\S?6=@'SOF*RQAHY
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MB-B\A$8*B^E[**PV/-X (R;Z;2#.9+;L8\9U($9MM?8OU,N<,!TN>GW,L?\
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MO-$IR,,H&K,#9@386MV\ZQ&6.RD!V  /.JAK6-NFMK:VK:$O4^,9&>,@Y@
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M.I^%8:/K.; :C);4V7VKG7WULU?W&.X9B0MF.FK9@/<Q\ZQ&'UR.6UC<YES
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ML& 8D:?=324''N%7OD':L,L:QLC@Y5XATM=.VEB:3J:X@S,H50!?*P6XL="
M&8^G*:RP5/(R*RDA;F0 $$%;!5'>_70UEFD+U[@7$Y(("DQID:0@9KANRDZE
M /6AM!(@P)F!"WMIU)!UMK]M)%@B-5[IE*J"HS9<Q0W8:>9ZUAFN1RJQ,6(9
M3HS&/F#*K"Q"FW4?96MY&]V7(Y$"9 IS9P4RD]5RB_,?(UBDN&IIQ=L]#!/A
MH^$0EUXC<1^P9!U! T(OJ*5>P/=CR"S$;/+  *#'8L"R@W-K9?B-!2XRL!G"
M^:$[CMD@*'C71760%;YB&6S*#?6S Z4:,VW9B+<Q.XB!U0O(QC4L01JI!&@T
M70EK4?=B::5@&V&52078O;D4I;-[M+4NPFR"R?"*"0R9I#S@(+@/V%O6MW8E
MP7M":?9["QT(3,$+ER0QN3E (%P+Z5D$Q&ZP.&:/VT=^3-<&V4K[*F/IS :T
M3>:YFM#DXLEFM($<,.46(UMI[CWK5S:DS)%-&S%N;-?.X&B\O6P':_:D2C[A
M6^^&@.P^):2Y#!N&'864*A0=% T&< FWE>A[D16]$%03N&1U=&879[RB,$#F
ML%<$D92.G6A.G+5(6I+V!NDBOE"N1F^DNBGVC]47UT/K0S9FB=ENA(9LFI-M
M"^KB][G(/LI21@)A'+PLX55^CS,"5CB-B,PZ,"36/6YAF"R!XRJ%W5LC'-<"
M/SOTK1AD,2O8R2 @\Q=A[.7ZH74VN*R_(PY"G, W-F>S$GAHB/9A'E&A#J0W
M3O6C#HT"QEEC7Z*/4 RQW)TN>FMZPPZN)!'8!V.61<F<@WM</GO_ *&.U88=
MAA@UBS M(4&<EKAG57&G<R7O_>WM2E*PC<.Q@4Y64GIE,A%U=8^ZC7)F;2_>
MB=;EH:W+\3 ^!4$,.&0P#,I-\KJ,KY>UPW6U;A4N[,U*'% *?"9@LEN4$J6.
MJCL=.IN/MHT7GV ]U@8X,$N08V*C.PS:A -"I[BW;M2KHQJP#3",2<C*X:]U
M=5:ZD9$%@,V8%??2EIV"0*8'4NR#6S74H38!K6UN1:U*-F7(UB> '#QKE)C)
MN2.;J>U:L9=F,QDK]%&3<A!:ZD21GZ0G7,5)Z5LPS+&7S9@>(KARQ.C64"^3
MWUAHZ\%6*(7,;.SHX6_LEB1<&P ^ZU88=Y8"$89"8LZ*3D5+Y;:::VL.E888
MQA6NYL.'?,JKU2V@L?: (%88?")Y X'.+JMV)T;OU]H^M88=HXGN#PU?+&49
MQ=;L9"+V%K'+I6&&<X;V5CNEV)DRL;$(+!>QMRUAAV6$."]\H&=64B]U ]FQ
MY2#:]JU=&&()<D7X9* *,EW=<H!!4"P&GV6K9ASPF)8+&SH!& K$(+Y%9RUA
M9KEOLI#U-F48<%9 [+D"AK(CN;GF #7%\H-O2U:,.F1T0$ E0 +L"%%Q<*%:
M[$F_7M6&&-HHU7+&HS%3)EL\@0#JP:]FL1TK##-D+Q LJYPRNS92&DLH*M9E
MT%K&UZ2Y).QAT:)G'*RR/( Q4\EQ]6[J2'RV\ZUUD.9NS>B!6'P<B*V<B-BG
M($)D):]U2UKZ-KUL*0ZT5)+7(4HNPKWPTV"P>'X:'CRP",76S+QO;:VI#7Z'
MK3&,^OKN$OBUQ'$UU=))>D%D.RF:9 (SESH!GU8FX!)&MWS ZT[J325KZ)C>
M,5O*^;R#;'[%:3'"64724 LZ*2P:-0%5TM<F_<^=-:5>*HJ^HXJTMZL]W3(-
ML%L(PI\[F1I@EE^;6R%PU^$!:ZY03>W:F=>O&IYM\QQ2HN&=CL-BO%&9\0R)
M+*&(@<YYLP)-@W50([#MTK7PAQ24/1X]YOJ7G4FU^,SX+9W!1\0D4V(F9"DD
M^(+F-(ST" @JH3-YCW>;?$8GK$HY*"\0U&E=7C=L0F^7BIX6>&F&GEWSWYW;
MV#G0BV*VG@EE<HIE&'@B#/)+.7%L@7-S===&4I5''>C%[FEV\A]'"J6:R9!C
M?'\I9X,[)VCB<%NUL_;^\,D#%5D39N+V?@FG2//Q6VA/!PX\/GTNN8^2^:)5
M:>5ZD;\E^/M#1PL8Y\2&.^7RPOE=>-*8B7PPQ.PO#?=UY,4CG9FPMI[T[:DA
M0,V"Q4>T]I2['PYF:139$B*7O>^EH^OM##T5>47*/>.:4(WOR&MQGR4O%#Q=
MV=LK:7C%\H7QGVUMA,+&9]F[/P,V[6QH=HRN9FQW"PTBQ220M(R'-G17%,WM
M"O4CO4DHQOD%<K2R0K=W/R:7R=H]F8I]XMYMZMZ,;,QGDV9OIO+O%-BL3PQ>
M149%GP2'$27YDCN!WH=1XJNTYU+.W>-KSE4WFO-63LD/SN+\@_Y%.'6'&;3^
M3)L#:>*PN)*00OC<5M?"L7P^1)-H8?&9</,LQC)7-%R-J.M"HX.M*[J5G8U*
M%&^_:=^T>K8GR9/DO[L8V>/8_P FC<C9&QT>4S8C#;J[*Q#X='YKH(\(\TRP
MMT!OZ4BMLW?>]3J-M99R:%0JT6[2B[(=_=/PR^2SLK$3;0P7AONO@,4,+(\F
M+/A]\SC*!43B-*-FJC-D2S'-T]*W'9=HJ\DY2X;[_+XAXU*&?5+O'4W/W1^3
MQA))GV!L7PV68_28W#P[.V=)C")\SJV)A&7$P(XN%%M+=*6]D36<MY1[S75P
MJ/*$6^Y&7>SP\^3IMK#B+>KPSW.V^D\S38?"[9W>V7-$\;QF IA9,9AE18W1
MK J>FA/GBP4).TI25NU@ZF#IVWI0SYH8K:_R?/D3/"%QO@+X;;'^:RB/"XF"
M'8^ROS=.C+EG,6%GBB,4:O:P6QOTIM4V9A'+[).>6F9D:<4_-37M(T^)'R7_
M )(N-Q6'39_@WN#B-H3Q[0PL.T-G['P>+@Q."<(\J\;9RX=)L3$Q# EPP#6)
M/9O4A&A%JC5FO:V@G54G-36;7 TZ>/?Y.7<C>7>G%XWPVWIQ.YP=,)*^R,/A
MVV7@<+A'E>V('SS%286$Q3X8'+&<S(&J.I;9VE0J-2A"I36EUG["4IX"E7CO
M*4XOLM8B'O7^35^5CL/'8N?<GQT\*]O;*X"<1UV_B=E[:EF@>S83Y@N'E$@;
M/=G66QM5@H](L,H+KJ5>,WRT&4]BXB5275S@XKF,1MK<_P"7C\GO:R[)P.*V
M]MEL/@DVL#N-MO&8[#XF"3%B%9IXI)^+&,.T1!( OGOY5*8;:N$?G4Y5(]DN
M/_ 1>)P,J%6U56:2NUI]0YNY7R^_RDOASM+\X0X7Q1GBPL3Q_-Y=F;=VIA<-
M'"<T Q3?,<0D<1+Y<S, ;@#H;3%':U%54W*D^QV0VJTY*&;E&'"Q+S<W\O!\
MIS=Z79^"\4-A3X+;\>(A&+P.\6!PVS9)$:QC8X=N#(J91U"@D&Y-Z=/'X6IY
MRHQ:OFXRS_/N&BE-9.=WPNC9?X0_T0%X4[>1-E^*>YN.V'C.*C':FRI5DPYP
M*)$7Q$<1EXDW #H)+&X8^M-ZCH73P^_&+U6MO:QU"HH14:\=Z7-,V1^''Y4/
MY''B5)A]G;-\2<'L;$SHLRS;PI^:X+R6$:AY[QJK.;7:](<:C6]3E"7-+5!/
ML4HVMNMZ<;_D)P[(WUW9WAP$&,W>VQL/;.%Q(#IC=E;0P>)C,;)=71XY6XA(
M<:V%KT/KX0>[*,K]V0/J*RM&"B_:*3#;+DQ AGQ1>*.V1'OQ>(AU'$5P0F8]
M"*+UT9JT'9]QM8>HKRFG;ON@/C,"89^#LZ*,*&5I&%PRV-[#H"#YC7M1:>4?
MLSOED D\[4TD^X!8O 2S.!B\.DBOF*OF(2%;@YUR=7!-A[S1HO=C>+6N@&?G
MSM-.]@O;8=L9&WS+BM*%CB,3$I& ",TH.G0YC[J<JK-P:4O.MD"ZJ+FM;BK&
M%PNS\&,%A8)LX!=Y J!I)T.8NMQ9E$A4!3H1>FT76;WKW?%=G<24I4L.NKH>
MDUF^*]HG,-NQ%AVDQ;MQY3.7EEEFSR3S-](TF(9KLL:%[6_O0*=SQ-1Q46O,
MTL1L,-&,G4OF\\SL=D8B;$R8Z221_FT?#P98*5#N&)Q>0 'IR1CL"32I55%*
MG3CVMBXJ4Y.I.UDLA+8S XO%3WDB?AJC&%!?ESY<\I:VI8IT]:DZ,8J%UZ1&
MUJLZM1REP,:;"E<L0<U\K!2A6U^46 L;BBY@KL,L'L=N9)$R*&%Y C9RX!6U
MS<D,2-.]AY4"<+!Z;D\C-+LDR1J;LLB-:P2P"1G,6L.OKYUE/S9=@J2<EV@5
M=G-SC0*5S9&'-V.96Z@%@-*-O)Y ]RVNA]-LX-E:R*Y$94J"2+-HN@&NM::O
ME8W:*XF-MFZA2)#E:2[<P)#=5).F4 ]Z2Z?+4WUL4!UV8UY%BCDO&"Q8JUG7
MLH<WCL#J/7X5KJY&NN@9SL_$N7!PSL'T-U5VO<!",@##KU%:5.;X7,=:G'-O
M(Y39&+6X& R"][Y69K#E)!8FP7->WI2NIF\MWZQ#Q-'F_<9/S)C,ZJN&>PU3
M,;YM/;MT  [5OJ)\D:^%4N;9W_,&T#=1"F4K<W+9KBY(5;9;:4KJ)]B,^%0Y
M/W&9M@;1<BT=DS2*5ZY0V4,2--+$UG4R^^1KX5'@FV??TK8Z\G"7Z-;!"RG.
M0>I!ZV';I6^JE]\C?PEO2$KG9=T]HNQ5D0KI<$$%Y!<KS#4H -.NM9U5OND9
MUM5Z0=S+_2AM$@DEDC;EE1%.H_TVAZVMK6;B3SFC-^O^UOW@A-R,:!<&VF5;
M@]>Y-M=1H?.LM3OZ2_/V&;V(?]#=^\[Q;D8EN.6<:E2 H>^EQRWT&MJW>BL[
MBDL7+)4[>T$)N$P+6<JX*,#;K?K>^FO>M.="VN1OJ<8^"]YG_I"RB0B4J6%F
M4G*2.ME"Z7-_MK768?7SC?P;&<T9AN#'H7;.& -B-<W8,>M:Z_#O2]S/@N,Y
MF1MP('(!!46ULY'O]^GVUG7X<W\$QGW_ -1D.X.'(1F-Q'HJ FX'2^G2M?"*
M%\KF_@6+MZ:]P*AW&P$-PJ*6<$!KL>8Z7(MK6OA-/7=^LW^E]=Y=9]0(7<C9
MXU,:D =>X:W8]A>M?#:7",;F_P!*:OW\_<C-'N7@!FS11L"N4J3<%NUP=";U
MJ6-A:VZD+CLB;XSL"(]T-F*0S8>/.+$6R@*;Z #RN3[[TEXV/!1-_I1#BY>]
M_E,G]*NS2+-!%:^HLI%_=D O6?#N5OJ-_I73[;>TS#=G9W)]$I56U&5;_HN-
M16?#JG)7[A<=D4GP=N\S?F# 9K\"/TNB7%S<VTTU^^D?#Y6L9'95#[UOVF0;
M"P0:XC T(TR#KUZ#H:SX=4TN@GZ64OO#L-C8,7M&!?K90+^^D_#YBOTKI?>^
M!E39&# R\);>J@WK;Q=76YN. H6LXKW'?\V87ZJ@=M4'3XZT/X9+F+^ 8?[V
M/N.R[/PM[B/_ +'%_P!)O2?A4N?B*^!4>2.3L_"]2HN.]AIKVZV%Z5\*J:)J
MQKX'1Y&,;+PO+>-3IK<"WW]16?#JG"YGP&AR7N.PV;@E&7@PDWT%KVOWK7PN
M;^Z:]K%_ :/*/N1V& PH7+PE'N30>[3H*2\74N9\#P_WN9E&"PX%N&+::>[X
M5G7U=?QL7U%)961WX$6@*WMZ"VF@OI:X H?7R%*E!:'/"C!NH&8DWL;'74]O
M.M==*UN!OJH\SGAIURZ]:SKI&=5'F9 B@ !5 ]PI6\WF;W4CZP'0"AN=F;W4
M?6'D*1O/F9NKDCG6E;TN1L^L.P%_=WHB;MF:LKWXG4J#UZ]^EK^E9OI<<Q/5
MQ>=S \*.3>VO6Y.OPZ4J%9IV0F5*-CM@L.D,[LJVO&5N/9]I#HO4:BE5JF]3
M2[?RB\%3C&NY+7=_&C__UKS.UC_97:%^OSJ?[,YHG C:C^R/E< BL6HD[J?Q
MZ?NI3--&04DVCM6[I&'8>8T]/=U'OK,FC+&6DFSD5EC#D_=^/CUK1BY'8=OQ
M^JL3%>)V'I^/Q^VMFCM6&CZM&'WF?T5LV?=/7T_;6&7]QR.VO7L>WI]E:-G;
MX5M6,/KZG[_U5M_G^?Y_DP[#V1;[.OXO237$YU/;3O\ S^GX]%&\CYK 6[^>
MEO=YUB,..V@]]_QI:L,.;6!^_K]WK^/.L-G([G3U)U(\JQF':XN.E[:>GGW[
MUHU<[>ZWX[5LVCX&PZ >FGV?;6C&?:Z 6)TU/GUMY:ULRYVOJ3U]_:M&7..W
MEW/[O*L-G-KV_4+^^L-G8>8MI?WGWUF7M$YLY!.FFNI_7^NL9AVOW[>_L.MJ
MPPY\CV/0VK+YBCD'2XZZ_"LN9HCD=^YMI^/.L--YWX'*ZG4#X_BUJU<T<DDG
MT&ENY'GVTK#+G4'T'6_[A6S+V/NK=M=>MP//XUAF9VOW!77I>_;]]:,.+:Z
M6 N>I!'[ZW?@8=KZ@@=;?S?"L,MQ/F[=.O?W]3Z?MK-39QH;:$>X?>?05FAE
MSXZKY'N.E9Q[#+W..X%[=M.@[CWW%88SZW2PL1^+W_56"3ZVHN0>M]/C\;UA
MM9G8A?L';TTZ5B9LZ]!?J+]/QWI)K4^-@.IZ@VO6&D<&YMI;R[UO4VD? @=
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M %CZ>7Q\ZV:.21J;: 7['4=JT8= ,U]02?3XV%^@U^-88<LNEB 2#VT.OEV
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M??\ ]C:5AAT+6T L]_I";A1?V0#TK#+F.YM9.K<S$GN#T4:<N@K9G$QFUFU
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M;#222G.7*+'V&C4K22:O<US;W?+8WAV!B]X-V]G[P;J8S";OND>T-Z8]O;S
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MZ'RK+FS[]%9X&CF_P/\ -^JM]AFIS<@#7[_TBM&[G8::^ZY(S5MF:'86-[:
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MO*;8_MMM#_#)_P#+-$CH1E7XR7> AY=[:BM@_ [CUK1M9&5>W3R^-8;XG?\
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M9 3'<O&>K%F'4W^RL-&8%(U4W&:0DK?0<.PM=?(^ZMFCJY6Q8Z J2 MK\0]
M ;Z-<UK,PYSG,V8D746#!2Q(', +7 73[:RQAT=@2K6OV('4@]2.]*,.(S?+
MSHMFN2<QRW'*H[ FL,,<C,S6(RD%A9B%N&T!  4]JV:,_%$:1(3F#9>1;)Z'
M46S==?.L,,<;775++]7H+9N@)O<G3TK# ,[%BUP&,?07%P;]1;46[UAAAFDN
M 2>@X;J@S$WYLR9KK90I'O-;O<PPJPDMI_>DG0A4Y@#TL3?MI:E+02SY,F9F
M<C,?9U;*0= !VS&WV"MFEVG1(S[+74/F(93](O3FOJH3S[UIBE?4ZQ@HH7.2
MUI25L "OU6N-!TZ]Z1/)7XFT9 Z*F=P;*6(=C;0A!F('LV/3[:0NTV9$E8*%
M0 I9G)M?B7]D7/;]%)E&^FI@*#L 9&<BV4E?XA9=!IU73K0VFM39E24(ES=F
MS @D<FOUG !8VI$A29F;.2"LBA?;!RKPY&&K!.I]GK>DBSF$-/>7(25756T+
M9\Q+*3H";#WUEC5SYHARJ<KNZ<L9T;KJ"_07^^L,.DYB,3Y L-W7(H4+(&/L
MQJHM=,Z=?C2HZFGH!V7)=FRBX%\S$!70>ROUFN#\*+%V=Q!]''<<G#1F;BG3
M,<HT-EL.@^^B*28DY?AW8A6;V<N6R'E:^8^6FEK]*6:N=R5R6"'E%P2QR@'1
MQ&-2QL=;UEC#E71 %49F&BLYS*"==<P*]*V:S.8FM[9O<.;BY4$:W)N +>G2
MM<3'V O-Q%<:,P6P>^59%/4#H4""6^EKVK#1EB5PTAE.4C*BD-=K=[%M 3;K
M6S0)1L[*5:R#.#D0ZFW5F8V[5AKB&.$G=&XA(*H22C#,25LH0+T(U!M:VE#J
MI6RU"QR[A1X:3B N0T;%22O#MHPTL= -/LIJ\G8+?(/,&P96O[9O_IC8Z,;:
M$BDO)7-AQAD# M(U@4('*-=;=+:FD=9EH@B]%@V*%7#(NK,&(E(Z*+7"]AI6
M;UUHC:T3,L<&8WL<BZ$?6<D=;WOK>DBMY^TRB$A24"6(.KJO1>NI'+E(^-8:
MS9V&%5BP$8 "WN2;DD:@'J0WEWK=A6[(PF(F1F*#5(PIMG(-K'4@D C[:RPK
M<[3&</\ 487)(S=LRZ$CTY-/=6-V5Q3/AA04.>,7LP-CS+;I;WV]U;A)-"-S
MDSH,+<J )!<IFN!H;^[0UO>?8:<'S,3X,,3F1&4W"D+<WSYKDG30>>ENNE&S
M0,*YMF79F81,1T.0G4]".&"NAK+OF(ZN(2XG8V8,&10P-HR$7*K-TD:VF6]%
MA4MKF@4J8G9]E-"QSI)<Z#3(+@:7 &HO2[Q>@F^ZL]0KD@#,Y:,H O#RJ+J'
M'^B%6!!'>A+>7$U=,#+AV,C.H8HARFY4LQDZ%3UOZUO>E8U:!@.#@=OIFOE*
MH^N4FXR * !T/WTOK)<A.Y'F%LF D5B0S<-+:&,Q'@I[1MUL:+UD=!%C$J2(
M6SB\;'("!;+8ZV(L0".MJ4[,PR9\K!^^>T<9U6UA8Z^9UINT*NP2)5.1F41A
MLQBU]G-)9<Q)UM?2D687?B#HGNSL9.)J !<J+KY#H!669O>09PLQDS'*PN%=
M&[:D::WU\^]9<W<&+)$KE9%%LOUHW*KKU4 V^-:W0AGB>,L,MBUW5VMRHMSD
M%C[)M;UK:1@)BC5%%VNPMRGT[:^1K4C <N9F5LH!$=F4Z&0$\S-T((-:NS ;
M868%,R\N4WZJO/=O7*1>EK0T"E101;(H9V8*P)*JJCX#W4AZFS/'&F4:]0&S
MZV(.N4?"PI:T- B.-+*HYAG>6ULI!!]ENA(!^VLN8"A%(7%D Z9F"<MCJ!<C
MH+BM;QNS8818=6D&87R@H,NEK]A:VAK-XS=!BX538A2J@W"M8J.QL.Q]:0Y*
M_:+5-V.7@6S90/J^R+"XTT]UJ3OHWU4@%/"BE@;EF4@:7"'N "-&]>M)W^P4
MZ=H@(Q$B1=0F7,0Z\QL,E[G4BX-:ZSL$V.BX<CE-C?+=K!BPL+7Z@9>GPK:G
M=YZ&6!$D U0(K@.I4DAVY0"18W-OC2G)<698[+"2&0(F9VN5*#,%:[9M;BXO
M]E;3OFM#+(#RP(3DR:96Z:=M&L+"X%M:)'01+5=P%2-;JH1\R, "5%F!C!(#
M:M8DW-;;LA(.APV=B$.6R $KH+YKZ4UK3LC=O<'JQKIH.@[=2!U^ZHR;4FVM
M!U"G?30S!%T! ]+B_P!]"46\^ [C#CP,.*ECAT?D&F9R&(L>@7+J6)H5>3A3
MR](+*+2N].9'[QU\;M@>$VQ,?B-I[0FP<D> BEQ!PD8GVA <=-+AL'AL##J!
MM'&<%C&2 L*J7/:@=;N152K90T); X"==QNNTK5?*W^5IO-OI/MG"XG?"+8F
MZN#Q,K[/V7@-JRQ83&R8>(1<3;DZ3H=N;6<ZL2I5'TJ*Q&T\3G2HVO)ZK(L^
M&V;34EUBTX_RFF_?[>+?[Q,VWA]F[J;1VQ@]FDF::/#8Y]G87&X@))"-H[;Q
M<3J'P^$20\.$$AVZCI32.[!;]3SI]I)RP^ZE&GZ#>HK=QL#@'WBV1LS';2@Q
MF%BPC-M[;<K/)L/ RP1QP8.'&85LT.T\7B51["31!>P)O2H]9/C9,)4W8QLE
MG8EWOGN_O/MC![$7;6U=V?"WPE3 /@M@[^X[;TV[^\6\^V3$A7!;E>'N B$^
M\V%APH<?.GAC@0,06U%QJ@E=Y.>5N(TC.4Y[B5USX#7;;WI\(-P/"3&;L^&V
M\TFW'VEB$6;Q$VBF,PVS=H;;+89=JXF#=79;C#_.YPLK'C,SRJP4Z 5ITINH
M]Y1NN858:6_=2RMHM!%[X+O7OO!L_#>%^]&-FV/-LB+ 32-LO&02X_&X5,S8
MI=E0B(8?"DJ""+A2#F-:IQC&?V1)CFE0>]9I7OP$WL/=7??=7#8'#;W>(^[F
M&Q#)C(\1AC/M'$;8Q$T6(SABN!DE@V9(F'C* QL9,MP=#KN;A)^8K(=RI23L
MED9L=XK[9W9V7\UV=N[B]J[.DC2+:6UL+AL%@1-APV2.2?%[8Q#[:QT3L"&R
MHC:=#2:=.$D[OSDS)1W%:ZO80FUMYY]Y,7/M+=':6[&P-X(]FM%'NOMO;$FT
MMG;1B5LT./P$\L+Q#%18F>TN&D(+9AJ>RDE#*HFXWU&M57M>^0W^\6_^+W-G
MVLV\&S]U<="T4#8S9D.S9XL9$)DRNL.=L1L7%[(Q<;!W7AGAL=+&]%48SR@Y
M*0VK*75^;IVD8]_,)\GO?":.+;N%VGX4X?:V&DGP6]F[4QQ&ROGF'8,\&U-D
M1GAP3R%KF2+( HZ>3_#RQM+SHVJ17#B0V-51T=RZL]2+6^/@9A=W4BQ.P-YV
MWOV'M'"KM+9NW=W\0VTL/B<-''$9))A&WSC!8M RB1"!ET-35+&U)M1G3C%\
MB"Q&S:=-*5.;<;7O=C+Q8S$8'&89\!M_'X:(/-A3",7C)8I#"QS1XJ)C+ T9
M(U#J4^-24([R^R1BLM<B-?FRW5*37>_ 4,<6[&\$.!FQTV'PNV59DXV!9L'@
M9W;$"S8S9[ P+99A9H]&UT%A2+XFD_,NZ?YZ&I4Z<LWJ%VT]S\:5XT>S,+C-
MFH<Z[0V9E^:2+,D;B-FCLRRR7(-Z>4L2I95':3T3 2A-+S%YH7X;"X7"8Z\<
M6)V3*.>.)Y)&AE= OT0;$WBS(5Z$$:UN6]4;M9H&Y622S%0NVHXPL&T=CX2?
M"/>"7$Q/G,1(:6\D13$X29R[K]15]?)/5/5\!+FV*3:VP-U-JP1XW8>P]E/B
MWPV%Q$N#P*8G9K8Y)K1LIPT-FAQ,,D9(>$F,W[=QQQ52,[5+[B7(!+/40&,D
MW9V9B9]A;U; VKLR6,A</.N'"8PF?B/#PL7B4B&+2R6.<,>FOF\76SBJF'G'
MMS_.P'+BCAMT]E8[9\F.W=VOBL3,;RR8600P;6'U%6&!-96+#4+[5*A5DG]D
MC?M$R2?HJPC1L?;6$LK38C#B[13#:"2X/%Q./I(_H98E9%9T(8"X-^IOHY4H
MZJSO]0E0?8<+D@,4>T-H300K)('>/CR$RMPGXZ( @)0N5#+JJTXCYV5DS35L
MP7AMJSQ_.$P^V<8BE 5XA<X:;*&43YRK$M&G-D.AMK62A#6458T&N WGQ^#<
MYL;@L4(H1:5742M>,Q&:5ERE9&DC# D7!&EK4"K0ISCYJ>1F8O=F[^XZ-$$V
MU'"M#'ALKXAS&I(#";,O/</:[=JC*F!H-^C9AX5?-SU%SA/$[>?!VEDQ& QL
M6'<R1#$,K##G@LSB1Q](8.''<$:@GR)I'P"C:R;%*J[Y:CK[(\9<-B(5;:$2
M8N=.&XEBQAF=VR+'EXLMV3ALI*(/:)\Z92V?.+?5VW0OPC*S'2V?XG;&^8R0
M&*3!Q8A4C^?XN.+%1M)FSF/$X=W!A.;0!;M39X&JG=B)26KT%-LW'3X!86V?
M)LO;>(QW%QPF7$)A'P<'#99!\UQ@;"S2IF5<INYS:=#29T)-[LKY9FG*+C:Y
MVBV'%MMI]K[0V?%#BL/"R8?"RX,;/ED1Q=97^;DX7: 5R<O0@FA.5I*,7FA>
M[)IJ.B$_LW<S>3%G$8G!;>V:^'C#\**8+:-2F(>*%X)<H$QPV#5>Y)>_NW4Q
M-*/FN+O?4U&G+B?)M^+9#QKO#N[C,"D6%69MK[%PL_%Q<9<P+G2 2&22/#!9
M&)).MZW:51?8VNYAHNRMD&>SMK[&V@KS["WPCQ!'SD87"[1Q6,V?CHF*A;M'
M/P^*A6QZ^V/74<Z"S4X>XU&;O9:!SB]J;8P$CR8[ 1-A(RL12<0X[!X@!I)5
MF$F1C&SI*>36PI,<%&I%J,MUB^ME'/5AWA-]=V47#?-)'V%B,.\=Y()W&%1D
M(X\T>%!5.$E\SBUS;SIA+9^)WG>THV]H>GB8+63@3'\&_E%[Z[BO"^Y>_.)B
MED&'?$2X7'8W"Q0WBAR8B..&>)@I0D@BQ))\A:*J3VC@?BW.,=<F_<UR)6C6
MH3IV6ZY<^)MM\%?RM/BQNK-@HM]DQNU]C((<.^T,3B9]HQ8@W$(F@Q$C2XK"
M$*,Q60LK5(83I$XQ4<9%.:?I(1U#J7LO--\7@'\N#P?\:=FX'YMO'LS ;;>"
M-L5@<3B4@F#6 =RLA4&U[W'6W2K=A<30QT$Z$O9Q&M2DXJUB:<,D.(C2?#R)
M+!*JR130NKQS(XN'5EN"II<]Y+SUFALXVD9; 4,PYK1H^K##@B^E88<UAA]6
M&'U88?5AA]6&'U88?5AA]2HZF'-%:5C1Q0DW=&SM19:&CK0DW=&SM1C1]6&'
MU88?=*PP^K##ZL,..WPK?$R7$YK1A]6&''GETU[]S^^L,.:PP^K##ZL,.+#R
MK=V;NSFM&CZL,/JV8<:WO?3RM6C#FL,/JPPX  %A6&'W6X(T]_7]E88<UAA]
M6&'U88=0 "2/YO3RK9A]:[7(T'3U/G[M*PP[5HP[Q#G)\U_6*1-*U^(;#+[(
MWV?D/__2O);8_MKM'TQF(_E":)P1&5?C)=X!4ZCS_2/W5O(&9*T89UZ"_>WV
MUB[#+F2M"[W.16]##L-/=H?M_8:WJ:M<RW_'X\Q239P=>]:,M[CD"MFSL/A6
MS5SG2^H_'N[FDOD;O?,YO?IU'X\K7K5K:F)\&=??^C6M]PK1'/G8]^X^RE:]
MXD^'NM^BMVL;3.P.I!M?S_;6C'S.VGW7K1JQU-_>-/?TZ^ZMF=AR=+>?J>]9
M8PY!(/J?+M6C9R&Z"Y-ON[UOO,.;W)/XN>E;N:1QU^/77N*T;.P)%OQ]M88<
MWNQO87_%_+6LS,/CKTL.U8;.?L6VGV]_=6&'8D>=P.FFE^Y/GK6&SGK^DZ]/
MY_NK!)R "+CR_;VT\JPS4[&_O_9_/6&^PXTL+: CROU\_A6LS9VO;0=_+RZU
MG PYO8"Y^SL3^^MFF?#S]2/C^FU89XG;73MKU_;YVK##L+VN;]]??TT]]88?
M:W!OI[OTGM6C.TYM;I;7N?QK6&'Q/4];]2.VM9F8<WO:PN#^KS'D*RQA\+?:
M/7RT]-;UEC#[O6&SDV\@._G\?LK+&CZ^EK?$]_6MVN8<]?A^O[ZPP^![?C\:
M5EC#MH/(_M\_.]:-7. ?,:C4:^?O]U;,.=;'SZ6'K]U:,\#G0Z]3:U8:S.IM
MVT_1?W:^5;,L=-?/TK+>XW8^/Z/U>1K.)A]^/*MHT<:^7X/[JPP^\C<6_01_
M/6C#EAVO]E_TUAAP3UU)_'ZJVC1Q^O\ 1^ZLR,N?=>U8:OR/K^^^O2M"LSC[
M1ZFL-GWI?J/M]QZ"L-'6VI'4]0;W]![ZT8<:#OI^G0'X5LRY\3>QMKWT%M>E
M;XFC@K;SM;KUZ:_"LX&'UP!VU'Z0-:PP^%NGI]_E\:UV&F?7TL; CI<6O[O6
MMF<3J3Y??V_!K:--^\X]=/QY>5;,[3[S_:/Q:M&=YQ:]A8>7PK=C3.>H!M8&
M^OWC3M:L$G!(U!/D;CH??VK#1CU()'2]_73J0?A6Q1\;FQTUMIY7Z$GK6&'&
MFNEPQN3TU.FGI^BL--^\ZCE*W-[YBWV:_"DMFCZP((/*"1EMU/V6K2,.MO2Z
M]>Q.0'2_KYTNPDXL#?36]P!^.PK##I<'3MWOU%_3H:PPQ$V(N=3;H/T_"M&S
MZ[&P-AUZGV??YW-;-'0J+'J39KV.A)[UK4PXURA0+ BXO^/OK%D8=1?77KH;
MB]K+I;[*VS#X7-M<VOL]!8=_05B7O,.+VUOS7S7/EWN.E88<7]K+<@M>_0@6
MOKW/ZJPPX7E%[CF6X OIYD=+ UAAU/,+KJ0=2.OV=ZPT8P#8WO;-:_0$_P!]
MWM>MFM3H05&8V+&_6YRWTN.M[UES9\UC<\N;K;J!6&CH3:X&NAMY:YBV@UZU
MAKM/B NN@-K6]_;SN*V8V=<P((46-@2;#2W4^ONI2T$L^(6Y [@&P'E]8$:]
MZQK,2_K.F8"P%[DGTO\ WQ-;2-HZYK9E+9B-,VH]>^EJT]3#HV@Z6'M @C,U
MM&)TZ"W3I6C-#JIYA8?6M>^C$+?W6]:V)\3$XS&XOTYC;6][VOZ7K#-3C0 Y
MK!@I(OK<GL/@:PT? H!<DW(T(N#F'74^^E(T8^:UE N;+K;6V@'8:UAHY92"
MKV"Y38V.GET[ :VK#+G2V8DW#,MU!M;AG4&YZD%6%8:.;7OFL!IE_C"U]2?C
M6&-V.AN"+F^M].H_GK8ELQ:@D 9B=1F[#[M*PQ'!7H+ZM<M8DW:P\]>U;,[S
M)'$P*L1<(2!H"VNIN>IL36FTGGJ:?89OF[&Y(5K%F )L0>P(\B*S>1K,[< L
M+!0547)(((.925 %KY<W7UK+F&.3# 7;*Q8]+E@!K:Q!OU^^MW-9\ .</E8L
M!PR#<J!HU@+V/5=#6[F9@9L.N<68DCJ%Y;@DM:PL NO2LS,S,4D+7!^J#K8
M92.Q T;WUB[3#'E)-[9>7+[?-<D][7-O?6FTM39A.EE/,N4@A4LMQ_'N3<WK
M::>:-&%E4G-EYAEU)[>2^NO3I2E]1HX8,MNFIY0200Q-B'4=.47K1FAT*K>Q
M6[6L 6S9;,!RJ>4AKUM,PP%;DAF*@'*S DV.I"D#I?H?,5M=IAV(SJ3(!9BQ
M7*Q5P2+$K;H!:MF,#B,QD ,Q _C+<#-[(+ZM?33W5HT=PJL.C%KV4'1A;KF&
M@!(Z>8I1CR[CHJ1Q7&:V8EE!MKFY3TTLI(K/ UF=G!8*+ YO891=BJ"Q774
M>736MY&'TC!!G8@*JY5+K=SF(.5;:@@#KVK2^LT?64$MT!ZMFNREK>V]RVEN
MU9V&&'-KD(C;4C-_%7KF5BRDL3UI1AC)S60 2 EF *VU3+S!@U@;'O\ S;-'
M)D$Q U=F<(N8I:$J+J2"+E6N0?=6&'6[95NV92Q#!EL5(.H5QJ 3TUT%8;.N
M=0S1C*H:3* $:0][%FOWN+5AH#-?F4I9]520+E#6Y&S:G4 W':]88=<Q"9;%
MDRY%-[LH YBW<Z@4I&F="0 JJPC;A, >N;,=->W3I2C1AUNQ)&B@V!LI&4@V
M'30UAG#(SQDJQ!5GCC.55#!2YD7O>X*J>UC6C9U,1E7H1KE8 $6L19#J%*@+
MV%88=I$)A<944EBNI8%E#+T T-P!I2)+EJ;1E.81ED+!C:-4-\Q# 754')E-
MNO44G+B;.BR$$C. N7+8ME8VN3Z6C+@>M:DKY& E9,N3(K.P0$ WRMZ9NE[&
M@RC9"D\S/F5@&F D47LR,([!1F(M:Q((L3W%#L].(NYD7$*51;%4E]AB]R E
M];)9D S>ZLLT9=,X,CO&9"49@V5  +#*>6\96Y/Z*R.IJ6A\4)=>(\+&S*K7
M.<*T;LS#KS(;V/:EO)"5J=I(0CMP\TBL0JYCFLILUT+&X8@ZGN*U&]S):&)4
M8.R %Q,0R<[LZ*-&4 W4!K'W43B),A&9'95 BS*A1K@D7"V91[5V/7O2HO,U
MP.1$3RW4!9;,0#8QL0I 8ZY0.HHPFYRT?ME@0D>:V3E#*5*J=/4BM&7.PPKL
MA-QS9,@8@,<W9"P-B16&7 ^0JCYW)*LR(7#73,DA-V6P(S*%'EI6&C,+D,K$
MK9(U8@B12-+6OS*3:L- R%U=!R%E (NVJK9_XIT'2M\#7$-L(<H"9G&LDF8*
M&SY@,M[G06'W4&<I!X)6%%@Y!(5S!22MCG-K#L;7L;"F\A360?80Q@'A$KRM
MF)\]%O;2Z@Q,?C6N\4'\!#)9F*,ME)U-P1F!4=5)\Q0)9-\A0;QN<J, K+(C
M&PU"%1T],W>M*2>7$7%9) E$#7.6VIT#=!E[=+4L+&&6>H*2,9.:[*1HIUT/
M8@]?=6"XP5CDPAF!N5 MH H&G;2MYBMT[")1T)'NL*T9NHQ\!0;V#=KD:@6M
MIW&E9X&;IP,.%8E;<W6XN?M-[V%8ER1K=.?FZ_QCY]NW3[*RYO=1R81:P8CX
MFWZ[:5O>9KJUV 9\.0I0 '-K>WXTTK>]V(%*ER DV!#V4H54@+<$]!T!\P*W
M"=EV")4V%$FS>(755/*O$S,QL5MJ/("PI>_'GF!E3SS008C8X9&'"4%Q:Z*&
M]KIJ1V%$A43T$;J$[/LOAJPS92ZW "6L>S :"X^ZLWT"ZMA?-A<@#-G9OHPN
M1,W0:ELU]2:U=BK)<$!OFC. 'N#(OQ6%?;1^EW:]*WA.Y$"S8-58JJ *FBL[
MLREB-#:ULVM+ZWL,ZM!8V"8 K>Z#Z3)U-[\Q5SJH)UHMD\[ GJ8C'ECORDL4
M0(J!F5,E[\W374>M)ZOM,.%)CMU9DS*H!U<D AFM<$C[J5NH7OKD#XL1:2[9
M-&R.K,Q)50$7349M-?6LW5V"NL[ TP\BR$@EBP8YWS6$2)>_?G!-#FK,(II@
M^%DN(PRE6%KA0.)D^N;=2;7[T,2[Z@U),_)&K2ER"3F*E;"QMY#2L>EPJT#)
M+-GRD%6RALVK<@ *AC<FQI)L& GB*0]^ILRC)E.@O;J<NES6& F.SE"K$ #4
M ECD!SD -DL2" =;VK# P2Q"J4!0,V50HS @D FU[6M6KL6DK Q5&0$GFX7T
MGF1)JH7^^UU-899 Z !3;.+=E9F"]!T [:5AB68/BB"W9;79KZ$F_N/4VOI?
MM]Z9>BQ2BV[ U1UT UZ@=??ZT(<I>XY*WOVO]OI6C;B89(B5L I-[WM8W\SY
MZ5LTXY=@",-VXA)NJV:_<+KE \B&%: .+X'=,*+YD4 WCS$C5LHUN>IO6EJS
M%"3T1G&'7*00-,VEA8 ZFP[:4:-K(WN/CJ=6@6P .0J+: #0]KC6U*[M#3@P
M-- PLX6X5"#8D7&GE:E1UL#E%F'A,6T7*%DOHUM&%@![JV^(A:@V.%5'NZ@>
M8ZD][FF%70-&*;!2 VT'EH/7]M,[+B/Z<,NPS=!TT!U):UEM<N>VA[5C\V.0
MXBL[,CIXX^-VQ?"+=/;.]6UP\KP87%IL#!<6.%<5/@H))L;BI7E^C"8?*"H*
MG-:PZT!2IU'O3=J<&M]\UV=I)8+"?#)JG]Q&2]MRLI\I/Y1&_>]NQL7M+>#;
M6*EWR\5]H[4EV3L_#3R8F/8NX9EPY^>2" R113RQPQQP\B&/BN%/6T/MK'X;
M%U[85;M"*LES[?;?ZBY[/V<Y35[QBEP[S6CO9NGLS;LSR38R*396Z6QWFGV=
M+-,>+-'=I9>.LADQ..8G.ZY9.(=".U0JFX\BP2P]/<=[[J67XP5N-X>;P>)J
M;/V'NS+M/=W9Y5%PXPN"^;MBR(<-/)C,7B<9\W2&!</Q)& RY-"!>M2KQIKK
M)JYJCAIXF*4$TES\?S_X)0>!_P FS'[IX+;N"V?C_#_Q.\4,5M*"/8#[/CVA
MC]F[CS</+!#B]@1&38^\F]DN)+R(^+GBBPX&;*V8VR.+A6S2<:?YZ=EC6(P#
MH1O6?FL<';GR ?'G>/;&U-L[^;][7CWDE^9X[;7B#O=LC9.V9L3A$^DFW+W>
M;:F\&S=E;M[(C2%?G.'PA3BA J:WN95U)K<B[6>CL1+Q&!I+<C);_<UKV:"^
M\./D+[U;CXO9>UWWZCVK@8=HXC&C [,V!X?8$[1V>NSC"OYIV0-H;3Q> XD[
M.K23%AE4=P:;SJU)*[C)Y=[]_P"(/3Q%.UXNZ?[E_B#'?CPMDVKA-I;-P7A)
M^=,:F&GQ,6,V#XC;LR[:Q+),8I,)-A<+AHL7A'.&3^!@C>,M<6N#2(O==][=
M3X-#O#NFIWD[-YZ->)%O%;I8/96R]HS;2\$?%+8K8/ XJ&:?;$^)Q&%$D7%@
M7%[07\V8-Y,*K @&.Y):Y%J*ZG*2)*+C+*,XM$5L?N=N'M+&8AL;'B-F-,N(
M:-,/C=D+C<-D9E4&7&1Q1X:&*:ZJTIB%QYZG$WJFF@4HP::DLV,CO#X+;+P\
MX.R=\]C<8?-W,.]>)PNS(]E\1Y'EQQVML+:NTABIE;A$2+R1,%) S&SF-9NT
M7%_GV$=B%U?HO>8CMX=PMN[.&.V_@-Z=CQ;>V#LZ+ ;Q;-W%EPGBC@MYMC*A
M<XF'=S:<@FV=C9(%RXHHG*PS+UIQ"NOBY1:3T;6ZT_9]S^,C*JG-[^\T^79^
M4COO7O%N3M_8S;'V/X>X'96[6T#"^,;&PS';^S=L%\L>W,1LO:&7@[.Q!#1\
M+#R)DS:BGE*E*G+>WWUW#D^X8UU&=+S4W#MR:&%P6.V1L':PV?@,9+L&;#O
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M;7G:BT8[:P^';$8;#0XZ HX79V)BP6UE0+96$1Q&9W$RR7N+MRTW2BY6;MV
M9A!+C+8@S8'8.SDE+02QK;'8$F971"JVRQ/-&P.4"X4T=05K1>8-NVH:0;=P
M;SX5Y9L3LK$X9S<Q1IB[S,J&0SR1&/$QR!TY1<]^FM\5&:3MYU^ )SLQU3XF
M/C]EX#8NWHM@;][/P\RL(]MPKA-J8?#$.'CPNW9PN*A>ULBER--+:W;+!N+;
MHMTY\N#-*=KY:B)P6YV VY/CI=B6V#EEEGPFS,=QI9D@D-T&!VEAS-%C'B9;
ME&*,5M8GI3Z$I*.[4:E(#*33[ !B\3O#L]HHMK8; ;QX=& 9=J"3%0/##+&'
MCP^*7// 0%YE#<I-CTN=N,9Y)N$NQ+/O-Y-';!R;K;2;!C9^R?S5BD%Y<'-B
MQM#!<1XS+B#!#M#B2,ACD2P!TMI61CB()J4F^65C++VAQA]WM@[1;@IATPF.
M,+21&Q_KE%5HHXR)W$4/%F8#+T_5J,ZL<VV996=^048[<+ [)FCAVO@GPX=8
MB^&Q4:PS-J[*8Y T@G@F+^V"!<418BH\D#4;K(+I=T<-(K, V#2(,4&'Q,N2
M2.^D3!7'% %NG;K6*K-^D;4)!5\UQ6SW8Q)-,Y^<8> A1B!(XAND;E/X,$#7
M-S!;_'>]O9,RTHY@S9<>(VC+,\>Q<5'M.+$R2.,.Q'SA=59,/&++&L>I0D7-
MCY5N\4K2,WN+0<P[2GPPC=9MH9'=TBA=I9HB\<J#B3N5D0SHP:ZVN+7OI27!
M/0R4KJR'+P6_&V<)!PYMI82+"C+(C)&D>)295MGCD'-Q2YMS#*1UI#P]/5I7
M!N[78.3NYXU8K9\$V#Q>,EC>00YABS%B,,[N"Z2?,V.27$-PP,RCE%,ZVSZ=
M1-QC[LK!Z=5P5G<DUNQXC;M;4P6"..P6%PLN(PRQ2+LVT5P\LBI++%E AE'"
MN"20%%N]5K$X'$QFU3;<5SN'C7BI9CA3?TL[ZJ^S8,>^S\/&9&V7\WFCP<V'
MF=V6*:;HN(69$R@#E %K4"DL51>:N%E4AZ2T&YV_X2;RN,;M+"183>+ 87"D
M2;/>+"1XTI"ZD21!%NZ9P'+*0ME(.I%/H8NG'*;<9?4#S;O$(]A8W:6YVRCL
MG;.ZFU9</BIDQ$F)QLLF):!(T?CS88SO>&%\JC*I&@Z>1ZE*G7^R4ZR2MHEG
M<VY-920IH-A[G;RO; 8[ 2RXB-Y&BGA7"?-9X,LC1_."P;B'N>A[TT<\52>]
MN^:GJOR"U3IU5F[,()-Q-[MB;1Q9W:E;&L\2<3@8O/AX</%SJ@.?),0S #*.
M4$BI)8G!XFBHXN/9=:@]V5&5X#L;K^-.W]AR)A=[=G8C9(A=,.NT("!"!AW"
MV>&0!3Q%Y;:DWJ-Q'1K#5XN>#<97X7L.Z&UZM&:C-/JR;7AEXBX3:6UME8_9
M&V3L:.+%,T^)V?B>'CH,--'F@Q0CA0),T;_1NIOFXFO2J[7PV.V3)]6YQL^#
M?XB8ECJ&+ENI),WJ?)M^7AX@^%C[*W3WXV[#XB[GMC>'%M=4A&U,#LUEB<12
M+Q482(K6 Z+8^=6?9W23"2P\:6UJ<M_15%G;MDN*YC6KA*JGOT&I1>INR\./
M&OPZ\4MG1;1W.WCP^+#Y$EV;C)4PVT(GF((1HV<MF76Q!-ZL"I4ZU-8BC*%2
MB])P=U;DUP?XQHX3IU&K67)_B'>1@W0W(%CJ,PL>C <IZ]1UIO4AN9&-\#O0
MA)]6&'U88?5AA]6&'U*CJ8=K"BV7)&+M./A622L;LN9QY>^A1U-KCW':C60@
M^K##ZLLN1A]Y]ZPPXM^V_KY5EER,.:PP^K##CI:P'7TT]:PP^MK>Y]W:L,.:
MPP^K##ZMF'U:,/JPP^K##ZL,/JPP^K##ZMF[L^K1H^K##ZL,.I'LE>G<=-/=
M6S#M6C#ZL,/NH-C\16&'%NW7WUAASTK##ZL,/JPP^L.O>L,.!W]];8F/'O.;
M?NMI6A9DBOF/^EZ_$4F>@;#WZQKA;\A__].\CM@_V6VCK_OY/]TC43[E$95^
M,?>  /N[^58#7:9 3I?6_>MF[>\$+8 'TMZ5K4S/0R UABR.U_V?"M"CLHOY
M_'O^ZL3X&7X<3);[*PSO.+ZUK._8).XK!1V%A]GXTK$S+'%M?/S _56[K@8F
M<@:=_7R^'PK+&]3B_46M?WWK.\S0^Z_M.@T\O,WK+F'U[6M?U]*WWF'(MKIT
MK#9V&G;TK#&?::6.M_M%OL%8:[3G3TU\QY?LK1ASH/(7^^MYFCCL-=;#3OKV
MK#:S.+VUT/E6&\CLIOJ2!;77OH:SQ,.PT'P_%JQ&:'/V_C]=;-'WF>_D.U9V
M\#9\&ZW[@=AVZ"_6M>!L[%A]6Y)Z=K _KK#5^!V!&G?3VAJ?B*PT=AYV]UM/
M/]1K.\W>W>? VN2-?QTK#$SD>8O:_G[_ #\S6"KGU]3UZ#IK^BM>!AVZW%NO
M?]=;-:G:UNVEM/?YUAA\+FWVV\Q6,SM.XO\ J&FO736M9&')TK,S-#X]-?AU
ML/=6&=IP!Z:_<*SN,.UZS0P^_GK9ESZ]89<^'XO661ESGI;IY_"L-(Y[>_7W
M^E;-G(%OQ]WO)K5S7<<V]->GK[_@:PRY\+ZW["UQK>M&CG0:W\KWZG3[JV8<
M'KVOTMZ]/UUALX)MV%KWN*PSM..NHM?N/CI;M6&KG'I]_II;]%;,S9UOUN>_
M<]+]ZQOD99G(]^E^WZ:U<V?::?&Y\_2M7,?8?=3Y7[G[.M;[!-CBL,.#IJ!<
MFP^/:MF'P/GJ>GNOV'H*T8<$ GJ?/[:W<V??Q;#3SOTT[^AK6>AA]8#3UT[_
M ,U9GQ-7/F\^ARVK=C5V= /37ITZZ=#VN*PSP./, 7.GW>?H:S@;/NX-P-#V
M-O<1[JSP,/KKH+:=[#]%:$LX.I(];B_4CHM*-'QT!O\  =P/?6)&7.O6^E^G
M;IZ?&LXFCZWU;:#STZ]/LK##X7[6TZGS_=6&7L? &P.ER-#YZZBMY&G?5GQ(
M\O3U^'I6M#+&.USFN;=O7]U9P-V1]?7J.^@7N?7M>MO0P^/?/RZ6Z9K6Z7OU
M]*UF:?(ZG, MO@2+W]+5LT="+@#H3WOHNEV4]Z28< DD6.HZ7]&'0=]*596-
M<3H,VMS;L/=W^VL,L=N6P_C']9^RLNS1U;N2 !<*MNS#J?NK9AB)N<U[VL3>
MVJY>OO%:-G7O?7X_CO6>)HX*Z J0 6 (\CW/NK##A@Q8=CJ /XJCN>G6LX&'
M Y4%K^I/<$E2>;0W %9JS#C0YK6T.;WCRK9AU;4$7*A@3=M0;!M!WZBL,.5
M-CF N"=>MSYWUZFL-&-LU[L=+'0"PM\;5AFAUM<7)M<#H;7MW(]:PPZ/KKJ;
M'4=3J+W '6MFES/KVUU[6S'L!TMZFL,.JY6N;$ DFPMFS <W^F6_;M6&C&;
MJP-[DJ;$@D?O%;,,=] "+C4V/NLNO4VM6&CL+$7 L1FM;0#U)Z$41:";W/E+
M:6-O,#H=+UG$2\C'S&UCS9B$4^R?],*QZ&UIV'5BHM?37F^WH/32D>)BY&,Z
M'V ;N I)%['6]_05LP^ES(#E57-P N@Y>A4'ZU8:[SIEL.A50""!89;6T'N!
M%8;O[S@A1=AJ &"WULQ.@ ]U*0F]N\X$894YAJQN+6L2H/V:5ES5^1P5 8H0
M01[+$"_K_I[G[*T8<F%3W8WTZZ GN >EB*V:. @4.!=@X474C1N74Z=>6L,,
M5K,YLQ)L/0 #M6^P2SJ01<:CI<7]>A^%8;L=N$;C3VFMI[5E\^MJW8TV"HX5
M:Y"."VI!ZCME%N@%JTW83J#H\-[.@R^G^ETRCKI0F^)M9Y&88?S&@LR@]SY^
M9.E)WGH;<69_FH*EN4,+W'3U^%S2%)OO-6.APK%2;#7IKFXA/8'K<4I2MWF6
M LF#=5RN+(X&EAF5@3]Y %_2MJH]# ')AB&<LMR18A;@*PT%LOH*4JK3S-6
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M%:22T,ZL#-AHQH5L+6LN@('U?.U9W@94^#0"DPB.<RHQ%QRM[((Z:=K5O-:
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M,.IL+J1F7-< ]QW%^X%JW8U=&.REKCH";*#H/?ZV-89J8[6 -[,;:7'3S/\
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MX'+$&<J -19#ET'K[^M#4O>$MF9/FV@(3,2/0: V.8Z$ZWK3D9NO@<G#!@+
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MC2E)HUW'QV>&8!5(Y"I""PR,>86Z93YC6MJ1JUCAMG#*X5 555O<C,V3E16
MU.0'2]9O&C#^;F7*<P".;$D"0YBMK-?HH[5M2,M<Z+LR144 Y@,X1\JHN8L#
M8 Z$V!I:D[Y,QHZ_FYBQ=1S.!F+ !VRZ90%U*V)]U*4Y(TXG<[/YK !7'+S<
MB9' YF(TN"-*(I-HRQT39X&994LX.@;F)$=U62VHC%F-AWO6]Y\S5CX;/!1L
MH^NK-< !;'4CN<HK>\^9EC&^SVL5R*44$K8VSL 2'7R -;WGP9ECI^:B>7(
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MRNNI<'K<6I%KH7% J*+.5(4'AVR]= .PM:XM2.K?L#13!BJ0Q5597]K1^O\
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M=<;RYBJE)1EN22WK7#E-X]D[^+)#MS8&#V1M^4<0;2PN& PDT:'5GP[ "68
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MK+&;IP$349>E[!F-OAVM66,L?<).I&EKBQ8WMVUO6;O(RQV$:$C0]";:]#H
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M,GT9.;R\^E'@VX]HA\0CQ"Y6"7-I3F)[(;7M;7OZT>U@5PAG!N2I"C+)GM8
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MH6QZTV>$3]&32-J5W9BNCVWN?ME3(V'PP7B1B5\-\WP331S"Y!?VCCB_("
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M[Z^^M:&-F0 ]1VZ>OH:RYB5S,JBPN/+U'N^VL=Q21W) &EKZ>\TELVCL!TU
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M.OZOCUTI D[K;VOK'J?=Y_"L,.2#;0Z_IK##&UK"VBCMY>[OUK!&^@.Y+!F
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MOV'PUH*C'D2-'(%+J>FMK@^1]W2MIZKA<D(Z/L.6%[9M2&&O2C1CQ$MG#-U
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MSK=5C*D\QU4TJR]H._/03>,W9PLDRXB&99YHFCNI4M(9R!&<+"S#*[E4R@V
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MD&G3\>[MTK3-VYG<#^<UAAD T%Q8:V/KYV[]*W8S4[:BW?3M^-*U8WWG'O\
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MW'N -_2]898YM<6 Z'S\O3X5K(VLM=#XCKYD?CX5ES9]:W2QZ]?QYUJYA\+
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M5K=C[/ U9'>-M #U/K^KWFD323RT-,[,0"VE[C]72DB7H8W7,F5=#V_!K0$
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M8NV2)89I&&6(R9.2*X OY5M( \Q%[8P6TL1+A\+@Q"R21.DR77(V)&7+Q)E
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M?%[.H5IJ<HNC5YK1^S0/3J.+8Z6P=\_#S>K&X==G83$^'^W4EQ;X_#[4F?\
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M,.:PP^ M>W?4UAA]6&'U88?7'3OY5AF7M..GQ/ZJV:>5N\^L#KW['R_56A7
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MR=KW'&V#LC>39F%BCW?W9@@Q')B-HXF3:F'QLL,96.V63&6^D$JB[(-1TN;
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M[;S7F/GNOLO$C%<'#[6X^(Q,,;200K-.-GQ1/B!-)BL3,>#'#(D:9+ $FY-
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MKPV"ZD=#>J@DUKJ="WI7X,/L+LXS\::<!20<P8$1!5OD"NI" C+I8:UM1X\
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MD\(,?A(C+@<7L?:J8AIX\3-)M!5BB5G21IH. A9@LN@8F[?"BTL2IKSENRY
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M;J#<UACN<%K7T)MY:_S4FQJYB8=+_8&T]+^HM6T[(PQL3KJ+=!^/C2K"3 S
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M6PM:M<1/B<6U&A\_QY4H2VV<A=23WO\ SUAAS;J.W;X]:PPYL+6[:?=6&'P
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M7E?O6I5*;34XTYIO1:]]Q5W:ZU%-A]]-M;/EPV%W\PVS=X\+&Z89=Y=BJ_\
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M[&EI< =VS!H6 :Q(O:WL^]ATU[4KAD)EIVG5E7H 1<DAF) L=;6Z?LI<<\A
M%8ZBW3W]?,]SUI5S=C$>8$<IT-SE6^8>9(UM6S1T5@K!2;MJ2,NI':YTO:W6
ML-'!.I%R0-1>^AS7L/=6U]9C.4&K:7LI;F[D_&_4^E;L8?$.NF4  7ORG7L
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M6T'4WU[V%89P/AVZZ^7XO6&,[?J-8:.!>XO^/Q>L,RMD?$C76W;\:5AEF?6
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MAWXGXW8TBIM#$SR238J-(GF;.O!N[2Q   %A%,O,IZ-8U%XW9D:T=^"6_?\
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M&>1S-SYM>MSIY6'!UI;MGV$/B:3WK\1LMK80<2^*D$(8.3BX@I.9E"HT@$1
MDN.9>OK4O3E%YD74@T_.$Y)(T6'ECDDCGDC)=KKS3A89V50Q=2BD->X -Q]K
MB'I>P#)\. 4;2@.'EP>/PXX B(=75AG).?@R IF,07AG,_4,!K18[R:LP4\L
M^'$='99P/B%@5AQ>,AV?XB[,@6;8&V<1(KX#?'"112,=@;5@:.2--I2P*RQ,
MY E \]0JM4K2K*4K:6(ZI&IAY[T/.PSU2U0U.VMG8W9^-EBFV=+LAL%.S[0P
M&)C>+$;)QDPM*T48+.8<7E5E%LH0KKIJ>#5[R;TT'&]%I..C0M=R]\,;L\C
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MZ),1E/#4D &_-4A2JIVX#&I&S[ K0XG"*F<W8QF+%1C,(F2207!12P=.&QL
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M6A3PC?G0E8(JR:[!R]B[?P./G3#Q[-Q6SH)43A$R9T(2>13$9%N4#,HT!T-
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M#FL,.!WTMJ?CKU^VL,[#GW^OX^RL,.  .@M^/LK##X7\NG36]ZPPXOW[7/O
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M]1?J-;4F1M9L&Q"R$ !&T.O4BW0CR(I(3=BFGF#5N0I.FA!!&I\K?Q;"L-Y
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M&.61!SC+?;$E(J[/=I%Q,J[/Q)L9%-V:(&T4)70H+FQ;RIQ&3>N@!OEH$DJ
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MW)9Y((YL/'F1@0&F:0B HJ92 Q!!102ESY@4XC*RN-I*/#4)9 K!<.D,4H+
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M;,GX4[M**R(J[^>/6[&"VOC=B0<+:VTV@>;%8^;B/PH$P8EPVSXXW>"/AE$
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MC5>M:LUJ%@FM01A<=P8(\-(N).'4XF##,#RO%)SKPU9G:22[$^TIOK;2U8+
MF#VU&)</#%L^3$+)(P>5)88Q&N'> -GF4YY)03R@_P 9C]75,D[;RMDC7)9W
M;_X3;3X'?(.\#O'7Y-FZ_BYN[X@;\X7?;:F/EV1OUAE?"3[&W*W@V-,V$EV+
M+L;$823$8C"XN-5D$C31L^;EL+&I*& 56C&K3E:32UY\BH8_;.)P&,E1G!.B
MM'G?Q(\;_P#Y/OQVW"Q6+;=:38_B;N[GQ,F&DV2T.R-JX24N_!3%;,Q<\LTS
M+<Y1'*V;7V;"^JVRL;12M'?[N!F$Z4X&=XXE3A.^65U_(17VMNIOMN-/#L_?
M3=/;F[&-C_K?$KM#9^*P\,CA\SHN-D4X%+K;,02<K#T-,9PG3ENS37L9.T,;
MA,2OL-2#?>LN]"/Q&)EGP^%<1QRHK&"<0@S(859VBA9PZ%Q%US:V%9&.>>0:
M;LKI^=W> #PLOSJ[31J\:8?D:-P!?V%3.^8%5D+WL >FOF>$4]1JVFW;1@)-
MGX'&K#Q,4J3QRG-APQ#OPRV7*S.+JHZ@ FU&<E'40X+VB WEV5+Q)8Y9@^&:
M'AK!%,A]ITR&627*0[R*M@!>UZ/3DN;(VM!IWMD1NWKV5"'D1XV8$W@XX1),
M.TJ\95DC"N9%$3IE%]23\)S U&TR"QM)2T0R^TMFS865@B2R+D:6*20MQ&8%
M5D%AEX-BQL#I:I>.<41$H99H34S*4>%F6)<\CF*5U#L8C'(6:0@A1H1T[T2&
MO8 ;6G$Q3O%%%>*0%I4'#1HC(L,\@9WB1"="$L;GK3J#;RY FK&&.&&5LTD9
MCCD+AGRH))75'<Y[:"[DVTM86MT(()#/9N+VAA>(\*1XG#8CZ&7#957#XG#Q
MKRQB3(#%BL. 2&MUK5C3:MF.1L;:&"VG"<%-B[XB+#A=E':1+89X2'=-F[39
M@P7!&717^HS$BV8T&K:/GV]B$9)W3S"_&;*;/"'P^)V?"DK2/@VSS3[)Q"GF
MBBD98EQFQ<62>"ZMG&FC:VR&:WH.]_J['VB^-P%BG01I\\1TQCX@96.4##Q
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M/2FLL[CF/(4$)S*-6&O?2A35DD.J/(%J0--=>EOUT@?4^(P?R@]J#![JPX$
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M<K#26]:W Q;,W"VMX@[4.P]U-W=J[T[:P\"2F/9V$BE^:K"N9<0,5+EPT,1
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MBA93/P97+,KJV>6*1>&#H"F0$>5.(I,%(QG"K]%(I6+)(<P"F2;AD/DR*>&
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MQYVM6 @*ADE6)7!',;@ J62_,0O+8BV@[5O@*48M7XG86)9HS+F7,JI(H*!
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MA(,D+Y),A=O5W(DYKWS!R NG4ZUGM1JW:@-EF9N(HS26=0&'TD+(=,S#JM@
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M, V(6/1\KM$#:VA%SW[5B$/-@1Y5DEBX8:S$*\C,J@.+*0US>P77IU%:L9X
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M/#XR+P_WZ<+FEFBXVR\=)$5XL841.<\I+6"Q@B_>K%A?*CMO#KJ\52A)<]/
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MN'Q2KMC!8O%R8/'2H8=D8LE7.-ZXI\)+$BLLQ6]HB+* =*DY3DJG4NSE;5:
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M;WC2B GBL6+QW!9HB3>[,0'1'!Z%0;'R-9O&;J"YE6$2%2?X@(=E4@C-H/\
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MM1J676^OKWK>O<8<WU&8G4>0N3?]0K5LLC#[VE890"-,U_,=1?KTK-&8< V
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M7M\+=?36L,.U88=2MCF%K^7X[FL,.P]:PPX%M1<FWGZUAA];4'R_76&'Q.H
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MV!,5-!'$&C?(;M<(JLR%#E7-Q% )%@+T2GJQ/8%;)D!9^!>5<K@6=R[:FV@
M(8]11$[:B6KJP7XC"E<MI%1T?19'L;'KG) !UZ45/(#.F%LR.MPV<!64WA7F
MRWR*%T*L&M>YOU[4I/@"<+!+BBP*AEGD0-9HPQ"I90BR M<L5 &;32M@_$+I
ML(Y*EB67)FS*WT.6-@Y(Z7N-+$"E*5C-0$6+L%C!,H8F-6(6(*0YTT-F&4?;
M2UGF!DU<^63*1F9FDN0QE 9/8ME50V8#[ZPUVF$'-&59;LYRBW* O\8$L#8
M]"!6,4M01%D$0NJ\-#P@Q',P)YNC"YOWK:-/(,(F"L79\O$%A QR!'0V C)6
MQ4J=*QFDPU66($.LK!L\8:X+'EBX8.6YC"7MJ/Y\U1CE9@R*3-S("718S<Y
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MF ?&[$EY72+;.!$C0+(6L&C=U7EL+6I>'<86W_1S^LDJ;47&JQ";DX3:VZV
MVL=M1O%O'OCM*/>?>+9^'BM#\\Q$&'P>+X8!RJ)/FRN; '6U9.L](M;D%:/<
M2-7=K2A*WH1L@UW]QN&QFU6E9@(3#'GC<79(TA!=;"P"YKZWT-0]2H[R?,=8
M6ENTHP7;;WLC,^WL+LW;FQCQU2#>#;NV\5@WS%AB(&_K.%& )RY9@0-30*%5
M.HE]^Q[4HR<&VLHQL2@W;=\+PHKY0$B"DKJ+*H9U)L5SCM;O3Z366;U&&5G;
M-#OIC81",\B\B9A=@.2PR@]03?3X4:+;R6@QE&[NE8*_G<3-)BI 3!%F=07
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MWV2[O[;_ )$0:VM%LO:^TL?C\/A,"8]I;5VCM.'YKA8>%AX,3BI984A#AHN
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M'\9IY<0P617)9>EA<6-_?Y:4K(7H<9.;-8G30#1;&]NOUA6]ZRLC+V.I# W
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M;3>818E02264([$,R%F*E?XUSFUHL%Q&=3)"8Q0'."X+%E",MQF!Y2S,!F#
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MP0,-1FMT)NJDH[O5K-Y_7;ZQ6)4JDM\>?Y;ORF?$'QGW/^27X7[7WAAG\-/
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M3RK>1KSNRQP#K:WO(_76&HN[:? YU/P\QU'F/?6A5C+%[1Z]#I\129Z!\/\
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MT;4'&6XLK,CSO-XJ8[87AKNILLG#PXO9FQ?S?.<-@HRT\T<;8;$2-%R!99X
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MXO9L\LJ*5&T, 7 L[<[ FUKT"I3:3LF*J6J0W$[.X_6UMR-WEVQC-C[4PA.
M8X?>/<[:>'Q*XZ-MF[6627#"#'1J_!:%XVB:-R;-'Y4/>G%76EC23W.T/\#X
M<SE1-L;>N3 3SR11IL]A$())$B25GETOR"*P8,+D]*3&M'[J-T"S>2U)M>!&
M)QNQMJQXS%Q0K^<XEV7BFB#G#8MD8K#B<4,K(I+(&4_5Z5EX3=N(\I/S7?\
M/(V4;H8D; P$VU>!,(\?E69'"K"5C&6:6%PW\'*"6UM:L<+QW4[6O;L$QGU=
MY2RI-9D:/&9L)B]\=AX3>K:*IL+:>.P>*V)\[<1O#M6/$8<?/,++Q$2),,$$
M=@2\A;H*WAYQE3J.C\H:L^ZP"NDI)3]%OS1'/M796'WKVON[O/B(EP6V9\7N
M_A-IPZ8>;![7M#"#&]OG XY5W<76,CK3:*:HQDE]E2O;G8+*$M[<;M%-*Y!_
M;L>\&X^\>T-A;>C$L^%QF)V?A\;ARWS3&Q0R20JT3D96D$2@.+W1G%/H;E6"
MG%ZK3\0*-TVEHF+?=';LNT\;LW"QQ21?-7BDQ,I7-&[I*V61%ZS9;:BUA0Y1
ME#T<ATI*2LQ]\1O9AMGJ\,A$IMF,;N[8R:>9US2S%4RP85"FBDBAQIV5XY-\
MA<:E-+-7^H,-@[\3M_78FEBF"CA202E5"QM8"3(0R.I-P+GI0ZM6MAY)TI26
M?,%5HQK>FD3,\(_&V18XL!C]HG$*XBR-BBS,64V= 3:XMK>]2\-HNM377)2E
MST&*IQPL_-;2)E;&VY@-N888K 3+-$5!S#IKY>=.X2WX;XO>BW>+3C]?N#B_
MV^7I]U*-\,O2Y'/WUHP^K##B_P!_3UK##FL,/JPP^K##BU[:]"#[[5LPYK1A
M]6&'"BPM>];,.:T8<6]W[_.L,..NOK;[[??6[B7&[N=JT*.-?/[JV:=^9P 1
MW&OI^^L-)6.Q%[7U[CTK0MF2*V<ZW.7[!<:6I,] ^']-]WY#_]2\)MS^W6TS
M?3Y[/I_KS3R'H+G8@<1'[/+UF%RB_2WNI2!6,\0O?T\JQO(5>R,PUZ=:TQ6]
M8[>G4WO^!VK+Y&^T^ []^X\Q6US-'<6+"^A'IU^^M,W?(SDV!M\*2:U/@PT'
M>U8T9:V9E5O(#X_@5B%9,[!AW'O]*V:L=B";D&Q/3O8>=:R,\3J5%M "#KII
M\:VKZLU(ZJ-+#SU#::'H/7TI3,L<VTZ#N"#U!ZCWWK6AIW6AW%CW4]0!8]=?
M7M:M"DN)U(Z7 NP!M?H?6^E;2,M[C(EP+V%^U^M[=QY?IK/ RQV5^Y .@6Q[
M=M:T_J,L=T:PU%LUP/2WOZ ULRQV/6]A<^7LCW>I%898Z$6(/;ROJ3;2Q%AH
M+5ALY.HM8@?6OU!/4>ZP'NK9A]T6V52M[$AM;#IIWK+F'PL=+ D@@ Z93ZVM
M6&''0&X-QE]FYOI>P';4TG>RL*1V4BY&OF5Z=>][:TDT?:$J3UN"+6U&;O<B
MPUK##L@SJS]"+$@ZG6][$:$ BM&6,@%^8FP %B;B]O*U^PK9AW2UK+8_6Z=&
M^JI)M6&&4$\O1F(UMH /,COE/VUHPYT!8@ 6 -P 3TM<=;&L,,@ !O?KKK?6
MVFHN;7%88<V(TTN?=IY?=6&'8>=M0>G0"_E>L,,@ N2!K87-[CRZ>^MF' Z@
M>1[ZDZ:'[;UAARS'ES :WU TT( %AJ";UANYV#FUNXMTZ ]CTU-C6S1V6^MO
M+N ?T^9K1OO.P-E(L;D^T+7'KTO6S;.X" C7V>G6YTUOVZTAJ^9J[.Q.E[EM
M;@"ZW![#SRTDPY8V&EA8@AKEB/,$>[M6&&0:A2=;:V'?U[VK#9R#[ L023TU
ML2+V^%JPP[VM;0W[@W^^W8UAAR/9OJH[VZ^A6^NAZUHT<@@6MJ/:-SWZ7TM;
MK6["HZG.?4BY\R#<K;RL3WK!9SFOETZ"Q TOY#]=:L8<W;6^ENMM2?+UTK5D
MC-#G4'4VN-.^I]GR)O>M&79V\M "H O^GXFLL8G8YRGL03U]WP]*UH*O<Z@L
M-.A.E_.VOPZ4DWF=U8KH#VZVZ&WOU-):OF8T=BUK:D-8=[A[CTT%J1NW[C#F
MPTT"VU+9M?M[WI!AF5M +:64@]?A6&)VR.]^WQI.Z;N?7 (UM:QO6GF;3S,@
M8&_D-!<:7.M:"ZZ:'/6W4>E]!\*PWVGW[;#U]:PRYSU%^70>MZPV<C+W':_4
MZ^E8;.P(:Y-K]-3^+5AA]<FZ\OI^[W"L,61ST'H!Y'4^H\C6&]X^TMZ&Q]:Q
MO,S>SL<:7Z&WZ/6MW?(V\E<XDD506N18::&W\U)E.V0ER5NT26W-IIA8)6,@
M15%G8D#K<W!)&FE,Y7J3LM"/KSLC51\J/Q@ECQ&+V+LS&K',\CX=E1PLR(7"
M2KRM='*DY6HUDKOD+V-@'CL5UDU>A&V9KRVK\\QJ8C$85N(DZLX DL"C7)-F
M1SF>Q-^U FV\T=$A%02@EDE9" VWNWC<9$J2@1M)!PN.I+.&?50HD7*;#J;
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M,$D>VC0*C6 ',+>ZF&*P5/$162U-1PE*3M*]C=+\E[Y:^W=AS[-V7MS&KB,
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M\OL@=O*EP](P"R+$N0J;:DA0V4:@A4NH!T!'6]&$IW/E 0J^<!;%2RA"V<]
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M0I)#=3;I4RY6*N=A!&>.CA()4"1*5123&(R2^>Y1W9K=;_L488R8[27:1AQ
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M!1%(U7#,51,.J6BAFA10]B\;'N0VI-M*J5:O.N]ZI*\^9T7 [.A@:?5X>*C
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MVITO?47\@/(5NSU-G:PO8=//SM6C5LSC^*5MEU!OUZ]?/M6[*W:;O8[WN6)
M!/E;\"L7(RYR0#V/0 ZWT%;L;,EAHI&4 $D^=AI8=.E:L8?9#RB]@570]!;W
M];VK+V,.S $J+ :@&VMAYZZ6TK##DK:QL + +W/K]IK##BP&EN;07 N#?V1?
MS%JPP^TOS#E.C$=O+73H:PPXT+.N9<QTO;0W.MSYTENSL8=\@TUT^ST4'SUI
M)L^"AFTRD7 UL+'OZM6Q43[+87\QW &MB.G<:TEYBCY4N1W N2!8:DWL!TY1
M^FM7L;U,O+=M!8CI;E%NMO=2D"/DL?+K8@7RWUU^%ZPPR:6[ VMH-2;]#Z&L
M,/E'G8@$=1TU%]1V!K;,,J$= ![+&Y'D3[/GUK7:8=E) )L#;J"-5T^VM&'9
M64K]9K]?U#STK9AW MZEN4Z:6[>?E6&'UM= /L'E:PK##LO4::7&EM/,]*PP
M^%M0#8#I<$7'33X5AAG6Q MTR&WFQ';R'6L,.$"G1K@FUM>YOY7'2MLW=G=3
M<BXO?IH/(7OYVO299(T<MJ%MI8].C>5AY7%#-G;H1H.8^XC0FMF'9;Z*NNI!
MZ7\^I]U9VF7.=-; :F]8M#+G8'0C0EK#W>M;,N=E/LBW8ZG[[5HP^4BQO8W[
M=+6/4V[F]8*CJ=EMU&IU!'KVK;%G(M:X[ 9B#Y"UJT:.<O1M3H0#?I\/=26S
M#M8::]!?7SMY=-?NK1A\/(]-?,V/D/0FL1AV-K'H=1;2WZ.U8S%D<D"UKBUQ
M;O\ IZ4C0)X'6R]KZC7RO6&61R#:_;46%KZ#W]*TS1D+6M=;@Y3IVU^-[T-I
M&-\CD7+$6%C8"XTLO>_<T@UJNTR!K%;"]_+H+$:GTM6,U'6YW%B1WN+7'ZJ2
M]19W7IW%K'[NGVUHWG:QW[7)'8&M!(^CF<@6%NENO<&_?X5G<+M;N.=!W'X_
M16&7./,DDBWX\ZT:WL[,Y &IUL+6TUU\^UJV*.0 >_7^]'W6Z5AAW(M8WU'>
MW4?S5IF'4C3E.I\^W[JUQ,\V^ICDE"@CKU!/U0.]R-;5DG;*YDI9/D)';VVD
MP$3/F*@+F!ORD#KF';]=-93WG;@1]:MNK(A-XR>,7S2.; [+G,N*D5T@R,&4
MN19KKKRAF(_!IQ3ANQWK </A,1CZB2RHWS9 )MSMJ[QXG';4VK&'Q&.Q+23R
MXD.Q,9S.@C;6V72VE;5.<GIF7W"4Z6$HQI4LH109P^'>&PN'40PM&^&C++<@
M@$680Y& "M%<V]!62H3U8\C43T80[6W9ACB+%+,T05U*YU0D\_(_M/8TWJ)*
M5N XCOO34;:3=:*)EE.%<*)/I4?*8I!*S983"H.6[L"Q[6\J'F.XS;MD <;N
MWA\*CWCX9),S0LSL3#?1N)?A'*3HH-P!2?.%YW$G\PP\,LIF)CCRYX7:(*)U
M5K21G/?)%E-R1JW>E60NXE=K;/P;.&_K>&0WM R"-T8\D@8ZK(D8(6W<ZT-Y
MJPM,:G;^[V$GPTAQ&&"LQ94)TXJKT12 >#&W\?I0YQ25PCGO*S1'_>[#PX>.
M>>**?A0JK2.SKQ(C$R90P7F:P)Z>7V:0@CCMXO-!.X=V:1W4PW&=^%=DG#-J
MJ+:QO1J:W7EJ,Z^8Q&VL='/FE:8 +$Q?G9L_#$2E45>Z#H-;TZC%+(C:E3=>
MF0V.+Q,@CC(FS%LI4!@&2Q8DRY3R#F]D7&E$[!I+/O$1M7$BSE[2Y6<.U\RJ
M,W5 ,S9;TY@FDK6(S%+DQ+F= SM]49XT)5RTO$\EN,JBG*5E9:C!NZLP',\;
MQ$($22)G*(&(^D3V!93;G!O1*=\TT(G;@%KRF,ET)*N<LA55=G#1ALUC?Z0D
M=/P")78!K,!+,LKO)G,( Y4LHN]\I#W%@VNEJ((EJ!S,KK(<0K,Z*4*!CSG,
M<A"]B !>M) Y.T3"^((>1BK71]%"/:,9.HL"H-C]7O6 F[V,7SL2*5D(2,)8
MYF>=G8BP+*+,A-Q[J+N*QH#/=6"J7D6/.Q NV3B-?AZ@WSDYAZ5G5KF8<#GB
M<D*>&C%60\[9K<Z @@64#WUD5:Z[31B,KE49,RKG4NN98QH+*&BT)TT-NOZ5
M=IHYEQ 5E3B<S@LR&.V7*+NH8!@,I/E6S#'+(UN2% Q<(+L@8AAQ%"VL3<L%
MZ7&I.E88=640RMAV5'E.9\Z'Z,Q(+H >C&UM>]:X& >;718[V:/D<9%DSF]^
MX("@ULPP8Q8XB>&HX2%P(^1WB:16$<CDZKHX-AUK-#35T%06.Y]D2$L""I0&
M4 !BP&HN#:PI47F#DEI;,+'C"R$W(5=3PQD5&SG3*>BV[412?$#*+OEH!2C!
MF8I=&=BS:$@-I<$DG3R%;NK7XB5"6B 66,'(5C&J@,5(+7O<E<MF!\C6S4HV
MR.@C>-ED"*^8\W#1(Q$A) LILI#'\>1(O@!E'BC*0L12Y6Q1E$GU6=3ERL 0
M X/;I2U]0EQR QQ7$LP*@WB7*,J9EOS64]/9[Z_=6G?43H"(L09R7A+%2<K1
MNYLBM[21@@Y\C"^NGPK=S7:&RSS(BYA=V16$@T!;ZRV%E+$'4#H:TES,#&/'
M<0QR)&F:(E6TTD3BM<YNHE%SI^JM6MW"E*W 4>&QYQ3Y?HU(246;*)"5T2ZV
ML"03WL:7&;BK+0S>N'"SH$CS(=%(-HP,S(<H# =V-9OF6? '&0B+D=0L?TDS
M6*\*T8?E4>VP4ZTB3;>>1EP9A8B1GDEX2M &6]E*$D$,JM:RN#Z:FDV,=F91
M*^=8^#'D%W:1SS,02+W!M&AT-9H:MD=TRB;.&CB*NQXD:GB'30I;H">^MZS4
MQ.V8M=B[P2X(QF*>\D(7B)*!PYXW!)65F%M#\:TDEVBU4:>\B3>X6^F.CEP0
MP\LH:+$P,94>8+ ="T"93F.' .NIH4Z4)^DM TZDW%Y\#=A\B[Y0FV=B[>P>
MS]I[7>7"XS$Q\&-Y)G"0A&"H%N5X9*FP.HJ QT(0;W%F1-2E4W^LCP+&OAUO
M[A-I;/PDBS\020*5LP5E 50!H=6)%_<::TYJ5-9DQA*V\E?D2(V7M%9TC=7#
MW49]1H2-+&_-?SIU":<=25I56TEP8I4;,H)4 @"X]_;[*+'-6'+7:=&4-E6U
M@IO<>NM$3W33\T[#0M8 CTZ?S5INXAYG1@00;]1T^-*CI84L\CLI/IKW/;W>
ME:D:D=6&I.AY0!;L/Y]:W%Y6[3:.%&:P) (!YB.WIVTK<G;0TW9G!('3*3KT
M%K?KUK<;O4TG<Y4+E!/6Q%K=[]:U*33,;L?!+#KJV@]Q[UIS-7.0EB3?H#<$
M7&G3[C6G*YC9R5!MF-M+BP\_V5BE8TG8^ "G0L+]R.X]/*L;N8W<[BS$:WR^
MG6_\U:,/@ "2>^;MY&M\+&'RV-] *QY&K)GS*.O0].G6L3,LEH?6U70 Z^OX
MTK?!F'8FQ \Z2E<V=>X)Y;6'O_8*7;@:.W-Y#X]ZV8? -I>UAY5AI*RL<ZWZ
MZ?H_!K1L^[W ^T6/\U89W'QOYVL;_#UK##@W-B" /UGTZ&L,/K'KH=+>I_4*
MV8<B_>W3M^/*M&'-88??CW5AA]8>X_I]_NK#,O:?5AA]I6&' L?@;5AAS6&'
M!%QUMZUAAS6&'!%Q:L,/K"Y/<BU88<UAA]6&'U88?5AA]6&'WV_9^FL,/JPR
MY]6&'U88?5AA]6&'U:4;.YA\:V8<:@=;GS-88?:W/E6&'-88<UAO+VG!_':L
M-&,AB"+YK6OYCW>=;,/NI)\OXW;7T]*PP"OG!(L+]A;E^)HZLT!JY2N I  S
M'+TZ'RMY=CI6K9W[!K4R5PAQ!0)(5T" @9M2U^^FO7I:C0&53)"8F*D#/;,A
MS=.49P>J$%3UU\Z=0>0V"C$* V9 ^4:R78HC1HF3-&JVNQZZT8T%9.475OHT
M6Z,8N?7JI%K6UI4/2, ,ELQ5<SVU55&4CGRBX:ULMQ;W482E8ZA<A<=,J9L@
M)-G)Y2QUR >E8;,^K. 0KD77,.AU)S#3J?*D3T-H-L(I61+=%<N>S9'LF06Z
MDD7/I0C!4[(!.,AR\,#B6M:YT)U';6U-L1\7+N'&&2=>"[17;$82;5WCD)N#
MC,.@/EEP: GR%R+^E0=-.,>QDMA;/'XAO2Z$%XF<^U-V(6>-5^<.[*ZEL^O8
M#K<4TQ23JJVD5<9;3M\)A&WW/XQR]GJD>'B"Y2H0'2XZ6  72PM0Z-:K-[U\
MKZ$I3A1@MV2\ZP82ZAA&RJX)8?QM.WW5*4YQFW'[JYJHK+S7Q$_CQ@]I"7"R
M.N#VA#RK,\:>P5S<1#(.>-K]-#I0G3K[^];+OL-Z]2C5BHW<<0LKVN0@\6]M
M;'_JW[#V9QSM2#=#P[3:F)P4;.F&VIO)O%MO';(V'LW#YF,$6*2>!2ZVS&%A
M_%%9*=6N_@D?3S;[$G]?M+!L+#K#4*N+J/>C:,=+<,VAY=Q/#U]UMF;7WBQN
M%BVSOGL\8[#3;7E2 )@<2T"8G%X?9O(9,.F#600Q%-"0;^U3BAAJ4)6>;ME>
MQ'XS:5>M%RS5&,K=EM,UQ?:QG-B[,V3MK'S[V8O'8>; 8G&-B\;M2:QPV#V?
M!B9(\7PYI+Y555T"G5AIWK<I[N(W:B48VU&RZR:C3@Y.<],^9J,_*-8/9_B7
MXFX7Q=\*MC8C8&[T&'P.X.\6V,-"<$V_F)P$V7 ;SM (T9$PV'7YEAY&U>(9
MFL=!6=L8C#UZT:5*6]6A)W_)?D=DZ+83%[*V<Z.-ONS<90C]Z_NOWW%,2OY/
MK'OL7Y0>^V[F^F P6]6R?$3<O#1;LXO>?A[>Q&S]O[K8O\YMA-E2[4^<-&-J
M;*DQB3*& 9<-%&!ES"I#HRZ?PB>'KYU)*\7?/)Z+L8WZ74=["1Q6'64'9Q62
ML\\[:ZFVGQTV)A,)X>KOAC-D[N'!038"+:$<^!P<F#^=8+$MLK$''M+$P*-L
MO$8=@QU-P"=-+%M*-.M@ZL,MY.^GYY7R*?LB<OA<8POO2X<#2MN?LO8WB#M3
MQ2^27O#M#9T&Q_%C>G&;B[*Q&UFA:#9.^VT,2<5X9;T;.Q&27#18C9&VIX%B
M:*SA4X=\K5SR"<ZKI05][**[>1?<2Y4\-3QL<JE%O>MK)+-KN2*_7BIN'O5X
M?>)^^>Y^^VRIMG;V;H;S[>W/WGP4:KA\+A-X-S]HXG86T>"D85)<--B\ QAD
ML!+ \<BW5P2VO&$MRV:R?8^/UY$O":KQABJ?G4IQ37<]/J&1WAP$^.Q_S=3(
M'CE5,J27.65; V YLJV%KV+7[4>G.,'FLAGB*<I3^QO+D)"?:FW=SH,5LK9T
MT:/M<WQ$Y5Y)UP\ R/AH 6&3YQ&7615T8-Z:NX1IXB2EHD1&(E4PL7%9MNXS
M^WM^YMN;2E2>)P,.1@\/"Z%Y%$DKE\\KW 5FU*DV7I4Q0PD:<;KC9E9Q>,E6
MJ_9%9+@)Z19<Q:"%(PDBB5S):-96B2(>R&%HT%P!YT^E5J*Z62&T8W62R!_Y
MCP[/EG6&.$0\5N&,B\)6R\4S>V6N.O=:W/%U4K7LS(X>G>\EF'..7 ['V/B?
MS;@L/Q,0D$<CAI)'*6TQ2&S,D"+?1?K>^F\:LJM:+J-Z\PTG"C3:@EO2&G@W
M VYM3&R[:&&FCN_SA"\%Y9L/&2[XL1GJW#8\GF/6I>KMBA3@J.;:Y>!&4ME5
MJLG4M:)L!\ _"S<YMRMDX[:N VMO)O%@MYI\=/A8<9&DDLRO?"H=GLV;#8."
MX&9@"PO;2JQCL;*O6<D]V-DB][(V=0IX6$I1<I;S>>6=\G[#:9\G;Y.VV-NX
M3:^\>.W$P6\.VML8N;%8/^M,#/@]D3X?%3Q;*PNR,-/&QCPF$V=&D>+Q+IF8
MDVU6H7$U[)1I-Y+G^:+=0C1I0<L1;?EQ:5U;E^4V"[3\!M\-K8K=_9VPMBX/
M8V?8TNS]MXG:.V(L1LZ;"/'-QY=DX3!A)=F0P%#$650",O<FHY2DFZBU87X5
MA;;U22E%>CEI^5C1;;^2]M?9D6RUCVOLW86[BX>2/$;-V)L],9CW6+%1GB8G
M$8_+)C&#%I(LUT8%O*LZV:EO/-CF%6C.*^^?&VH4XGPMV)CF2*#>.8+"N'P^
M'P4&S<#L@3(N':PCC3,4CAB,:R.@NZ@=[UM8B:OD*E2@QN=K^">Z> ,1Q:8O
M$RQ.4C.T=K-F QKR19@"M_F^?F16%[ =.RXXNK%96L"="%S-NUN%LG99Q/YO
MAPD>'AB?#8;B(DAE*K#%/P6".R+/.&)86U7WUDL14GJP4Z27#(46T]EXS=Z#
M%X;!8%,/!)AR<-.F%N<4[QL9&:6)KQ(LC$"_+292DEK<#U--O3,CL^(VOM7$
MX;#XXB$[&$F-FB"I#^<9+Y%CQ"+G@G@PZ1 @7NQ;36]A:AHP2RM8+L&<7M/=
M[:F$&RH]H1X.7AP1([X<,N*9W611$03></KU6UJQ.V:$N/ 5NS-E#!;N8:/!
MQK+B3B$CQ&%3#B"3"IH )'.LRLQ)+:LUJS7O$3B]W*S8K=YRVS]W,2[OAGQ,
MD#X5EC5D@BC:;YOG>%RACC*(I8:ZL2-*UDM1M*$MW09C>G:QA@V-LV# +A=J
MQF*#%8B!@W];<,%DPKPBXB=0&()L!ZUB>=QM4I[RM(2,VW\7,PN[-P\.T<V)
M@DE@58I7!D$09BZ.5 4N/:M2MX;RH>;969VVWMW8Z_F_"PO'B\5AECFG2?$<
M7"Q$N[?3YP6B:-'4*HT;+<ZWK>^P4<-*_)!?@=^MIXS#18/$8))]DQ8TO-(@
MX4T,22-)PHY8[\-)(HCEM8D$TEN_8*^!03WD_.L2V\(MY8]Y=K</!8'&QX;#
MX/!PXB55EO"LV%7$288NIN T4PCTULH/6ANZX@:E'JDDK6S'EWB\/L*V"VWM
MC9SM DY;$1[/Q["0Q/HJHLK@,$5M=>89A\-J>>>8FE4^R)6&'QNRMN' I"[X
M.7:11V:*".,0O$ F&?$)B$SMQ4CEL5T#%KT13X)9DQ3IWSOE847@YX1;7\0_
M$39VP-I2X2?8J[0P&T\= <(V$Q<6S-GZ[1QC8J&-I&Q6(EY@S>T3UT%2&SZ/
MPG%1A'.VO81FW,?#9FS9XE.U3=:7>S=BN&P^#PF$P&"6)L)@\*F$PT-LN7#0
MHD.'NC Y0((QG(ZL2W4FND4XQA!06B1Y[KN=2;G/.I)MOO8 ,2N'82!F94B2
M('(%MF-V(ZP@BPT)ZT1-70"UEF=H\.)"F6-6E68PLK<_&NG+P<HL->F:Q\]*
M+O2Y(TK<0KV]MG86ZV$?'[P[:V#L'!*+/B=N;2PFSDR*3>=?G$L;B-"MB+=;
M7[4B5:G#XR48]X6G0JUW:A"<NY,B3OM\O?Y'^X,^*7:'C+LS;6T\-Q4_->Y>
M$Q&\>,?%Q(66!</@4:(J"M[DVUII4VI@J/IS3[LR;PO1;;F*SA0:CS;L0QW\
M_+%;HX6/$R^%?@MO/O85B(BQN^FTL'NKA'?(;'$;.02;24RRK=; FP]:BJW2
M"#RH)/O+%A^@.+MO8BJEV16?MOP(0;__ )4WY6V_S%-VY-TO"39"\7Y_!NOL
ML;P;6BA#R.)#M3:V1\/((% ;*AMU%1E;;F+;R:2["<PO0S9E&2Z^,IR6MV_
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M9+EI8WDNLM[V"FV?*#_>T1*XUF[=X3XS)HQ")GC7*AC8LT!/%N2,ME%\I-M
M*+&3L-*T.8FL5B+=80A;A1!XK@.![76V9E^M:UJ<TE+CJ,*N[RS$^ZNI>16
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MPP!%>YM;UK>ZK:FG%H<G8NR\09<#AL.&B&,$28>63AO ZR,;322!LH@REK,
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MB^BN2>G:L,.AF$;9#)SZ.F9>?*&N3%U0%+VZ6K9AUXL;FSR%F$<JQ2&[/(Q
MT=;9%]=-*RQJQG$K+]%$+F4,(Q$0'4PM8DBVG%M>]P*T:L=Y7:4F)6 D.:2Q
M#$(Z= %4@79P2U^MZS,RQB8NXDL V;(2A.01\F<@WO;+T]:PT=PP8C,6E1LM
MAE)"NO5HV!!5">A-88=HEDG9T51E=D=1)RA5CXC2$$ZEB4^^L,.LX@'$,;ME
M9$(:62X90Y&5UU 8!1I?2L,"?%2B&81+*$#0R%'=EDM)B&C0*UK*O#'GVI2?
M %+4*).(BEV07#'*1*P86-LHR6N=/.E/3,2M<@*Y*2%V8.0F4G,<][>VV:Y)
MN:7#)/D)GJPO+N,UB61E?,;K?I?1=&D-SIKI6XO,"V!(\BF9@S+PES7M<NRC
M-WU#$,.M]:<)W7>-VO..V?C1 Q%UE>0(]M&R,QS#^+&P _[%K>CST,T>>@9P
M8C,4$2AAET!R@%%&4%6!/T@<=?(4FQF@).)*JXU"J]V90Q'/<,-+$D$:GIVK
M2N;U.8GS112J,@)<F[<I'F6U8$VM8_S;U--6T.!BLZHJK:-'#W YB62Q%S9F
M4=JU<S4-8L5=8V$DF9RD9*VLZWBY"HYE(R6OYT10NMY"<@7#CW9S"@L%:,D.
M5RKPT D>20@DW<7'D-*)WFPT&T0RF1'CE"!BZ+<%D5&D#1VT).6Q)\Z2X75C
M+AG!/8<LR3Y#9HA90'YF+,IU).7JO2^M"=XY&"IV5B1([*2JA(T4Y[*Q=]6"
M-T9+BM.R62SXF1RD/;N[LF-,-\[R*7+(3D=4LJH2C:WS(S$Z=;@T*>0XAS>:
M#WYQ\RCEFQ2+%''&I^;)<R(9 &SW479&)O:@O/04S)@]\5#1/A&2*6)T7.YM
M"5:_#+AA:RV.G76ASHSD[\3-ZR=GD3(\"/&.;=7>'9&/&.,,>(X32O<G,R,2
M44(0J1RZ :#77W1&/P<X8>56/IKP&-2"J/)><BU[\DOQCPF\NX^P<0\R3328
M59<J.IRA2Q"9C<,X)U/G4)&<H.,&FFS,%B$INF_21LHV#M:*=(QF1G(2QS?4
M;+:QZ'6_2G\9/B3]&O9V2%NDJR &YL=+>172VGG3V$LAZ[S\XR=#ITM^NB"#
MZ_I<'\=/A6&K'7IJ#;KU].Q]XK#;T.;@K=M=;_JMZUL2?  ^R;>>E:,:,9%P
M&'+8D>=*3L8G8^":ABPM?[21?]=*W\K6-W.0I!9NH!N/77KZ6I+=S&[G.?6^
M7MIKH//XF]:-'UOK6N&OH?U'WUB5S$KG7H!U4%M3<'W>X 4NQO=.RG-<$W Z
M$];_ *#6/+,RV1SH" ;&UQ<C]'Q%:[1%\['PN"2+D>I'QM;6L[S9]I?7H;7M
MV-_U5LPY!UN""+95'<V-F^ K##DZ\O3N??Y>M;,.I;4&UP+B_GVK##OJ1V&;
MKY@6MIZVK##@#+I;3J"3U/E[ZPP["Y-S]GE\>^E:,/C8?$_J_=6&'-89WG5B
M+6OW T[?NK9F1R+6%JT8<_CX5AAQ<WM;3SK##FL,/JPP^T\]:PS(^K##ZL,.
M+!>@ZV_'WUAAS6&'U88?5AA]6&'!OVM?UK##[7TOI?K;X5AAQ8^?0?KOK6S#
MM6C#ZL,/JPP^K##C77I;M^^L,.:PPX&OW_<;5AA\QL0.MZPQY'/WUAAP3^@G
M[/YZPPX!)[6]];-9\CM6C9P#?IV-OLK##FL,[CJ;B[7T'5?+3M6&[<>!QS$7
M#@_ ?OK9HX 51F%SY7.M88!GN<UC?R^[]%'CP!5?2]@#E=N&RL#+H,S$B,6[
ME?<:P9U1/XL )D#.@<WS%;KVTS'FU^RB0&E33V"9Q'\(RV*@NBE@I=N7VB">
M@"D4[AZ*&H2XED"D*X9A?/Q!HP'_  NUO*C&@OQ(5O9/LQKSE@S"ZD:#4"Q(
M-O(5M*[L8!Y;(7R$ZNG*N6\H/,[2 @7#%C:C+)6-'2)2"\MF+%@ \;AQ_I0I
MU'E6S 6K0\OM%B;.!8G5B + "Q6USYTB>AB#'"JQ4(RNV89E"V4OH+H<O-R@
M_90C8I-GKPIXKD B102.8%=1E'>X H%1>8T&H/[+'O&ZWH@*[R;;*A_I($:Q
MU)0IPV4+U#%ES>ZHS$U=R@FW96#^GBJ@T6P8<2VW</,_$EBBQC*C/IPV1BN5
M@WM *EM#2(49U,!5FL_Q@9M=:KY+(D5XBX3%XC<+:N#P<5S+LO'Q9=?H\T%E
M86NPS$FP%56+G*:A3YJ_LU1.8CS\*XU/1<+7(,_)W\+\/AY<;'M<X6:#"8M9
MVV?B81(S-*3(27D7.I#FK!1H_":DY2NGPL/<#7I_!84DX2C&*RO9V)G.-C;-
MPFT-CX+9<*1;2P<\,2Q!"83B_HL3*7MF(C(S+WMI4]3ZSJ-QSDG'W6$U_@O6
M*U*,5=9+\J(\>#^S\-C/E0^)>UXKM@-DOBL/@ J&-8VQN"P,*"51;._!P)^%
M04)[VTJF5\DK]I.[8?5='Z%&G&UYMV['FK=PY^_OB?A-W/#=<!#*[[Q[4QFT
M/F4$=I1#A5QTB'$S W$85=44ZC]++:^)A1H3L[5&\D-NBVQ)[6KTU*/VO!WD
M^:Y=Y!O;T^)P>S'QD<X^<XL-B"C)\X,\KR%YI)F8\,M(6S@=F]!5'J2FXMIJ
M[XL[=@Z=&.(C3BK0BK+N-:/RD-_\*(Y]E8C&8\SL@23"0LK1#/HPBB53>(GV
ME4\K&_2HF<KNR:3N77 8:-.*<7DEESOVC6P89?E9?)CWV79,EOE'?)*P<.WM
MO;"A48C'>(_R9\?C)XX]M;,B=GQ./V[X5;1.)$O#4B/!O!%?B8F.UNPE)8K9
MK4%>M'*W//4YSMI/8_2&/W.S<8TK\(35L^YZ9=Y-3\E+\H#9.V=A[P^ .U\8
MT6V=FS8C?S<C$8B7BC&[-Q;)%M_8V#<%3B)L!C8/G04&X7$7MUJT]&\1]@^!
MU<Y0D[+Q^NY2^F.SW#$_#X?%OTNSM;^HBQ\NK<<[D^/NW9L/!A<-A]M[6P.\
M+8@8<1KB&WAPTL&S=I/B(55.%B<? \4^=>2=8B2.[+;F&ITL2J]+2<<^\=='
M,5UV%E2F[J+U[ OV3NOA_'OY*/RF/DSXJ$XK?KPPV?A_E?>"QGD<S':NX^S!
MNYXL["V$L,<LRX/$[JF+'KAHRK8S:6T;D%M:C)1>(P$J5OLE)[Z]7BO?=_42
M,9+![3H8V[C1J-TI]F]Z+:Y<.R[Y%>J7AC%QL['$0AVDBQ;ETE6&?#)-"LN&
M-BLH9C&UQ<."#TJ*4X^\LM6G.E-TJF4HNW\@W^\<4QCQ:O  LJ2R0<.QS-*L
MP$68BPQ-@&"]P>M.Z,]&M2-Q-&[O*+&$V[LAEPFT8,LJ///"<,ZY8Y$9#])'
M(#=[B-<K$:%JE*-17LV5G%4+1E&WG/01\VS-H3XM9HY<.(,-&91$4?/QH\/'
M964:FT;ZZ=13^-:*27 B_@\K6NMY(!X+8V)Q,T7%5G5&X'SB]A;+)-&\Q>S.
M!'*!ITM6W56JL)ZN:R:8\7A-NAL_&[<3YU$9EXW%;%DR2A,)&K/-,JJ>2.!4
MTZD]*#.O+6&3'F'H)U-VHKJQN*\#]U(-K[-G5,)LUL+@H\*(),3FPT7 CEPH
M=@TB,<./I>;,1G>Z]A:#QF]-ZYLN&S9]7%QRLB<6X>YFT<'#,C[-@FBF _,Z
MIC(ECQ<ZOQN$^'A*XIE@BN!S9>E1UG&5GJ3*J[\21NY\N(@P\V-VWL88=EEE
MPL^+P& B.T(\#A<5'-AVDQ#RE(#!AYVSN<Q=$;O:V&2:]%6WAY,'M_8T>#B?
M9N.V?.,3&LL<N-V_CF.%QQA#R0#"X3+&\;1J#&&T4DWUI$M+/4'U4Y.[NNZU
MOK$'CI]V]I\39N&PV+<- N*Q!BEQ*SX.=YI)9I8Y)F9Q.%#,J$&ZV.N@ &T/
MX1JV\^S$D=L"#"8O9>!QVU9EQL$V#QQQ^)Q.*A9<%)82(1PB L:<R]#(6M0G
M-)VL$="4I1EEEF-]MK9^!V&\V+P>T-JGYE+'B,#$C3),^)D5N+&\4S76-;*Z
MKJ,OOK76-:!84I2X)W";!^(^)PKK&\RX]H9IXY/SGAEBCX&'5<MI#S LC* P
MZ_IWUG&V8FILM2R5U?EH=W\<,?M+!XK99W9V?+B1AY)5Q6&E&'PZ1J[\/YN6
M!1\0H6S*>HUI769Z- 5L;JI.2F]-"..WM]9]YL1%,F#&S)\-(T.)CFD0F58K
MSDEXK))%(P5<H ([TNX2.'ZN+6N9@V9 NS]J/C-G8>#:&'Q&/48_"R3A7EE2
M2=L1)&GL@)-, /[U:U<U+.+2%KM7:L44$6.B;YIB8EQ4<T!&5TCC'&416UF$
MF4"X'+6FQMU2:LQJMY=[7VI%A8<3)BEO+B!B)"3$84?,T-GD153FD! [V-;$
M]7N+(8S>K=O ;3VPFUHY\+)#PTDFPI>2XF@;A1R\@7/+*5S&W3O6UJ#E![RE
M?*PVVT]FRN3+AHXH7>5LJJLD2.C&+$0+<#-QF6["]QK;SI6^!E3<O.C=+B*+
M=WPVWJVTAVGLO=V?:4Q$&"Q<N9\.L>.#XF9&C>3@B8QPSJS*+J0=>E;3OH@$
MIT*7QLEO<AX-F^%6V=@<7';:VCL#=W:$&&PS2X48V6>1@^4J)XHOZWXA56)*
M<JTBS7I($\9&?FTHML5<,6Z/$P^(VGO-)MC&X1%7#R[(@3"K$,.D9&1V!^<,
MH8@>1-:;[!$98F66Y9/F+;96^6R=FX<C=399*'A'&8S:3OBMH//(0HE8S71%
MRQ.<B"X^VD.HDVK,<? )U8^?)+N3.9/$S>:5)I,/M/\ -;)AI?FTFS@D4L0,
MD+),8WNT<H?ZZ>PX4T/>M+>5U^>0[IX&@F]^*GE:ST[1DO$3Q,\2O$1IIM]/
M$7>_:V!CCP\,. VCMK%+:?#J(U17AD5\23'8,7ZD>6E*>(K37V23;0JC@-GX
M--82C3@F[NR7XR/N/W1V=BF65(II)<*L^(BN43$1XF8-')+=K23!D-FU-U8]
M[4F,I)N[U'$IW6[NJWM_X HDV="Z(K8=V818>/BN<[8C)$KC(F@6-% 4@] H
MI<9-WOH@;LUGJ<M.=CJDWS3B+,^'X:1(DP:(-9VYTR!HZW%W8G=CR#R'89VA
M/QIY>&%@EEPUXD3Z-[RDR1W(90%"J ;DMZ5CDD[&;J"G$IA<-C<JB'#Y&*XB
M.3#/RE4S0/+]54>0DDWTK%+>$35K6"S$139=#$L[222+*F<1LR-"<,J2+8<%
M&9V(/7M2@84C9?SUI"I4/#PY\TA6%WQ*((T5'-E>+.KDZ="+W-;3 SAQX  X
M?%@8R)(E EY.(PSIFB&9S(NK*@8V#>9K&#=DFK!=M3!AYTB:166&7%)))"L9
ME=WDD<1-)8G+9P+:6 ).@I4)6=AE76_%6X"/Q>QY1"8%1W@,BXF?"Q*A>(PM
M>'%)(QMF9<PL#VO3N%59I99$?.DUR YPT^T LD!#F!)67%/'D98,R<99L_+(
MZ$#0=;&E;UL[@)0=],@HVMLX#%()85<1Q1V9XT@(9NSK'89'!'7SHT*F6;S
M5:2:TS"%]B8J+Y]+(W 48:1X',4/T+%60,$(L5BG*F_4%1V-%59-)=HUGAO.
MNUP%]NMNA%B-BIC9,!A6A:*$<:;()<$LQD"3BRD<*.8W-AU>MNI;+0!+#Y\A
M=1;NXO#823"8K 89X9FD6+'HIEBBF;+ERK!E:S(/:T&M)=1-6U9BPZX@:.+#
M8.S%CB\.(9B<*ZAL0'7-']$I *J6'*YUYJTI9Z6%1H*_,#Q[N$S13O%+ (A%
M(^'D0RK)AV0-)F9".4DZBDSFXY+4<QPF:=A5[!V0F&FDFQ$915E*X?"X5%C@
M,<N?)+*=>( KC*IU# 5J3;R:S'N'PVY4N.#L.*!L>$@4XM$P\G"D^:*D[1QE
MH^)("1DCCFE(\SY4*3<5<D:=).I:V5A_-WMTIH5PV+Q6(5I4C!D7.I1P"F6*
M-\EE8@Z>1IG*K?WDQAJ+I0\[-AOO+O'LS=#8VTMJX^=\#%LG 3X[:,S'(TL4
M8+1P8?F(EQ.(4V7K;RK48RG448ZA'54(.K-6@OS\34KXC;\XOQ/WIDWAQ\,P
MPN'DCCV-L]YA(NQL*,I>%V0(/G4^'E)9P+%@.U67"T%AH;M_/?$J.*Q$L96Z
MR><$[(/-W[8:7"S11SNRXE)EPTH4\(13(80S&R9RK-S=B1WH==;T'?TAWAVU
M:^A*_<K$EWP$JM+C&6)9&Z\O9$G<WO)<L2XUL *B:RL[<2P46Y9\;$D]E11X
MJ))\5'P62+AP!XV(1B)&26/-?61&-QW44UWL["W-Q>=@BW@W-PN)DB,4B (9
MKI(KY)G$[K%S&PCR*Y'>MJ5E8W2G-SUR0P^\NROF$^-$N'B)&7##A(^92K?2
M%D>V9U7732EJ[SRL3%&:W1MHWBPV)D$R&!^*D.%Y9%&(21A/%:,7M])$>ITO
M6VPRDF\LF2'\&-I_-\>VS'Q&)>!YVQ<*AV/TG1Q'<L54L;4"JK*Z#QEYKB3%
MV-C(TQ"!B\;69(^-,H5>"CN. [W+EY"JL;V!ILFWD] $X\3;#X*3?TR?)4\5
M<1L\!]J^%.\.Q=^</$BN98I,0GYIQV%S$B.2&?#JC-]0H@;L*L. Q$L-A)8E
M>E!I/N.&^5:BZ=:AB(YVIO3O&I\7/"'=[Y3_ (0XS%;K#9N#\3=TU@WGW:QD
MZ)-A\8O3:VR-IJH3$8O X[#QN!]9" 1:IS XRAB*:QE)WI-VDEKVYG,<#B.L
MA>DO.MF0I\+O&YO S<KY1.&WUW'3"1^&> ^37NOO'LEW,,F.DWCWS\1(-O;-
MV;+RVEV,=IG:&&D49B(HRIL+%QC,-5VA1HTXW?GS?;=+),EZ>-WEN.]^)*'$
M#!;4BEV_@L3L[;FQMI[ P6]V%WLP$YQ"[3W&VK#-A]F;S8?#@D;0&; M@=IQ
M6,D6)PA:RYM8.I1E125>#512W;=O#W\QW&49YY">\-<?M:&7>G=6>9<?L/:^
MS)][]RMO-)E3:>*W4OB\9@,+ATLKXC%;-Q$D9M_"91IRT_HK<O#2UOK"U5%6
MD+7<[>O>O?+$1;+P^-PVS=E;0:&7')"G$D3"PL'?#-BXR(XF8 91V!MUHDJB
MC=--Y"7!N2BGEJ;0?"3=G8^RWW=VG (6Q>)QVS\.TCW9@(&<QQL-25S3W!.N
M:F=.INTY-K)W%U8[W?H1*\:ML+/M[>;96S)X8, SX[8:288C/A-K.V(40%QF
M5WPHARZ "1G '0TTK5-&D+PRM2SU9KZ\(]\\+N?ON7Q;+@F&UMI;'VW#B-,-
MM+BJT?%Q"QY3%)&-1IDOUIYB\.\30?'S5;L$8>I.E5WH\\^T=K 8.3=_QPV1
MB8HX=D;1WAV7MB; RMATA@Q6RL7''$D49)$1,@$1Z%K3'R-,%.53 2@GO.$E
M[+<>X-NNGB%+2#BR);8["83:^V<-C,(<-BH-K8Z!F&(,B30QSRYTDM98PQ.G
M859(*4H0DOO%<;.,K-15[.X9KM3 3))#A/F\H,2(I5F,D3*J'B1"X0!2W-YV
MI0A*P=QQ)PRR39%Q""7AQ+Q(Y;)'+(\N6S#C%N;32U89:[#O8^TEBFG9EQ+X
M6-L.DBF%6:,M(@ PEN4IKU-[4&<<P\8[O>.1L7;1P[J7$GS60$6+D<.2.6+A
M<=B<^:1(\QMRVIO*FFS-V6]O18]VZ^WE")B"<_"FCA@1Y%LMM2Q L"C9]>YM
M47B:*UX#JA5DXV9++P]WV<-A6.(DX&0D%'$20LMS>(+S &W2UQ3"$NIJ-QRB
MAUU5.:W9YQ-GO@EOW_3#@$P>*>/YRD"(+NH,EEN9%7K:VENM6K9E55HMKXQ$
M'6OAYNB_BV2$O;KH+=>OW#6I?Q!VR[#FL-'WQK#>1]6&CX_;6&'%@;$C7]'X
M-89D? W'E6&'W<:?'RK##FL,/JPP^K##C6]M-;V_?6&+6QQ8_P ;M;X^?:L,
M.PTOWZ_"L,/JPP[Q>V=![/7OU'7TI,]!QA_3?.Q__]"\3MO^W&TNO^?)_P#+
M-/J:O!=Q 5[]?+UF %%A^NEO6P%-O,$1K86'OZ?=]U:=D9KF=\I\KGU L-/N
MUK5Q7@=\@T\N]ST/IUK5S=^6AU-KFW3U_76S9R%U%B0/, W]U[5J_O,N"0IR
MZJ-/AI69FK>\RH +64"_XZTG,6L@4L72YO<=NWZ;UAN[.XC(]P/E6[FK,R!0
M-=#\.GZ:UV\11A<$=SIKTZ^E;1JZT.M[B]N_Q_8*48<Y0-,MAH?/I\:W?@:U
M.0N@ZVM<Z&XN=>YO]M889".?,M]#J0"+'N#>UJPV=P,HU%O(DC[=.M_NI+U-
MG-A;3I]VOEZ5ILP^M:]M;Z@#IT^ZM]YH^RCOIJIL+>\]1WO6[V,[CH5(LUNB
MCE '4]S;]%;,.2!TO:^HUUOW"GZHUZ"M&' !NU@ ;Y2+6O;R&H&AO>MF'.70
M%EN;V4V&H];7M:DJRR-G:PS&UA;*N@Y?77373X5J1ASY9AYW/34=!;7K2<C9
MV4"^HUM?7IZ^598P^'<$#0ZV]>EKD=:RUS#M;E-O4==;>X7O6K&'(%AT%CH#
MY68DCWB]88=M !W/-U]>XZ5AAR![*JFH!UL-?(?"L,,BKTTYW ) M<CK>YL/
M2U88<Y0=#F!!.8:'W:=+5AAFRBPT%K=1H/2^MZPPXL3H2#TMI<#R'EK6&'<"
MQ[=-;6M\.]88?91:W;OY^\'J#6&'V4 "Q )'06)N.YOK?7XULPXUOH ;C7H/
MWZ_JK1AV UZ:V)[: #IZ5LP[ 7M90!J;"QL0!>_3J>GNK3=C#C7]5[?=VI+9
ML[C5@  --21<"P-]-;DVK1A\%UM>]UNO;F(!M?6L,.;VRV!+%A<GEM8=!KK<
M^M8S+F7*3Y7O?5&_3<C2M(T=@ %RZ7/3E(UMK8^HK8M2:.=%R'+86L6/H#W]
M;UAO>OD<KH 2+%K!;ZM;R/D#6\C,S)8=>MA:Q'Z3UL:PUVG7+K;0$:];CUN#
MU'PK#-&<Z=%M_>ZZL#W)[6\J1;WF'( [E;7(/>P4C4#UK7::.;9KG+<L6*MW
M 7K;O<BMF':UU!&7NQ!U-QU];D"LN;OQ.&&F;+;4!2>I"CR_OK]:S4VW<ZZZ
MZ7/?3H3T'6M6R[3$['4Z@C4:6T.4WO\ &U)W;9F]Z_<=@<I)L/?U/OZ=16K9
M9F-Y' %]+7)U-M#;T[7O2;)Y<1.AVY0HUU/EU77KZZ5IQR-\3*&U.ALH-Q?0
M'72UN](MS-'?4%CEZ"R@==+6^!O6FD\C?$Y#7L;6%CFOU##L1T(I#5C=SF_0
MCIIZ'4WN#Z5F2,N=P1:W8]/AY]R#6U;AH;NCZZZWTT( MZ=CVU-;S%(^%F*I
M8Z GWV_4;5B5S:D][-G)( 8BZD!>I/G^NM/)!&US0E=M[37#))=K')F#WT!O
MWZ#M0+;TNP;5:D8Y\" GBMO-B]N[9FP.$G9XXL0#/$I)&4FP([&X'2G-".Y)
ML?;)P^\WB)*[>@1[%V:JY0L7,Z6.;+= %]J[(?:/7RHV_)R)^,9)6>@XL6'"
MJ%6P&92K9LMT"V)*IT:_3SI,KS=V;;2 .)B4K*NA=,Q5/JFY/+K=;L#U[4N,
MN%C:66?$2^,V7&\9XR!'6[:=^H8%0%!RN0->M&;NK"U%)W$Q+A(49EC'$G36
MUA&H6WL95&4'XTSDK3[1S"TLV)S:.R<N&SY<ZA).0*2 7L]F87 RJI^!^TKE
MNTG!J^3%6WG>]E<C]OI@XT+R>Q&+(5R*5'=F!).9AVJ(J/.W(E**5TDB+F^>
M.@P<\\7$FG@X)Y95<(X*WT<V/%)T.A'I0HV'JC8C/O7O/ABDV2&.RWM''P\_
M$*&0K<O=E8FU^U!M=V%^8G8A-XD[X28O$OAX97A@"$%3(%>!WN#'FC),F4C3
MIUI=.&[GJAM.I>/(8C%8B0R92[$L"%#-&B1R*MFC=#;,=+@7 /WTX@LA@]<Q
M-8G$PIATD$@60,TCJ69)%(<LS-& 0V=AKJ*4)TS$!MG:H=92TD2M*Z1%$'$X
MI#74Q,]T)D"6.HMF^TD=!IB'KW""Q#97#A4RS%XE14:R!1IS!<@D/J3:GE.4
M5WD75C((=I,HPN5E,D@5U<"%F(C)9+@91])D4 F_>G=/SGO#&KI82\QS!T-R
MRV*ET"Q2D):RD$D@_P :C*U^P9S,19$125:-@4+M"P=2E[V6P/#-]" =:TE=
MB&KJZ>01S3@M8M=USM9A<Y"]@LO9R =+D&U&4+H;SG:P&XZHK7=0Q<)P\RE@
M"+\4>UG44NQJZYF NTHC)RB,I(I>0D))(MRMEL6RGSL!>M@Y.X$<E(FDY2I(
M1+\UG=4%RH(8 9?OK>1H L7+R-ESL5N1FS1 :+Z!:T89<B*P"A58F5LV:ZY6
M>4+&A-_95/M-;L8!P"MY&"9D:P>X4S!7_@@PL6M>Q7I6&&-IK,Q*LI>5BZFX
M49&+*H5254$:5A@(.BJ(F#$J)& (RH[GVN9B3E!Z=JPPY0%I W0\SAY'4!T4
MV87!!OF[5B,,WSB-5L QU9I$S77.%$94D9B4N-!V_1H0]3HLJMP68MPPS1VB
M9592H'+)<*&6YMKTK##D/J\BM(&;^"N%/(KKHMLI0V3KKU^W###BY#Q;"%Y&
M=2%T C'*G\*<Q!:X/4ZUA@6R21)QN)F!FC"(&&5TOFCTO=(XPPO?6E*VH.:S
MN%7'7*\.525F.=@ZDNB%U',=(]5Z@:WHO5IH%OM,PS/&ZC.I=@7:0)I:PO'&
M0J!0";7.M9;=5A,G<+9%19.(Q!47+N6Y%"JX%Q8-F++:L6H)A>S2QAV4/)"2
MJV'L-8\WF54#OW[T>+5ES!-7D<99!PA'R2D!59'RH^0$F20ZYBRO;7RI6N8D
M$0(I1F995X?T8>3(,I 0!<XUU+G+YCR[;,?,&"<A8HLKH0KJ9"05.6,:W5R1
MF\M3>M-<>)HQ1F09BK.B@9WD",!F9KB)6 OFL>MM:T*N"BZR(&#-(\0&92&5
MU (Z@WSD?96&;H;Q.[A[!E +! #D"JR-*2;#H6L">U_2B*;BK6R$&:SI9HB&
M*97DDB)9$C'=;*2Y/UK@:_>M236=C#,%,AG:Q>[A0\9RJ@92RM)9E12Z@WZD
M^E)E*V2,N"8WECR-&68@D2PH>2-EM[0LUED07-^MS0W*[S-7#?9>(=<0DR'.
MBJ9;%[.23=@1<@!#T'I26N1N.3'RV+MTX?"2<1YBI7*PD5\@%N4J200&S"UN
ME::3S"]8X9 C&;QSR,BET40QM$(59K7-E^D;7.H!O?6_I6HQMFC'/>C<+\,X
MAE,KJLH!E)+@O$S)H#EO9QSZ:UM+,0I9CX[KSF&##RPR!)5@5W(3H5"R<F3-
ME8J0!K?MI0ITXS3B]&;@[*ZU-E_R-?E5[>\.]Z-E;$QNV<5+L^;A))AI79(,
M/>9"V4.V0!E;7IJ#4!M39\G'K*/#L(C:,94%U]+4M4>!7BQA][=C[/QD.)XB
MXG"PR*>(A%LC.[@AS=CE\M:@Z%=-[DO2N2&!QBJTTWZ1-/8FT^-&I#$AU# F
MY)2W4L>IO]E2%.I:Z?,L&'K-^:]!8)S :=?7M;]M/HVW;CV4;YHY&K'IRBW3
M7X'RI8AJQUM?+W!OI?0#[*T)9][.A%]-#W)UT].M;,.PL.NA/6YOT]=!6C;.
MMNB@WUN2.VGZZV:.6"W%]-.EJPPXO?E4VT-A;K\;]ZPP^ RWT)-AVZ7]:RQA
MP5NMKD6!T(Z]_.E)V9B=CJ$ RZZ$Z@G33UUM>E.3=S=SE5ROI8JQO;^+Z]KW
MK3=X]IINYSU8Z7%S:QZ]ZUP$VS;.0?7+V&E[=+WZ=:W8V<E3H00>Y%A8^OE:
MMF'  -^Q(-_[T7Z#RN*PPYTN1]7)F'ON=;^ZL,/K92 3<'S'0_?YUAAV.O0V
MM6&'.FE[=?OK1AS^+UAAP>W3KW_5ZUAA\1>WH;ULRU]3ZPL>GGKK6C$D?7Z>
M1M8W]+_JK##[772UOC?]%88<_C\>^L,.+7M?[/7W^E89J?$"VFA\P+_=6S+(
M^'W]N4C]-ZT8?7M;UTK##FL,/K7_ !Y:UAAP/=8GK^.]88?']GIWK##FL,/M
M?QK^RL,/JPP^K##ZL,/JPP^K##B^MO0'[;_LK##FL,/JPP^K##@C0_'[ZV8?
M>5[7_'2M&'QOIK;]=88<UAAQKY_=6Q-I<SGS_1Y5H4?:>588??@^E88<'OTU
M\Q<?'SK##$P (N!8#H-/VULPY*C3*=+Y?WUA@&.;V1HQ)U^J+?WVFM'7,#5]
M+V *;2*06!([JC+>_P#K6MTK!I5T"'$DB.1""48YE!;V0+7 )N2*+ 9U-/8)
MO%*N=DR!B,K%FD6P#"Y Y@3=;>ZU.XY)#8(\4#R)D?+<W;(N@'3("38T4T%;
M9BY(#.N=@$8ZLJ+Z:V/QI4/2,,3*9"2F4 YQSME*93<V%C<*I%NEZ,:.Q )5
M6M8:Z+FC5E%P"Q)'-WT[UAAE7F4,0BFU\JFXNRVTT6P4ZTB>AM!SASRYK%9
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M5XRC;56$8B"JT7!Z%C/Y!7C_ "28;8FQ<1M)Y89#%#!'(47I&@4)*I<!!Q-
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M23E ]UC6&^!VL2O,#96N/7W6N=;:5AF>G YRZ9@/<#ZCK[JPVNP[ %KME
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M7R/0'TU[=!8UFN1M9'-]!F]D&_KJ-1IV!/6M&SNHM<6!TUO?V?2YMTK69AR
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MTT^XP[@ Z9 "=4#=#IKTN#:M-7XF';):UPI%E%K#3L2#I:M7L8?6ZK:P"DZ
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M@^:7= TT0$GSA=<C.1D:)I#?,+C]-*2OD,:BW960VV\./PD2OA\*#!*$XJ*
M641.5U-@URJKKYWHL(V8!M(9+;TT3XR-$E?FGSW6-0[-T4A=;9X>UZFJ7FPT
M*_BVIU&A&XI'(FSL5>*_%;.&A@'8L2#=O07HD7G895(YB9Q^=;A 6B6-I'*
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MO>VI!T_9<5IM,P["RV;^,<O6_2Y_76)\##LUM0<Q-\OGEN.FG05CS,,RA2$
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M!'+]'Z@B_E0):&Q18*RM9H\J$B[L6?5NAZD"Y^R@S#4]&'F)PPFA*YFL@'#
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M(2=1*9A-& W*7R"]W;AL.(PNH&5=#YUEC=KG5I0A475S*5*9T-Y+R.UQE6P
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MX_YW@>)%B%=&;$QEI7C9;9E$+!<VBVTK<LU8U)V5Q9+&,9-B)/F;Q*)6=8C
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M;SN/=6TKNQC,8_BM<%6RVT[]^O<T0'<ZN,ILI)-NXM8_Q?*]:MGD:O8P% K
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M?%#.,I0.3[+<I7A <$$,A/?E(^&^':9P)'[I[,AVG)!))B$-@S E!<D@JHB
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M-AYH</,6?B%A],SEN(JY& *W(N"2/@RQ,;->T<TY1@K&SG<YVP&PX<$KEIN
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M.94LPS#XUI22U;8D3VTL?MG#X9,'AIY&?.DT4V(PT:+#'DRYI\[1\3(DH&8
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M3& 8E#G0*DD<F($:L9#"'5U!6S>T-14%2A:K.ULU=DHH[BR$K#*9<=#B\+>
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MDE4Q<2&!))&"RG,$NG#?AR,#RKE4@>IK?5K6PK?EH<_G*2*.-'$<IRF-)65
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M4&C=3(5E9U:0V 6U^?3*%4: ]ZR]M#3BGJ%N)A2-TRY'XKHJ(EBR&0M'KES
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MU<*^.QV$P^*59D?#.S8&!$;C.D#N+%L^3+/8DV! %O0YP$5- HVE'A(N L.
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M/10$WS\5559X=G)A,N)4A8E2-U:;GXV(B*J38*A900.E8E8>X#9+D]^KZ-_
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M+7-SE!UK3=S:.UQ87UN0-.Y\_345HV9M#K:UKKK^KTO2;-&[G1B!T S9=6+
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M2)2H3O!(4-QU%.(/=U&M52DPBDFXD4G$D :5U<*&?,50\[%3;(3E^-'6>:T
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ME5J59N=9W?#L[";I1C""IT_BUKVL<7'PX#AO;EGQ<F13 $?-@CK=(; H(@;
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MD^\RQR,H)&:^H)%@1<GH";=#6C9]H2S9R,N8"P+ 7TU-M2#V[5HS0[ACFL;
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M1&D,3RNRQ)&MXV4-8L#<"]KBL<5)9YNXWE0A-[TM1U]WO&7?/9,V%Q$>T,5
ML,T;1G_1%D4J3-*1,'50HT4@ZT\I8A1:C**W+9W 3H6>]%NYLM\#?EM#9@PF
M#VQM"8&*##0N7QF?#28D+B@9\S(LPFDE8$CR%KG2F>(PF]5=2C)6;T02GBZN
M'BTU*QM8\-/E:[N;S10B#:V';$2QQ8J2 8I$D7Z-%9,C,0"S>R+WR^58Z$HJ
M\HM(>4,?&IQ5[$P]WO$S9V-@#?.(6SK$ P<.J@ELS*S-9F-[:=+4VLM_=O9,
MD(;M7/.XYN#VKLW'1%"(99"$=HYT3/D!R-*""RD%O6M-)9\#%*UU%K=$)O?X
M6;%WB^<M)@<'.TD:\4/ N18Y%5.";1W(,C L>HMI24E=.RR!U%&HO.R?9Q[S
M6O\ *&^0KN=OC@<0\^P<#G=I AAP4,9D<I<.W!RR^1 _C>E/)5[QM'(KVTMD
MRKKK*;M-<KE=GY3WR#]Z_#5L7M/86R<8=G&3$8B?$+"%5HU<O'#D+RL'5#V^
MZE45#$1M+T\R/I8O&[.?V=.='CQ\36%M'"X[96+Q.RMH8:2&> XB)\P#31R1
M/(7RQ$C4VRF^E]1UK4J>Z\]"PT<33Q$%.B]ZZX<#-!B%@B<2&P6+A*S!B[&Y
MT$>E@MK7/6M6]@:]UDSCYU'&0&#0@*&#L[%VC9+($CS-8AG[Z4J.3!MY6.J8
MF2(C("+DK:RQK*5*1L7RJ"2\A-M3>WVEO9Y";7.K8YA(T5V^<%@B1!R3D'1D
M=F91$ ->X\J-%W0"2:,^#Q*WE4@--B (RA65@#&_U)%*H P)T8 ^7739I2\V
MW$6>RL4OT,:DV1]&=C8DDJ"MT+1)&!8ZW-9F)'0P@AE$"X<,C3\)V+Y";PA#
MPVD4C*UI&U[ZZZ4.5[]AK,4^%GQ&#BB)DXL4F'-I4P]L^@.4J;G262^MKK6)
MF[-\@'!/(\F(DYTE-VCB1\@94?1Y%:T98L387N+5M"7D*784?$D EE^;1YV8
MM'(<.@8B,.F:,_PC! ;7M<^M;S:$Y^TESX5[2XF/PN'D*E"#!B,1(%AEBA)^
MBSR!Y))I38 9586ZU%U8)2<@D924=UFVGP(P^&;:.P5DB'"FBPT9DR,1"D^(
M9%X]F(D9F1RK &UB- !>#EZ+3SS9O:"4J':6(_ K8^%CV7@9(8XX?H,,KA0H
MMPE"LC"UU=^I]:C(R4YM<4\AO@Z4(VMJ\R<&P82F&BNB1+<AC:_M'E("W%K>
MZU.H9V1/T8:-#AP+DC.MQRB_<\H[=+=*?THNW>22T!E@2#8^R!I^+4X67>8G
M<^UMEM;6]_Q[ZWQN:;MJ?:6 N+C0_MK.(EK>T/CI?6_3IZWK6IK<9P1<J?*X
MK-#4E:QS6"3[\?9^^L,.+G334DV]WKU[5AG ^]+#2][?S5AAQE&O77K\/VUL
MP^&F@N>^O3W=ZT8<V!%R.@Z::?JUM6&6RN=>I5M0 >_>XMI]M88<FY(M:UR"
M#U/H.WWUAAP#;06ZZ7/3^]TOK>L,X'UR0;\MCVZGM>W\76MF'Q) %\IL>O?I
M6C.!\FH)[D_C]-;,.0;VL#;UZ'M^FL,.;6Z=S?7[ZT8?#74]=?L_ K#-3GX=
M-;]JPV??9T%8:/O+T_F_76&'U88?']GZ?U5AA]Y_C[:PS(X-K:]*PP^(N+:5
MAJ2NK'WN'3\:=N];-K-=Q]\.GNK1AS6&:GU88?5AA]6&'%Z3OHW8^.HM6G--
M6,L<=*$8?5LV?=SU_'Z*PP^K##@B_P!M^GXM6&CFM&'U88?5LW;.QP>GZ*PR
MWU'POWM?TK1HYK:U,.U'-'U88<UAOB<=_3[ZPUX'(4AA[JQM-!S$Q!Y;]>A
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ME<B[1#EX2J)%0  KE07J,KT]ZH[LEJ$[4K&#;V\^-^<PX9!/AI'B<QM&7NT
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M+1PRN]\2"%?@&XX$93+;A 6N"25O\(7%48JHU+)W&<[WL^1$S;^*@19H.'&
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MU^J;FXJ,Q-*5&6>C,V?7WKTWZ4=2#OR\-UX-HK!CFP4CSX3'B6.>3AH&>;E
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M,Q RLCD$@FX%N:U889T"JY/#4*;:: ER<K!?,6K# SBBX<@1!:-,^:_4*3R
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MAW)Z@].HTZ !?+S)-:,3!*L+:DDA[ 6.JC2_I:L,R.Q  N;^R?=J;"M7S[#
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M(-)(EDF,:E[$N#:@-.3WEH%C:X^.XVP(TC. P<,J8M52;$@1K,)H1 01Q#I
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MC$<BM')B&/*8S?2W>MW=[<1U&D&NS]E0P8N(8C$?-EG>9U+KQ<^(9/HQ$/\
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MA9'S0O#-$ZN%,<KO%GBD&7,;(ANO:ESFE#,R"S[1_-WL-/M54>595&#02\6
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M96/"S+)&H2UKW5U^%@WGO;W_   L'4ZS!TIIY.G'P0D4V%))&6,<$$9C+1%
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M==#V]_K6S#X$-TMH;V/7WBL,.#Y$C747 )]Q[5AAV&EAKKZ #0?;6&[Y'UK
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MTGO7L,/XLX>'$98?F_%CF<HRND<DTBQAA>-VRF) ]O9ZV--ZR4FB4P,G"\N
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MMKFQM66R,M[SH(8U7(S*[7:P(N!EUC'EJ?LH,KJ7)F^(72LB)8 11MJP.K$
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MCQ1PR)96)"GK6:"*E1J-V&NT-D8:##8=$!;%;1#,Q#!V"QQM,S9(LP"R-'&
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MLJD =-1=M2-14SLZ+4&1N-:Z[+B$W,I/=3=@/K!W*Z9NZFQJ2:R:&ES$<8$
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MC?6YU]U@*-%I+7,/ID=&4*3?0!0VG;7MTT%+C*^FIAT!_P"QA<>A!L:5X&'
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M1WV>,HA"*RQHU\[.JNH>0(BOI8KS#3WTF$4W=<0U:;W6GJ+."'(L4\A ":H
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M 1!V%G9E,BE6MT5E2(ZWZT6EE-$;55UES)I[O11ILV*2)>:0EI)&]N1O,GJ
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MM/EM:Y OI;4:#OH=:T;3/I"0NO:Y!%K$=LP&NE)6IO4(\?81D DDG-J.@^L
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MBD&P(9+Y6S:&W<ZV)ZUEE[33CR.#&G<&PN"0#JH.FN@!-8T^ EIH^%LI9%U
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MUAF*EM=+-Z>6G2L79H"J\#HH4V/*?/5M/+X6K8$YY W;R-KZ=/,6L:Q7-._
M[7OHNHOKTZCUZ5G>:NT8VTT9A:X!!'GY6&I]U9GP-;S,>4-9BH95S*,HLU@;
M:7RUJS,NS@26&HN!<Y58"PM;46U8?&M;K,N<&ZA64C*=60\N4L"%()]KK:LL
MT9<ZJ^46)Y6 [&P9>HY?5NM89=G)94)#!;BQY22#<::]+VK$S+LZ@E@5*WXA
ML PNHTS7+>R#=1]M8VS+L[L1E>7,0RID98V! (%B18UAEV=1B%5%1F(#!0IM
MFS!N8FPUO=;5II/4VI-&5Y@5!8!KY3D/(0%Z.>@L+TATU;+4WO'8, ,YR-<<
MF1\H%O.]ARBD]6S-X$1N0"<P*!1[74L;7N21:W3UK3C)*XI2OH9&92".H4WL
MNIN-;6%^M)%)M,[!PUF'*QZ*=" ?,=1>WVUEQ2F[YG=7#"PY0"";WN3T[VM>
MMBU*^1F[]_4=A^HZUANQV/Z:T*?,XOZ#]=;%0:TXGVA)L.O3TK-%F+.3R\H[
M]36M<S#J!ZC[_P!E;-25U9')[^G[:Q"(Q:>9R"+*/6LXMA#L0+: ? 4E,U)7
M5D=/QIK^BM@]V1]>MV,W9'W76M&;LN1Q>MV,W9'U98UNLY'J:T:/JPP^K##Z
ML>AAUM0=R1L^K>Y(SC;B=J*:.+UNPK=D? :V.E8WE<*9;C0>8O2+&SH.;3HO
MI2FU'74S4^S'3EZ]-:";.A( %CYW-K>ZL$S?F@1RHZ!6'U1F.<DGS[:$UIC2
M;5^P*,62%*AS?,'6X!Y>QN#YUNGZ7L&%70(,7FS2!T#ZK(1G74@#-<^JTZI-
M#635A.8@PE=5(6)F +@KF/<=+T_IJR&T@CF(7,%7B*;-?AKRJ3VZ$VIS=/-&
MC"<RD$$&SL=!T)U*F]@"+_;6S 4K9E76V1O9(-]1?5=#8]ZPP%):(V=6)D'*
M<PSJQ;,;_P!X!]U:EH;%#@"H+'E<&4*E@="=6(-C;6U-JO )3XBKPB(H,A-[
M-9AF%['K;SU--I:CJF@[P]F0$Z9C<Z]_*FDWJ2%+@@8A )]:3'2W$?K1=P2[
MR8/Y_L3:N&R9V?"RA1;-S68BP]U)G&^O)CC#2<:G9;Z[FNO;N%GP^)Q&',*A
M5Q/"#Z@NXO=0O46^ZN>XNFZ>(G3FK24F==V9B-_"Q<<W9&/9\40CRE0[AKLO
M,Y(.8)RBYLDH ].M-Z=U9,=59N5Y+2PI=KXJ/8^#:8O&![(\V)Z 9M%Z=.U&
MEDE<88.EUU:RS:8T./WRV-#B)-I8Z%98L)#*%,I#DS92W&MT'"8:#O09[J\[
M5ELP^ K.'51;2?U#:[Y^/FP]WL _YM$(@Q6SS/B\7E($+MAOG &$BT9Y6QK$
M-;W]*#4Q,*<+\R6P/1ROBJEZE\F:_P#?KQL3>='VCM3$KBMD8V#%K@HS(?G4
M^+9&>#$XB'K\UF RJHUS:^M,X8GK)/D76EL:> I[U'*3S[2(.VO$Z.;&9\'-
MCW@R89OS:#AEEV1-A<%'AP(97<QD1J;@'J2QZVIP'4G*.]-WE;-V&!WAWIAP
MS@B5C((<\&/AG,4:M))-A52:!HP2ZF!B'(UOKK>BP&TVMUMK,:#;7B7B]D8A
M^%C9<'&LT2):<B-2R*)L263DG,Q[6N**M"-F]_33N/HO&O;T,;1Q;6Q$N24.
M0\JE6<('B#*6$:PNLAZ=5 )ZUO( Z$9WLLSMB_%3&XO#"1L4KR%D1I ['AX7
M-SM#,ES&XE=N7L-*6H)H8U\*I1>[J$F-WY7!A,?'B5V@D$V'>5RSQ2J&1_FP
M@@.LD;!N?3J+G0TKJ'<B:F"E&-VGI<S;+WSBCB@$&(7C32M.LD\P.&@.)4\8
ME4%A]$ 0I.I-;>&DEGH1\J=LDG[@7+M<G$N&C+\7)+&I/T;9$BD&(":O&I9D
M-KZ<+UK2IM*_W(W=*.K0H\!M7#Q.$XN'AEQ.=R!,2F'PHD#38$K&[PSI(L@&
M:Q(I#AG<1*G?)!1M/?C%QC&PIC4ABPN4X<*0_ 0-_"0"/F:\@554@D=>G1+I
MW[S3\UV5K=X*P7C'#L:?%!YE@&T@H,+SYYI)A\W4YK@,1ECD90O0^^@UL,YV
ML;4VGG:W>/+X5?*:W=PNUH]E;0VA#B,-C9T)7:$Y6?#XJ>V1P[.K,D+<I119
M:;O R7V3/M'5*K"5HIYLW ;J8_ [:V#L[';/FP<^'GPKRB7#D39"IE,"M,P#
M%F:,YAK=;#L;-I*SMV&ZJ:E9B%WRW9V/M.;%XJ:*+#XAE=!+B(RQ6>&0\#YO
M)8&+C%E*K;IKYUBBVK\$:4W>W!$7M]=WWVBDS[6F$4N5L+%.,O5%S.6RH67.
MT2@'M>BPR60\A)P>]$0&S\-%L?9\6&^<_.HD48EX\2IO@C.9!)&LS("RRRXC
MVUN$ :^E'BG855>^]ZUL@0^(E>(##QQQKF#+ LK)'.@=E55986R1NH.4L03T
M\JV!$=O"^S,)B(3)A\1AEQL#X=H94XPQKS1R31HB9@C<)O:+D$=.U;0I1DU=
M:(*EP2KAXUE2 PX-E:!\06$F(6)R%CGU-PCDJI(LJV'2L-7XA8FSY,&.-/!\
MY7'8C$R01X>4+/#$X)D4.S+G@)0B_06]12N!F^I:K- /9FS7Q,AQV(QHQ&!4
MA>$LR0QK&]L@:9&,C30W-P ?MK!,IQ3LL@5/'&N)APD:.7PV*E;#PQYW1L-*
MH,TDTLH!/$0');HU)A%J]Q&^K71QAC$T:XF%'PWS:11-%,2H3"2O>.%!*I>\
MBY;J; $D^\G8";OF\PKPL4F+CBFFP2QQ389D65($6;(<20O X8RQQ@>VW0UC
M=F:;MEQ!.&$.'Q6*P^#59DBF:.0Y,\D)=9I"]BI"X>3(!>^AUI$TY6-@.3$X
M:&)YXX6GQ$'$C@@C0Y9!*(Y+S%C>6[LRYQR@ "LA"2R9J2;"W:^(FDQ6&81<
M? R-'AE @99(YH\.TPPT<;%%.5PP%_:[4M9:FEED]0VV9@Q)#"<3A&BBP^,,
MSZ:NLPM/AUB0<-)0T8U)L#<=:;S5G?F*WD=]H8R1)1%\Q8OBXV6%%<X?CSP%
M'C$ 3E2:-+YKD7ZUBW7J[&+-9!=C\1B\1!\TG,48EAA"9WY9FD^D;@A%8F9R
M_.YU'#N.]M[E_1S%*P%P6S\=#@S'*F9,3*,3'B95:,G# 7+QL%$C3@*,K-U'
MIK6)13M,Q]@,.,Q/SI&^;8YI,2(S'$T4"M-'$R-!)!PB0KXA8B';2X6_:MN,
M9>@P<N7(RXJ65%A9G2%9962/A,[2G$XJ="8HN4AL%$7L771C>W0TETY"0U"/
M/^<Q(\IDP[)#AL1 $=KJHXD;F/+&J9;F]^G76DN+6IH!B/#PRS1([.S28?.,
M/GD!9(HHB)D-L\9>4#,+@-J=%I(.4XN+2U!V)V=!GFFCDGA$*I+SRYXK7R!!
M&I!RA?>,VOO3+SLD#;3@EVG8XC$3+!'%AXY8HL)%AV2>,,SNF)1HI(Y$5I'E
MD5C8>5P>M#::S8BR.T44$>%XPS)B@\L>(DE XDDA7V[G($A#.57J %K$F]#3
M Z\$QPMA<4C3@A,9)$0HQ9AP^()B-DR.RV"GJ"I-'BG:SU$O+-A@X03I.SB*
M;YO/*D1C58,.H@!AB0L5)<\W7ZQHD-0$\D<G#2OASP4/%DP;R.9<KXDNV3,
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MM&%WGNR=];>:\[>!,;7QLZNSYTI1RWHY<[6T]Y/;Y(*>(6SOD[[4\1H=D8C
MX_Q+VMC?"3&X[;NTMA;3VTWAMB-C;L;SMLK=;!-A5VI#NQLK:&QY(8\5F93)
M(P9@U@6TX4Y8S=I/[''>>[;[MZROIFKE6PJ?7JG4<U"#WTNVSCF]&K,?[=C
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M<X/ 00XK>':IM.VS(%GQRYPJDI$!PD67B1H3*5!6YN>]:DVM-1K.33[0[P^
M^9X3CQEQ#C<+AL6(XY DSK+&)D&<HJH"9+%;ZVI"FV[,1OMO=X@';&RL%M&3
M 2/'*QP>$XL9*.&&(GD*M P&56SQ(5)[W^PB=PD&TK/6XR&U=D8L?/()OIGL
M,+AI);QND\4S3N(P!]'AWC4*#UNGKJ"6;RT)2F[Q5Q"[Q138[&8H8@*@?#QP
M$NSB0O$@M&'56*1CM;5N]:WMS,(NP:C;>SE@QZY7,[+@IHC"I<)/AFFXLJ%V
M9&23@Q@C-:]$4IR'J%KL+8890[690L:R%'C=N-);*A8AKYI-0+T.<GN/E8U?
MB]!B/E6;(Q>.Q'A#N7@L3"-H;3V]M7&1#$RHL46*;YIA<([+PTS)&TK%]1R
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M6[.S-G/E2)9FUD80;>6OO^RD33:R-&%C8WL+7UN0#]G>M@9M-WX!?.+W9P5
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MA\<Q%@,K*I!]_ETM69&' .@^L0MB>F4_&U]?*MFG)1U.G1B;78=1V-^WE6_
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MKD"!B&Z'*S/HM^U88=.,5)&4LCDWN<K(S ,=0,V5 1VMK6:FCM"]LQ;5;'G
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M&)I3E37V)U7)/LLHI>U9E9A./7UX+TE5=URRB_Q,1.TIVCP41(X6*RLT<=U
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M=.NIL";UAJQR=;%3;+U)\]+:==1Z5AON.3:S64ZVU'?7R[5AF1C )':]Q;4
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M1B[+:YN.I!MFZ[;UL@NHMMT]K8"%<0C+B?G*JDH,KAEX;Q O.@D(LA<6 !N
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M*S!2FHH!-OB@4\0E69QE)(9#T!S,+%;_ 'FB)KL-QJWC:^0?[,WACE)-U*E
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M$\35$,;%DB>YO*6C/46N!6NLXW%J$;VLA3;(P<*XR-BD.42D,$%HI(PMLB(
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MVKL!TPF AA@2.-D9,1B1E&&X4D\<B9Y3>6,DYE.NI![&E*K96EJ:O;B%8Q.
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M\1F-L8J.28KB )+2\-1HP4N;#+W8G,*%*2;3D3>%7FY(+%;9\):*61!PQF[
MJ<O0V]"/A27**5U8=68"FQN"?*D3QRK+HN6[68+92=!TL0/[VY[4AU$EH99A
MK@]B6@O*5(=8V 51HN92Y(ZY58V/K62Q$;)I< T:.5YNR8YVZ&S(<$I=\J A
MF95]A5+^V/,V/0=33>52,Y)I9W"QCNWL[A]O#MK"X#"3*,@*P%OH[68*.K9M
M0>8>Z]'ZV*C[#4U4?FQ3NR+6^^\>'APF,FQ,@&&DSM+EYV5@I*93>^37M43B
M\2F[W6Z6#96$EUB;3N5O/R@GBTF(FVELO#NDN031H P^A"*SAY+\TZNX N-1
M^FL5VIU;QSS+G%]50W=$:#MO8QWEGD>261C'FR6&2)E<E>=>=%8GIW%2&'CY
MI7L95;GO+T1!8YX\1'*S+$N(D&D<9(>*0#+\X"FZA@NBWZJ;U(4DT\R"Q%13
MCEJ)UTQ$G"1KF50R(Q+'AI'S\THTLY%LO>]J=1U(JIO)IH[8/%,)S(@))+QQ
MG$HS,65[7RE2'A)-E%+>68FGG4S'?W1PHE3#RL;121&-FSV:)\Q11P^JHQZW
MZ5&XAZ\,BQ;-I;[4GH/]L;:&"V2,--,\+\(\KB1EA(74B1%L'O;W5#58U*G,
MMU"I2P]LUH'&W?$'"28&4(S_ #CYLJ"[JD2O+(<L:&/-GB6/4KY&M4L,W*[T
M#8C:<%3M'-C!;5WHBQ#8N6*4H,D44F9F551E!468YI%SKSL.F6I6E0BN!5Z^
MTX[\LG<;':6WU>9W,K2NR]4D8 !1E(@S:L6/I3^E0^^R(;$XYU6WP$*\V(!:
MTD;H6&?,9)B,_4GB$&P[^M/5&R(.I)ZW"UY5E9W=9+*[K%KF#$F^0YNZL?A2
MXW7HYC>7V1;SNK!=B)78B]I)&R2%21FOGX3$^X4\I)J[X$97=G9'& Q(PF(5
M\UEB+H3(MP_,4 A&H1"H/-Z4=PCHW= :4MR=Y.X_^X^UL+&^'DGF3A2W#+SV
MC-[BQL.A&G:HG%0E>63M<M6#J0=**NMZQ,?<W&;.DP&3"O%)+:'(K%62<-(&
MDDN;\R+UJ$J.HIWS+CLY4912RDQ\L%NWL#:4$;XO"H6$),AC ^CD3V@G_"V8
M=9.XTIOOS:R9-JE1W?10U6^&[V#D^=)#"5X,J*$6+)+%A623AF/ZC76)?4FE
M1JR2S&E:C#DAB]I8*/"Q(C1(6$J\-(2'='B+(P"C4L <WNIRG*^I&5J:BLDA
MOL;@\&>(B0RNN>\[L4S,PT61^ZB]SWI:F^+&$XQ?W(@MJK+A<XBC*Y9G#EW*
MI(P)SL.V9+=/2C0LV,*JW;B&Q#,9[(\:M:5\J([YM,W)'IDN1U\Z=Q;Y$?4B
MO26H1XJ.2:61C,JJ&C +\I83AK)Z@!/NI2&56%^\(IQP>:4K]&K68J2,[(+
M9?:52;:]J5#*6>@U<?8SHPD0Y5"RR3QGAFQL7C02&0GH!S&BJSTS0BV6@ DG
MX;F!77B2%3 T4G$9 Y8A&0\H3E.6^FE8:N9E!YE8R7=DM/D_@^&H#V(&4!F%
M8;!.5(BTEF "!1(PYLH/3(+E<PM6&72S9]#FEDEX8X:$*%D%V:)%%R&!T ;W
M5G$"W>3L=E;B.[(8XPT/%9W"DR1WOD7^)(S D'RH\9126:O839//B<X8 XC.
MRI>6,,4UD;E6ZH&&C, >M;WH\Q.ZKBPV-!-)=U6.,NS,TCEAD"9;EDRV4$,
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M1VU/*;V(N".BV]??6^PSL,BD]C?M^JEK05F9;D6(N;C490;?JO6S>1W#D'*
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M$VUMW%8*BTM3D,N6Y7SMTT M^LTF2=Q6]&QSH;&Y 4BX'?2]C[JTDUJ:4D?
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M%3%3U<A/8C$.Z1R\(LLN=8D29OHHT6[E@P"3$R$%3<7(Z4YC%+O&4I[^>=K
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MQY8CDL.,Q9@W+<CW4;JXVN+51IF2?:,F(R".-%G@1^(N*7AY8$T<32:E;&P
M2]SUK:BK&W.=\Q,XO:LHLSXC()F6-AFBBE"99B!E6X-V# -?4 4KJT*51)7:
MO(2TFW8V<D$$9"%BR@ADB.5"_5S(ZBX/2M.ER1D<1=V_X14;(82P,(VRQ\-#
M#!D5G);))(3,4)2;.3ERDW^RH_$93SY%@V?!3]+05F&#Y$DX3@,9%D=@"%(U
M#K&J,Q8W&IME.NO9E)QDW;-$U#>62?FBZV9&ZX-L2\L@GDC!=GXB,<F5<[R
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M#-,HE^EB+0I<*L4UTN#?+:X-;4H:18!WUT/L'BTP[ P\63#QO.D4P>2%0\7
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MV@D=$7)%%&T>8:22S88:19+6O6I+S3(3O*W(:K;6/=L:_"(B"@*5"$DL,MY
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ML')T"FVI7L*-"&?G)V!9MW8">597X:K=I-00VA91<LJ]!I1%"*X&& EK,L0
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M4FSKQ(V ;J;D7'+[ S+KYE=?=6MSL-WES8&S@B1@0I.BHR9CI8&W?0TO<-6
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MLQ52% 9F86Z:7/>^NE88=74Z DFQ%PFO<$].E88=FS$\0,5*<E]<J ]SVO\
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MF3+)8-$0\QN0V9;L!;4&]89P#A(5#S/'(DD+X@,)850B4.G/&\A]@"3336M
M M$S+('8 S2SQ(8U<658BRLO$T)C)E4F_M6TZ&VC8/9H7>+%8LR88!47%X-#
M'B'ED,0#C"1$,(T!YF)M:M +,%X;$X=&D8EY(2$+-,9,XB+@1,YYA&PL450
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MCO$?[.[5_P /Q/I8<4ZU+4?BH]Q6<5\HGZS"8D7%M;CKVO1 !U;72P/XTK#
M/(Q]PZ?NK#1@=N_7T%:?(2SIF%KVO^H^M:-'V8"UR =+=Q67X,P[ V\S?N>_
M\U8LD9H[F96  'Z>GI6TA9DSFVG6W0&WQ^-;,.PE%M=3]@MZ4FR]ILY,BG37
MWD A??>M,PPM+9@"+EAH+]1Z6TK1A@>945A=RP938 $C-U /NK:6=^!H!R8L
M>RC%"0-<HS:FVAO[)4:UNQJYA3&H"-"P#DLU]1IF"^\L-/2MI7%!9C=HVU-Q
MGN% 874-PRS'OUK:7(4FEJ)G$[5C7,%>ZY6OS7<Y23>,#N2:(HV .5C!#MV(
MDGBA;*5N!<M?569;@*PZ&E;K1I35^T4^SMHLR(HDRR+E.=>:XZ"Y/GY&D2B[
M]@6#5Q<8+&AN'?E=19V%KEUU-P/,&D/+(=JT=/1%+!CAD3.!D!S6#W<L5]H]
M3;-VM2'H$6MT&$.,4@%@0QTYS8D^G6P(K1IR:=D"%Q@]H#53?J+*MKYVO:XU
MK3;-7]X.7%9W 5KFP+ 7UZ7-^EB:VF^ J_ &"0W(6Y;097;2Y]HVN05M:E)\
M]39W5\I&906^L$%A?H"!J#>U8^:$NUC.)1D)US$,+:^U?V?2U:L9;/L.7E5[
MKS9E7,MNF8#4>I%_LK:T-HQAV7+F9,[#EL 2S'H#<"QK9AV,ILA)7-E-[CJ=
M1< 7TK9AU5[@%KY@"%*=#WL>G4UHV9!B-%)'-<V!TO<6 ]<U[_"MF'9)U!4$
MG4',>RE1;XEB+]^M):,/E=<I!DS&X>Q.H&OG;H:WH:.W%!"J.I9ETMH+&Y-]
M.I%9=&'QE/1.2QY79AE9;Y=.FI/:M:F&02(UA==2UQF&@'?XM6K,V<![$?6O
MY&^4B_74];>599HU=';.;7L2;VMYWL0;==*T9='99&T!5@3TT&M_YJS+B;/F
MD !O>][6/3W]^]:MGD9<[<0'3,-=0.M_(5M)(P[%K"Y/L@:7)T)ZD7[FLLN*
M,.,Q;6WL]K?IK%8P[ VMZG3E#7]->E;:N8?!KY@PZ_\ :NO6WE6C#XFY&E[:
M7Z<HN2?.];M8PYS#0V L-?=VK5C#G-H;Z:BX]"=/7M6K<C#MFT!L/:(L=>MM
M:UNYV[##D'J2 0386\^OW6K;7#.YAR6L &M;SL#IY"W2DJ)LY#7]FVG1I#8>
MX"MVY_48<HZD7N=% MT%^]JQQ:,R."P.FH%B23KIY"]Q<UB1AR& '46 N->8
M#I<CRM6FG<RYR6.@(8 Z @ZD=?TUEO>8</FMVU'<ZW/86M6)*YAA++WOT Z:
M7N+=KVO2[-&C"7 N3H.A)Z&_E6\C#"TNF9R%49<K$7O?4@#4C516+4P^,B*1
MELUP"-;"UC?FUSV\J4:"3'XH<*4(XS\,'+>P%[$G73E6];3L%26[F,7OWM,X
M; 2<I9E)$BYF!*YU4O=.:P /372F.(J22=PM"GO5%'[J^A%R;&\2>65ES&;B
MR1LK%U* \A+L20&/0U!58N4F="H1C3IQBO12&WWIWGCP\YS8@A4*#)(8^):5
M;DQ]?8< 'H;4TJ)4G;BR1I4IU/.@,+OEXUX#8&&Q"R8M@(EQ#1R1FS.^2P1F
MS*3>@N;3[+CRAAV_2>9IR^5=\M3;VQHL=%L?$RLJ'.@$W"?*K1 (CACRR,6!
MS6&G2U.*474DE'BT,L?+X-%RAKNMFKG9WY1_Q!V#B<3%)MS',,4P1%7$RR3)
M'#(5<M(9"Q;AV( Z7'PD5LRM+S[^:N!4:?26KAJCWHWC<5&\'RY-H[\[&2':
M&U,:D30-F G=)&F&MWDN&D:;ZZDBXIM5V;6::S;L6##;<GBTG&T8,BYO%OIL
MS;<DTH5G.(5X;NYD:SQRJ>&6NTERJZFQ%]-:9QP<Z4_.5D23QU*5/<UDT-#C
MHC&))8\2T,2,62S2!B@!S!B68Y03VIW&FD],B)K-I7BVAO-KHQ+32,;C*(5!
M1G;Z)XIPTF7+H[9D-KYZ*LI)+@R-Q$VXV>8B)IXXI&<QYV4$H+D*H+O]('Y2
M6%P2*D:47.S:_.Y#5ZJI9/43F.VGT4R'C.)9 I9(Q(0"%CN@#$CR-J>PPR3W
MB.K8M.-N-A)8O:C\T;F2_#L,@+QO<VO[5RZ]M.U/(P6[9D3.O-OL"IY3?AI(
MUAPR'D)3F[@W;VM;4K=0'>>B,0,J)&B,68*[C,@)%GRLI89<K-<@>1I6ZN(K
M>9U9RN574<CL1:1LL=_L%[]:S<1N[ODP5'C64,&D8D*&+(3W^H+VO0[<@L9\
M6PSPFV9E;/Q9XT=;2JK\T=M1PXE(7B,!S'SUH=2@I+-9CFG7E?S6Q>[+WL:%
MD6-F8 +&6=R[LIRC+KH&RDU%U=FRD[MK0FL)M:I2:C+. M,+OO([(JL5=A*F
M4S%D>3,RE)"1:^1#Z"U1[P4K9Q=B;CM>DWF)W:N\6(E>;.8Y@4"@HA6-;#+G
MBDU+/YZ6IW0P24KRT(_$[1G5C:(C@IE:)0!(D\I^EME#'KK-[41TJ12W8V61
M$7<G=Z!G@4CL 6RG,A5UU 7-:4",\K,OKY4EIF!K-(N'LJM([-+>);*8Y )#
M&K2@JULHZC[*T:U/H)G9XV=@@8*#&$6[KU>-)#S9A0MUL.G9!L\DKO(D;,BQ
M,<_#.?*N46<-RJ% [6/[4;BU':>6H'$L\2M(LK2JA(#%+C-)E#$%>XS#2PZT
METHU#<<1.'HAA#M,6R!I8P1]*@)="'>RRB_\8@VH4L-!Y(<QQDT\]#E]J2NT
M;$QB)V>!!(S$L%8VE :P&@ZZ4/X++1,)\,E+4#/CU,@4E+_2Q/=M%R\RH0,Q
M*BV4FWW5KX.]+ Y5[\3"^)+) O#='($I"KE34\HCMH%(\[4MTK:WL(=5O1Y@
M@%"SELP<J>=1T#QC)%<6! Z"A/)V"1E&UKYG,8R-SYC%*.&D?"SI=%LSELUA
M=@="*T;:3 DYX*,K@2HF=G!((56L%"!@2%8G4 BLL(>K,$B12)(\855$BJ(;
MV2/-8DA/:N&\K_M4KZ"$LK<0WAAA5<PBXQ$9,2RBR9E()>,Z#-URW-ZT&@EI
MHQ48?)(,/PN)D6$1A<[*DJ6&9Y>]P?9-^E-WZ3'2M;+0,(L+QG<<%\P.1E1,
MQ.9+(;FP(![UK4V&^S\+!'.JRNT!B N42.07"<P"-F5/4]=:4;>@O,(L$,/$
M6+,/FXB4#4-/(.>1(XLL<R* +,U:LV[#>KJNX.<"55T8(621\+"001B5S.H(
MP^6ZW=G TMU^-'IQ:>:XC.JE*+N2M\/=HSX480%VCP:NMU#(98H.(TACE#J>
M*S J,I.EZ/5C*R(MM7MQ) [/Q<^)G2&.:1RL^*0\8,7=92'A9)>9)!$.4)?E
MK>BS-2?F]HK\?&\L,21&%'9,LC. F(PZ7SSF-ETU:0 KTYK4)S:>6@!N2TT$
M@N(A#8J)(XGEE;!PXJ!XU:9HS*3&MA_!@G6^EC6]Z6M@;:;NR1OA]A%EQ> =
M$.=)8V2+#Y0AR'(I(<!N*MP.IN/2@S<I]UQQ3E:&>AL"\/\ 96%DPT3H@D9"
M"08>*68R,B(R^S8/?XBE*FE9C:;C.3OG8D_LO8T:8<--&J(BO!-'($-PD<@:
M5+@B-0P(L#VHW4\U<3OR62T&TW]V=A1!B\. &R!YD+(K\5DBD(C67*&53&Z^
M76M[K2TR-2;DDWJ:K/E";9EV:DX"&*-HIED@C/#E7(?;B*M;)E]I[YATIA5A
MO5%V,D\+&T-YZ7-4?B!M[CRXH\13+B,<ZP%46(G+,W C:$GF5M=3Y4&HK-HL
MM)J*2[$,/M/%LL^(XB#-)<LZL%9HE8K(J%<UD!Z@V(H<4T[L?P:<;B#Q^2(O
M) 1B(XF<QQHJ_22 @F1SHQFC23E\Z(LK 9YR? (XB'Q+%UQ)1WM)PP]V615,
M:YO:5V?KKU-*E**5WH9&+<DKCC8+8V).&A(PKB^)XC, RO8QWX8(S9A*HN1T
M)%-'5BY9,?QH2E"]F)'>/8D>'=\TDT)SK(\131 R!E41A4!N&ZD7H]&IV@94
MT\F-'M**)'EDPQ)4 @(Z\T<@)S,WUK.3>W84=,;3II+(3DS\%DE$<LK$D.JM
M=2R!"7TZ^UIU%$R8#=2S#W"XS+*D4DDD1X8E)<B);6OPUY"S=?/O0IP;>F0>
M,I*S'6W8VK+GC=9B75.2,L2JJ73.Q#6SG(+V.E-*M"R;2S)&AC)Y9YW'O@QD
M+Q8*3/=9D=E,:NPG-\5$N=#HCV/6X[4P<4]=2PQJWBFWG83>\6)C3"')*HX?
M&0%H0LTQ_B"<YV!7LP/32LC!9V%JNHYM@_Y/6Y6-\3/&;<O=3!X?C8K;&U\-
M$^'>.20M&)(9)'D0Z+&ICRNW>]_.LJTI]7:-]YY*Q6>E.V(;,V16Q$Y)3E&T
M<_ ]#/Y'?A-A-Q_#S=C )A(H!#@<.KA8$0I+PTS+$0M^"IZ6\JOVSL*L-A*<
M+?9%'/M[3@>SJ?6R=9YN;O?O-D6R<(T4,1*A0#U'UETR&QN!ITIW-W=RPP?F
MV#UF:QL";6!OKJI)/PL1258U-JUN('+#V2NI+7!TL";]S8#RK;7+- C#D#HQ
M#C,0#8B]K&S=K:@CWUM1::NN)CT KY"G"8,Q"OE5-6!]3?H2#1-,P1A>4$JI
M-Q96#9CEL$7*->Y[ULP#O(I"WL$+%3F]>AL.ER*PPPY@A5\H8<)@",Q4$-8W
ML; A1Y=*PPZ<5W!%KMF;V;C,612 =1[*Z_'WUAACCDR$.5S@W565V9E)T]@@
M7MW[5AAC+$.JCF.8@#IFD*O8!!H@;6L,/F;0A647 -RA;E90"HN#8*P-88<9
MB8R3)?AVT[6N+@#MK6&'6Z2,C . ";J=+J) 5))T !!K##Y)>;G*A%%Y JW<
M/<@(3Y6U\JRQJZ.GSEF$BY6))LP.@8=591VL0-:W8UO7]'-F!Y78@%3(R'5[
M66S *0X[%;6Z5CMP-K>>J 3S!'*E<B#V0G3,%8YO/+<?::4E?):@MUK4+6EN
M!>4EKY@2>FO-<::7IT8=HF+LS7'(SL!YG2S*.Y(K#+HZ\="KN%-@X#YAS,YT
MRB_8WK#+HR1S,8^<61B""4N5 -K&_:XH,XR<LD:8)1\P&7AYW4QW=LJC,H<Y
MAVU!^-(<6M48"(P!R@/?A@%@3SN>AOY#M:M&)-Z J)E51Q,RA<P8NH;KI:XO
MYTAM(+!-+,&)(%B*D7  *RGHL9(-K6)NQ'7UI$FFLA8(CN0#ET8W#'0 VU2W
M46ZT,WF"$TO>UV%P1]<"VG>]S6Q69D7*+"V9;7%M-2>G33):MFS/&Z<0\0V
M9BK#ZP+I]UJT8<WO(390B@D%A?0L#>PTZ5G#M,!2E/I">'K;*6&93S:CABVM
MNGE6A4/2.R-?.;*"JELBID*D"ZD9M!K6@QG#$1!3?,RADOI=FM<9@21I^BL>
MAAU4ISV#L0 8S<MF)<(6N;FS W^%(LUJ89R$#*2P566S 6S>1 O;6]8M39T)
M5& !ME'*%ZL.X(':U+-/3+4PL4&?E#'.' L1FS95.O06_56\@3G)'P8%B%,3
M74Y0+'*?J#MJ#66,WY=AT(4KJ;L$"V72QO>PM8_?6C%)WST.,POJI!NP0GB"
MYRJ1KG-P![ZRP2Z,RFQ;B<QL Y#-8,PY2#H!;KZ"L9LR%AU.8\I  7+H?)A<
MM>D69APEB+E2!8!00+JW;KH:RS,.3F%@K ,XLSGE&I*J+#J2:RS-GV=3=!G+
M:#,+BY'M:6L;5EF8<VY2 MLK9C:PS@![Y5&C7^^LLS#-S7Y5:S -<Z<O<:$
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MY93P<7M[>S:6T]J;.8Q?PF*CPFSHHVS7&12 .4ZDIMIW>6GB$E2O%/[DU_\
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M,P\P^)S$"X#-8,JC0Z=O6M<18<8<ZD%6/0BUB5\F-^EQ:DK4WP!;-E'. @(
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M*^7/9=2W*23I9!<9C;OY4'-!%H"Q(0(M"HRV-QR@YQU)Z"LN;,L+ALP<JQS
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M922#:V9K-EB ! SCJP]UZ1(=1=XBPP]FZ9&46.8!K6"K<@=0/0TF.2" Y0I
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M9PP?,%XJ+"L11IY(1/(N= OU=2,Q)T%[FM"#&!PX'GPDD<>'L,: [<4B8,8
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M%U=BDP*&-Q'A;!%8C^$UN>U0^+K*I4CFB6P=*5.$N8_OA]L'"8G:Q,DN&PT
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M8P[!>I(Y>FA7_L;2V@^ZM&S@+<DY 1[-AJ!:YO:UKDVK#1]D5M3<CH0;BW<
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MH6L3]?RI9C ;JH4D'7,^;3,0A;6W<=M;5K@)X&*5>'E=6#JN;*6%_:%\S=[
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M;N(XU.47EY\N:,FQ!![UFY%.U\P+;MV .7"S8N88J6)1+ )3!ASAY8(<5BW
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MEBEXH;2%?K1BX8D&L-Q]"W$X4R829,)'A&)D CC=Y5?@).Y$<L:D#A2$16]
M16,"]+AXN ^?1R 1(9\1"4DX01[<$\L;SFV1R@M:M PTP>%1L/#%#AC$\<(Q
M#I,$LR\=82'C]F;*L8RD]+UHPS#"B"3A 3JDQ>-66:-I 4D$A8H#<.+^S?1:
MW>QIQ3U!BI$JN\4DRR+AIT1# .#/).V4WDS&^).F7WUF\EJ#E%+O,WSC#8;"
MQQ102XKZ+A3.G#C!9TOD8N2<T$L)S :VO>LWH\P75IZ :65<;!"(6B0B/,\4
M@:..#-RB;#Y02,A5BWF"/AI./!@K6"G$8N25E$<BHB#YNTD0.;C8<-\[D52,
MI#0C2X]KI6[7--7,2;9B:&-D<\/$2!R $>9XQR#,";*.49P+7)K37(2U8*<9
MMN&)A-%FR$_-WA4@DR32I&56($\!8V8%K>=;X&T)7&[<+!$B9(Y3''&SE\GS
MG%-,TTN66Q_K=$%F_C$TD2 8\5M*2'$8H8.3#Q9XN \<-T)>6V8 <V0'ZQ&7
M6L,!I6TR'&B:SJ["=)LP>>.6,ZV)):-(R2-+ 'SI2T!3](Z\/ QIAUQ&4KPF
MGAGC=2X:_/(RDDWM8"_6MB "L9QT$V)65@!$<*%4',&!=!E(Z%XU#,QT705H
M0FMYL'P8HHXP7#-U#A^,^9;)*2SK.&R@E6!!/4^ZMB[KFCM@L9P@C$F2-9',
MC*%28Q"8H<Z)=7="X-V'2L,#!8TC!6;$E(,3R).O&EQ/$RR210%1F9,Z@WR\
MMJ%4DG')\3+7R0"AG.&DE@C>^*FD.($>) X61G9""WM'Z,%E.@'3K033BUJ8
M3,%Q<&*:8"',Z2?..(1G!^CXR"X,+J#E[&L-'SP2&0_-YHT,+RNJD+\UEBE#
M"-8SU091HO2L;MF:;LKF? X?#3R1222A\.H"S/&C9E::RM$&2Y:QB.6_=: Y
M7S$[[MD&\4#11F1I7975>*Y5F18\/#ES1BV9E9;:=RK>5;AD[O0%*68>X=8/
MF\,JM$\#D/*T>5N!.%RK((CSJA4\R=&&E$NM$P-1W8I-G1X-L1)%$WS: A(>
M5F6=\3)=B53HC.RM=>HL/.M@G+=0J]FYIRL,T;2<+,BXF=,J0QQL8[AQHC,H
M]KJ*Q+W ')I/F.-N^)1"%PI2-@V(E!?,T<(^AC'SAQ8S2,W-Z*+]J=4M+#6H
M[.[U'#V3$KX&2:?,V(#!DPK-]&H:.+*(CU%S>P-ATHN5[#?>>\=L=(N6&.;#
M0.'3A))(MRV4ALCD#FE4Z:ZBLLA2DT-SO<F;"SOA(@^*5,0ZP<->0H(R#D8<
MP"G[#3>JI)WX6!U9O5$.,?LK"8O?^':\F#2<[MXG ;6P,*W$<NT(<1'P8G1;
M-(LN(-FT/**/)7IV6MAA:\WO<"42^ FV9O%?'[U8+'+A8]Y,7@=XMK87"Q"-
M,='M/#[,Q"X!F !CMC,(\BCN1<]Z:TZDI*.&46[=@RJU8WRL;9?!#P]W@PF"
MP.U=NX4Q)BL'#'LS8^%Y/F#B1UA?%K[4TDZBY8]#4O2H72WUQY"I5I]5:RW6
MB8.(\,AL_8T6TMLX1=F[3G@:6&</QHE$I!=YE;^%Q$L4:J1;15M3K%4J/5JR
M:DN8%2W(WD\WH0R\3-B8D--!AIEVH-K;&V]N^%.%7@;/39V'GQ#XM)W%HWD6
M)& U-RH'6JMBKRDV\K$SA91JQ2M:QJ&?>G9V[&QMJG X;"X_&;0VIC\+",<H
M!@,8:*7&XI9^;$3X9AGCMY"U+^$4Z<<U=V)R-*K4M4ODD:NML;>VI/O3M;96
M$GEQ6T=J[6Q6+.+YOGDRX=^!%J;,JEY_X/H2B^M';BX]8\DN TLUYNLKB"WP
MW+V7O=L'\Z#9,&%VUN_M%]E;V19%#869 9<+M+"1Q@*NS,<+?2-RF0F].:=9
MPEK=260WJPC5CYJLTQBMO;-Q>Q,1AI]G[4:+#VAQ,AXCQC#SB$B99AF+3Q9!
MU]D&G].>^KM#:4)0S,&Q]L[-\0]F;0W4WN>/#[>PTY7=?:4$8;$LCPHLL4<P
M"Y(Q*D;#*0RDT3J*F'E&M2]!ZWT!957N7S8DSNUO?LD2;/WBCX\^RH7FP./Q
M,/SC$XK" Y!FQ>5C.R=0A-9.I3E)5*?FIY-?C0YA1J6M*+=@BG?9J/DGP\D4
M#N,-C88F$BR'#NL1Q&'1@P569\RZ6+BQTI;R5V(>[?=>3"G&XJ?8\38S#$%,
M(9$AXJI)+)AVD8Q-*DV4OB$#C)]5;\M;4%4\V6@.7V-;T=!MMH[][6VO)+%,
M<1,PF8I,)$R<%"4D26P SJ5(" W)T':[V&#ITXJ<;D;4Q52;<':PB]B[;63>
M&3#.D\HQ2/#BX<4V6,ZD<Z^VA0:K?K3Z4;TE;L(^-1]:T]!W-TL'LO!+C<1D
M;"/&_(C(LH(#!1,"VH9R18 :TRQ,ISM&X^HJG%WG;=N.%$^PMK3QO)!%-*'<
M*BZ<8P*V&XA&@Y[*YIC/K:>4G9#NG3PTY9*[%Y%NM\Y*+ /FJ2E O% )P\8(
M)*MUE1^RBF4L0XO/-DC' .>ED@MVML8[*9,,RN)TPJR.$49%8"/A38@7Y6EA
M47^%)C.4U=FIX94N\*4FQO#B@X4.)D3)DDB66"1Q)(YS&2.UY55M%OTK=KNP
MF,?<*M-DR1X/B*W X^'&&PZAU9^)&X<O+F^F5LQ&I/>@SFD]VXXC0SU%QL#"
M8B*5<D$<S*V5\0'$8$K,<MIGR@O:,*/4T"I4\RZ'5-65^!*[<?<-=LX/#8W%
MX:<P9@,7$TV9DX1NR($ !Q$X8A?,5"8G&-2M!W9*87"2K1WGZ(J=M;G30X.1
ML#&ARQ3"0PQLV(SSJI6.;%KFF=4$C7-[BU-:>*:=YNZ'M3"[L/-T(^["V9+L
MS?*,09<7&> \<>(D9I2AS1%V,EVGEDDN!Y 5+U*ZJX6_ 84J.[6U)_;7W0?:
M.XJ[6PF%3 SX#!P2.<*>#B)(Q&0KYPH_ALIL>IM58IU%"ONO.)8Y0;I;WHR!
M'A"N#C22:4I)",*\6+C=>-*N)2XA>*1[Y65U.8^E+Q,O.\W) J3C4CVDJ_!8
M?G':$,2)+(\F/;,\(RE<1"Z%;(!;6,\J=R"::2;?$;8F<:<)5.1O]^3INY\W
MW?P<[QNLP0,Z6!L!'DN7[#/I5TV72MAXW1SUU'5Q$ZK^+;%;XPX6$;+;#O'Q
M98VBD=$+J%N;-G5='L*C=L)SIN+U'M!WK1Y*2&[\*MFPQ[6;Z,0P+  MXLV9
MLUFNNI &NG:H[8U.IUFBR0^VO4;5T]2?6[2I'LY%10JK&NC#47M8]SVKK^P$
MU!I\BD8S1BBTJQ;J? C6[:G!*BW0WT_'QK-U<C+Y7.;CS%;-;R.N;R _'>LM
M%ZB'-G7/;T^%*44^ GK&=3):Y!OUZ:]_VUM0D:W^TZ<;+;35M;=_?2E3OQ-[
M\CXS7T(('7\6[5G5\F9UDC&TQU"B]@"+>1&OOTI4::6IG62 LDJCNK$:]==?
M/UO1%%")5>T$;.GXF*=+#2 L2.GM1#]=(Q,$J2E^Z_*&P%12KN*^]?BC_]*[
M/O)_;[;-^@VABOC]*W2I:E\7'N15L5\IGZS"(L000+#R-$5AOQ.KL;FUC\?@
M*RXJX#E/2V:]]1E!^[I:M\# &SZG5AK8Z  ]M0.E;, [&Q)8D7T [ GI[ZUV
MFM#I<  D@>M^OP[5GB:,O< _$_H^ZMVX<3:U!"FVAU'4@FU_T5L4<E@#RBQ]
M_;W>5;N:,+OU)%FN0;=O@=2*0WQ,8!F++=E76U[GZWP[$4DUWB5QI(  (.:Y
MN1W\AZT:.F9KN$?M9@8F-FT]K4L<VGU=-*4A$M!E=Y%"02$2-'E)8W1@7[C+
M'8 95(UIW#TKL;,B%O=%99Y '4F22]ES!T>1,QY=!<+<5)1M9<[&VLE<A=XJ
M2A<+(R2F-BS9HV8H)4&3*0IL3*%DHL,F-ZWHFN7Q4E6*?%\)))XU!8SDC.+I
M<V[D*>XT_4JJO-!1UL1022-]JA6;7/E8@YE&?(6%\AZ%?=^BF$=0E3T?8;2/
MDH([XU98PDB</AW0%8S:/E,S6"L1;0"I&-NHS*\E?&1?:S9[L%#-@T0(K2*C
MLTC$1V[Y+^U( $Z#SJ.J>DRT4DK=H\^P48)$W"&6:-,A=2ID  #N &(R9B;:
M=!K31Z&/4E1N/!$J0.JV9$12H1"ARC2WL]:'-NUC=-*]^)(;8"DJ2%!5[.?9
MT4D 9<M_K*::-/B/(YL=O9$0* V9<H7, X )]H@!CJ0>OK2'=L?QO86^&46S
M*I Y>1C>['4D^G-6Q8-&MN@)!ZZ :GIZ$5HV?=3TM?[!KU\A85ET99F:P(T%
MCT!&NH]IKCL016[F69R0.H'1+!3H3ZVZF]9<RS.H^%[#VOT@]#6> 2*:1U!L
M2.IZVN#]ENU:;,<=[B<CL+@$=>^;R Z]*R_,2XVTS/@ &N !T!N;W'<]:QLQ
M0OKD=B3S6L!S6U]1J._45ES>YVG(-Q:]B#I;O>VHZ=+5AIQ:TS.,HOF S#MY
M7_=67$V9\0>S V(+6L% [:]ZW=&6:U.ZA;ZY;W-K=3]O45AAQJ#>QZGSZ5HR
MS>A\!F8MRBWGZ_9KI67,LSX:]6-^86L3>X[>M:8N%TSY0 +,O-<@:D7L!J;]
MC>L1DL]#DBPU4#RUU_36[FHJ^I\+@#0ZZ=SIY^II(I))Y'RDDVMS= #H#^^M
M,W9/-G8+8DGU.O5?_P &U;33[A#2X:G+=K#T-NM[7'W5LW'70QABN8VN2>6_
M0VZV\ZT*9R%8DW%@UB;]B>EK]JQF79S:X!(%U90#UTOY#7K6E+FK"7VG(TL+
MBQ'F#K?06&M[5NYIQY'/+<93J.HRZ6]?2]9O&6?'0[',0=1H1[(T /<^76DY
M;QED?:=-2;7T'4W&FFEK&LE;@;LCL]_XH&@ 46O?S/K\*TM<S9\ ; $$WZG7
MH3:X] :4[6,X6/D NM[W!L6.@T%^ITU)I!KQ.IS :@ VT'0=>_36MQU,1C:X
M(S#-<CIVL>W2U$,,=M0;$64 ]];^E8;,;+<G0@>9%K5@EKWF-A9B3;+^CUHB
M-6X+41NVUY&$B(O*PLMY,P/<@:@C]-:?HBV\B%'B<9(=K/ENJ++*L7&4<]UN
M0E["P]30)>DKDKLJ5KHAEXDX]I4D5FC13] JB8(SSL"18+<+8"XI_1BK62)G
M?LL^8T.Z&Z;8O:GSJ18Y&!LI2)HV(:4.%^CL&]Y[:T*M"U.]D%4[VSR)9[L;
M&."APY.'>)^'Q9G5S,S.4"JK_2&-U TR]14/6FJ<N1(P;E#O'2AA.=5C^CDE
M6%@&)CTRY95RBZI8=;D 5#2;E>3'<%9=H(Q;I!AY)+Y6A&918.R98D(S=@ 1
M?7RH;:0:,=^2BN)%#Q@\6<'L'9V(=L3'&8[APC1.P9@<S%0]Q'(!S=E'6BX>
ME+$2NW:*'E6M#!4><K&E3QM\:6WGVOB<)LYY9\1#C)Y<,H1Y4XT".A"RQ*T7
M"UZ$^E3]*A"C333U_&5N=6K4J=8VMQD?L.-ZTACVI\W8HQ5'=EX<*\=<S\93
MI$9238&UJ%5M%-\AW"HI12=\R-WC!OKO!@L1-A1@&0C9[R!\C<2= LA,@:V0
M*JQL1?KEJ+IUNMJYZ)Y$CB:WP?#+<5Y6XD)<;M3%;3V@QQ\#SR9LKM"J.>&;
MO',V?Z(..^4DV%3,)I0NRH5J\JM;SEG?@/CN7A,5C,/AS%@X7$JOGD"CBIAX
M1EPX"<($NX&;S*ZU"8O$^>W"342T[/I1E3^R03D,_P")VYN,E;$N\,4RNV*=
M,L$B28=@;HK2Y<O/:VIM3B&T(Q48RS9$XO9LZCDK?GR(:[Q;#D@</+'+D)>.
M2-ENV$F74$:<Q/6WE4I3KQE%.)5L3@.KEFK"%FP4\97.%#*08R@*(S/PR!H,
MN8D=*=PJ*6;R(FK2<'ID$N)PKM'+F#W0<N341N6-P'&CN;>R#<4K>0&4;]X$
M,;11D1M(;V9'RG+<F(,0;9=+&_N-;NO89W'$<I3D5 [!<HX:DJ5M8EF>Q&<'
MK6& F&53))'HILF1+W 4CLW2PM26T$B\@9'*Z22.X(M'E$S2%>>12R2#L&1Q
M:WG2)W^H)&=LT#5Q2NJLX+,'2(KTS!; EEO<&PK6Z^P5UG8&F&Q+9ECO($+&
M2-0PX8(T(:UR.NM(:"1J('02+'(+(LRB+BELUV  S9N&^4@7<VI+U";R,\TA
M:*.1 R9KLY=A$O%7G5N6XX;'OT-:%&-'N\[SQ",+*%5QS-$]] 9/X,)[ZPPP
ML"S$2J(H)<Z1\-APUS'^$ O>2Y\M*S,WO21FBXJR!8'@8,41W.:/53E$9S="
MQ[]CI6S<'F9)<P"D*91E"RR3(T<RE.B0E.5HR/K:U@4!G"-B)-5#6X7$YQQ$
M$C&XL\8U5/?I6[@G&5] HQ$2+GX:D ,8P6:[',;J!%I'R@VOWHD9/0;U(J[N
M U#QA+Y@L8)$2CB GZP9%"N !U[45=N@#Q.>.<G$7(L/$51E^CU70Y;EF* U
MK(5O260=X+$!A$&D<%9&=B3=#&J@9<ZW8D]=??0:B0YI3RS%%A,2J&.2,JT@
M9\W&%H ZJ7C501"P+*>I-BU1U9-727YW)*G(-(9[9[-Q5(#*G!4H 3ER<56:
MY1;:]_OIINOE]0XW\K!G%+&$:60L(P@Y(W4.I9)$T!U=")#ZBMYK705O99,,
M$R8[+%*7^:NL+2L7YL/'DS<5+<QB)0^ZUNVF7-[[X6N&4$$D)9(;.J/&.,PD
M,;Q\:S2!7LH [ZUL6G=7898=<SO&DD3\$L)B[(#E<X@(AS(4"ZBRWK&:EH.E
MLOA*D2S1($$15EL$1@%#(4/"Y4)Z7-$7HH9SE;(YQN%9Y<DB,$"H@*J9<L4P
MS%&E0JZFY^JMJWG?M!-\QWO#':,>!,,<\Q,+39HDB9D:)(TR@IU#L\@N;>^G
M$/0[1CB%:2DN9*3 8J?$X&!HH6FC@=I&@$D0$JLUA$R%N)B)9 QSV'**WGK8
M7>X&AP:2XTH(C@PF-B1%,CY99&F$O#=L/-$1AH(@"&:X([UHRZ'=W&V+B,;B
M\-B9(TQ!,LJN('$2Z-]',&]EN(#=@VM-\3Z.6M@<G'=<E9LVK^#VYY^98(8A
M2(,-'!BL''#'PV>3* 7E1K!D27,%L2"16L/&3HR0V6XU=WN;#]R=AJN"3)%E
M9^$<Z(JY\J@$R@D&1I.H [&LAZ6;T!JR=D.3BMGH(G,ZHD2V S!D4.OLDQCZ
M52&T.6ZVM?6]BSE96%/)7(S^)9FV=A,5()1?&&<)$N7A9%1+D%"1&7<DKKS
MW[TQG*T]XU%K>N]#4)\I/>["879.T\(AC"OQD=ED?BQRPK=(CPC'*RS>T&)*
MBUJ8N,ZU5I7W43.'A%S523\WBN9HU\0=O'%;0QDZ$D//.+3M_GB22R(DZYC;
M$70E>7V1K<W-$C&RW>!+X904G;)<!I9,:3BT)4HZR1QS(#HO#),H:01HK%[@
M==32G'W#W>X<#%C=H-'A)@T:R1$O(J,JW>,.R<T@9BGS<R#X$UD8YFY3RNWP
M&EVLTLKB= [\4F1VO8E5 )L3UCBE) /09:=1261%3EO2;$W*I3%QPN)#Q$]L
MF.2\J7S"U[Z WOY4:;O%=X*SO=:@B'B0%DPL=S%+)*'9PJ-]#VU(9FXG;K0)
M14E=CBG4J\=!3['V=CMK8T8=248S+'QHR&$JF5WRJXY2 K:^5,JE2--:#N%6
M6L[WX&P?PD^32V\.S<#B6P&(Q1QBYBA"21-"^0/*"]@ LB $@]=*8_#;O=B@
M_55)VFI>8^ YF\_R/YL5&CX39H#SO%PURND@5.2=D,T012L8%@AOI>CT-I5\
M.LU=,A]HX3K?-@FI)W'>\*?!_";D8=< <)* L&2Y9UF,\;20@-;-(P+QL3>U
M\U-NME5Q#JUM&[A<!3IX3/?W6S?O^3I^25%M'&+XD[R;)X?%G:78^%Q:\141
MY /G.=5*\^2X+:A;=K5>=E[/HT::Q32=23OX'+NEFU*_2+:OZ5J;6SZ3SMI)
MJ_U6L6/]T]W\-LK 86"&$*(D0*1K<D"^46T04_Q%5>BA_LW!TZ%)12T7_ +Z
M.$6-A8@9;=@>O+YBQ'QJ,E4L\R8X+N,PC  Z7MJ;7-[^>F@I'67>6AEC[)<Z
MZ^\"WPK76/D98ZF.Q-KZC[*4IW69JQB,/D;$GNNGW]*6IK@886CT-@F8+8$G
M,'U%O06M2U)W,ME<QLF>WU"A-P2+%;W.4@^S2E*PG0P&*[%E-U/0C4"U[WM?
M2YI6_P S-5F8&B8$6L+'7N/A2D^0/J[G4!?K$#,2- #=3U(.O>MW:8F5- 62
M 9K@V96L#:VFO8]C18S;U!NFNX#-AS]'8:IF+,?72P.G<TK>C?,%NOD8&PVC
MKS,6S*8P<H;.0V;,>R%?OK=T]#3CS,8@8JW%C)*R75@PN1:V4JNH  ZUEA.Z
M<F,W+"*)!:_LOF-A>VOJ.FM;2MJ9NG'#LJ@K99"1958,">8A@>UVK'9Z&MUG
M&0"V:.S,&5>P  L+7MS&M6-V9B;"Y0S,AL5%F>QRM9NF8@9;7N:RQJS ,V#9
MLO)?*,V=0H ;K8Y2<VEM*7&3CF@;C)R8628-@W& 4.UKL^47 /LY7MUMU]*)
M&K=YFMU]@!?#R %\JLG%+%@$"K?L&6Y.O:B*2>AIIH+FADD=5<@A7D4N2R=F
M(!R@V"CSTK9HXEA"9%SJN4#F"@WY6&C WS7^'W5AAT*@.JL[A@H(5^=_/3+<
M!?.]88=B'RHKA ,ZGG!3ZB@"^G,VH'OK##"RQ*RE@UCF9<I!4YEND=A<D@&_
MQK# 0CL,K)D2]P0Q746/5?04FIZ)C!N&(>0K8J;VSMH" +D,-0 ;:4V9N&H/
M5T#(-"S.Q"FQ01="C L I;MK20IV50I*LHSP(QX0+YAF=26"VL_T=Q\:U+0V
MM02JK=209M7*ZV*\V;,Q[!5(H(0[VU4M>^7VC]1<P)"KJ6)%Q\:UX& E(U8L
M#F"Z,'Z9!U R]B:Q&'.:]\V75O9;N -"O\;7J16^TPY+@D9@%*BPRL+"^@)6
M^;2L[S#+FU.4C+*H52QMDRZ.W;1CY5E_K,.2$SJ#JEU429P+."K.W-I:QM\:
MS(PRD@Y0= 0UR4SLN1A9A]4W'2MF'9)+M(59'%V(D#!;V%@[1"XNG\7O6&&)
M"A2-"S<0$/IJ'!Z?Z70BL1ADD8CN$(%PRN,R@=#:XZ5AAW5@H1N7B6+MF<$/
M"PRB.XY4<^O2L,.7E]E@25'5.P!_OSH=*PP[<4',H8L6T4'FTZ,3;0$#S[UA
MAF#D.OD!UN+6&I/D;"M6R,.>)E;,060D$'/DT)ZCL=*RQAV60',,IO[09B6(
M'F"+C05EC#N&YK!= X LP8*,MRU^C GMVK3,.XE8W]?:'>X[#^]\ZS,P%A@S
MJ6',IO8-R%;>8TO^NLU"0:5P8"XN2+EC]'$"H_[&;SM6@AP;)EN&*V+7 Z*1
MH;]+:5FIAS[3:#+:P3^)8ZDDVK5C#L P(! XC]S;+^RDFP&ZKE#*R@@J%S&Q
MMEYBP/<5M7N:>@'E:,7!8VY-2OM^H_C:>M$&Y@)E7*J%B.(/:RYAZ:ZWK1J6
M@6$91=CF&=K]"P):^H&H.M8) ,P3+D4%09'<9]+RCV5!-B4/;SI4=1$]/:%3
M-S&1EMI[-K!?+,.W3O1X@0%(06D:77-HJ+8D:#6PUL:4:.@YU4:!'X:EE(OI
M& 1?TK##K>]PP50JS97Z#B"P#7Z$E*PP^Y&Z*0AO;,;@VZVRZ@5AADC5;.4)
M9E(1Q'=58#H0@O$Q [WM6& E$D*QJ&#1W.;-96LVI!] QM?I6& F,H.JJH86
MRJX7F(TYB;<HT-(EJ;#3#Y<I%U!  8W'V7T%[>5#GH+IZAA"@%B&+WUR'3*+
M7M?7H*&&#B"^3.H4E!=8P;=6L1ZD"D37$5$.(&(!]D#*PM<$>U>POUTH,@U+
MT@>IO>]NNFO?TH,HK@/(RY&5; ].NE#W8Z6"PDT[<! >*>.EP.X^VWA8+)B8
MH\"A8@",S.UW).BBR]:8X^3CAI7R1-['IJMC81?,U\1XV:(LF'PT<^)699,I
M+Q .X*R%R;"1%(O<::U14^6IVNFO,2[!,XS:DTNT9\-+*JQX9,-)BEC!"89W
MCXY;B$7FNS@$7TM:AM^?VAMU=6I+5LSX)8<1C89<2%#8>1'P<VN:02CG5=$$
M:J.BL;UB=Y7!U%:-GJ&&UF=-DR&=SC#\\DG6*,<!TC@=9(8<S'GXG4$$W/W+
ME9H32;5:_#(8/>C#;/&$E;%#$;.PN%V=B&P2JPM+M7@"2##LZ)+.%YAF%LNO
MK36;MH3.&FU*ZYV(2;S)B-H-@L7MC#S8?:F,D@V>L$(S+\VPYDFEB,EDX23!
M@;V6@VE?,FX-48NBFMU@3$+AH9^&,-&2,)A,*\7&RRP71'FDQ$J\C*DL[:9L
MVGPK-QM<!M5J)7L_K&[VHL&+VN<7,<)B8,"1A!)"D;XB&63#QB%$XO&=8[,"
M" O7XE<5:-AC.M*63T$)!-AL'M'&8/)(AQ+H)Y\4PE!6.TO&AD+L TI=4M86
M"CM6[>X YOV".WKP$^T99L0A9=L11-B8(H^&(L7)$ET3$*D:G$9 1:QN16\@
M+FFKH3,6&@7!PX/'\3 X[$X88C'PQ*.//(RR&3AIJZPRR!5RAB5(K&D">]<"
MOB%?#IL9-E_UQ###ACB<0Q!FP\*".5!)&SRI#%P!F+6+'WUEN0BS;OQ$G+AR
MJXO#85 R*5EL)2L!?-GE"*W*5=$("DW/EYJ%Z:@K$8.3$1SQK_6\>*BRSXC@
MP*[/B(;X=8IV:X@PX"!@.K,!WL4H3') /8V#Q.'VEC,1(3BXL;@PC1/#-"CX
MF,K#\YP[9@N&.491E%^YK!,TF&0B$DN)FPT$SP([PB+%-(_]<6E#QM<EY0.$
M@M[;C*>XOJQCB9V2,HCNN)XC/))AVE*2)%-,PER.P(00$MR@]!H=16[&*(58
M7"31PH^/ACR?32R&'(HG;YVJ-%E0MU62][ZU@06&"V5@9.//9%."EQ+10JSI
M*F4_1),4YWB00W53RWOZUK0 XWU (PBR+BXF;.L6+6:?$JRRRS )(W\&SNB<
M$.!9&L0.E[TI/D!:L['&S]E0[.8)K-A,=@I)#,C&48AI)X3)AVB,BR89V0+>
MS!0 #;4WVW=F@RP\$"86*+%RS+#E:!$S<-!%<B/"RA#';@-K=V<^E;44U=BE
M)KN">3#3+BT@$F+?ECQ D9F5)&PTV6.-G5(F,2(ZD62Q%]:2TED.HNRUR.NS
M,'-A\1Q\?"YY!#<"RR._.SI$$5VC)S:D7-ZP5=\&'VS-G?-; RPJRXG+.T%^
M)B67,P5%R.)  XS6Z6K1O?:[[!N^$DQ.((A>-8I56/$2Q!"(IN(C)+'*ZHJ
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MJ%Q5=MM(E8X.#I;TO3BBP[X >'N[S;M[%8X*-)5$:1.@^;M>5&D?B.!I$IA
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M B$,HT&O2DO,<*H^.@71<./:4T[8DO*,ICSYSA\&HB>)HXHCF$B8@,H4"Y#
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M#:), N'!FD*YF48A9(6X,#PEU50'U<R1W4'S8:5HU)V61@DV]@L-$FSDG9)
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MU!?#<6(*+&7C:@#O?[#1ZW=OO-K@(J=4LI;JEQR$UA,-N4,9-%C@K*T\>%;
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M6E<.TQ9204[0B9T.4)>V:]@?9UZ#KT^-+2R"3;W<B(7COL4S[%GQ", T:HQ
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MF2R"'$1HK)>56 S.G*X#:>R3E0M;WT:-K=HSK1S 2)*RL$2,O>ZD*!&N5+1
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M98PZK" +Z!D!(S E1UZCW5EO>88V4Y>(QZC+R!0#?L1H3>]:X7,,;N8V0V4
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M&^B&1G+BUAY'X;%K(;Z;:4G$AC25@)IY1"TT7!:+*@*O%(642.Z*4RZWO6A
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M5H)9&#J"(VD-S:HS$81.#>\KI?66/#8CJ:ZDWYKU-4F]FY9V=CYW56<I,/H
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M+@5C,AQ!C@  %S(KRR9492!'%&<UR;#1I#<4.3NQU%9=IC7CNP6/6S99D10
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M&5Z'!K>W7Q(&TOA,G9ZDSMJ;+AQ&$;YM&8^"[J""(XWGC#30-(JJ$Q*.4(4
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MCAO,\+6 $V:_4D6M:MAH^BC _ #SO9UF@R23HL85IQ&C!R JDB4-9; ]ZPV
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M2L'6TC'B/FF$5)G67!PRRY\TD<<CJ5"B6259 2>@U]=*2 C&4)-\1D?$!H,
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MKH.MJ7#B:>C,#Z@%3<$:ZZCT7XTJ/$2]$!98[KFS7L?9Z7[ZG2]Q1HRLLEF
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MRW-H/+4:6I9A]E!(+,UASY5/F.OK:M&&%5+>RX/.0H-K@=;WZVT[UO0V<&,
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MDLA+(-6\JPP+GQ$8A+10XB)II4FE<HSJ]@>LBV5Q<=:V8$6.VPYDS+(JRXB
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MLX%BQUMEMTTOK<BLU,.;@W-F4-8* P-O0*-=:S0PXN0MLI/JPL1_KN@K##H
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M%%C.<93E!Q,IY20#::'MU(%)DPD.S44$31Q0Q#*2TKNQD*YHU"W.<);-<.H
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M8!KAH\SJTAYN9KVNI[6!.AUK)2X"6!9X<M\B,0P.:1K<A7^,MNWE2EHA#AR
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M3"2CRJ$Y/E8^$>S=N[_^)"[%V>'XS)O%"JHLT<^ VOAHMI,T;N_$PS1G%OS
M<M[U"X6O*-)37"30YQ4%1J3HPU33]Z-:,.ZYW9Q$F#VB6):-I,*6=@L,9/\
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MZ"POUL3YW K##YU8W" !]+?I/PM67LNPP[$ 7(&:P&87[]K>[TK5[F'Q (!
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MLYDU5#PV.MM:7 '4SL8TQL$/$D?!2LS88 XJ5LD:1*0T;M;FFU%M!2I S--
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MJ<3(ZN0R.X8/<L"3F*A26S+I:_;]#'$ZNP:-K]@U>[,8EVTG$E?,T@B6.,7
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M]?=K2K+4V90UW)-B6S$ ]P"!<V]:2]#&?-<-<+>X9CIIRCMZ:UD3$<1V!%G
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M(;21ZZ@W!.M-:VH[I;O'44\)E*WBE5^+%8*TFJA?:'G=3?TIF[W)*-3S59<
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MO772]+AQ$2U C\+-E#.1W!2_Z=*6)"W%,#(5D7/=A(//I;7ULM88!&CXK<J
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MB(&Q+%9Q:6=\\I0,&C!X*D"WLVI.6@XZMI!>\V*^=I\Z6+%\1<1KAY)D:9G
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M!YWL2.UC^BL[]3#EK$DVO;6_:X U^ K+V1AW RB^A+#2UC;UTK5[NPNGE([
MZ#2W\WZ-*UQ'%T<==2"-; _HU[5HV=AI<FP.A MH1<=;>FM889 O1LH Z#3I
MZ]K7I-^'$PX-K@YN_O'7[JQ7L8<YLM^NK=/0Z7]U9:_N,.' (L0187!'GVL*
MQ<S#BU_:&MM 1UT^^M]QAU87)!RJ;K>XUT6^@]]8G;,PQY;F^A#"YT'U>WO-
M+N)EZ+[@#D(SDJ6S#H/??TMI2AJ V5225**/XO*2/CVO1!+T9\0"V4J#9?0V
MOY>58M0-F8I53VB/9NO0]3V'>]&B^ *>J"'%8=8G(=<RBX?3FL_1E]UQ\:6K
M-7!A// !=38YOI RY<Q!TLHZAU';2]98U9&%T(461GB;,P<&S9T0"\BFPMIT
M%:L:MD%F)PR"1"0,HXG$M:[$J;$>9!K: S5Y ,87(J2,H!);.;CV/JLGF1Z5
ME^1O<L]0W@C6P 2PLF<CN/K6\]+TD(&6JC+9G.7E8J-%RZB]]#:L>AH#L E[
MC,Q9"J@9&46OJ1;3XT"S% N,JPXA.DEU47ZKJ+D=R.&*QY*PL&8>Z@(64L!9
MKK?GO=3KTLHK$8&B#,(I+QDY7MKS(_FPO<>\UAAUG&12%7/E]AX@ !Y!B;$"
MM\3 IER2!@P2SV4W'L.?K+<]*<F@,S$V9+'ZX;AQALFMCYA/2D9 P#(EI#=>
M6Z*H]K0\Q:W87/E2-_L%[J/E0 \@S2(FF0*I/%_@[6M?(.OE6;_89N@Q(+@<
M1&>ZV# H1&W\5E^LVG6U(WI=IO=1G7#J$)=  @4A;<Q#V'OO<4G/4V=H\*;^
MSE55_A6 ;.!]0]<S'SK>;U,.KQ!2$$>4@9RS"Y(^(\JPWNOD8#A59_H]0 U\
MMAF!.@ :P3[JPR43&V%S7'#)<=9 =/B-+VI6^Q&Z@++&%Y H#*Z  <P:Z:FV
M@MY^5*4S-T"%%@=BXC^C9G;U8FZ #4<H:WI2T[H3N@H$Y38"[$<R@D$7T !U
MN//6DMJS-+4%H@%R4S(6.8%.=>'&%U;373KWH-Q5E[ T@89 <M@P)LPM8'O?
M7FK:?O%K0,(0MEOSK>X100P/\8MI<5K<3,#7##,2+69NIM[*G3,J]M!K;6A-
M6;'%+0-8P <JE022V:P!*D7Y?>:3+0*"D9>46!YFMIHVM@3ZFPH80R @7-AU
MYE'G[@.E;X"UH90O-?KTL/A]U:;R-F2X(OT'XTH+3N).:T;2;T.Q-D8WUTT^
M/VVUK!Q#*.>IV 5B0.W7UTK0HY!4Z6('2^HN1I8VK##O:W[JPWF? "YZ'II;
MI\>]89NGP%NUOC671EF?#JWN/ZJQM9!(Y+,^'LG]%:;C?@:=WH\C%+##.C1S
M1131L "DB)(MN^974K:M6B\Q$H1GYM11E'DQH=_O!#<C?V!SBMG1X''B!HH<
M;@XX\.ZYF+7=8PHD"OYCO0JM'#U([M:&\NS5>T'"&+PLNOV95G1JK[EMN#]:
M.C-:OBUX0;7\-,=+A=IP#$;)G63\V[:^;DX8VNRPX@1K?C$Z!F/6JYM'9<J*
M>)H9T>[3L+5L+I/6Q=?X)CDJ>-CIPC.^G>NS@1MVCLJ'#J9DP\@=2CR0,[EL
MKAN*<Q9@(V60=]*@,SH5.KO0WKY\>QB(VEAHHBD9P,<LQ1K(R(W"AB"W9%-@
M650->M;LV*WI/-:"%Q^QT@V@CPPIB(QFQ+J&6%PKQD1]$# J6-Q?44B2L[!*
M<GQU&^QF$D^<!88HX(9!PWQ+7*DH6+*LK$LI"$>E_C6K!=YB>Q6 5Y&FPD.9
MX6?,KR N;(O.F<ZC2]K&XK6@N,G;L$F,-(SIF9)QB)'<,L$9RMF3.F10H'#R
M+8],QYNU88VWJ =H85#\XXD0,P1T)CED:**-Y&8@X<:+*2==-.VE8:8W6W=F
MF>(1*HC6>(X4V;)(I)+*8YENZM-'$1?3+\:3/0<4VDTK9V&SCV/*,1&09072
M:T4V(GPT2JK%<S2&S8AEA<*;\A*GO>@V0^ZWDL@%M* X.?"HK%5G4<5Q&((Y
M4-T18W7+&RWY6('0ZUO(2Y;VNH&@P\[FQX4:Q1AXW$\6=HFB@=A(DBG.ROF%
MFT %:8.>H$Q..3(\T2&>1I5@"Q)>3/(URZ/"%E:R=[V'04H:YA=/#Q\C3))+
M)''*T4T>% >-$$B*A5KEI1P=,Y(M?XZ R](!R\&&5EP\K&7CJ[HR!PI'&E#Q
MJ6RRJ&?3JP-:8.08;*P.'Q$RS,)<5#(\\GS>2,0N,0O#XDSC,O)F8<O>E0XF
M@KP$SQ*TF)PL;"$F,QC.!(J#-%&J'^!)*FQTZ'W5N68HSC'KC2\3B)(HF'#=
MRD<@LRAHD:)<I@4'SZ@^=)-F3%##30-A<%&N1HTG9D)3"QS1NZF2(VS&4!""
MW2QK####B'3$-"C+B)VR/)A\:%;#8=&6P:!43(\ME) .NM88<81A-B(U?Z6\
MF*?#A(P2\<\;HF%<641B\!*KW-^])8F1FECC2(O!,F*DR(8XY$X95$1;#35>
M$]Q>UF^!MN.H*?HA T AQ<F(:$I)B$XV)'&&(CA5$)E;#FY5$EB!&6VAUZT0
M#Q]@?;/>1L&<)(I<2/EPV*>R1+&\4QRJX#22R+(\8 *BQ6_<$::N .,++CC#
MAH<2.)B<-_6TDT0?YQF71@TY*C-+TL  *2U8V!Y<3@X(\0I><,)SB<1A>9<1
M$V'1OHI""0,Q(;6Q-K=ZT;2;T"G!OA\8<1'B(\0DF%XDSNZ@QRL$61I6#J04
MRR#*OFI]:PVTUJ9GCADGBA4'$8"149)8ED5)1E*NIA3D.7,>4C0BL-)M:!SA
MQ&X2.-G,$N'BPV&BDR1R"&*%.,C95S1N(T9E8],AK#&V]1/[5G:YCCA5H)"7
M9PTA>)0X40%3;V'0\P&JCRK;R%*5HA9@L('P@EAQJ18DXB09)97EB,L?TN1H
MLM]848K8B[Y?/5%3./M-3E=6#[&3XIYF2:,RALDF'+ 'C8;"*JL%,(4++*@-
MPQ8 =*$D\U;@#%/LO$X:79R2.N),L4DI$9D9#'$<Y,4Y#6=# 0BD]&(%8M?9
M^0&]0!BEAP/#F:5<5B),6Z18:)N)'')-&F*2*0&[%XHY,K-ZVK'D;CJ=HL5L
MY<'&JQ+)'-*\\\6+4/*8W.>80J4$V9)ER DZ UF5C3U%)LW!JR!#B^&)VQ.*
MCQ.(0-^;XSB!)%AQ&I.874J1:X+ FM,"Y-O+0,-GPX9Y(5RQE"DN),J)8B0M
M8B8E2'!M<'MVI+N:;RST':P2B0[/Q$#XEGAB1<3)!D,9<->)TLUY"- +BS$V
M[UN.J&W 6&[Z"+:V?"N6:3$L@5^0M$X&&^C67+=6D2X/0$'M:MS>60B:O&PM
MSC,"<?+AY8GA&&;YM RQ%TQ,R$),B,.KB1P2W06TH23;L-=QJ+2UN)QY<4=H
M"-(HBV%Q"SR.(E8@Q8F7C-(^H<NI!![VHL8+>3[5XB:L+8>=M=UEJWY-TTD_
M@ON%/+)G:386%(-K$*T:,JVZ !>U=5P[3HTY/C!'/,%OK#7;^ZEXCY>M.!S>
M3/NFM8\D:5[Y'-[^_P#325*[L*:ROQ.I \M1]M*O;,U%._8<DW !TM;7W4EP
M4LPM[Y&#$1AXW.7.54D%19A;K;RN!3>K25G99BXRL[/0A#\HW<?96\V&.$F@
MB7'RQR-$6BSELBZ1FUA<W-M17.ND=')V)G8U:I3QEX.R-*OB?X4;9W$WVV5M
M&$XK\S+.X/#=XU$N7-EQ1#<.:&.^BD:]*YS*FHU6WD=8PN,ABH*$OC%'/W#N
MPX*'>79F#F6!<T42QV6$YHRYC"6T8!7",2>E%<FU8R4G![J60UV]FP3LZ?@-
M'(<'.!)+-*["*("8(LN T7Z4O92O=?2F2K=7+,.E&I%;NHVN,!V1CIL'C(LC
M0K.B0L8V;$ACE3%"4DC%*J->Y  M3N%>-2-UJ!E2DC-L[#Q860R8:QDE7+%)
M*4/!>1,@9%UR3);E[>5%A-Y\P,M+-9&;>_=1-Y=F;M[0P2-^<MF[6>+%8N*0
M),!P#C%6:8'(D;/%;-8E?A1:M%U(JIK8;4*\:4W37$B9XB[C;4VZ=O,L Q\R
MIC,49\1AQ.T$;@F2 90&D92G4V(ZVJ,760KMI2L3T-V=#V$4?##9OYYCWIP.
M/PRX;:&[F'VA#AF:$1RM#BH9/H@[+=$D*=>GZI:\H1C;/>S8RLI-RXQ5D$>P
M=N;6V9X:[,V9M[9L<N[3>(&W,8D+C$XF: S2/!+- TLQBPUA!S95!O3J<X2Q
M"C%>=U2N1]*E.-%QXN3?UDZ_DFOC-T\=@=Z<&QQ&$V1O LHPJ*S"38\]EXC,
M2;F)7U\J)3KQ;ZNV1&;1HU%*%1+CGV#L_*^\/=V]YO$+!0;#P>&:/Q,V#A]X
M-C,\4"X;#[<PLC18_!JV58_IV2,@ Z/ZU%8Q?9G5IZ70[V3*2I3WO0NFO:0W
MV3NIM39^Z&\.P-L8*.#:N[<N*$\%G$DW&C 5$E<9!*J&]P>E1M25JF]Q)F$T
M\ON2'NY!VELWQ QNTHDECCC8PKEC5)5SS_-L\Q0*<0I!Z$C2I.O*#P\5JP:I
MVK2;7M);;G;#;#[W3[6>- FTHDE51A80\3K&/G)D"955\VH ':HZI+[%8<48
M_9<R3.S\3*9=FS882O'#B76"50H!6%DDD$8ZF5K=.E1%2'G$BXJ4;,FYNOO0
MN,W.>/&9L^(P[9^.ZE8R(?I>&7-CG[6.M-E4G:4-YV!U?1OVAMX [KQ2[3VQ
MC8P%CVAC6GD=>0K$D&5 E@;J6OH>].L%0EB)6(G%U'A*$YK5LF_NWL!X<6JM
M%)*ZF/(SKQ "-",S, +&K?@,'&A*RT*=BZN(Q&[=#K;,V:\O CX9C9'67.L2
MBTC2:*KWMD_O;ZU)+SZN>@TQ#6Z[<B1>SIA@-DR3.@1B J67* % #QE+:.[<
MU_*IB$^KH76MQANJR808%Y-K[0EQ/#1\/AKIAD5[ DR<ZD ?Z'V]*%A5/$5>
MLXC24NLK2Y1';W;619DSQB)1T8C-K:V1^MR>Q[5:-DPWJR3OQ&&*EY[;%PQS
ML0=">6WNT]U7V$-R*[B"J2O*YSEO;*JY1U.E_P "LTUU!' M<V&ONZ^M;,."
M+  D:BMB.TX ('NK9CS9SFO?2YOD\^FGWVK1HZ]%L!:V@'W5M&&!AH1;STM^
M.]+1A@(Y187Y1IT_%JV]3#!*+L"5(MTO^W6]+CH(EJ );9@#I?X=@:<Q]$:2
MT 4U@.JF_*H"WLW<GKK1J=]Z_ #+0'[KLIVG.!>XP4EP1:_T^%N0+ BYZ^^F
MVT_B%ZZ\&2.QU]M2?^MOQB?_T[K6]']T6V>G]LL5U_YJU2M+XJ/<5;%?*:GK
M,(+#4Z:]]+#[^M+ '0GKK>_E6&^ "D8Z]"+=?=^BEH0P%)<VT!OY:#_L;SI2
M-'1AK<@BVEA<W_96T\K&<#C(S:YM4'3H2*W<T[&:/)E LRFW+K?[Z0[W;%+2
MP*&54UNK+U/9J3>[-G1@;,3T*CFZ9.ARCSI5^'$P!ODN6*A#8J-?V>M*5S01
MXHL1S*.4V%R2-?/S%+X=IM?4);&*0Q#7!0F/Z,<I'7[*W'01,0VVLJ12+EL+
MN1GS'G-M1V"WHL 3ST&#WT=(Q(AEN[%E8</,A3E)"WYK9B;4]I^B!J:$(O$-
MRT&,"A3Q7=K,<B@)E+1C-JQ YLOK3VEH)? UJ^+T\C-B<LT$:IG&52P8'B+<
M'-J"Z@'R!-/4,ZDLO::WM_U43SJ')CDX@#&YL07>R7ZH"#?WU'XA^?[ E'SH
M-C>;F OM9%(-S*A1@IM;BPJZ@#7*XDO?\!.'BW40'%Y4'W&\WY,Q4;JPJL$"
M8=)'#2L'XDDDJ*L00GH44 4?$_&6["/V?+>IW)Y[!LT42WBC5FC?++Q [E;:
MB4 F-;BY%^:H^?I-EBI?%ICW[N2DR1&(1HJI&O.N0JYMRR: N\BW/I0ON\M1
M%7@2[W*E1X8@"BKPU(0JZE H&@(Y<M[VH$EXA*'$DAN]I'ARMM-38W%OX0?Y
M--ZOI^P?4^ \>SR&BB,EM!&0@O=U L!]@I"'RT%'&?HPPNH(OE)]G7IZ6I$M
M14=3*+!;EOW7TK00[#)U%CVOWN!;[JQ:F.VIW77H>G-[NWZJ4]3<3F^<V;H=
M/M]UJT;U/AHMQ?493_%T\_/2L,[>)\,PZ'H-0-?M]:SO,S.V<@@W;7709=5Z
M7\^M::3,,8*WMK:VOG<ZZ?;69+0TK++@<COH"/4VK?@9X'.N6PL;W/6Y%OT5
MAO@?$$VTT91I_&M6&?D.+6]-.GE^!6(RQ];4=^NGG6V8SD$W'4]>G33M[JT8
M=P;ZDY>OL]=?/WUALX"@7OFRW!:^FE[#U.IK1JR1W#*H!'4K9O?<W^XBLLV;
M.F@NI%[:]/Q:MZYF';4D93>^EO=S?;RUK0P[@C*#EZ76WG;6WWUCU,,8NIS*
M.AU7R'[*WKD9W'86(N"%#-?7I?46^-:[##L%!1KY1>]B.I_3;04F1IG9QID+
M#+]&26^/N\ZU'4TC$>5@,PL'/LC7+W/3I:EZB@0=+'KKH5T51;R_C4,0<,1>
MY-P!HQO[K>?>L,/ERVR@"ZLIZY>O4DGTK##@VRJ$N <@86TS%6-\W?I6UJ;6
MITC:Q-OKZ#TMWI4M#;T,RDW7T-A_KSE/^52!)C)&4D'E 07 !U2XZ=+7%;CJ
M;6IC)4NUR-%O>]K6U]GK2^ HZ<I 6^:_-;ST\NW[JV88[@C0BY-K=R/0]C6S
M#@DBR=ENUC[0L+\QK.TPQV%Q?H0&^/\ /6UJ:R.;$W8"U[:@?7%B1W["E/2Q
MJW$#XG^#:]P;$6R^SZCRZTNGZ78%CG!C#>(J(\#V+98PX>0$@VM[-]*-H-?N
M?::J_%/8,./VAM//"CEN+GBDDR"1EXB,V7HZ,#H*RD[-R6I.T7OT4EJR$6U?
M"O!S[861<)AY,.)G#:KE:YXI4H\>:T;/W:U.>M:5P\:5)QWIYRL2X\)MS<#L
M3@&.&-7M'G=(REC=<BFX*$#T.M1&+FYQNN8XPZ<<H>B39V?B8HL,C,/HTC5<
MH5?I+*+/V!UH"0^C.R[#/B-N0P@R<10X0FR@HP6U^8"X(]+TJ,7)V7$4ZL;9
M:C:[T;^Q84,6Q#1 (Q#-,JZA;C(+,2Q/04.K%0OO+,<TG*<;+4AAXD>,6(PT
MV)@2662.$L5,39G.7GM)F51&2/457ZTLY6UN6C!TJ<::;]-++O(;[R?*+D6=
MR,3B9#&)[89Y+(BR23O'DD2^9PXN%)%SI3"=-R:7&Y+T:M6*OP(\;]?*?Q6'
M6;/.J1RP@M)F=6!/.!';/E=2FO2A3PK>I)0K2E'D:\/%?Y3&U-J[3Q3IM$YY
MII,BIB&:13]))GE-PBQ2X52!Y$T[I;)G-7:R(_$;7I4U*G&5Y19#?>;QQVXW
M%"XN/%9<7BI48RL4,$GSE2'RZ9D-Z/+9KA-)<B"QG2&I"CNT96EQ(^[<W[VY
MB7-YCDD+67E;@*]U+F34Y6!^^I&ALZ"^,S95,3MK&2:\]C98S:^:=B!*)'@9
MG9.>S#(L0F(T+:=>E/H8:%-VL0M?'5)2<Y/[(]0*NTI""RR$,L<T::DY7OKU
M[#[Z+U<4]%<:?":OWP4MB%,KNTAFBX2&21W59)+2?2QI&+ +Z46*S[1M*4N9
MPB22QM.TB(-,XC?D5Y$#$O?J+G2MYZ@;I&<8B.&).:.2)'* W0DREXO9%@22
M:V*ZQ/O.),=AE(+2NJY2H4$\2/O 05SDR2B?V.E9FQ$JC]H52[3"%Y(<DA>5
M8I!*LF6RC*QRC-:L2MJ#E4OD%_$$I8YK1\.4I" JEX%U,IS'4Q Z?=2K>\2<
M(&BFD#(R,FBM&CO&2XL&B[B.YK7 3YQWX3Y5>22X&:1X\KE^2,+<=?\ AOG1
M;IY";=A@7!J1*6(?/Q2228S'*;VCNO$N"?*D[R$=7VF.2 YAF #94"AKCAAK
M7U-KN?.EIWS$]6P;,JNA6.5 B7$DC%,HGR#@M)?JJ_.#?S-8NW4(<*K-/(8V
MDD=$"Y"";YN4JZ]$<@]16LK  VBD4-AXA#&H-XW:W%*9$XDJ@#60Y8@"3T-9
M9KO#1]%!EA%=E4*H,ATD)<)<,L(O#&P-UCZ:ZFU8QU3]+V!B\9,8,JF>-)"@
M*V4^O3J-*'N6T8;=1U2)<QA0R8<JG$SE3EC14,RV+7!9N#U[T-FLM.)V"RNI
M+D69&R,J!G90[96EZA25[CK>L>0N%[ B)U()<LH,>19'R.I"&P90!<%2MA09
M!X^B#,,(YF>:4)<*MP+AD&<Y(.4L>8'RI$I;J#:+VAY#AU:,<0*7=D>-'E+/
M& QD(4+9E +]QI0YN]NX7$4&S\"%CA+AOFTC%9.&Q8IG>&-<0MQRA<MK&@U-
M/>.:2XL/XH\I>\CVCD="C"UH3R 1CH +=J:#BX728@+-%E'$1BB",L@)#NS7
M-@7N@\]:=T8^:-JDFI9:&)'" /#*LCLTJ.9;75%(M#'< AU&ER!>B1@KV62!
M2>=PRP<T[LQPJ"+FRE6RV58P#92M[R2ECK;I6-6D)W4W?B+_ &/L[$LHD9$D
M08=%2)F,:1XHR7NLBV>Z#0BF]@<X<A]-QXU.)P[*(H'4A\3<"1IPHRO'K=U&
M(Z(+7%%?Q:Y#=J5LM#;/\FC 1SC9\967#&'&8<C-'Q^%!PX>%%=F0*L?0BW6
M]+J3E:RTLB$K^EF6,_ +"88;L;#S!58X3#YI"2JR,J#^$3I$#V:@1I-4W/C<
M7AWYOM9,[8R&*-6:',BR%;W*LVG$S./(9M/,"C2:N9+TEWCBX*6-(F8HA$F0
MEW#,J@@&R#I6M0X3;Q8]DPTI)0%<Q1"#'(RVT=+Z-&!V\ZTWO/<X"M(7(->,
M&\Z11XN%'9G*-)EQ+!(I&)A0H9!HJH!<4"KNTY)1]-C:'G-RYFMC>7>U)]HR
M0RXJ1FAEX<9$<?" U1V>3F8*O8VUIA.G:;WO2'U)QC"SU >'V_ N'AE.(CDC
M#QY#PRS*,[Q&5GY38\6XM]6U(E33>>IN57+(6VZ&TQM3:"R72.!7PYC,+$P8
MACT:QT+$^UF*@'I6H049C:I/2YL(\+<.!AXG,?.Y5@KJK<5CHPO?V4 T !'J
M:?Q@FE<R+NB6&S%C.'B0#FB )&4CVS?-H!RB^M$BDG8*H72? ^VIA "UA<92
M7 )RY@O*56YL >FM+DGO]C$N+T(H^+&R>+@\65G:-G@Q$KJXT&46.@N3)9@$
M-NM*K4DHVXC:MDKFB?Q(\+<5OOXS<!8)F6+:Z8AERL(##&D696!"W#%;].I-
M2V&;IP@^%D4':].6+K2HQ>ZWE[RPQ\E[P^AW7W3V-@EAX2QX>.3(H54$AB8D
M@GS6U2E2LZNZWP5B<V'@%@L/&'%*QL!P$(@0#H2SL;,&O=V/47IK4=[OM++3
MBHQR#Z$KE S,"Y/0Z&U-)ZBGJ# PL6 -R/:.I!Z >ZA,PS*<X6S9K7'N_GI.
MF9AW#7S'R'Z+_KK37 PY!LH/I^ZM6S,.W6L,.I>UUUZ=O6X_56)7S,,)*9M!
M]4^T2OV6L32^\PQ@@]/=[?3T'8TLT=-0I  ME.JG-;4Z?&L,.I##(+=1>_NT
M]WUJV8=0B!K=QR^FFI_36&'P4@K9<S68!/JD&W,;Z7!^ZM.QA]8W6^8G,;V[
M'L#[C]E;,,B@&Y)]EKC+:^NAS=K$5IF'RHO,=3F/?3VK_HM679AW7E52NAOD
M'P\NG:U:UR>AAV55!U%P>8CR;37[ZT\S#O;KWOS >673[\U:-G8=#=;6&7R]
M1:M<<C#I87OW_'[*V:/BHL#FRG-\#H-#6<39\1<$^8(O[_6L,.I7EM?0:D=,
MVO3[ZPPZE0K%1IJ2/0$KR^IOK6(PR,#S:WYE^!RG4GT\JQ&'4@6N;-;7-?+T
M\CH:PP^!L+*0/,,-+.+D!O.XK.)APP4"XOF/?M8];=C>MI9]AAU#=6'^B\OD
M.6E67N-'=0+Y1H+$$^1(OTT\JT]+F' 6P OT4:_&]O?6,P[7!).;H.G;]E)%
MT_31D6Q[Z=?W^5:>0Y.!:Q'<]*V89+DV3L!K^/?2;?=<3#@(+^?I^VL<C#@C
M,3Z:5O1&'9S8!B2 OKJ!Z4E6T,.&/D&:V5;GI_&[D#7WUBOV&'4V+&XN3;37
M]0(^^M^!AU.6QURV&@\[=A2L]#-0',LASY;6S+U_O@!\>M+0VJ1W7V 22/,!
M;)Y&W;)V]UJ(M!!U*!;DFP*]>]NM_@*4M1+T?<8918=" S"RCJ-/:'J:7'Z[
M#>7I+O"W&1Z6.F92ES[=B#>UN_E14[H"]0ADCC,R%V]@J J@WN&'.Q'D:V).
M\<2LH47D*@N&4<O5S<CX]*T]#'H YHT.1WO=9&Y,MKZ=.A.M)$!>T"C*HYE1
M6-NR,26L!IU-*0B>J!<)9PK2(0<A?+'H#87L;>ZDBP03F+9;)8L;/U]CMT.E
MJPPX/TME&1VR:DV^_P"^L,.5B"J",A4*MAF/*1JK =RYZT"X4,\,"Q+-W8#I
MZ>G2PK%S,#1(P0C*RFR2<3(+<6W6]9F8?2(<HLSY<K"6SI8M8V^S2L,"62+E
MU77]'Z*<FC#)$C&^2-/]#R1"^GF+VOI34W9'419FX84%F:ZR1"X%E&K?W@M[
M@:V8=XXU7FS<_8Y!?R\M*P5NR!4<# $$6XC@%^EKGL?.]:#&;A)VS.Y(4F_9
M9(0.MNH%9<3N1Y&7)$J(MV=/)N0=^U;";LCY8XU;,6O( ;VYCE\O.UK5EC-Q
MG1U0I>RJ&.EQ[>3F ;W!JRQO<8'X9 9U!)>XL>B>H'PK+&;C <L6:S$7*6U\
M_,_&L-2AEV&%HPQ4!2']N-V6Z6(O(I'0V-9<'N1Y'(C=+YD42$Y2R_P;*=1E
M'12%(K#6XC.A5K!@Y$AMHO9>Y[ZWK!&XV"XP!8#.<SME!'0?HTK,C?5O@#XE
M.F<*-?JM9K=@>FHK5[:!%35LPUC!#1L$90&R@@]NE_/44B05*RMP#2,<QS$6
M0DYVZJ6'LD_&D7%)7!0%U Z@: 9<HZ=B.H!%#XBHQ2>6IW5;9K6!N>8&X7IH
M#WK BRR,R7[Z&]OV?:*1/0PY-B"MNK7O61X/L-\#N-5O[A^G]E#EZ0>'HHR$
M AA:X 6QMU%NII(H[*  #;4C6MBE&ZNCN!:^G>_VZUHRUKIGQK#&\K'%8).#
M0I^D;1Q2##ZL,/KVOZBEQE96"PT.ZMTOY6^\T1><O:*"/>#=[8V\VS\1LO;6
M PV.P6(0J\6(C611<6S L#D8$Z$:UBU<9+>A:SCP8TQ.&AB5:64XYQDM4^\U
M?^-_@1C/#O:7YRP$1QNZV.Q$K&0^W@ S1\/"R >W$2.4_@5?:VRXTG\(PWQ3
M>BX/D6?H[TAJ2K?I3M-J&)M]CF]))<^W7ZB)NU-W6^FM$UXQB,JS "_%9K<%
MQJ"% %K]+579+/?XE_<G+SVFDU_)EV7$#C]G2&)B$>.6%$5$<*<S=%SW +)8
M&U9%W5Q<96C[1M<=LZ.264M$O#)"0JJ66.<]':-C8PRR9A>W44NX[3NLQO\
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MN!J;74]JT+!4V'!Q*XC"X@8:1&5F**D,'"@3(3' _P#HR-RV/7K2D#G*W=8
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MD!51<R% CSB^@!*R7%M 0.E+?::/L$L<V(E1A+&2"V8G.9I!_HP'2TG2M/0
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M+/.26:2!#J>&PM3=RNR3T8#BWE7%-'#AL4^(8PL526,QM'B H4R@1?Z))$&
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M<ELO:RWUXG^OK:T,#:+,W#56[?Z'Z_9VK7$P%-$4]HV!%FTSZG4:VT^-98P
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M$<*IQ9!&QD8$K8>S2HH0VWJ"<%%#'BFDQ,6*DDB7DBCA$I:7$IEE<Q 9LKJ
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M$ACFU'3E^ZMH2SX!=6&70G3\>E9V&CDBW[NGPK%F:..WLW8?;EO6<>PPZL;
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MO/LA)$Q!1+!EREN8E'.J@  C4=;4\IU$K<AI64G:Q%;>O<.?%\7B1R2<=GC
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M !<$K<@$=>VGE2D8<:7(!4WL+?Q+GZO2]QUI1JQU(#*23<]1[QR]?C6\T[<
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MQ5<5\IJ>LQ/,/9)_=^RB $8Y 1<G4?C]%:1@7,#=M-;_ (Z^0HB-&%U)((T
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MB,1AK/8"[@^^FF&ISG33^\D5^E6ZE-\6S>CN)MB&7 8;#"8L$0K(4>QB8O\
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M8!V2ZYKBX-LAT67_ *^1\32X%8$I^D="+%&4%UL8FOUUUUMI>XK YTL&52
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M)\/A5YE;%1P(8H%LXQ<4S.I;$2.ND65@]QW4BB)W"'7"F6&8XM\3%#AD"-#
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M^+P" #B8:4P!TC26 KAB$;$#*9FTSY?::]SWK(1<;\B)Q$%%)&X7PMQR-LV
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MGMK(0-'%M0!Y4G@:.YTL%'M$VTZ:W&GG:M\##&XREP<UR;_;K]W:L,.BQ,"
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M-\-F"259HXP"5(4HUU,;WN3?6^AO45)WE[2Q4\HKF,YMK9X< !B(R5:\:#F
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MPQ;AW1)(VPZQR2%PI@?/(J,REIHW3OVK1L^:00S10+(L:+*K\19AEPT8'&1
MC)S."K@@@]:PPZ3.PBPT\*Y)&B@($JKS1HO#+S9 ";E2UCYUM.PB<;Z *9?F
MF;%?/H<3*Z&:) D4L.F90KQ,"W"@+'H-<WI6-F1C;4"1X[#J%BQ$,8Q28?BK
M8E8%FD8B*;#F/+ES&X"&]K5B=C<HW02XO:AE9,,PG;$.X99<J(T,2KPYDFN
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M@TL!6:Z&T+;"0KPH$D500\HE:-8^)87D !ZD6M1%H.(_%B@^;"-)+&)0DO1
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M]A\0%%NY/X^ZM"IKS3K:LT[P1Q8>0^RL;9LX8"QT'V5N#>\*AZ2,1%R+#O\
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MQ7-<W4Y0?4#RK9OM.$3Z,BYT8C,3< >[]U88=3'&<HRW8_Z)?[;=:PPRK"H
MS,@ + DFQ*VUOKU-;N8=EB%@MDREE.B@@J5NIO[K5C9AW&&6S"R"\;,=+/\
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MY:?$_P#:U+B8M0+(;"]NFO2_W=Z(A1UN"S76QLMC?+;U"^E;$R >(FR,Z@W
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M$M<I!-ZR# @ #0=/LJQ1^Q0C3[!K+SY79S8$:@'2WP\O=1(YQL(6I\  ,H
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ML&(3$3M/(C3S03M81G#L+$YX_P".#:QZVK$KY"I^B$$\D;*(Q([1+S980(I
MKH&(11=6B"J;MVO[Z4HRCF@22EJ!"DF-QIPF P^,Q&+4O!'#@H7VABQ")G*F
M%L.LAS-GYEM>WNHRC.IYL=>Q7N"E.$(Y[MNW1=O>/UX:_(U^43XOXC^Q^Z,^
M[.P))6E?:V\G$V:$/%18Q#AW_KF>R?2V( -JG\'T>VIC(J<:+C%\99+OL5W&
M](MF8)N,JBJ27")LK\,_R9?AGL'"X;%^)NU=H[[8^&")3A()EV9L1F1^,ZM
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M(F$<CR)F&4BX-"J9)L3O>=V$^=Q\-A!LS#1/+&<05:0DG*T&%[/9P,\MM%
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M A0][DVZBU[TS5/K'?@.I245<GCNW]+NGLMA];9H-@;W-@>NMR:K&T:=NM7
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MV>,@D7ZFMFKG,&(@7(6;+&\<D<J(+F.R@Q$7OKH/C6C8<P2F52@,O$&<.;Q
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M88TZ/W-!SWH^T;U/1-SGAABX&V?L\0F57C1%);(6<J@#L2,QRDWL>XK<+[[
M<62_V#P)A!,BPJL:(K<7.; *&9BQUDNYTMTZ4F2WI6$T\YJY(G='"@B&25!&
M415#!&.8OSFQL&RE>W87I<*3IIR$2BY5++@R0&Q,(I19$7-Q  &U.I%U 'LB
MZV]]/</&+BKZV'$JCC#<XH<C X$Y+Y,N?G*Y!<-;4V (MI4A22WK#&K&_G<3
M)-L]I"S6252K.[%;9$(55"W&K74FG$&[7[1G+SNXQ0;*8!KHP7.BBXNA 6X/
M0@.;Z^M.(U(I9Z@>KS,J[$,F=Q& RW4+Y G-< "P)RUOK8=IG5BKV/L=4R2+
M%&69;EV7-E#<W36X!/PI%2K=97W0E.GGVBYPL*1J=#E"KJJV/?V0+76_6F=2
M5R1A#=60.5 ,Q(MS6L/9.GL#SZ_::$Y> 8%HBCHMLPN$(N0.A/G8T)LP$H@(
MM86"@>[R^R@/4-#T3+8:7MH!;SO^RM"[<SD6'6P;T\O2M&6L?"USK<^6G\^E
M88?=>UK>[]IK##X_?8VK##GX:VU/ZJPV=;:ZZBQL+=-16&CYK $@#[*V8?#+
M:X[ _C[JPS(YZV-^WX^RM&'!-B.]].O3X5LPY%AH.U:,/M+]!WUTT]?OK9AQ
MH=.NG73[-*T8?$J-#T%OM[5LP["]M;7]*T;X'U8:/JPPXN+VTO6S#XD"QMJ=
M/MK1AS:_6L,./LM6&'5NFEOQY5O01)+=.!U'X[&MO3,3#7V'<@FUC;6M!3ZQ
MMI:_G6&K(Z$-W(^'\PK$KB9Z' U(]_\ /67RL)CZ1V8=>FH ^-ZP*<%02W0
M6]W2L--71U'3-H+?'\7K!*BT[G>V8=,HZ^^L%G70%AVT^RX^/>L,/FM<^=A^
MG]E88=7RVT];]?AUK:U,,1MWHPHZ,%) (%NI^%;6ES+(#G4<W0<P T]K2UNE
MC2T8!Y0P -M![2:Z@]"/NHD;,T I%56)N+DV L#^\T2+N!EZ3"YF%G4E+G,
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M)+@%_H\H*\._O];=:UH.83#J/%,<SK(,B$%HP?:SC,"!WZUJXK>[$"TQC-H
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MQ;K 4Z.4+X;+Q9+ M9F9"W9+ZHVFIZ6HP)\.X3V)>7BLS3(CJP211S*S*O4
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M% !5@3?IY6[@"]88<E+*+%F >^EO33W&L,/K,PM;H38-9;CWCRK##H25-G0
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MLHMJ0R&U\>PC<MPF 8.9&51]$D3NA-C>]Y%'GH*:SSGJ(ZZZ$#CL27+%^$"
M.5I+JEK(@0VS?2-';XT.2&\GYPEL7C CS+Q66/Z,F,J.8VL'O:X,4C<UNPO2
M= ,Y>\(YG2=R>)F-OII""K@2*3*/4+)87[5H&=4D0,$C;/H>*PO(,H%E(U]N
M]NUZU?*YC.L8DC9<X9HURY2#;.R\DK2 <UF)/NK5S#MP\J7:19!(S9F'(QE
MY#<6*QH/*U8]#0!C9VDX4DL+++JA0 ,M_HP"2+V!U]]($=J.9#.F'>9,N2)$
M:1 !FDXG.ZH&UN@?6MFE9L*V,H8V#PFZLA6S<-)!<-?N=>E%%G8_1/'S.QC
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M0F.@+7$(]HV!01_0J) QC,;<Q8,IS'7O>DBC)QT*M$X<1GB*;V$>>UHV3+S
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MA2%R"5'(%U900@&IN/*];,"+$M+Q)"M\X8%V;-G8NP<WU;*Y8WR@D$UIF=G
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MTZ:6\J(G;+N!2$_B( 7-R^JF_,=5/8WN+>AI0"3;>:$9CXU3BYHY+J'5N@S
M@]^M]=#1UZ*&LU9]@UFVHW(?D"R@NN(#6=",T^4 6/.% %[&E+CW 9:#1;5@
MSEG*D*1;(WT:G(EW!/"!5&! )N*(M$!>H484AC&R*X +(KNI9]/;!5KAE9=,
MW4"L9H&(DASJB&^MLHRV7T^EZ4@V=9(D,=CQ8Y!D4MDNQ2^4-FL3I(?^Q:W8
MVDS-&"Q5F1QG42*<JE2PLN4+T4=]*QI-9BA48%&O(YC)109 8S8P!5OG-]9
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MH"V T;_3$7M]U8:N<<O,  >8>X$=P.F@K,S+G-@/0D7]_O\ .]8:N<"S*;6
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MOOK&891PU"DLP:XZ"^H]>IU[UH"WF9551F+$,#=H@%%QZGW^5:=S:.6556X
MO[>EM#T)'EK6XJ\K&3]$Z!'L3=LN:,F]NZW-O3-6W;>L!S.U["^MBPU;4D>O
MGTK%D8"5 Y0;.6.:Z]KC0&W7K0W?/D)Y@T(5RD:Y65F/7K[Z&PM+5@M=+W%V
M:Q7TN-/=K0&.8@A0 %##,Q4:ZZ>1TO?6DN_L%+4R*MB;V_>:2WD$,HL.H!^Z
MDL=V2!"#2_GV\J#+D(47O7.3ZD+[Z$HR:T"-TXY2>8&GQF&P^8S2I&B#,Q8@
M7%M#?WTM478%.M3CW"'VGOYL_ F2..SR*0"_U6\B/(6M1%2;RMD"ZZI4R@GN
MB%VGXA[3F)CP;QQJSC*V89@ -;>6M$4(K*6H:&#KS\ZI*R? 2DV\&UL:\QQ&
MT,2PR@NL<C*JJC%2552!F[6I+LG:.@YA@:$5=QO+MS"Y'9I)(VDEE;7*KW-[
M :FY8 DZ^E:NQQN0C%;L4O8'&!P7'8?5&1$R'F+&P8VO<DFE1@Y*]S5KBXP\
M,<,/)'PS868J1<@:V# %;'\>9HJRL;[P+B,0L2 W1'+&Z$YE))ZL>HS#4THV
M L*#/BD#!"V;K$"+7M86ZD6[]#6C 'XGX=QNRT\5Q+@C%B00@L8T<+,&4 G*
M%:M1S8F3MF:R]_7& WHVCB9(<F$Q<BR0R-&2G.HO*N86SA-:K>T*6[B7VV+Q
ML.2KX=P6J:-:WRB_%G";-WGV3NR<6CS[2EQ*PHMH96C0:2R:Y>;..MM1?4U4
MMI5)QBU3SE?ZOSN=3V5"G3JTX-+SE^(8*:6':"6!ECDC0*93*)"#F:]Y;$27
M#$E@.7[S5W-MW>I=X04(J*$W*9<.&CFC(5>)#,ZS@32)Q%L8^C!<I',.H-:N
M* DL[9B904:,.R7F"LRHDG#:1@,P5%4$#I<7K+B)6XO,76ZF^XV5C<-&9)6@
M^C,>)5FPR,$?/*JLM^(29;$_6%AVK,V,JU.,TVK$S=R]^Q(N%<8AXA,DC1R(
MQ"1QL3RM&K9F)MU[]*-H057#Y-H?W8V]_P ZP\31XN,97XBJY:-FC09'NQ!Y
M7<'3K3J/HJ^MB-G26:8KUV_%B5=.-%+FAEDLK$I&T<;3Y47KR+%J3K<TJ]AL
MZ3B[\$PKVKCR X4-&RRAKJ'>)\T;,!E4$J3EZ]*UKF+4K96$/C8I\9,DD<DL
M,DK2N 5S*,P5D(;6X++VZ5LTW?A81&V<)B[*,8 )?FTC-P5RQQ2)/%:25<UB
M6!^^MQENN^5S%:UFVAF]X&>"?#K);.Y9"5B;-F==)!E-P2HZ]*74E>UN1EHK
MT1N=H['Q6.QS!,R1NLBQY#U/T4UGA4")@ 3Y6N?.D1=EHC'>_$ _TM-L^$CC
M*G&13)-GN1+GGD1 IN8S8]0>FGH%[[-6$UCMF11$\&.7$2&5 \DC$R":50PB
M<$VY5#$$#0&EQEO7-!3C-G31P&2.+#Q"*'#-\UG=V$D4F'LSQJELV)+ZK?O6
MJG88@OAB>62.:7!V1,.R00E0DTK(F53B9AF+/F;,0+=-:'KFS#%MR.14B5 ^
M(EAPP3%!!E,>=W.=%<V*QQ1\-;$BQ]!1(\3%JA$XN:)^'(TB1&9T,#*%R10N
M#,T"\+6XC90+Z9A6!9)NU@N&%P>.Q$&:.5Y88I#PV58Y,;.BL[(H6[R2C,H.
M49K 6[UC5UNI2<GINK,#.4:4>LJ-*"XMY$D/#7Y%WC'XR[.V?M3'X;">'&Z2
M2*S;8WGCDCQN/PT@XD9V9L@*,1B$+$'-)E!OIU-6'9W1C:F.W92BJ5!ZR?I>
MXI^T^E^S,'>-&4JU?E&VZO;R)L;@_(,^3YX>[/:?:6[\_BGO-SR3;?WM7YSL
M_9^/O>9=F;&A/S3"861P,H<,]JN^!Z,;.P<$I4^OJIYREE]10]I=+]IXJ35*
M2IIK2-]._B.U)N[LG=;9'S7=_<_=3=V./$36P^P]C;.V<DB<7#*99?FV&21Y
MEM]<DF]6.AA\/2:5*,8KDDEX%4JXG$5I;U:I.<NUO\H4X+%[7Q.RXX,3C,1B
M(EYB7E/*!)T ?4,HTT[4>:BF[:@>\>;9KE<'@42+#<")N:*V6>%&R2F:(BPS
MDL!IV8TWUE[&9&[?:"-X#)(MFYI4R8M9!*%+1GD0,HY2,HL?*E0:6IN;(_;6
MPLGYYGM&R992]E5+#BH6"0N-5 (!8Z VIW&>68'4-=CX9@T(E*1%96+9I"%C
M<AL2LCZV)DB>RCV;7K4Y)JQC%0[02ETF1&A**&:0*?FX3-&X0G5<YY@?2D1;
MB[K42] )'#!&Y?$)'\WCCM(Q!;Z66;$!@#V+H!<Z7O3B,E)*P!: +%SX? \>
M$20RM*@*<JVBC_T-;'HT0Z]ZQK>MR-7T$/-B_G4DKG):.)XG8AG"N>99U753
MDRY?0FCQBUF#E*X1[0XJR9$R.UFY_FXRO?CG.2#<2"P -'6@%Y, 3K,XLT3Y
M8[ NIS!68+8B/VKD]#6S0-P.'!=517D9YA(48E64P&,L77H.5B->QH$YW=EH
M)%YLO#*T[OK"8U)B#Y#'*[-<W0:E@N@TIO5RAV!*2O(76'."1+I&> B9EED
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M^<KES-RBRZFXO[?K:FK'%/5"NPK+F2Y(;4 ?5MI;-UN;T-$C#0/US\/*S W
M8LHU*@: V[ 5F00R=@5O:PZWMIVU[5I?68<*.:XZ=P.GG[O*M]AILR@7L+6"
MD].X]:V)6I\2"1H+$6! [GIIZ6K6@L^"W)%ST%M;6[?^:UAA\1T7-T'0B_QU
MK##M;IT.ENEJPPZMH5UMV^'8>ZL,/K7.7H+=1^@^E88<-T86!L%L3UZZF]88
M<$&Y/7F^P#*UAY7 -88?7%P1TRZGUU&OQ%88<Z,2=1E'Z?V5AAT]E2U^M[_Q
MNHZ&]Q6&'4D:BU\U[6["]K-\:V8?694&774WT!N!T!OTM6&'!L0&3*KVYKZF
MP["_K6C#L2H )<ZZE<MS;L!II:L,/KK=3;0 V\STZCX5LPY]K6]LS:@]@.E:
M,/M5]G+=OAS&UQ\,M88=M1S7N#<LJ]AT! '>]8:.JGV#90#?H-.O?U%;-G+'
MFN+7'0CK]M9P,.+@*2US<VT[="3>M&'?0WS#ETRW[V%[CUL#6&'*Y=""20.Y
MZ9M=/A6&&/4%N:VM]=;V-_7RK##L#<77,03F86%['H1Y 6K#61SFTS-G&4Z
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MX_9XJK8"-0>VM9V&&8'ED7B!EC)>/(S%68C7E;30:5HP XC$F,0NHD#.H2Q
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ME6P(7J*/;=9'6<HW'=V1OH,0D<B8B)Y&N6@0'.8V7(L)<JG-DN2>X8BE*.\
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MA@X;BMPWE4H0QC ZKV&E/(SFY>;G!\/SS(#$[):I]903NV:V-_O!G&[NXC'
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M=59QE7TJ1E6C4E>61&8K O$0:6BT-:>]WA!B-G8@E<.KQXC',C21J",.IA4
MSL82RLH%M/K>M"Q-;<=H),A5LZ=!6WKC-;>W)> 1G#PR<0\2-F=<Y8JP*X92
MV3614)#=KTU53>])*+%2PDI1NLAI=L;O8K#))PTX$@A2&2*6)4X[7O>(6M,2
MW\4"MU*<7FF-5AY1E:0W^(V:8I(Y(PR<5F)DMPP,Z6RLKW L;>@H,82ODKHU
M*GR"O%8#+&!%"[,,D,D\BM98BURX*".+*6'0:4O<BN"!.W!.YSA-C2LZ)'&7
M622,1Q*A,F>W$!B+WM&+=*Q07(W&$F#IMCR*)I'A(C4AK:A>.9&41R/_ !5%
M[#H*0Z2"=4Q/XS8[DO$Q*-<L2\8=LL>BO=/JR6%QWM09Q:;-NG?,2V*P:QEE
MEN)"]H),O$S"VMP;V12?A204HM!?%ADDE9<RM*L;$HJV#*!G60%M.(9!E]*2
M]<C+/D&>7@X>3@K9D*,\D:&SLG2,B3DDMTL@O21?5R"=XI%B/SALB23&3GS%
ME,JW<JIC)6ZZ5AKJY=@!?F/+D*6>-9F7VES$J6N!S$&][:7K0AY *0L CD1+
MGZS6RB0#E (&A/+WK8FSYF,BQ9K(2H"6:S+>UVE-^J Z#S.OK6&61Q#/E6ZL
MZDQR2:DKELVBAA'>YOYUAL&)(L8 87$BM8G55S^U9=+,1H3:]8C 4KJDP#6X
M:-(3E=A)(0W*6<W!L1>L-@^)'D,:EH8\Y1WED(89&)58T%BJLZ@5AG:**!U6
M)=7L(S"V$=06DDC&0N)!S$"W7J:0ZD5D'2C;0$HJ0E9)X7DAOE,<;GF8#*)1
MW"ECK275=\M#=^" 90220!4,4T4EV8.>(5 -B@'M:4-N[N;2;9U>\DDU@P3A
MI&79 )&96=U<G3*V45IK((DTS)"[R"$"225V;,LD1YHV0+[8_P!#/+K[KTEO
M+/47%9Y B*)U=^(QNK^UKD+VX@91RW:QZWI&\K!%%MYZ ^-(&G5DACXH5V(M
M=74 '(1<BSMUI.^[V6@3<RT#..%V8+PT "W,>9C=Y;$9;= IN*2VWW"XT[O3
M,4&!+01+>)[R"4HJ.% 6U@,K:\OK0IWW4.J:MD+#9&##$EL/&%26(1"0JA"E
M\SA<M@X4DFWG3>>@YI<20^Y,:OBW@S+)"CB4@#A/)#'+'GCL_P!#*;'2PO49
M4D].)E2;2R-E7A#LS#S08!\)&6:8I&J2%I&2$ <!K$Y4=;#IT:A-/0:=='CZ
M1LB\,L')'%@3-A3!+AL00'L2<1("ZB-590J\LBLVO-WK<8>\W4J[T+)W1/OP
M_#X6-"JE<2QCE#%1&Q=2 %AA0F-8V[GM0[O?:OE88Q2ZPFGN3-/B,*IQ&19P
M<SW9R4-KLBO]91(3KWIY"323>@B;\Y\B3FZ:R)&DBI=>5VN69GS '.,VO*.U
M.-[?BF@:=Q\]BRD*A>4/G56.AS97Y0#Y6"].U&CZ*,XBKQ$F1 RCZ-2 %^L7
M(U;N;D]_*BQC%ZO,<#9;QO(P<1,.42.,V?.&[B_L@/3N%D-J]*+UM:Q&O>'?
M':&P)9)WS-!!G&8-F+J5E8K<.ND;#06TJ1I*,HK+-HBYTDIVB//X?>*N"VE!
M"#.(I+!8XK=;G4ELY!(/V5CI:K5(;RK3H5+236?L)+[(VQA\<MA*K98U8:CF
MN+V-O:MY4QE!KON25*LINV5WR%'%)?+< 7[?Q5[6MTH4HY#I-K1AE$;@ZEO(
MDDWIK)68Y,G?TL+??23#CR! (MU-OYZPP[5AA]6&'W73MYUAAP/+R^-_P:PP
MYOW%8;/JPT<#]OZ:PP^[C3SU\OYZPP^!OVZ$@?M%;,/N_P /L]WOK1A\;WZV
M'VWK9AR-*T8LNXX(N1Y:W]?*L,.:PP^K##ZL,/JPPX\JPPYMWUT^SXUAA]6&
M'&M^UK?&]88<UAA]^![ZPP^&@M]YZUAAP3:WJ;5AA]Z5LS4^(!]/=6&K+DCK
ME &MB"=2>VG[:PRR1R+7Z6MT/GI6&SC2W6^J]3?O6&')[]=;=.W[*PPZFXU;
M7RMT^.E88=AK8VMYCS\KUAA\0 - H]XTK##BS>GN&AM[^U88<'S*?:U_TUAA
MA86TMTU_GHD7D;U69C8Z:]>WG2U]0F<5NO)&%^H[W7F[V]?>*6AN8KZ 6N<]
MR+VY>Q^-+XWX6-'27J;)=002 QUL-1Y]:Q7MVF'611T"VM&P8@G*0PMS=B=:
MVN9ABR,0+FQ#6MZ=CKI2MY(QO,#RQDF0AM18GL=/U4M2R!32 ,R D^BV [6\
MK>5Z-#..8UFLPHQ$"]U4E<N4D7(8B^4&V@)HWFWR V8!X#"SB-F>S!D8G*5M
MKITM:MO1FCDHQ4!,IR78L68*A(L48'V[ T V%&(@"@%+AU.N4VSQ$CK:W,+Z
M>5;0F3S0!D@-F4V+$74@:,HUTOHI4:UH4&6#P]T4M[=N5B+L?B=;FL-IM:"A
MPD.5F90/HVRE0+7TRZ*]SE+>5;X"HW]H>1Q$!%8*,_,=/9-NWK0IROZ(YA&7
MM,I#95"@YL^77V3^KI6DUQT'2U.1"P 0: ]?+4YM?.PK6\C=T9 JC4D$>G2L
MNWD;.P15&4@M[OW6I#DV'W5R1F47N587!S#EU9K?>1;K6F;.V07?0=.P\]16
M7,,86,L #U6XSC-]M].E9=F6N!I9HHULQ ))#+F%QG&12&Z@9M:4KB=WM873
M8_"Q%SQ,N7*"RJPS@I<@ZZW-;4UQL:ZM=H12;S8558EU-V*B[>SV%AV-)<WP
M%*$>0D\9O;&S<DI92W#(U))"AB;W-PCDV/:DJ5^(6%./)'1=X6GC 3(C(%);
M-JIS=&MU<^=S:LWES%]6N1BGV]*@(-E-I2?X2Y <FQ.;72D[S,ZF0DMJ;W8B
M/.%9,A>VM\R  /RDFXZUF\)>'J7U$/C-]L=$1$[2.9>*8V,B%3=;H=>F6A.K
MPL+^#WU8G9M[=J,Y82YA$.&ZOJJJTC Y=;7MU]WNI&^VS4<%2<LV[L+UWEQ^
M8*9W8*9%3.;+<A2+'7E6^E)WY\+!O@E%9!OA]M8]I PQ.:1#8+9@MS[6IT-C
MW]*S>ES$?!Z7(6^RL1C':-Y<0_M77F9E3-U>,C2,/W(M>CQSBNXU\&I\OJ'!
MP^T\5A\-'&LMAFG?AL2/]#!!#C7J+UM,U\'I<OJ"3:6VI);QOE5KDQ^V1G'M
M%R/:L>A-(J-JU@\*,59*PA<3C[NZ.X99GRV)8'47R7]K)H=*'=Z-CA-)6"1I
MWD6Q>),W-D0\JP: @'J7( HL/1,R>:.CRRA;(X4"0H 8[@KT4D]R *4;.8F)
MFDXA,@ 9B61<N<*,JH2-%OV\ZPPS(SJ<V5#RK92;(Y89LVEPI4M:Y\J4K/O-
M!_LJ&6:01F.[R<_"#DW'3C<32Y%J'*.]IJA.]G9#K[$V6F'B#6CXA-CQ"<ZZ
M] YTYNI(K<([L;/4TVWJ&>-E,'MV \@0WQ)7KFI:-/02TV/+R2*6LH<E5501
MDR"Z]#RLVI\S1%&ZN!M<'[+C,\B2.5C+#DLF>]C=BR6(73OWK4E87&][<!>%
M3'$'7553,S7N97*:*M]0!<:=!0P@CMJ90#?*9)$!,3+GL'RL+$WOHO3M<T2*
MDU= 97WK<!1[O(4PCW*)GZ,Y(?.;'3R%NGI6IWOGJ+AZ(-Q)YEE9@]\Q&GM
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MLT(#,IC71E='  Z"L2OH-YV>:T'1W/WPD587Q&9A%(H2.))8H<P12#&Y-WC
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MYRB(Z6(8DZ@ C-:W6P+5ED8%.+&5)'9N(;6&52+7;MTZ ]ZTM1$M&)_$LHS
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M2IB)/.KK)S9A)[(8WUK6\A+4>($?#JT(.4O()#&J.0%L=;@$=+FD;_"S!.#
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MD7$C99(HY(A&\8=5*F0D*KYB/?K6S8GVD5^6,%BC.\?0!(@V3.T=FLD8O?\
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M9M QF;A&*66.5YHS*$9M+C.R"%K!1+DZJ>@%)>8K>D$./VPIFA3#C,&6T8C
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M#:E@4KBUPV[F"?#PR)#'-.)$F,LIR"'*>)%AW22_%&73DM>M!(4XR7&X=X/
MG#D1_1G"!N&LJ0)8JHRK&LE@ZYBAUO6=VH50BM$%VW<) 8)8VAC8R@O!$RDR
M"00RD&-T ,L8MHK=+5FJSS!SC*^]P&6VYL?*)Y9U(<NL4L2"V4-?AC,-9'7,
M0S=3>@QU7(W5@ZFF:L,'M_"N9L3\YAD9EQ!M=KPC#6M$RHVG*1UI->_N(^I&
MTA'?-UX)$N2<7+MASD#D@<%06;(221?J=331I@K/@)K%X=(EF)N;.C<ZAS"F
M5='EBLC+=Q23:"M\,8&S-+&K9B8AJRV5C9RN@!/45@D JN>21KV0RLSF0D*T
M80Z "Q*D4&6KYB>(&ERQ@J2S-E#K<EU0*VM@2;7%:-&,\,Q9AFCE9KQN061N
M'R2 +IE#$&UJPS(Q*J94"F16+96'U$Y<Y+N=6&4C0=#6&CD17N4 :Y9R"B<L
M8)L0]A?/U([UA@91X5IH(^&@$@>$L2YCCU:S/IJ)6&A %9O-&MQ"QPV'B3#$
ML26BD87+96L6/1F)!%M--+5J]]= L<@>L.;D*HR8A5%I&XN@D("G+:UP!ITK
M5USS";K"S$1K&T<:YHY48<58T5462]V4CG9C?N1>M-KVF;K G"9^([LZ95>9
M<A&4('9== HFN38VN!6M[D;W?>"(HU,,37:,.8\CR$!F-K6"IUCS'2_G29-B
MX9- W*Z%BT9C$:ID8-GSFY5\WE(%)LO2QH4EE<-%YZ&> N'81%#&TC9B+#(7
M]FV7*U@GM"D.]@R#"..,2#(267( 1F"E #F.I.A-(>2[0J5L@\P"\L7 R/PA
M*8!-(^:21AGEA))M&B*V8=C0>%N 9:"PV/A>,^'>,!_HU<EE;(TC7129@0R,
M\>E@;4*5DPC]%/B.WN_L)L?&$BC9&C*LP82!HBR)"H<W!X22/<*-*%.HDK!J
M%/>)/;@[M2QRP*((<3B$QBQ.V&"1AENQ4Q9QFD8)96OT(MTH-J4_.DLS=6FJ
M=ZDM+:&SWP,V.QP^"B,$D95FE5(Q')](SW,=@$"*"+%0>HH:<8U>P@IS77VB
MK)FT/PUV1-AH<#(R1F:5Y!)GABC,4C(!!&[OG*I+'T"&Q(\Z36DMY\A]3ING
M#=XDOMT,!AXCA(W@#A&8P,JR1N#*;C/(;Y@K7L3>AZC-WN[ZDG]V\/F6%;W+
MQJO12JMG]D.%# V7KU%.DO,OQ0"KE8>[9<W"S*!&T>19%5K-9[ ,.(239!VM
M1HO)<S6]::%AA]H",<Q(*JK129@P9<P!*KD5Q?/;32BQ6\KW8FIF_:*S#[16
M98XR#=W!OJ+#,P)UULQ%.J.67 W3;WDKNQGQ00QA3,&8A7.90VAO;G-V/ZJ5
M3TOQN.4-EO'@8<9'-&+9BQT*N][CVLU].G2GM%I2-2@IQ[;D;]\MT8)C._#X
M9R2<PA4YG#60*3=P+#6I&C-6;^Z0"KAGNK=1&G#[O8S8&\ZXW!EHD$L;1M"[
MIGD)(;B%",L2 :6Z:U(PJ*<4I9E2VE@9R@WQ3-H?@UO3+B\#@XYV+,(XX^21
MFCSK&ERI)LRFH7%P3DWVA=E59Q6Y4O=$K<.ZLJ.18L4T'2Q\O0U%S3MV6+;3
M=Z:?8#P ;'6WEVZ^7E3<V<GX_#-^K2M&'-88?5AA]6&'U88=0#W %NEM/P*V
M8??6]PT]?YJPPXOS 7[FX^ M]]88? ]1KJ6 ]+5AAWK1AP;:"Q)].WQTM6&'
M4&YN!H>M_3O]];,.UKV-SIY=/C6C/$^TZUAA]U)ZZ?9]GPK9A\>_G:U:,/@+
M#U[GSK9AS6C#ZL,."+^7Q%_LK##[RM8CT_36&'-88?5AA]6&'!%_VCJ/=6&'
M&7^^;[:V8=1?HP'E?N?P!6&'.4#XD?IZ?96&'UKD^A&GI;]9K#5DM#D@::C*
M.OD?U=:PV=JT8=; Z:BQOY:^E;,."H&I+?;U\JPP^ZWN"O3777]%88=M._;S
M/Z:T8?<I\C?W:UAAPVBZ:=+6_56S#%WU^^L$RT,#W!)'QM[_ -]'A:R0%M\W
M8PL=#<]?6Q^VB(283IEL+BVIO>Q)M>E(P[93:^EOQ^BLN8<,MA<V/;+U!'<V
M\[5ET8=& $=@!F#@@D: =-3Y5M+SNRQIZF%]01= VM_:/;L.A/E2U]1ED!&4
M,"+ E=;Z+]W<"E1=F-IKS0*575 +6(Y@;7(YBM]#TT]U&6>8WD=&CM9;D ',
M/K$D:Y03>UR*5=-7M=B ')JCR9""+B^;J>UZ2C J*6OJ#=<OLWL1=G3+J"6!
MLK=JVQ$&W>Y@*D LR+<6 !LC$1Z&Y'F3KYUH6#8P75<I1KJ+ND:DPD:V&;J;
MUM"HA[A$918A20.AL5.FENU_OI-30-36H9Q)HN<JI4%C?R\M>]Z;RTR',?1[
M3L H.IM>^MZU=A3E6)8964C+WY;_  ]]:-'#8F! <\B @<Z"UQZEO6L'5.EP
MNQ-;3WFP6"1P'#/&MSE;/;X-?O6^\W+*]AF]Y/$*:*9XHY<^BVCS,N4V]KE_
MTXK+]B$N%2=G'2PU&T]Z=I8Z1KXMF&23,B%TS%O9RL#I;M26QQ'#JIG,3)Q3
MS)+*V,90 @N2FA)L)8]+NTG0 ]*2.HTH1]%6/E*YR@7*P#YR2&<EE6QT&CWO
M?R)K80Y2=71N&Q5D<<6[16BS=AR\YF/_ &+6K(T&<$*NHM )27$=RY*V<BY9
M=0Q%]36&MZ(Y&P]E!4B9K9(V<LSEY,X#69LJZAB1IW K#?:+R&(1+R)R#V'<
M<X-OJD\P&IK9L)]HQN;&3(H4,0<T98$7L;%;@@_&]:$R]$;+:V$216L,V;6_
M#9[9KD"T>AS'7TK5EQ-K02<VPA,S,L>5W Y1$@$67NQ-C)F []*;NUQ2C'F8
MXMWQ9U>!)#8EEX:(MLUGT$B@W(UK1IJ/,<+86R84CC<PZ(XL ;Z>QJ>8E2%M
MU.@]U%II-&X_4+/B0X?"D92'CYA9[<5;V-K:@(1\:*C;T"':6T&^FC5[JD8X
M3*YNS=RVNK>^L-6;$5CL0\A,S2LJ67,5<O\ P?.5$9) +#0GO6&+)V"1VDD)
M>^1 .(RR%E8J![+9>H6_2M"SI "V=I3$\4D()T+(AS=&=KNKWM6&',.56X;*
M&10K9LS*]T7*0_0$9KV\P:PP%9/J@V1KD*"<ZW^J'&I6L,!^&PKSNB&,AS90
M!JD83G4_PB@%O=6&F[#H[N[$=UXK1>V0K/>UE)O)E%V%H[6ZTH0\]1S8UBB4
M07)(1;,IRKU%LQ%LQ*D5IF!-M#$\+/&TB0AED;,W/?(2,N;L3;2MI7,;RS&Y
MQ^,DEQ"+;,C+=] <O7+H>A(M?WT>*LNT$W<Z8,YIR%)-R"PZ:#HQZ A;Z#TI
M1H=O8$0"JPM;ERLHL;9;:VZ#T[4V82.@I)E8*JG(4(($8 SN0N9F5NJD5H4)
MS%X>(N,TI&9+A$%LQ)S 9]+%+ ?"EIVT!SX!MA"H@!RGF NR@<H&EBP%R?7O
M6 [OF=\26*Z68VRQ%22+L-2Y/0V!I5,)-I:@3$2I(G!7*5D0!L^;*JLE@"+%
M0WWUC7'@-W/>RT*Y7Y6KPQQ6/\,/$I,%@TDFV%CMG[[1F*,-)!!LV96Q.(PQ
M NA3#\3B!;9U8@Z7NTZ3T>OV.JD/2AX$YT&QJP?2&TW933C[99+^0KA[B;3?
M$;.E@@GEXF&F"I*_#3YR?XR-)<,98W!([%?6N2U8*^6MCTC@Y2C249<,AX\%
M.;18A90X#KAI'Q$+21EA:3C]>2TD=B ,OEU- 'FH9XC'//AH<3B"ZY'+-AX9
M'A66.8L([DME=()$LBCF53I:DM/@L@<G;+@"TVG@_F-VX:2+%*,1#E14A)7.
M<BAU;B!7)-[MI>_DEWOGD!J3MZPCY,;-(>(,JV<LL:LXEB+<K.)2SB,<MLHL
M0!3EI)Y#.;SL@AQV)221TPH>":*+^N,3_7$0*YL^N)S9"]F/PK(WN-9<0DE>
M.$8F9I,\($9"LSE@Z,C#A22$QB23,+$"^E%CG)7T&D[YV"B''1X26:#.3PB'
M9 S2/(CL2L43:":2".VBD%?=1MU=@!2MKJ',>\$D1FGX<G$'" GEE'&"1C-!
MGX5HHQ$W4L"0MQUL:TTKV>@154EVFX3\FA\DO"?*=VMMOQ0\0,;C(/!SPTVY
M@,)CMEQPF)M_MXQ@4QHW765\L@V?L["2X>3'N"Q82QJ#<M4_L+8WPJ3K8A?8
MHZ+BRI=*.D<MG8;X'A)KX3+TL](_E-]N\FW1M*#';N[O8/9NP=VMWI(ME;.V
M1LO#08; [-P4*B-,%AL'AHXL+$,@&;ES$^T2:Z?AJ"H4HI6S6BX6.'XO$U,3
M4E*3;CVOZQK]N;1_-D1P40 _K4 7(5HAPY3)*2O*+Y1;RI[3CO.[S9'U)-(:
M':&U!BY 7DE2'Z6(A7BD/$XI%TM;(A %O2GU-;N3U&<G<0F,Q9&155 $G9"C
M NSJJGFL" FGE2A (V'@SM+%'+AI%7C,L=XG+/(ZQ@ ,SW5%!+6[T*M-0C=Z
MBH1<I9$C]RMU,-!EXD9:4R<["+A@2(+ :J"U[J2=;U%5\2G;=SYYDI0H26NK
M'NV9LIXUB,T4;F-PKN#D"J%:[)E^K8_#XTV=;>6:L2*AN1L'LH2/5>%:.)V4
M.6S,B>S9NI4&^G0_"@J6>1O@[\A-X_:,8:$J$A$BN940F3,T8SA7:_(96:P]
M"13M)RT-:A)M+$+P%=1GSNPNLEV7C)&6T!ZH5RW\A;M2XJ2=GH!JZ"4Q&&GQ
MLC)AHSE*F&5R%S+&PL71\RD.K]P;T1.R]HUDKY+F <9L],'#(P(9I(KH\N;,
M+&\87+;,SAO,D916F[B=VR$/BV7#HO!SALSPNI5R;.OM9B260LW0Z"MQ R?F
M#?8QA@\0V%)FFD:R.63,$9LMC$C2! @RM[.M_C3J*\Q,"PBC>7B31AU1UG6-
M5>,H[Q\Q9P [2@K:U[VMTHD6D):N<2(!'BII."RJ\;01M&QDD23,K$2&YT%Z
M4YW5E<'45D!94Q$]S&&P\3#.Z\ID81K9;%M;2(Q!\Q2J;;EF^ -!>L^$AD1)
M3B&;(N0QJEU<EG97M<V06]UZ-8W8[33C)PP(^'Q 2(0L@#,PD5Y>(5M+9#H/
M,UAG +A&9'G^EC2"1U0%.$K9<_\ !^T]HP>P'[]I&T@QE*X?B.W!9.*(@\:E
MUC&1HQ&[&XLZW)MY5AAS%A5@E0KB%;#(RL2H=T!;-F6YYEYG!\C6S8K,#"%R
MK>.1V<(SYN>0DW(>.*T<,:+TTYC3-O,1?,Z;0VC D,@"LCA<KO$KAE12F:0J
MVC@WU-M:2\LUJ*C*5]1#[0Q%VA19)LAES(_T21LCZ@.H6Z@&MP3D]VQN4LL]
M!/8K:$2R1X<CB(D;L)<PU>[*UPN2X5";&^HT]YXP<7<!.67: ,R<"1I,[9XD
M10KB.4022$9H[2,&490 MM!1  5,T<4LP=BT<42N%$PC#%9%N9U4 $!+V[7K
M# NQFT&5'5%7(U^%&I<SRRNO$Y7B(NME[]J(H99BD@NAPFTL:$GVHQPXE)$$
M2/K-&R<.*-RWT8$;FYL 1?6MMJ*RM<TTFK,-,%A%PY'S6".)HF*2&S.HF5"W
M%>4%;!1UMT%"E4=["5%)W6H>()/:)A2,YHH0,J9Y /IGB0@<=W[!C8"D2M9B
MXM[P-F"XE$X$<4;Y T)C,2>R&CC:10)FC =LQ %B!VZA$96#!6L4,3Q"=#H;
MR(2C(^0YI6RO&H+.1H;=*6IW=K"91NNT"RR09SP<Z&20B 70K$BMF,)50"]^
MVNE+L(W&!,3->>,K&\/$'*L\B3<$#1KLO,IF*&U^E8)W6M3EN$4=N' LDD;
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M5 '-?W^^FRT'M+F+/!/=0S 6 4 =";WM(1U-S]M(0\0?1!K=P2+AB+:=A;H
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M9)!%QHSQ4CFFQ!8-$T<+MA0B2R>P&#JV?3H#3><WGJ&L^8;)!%&Q;#RIDB:
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M=P /?UUZ^IK##JO;W'[C6&')N%'5CTN.OGZFM&SX&XM[)U N=??KK6S1\-+
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M;D>?[;&E-V]IAQJ;B_*+^X ]=.XK>7M,/@+LRD7L 1K8GOE![7M:M/2YAT+
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MAL)\1$SHTC($%WL+Z* +* G;05M:B)Z>T[;,OPUOERY0#F6RFQ[+YZTNI9:
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M;J!RBKHH)-[JB_6;_77MK^BEA(]9?SM '(@YE!NMP)0Q 8,6'( #J+Z_"L"
M*>8)G9U_B)F3VKVUD]UAKI:M"TK@1G.4I&ZM(XYKVTCMHT=M2Y('PK,Q2AGH
M=%G-RQ!(2^53F&9K6"]= 6K!6XSMQ![+K9I";D,"1=21U)Z&L,W'V&6-B4"@
M."K9;@>UWOZ #RK#>X_8"00%*)&91]5C8LLC.'4>X6\JV+22T!L.4W0 BX8Y
MB/8N+J;"Q(%JPV&B78!;AA;*YLPUR7!OI8@ZT&9LS@=?++EMK[KW.M)-G##Z
M._,".A(Z=A6N)@#G0 $%K*"I-AT'F.I[=NM*3>AHPEGS,%(/1GZ#+Y$7ZT7=
MCR-!/M/#"6(@J.8.6R!5D((-RH/2.U(44Y-!$KQ[2$GR@MU7VQNUM7"*MB^
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M$3PQ&61E@4DV-JVVK9 Y225EQ"[\ZB/$0I%'#BH"QCQ!:)V#PI!+&$1^$;M
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M(#&RC+E 6Q[W-+:3U- *0S.&(+ 3C/S7"R ^P'4GZ50P-[]!2E3CQ0B3WNX
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MR2;$E*X/8V],_//LM4?)%AMIRQY_GF&5; 26#>^HG:.R8XV,L10\S%?>_?\
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MUN/OO;6L--'.?F(MJ>774 =;^\ZUO4TD?%E:P4BX(!!7F'D2>HO6"SLQO<6
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MVT$MN[N%A,$8#B0GSIP6Q6(E6-X\.D:!N*^<$FQT%94K.3=M']0.G0M%7U'
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M&C*$PL0/$-PZ9G0IUB8I8GL=*V:#>'9H,,.5_F\B*DTTL**;DPW0/&95SDV
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M<P\A>P 6X&11KY@<WGU:MBDS.K6%[9C<'*?7OVZUI&CMGNH-LVOGJMC[(]P
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MFSMZH\0XC#KE^J5;0V )^^])E!ZCVGC8M(6^"V@F( :[+R%PMP5-CEMUN.E
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MGM&KL54"\V4#(!?IES:UAAQ/(D29 K@BZ,YOERJ>7-VTK#!([4Q+S.+\S*'
MRGDRW]H]>M88(V8,Q.2,AF!7/8V\@X8WY6UM:M&&/*Y2 <%2K,RER;Y$[MF%
MS<%36"DU8#K%:9%1[12'*4OF3F,N6PU(RJHTTK#;:' V'LM;RVR2K+PQ[)!
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MXCC?2_&.MC9P;=HO=6?M_&;?<1+^:]AXG&$B7%XQ'Q4\J\'A\>2(JL:7(RI
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MA*6>-5SY!()'R:"T;@,/]=1]V/)!+(#-+B6+XF'C*I=BSIDTL+1$J;NV518
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ML_:8<W70^6@Z]_N/2M;K>INYU 4DDZ?Z[K]M8XI&'8A5&@ZZ?CKY5I15S#@
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M85R*;$YF8@,QS.,K?QA&OD:RUN\-&"6IV2$MDRJ%6V<$ $W.MV L;BLL+T!
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M0A !62TJ^WTM6?9%H@G5+DQ$[7V?M:=9<(FS-I%C.F8QQ-G,5@65'(+N@?\
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MPJLIF4&^20F0W[D:TW\21D]YW#3$8? X48EIU254C62$HSNKR1ZF"1%46S@
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MB0+.\KK)PI+:L%1 +]=*U\ I?NOJ"?IE#[U!Y'\C_9DD&&0X,YDGE02QP/\
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M*4J4(5UA$D'&<'B+;-F:="3<W%99B')6[3,F,:7$HA$4DC%#B"ZDK+)J0H)
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M&[$AT5K68M()%CE>[+Q+D:6[4B4NVR"*FY9"^P&P)8OG,:0X<(S <2XX\L0
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M *PPY-D%Y&.8 <,K8NQ'<'H5;UK##MSJ<[D+=6"9%9R3WN+VN"*2VTS.!U<
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MS.M8[HWN,3.U=[BA>TB^QFY27!;L;=#ITO6A=DAG-I[Q8B;&NYEDX:GB K<
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M%W+V'L@1<)I\3F+RN&=;,D4[Q/:_3+%&3ZT-59/0<.E&-D]0]79^S,/!'%#
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M,R%0\ &3AL;2$+V+ MIY"G5.FYRW;9 ZT[W&_P 5M'%R*LY<.Y!:5!*B9(]
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MPJS1*$O879O9OUNOG]8_;6& ^'#:(04!MG=7L3&"2,RD]2P'F:PPQRLT:%I
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MEE+2%@UUXA!LCHJ"PYKYN;_2]16&!;.R.Y1BS1DV>SMFOH05L0=>HOTK#+\
MHQ3LH=4>0Z-&ADU?)>X#$^2TN&IED]1.3O>0JPY45B HURG4%F.@UH@INR$_
M*@Q+.5?/!&XS1LMS+*J@%8M+9@PUK0%N[N<K$Z,A<V&'599 T@_T5B,@TLI0
M6N#K6&@TPK'-):1&C(8(;6'MV-@1?51KY]:PP5>!(+ A5>R*3_%N=00-!<5C
MT"Q]$6>RP6.@) 7G=B++<EM+ZVUH1@L8&.IN3I'9AJ@L@6XL;@D5I&Y9.R.Y
M8YN50PC<&P*V M9NNI)%::XF@4A2SD @%3GRBY7N!8W5K^@%J2;,4[&/#YV)
M*EE!:XME86)L.A8=:W%79IZ"0EM)C+HX)/\ !-_KRQOH;$,H-/5Z'L \0Z6V
M5+F["Y"!M2R^T3Z$TW9L&0RLP.:-AU)NR= .4#34 UHV88A:25F! D74L=2I
M)%RPU[6]PK#$VM!JMKX>;=+>G#[PX2#/@G0QX](P5#X>9^=PJ$9FA(!N=11(
MVJPZN7#,(DEGQ 7C!LO=':FZS8C;4. DPFT(6"?.!&\,YE5I2C1GF!,<A#DZ
M$-8]3<=)R53=U6FG 4YY:VDLTRBC^52^2ULOY.'C[@=Z=R,.D?A?XRRX[:FR
M3A<,(\%N[O?$P?:.[XX9&'P?SJ"6/$0*H4.CD#I52V]L[X+66)IQ^Q5'IR9T
MCHSMB.-POP>I).M27'BOST-:V$99S\P6#'XG&329K.TQXI07PT<7#(3-B74*
MJK8V;6J]*+3S]'LU++*I"*O)VXDI/"CY&_RF/'K:F%P/AIX2[Q8C!XB?$8;&
M[8QF&;8V[^%.' RXJ;%[2^;1%,A4$H69B#H:D,-LO%5_.4&J?.6I%8W;F#PB
M\Y.4^'+VEC#Y!?Y"/PKW9V?/OE\K6##>)6]F+CPOYMW,P\L\>Y>P\\;\19C
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MXNPA5&4CM>A5H*=FK7L;46++9>),2$+(PSC#RA)I&&,031+"29+,H@15"D
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MT$[BK",$YP3:Z YG9V.EB=46P[:'O3I:@I:!:F<2%Q<JMT46!R <I&4^ZEB
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M9Y/(0TNTP)2'.J0NK#AE\YX<8S*22));G\6ITENJRT&]2;?O$WB\29DE:.)
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M;<WP!,>6]];9Q\0?L)U!]U#X"UF@8HN]FT%QET&EAK?N;BAO)9:F/(Y7.;J
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M.V<Q3X;9L:\G#Y!<<B!0ZE%8.<I%R6-[T/K$];A(JV2%/A-GJK*X_A(W(N5
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MKEZC_P *)__2NL[RD?TQ[:!(']DL7]O%8#W5-T?B8]R*GBOE53UGXA%E)&4
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MB'B>)8=.L9M(I47))U_0'KJVN\S:Q6(7W;,:[9VY,SEMM8Q55I#Q1+.9"LJ
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M3G%MW.#FQ>(6/"Q*Z1@+.A0*3(;6*$:DE;7-J4HMO+-L;U'&*=1MJ!(7P9\
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M9EXT<Q;.W$X,UY&P\)0HQRX.=&/8"]]!29.T;F[*X$GP.*/!APY0A&D=F$)
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MPS#9Y0R##A8^="UBV1E,T32#A:*3D<V;J*W=-:"LSHVSU80YFE?Z.0 *%=)
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MMF"W7SZWIY1JJ+NKC>I24TXV()^)7AMC]V99)721\!*TP BB;*YES!VD;FY
ME@.E2D*BJ1=GYU[HAZU!T>XUQ[=W;AW:WLVCLU8W;#OBXL;A9"<B#"XD2R\(
M0L,Q@AES<WU2>]2$9.4%)ZV&S>5N IME2'YI+(74+%-$[.<I:Q54$90B,Y9
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M5]-<QM:YN7NU$-L O)+B3-'AY&7*#E!8@ YE,S+(^75U((!6WK6F[K(2],C
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M]Q'-K: PQA40G*<S):X!D6^ELITM?O\ "@\1<<@5$JGG*+8#*0;CH;BX%@*
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M-ZPPYX;H]EY(U2V8DJ6<:L+WSD#W]ZPP%1M'PQHK*6%T#29G(ZW<FZ]>QK#
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M'UKBYHB4N0E,$08_%85<D;YVD<HB2=8W0"4O(3;F*,%OW(]:4U:PERLNT4V
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MEU4!;@DFMM-:F QW8HV41EBJY7)<Y"CIQ.5@,N93YBM& .264EHD0L51"+.
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M=QSL/L8N@=H#$TB\/,<ICRJH)1$%\B+;E ( )IJY-ZCBR>J0;PX)56+B*6R
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MI-[5AAD7A@9KW)-M="#WMV-889;<IURVZ.R &Q_O5LP&M8;.0@4YC=EM<D7
M)]5)-Q[J2V89V)NBN,Y',++=1?6VA!%:,.<X-PI5+D:D..AO<C-H36C#@$Y2
MH<N<V;6_?J 38@ FL,.4XQ86OPQKE-C;7M?U/>L,.YSLQ7-F&8L0W33RR@5J
MZ1AV0*USPM.46XEHR4.;,5-R3?3RM6S#B57"W(0$M%RK8A0 <W73OKI6ONC
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M""GSP3R2( X$S?PAYQ'EB81F]DX8<FUQ<:'M;78M!.AT&$42@0B>-EXIF=9
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M95C<JADC7.NB '2,2E3TU%QWI$C ;'CXW>6;#->*6-)5A<9(RZ6RK90"C()
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M*B]RVEP!VK3MP-)LY#1M($+%E(U4*22V4'.ZZ9#?IKTI#1LP8N=8TMFL,M[
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MG4H01G#J]TSNBQM'!<1\0NTH5OFHF9[]EB\Z'O+5:FUS'-P,>(AD5IHTB5^
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M^3$K&_:7."6+W ;,;A8Q>V8-<&_:ERBI:F=:S#\\5'(<-Q2[.J)?H>D<CBX
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M^0EQ3:;X&&24W4(N7A1*K<1LIA2:6*/$B,V+!H9\2SJ>R0F];2N[&-M6$WM
M"52)98EDR@REQGLQQ&2:%&TLL&.3,-+A6HJ5A,G9-\1.[9"##,[Y)S.'9PC%
M%P\B2D1/&9<V67![5^C%K#+,*6M14<["IW(Q,^U-UMHX+#0R0QX?%?.,"K-8
MOA\7Q#.LC,"X.'Q43JHZ$"@U%:>]S-5-Y/S5="%Q>YLV-Q6(:>1N #*K22.6
M,K9";9S;Z 'V@>U&A5MFLT!:E)W:#Z'!X/9>"B@#B&P9HY) 04D9@>)<9<X8
M@ #N*#5O5ST[C>Z[Z+WC7;[;R+"<&T31\21&3$%,I0 L7,S$6,:!EM9KG]1:
M<&H\Q%:2X9Y#53'$;2?9F+0\9(YUE(=),^-7,SME Y@4N0"+#I15:-U)9@G'
M?R''W5V'C)\6KXJ!8XL23)+% JJI$BA@K #A1LC=_;-M:#4DF[W'%.C+)CQ[
M"V0$C= C1A'CAC>:5C=^+<, .H.@-^U-92OGQ'>ZQ=1X9,(L4<P.2$W?*$R@
MR&/FE( N!ET]]-WF[BE%KB <;CX8B&60")F?APA48%@;,VJ]#6"A"[=VO&SM
M(LJ0K",G!0<BF161=5YN);4'H#3FG!V3[1$GGV"<AFGQ,^8@B-(Y&67*,A9I
M&3,2O,RE />:/-J/>:W0UPF"3Z(E#(\A96E*DKE?MD]F+MU%"<FQ.@*G0X>,
M1/<QD($>)5MP>H4C6X+=CJ!UI)IL36)>.+%0S H83G,TDBY>'<9;*J!<XMY?
MS9KD;7FQWN(W^\FT([EG>/#B<2/"IL4NOL!#8$ W[TZI1&]247F-[%C@^)EB
M>53QEAO)SYY=05(N0H$9T/OH\E%(:;U^\%;-@0N  4Q!D9GY'#'*^>/Z+-S_
M .M-)\SM% Q4DCC4N_#XS@S+E9"C WOH20#W%):X\!:B8IV9V$>8P0(RK*ZA
M+R .65;G4*0Q.FIH>XC+(R?-.4B%N*H"&99%RN[$."JFU@"'-#-!='@Y)2T_
M#7*SQL8\QYB@*+GRE"+ =O*E;S-<0LCV0MBLX>13.SER;*J*!FR :C(R@7;K
M>EIQ:SU, .*@@ACBC 64-&O(K&-8D#'6Q]HV\ZQL0YV .TL/AQAA*\80R,BP
M2(OT>:^J#4"^3J?.M*XGM$[C,?A(2[(XRI$2Z<-'T7,BQLVJAILUV[H12F;<
MDLV(+%[;S(BQN1),MF9T6R(S601S"]]=#H*(H)._$;7=FN GI8'D88;/&TCO
M.\DBL'!BXR'A*&S<K<0^9I9KP .)PW3)>%9II!)8*9,L;#B,1TA,B]+5M-+/
MB#DLPDQD?TJ*LC/$5F8NIRMD O%F9;%QE'0^=&CGWB'IV!?BXTFBF"AY$D#J
M\2C^%G8K8(V@!BR]S2N_02[) 'A'#E1%#F#+&%6->6.0R(AD#!A'= S"XK 3
M?+0ZJ'BQ#2&7$"2)@9 "PP\0BE9EBA75WDE'+(P)OYT)P3=P;%7@]OXN1YIX
M\'!',8UE1)&7*[QFSJ#$;6O9C8#6E1BDA#DXO+B;'OR;>UL3B?&;>G XHDNW
MA9MC&)W 5-[-RHF&;35FF#6MW-0VV()4%))9U%X,F]B3E+%RB]%3?C$__]2Z
MUO, -XMM'F%]I8N]S8&\K:CTJ7I/[%%=B*KBOE,_684$! O(K7Z:6(^!ZT3,
M;V. K,#EL=5N+CH"+]![ZT;.?0  DV(OH0/*M:FCD@%@!?(!T#6LW?4:WK-3
M#J "2,ZD]@R\W3ST_16&]>\R!!D!-A<#,;'MWM_&]:PP^)[@>0L/P.M;N:.R
MA%%@H0,;L+?>+:5O@89LH%FC RVU)YOL'45LPZ@6.;4*=2;<H/D%T-C:L,,P
M*,I%_4 &Y-O('V;UAAE'# N\L8^CO<J;'^\%CHU88800JJ5]EB+*;AAF.K,W
M=;5AAF81(P>Q("Y<HZ@= Q[,6ZCRK##I9@TFI1D"N,YS*54751TT8'7KK6&!
M3-E)+7N/X1E-K6*ZV4]*PT]!/3Y0RA\H1VY >H .;6_N\J=05EEJ!:6Z PGU
MI#G"J RY,P * 7%K:T00*/9]@H*,S+'%FC!T .G*1W&IH$U?)CB' 66$Q"%$
M2-[% ,RLH-D;J0>E[WM0,[7X#R$[9(4$,LA+*I(5BK!;K8GL2.NONK-5F.$[
MYH%M(%^D=0S+=C&C$+<CJ1H;Z:T.63LA5V$V+VA;-=LI%BEWT"%B"N7N00=:
MVDQ5[=XCMH[:BBC89[-](0^:S%P"2/(6;[:5"FM6;52;R0@\7M27$E%,G+E4
ML-;6:Y)T-LPOIW%$W5>X>,;K/4ZQLN555P02<B$6=LQYB7TNI Z>=:<5)W8K
M=3!0>YL027)*JHU-F-E*7 "#SOTK<5NJR,W4=@HNBEF9GNS11-D52>JM;H0+
M=ZV99'9BG# 60FS9_9RH"I]FW<"^OG6&TK *?*RV"N!$UBR#E8&[,"FI*C.2
M/*]88$F-/#RNA:1"",CI<E&/UNUU)T_%\,"";#D2ZAERJ'!(5E51JJY38#-;
M6L-W"=XVC3CBP+641#+<(.EPNC78=:7)N"LM&A1Q9Q9",Q=\YCL""']HJ>^6
MWO%#,!<**\EERK*'N69K*JJR-E ]2NM;$W!.06-\^8ZGAMFY0PL>MAT[=:PP
MSB&.0L2&"LQ)?.48OE460YCEDRDV/Z:PT?)$\:WX)R2@1@2R9N'<LH<EKELJ
MBY]=:PPS#"HK)(R&090&"D!!(!:_%M=' '3ZU_2LXW,XWXF+YMQ X,0Q$3,P
MD$B*&Z<HD090VIY6TU^[>]NYF/SDT^)K7_* _(7W(^5!X:[8V/M'8^S(]L&'
MC; VQ%@(EQ^Q-J(C&#$P8E8FE53);BY64,M3NS]H1C]AK9T)?4^??P(Z5.-)
M.$LX?GH4)]_-R-X/#'?W>3<#>["8G9VW-T=J3[*VAA9X)L.9)\-,^$XT1=<L
MF&Q4<*RQR"ZFYMUU-5ISHU'"WV.^3YHA:])T*N[+T> F#B%5"K%'X<CLDA!:
M,1ALN8N;MF#:"^GI2+WT!7]QS-%&X6<2":6<*.&P1<Y2.4+D M=A<$G32E)F
M&"2#B:HP9\D3%B[%UF4%7"DME)MU46'Z*2TGE(S7O,*I_",7>,-)"2EK38=T
M?*Q=E# QR*?*VM#G&,4K&F=3(RL"ZMPP$MFYE=B\@T0$607&EN](LC(I/4,9
M.3#O'EB9P<^&>,AFF26P*.S!6(1;$"VAK%KEJ%2CP B3."\LBQEXM)(;M;*P
M6-U606C5\JWYB; 'N12C.WB8@LV=)8408<!YI+-* XF8Z+QBZ'ADCV01?RK4
MHKVFI/S3KQHY->9XU9P</'>%GCAB?,Q*"\A>8 L2-361;CIJ#N8YUF&17CMQ
M\\211( T4J%B7XK%5RJEA:U[W(K')LVFUFCG!0E(9")LSAG&=U#B-CH>:0*.
M8>^](;N;<FT9W59 8L.9I26#/,AB#/FD"<,*&M>T8M8"VM*3<7?(28)$FRR!
MHYH(^'$CI(075>O%C"$G-?TI2G*]\A4=3*I0B-I^$XDBA!1$YV9&DC8RN%"Q
MAX[#*222:5&[:0MY+(!PHLH"K,LDS",Q1LMGP^3, K#H+E=31M.&0AML[XTQ
MJR(TW#5N1QPTD:+$%"25R@.BR-I>W?[-K+@: #"%)$AC:2<_-<0C.0YR'$2J
M<URC::>^WW*M?4PS@Q*<1PKPY!&N<0NX#$\VC(+LK:W/:D..6BN8!R8HDEXL
MBQ2!P(24558.0!+&;71V+7M?2DR=E=& QN'+AY98UXJID3*&D]F22Z3,5L,R
MJA+'6_Z$Q3:M+B8!@R0( 82XF162*4VC=LBK( X$C"1A<ZD7%:=-/0RQWF+<
M81PQ@3QY259F+R+A\TAD5FTE5%<YAIFL/*QUNJ*WC-$!S&SJ,L.4%0^*G3+Q
M%C;^#E"Y]&UU46I+G+0U<XB*K$P5LLDDC*N<61AFRYTYBR2%-;L #24VG=&<
M3B7)&V'5V58HFCCSMABZM(;%\ZJ>(S9]!EN/6E=9(R]P5/$&DA@5,0[2N)'P
MKO((@"9<KD6,04$W5;_ UBJR[# (3A@P#N9I,HCR9"B17=@R==&06M[OL5&<
MI.ST9LR,D\6>'@1<8F.25E)1XH4UCDBG<6$LAMFN3;TI;A'=NKZ&K 5FX\)X
M97#@*P>.$,6=[PI&"%41D,RGS.M(1M-K(Y?#F<2*))8A&S(D;$A28W+V#FS9
MR6%P!TK.X)+3M.CA(GX0@0RF[/<N^80I&K,Q+A<OSB07TZ:5EV(WF=,2%A:&
M42(L<N4\/)>-K6)!)ZZ7Z&L6;$W?:!,1#Q/I(Y#"9,SPN+?1QF3AQJ$:R_2%
MM-+W[T9TXI.QLZ1R1NK+B&:,P1E<LEDR+JD+@Q @N]]3;6A&]YO+@ ,9=$;#
M<-A($9HG',Q((=7*<Q13YY=:V*NDA/XB**6.Q),@*W "H6@=BKL[$ $C4WTL
M*PTM.T*,8L0D,1?B9C([1\5XW3*!EL20F46Z=:PV!\OT;1YE>,QHZ!M<@LQ<
MIJO\,SY#_?5A@ EXK270Q@!,@C/.HD#@7N0 PEMH=.M88943BK"T,E\7$[J<
M.\3I&3K=,H#:CSO:A;B-W.BM&Z2N\2L\C@HLJ.Q9G2./+*X*V4#-:]['7WKS
M,,*HQ.:< 12QR-97("R*.49,V53F'8=*1N*]S#'$5SY8GXQ=!($?*(R$.L#D
MM<7'3+84O7(T<H8[AW19994#01*^0LF;VRX4W=57*/(4E0BC9B;"*1(XB*E7
MSQF1RI6,\_, 5#7:XMI<5K=C<PP(%*YW#A5=T=%'MJW0%19KD:7N*VH1[3#*
MPPLJ#A$(5+V:[9R%A+ ,%N1:33KTH#DC5P*5:9+G."TW#:6^D:"XN5/MW/NM
M6"=3*2M@TAE,*"RHN5$68#-)F!0\.Q[]P*UW&&  .N;(JA^CO8V9C<,%T.3*
M>E9<PS</(Y$2DY S\55 ,J@JBLI &0AE!MVU'NV88T,O,P"L,Q#NB@1B1;L8
MV87'T@ZZ&YK$:.(PS+F9!&DO*X520DLDC$%2 2.3KYG7TK#9UD>-"53@!W4L
MBVS<6XRF1F-N@Z:7O6&@*H2($Q&59.&!''8HB2*PRRMV9G\]-/OT89WE82+'
MPVRR63B*JLO'/,ZE@P)77XUM&SJ5!69K!$+$)WD5$%W*@,I1B/._[-^ O@!T
M7(8\LL9:#,'C)4,UXR%+AF 5^=K]B:V;X'.81RYUC9@L;1%8V+K=6NA?5@[R
M>=ZPUWF)V9$B(B42/,4SR9^,4C7B.A6UB1$1;U^RDL0SN5+YD$:*WS94,K<A
M&<$<ZY<OT Z#2L-'9%$2$.]W"9DL&!S+D&:P%I062]Q:P-J-'T4:9@C7)&)1
M+?/"S3HHSAU5BB.-18Z'IK2C#@ @G_0X"5D!<2,P9M278EB2;>>EZ%-)9\3#
MB#$B OB8I,L\)=74*H!4.3"@;-F(:1R2WK:LCNQSSN*3:=T2(\.-ZP#$,5($
M"@+B<[F4QN#P$9 ";J'[?;>I2E6<J::>8TKTNLGO7)%[&VIDPV*Q6%,<DD<R
MX1LN2,&-P\,C0H;"+4EV(-KTX4FAG*/(DYX6>)FTMV-J;/QVP=IXC8N,V?*&
MCE1G8XIXSD2)2CEI%GD1KI?+D-Z<=5"I:WQB#87%2PTMR^3+*?R9_')-]=QM
MV=J'%P12X^'#PX]H9\R1;1",<5AHV4F3BB:-LI-AE-0U6[E**2WTR6G!0DIQ
MTDKFPS<_?.++ 9);F1('1#G*H&O)D)-C<%C<=C]P:E*.[O)6D+C4;7G,?O=[
M;\DK1_-Y<WSA>,P$F6,6/-87L H'2U,Y*\;R]*YIW4KIY#U[(Q@Q*PB18N$R
MDQLH?-<KH==->O3K01PLT*G#X9P&)#2VRN&C]H+DUOG"@"YMH30:DG?=X!U"
M*=T&T<;.JK96;A@Q  BS*3FSDZEB#K0A9CG(:ZHRJ  H6^4AUUL;WTTK# GG
MDD8YF1"A47ME,8/?H;@VZUN"4I;K$3;2NA+XN9@8V4+(C-*.'&3D8<UAKJ"
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MD!8JQF+\/(4XBN8BC)F9CEN .E'<E1NLK@;2G))<R1F[NXT. B@DQ&&593%
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M2QN[3,B%#*R%SG'LE05 M:@223- :93E5,1$T$SI>*9@2LB+PVD>4BS$E1R
MFP-[^0TNS0PZ-)(%@,S)*)5S0RF4))$'?F"(H901T ME\Q69& E@C*\F8EHE
M7)#D;)F1B1*Q#1DS0JQ8L!;3I6K<##"DF%DXTA$Q$F(9V46$:N0I,PE NS0@
M&X'?2E*\6G'5&&3A2XV0L)Y72;3#):4%Y2P6)"A5B$Q&6UR;#O1=]J-K*YEV
M!953@R LEI1E.4A#$1([R$B<.0R9M&%K6%)6O8:.8(S]%.%<B,O+*3B74<%X
MOX18U'TC#*.GG6WGD*<KJP7R3<:\I?AL01(<H.6.2+Z92SG-GO&+6Z&E*$M'
MH:,$0<1-')B6EC60JJ,R"1%=F%P0+WLNATUHG5QN8"6CAD<"SY,F3++9'($@
MRK([!Q:-M1E(I;S3788=&@CFPX3-QHN,J<=<T99T4AXRW0J@U72Y(IK<T%L@
MFS2\$L7B421EHAQ&5NHXI.=K*.A-M/LU<4$N+>&640S2\(8@ +(4'!595E!B
M %R%&7N=#2A>F0 Q.'=6+N8GCRM&Q !Y>B$J<P87\@+7K#3R"QF2 F%H;E$T
M4D:%N<1$\UT5^8?WU89W@<(A1<D32(I1$19&9HXW$@<ZZE(73+TO<7N:T888
M8V")+BD, XSJMI)EE;)?+Q"NH20=Q8^OGALP.9Y5*\.6.)7C*)QB"#SDD%RI
M,=I.AN=*UXF'&(9;D2\I#+-,RBW#D)+$(&8WSFLN;L<@#$QQ".."$&./(2BK
MQ>$)"=1TD?(M^@U/PPT (Q+G=)""+(T!1,S*PZQD>TA&O>U9KW&S.)XUCFSJ
M[39U<%FRA5;Z-I2&T)*KTZ7%#E.WHB;G0R<1P\?&C;5SE*%T>)\K*Y(RLP'D
M*UUKUR,O[SJZQM''\W8M+)R2DJ+O(#S!NUB+7M;K2MQ&K^\QF!%1C8EUF9%&
M8Y _$T %SIE\^]":,..%%*(PRVD)N3G95B&?4RAC9UC(&EB3WK1A\4XCQJS:
M?21YF(RF1.960#D&<'3M;32LX]IFIRTBL\DK%R&AY$C!4-(3[)YQ&5#:G3VA
M]FWF9<Z/9M%,@^C1I4 LG$ YW"J #;S(M>M9&'196*,%+Y289"@(17*GF((M
MJS$D6TRUAHQ*LDQ/ @S%)QE"CB&1%&A%[Z*/ML?.LS]AARW$OEDRI*&<DA,X
MD0(&#!0;M<G4 BP'VXC9SR2(@"H4C)$EOK2<23/.6"+D5 H6Q8G->E)"DC$\
M:H\N1!]-*H N&$48(9LK93G0CE)-[_HQNQIO,X"Q\61FDTM/(H<]$!C1HR]\
MAX9O8  Z>^^7,WF8)>#.G!C9X'BA65Q$C*91'HF9B3E;6_:LN9O'58I(XH\]
MVC5T=9<SF0R*;R(;L2JO>Q;H16A-[YF*-U<WE1XQ(66.TSR"7+<W8KJ0YN;Z
M?"L,.X,;JTX4K=K92\G$#VR 1LQ!6.RC2_>E*;2L88I(<454PS%9"LALF64J
ME[N'(SY7)Z"VGK6]]]AECLDI2259#(.)E=X\Q5+JHSBS@ !K:6-K^ZDN3?<8
M8LCALH#PAW9H@7N)86"Z=;7#:D]FO\$F!OL?:\FSL3F.1\\AA:/,1)&0UBV@
MU8-W.G2BTI[DL]#,N69*O<K>Z)EBPS*&C>(Q!V=Y,Y=;2A8%()D%RQT&M3,)
MQDAE6I2C'>CH/7L?>!,,N!DP<LT@ADD3-*ZQ1PQ1\JJT0C9I+B^JV9!U)!%;
ME/SKYIH:;N\[\#9+\E7QWG\/,9A\-+BY8=U=J/ -HGA%H\%)(W"7$X4DVAD
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MO;,4^SU941AQ'3(]KB-70'0 C+[1[>=-^7>$IS3R0M]FQY P!YLD:)F\K]9
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MV K 4G=VY!1-Q"KE& RNS&,A4&HN6"VS,3?L>U8)"PLH;,+Q9YPX.9N@^C"
M7)4%1]M88!OI"'CRM&X(6^C93G//<@W)!HT7YJ$M(S<)8TD1\I>5@"X(S,-
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MCDQ98"4D!.5)3&41SE7A<O.2>XRRZ'N13247?(>0EE<,7Q C1B ]@!P\AO\
M1VT&O8BD6:=@\)MI(3^+VD[E=2J@,%)"V%_JZB^E+4>8>PD,9CFFC905C)]I
MV49@0^7Z)M!J "?*]+#PIQ6>H7:1ELJ?2LB'WJ-"<U];#H>]8&!$1YTD+*$+
M,SJ<O,%464]]+UIBHZ&;.A8!?I;1N=>@O8A5TYB+].EJPV8@U\V5+7=LSJ<B
MD*7L0O2^OVBL,/KF);MRB18SS%2+KRB0]P"1:W2]88<*ZJZ/G87ERRC+D?G4
MF]_9,5O.L,,\F5P&>,.HT559E!^J#(O9@5[:$"L--V 4L8D(65@$# &R]@+K
M[-P?+K6&)W ,O#1A$&D.8L74HF5;BZV/6UA6&PJQ,#NKL<[I'?*JL.55-LQZ
M&U8;"Q@ .*@ U,.=];7*ZQCV2!WOWHFY%6NS?8!Y,4\>>+C!5A<($-UF<,C,
M[6MDLV46RFMJG%Z,PY.T(FX.'LP$:*)68V<<@L;Z@VO:])E!K3,RQT&+RC*S
ML"Y$:EG&2Q-P'8^R&"_=6MV7(T9$Q =Y%7(1))H0UPH"@76]BR\IL3I6K-:H
MP&#%A<C,02S9E* 6'*,H>V@NKWUK%%O1&'$>):Q0)KG,>8$W-BK"1NPL3TZ6
MI<8-ZY&6!BXF-K1O,"XD 5@6SLSFQ6V@&4#KWI6Y&.NAJ3:T"S;^Q<!O)L?$
M[-QT2O'+')'PR@9G]M%O)TMF4'3O1:4]R::SBL_:M&-:D&TY1](IU_EA?R=&
M.\/-X]K_ "D/"K8+'9.(FX_B+N]LV#-- UV0[>PF#A4@*R@&8J/[XU8W76T:
M6^K?"8K/]U_*,\5AXUZ:G!6KK7DROQAIFBS- QC^<)'&1$Q8F*0)/G;KF4FV
M@YKK8]:9*[U5GQ(11L^TRA(WC1$D:.0LSQV1$60F5D2S$\KJHY5![:TKQ-W/
MC@V>94XF2P=@IDRK.00".(>5B3[0&H-888XN'AHI>(D;"!D 1YL@>TF9AG.M
MU-A;O291WC#'&S0XIT18Y(@BF1Y68K)?GR1#V&)O:_[J1*&[GQ,3W<S-$@R&
M$N! R"$*HM))(06BCN6NANMS?H%I,<G=F]\ \,%"F'F:3:1 *02$75+E71W!
M(6UOB#1%NN5KY"=>\"LZ !&A53Q'@D*!F.:,N'#=P#&I&8>=(>HD%RL9!\X2
M&0H&UO99)%)Q*EU+6&0#)<6UL*0; Z% \@$D<C,0S%7D7,43ES*0+L3HUM*U
M?+L,.S#AJKR0\6!Y"T@SJI 54RJVN8@RN38=0?2L3-F2'&8O"PMAW9(H0'0K
M"C""2'$2F1U:RW;0@7.I-%A'[I7N8!/I29^.\,L<CQHAS-E4,0Y:%(^IA5=+
M]^M%:35EDS9RB&,1QD999&D2.0!0K+96X9!! "W[\U)4%>]W9&K'.4+BXRL@
MDC0Q/&88[MAV0'.\EOI)!KY6%*:<8WOF9H=Y,*RR2JS\=^(QA:0O'D !13PM
M0CN0&MZTE5;+)&KYF&%%CD#\-3PU$EX3>-'/)Q,IO9[ZGR[:UCJM\,C=SO,[
M+A<*DH#L<T13+G+RQRK(92UKHHPQ8WOU %(C*\[HPPQ*KO"SWS2,0D"($3E2
MYXC$C/D)TOY>>E&>2-G548SBYD699LO#8"4,MFRLSG4,_<BM-[L+Y6,.<1+D
M2= L+11NY;,CI)*EU D!:RV$CVT["A;[UXFKG(P\C)'AR0PS-\WX40;BJT))
MY@QRVO292WG<PQEG+6ESS+R1PPNEW1$NY61+D"R!@OF3K2>XT88L)*S%H7@Y
M@"MFND"/FRSKG%P"UP%ZYJQ\C#N9H3.DF(9L1D$444D2,&'".0&1 %!;C'_7
M#K2DKY<S9B?*N9"0L;B&2!<.ZA(Y2JS3.4;VFXKVMY4MT]U73,,4LLCR'(LH
MDPZ*CNTEE61SF"YU;,&?L.@K44F[<#1E,DS0F>0Q,(L, 615"Y'DX668&Y8L
M";D:]Z+U45Q-V"\*QSM(\@1(;29<[,,-Q."&COE1"Q6P\A2E!)W3XF&)8HPL
MDD2R+AY2TD"2J3(4#Y9 5(S&ZW-Z7?B89!Q)F7,8(V=E9I&3/&58R,LAZL$2
MX'PUTK5W;(V<I$\BLY(.'$;K),P+&8F3Z<!1HFE[6Z"DS?F^PT=(ECS.4C,2
M.Q1@QM$;-FXT=SRO;2_E38P#QJ,SH9^$T2A88N&92%N2)C*MU(]*RP3=YA5B
M29(2I>20J'<D1QRH6*OG,I'LZR:%=-*5P-L(9'FX[!(F^;Y56!F0#.'+(+W(
M.8CL.E:O[@>\PKQ!NBJMP)"T?(N>[POPUC#C,<S=36Q1AC=X@^4()8WS#D8&
MP,BEF[@*C_=YUAG$^FQ)9YH5>0*R*[$2)*\^5!HH-A&C$=>M89IF !&V>,.6
M9%+_ #@W,2I)>RER<VH&M:-F $JJC5C*HE*RDMF#CE>5K A0>EOYL-G*QHRR
M -E1C8L6(C$G+K&#8A2T?730UAA@A97DL"Q>(NSI&S9BX!L_*MY%'D:#UKY9
M&KG4YVBDQ$]UB9F5#PPPXLE@J@!@0M@3;H*2Y.78).!Q.7EX2)&JM= 695.8
MJUSJTA/7RI*=\C9]SB7Z2,Q1Q9LX37*3[$@*W4O8T3?:LK:&K''%6-;,Z6,@
ML,O-<(@6X:V62S,?>*1=LW>QV$?'CC5G08DOB%,K$Y0,ZY39<P<:=/6L-&%H
MU5T0D/&652+@#*.9HPUKI=A>^I K+F&.1AQ5^A5B(Q(C+FM&SR9IF*:"3(";
M^M9<PZJC%03*6%I3<#18)-!=>K,+_96=AAS&%PK!@T95&6[NQL.$[",1AA;4
M$+8]0*S/4P#YI(1.5D,,:#BJ0+Y3$Q5B46S9@21E%P16&C+#)%*H,;L3PYP%
M (:,/=5)!MPPPM;N;^^LMGD+21CB4Q.K->.2<!9(X^JO%))( %-PRYI,QN-3
M6[V5N)K>MEP.9;NC<3*VCH@5LK,&9F"%%'GKI2?$TW?,!L<]TQ#9R7C>.)M$
M6$AU4]"<\DA-[]/CILT9FFN4R"4P+'D:0HHSQ-RL.7F+WZ7Z^=;,,4K,9&A1
M7$85<DJLF?)E'*X:^4Y3K<5HPR1(F'S*D3KE'%YN;)Q=2JDD:H.WX&&'1G!(
M"A274Y2$#JS@CH=<MQUOK>L,.BLZ%Q&^4*SDQF^1BOT3(1H<KL+]?W[2N[&&
M.6(JW'MG5<.^8!O:,9N24OE3A$BP'7]&-6=C. *(DM&)H92W"7FL!Q&-RV5@
M24>]CI6C  53/')\WRM<ZDYG9U',A>XRY  ,Q K'=F"NW7WFDV/CF(:48?/
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M2LK&'>62\:QK8HLV=F9!D=C960-<, EKULPX+B4R&_"&3A&S'4);)UUUTK#
M9$8B$<%7<IE8,3[)3*OQ4BX/6@2])FPWPS'( 0TF0@MDL%5!RYC;7,64GRK1
M@>0<SACDDZ',A;/KT#=5N*P7&5K(44+R*Q!0!3:,LQ!E%U#7'8D9OLI&[O9B
M[7S#_#6!COF95MG;V3DMZ<H;KI26K.QJU@S8,R,!8A3<.?;L=50'KFRD5HP
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ML;S8_#2]KKQ/6L4;.X([PX:$,49Q",.A</&X<F.1+HTDA.4H))4MW#:'I2C
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MK+V,,D:J%U#Y2,@*@EL_J;VRZ^5ZQ=AAP8CJH)N/;#7TOTM<Z$5LPR1*8RA
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MZ) P[ACWH;EG8*EEVAOL_ 0/BXH\*D"XG$K] \F'#)'#BX^*4$)(,0V=C<5
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M*;$, 5(L:PP[,N:/4K&I0R0YQFRV8JRL3F8CET!\ZPP+WE"VC^O(2%/16/9
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MW5A<9<@&:52HS6(/(5)/OK ]+T6&4*2EB+H\:2"0P]&(/L%6%K@'MVI,G97
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M=R)E0E96T%)@,!E:563) H$DZ\7B65C$QBM[1 B?$-YW]+T*4DQ:HVU8;8/
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M&PZ$2@=Z3-Q2NM0E-)RST%!A\(QB4E&:.***1@[99&C^EECC%O\ 0VV;(86
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MI12MSL.YLG8#&-F,0+SJ$A?)8$6L!)>PO?OU%-JLG'*.9(1HWU>0L</L81+
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MS8,6X5K#O4?*5*=[,/YT/25LR4V[N\L<V8K.T>8([.H(S*K%5!,C$L00;V(
MIIN*=[JQN-6ZRS'SV'M1<7AXG:2(F-@7#/FR.<K9+B^=I,MP.B@VIM)6;"QG
ME9BMQ@3&0HT)43JIFDA5;2$*+J&MK?W&M!I))Y: !(@ZO'G8L>$[<(#.>5GL
M2Y.4 Z6]+U@DY4  "YS.I C+K?+;.,[:6*WL--16&!O@5#*J%.'&Y^NPS*P
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M#9L))90$99<LI8DRY96Q,?#)T!^;SE>H "_8AR,W/>&FS\+B9ID1(2T^(>8
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MS--\ZC4G,\;.7!C4:LB2+<6M=3?TI]#<2NM!JU.6=@1L#=/$-B(OG$=TCSL
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MI6&;[/HFD+2\)5X<2&9E)2,,XOFF*LI61RNE@+GM8UAM2N[!?!*TMYE"NZB
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MD5+V;4DMH;9;7]16&&=8XR"]TL#P[9"SA7-V(%\S-;32L,!"0YR77F1&"J@
M5E55MF+$6 )[==:PP[E"IRK$ZDJQT"@.-;?2?Q[VM:U888^$8PCNAD)S%+L
MP=B&*O;KI\;"M-7-G'!!4D9%*@1E5 9B.9\[ ]0IZ].M:2MQ9AU$#F2,K&\J
M$*-;)''KJ23S$6_=6Y*Z,'"V)AHX83)P@@ L1F%PI%BZW^JQ8V]13*K*3;[B
M:P-*T-YZ@+:>.*!Y(V.5I!&]P2!]50.Y9S64X[RST'-1W?<9=ESM,XC16!?F
MDO8AP.60$FYC",1:YK)Q4=!,5Q'*PYC:%K\PRZ(+BUA&-6Z6%NVIO0Y99CA9
M)#6[_2M'AI3&\:KE/*S= .N71CF\O6B16\T@=;->PB;M=#.<3(06/$R@E[H
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MR0 "5Z91WM0WD\A<= U6-F706='51(WLR#K8CN+4K?8NX/2%4'9CG 5@B7S
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M3:, N*E)'#"@LI+%U.3BGV;$\Q="![[T1.ZN:,0C",A'M,  'LBJC*JLN6Q
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MUSX"9*+CD\Q&8N1X\8DB,N(+PSV;/E1Q G'P1RBQ.)>/9J(I!U$O]]14DED
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M,3D<.!(1)(')RD&-F!4GX 5O*_:8<R6$<"92Q$CI.\8/$B,@R+&3<A[YNMK
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M!80RDR!64"P0'*&9BX+."">NM8)E&[,ASM+=GRIDX05D5I"R@976UN4'UK7
M48(D,8(>,8ARRQM*Q8F K,K\I*L6#C$ V-PMK:UAAG<$"0*[*4L62.(.)TSD
MJ+%@%*DFX"ZBL- 1\L9+QDA W14*"-G49HQS$$DF_32]JV89,UT?@NI5I(5Y
M 3(P"C-&U[QQL7'6W06K.\P^E59T"R+:9K.T9%N%#KFL5[WT]:PPRH"H8@&-
MN$CH"2P5BMK&+7.N502+#4UB, >?$J2R311B-8I&7@<J.[ED+1W7.573M6GF
M[\3,R1WAWO>8<'AH\2Q?@EHU?,D<B/9(XWD8@E(A(#=;&XUOKI(X6M-RM]R@
M>*I*K33CDR3VSMK1<2*7#8I)!))$DS#,D?SC)SVOGSQ2L>HRBII34E9ZD%6A
M)7BT22\,M^L9NSB]FXJ*=(<?@\<N+P[)*(I8C"<\<AM(KK#Y"_-K1''>CN1]
M,<;,QL\#7CO?%2R=]"QO\F?QLP&_NZVR\:V/AQ&T)(8L)M: LTBX+:V&"1&0
M!EXJX?$J X-RH)MTJ#KT=Y-2])%C;A3>]3SHRS3_ #[38'NYO$!#"\N)5&6;
M*0"KG(1EN8EU D[#-3-TK1]@G>O-=I(38.TAE+-F F*$I*P9D#$D?PC9@0#<
M>5,91\ZRR"2=AZMF&'$X>,@JXBC"9W4,RF3FC9[&SY1I2>P6G</8,+)$H8B[
MD,@$8 5@2I60Z\H2Q]]9?.W8*#:(*KDQ<V8 :BS#,W,->7+FOKF!]/,<UO7E
MR%P=G;F&I7Z(A@A49D%Q9@2P/4-8C3SH(8P3_1O?5(V4*ZH5)<79@ #<K=FZ
M]ZPP)I)% =)B5D8$:V4HF;,N6SK8VT-&I:,V@.4+W90;Y@MCEL(K W!(<MS$
M]QK10-7TO88)8C$S6N$O:R'1T(!+$!#E8$D5@(".JYC&AX<43'60DW) 9KL0
M"-?0UAAPI<@$-9'?,CQJKY@47Z-F()R@W[5A@.!M$%L7L7S,5#D%A:[-90$'
ME:L,.5S"-;-)(C<A"E<M@%+6)URJR@VMI6&&>&._*43+*CN9%!,@-SHZG* -
M/6L,,1NRE Z71;EHTOFMH')+ $J#K[ZPP[F(@W8N4C*.RL54M?57C;4 WO<6
M-88<<KH5+,J-'*5<%KO)>W-R<SB^@\ONPP$\)F>,QO(\8596RJM\UY"\9D9;
MAFSCI:UO=;##JT8CX9(4W,C'B68IQ-%%P038][VK# ;%&0RF2/D4E3(R@K?A
MYBUU<D."H%R*PP%*[$B0NTHT##,<K.X&HL5YBHM<WZ5AAW:Z\JJL4<O*DF75
M;'F4FP+V/J+5AAW0*ERQ9F!-LIRW9-#8\QY<PU]:PP$(JJL1D9[L[!>)WNN>
MX/?XBL,.&B8AK$HO$0W"V#*&NP4CJUATM6&'=#FD0NBY6L2ZV4<RYKLIMFL3
M:VFHO6& Y5 4@,MFL=02<I9SH;!0- +7K##LJ#*H874R!NH RAAR:AA<^?;R
MK##AU3B,QRV8N6!8G0>PH^JJ]!TZUA@#O(B( J(I8G*&!)Y@ +D:74D^EJPV
MK<13[(PS/;B)&0';(@ZG*+JS29E"K[Q32L_NEID2&!@Y35]#%O!B5A5@68H$
MLBJ+9;$9@>Q%^AOJ/N13CY[?82-6>[+<2U&MBQ!:221 2V<HJRKF !=K.!H+
M@'I3BZM;B)''W=8!$"-'?0,A'*S7N6ZBQ';6@5/2MV&XO.PZ<.3AC,JV0KF
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MY ,K JB+S==&OUI<7P-WL%TLC!"@.4K?F>P4@6T4&XUMUOWI8)N[N%[!I"S
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M217))6$RJZPO8V!# F"0"XMGZFVN6LS&TUH@GQ$[FTJJL1DXDPC7,<V(C&L
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MJJ[ 96S69D8@ EE-NM;>1AEBA9HV>9@'=2SQ16SF[90PMRJZ%>;N:SL1APX
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M$;-H((Y^& P4C-G-W<\2ZY5;ZL8T]3[J<C81.WL,$+*$C)X1-R7S*Q %P!W
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M"+T/?9JX6ROE34D$=;Z'DUY;:&]Z6! RLJJ4YI+J!Q".'[37-LVMU.@K##N
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M9<P#9G]O,YYK@$$"AZ&>AH#3% BR*%>5G!C:P)0$$([J>Y0N]K^59J8O/UX
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MOH:)U:268E>DP@DDMS1M,N(<0\=W4*AQ3@'#*$Z(_P"<<.#<=#(?/4D7P,:
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M#-<Y"; BX4+H;]ZU8U8'I96:.-&.H0N;938@EP =;TH4?3.8A$QE8IDE&4$
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M+NJL+*+)EM8!@0>O6D;G::L%,J@'D!$HXB)G%US>1\U]:4! 32"7*Q<$&]E
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MDPS1QC-+"&9N0HRQF*1B 2S9CF7SUK#8)AS0%M2A8E<N3/Q$9P5 4&V:SGW
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ML I\9\WSB[-)$(WES NEO8-SS9HY%>^6VF7["".M[ ')BCB;K'*C<XC92H"
MK]' R7*MK(Z]OK^FN&=;V!?'C(E)D1)P\RB.-LA)$;'^MTFU!"$1O?\ BW%8
M9UO89?G+99)DEC$C*D"A%$AD4#B0HQ=3RK&&!M6[&U4N[6.N'2/$,87RF$I'
M#&RW= IGE6,F0Y3>,F-M +]#6F;G/==D@WAP:S2C#QH4PPGN8F]N26- ;+)=
MCD1O,4B4MTQ-SRMD*P8>*1N  6S"*1@5 5747(##L"+4!O.Z"I+3@&*1)&DD
MBGEB"JQ"]@ J*!>Y ?6]N])S;0K="/$--$7R/$ 2,^9B;<V< '+:QMU[4LV
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MPL=2;U*;JC&R(UN6ZFM;"FQN(PVP=CXW$8H&4KAVC1"Q63.V>5QR90(XW2Q
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M@$L#976.4')*0,UT5S*TJ-9$ %LI%R>]8U=&':=6B23*^(7%R-!(V%X:R))
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M]IF1Q!$)0X>4*' 59ELPC;(I!5=-9&Z6T%_2MQC9W9FH'D1PXU:2-22RA29
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M+"[%@V95[Z@]C6&&12Y1@VF>S&SAA=W502.Q'E6&&5OHUB>8,8W[?4 D1#8
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M]ZPV%LI(*D"]PL9$>ML_0G0W K#'H%<\KR<.-E,:975B;7"9\MK@^UWO:M
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MCBZYQ9>G32['J.U8:;5M0KGEUUY%5HP60"TG'^C4H2H)"G7X5H"$.)&H&9P
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M2%X;9;6-P*,("V8\1%>[DB,JV8K[2-P$)'5)#!(#UU$8/NPVG9W"S'3.(UA
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MJ5\RP-^O<"LU,,P#.>8@9LHU'*OF0O0#7IZ5LT<JH64EK/&%8 $YHW*D@'(
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MRMF7,K1L6)49[%7MK3N'G9K@1U:JXD3]K[4.)GE,K1F%W #AW::-UEZP*-
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MH%B!2D9:XN;%LO5;Z,=<[,7N+7'3[<, CKQ-%49,C:9I$8'-E!)S$VL+VO\
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M=K3%_I(S)9 6*V+7UN2.U889D^CRYF-R6864D*W"E<6((U 0^E88#E)D 5)
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M7O1DKNP&=LY7&UVA,7)9KL&S1@=')4YLRB]SG ]*/%65@#=P%@_IIR^1K#*
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M9EL%1+LJ%N8AKDFUKWK# 5"+.N8*(RP13+K8*\1TN22"Q;OI6& C#+F3$(Q
M4@E,H)NIU?A"WT18:9M?=0)>DS898=%9#B#'E"S$7TSY?I8E!'4V!!OWM6C
MSC-VSM<*QFRZZKS@#72P-_MK# PADEUO:W*2@M;66VFF@M%?XUA@8P%B@RK:
M.++< 7(L@!/>X)%_2M&T[,&$,T889R78"X-B% OF*ZG4>O:MQ5E8+%W5P1
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M"3[#$:C6Y*D]*PP[HI4!A>,AF)>]^A]JQN<Y^RL,#K#K)*?9;)GS(JD9&"]
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M3M#9[(3T/$]].*4;*[XC>I*^G 0^*EGCDF5(SB06S1%2PC,<#B14X?\ H6;
M8C*"WM%+=J,L]-0+DUW@#$XA/HE@218TE2$R6=<5#)A9DVG@V)?Z.Q_-Z)K>
MX?2MQBXZZL&P/*IQ"81\[X@HK23R!>&&PLS0S\20BR%QA<8J =>4UOP-'7$Y
M)HWBECACGQ(2-^)GY6=OFDJH4S6OAW4^:]:PPZY"[87#8F2**R12M-"MT@,P
MBPLH3J3EEQ$I!;72YK3DD8"\%@)\=Q(U^A#S2"5&+((B%$+,I&C S19R ?:-
M!U=Q:60L$,&'+8C@MB&2!L3@S$4CFXP9]H0E)&T2%L3@Y$L1?4^=;-H&)LU8
M73A(RB-9,+ 9.(89GXTL>&Q&=;L_];Q8=@=%(85J4E%VXAZ<7:XH-D;%>#23
MBM,9(9955+#,C_/DE>8>R./ABIRZ$-2)235D&C'/,=K9FQP00$A0L(1D=M%=
MI#'<GH0-G[1C*Y>ZF_04"3:?L#[MG9B\V=LZ6*0G*0X:(*K&S)B8 &60FUBL
MLT+?ZTVH4KWUX#FDLKBTP^RD$T3!19Y5DD 89D1W$1M?4 8?%1D#T/I0+^=;
M@';20;+ TQT'2 @+8'B&=5:4-ENP8SJS"^EFK)245?M$-V!&1H4>(@!"A21+
MD%GRLT>1NH.?*OEK0^M3=[&EYS,,\CF',(XRQ4G,23.K61Q&<MKKP9"EST9?
M*EK7L%-605XIR4A55*E'61[O[630@J=,C*;&MFE&[ST ^,E*!"%*LJA7%\B@
M)RSQH#J>(L9M[_0THTTEEQ$Y/B21S2%BYX;2-F5E>'EFA .E^"PU_ PQJSL)
M+&X^,R-AXWF60Y$4G5C##;#,V8:<\4BL3_>4N"^Z>@D3&U]I2X= L<TC, EI
M"0,TTAM*)NED 5N7J;WI2MO7N(<[9-9B(Q>THV()*IEF4EU#%.'A^<C*-3QD
M8J/6E+-V -V?:$S;1C$L0#RF,HT1<$A8DC<@7<7 ,R.0Q]+4I1=\[6$MOV!+
MB<0BR!<4T;+-'*NG-D8")U7.+?P9B!![EO0TNR6:-!=A\;F6;%,J3*(LT*J%
M0+#&L#*S=I'#( 1WO[ZWJ8#]F1O(,*B!OI(_ZV M?AHS,Q>^JO=M%Z6I$G9"
M;WR0X6R,",: $SCA2HK.P!8-'IT'5,Y!/I0T*2Y#B;*P4BQ)##!GE!!92"JE
M@BYI%!M< 1GKYTB<EZ(YI0LKO47F$P:H\;E!"2+.225?*0",O8DGM3>;26[Q
ML'C>^F0>HS!6DX9#G4&P.5UNMR&T/#6U_.^E E:X0+L3-%#ESR"1I&)0D919
MO:87T]KMVI4(MYK@:;L(_;&T1#>=I A='#*2"O$C:Q&4:W.FO2G$5O-+N$2E
M9>P9+>[>&/#8<LK,S*%1D!M(PC8BX;6PO<GT%/H4FWPN,)5%![TB,&\N],F(
M;'2IBW!PL+NL2/K),9%"A"1R.JM?STTI_"GN)-C*M54VMVXCMG;5:=UCAF.,
M"XA4O*RM-PI%XD9:]B2DG4C2BNUKV IYW)D^$F%&(P,DA"K(DJ*(Y)%=F9$&
M<2!?9'+<'R-1E565[W)/#RLG+@.SMN"2/'[,Q8M%"N+1F'*4F*7AD5!H5B+*
M#8ZZT!9Y(<QR@X<;7^H8?QTV1/M+:?%PZ/:;"B%0L9X,L6(8/)(VFF2<#+;H
M*<X62A*[8RK0E.BK<'XA%X=^&3.\3XHN9V$>LX5!*Q609,PO=3( 5&M@:-7Q
M666B$8?!SUEP)8;$W>P^RT R"ZD$/(%=Q90#&+:V+=/(5$U*DIRWEDKDC"&X
M*?&8U,/AI3E2,.K=;$J&%B;FVOWTF3N[H*DAC=[]YEP^>[#E1P'5L[E921&P
M70AP?,:42E%MFIM1BW?0C;O3O;*"CRXA4!41")ELNAM=;?6?H3ZU*8>"2(BM
MB9RED,5M_>$XD2*)6B82*<.1(K<4E7C,.6^;AI(MCZ:]*<TX[FJ8RJ5.L[AN
MVPN/VIB'D:,21+(2AD3B/'DRHT4N095>^HHK=LP.ZY/(?_P^W.X\^!DDA$D@
M9!G<'+$LC#*%?H,HO>_2FV(J6A9:DKAJ$(+K'G(F3NKNG!AHH&$3*\,(1KE%
M(R.6,AS:.K!B-.]0]2<FMWB25-;OGO-#U;*P4L<,7LL%,>5F%E4*#8$#7SIL
MHI>D.=<UDA0Y88D,O63(A4Z@1%P_LIJ#8IK[ZV;$/O!MS\UX:<R%8ERL2^?,
MN50K%F<&VN>EQC=@*LI6=LDC79XS>*$NU-HC9N""RJJXE)&+DB$%6#2OP]6C
M8 6MWJ9PF':6],@,;C7&6Y2U>I'F+9TN*Q7SG$VXDD:*#&<H*\1UA5E;3Z7,
MMCTTJ1NTB$;WM<Y#<;V;3&#,J,ARM+'A7=US<+A1,K2$#JCMTM3BC!M7[!$Y
M),1^R\><5M-8ERJ</,!'=&7,')2-60: 29;)?JVM%G%6[ ,)7FT2$V0P?#18
MB8QQ&.)D>##1\LD42!U<.W1->8U&S=WN\0Q$GQAVZVU]M8K"B=WPD 3$89(2
M9E5C]'8->P0$'X4>$;6!R;;[!G61)5D2(HD*)GD?#.I=&<NLL0S?[\1_-@,N
MJ@&B.(@-8,S1QR-!+&%,,&:)")8@G.&9&Z2R \S:K:MF!GA<3)P,3*C1JS--
M 8H5#1/.AAX9?HQC^GL6 L56E)BH>D=XIPD,IBE;.4<& JV14#9961B+ R.P
ML%Z@4.2:SN%#1XY4B@BQ,"R&,Q3O&K@ED>02\3(#>+EEO8V)MK2%D8=V"X>"
M61.*>.HBA6,"SD',<1E(/"5P>UJV8*+98CC09L*,C1%,\F=R%#)(TN<<I+2*
M!Z6I$K"HBQV;)\YA$ =+"6+A9O\ 0DD""5P_1F:02,=?J'S%QM!8RW7V"\BC
M,7!O, KE'C62,ZF)K,!ENR*1TOUH$X-7EVAT[K>-FGY,J-8O'3>],I5AX3;9
ML%5Q'D_IMW"N27ZR,XOUZ&H3;/R6/TB\)$SL/Y7+Z-^,3__3N?;RB^]>\.9K
M [8QX%C:WTS6)TZU+4?BX]R*KB_E,_69U@D5D55"ZJ5MWO?VM,I/6BZ#<&ZF
MRZ9Q;+=F!T]I3:]K_&L,."2>@L5M8$WS ^:_6^)K7>8874!P0"+N%"^5CT'E
M;I6WD8<2%4OS FU[7)'4Z%0 "?6])S-G1Y4*-J$S= %.8%E%R>8$D-6[,T=(
MR)% "Z:WOF Y?(G4 UC-KD9%*QJ6*#1=2O0$'J$US?;6M3 ;$>(MF)!RG( M
M_M/8L/?6S>8)O;S%AJIUMEZ]+ 7OZ5LT?$*-191FO87.EK7M]6L-'?,B\20E
M++&<I )N18:$VU[]-*PP)<=B  ;W(%LH#:FY8-=,HS 9?2M,)%68B-HXX-="
M"JJ&+::7 S+<6 N0>E]*Q(=1BN(DYI@%)D&1GSFX)#(IYHBK:C4M8^@^S))L
M>TXJ.HD]H8F1"?I(>(H=6(&9S9C9K Y0& N-=*+3C?-B*KL]T3DKK*[2B1LP
M56*N% +6.@]JUCKTHF;T>0$&PM=BB!9!+(SM(==>EEU7)9KG\:Y;+/4P'H2"
MAE8HP8'F5"9?JDJ_2Y/4=ZRYA]B &!5F6_"<"Q"70,2'-EL';46UM;UTRY@F
MW$QF9H@6CN8QD&0!BJ7OHPRY5/3K>MWX"6[ 9F,CD*3DN_#2ZY2#;.SALO#*
M$==0:T),D4L*Q]5<2K8ECF*1JUBR%;-F+*;+_-6&78/)+21,DAY J%;OF##7
M6[,'"WUK$\K<1:T%7LJ0QR*CR ,Y6TDEA&<AN0I"DZ7\Q^W+75A496E<646<
MA&>P4+,KVLR6L#&UR^9KDZ=*$.PNQSQ!=)WNR,P<H[VMF+)=$+#,P(Z:>M8M
M4)D]U7&;WLF2..8QR,4*!@B_PAS+=0"=2B,;VTO3F.:&4]+$6MYVGQ,Z*576
M2;-(ZA%!R$*ZV=@KAC;+T-/::L[C.O*\K#=")F9NKH@F#.O#^< ARJAE%Q'<
MC5NU'0UT *LS2Q*V5X5>Q,DBF7I9T)>*Y(.@(TK=[B9:,*Y<._SEE56PR%I4
M1Y([A5(SQLH9;#*5/-ZT2$KY:6!@.'+F:0A@(7C28$Y04'$4LRME,C.US<"W
M>EWRL:%GL#&F*:,Q3*<N5(X6SA60D7.87 9+>MZRR::9M2<7=$BMAXR4HJ-*
MDLN<?2')FR!5(17&8,%S=P#3.4-V[X$K1J;T%?4<"'^#<N85F=4NEL[%$ZD:
M*+OUUU%"#A?*N6)IP)PL9!2%%7.P5[R%3W N+@BL;X&FQ+X[.9[PJ&5P0B29
M6?\ CHK!D8!G9B+@]JP0)C@-*).(\3@%L[(9.3G0>TSVSDGH!VK1KL#S!LH^
ME<(OT<:H(UYR"A;F4CF8#3L:1-Z"HL/,#BLIDS,$1-#-" LJJ#<@-_&;H5\J
M3J%[. =1S$*#DDL9%D*E%9V4A6NNHR 9K'3]VC RP^(1"6:S:V!U+H7T0$G*
M9"C=M *2U<VM198;:-H%#*))6C=I<@"NO"1@)&36YS,"+6L16U$<];EVF$XA
M9R&NS1AY4D5V*:AF&72^9; 'TO6;O:(G/?###$31.X=U15S21Y.'*^0&RQL%
M+",*+9K=ZQJR$< W'#B >)V8HHB!89\E^*"0MR=1Z#I6@BJ96:"O&[0=5D"N
MR@BR!RMA86SIE^MZ>59F:E45LM1+R[4DBUXLQD*(%&89"[DHP L+E5U&O:M+
MM 3J.2M?*XD,;M0-$H21KQLMWS/FSOF)B,1+(JYNI]*/&-X]H"5;==M6)V?&
MM)(DN9;6RQHZ.Z+&PN%D%P0RL3;74FB:#=R;=SJ,9._$*V(5%NS2(C'+U"%W
M!70ZCM:M-W-;_+49CQV\']R/';<+;VY6]6Q=G[6P6U<&\;#%X:*;5X\ACBF>
M-UAG5N:-_:5M1K1J-=TI//[&]5PN!J)-[\?2X]I1>^4;X$[V?)O\6MX?#G>;
M"8F/!8;%8V7=S:@PY:#:VQ&QD\V&83W57QN%B^CD0:@GJ;Z2,HV2FO1:^L%6
MI;K4H9TVO<^0SD#9'C962"TD32W,I$KY- T)(7,%U/-;6VM:3N[<0/:M#XGB
M,502.S.5 1\L2,[@%S$+Y0XD T.EKW\MVSN#DM6<M_#+(%FR1LER\>%,22/
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M<6*ZQEF"Q-J$D-M=#I:AMN-V\\P/$.HA!,UT>0C#X27@S:#/*8R>5BV<Q'(
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MYRD;  J+^=*$.?$ O(QB;AY%ABD>12>56$<DS+G%R+22S+=;'-EO[L-J=W8
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M HPUZ5AAV#Y[+(5R2(K$9A?,)8#Z@: BL,,L(9UBC( 94!:QYM(L+'FY18
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M9+,_&E46NC 6!OE8&UE]:P38P@Y8@%=FE$I9(VY $C]A4,>IT.N86MTO6C#
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M+1^9K&8S,D;"R11 ?1JZ)9LS.I^D,>;,MSZVK9AU996^<JN<<60*UCS9+*>
M$76^8 Z"WK6C#DKJ)E7Z1QSZ:9R2KE@<KD!KVM6&=IAX4;B*18BZQM#&7OD#
M,2Q?B DN.EK:UO+@9D"=&<Y,.$2-W&DKYB)#QG(DRD(<B$+KU(]:QOW&N &A
M2,.8\Q,>9P(W>Z@#V+R#5I7(]UZ5H["=Y)V!0$?,2ZPR)?-JC!0P"JJ LIS
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M$>W<#S;*,2,YPV30$E&^L1W#V[TN.?$3*G==HDMIX%(I);ABG,RJS.% EA)
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M\_.H*:N5>0DV]VM,*EE(?THNRL.1AP3A\Z,7:V5R["P0/JN7KFD"]K]*$.>
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M&949M?45AIYO/4PR)%&71&=PC+)GDZ$V!;+?FC!/1>PHL(7M(Q&! \Q'TC2
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M0RB[7[CM6&&20*P )<YL[,?)M2N4V(()73RK##&8[))F=596LI:[DHK%9'Z
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M(V"Q*.+G)0,\F'QTBY?]$C1<5./14M3A1NKC<)\3G::$*4D*D*<TB+$H);A
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MT,5G,C(JO&'>51?+=2-5-@5)9 5![7K$TWI<%4G99:B6VACGB16>/B.^:.,
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M69AA=U+!F/\ H8-UY04!Y[]KW'OO6S#XAE4\HS2 G0EA=@-2/?\ IK1AU<@
M*03=0N51E8&WUKZ $^ZMHP#J0I4900#(4!8Z%S<YM+FPK##@V7V;NI>UD(,B
M@BV8VT/NK# 0B95(86-PI<=0<ME!4BXZUA@)A81J5*AREW7,1U.A)^MF/E6C
M#MQ,BG-[RH.K7U]VEZT;02X_$A(RHS&1KMS'E5<Q];  :5@2*L-QM/$2L\E\
MK)<+U4 *VIL3J7OWK.(ZHQWNP)4"Y;YLPB91;07( %LWJ>];'FGFH*\7/*&D
M BC8"]\UV1<IZA@.H'7UK!,Y66Z)+%XBS2@WN5SQ(.SG6S6\[W'>QHX +59
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M!1@DA7$16X5HH4SAXW996: =#>QO'%?.>A'2L,9V?&22*^&25I@2LL84DR)
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M<DJN5*FV:28FPZ5AAA:.SJR,Q,JJ;/<YY"+NK)["J3TMK6&&1 XA<O L7TJ
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M=O;#%B+L3_?<PZ5AAED<LAX<0S"RKRVOG%QUL25 U]U889K WD4K98PV@M<
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MJ5C-KK=K#V PO>L6;L;#;"1(6>.RL4*,Y8!AUO?K?2U+3W&T]3 UPX9FNL1
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M-VSJ'&0!.N2]S>W>L,"_$(9IFF)'$*)%<: E7CD'36^5"/?2DXVT,"UA*,B
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M9.#:16L7!5@<.9&7.S<16'0D$#45BW7YW%&-9YZ#\^&F]@PK#9>-GSP<%L/
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MTL2?.@AT[!^Y(@4-=@;K954$V[JUQF&ONK35Y60[M?W"4QD<9F&C!R2%-RH
MLW*YU O]E+!J+;L$N(Y ZE ]T*94M'9^QS?7 _O;UEA6XPN8*75WRC,40L1K
MPP7<@E6O[2C[*PTXM .4&/GC+#)I(S!;DDG*H36PL=#>MQ=G<2!EL!=VR%P%
M(<#*^9Q:QUM;W"CFCF[V,:$ A@%R7-[HJ<PL $)4W/:L,!<4KJYXC QG("S"
MZJ +/ULUSVTI,DVK(Q<P]PTBA4R@JR@@9R%4Q$\O*+W)Z4'07&26H;0J)" P
M"D7-@+$@#4 B_6]8:>;%#$O"@XC9D&18T493F^C;VAF  M2'Z0N*L)3&,Q)
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MO2XZ Y:B3Q$,0R.6=&E!;,>=A<$@$C4  4HT%K@D.OLWD6Z@$'AG3J-,QK#
M5'#)<.+6&MD49RWMZ,;]5>UO,5A@>X;#2(<Q9V5URB.VK-]52=03<UHP,X8R
M!(&<J$9"ZV%FTLR ]3G/6W04-NXM*P(CC9BRJ!&5!5E4\N6_*<QU/7L;VK0H
M'88YF+Y5)M)9V8VR.1E8C4ZD6\ZPP%QR K'ESJ,S6&I!/2YOI8UA@+(4E%U4
MGERI958G1;^MZPP[=,@?*L>NH)S(;:$]C^NL,,3*Y4BZKE(6QL-"-)#EZDUA
M@2XM"&(DND85_9-F-KV)/F!1(Z"9:(()0&+([C-H$ -LRG4-_ISWI0@)YU
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M<$S6E5EC56"*7AUC=,J@VD-[ZFQ%,YKSO8.J;4?.R'MW=V-G=)C%9&C$4<9
M1B;L,SWZJ2A%NUJ:5:EENVXC^C%S?8/3L?8T4:)D@B$AG.8*A*,N5>=CKG6[
M=J9RJ7EN#^%.T>T=39F%159FC"W0*'(RVRD J"-0IZ?&DR2DOW0N":8<*JHA
M#2D*&6Z1Y2,@YL@?IS'RH75]H6Y@Q6(C*RQNO#8IF C-H\L*$ L[>RQ#=NIT
M[UIP:5S5[9B!VEM&;.Z-,LEE,,816*G4'0]CKUI4:;NFP<FGFF,[O9ML8:-H
M)FEFL[F55NQ10<S1M?E1LJ$@G2G<\DDKW&$TMZ]R,N^F]8; 8I(7^C@B0$B5
M1(97:S'30!W* #M8WIYA8;S5T-:\HQB[^DB.>WMO&2)H,&7EQ,W$C:0R?1I)
MD)E#QJ,Q5".^E2T(6LE:Q$U97N^%AGFQ>)D<H3FXC1F5I(B8TSB\A)!]KZ3M
MY4X4=U=HP?8 ,1(F(PL&&F+1A9OIBC+PHXR+EG<_3*Z CJ;5OB:5[@'$S)"(
MT;%-B7S*$EF8?1QPR*T<:!05^ED4!CW%*%F+ 819)(8\Y$SF19(BZH(Y2&=0
M P(5;9<J]26TK3,)(^&>Q'#899D4<+^N%1XQ&[&WTJR@V%K]WUMTIG6FG%]B
M'N&IO?2?%HG3N#@%RPS$.SPR8=,C LR^WF"(UF=&,?4BPO>HBK>]^98Z,;QW
M7K8D]LN)A I6!8^-D5,PN;M?0^0%M3TJ/EZ3'L5;(,,3(589@L)C&1UBSKF!
M!Y1:V=9+:VZ4FYMA),8V99)LRC,$30( U]'('M(/76PHU/*_<:3S$MOW [QX
M-H78A82H")GSW:P4+U,3.>G6U$PSM>X"<=]2CQN-+!NX)9\._)&IX1$.C.',
M(,K3#7ES2=->E.G4BE=< *H7>:R'-V1L". P/&+JI,C944QH1W4>T";TRJ5F
M]-1W3@H91T%YA,,J0,)#%9\Y0+I<C.4;33G#B_KK0:CWVFLD8V[Y:'TV.7#Y
MA$6M$_/F6ZW46/M7!4D]JQ1<C>\AK]YMZ#AN)&&C>0L6?))PT5.[93RY5[T:
ME"*6:8VJ5)+*Y$'Q0\13&L_"F8.D8)2&1BCR.3E4DGE()U/:I6AAHZRLT1&*
MQ"TAD14GQFT-NXTSYL3B)IW1A +&))$<$B1Y">)'D!&HJ1C&,$1,WO/>FVY"
MCPZX3!X3%8W$%((<$2L@E(=Q&B.P1.%H2.':_0WI%@.\C6+\H3Q,_IMWRDV;
MA,3B)=E[+,L0V?!)=I)[9C>-B(05!%R=*D:-'=>]EH-IM2SLQ&[K8:)H\,BX
M7B8B(1KB8Q-+E?$S1AV>!1>)@L!Y2MP']*7)23R>8#B2KW.W78B!Y\'PL09
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MJ!KI6\C60#PRRIB YR$SLS6)S"Y8YF9K"SNK"W8"]#J>B;CJ*6'!AH,1-(_
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M%2+FU^M8:XF=F0&0)(7+E9$P^8$<K7U=0S*PMT.@K#?@$6-F>0LBPNZX@E>
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MAI/448PJL)$975BIR3$-)F4H'9N)J>0,!8CK]V)):&@%*6>>)' 926&0!N5
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MEES,L<4+S*' =>&R -;UK8E@::"3*L4#03R3%YSJ%X<>35AFT,1OTN#6UD:
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M+&AB0/&DB.\Q=A<@ I&J@:,1J">E;3N[&]XS;%@:3:.'$J+="LK*09"LC1Y
MK.ES(28@06 RTBH_-%Q6\[$P_#S9QFAP;\1YI58AFE5[*)2 RSN 6*HIUN!8
M5'5FVFEK8E,/'[(B:>Y$0=HI(PT9+Y+Y2]U62;,P=0UE"7OI>U1D[Z<2>H<B
M0&"C:*(,S.RE,N<^R<XND9M=@OK:XIC)^<VM+CL$XF9#&H= 2&(01BY0H0"5
MN!<&])S;R,$;CW0*[2EFX<V?4L BC6Y! N;#IK3B'$3>S0.VK",7LW"S!22T
M6D@MS(I!!%R,MLVNHM2%>,[<!$?3E$246"C65HUMALQ>SQQ74\[,,[\S&\;
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M5 K@FW!1V:(@*40Z:D=1)?3SK85>;'SCEY%5@D<8 *9HVL&9P19D M>X)O\
M"L$RFG%I&#.S)PXRV5P0SR%1+Q!;E4C4)UN?6L @J)P,JHZ!G$4EU8A@JM_
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ME9ZHS-+,^#R1F#(BPY6822=%8J)Y(GNV:S.\FH["DNHT^PS>BCO"SRAI6E8
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M&BO+&X-A_&L:T8"!94B:8%4B*1@ <A)3Z]O9-].E88='4#+(H(SL%DL^30-
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MZI_X43__U+F.]#-_3?O$%T/YXQ]N^GSA[_&I:E\5'N*IB7?$U%^[9BBS6 N
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MS@#* N<<(] ;2B_:]_2L,/ER\9AE,/,$8)<JVJG,Z^R"<G8UA@(!55)!C;^
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MPTL2<U@3S@5M.-],Q(Z'AY'ADQZ82!5QT>?(96PRE4D9N*9#QK6,#ELMOXU
MJK)]@[P^<K\"?GAYLS",$O8 175Y,QRD6S&-0"!;TJ'Q,MU9:DW2BXU%?D2Y
MW0P 2*+AH6C$S!VDL'7(S\P6^4AN(+=[U%SG=.*U)J*220XDK%(A<JO#(S-8
MJS*Q-CY&UJ9I.Z7%"WH)+:<S,LACMG5''#:]F!!%P6';2G$<D::RN$#E2)7"
M'Z,%@;(>8AE:*V:USUOT HT=!%KL,-@RI/N[C"V9FP\[I&K2H9'[Y0P)M<'*
MOI6VK3N^*!3>Y5WGI836TL48I)79V#-?B(P+)$X32,ME-WC&IZBU+2R-U5=7
MY#;;:VIDBSM(DJ#F#')?-FLQ4,X(![4>"5KVS8RE57L&'WTWDX.B@O(S!70,
MQC*AK,TH2X!>*]QTS4]HTWJ[:D;BJUKV(_;0V[B9'Q"8B..2-(>1@"4RJ,S,
M2>8R\P ]U.TK$;.JY<["&2$2WB<<6-<V*E>:[22HIX@"%+Y0JG1==>M'$> >
M8.+#X6"3$I&D96)%0$L+J(\LD@!)%P1?RH4LWD);6IIQ^7]\I?YYM'#>'.Z4
MY?%LKX>>**22-$P^BS8W$*&118J0,VIOI3J%)J&?I&\/&4I.H_0(_P#R:_![
M';V8_"[8VUAG79[&*7"<(8J6$X;@X8Q<8<-E1W.M^M'IKS-[*QK$3BENQU-S
M>Y.Z^$V!AH</L^%4CB@1GPYCM&,D7"X,8&4N(HS?.SVN:95:BE+>LD"C>V8X
MFT<7@-@X"3$M+#"7A0_-RW$(6-,B,A?HP[B]]:2G<VX.2RU(P;Q[PXC;##%X
MO)'ASFM9S&L12QXBASFE&93I8'6L\WV&\A.SQB0]3PW&%:5R54!69"@5209.
M.&NM]!D/I<F^C1QC,-E=N%RY7#!8<L:R01+$5)4@2YD9++86*:&EO(2Y)',:
MOD"X@\""3'-'=$>)1&\1X<LPB1HA&TIT7F)]*RX*[ [2K$I!B8D"\@2-1B7
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M6D-;N3,MD"P56(<15E618@Z!D#.09')!*W1!TR@F]K>[#6ATDC0J^K+D/#*
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MM=59".,JL''$8EG+<\F<+;LKWN#:U*AZ: UO1&/V\(!.RS6XL<3,3"I"VS$
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MQ DCCR8>[)E!)0YCE&4D/J>M=*V-922YETV=&*2:U;(H;Q$M.7;+S2L396(
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M88PN)XI:&.##Z/',KJLI,+R.P(0!!D8,-;W%889;.D05HB,5PHAGA9%C@"N
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MIQD4R<% <X96>4J62R_QB+:CRH+EYN;R#THW=WH.WLW"!5$*$(!DD9V%R<Z
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M*'@C+;VB Z9002UFN;71F9;'RUK# XP\2'B,@5 4N'09G;*&(5!U)RD?;6&
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M<U^EN@ O[JWV&DK(^L!JV6X%[D<RJ/*^C>NNM)OF;/M,@*Z@E2;7%A87TRD
MD].M9Q[3#$W*PS:9AFU)SV)T T4??6&SKF*1L[&ZA+A"-"%9S:YUN0GW_9LQ
M*XFMJ3+8G1,W8$VL.@-K,JCSUK2N\T%62L]1N]JXD.V0*2<C$,"=+A@$UN;9
MB#[JWJ+ASX";<PJ$S.W,&*EBP&G7-[6HO;I2U9Y6S'"$QM': C1D$CH%25E
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M51P W$EBF)]H J!U--*M;>R630WE%^TS386&)<DL>+6)I%0'#*TD:/$^>>*
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M\6-QV(Q&&:?%B=XS*(^,29@8VD?,"Q&HIQ4W(QLO2&BK/%5G4FOL:7FQX?\
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M#3*"\$$=HB,^H56 6T)OJ";BF^_O/-^;<3N1U&6WYQ.(F?#J[EC//)91(+%
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M_BUIJ^AB#^  ,ET-YF5"A)(D5H8B(G93R:N&];T-IK(7%Y@R%'4"ZAQK%E4
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M,;]![4="E!MW,.IT0RABBR709!F8&.T*@=PI:53>WGY:H:L[,V?0&-2% *H
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MC:")(F?#B E)&1K,Y,R%55SIE*JP/[ZU&$E*_ U8+L0H"R+C)4DE9$!=7=T
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M68"AL@NX8@J6)!OJIRJ=->E%=P )ZY3FRM92S2@$6(Z*+W]U9KJ88QF(LS@
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M_4N.NM(DG>_ +JKH$R(3SAA[+H4-\ILA+-E'5P.E(,.J(+.P;-EOE0BX:UP
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M@Z4-"0*[290IC0$YKJ4&4 G(8V;J,ERW0Z"L3LC9\)E(4!\BDA&%CE1;E_\
M7$+:]^E;OR-&:.0(;2'1+R!G096R\R!=#F1B #Y"]9O&'!>%I&E0R(>'J(4T
M9'9<T:]$!OZ=!]B7(PRH>=#F8-)G5B#8<K7)SN";%1V-:WC9E)3Z/F=FD=E!
MS@@B(ZDG2XO]M8W<T9D*N)C.@?!VD66-8P5.896SJVF5@3<6/NK5\LKIBVE4
M:C+0J%_EDOR;6+\)-X-O?*>\$M@9?#W;^.FVKXF;M;+P^<[J;1Q<JS2[U[/P
MV'15AV+CYIV.*C1>29@QT)M*P^V:3J0^,2S1#U\*V[7TO[>\K_X7$F91&OT_
M$>-F(<LBL1>)R$958R+KI?+3:^=EGV\"+E%+7)_6"F6&TO%"S94=,L3,2CWX
MA(#&X*D#4'I6GR0E#A>#6V(ME[\;-@Q$L\$6.F"KB8@TPE^G"HBK)= 6L2;@
MV(J(VYAU7V;4;5W%-_\  1VU8WP4TO22;-XFRO#'9VU=Q,#M.7#2S8I,%-,N
M($:E9X.*KQRR21E8B4%^4G0UYHQJJ+%5+/S+LYG5J6NKYZV-?WB=L#9F$VKB
M<,8!"J6B$4%B9B.=GD<1L8S>55)OH(Q\'N!JS=*TGYWXN\CI2GOW0P^TMVUD
M48N2T#$H85XD<C6CTND3*^=) -;V"^M3=+%RC!1^YL.J5>2\UYH;_;.%X<TN
M'$44L2MSAFECA*M)';$(P( ANX_O3:Q%26'Q$K71)X>I>.>HC\5 H54P.&AP
MY*2*%=!B,IDSNY=/JJ0H"^5/*%66\VY,=1EGYS;0C\1L^=>(_"B59HXEL@7+
M+?Z2-6)#7$;:,;:]-:F*>(3S'<*JR0F=JX!&DDO(KF3/&_"89+HL>5L.'C "
M!7ME 4 WM4OA,7*'G<$2^%KNVZQ![6V2T8&)BBDA:%Y6>%6+JV09>(&MH&!U
M]]6+"[0=1J+U9/8>O&UI,2)CD=)<.WT"Q3!A'D%CF;/$ET"AE+$7L>M33:2O
MP))23SCFC+%B (HR227$:SR2!UCB)4Y1'*Y-A\#6)W-M99G1,A65H<[E D*N
M23G<<Z/)_'X<FE_*MFG?V&90P=HR1(C/FS"-20RMU()M[)Z:VO6#:YQ(PA!9
M@%D#9WA55XC6 X;91J4M6;JY"NTD9\FO:$D>^&&^DL%GP[98CPV19)0T6(D;
MB FX[:U1^G-)3V2YM*Z(O;=W@)+D6 -@[4Q.*\/MGKB\3.,08$+X5 PB8-)(
M?IXRHS0I&+1L6-K CK7D#:*ZO'58O3?LCDU5)3DLM1CMI8#$8[B8>-4<2\6"
M2,RVGG57BQ&',DC*+F9POG<4WA54'=:$95BE(XPFP4CQ48D@;!D<)XCBE:+V
M?HT CD1HI%:+746-"J5Y/B"4$\N('VGL^3B.8\+/,V$E$>&RRPPX8O(946=U
M#%66&)!;2P;05J%1W3RTS!3IVB^T8[>YWPR8L) [9EQ&65I+N<TZF%)%4*ZW
M"#36K#L]J<5&66?U"J$/.2>69#??_#XB&2<S&TJ7#PRLS%<.W5EU<-+<]*Z/
ML1KT>1;]GN+LN'X_R$4MY LN,F1;<*[A79 <JY5 :1+$J(V[V-C74MER4*2<
MM+%VPCM35];#9X^-C*J*0@9B6 !9 5Z<,D@$&KGA)7@EQ)[#RRN)R962:UT&
M7,1F7F!.O$Z'FU^RGJ8^"[Z8M*P2YS!\B"T1,DA RJ0+D+J3I2C#.2JK,(S"
M.:,I*L32Y5?J(P<@>S#FUTK-1?>90D3I)$9)+VM*Y9D!D89P8KWRQV/PZ5L0
M]3-'DR$ J1PA(;G.\6:X"9^JD,.W\V6;9@^?@[NJNTML8.9XSB9>+"SQR#B(
ML;,%52Y )#6O:J_TCVA\"PCE>UHNXPVAB:6&HMU))7-W_@#N/L_9N$P,BX7C
M3F2))88.5FYU;0<JPY5:]K\S@^6OFC;NU)8F;WFVFGS.,;>Q3Q&+FH_%KCS)
MI[T[RQX3 KA8T:!,,.'""J22!3E 5F3A&01H2I5B5OK52BG:]^!7HY9OD1%W
MBQ\,V.Q+XC(LKXJ7#8>60K/$4E:.5ECC/(DG&!NVHS=*0WF]W7(BFYRJ2:S6
MK]F7@'^YV&OC)L/-,3\XBDAC#.US<B2+#QR)8AF07(N%85&XZ6]&RMOV(_%S
M>XG%+M_&R3>[V[&S7V=AIXEA*764PE,-EXRR\$Q2*T-FAG12[J"+7!OK56K5
M:BF_OAE&+:O)^<*)=E0'" 38<0Q@QEXX)5F9PZ!N'"0A/!"$*5:UB*;-RWKQ
M%RC=Y/S1A-]-R<#()V*J\TGSN/YG*D828D-)#&' 9%+( #ZKZTXH8RK"I%IM
M10YPKG"-TVK.YIQ\?]S\/L[;>UV3"!2DV(SH<H4N_([9DZ@6O?SKT9T&VK-4
MZ45*7 ZST>QLYT8)O@C7YM?#Q18LQH4CD:1XK9V2)(F;*7#WNS%[6OVO7H3"
M3E4PT9VN[9YG4<-)U**?,R88.4C'#D9B5XJ+)EL59CQ$))7(9 ;^8-.=+/1A
M^+Y!J5>1'(G1I/X;A@,"%55Y"0%&8$VZ42Z]AOP! C"QLAC SOFS1OER!<MP
M6!)N(@3:M-A(Q:SX'8-"<B72;$M'GCSA2ZY=$.9EN58:WUTHL7=!D_<9(BSE
M.5 >*N9RS92ZRCB%3T"G*2#;2WK2C>6AE*R)&H,D>(RW1UC*K9PUG*'14#1V
M(TZFC0]$2S,B+&H #)"Q<HKLO$X?LAA86SGN>YK>\EJ;7:=@#&(^&H8(1FXH
MY6!D4E&<*21D%_>?L4FGFM#+6!<D4!&1!+$;@*F496!1<B1L;E;YM"V;3RZ5
MMH%-+>!<6$G2-^'RR(%O)*3-\W"@CAL;%26<CITK+9";9!CLR,O+.61A\V;D
M5E!,FER(;-8*IK-%<P4V!5<2KE5<2I(BY;LR@%[M'P+WDN!S:BU:335T8*F'
M!M&#AP<)*V9Y'D 88E4*AA&&:ZA>UO2E&7!<F'B,*!X^9%9I$A=6!C.BQHHL
MA(MJ;"U89?.P7RHJ-,UQ& L9P\3*<T<R6,3@A1GBLIS'OT[5LPZ)#%B%82-/
M%(QGDR LN821EDC4V*F(M<VN+7HU+0V@O=1PU^C!7(#B;A!'"5>11PE%V<9K
M9O(FB"KA=''()E(6-8B9&ADC+A8YAPQ+$0UR2S*>O<GX[-=QTQ<+8@3<-640
M.DS!" UBUV2*,!0--2!2)3C%V>IF2R,28?YPR& W&7.X?E*K")2<P?07*-;4
M]O.MJ2EFC%DCN3)AHQ$D4T*CZ19\C.TW')66-I198HPH!6U[W[4HS4#3/)S,
M\R%7#)A\[@KG89'"*N8%TB)M<7-8:"A[:Q2/$N:0$F5,[2-;,S AAD#!A;]M
M)81: 5UDAF2?",$:.[9@TA5AHP82'4V86[6K5VG=:BDW?L):>$WBABHY<'%/
M/_76",$9PLT]UE@SPDHJN7(5E#,R]R%O3VA4WY6>HTQ%+>TXFR[POWTQ4J8(
MG%M)AH,.%LKL)&82$H9G4@!26NI -P!VI[B-U1M'4A=ZI"OU<LXHG9N;OM%@
M<;@\1#CY<)+ (!A7"-&TK9>-&TS+*%4_.%UO>]A>FBCOR<20AB73=XZK@;5?
M +Q@EV^<F+D,;QL86SC(SDY3Q$-VSK(3<:]2?BWKX:"T+#0KSQ%%-6O8V;[G
M;PI+AL,RE789D8<R*;9"Q;E(( &E^]14X[C:,MO+M'WV/M$R!&7Z,RCH]V 2
M]E(!TL=: Y<4;2W<F+961N&8REB K%7+W/<=!8>E9<5='/+<AP %O<A04U.E
MR;6TK-=#&CI&"3868$BW8:G34VO8#X5IW$V!,,&5@IT#$$BX:^H4#7L&(I$Y
M)KN'F'@V**)"(U/#)!.@BL"%8#5ARZW!\Z:7)I*RL#4$)&7.&"ZCVLRN>JW4
M,3;WUALS8A<BEV4]$*6#, +96N.YS$6K9@38LW!)&8*INH N>VJ#IE[>=;3L
MGW&!0\8 "AW7(,Q8:%@QTSG2VI\Z5&22LS ; H+:A"P 4-U;,2#FN!:V4'6_
MI2# _$:B$L3G)-QH.70V-K @V%:WDL@J>7L$%M_#WCF9E+YK@6*AM0>H-PP'
MEWHE/*0&2RLR/^T,.(L1-G4.)6(C5PH",G:ZA3&#Y#0T^6:N,ENI]MQK-Y+@
M975,MKYE+ "0W50.H.5;W-M*7'055ULAH\;[#2/'".&V8AFU<9LI;+:PL#]]
M+47>_ :M\%J'N[DA02"(,MR74ECD!&H4]#H>@Z6K337<;NUFF2&W9G>:*-3P
MBM\[EP6<H%&4J"21R@W44UJI;V0_I9PS%U$4$846RR7B5EX@4N6S*Q20 GAV
M[7 -#"B@V% LV+A5@QS*KK87&:]KW[!D!N+UIY19JUVD+C;D_P WPY#*BLFB
MH39%L!8D@:$BA4XW=UI<+5DK*VMA@-N8QI"ZQ,$NKY'92 +SHQ!8W(8Y;>XT
M]MFNQ$9*6^[\!;^';P#$1)B$2-S#FS!!)&6S7 +$ *QM0ZMMT-A%%U,]/^$>
MN&29Y7D1$,=\JA4O< @#I:Q!ZBAJ,+9ZCJ4ZF^UEN@UX=I7#,ZD/>Y#&Z@#D
M !O]>PZ:4I*E;-9@F\1]SDCCA[3)C^D!<"S!2!<D: 'E/WBM-4GE8U?$KC<#
MR-M&!&!PQ=U8 Y+L2;"07S-J /?2=V@\EJ*53$)W<4T$>+VJR*5Q&&DC!4D2
MZA%%[L,PZ-IY5KX.GG'4W\+<<IQ:7<)F3;.S3(]G#',;*QN392ZC6U]16.C4
M6=C2K0GFCM'/!S2LVKKDR *5Y6-[K<7N5TT-"::=FF+OE<-L.%91)<Y'%@2M
M@IZ:Z\IO6F\K<6%CE ,N%]%(I +D*Z ^T%/*Q&FA(H;R=F; ['DRJN5FRVMH
M3?S[B_NK1ABF1HX[WT#1M9N9CK=QYB]JVM3 %+(JO<&/(ET<97S%F&A07UU/
M4FC"GH^XR(&SG)D2X&4,,O1=-1< YJT !G,;O>R@HK7Z9CW%M2/6M,VM3F-2
M&!#7CU+'*0=0>C6UTI&Y(+9G57(RJI)8JR$$G*V;H3VR9&UK:B]3361AE07*
MV"QNSG,O74W4?:*6",-[?1@J68*EF!L;-<V+:=*PPQ%#$,K1Y18J&0D$$QJX
MLHU*\X^-88!<EKY2/I&"WE.94LO,\C'L;=.U88!(+NSDA0B26&7GC-YL,IE!
M-KME]+UAAFRJ(]0.&4-@SV*J^5EDR]RX<6%88!501RHY57"-:,9;1M9\A5HR
M3F<'UK##.)"H2.,I>1"$6[>V1AP"SWNO-&_;].F&!YA9,UR(\L<:\P+WX;JI
M+VOV8+<>=Z3NH5O,S"3([!+YEMH-3R-K;37Z.D[K-[R.ZES(C  78 ,R@ YU
MNEU!L0!116^@0YB*H<X63+J;M8F_U+*+B_:D><(;CVF;B*L:$#,7"BZVD"\5
MLZJ;D:VZGM66D9>/:9EB "M?-<%[GED9 ?9MJ=#VK-]!+H+F;AO(2@#%-687
M*W!*#2_0$>ZDV;S$MI,3V.94RV+.TEKJB6B7,]L[M<$,%'E2P83X@1I$420J
MTJ)$G/G8\4Q%WD2U[%\5UOTO2]R3$RT,,,?$=Y&YY4"S+&HR1RM*VIS:W0M=
MLMM+UKS5D[W$J:2LP=P+WC6-B6CSN;D6+EE(/^NE'PK<FGH+1DE2-,RWS2,T
M@B+FZ?2-C.$J]1E_KQO=85FXV9<*<7B%BL$C2(.;9-"SJQ92"F:PU87'E14F
ME83O("27.24F2QS('0@.3,T:HL:Z9C$FU& \@OI6I1;61O>0()NP8!UXB*3J
MKHLQ6)Y4!(()!8]:5%620EZ@V/+G8&Q"9SDLMQP\3A;M)&ME5CAR^OD*V99A
MI"R&-3DL$50K-+9F<)"S-FMW+G3N0:&^LN[-6-;K!D0 7F+JQ)SL20 Q!R6-
MNI)6]"=[YZA%IGJ"8HD'TCE6YI0NM\]GCY6-AHH<VK#8(0 O%KD8\R@@J77-
MQ;DZDW2L,!W#OF8H!Q(P$5B;JS1L5OU47,GEI^G# 5$K2JSIU#N%O8,%#R>T
M +#TK##G#QY\S/>ZA0!E!&E[YO36L,!@7*JG)RD*O8>R I(%^A(K##%*VC*N
M9GR<EVZZ]S>V@TK# FQ#QH^4Z.0HBS*6NS\*(W\K22?9]E;CG*R-/)$:?%K>
M41P_-<//FE,'"D:[I'ALZ\6%RJ68VFS:GZQM3^DE>XRQ,[0:6J-1WC1MF7>#
M?G$8-KI@]VL'A':TV6'&;2Q,)Q4RE+A4D6.47-B0VGJ;+A:<J5+?RN]"NN=Y
M-L3FSE,20 -!%P%2[+*96'%;.<.PCRJ4+JV;J?U*G+>R>H.XNMWMES[5VMA,
M'"51XI0SM%$3$L4D;N(4L58C-;K>UZ;SDH*[%0@YRW>)L"W W0CV9L^",1 Y
ME19K!.#Q$GCTN5O_  "DZ@ZV'3I"8BJY2)_"X?JHY?FQ\L#AN!#ECA4R,B0N
M\BK8WB,9(4%1D:07)M0HYQNS8%D/"6-[ C/"@D49FM'+L_%Y7C:ZOGSNK WL
MO3J:0[;]NPQ1WLD(W$X&=,0O$ X9B@DQ26+.Z0218,LF8EAE>)AE)U77O8*$
M*Q@Q(=RHBB6 O((C=;H8%Q<F"!C1?8)7$"YN-!?WZ%9<3#"L4D;\.>)L-97E
M&60ND0DV=B$8%[ZL%;-;N6];X;#3 LO&;"K*8UM) CY1:-. ^1RPU071;^5K
MUL+3C9[ST:%7"BSYQ'&V20*SNQ"V?C/,'12;.DC[0 ZCEUM0EGF$M85&SI<\
M22Z'.5C92IN,R+,"Y.H)E8ZZZ5LP5N$D:=TL#%PPH=0.6Y-Y"K$!LAAC;RZ^
MM-IQ<7F;0.VAB(4PCSA5Y<_&#EBSQ1JZ\JAK,H=#;45J'IHVM1KTB>=I)'<M
M/([*J(&O($(0!;L0UDET]+^5.$$D"L-@(RQ@A9$2Z1#B(#(2H"S,5-K$RSMW
MU76M2R5P;%/A]GPP1QEUB5R'3.AS0%NQ*VN"67J!I0^L?W.@-ZW7(%IAXWLX
M5U36R$9P?I(RSJ-20JR$6/GZ5IR;U%QDEEQ#O!1#ALQ(L3PW)YI18*64=6;F
M4Z][BD-AHANI11&@)SR$=U+93H"]]4()U%JQFWH <1*54L)4R96%BV6\@<KU
M07ZJ:2)"LRH2<R$9M<A+$VTRN+^T,_8D6I43078W&1JK!;B1LZ.V?(BL[1>P
MMB+A5.OK18P;]4TW;,;3;^U0TYB2Z&&P"JY9&:YO*S&P+%.HM1=Q.RMH FYY
MR>4!E][]Y88)(8L-.LTDRE9"21E"L,Y(# %8[7MJ3?TH\(<]1MO-W&<VUMTH
MT@:=#)&A"K$SM(]LTC&-=0RR*X %QT-.(T[K/1Z#.=6<6--C-J8B26*4S%YY
M'8PJYLO!)L8PXTY3J1YT[ITHI6>HVG4;=PCQ6T)C(8Y#D470,2LE@2[Y5#=P
M W<?L*H).Z!N=]0IQ<LT?%BR&5G&8LRL9$C1LRNC1E  ;=#?2B@@(TIQ2I&B
M@+*P<R65$C<$HQ>,7+GZ4CKWK0DSR88B7!1\L;,J\*0&595B.N9"FAXK-:S&
MPMI6&!YA=WVEC$N5Y"T]HW<@%F7F>.QLSKPP?C0G6BN814Y//@.EN[NZ))<-
M(\ SOE:0*<S!%100&R(519=&6YYB/@SG6=\M;CZE2;L^ ]^R-EQELD<,9CC*
ME[Y>0*+YE)CO>]Q0I5&]![%;BL.!@,,F&19)(HYBMFS*G1F#)86M>RL-:0VW
MJQ<7&]Y7L*39VS8Y7S%N+8\5<BZ2+UX:WL.2^M)E)+4<0A'TD*O PLDD>:.+
M5I"I$69%3*>0C+[>OEU%-934==0RY!]AX8X5C4$R1WSY.8,&>Y4D: J/NH<Y
M)H)H<-+RV=8URR$RLJ>VBFZ@V&A_32$FW9:F[A/M#'QJ72)E =&*=4U!4E5Z
M9A;4@Z:>E+W))I]H.330VVV=N-&)D/!:=8Q++APK$E4-P!*6(=LFI2W2G2IR
M>:M8#*I%92&0WGWF,<4R1O(2Z,%B@8L(6DSZEC9;9"&#6TRVHCA)R5@+G!4F
MEZ9%3?\ VY)Q!'A6-P95>3$\[Y79V&<,V55<,O;MTJ3PL':[YD)BZB<AHMI;
M50X.2 J1B)@L>>+40E2K%0IL(F=;V.H%Z>$=4]!B459@G#>3/"Z1B(,^=W;,
M&;#RJ-&=0I;W#K6QL!%ECR< \<//!P7D9VBS!5'TF&(-R58E0>U8;.<.DJ10
M8>1[QJU@HR&>2%TB*MQ6N3+=F!Z&YMWK:5W9&'$T+XEHVQ?$CECE9>1BDA$?
M*)4:,@.,R&_J?6G$4U&S-A=)*P2,PR"25W9&,DKH+DR$"9@P)LAOTUL1VK;=
MD8%^*A6>$1JW&8\*4L6X4BPN;RQ"P"YXF%R#FY??2+JW::;NK<0%AX;8D0YF
M.$*MG6()D*JP#-?*6/$4Z*OM5O=DU<'=YI"=Q;()I7>-I6:5B%4 I'$%DRQE
M#;.8HUN!Z^FI8INT5J"DY/S7;,-]C8*;'XV-(W5@\$;H\X1L.R@\Z$94[=BI
M&E:EDGV(+03<]UYV9/7P7W?^CCD,,:OG15^B)!:XRR),X#\/-V!MZ5$UYY-]
MA9,#1B]=38EN=LZ/#89GDCO;ADZM87 -P1[(S#R-05>31-TH**[1Q6M().58
MPC+("ANS1A><#,M[W'2],7F[AT%&,D*PLQ$:R9U 53D#WM9F*@!K=[BBP63M
MR,D[(;?>/:4>'A,S2PQ@ C*4!^DN&T^J!9N].*:=]YZ#2ODE<B+X@[S(L)O(
MH$I,8C!:->>.582<I 4&3*+V-25&G%Z+0C<3B=U6Y$.=O;<DVEC,05Q(EC&+
MF1VO=,RR9XPB91PURN![]:E*</-RT(.K.52>?HA3@\:-E[8V=C(7C@,C<-Y(
MF=0&#9A&77(%O)(,Q.A%%=I*Z$QE9=@Z^+Q*R-)([2!A$@2+B@O,\D2O*_,;
M% CZ&_6@BVUNWX,;#?'?'#;O[-QN-Q>)C@CPL6(#JR!\D2IR-*MQ<WIU3I.7
MHC:M5<5NK4@E)B,?XN;W8K$_.S^:-B2QQP(9I&P.,EGB>4SPJ3>5\,50KF/6
MI'=C2@T]049.G'G-ZDB-B[#@V=@8L+A88X<*DB&(,0&+, +E!HSE@3F]H5'U
M9.4NPRE'>>\QS,#@WAA8M"[JK+ PD;AW>^?,!(#>,CZV@O2.Q#R.ZLV([:&.
MEEDDBG<!;9(BRJ)";O'Q(@ <@>(@$ ZUIL1W")QT3++'A()DD(15C0YK+PR6
MFSL22"0!9==:1J#EJ%DTC3E)4PXXXD>,(KH6!AY2L\B+9XN)T# "U8) LW%%
MV1I9(XF?Z0XHRRJ% D=7D,ERW$:U@+ 6HN\C##E3@22R< 1", 1.#+B<.S2!
M9OHY6=FG"@V%M16;R[1.Y$Z-%/A7.'CA,_#+13!1EPTG#2T(9E#B0/WM6]Y
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M!![S[7; 86=HRCR)&\H+2%2SQ9Y20?J(OS1A?H2/6BT4G+,!5GNW->_C'O\
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M.7R0*8HWPH;$! 8VL5C<Y2TC&^O:L1@8HS2G#0J(UAG9V:$O"\^1!E,@D9B
MP4Z7UTK&C !-JF61 0JQK*C:\$Q11*V($B^V)2I!/8BEQ33S, 6)BXH>97/#
MG;-(D$@SI)(MFFD!Y2JN!R@DD4LT$K(%X@:)N"BH97=75'$C*[M [<T;12H3
MIH+VI75R8APDWV&(%8I1+%98I9FD6*2-+JN2^>;)IP;BZ=SWHXDXBQ$6:&6&
M))B7:)F,K!%9T9N-)AUU%GL0;6K''F9PN.WX,;C'??>\X>=L1/A\ Z8F:6*)
MS$RD)P4!4'B)-(YE)[EK'6FF*J]5"_ >8*C*K)U'HM#9AM%L!NON_'@55#)!
M#'ATR<G,H!!>WL@$'K4!"4Z]9R?HDO+S(71&/:4TVT]HS,S.8Y.)B$,<RNYC
M,A&'1LMK<"2[6-2,<EF,).3LXZ"JV,CX*)"Q'#9@44Q*0SR\C/.-39CT-Q0*
MC4G9:FV[*[!6TG"H49W892F4$QF!%1GD96Y@%SA1I0S!!;2D8QC$!E"1"3AD
M#B6X^9V58P%:TBVS#J3TK=FW9:F#=;6"XOE5&$.>+B'K'&"<SEF4DAR5LHO<
M7 /6G-/S4K\@=;T5S$YB9D$T$<<=XXV:$PNR&7*ZP/+(SK87!/2C7&U@"@&:
M>0'AK>SH4)1D)Y' N UD&6]$28B4E9KB;*?R5P7_ &HC?1LD22-X,[P,5216
M81-OOX=\"ZK?01*->U0/2#Y'%?ZZO\&1/=&VOADEQZI_X43_U+DN]F7^G#>4
MW*VVUM &WUQ\Y>X];>52M/XJ-N15<5\IJ>L_$"PV*'+;5'MJ?:>Q4>8N/32E
M:#=@@EN8MGR+>UQRGL0.Y K>1ATTTL+9=<PY>GGU.ONK-,^!K(ZL^4.YN593
M<JS,P!-Q8$&Y/H*U=/(WQ$OM?%%2 C6+$+S$$@@:LP%AT/D*Q(7P&@VQB"TI
M&=3F'">S _2+(W1=#8BE"J::S$QBF!B9<GLEBV4G.E_; MF 5QVZU@?,(\5*
M;.<T1 1AD"FX 1,I)UN1[JW'4VA#;2G269G20,BL0BC-FC*FS7(&H![4>#6:
MXC5ZL3.+G76/. +%H[%^$[$W:1V S@@]J(HO)\ 3Y!.TD10A6-[\KYFSI(CH
M7*"Q/"9!THUGR$W0$<N$1'$?*8U*"[63*6OT&4 ]C2M%8TV!7CE*.8V5LJ@<
MIL,^564*GM @-YWI2N9=<0& \:FUW(()>:ZA1F.8*'8@A?<:4HR:$MHY$A;#
M+&5X@B:,&(N"TPYR%CC4!B,X Z6K5L\]38(5@3(S(!'>Z.J9&"6LB,I;JAY?
MA6GRN;C]0-$A>(96B4J!G+J_$L#S!+!LI ^!I 0%IB#\X@X(8".-665@T8!+
M96XN6P.5E('86K/$T'JOG ;(+L&+LY!#CH&&4G(I T(ZUI&<0U1H8\)&I=BR
M+Q+%3*$#M:PY@$2_UNOZMRBVQ9R50XB(DR1LT?4,C\2XS<C-E (]P^-;BFHV
M,852%9.(\+A)51@JRL+RJCV! %CF-CVK! 7YXYDS$<)X<QF!9[.Q=B%",,P!
M%C>UA?K6&-&.$)WD+HX(X3<98U1XR[%U7*#P[6%KAJV:#1.'$D;A&$CHC#,Y
M 61.0VB4N5!B4>76@V:SX"DP9AX8$82N>$TA8B-8[YCS$"[W:[*/JZ6]:WW"
MPQ5URI](,LB!6 8<IS9%CRG.0^;0ZBL,"B=\^<!6CCRN5(CL2MFNR-9<O,.X
MK:X&GH-WM:>-)&B3YPL16S2\2SE7LKLUUYBH)*]SVIVLEGJ-FU<3HO$0R1R!
M0REKY3D:8NZN-;@.;"UK@@GOKLR]\P<LAD7)&76,1B12SFQE-Q)#;+Q"S^@(
MK?@9WB;VCAQ,UN(8XD'%58@0T=VME>1<S'(W4$6UK%DS)(2N*6RQI"+L5)::
M9<]V9LF5IBP CL 0#;T%J,!$OBC)#B"V(2YSR1((SPP[$H%=2RO( M^PL:6-
M7D[/4+VX/#5H\V6)$1@'U+W:0OF$:NV;B?6 M6[FM6"(5PL2(\K,7*O(@#N9
M$C(YQHSQE<W=K&_:L2;TS-<;',V'14<\67(TL;<**7E5GB5XP0F5;M(QN-;6
M[=RP361L#J(PDD.<3M)AS(T4@2\?%"\7F"9@6! 74B_6B&S+L_",91$8GX9D
M:0MR!QPGB)0%& 1D4"^;5NU9P,XC_P"Y433HANI@XKR'G9B&&4Q7%A=B/:M<
M4QK-)ROHQ_13M[!;[:FEC@C D)9"V>*,)FNQY+JQ!*D>7>@1O=AY";BB$>1I
M+AGXC&5&!8+E!C! )R\NO2]*0@^5<ANP<7RN_#>[,#T+LUV;3L!I6&@!C!,P
MD5'5H[ L&FNEF(,8Y48EW*VTU%]=*QYFG]0GA'JM^'<Q?2#VG8,4=!FN2R$E
MM>JV];4N2;BD@)G'"+JRG-PF5$5F(R%GZ(="\>0DZC2D[LDNPV*+8ZA'"+8R
M9'+6YB [,J&[64 JY[WI#T#T[?4.SLG#,8HP.=""CQA@F6]E5B= WT78$F@R
M:3S'L?00X&SH88RG"8!4$5U0MG!5.H:Q75G-Z 'O=7%0J"0JKJH?,5$8'-+8
M:YR&U((\JV*!T.949PH+ 9(ELW!5LR"0$:,3E;+>UM:WO1TXBKH.\*6X/$ 5
M&8-&C$YH2R%1D0:ZQC2W>^E#;S-'9F-XX5S*!+=E&J"_MD*+L XZ7K5S1E9U
M5'504X9PY74$A \H)87!';UK5^1LZ32JO(TBJK(I#)*S:DDZYQ<>Z]:,"UP;
M98XUC,=GE,MF$JN#8WO_ !@.X-;8EOWF!)VN,R1R.C1*TH9FS*4 ",2H(4*H
MN,NOG6M<S5V"PP+-($^D8$6%\BJ =$87MF/:VM9%V>>AM//,+Q'='55X:A04
M+6$8>0YQD+,K68*0=.E&WT+WD#X T:+]*S1\,,$=+(CVT!:ZGBD]P;6H,LV^
M\T9)0JJP1UN4+!CF-W^C C!XC@$%WU.FGNK1@'0PJI!XV<"SEG6WPUTL:V[F
M!@7"A@Z/<6 ;EMF "L.N4];7O:DF',T@0#(H-AS7:YRE^$2%4@-9K]#VK##J
MTW$:PN;@(4'(%R:(S!A<ACY5AAWC/#X?#$G$ ,@X;:*YFB"DA@01E%SZ5AIC
M3^/O@-X=?*8\)-[?![Q0V!@=L[L[TX!X)$Q,<;3[/Q@B_K':V Q5EEP.TL'+
M:2-XR#<6-&PV*GAZO66NGDU^,#7@JL;+5?64!OE?_)3W[^1/XT;:\)-]TQ.*
MV<F)Q6,\-]\I,(RX/?7==V)PQ27F!VQLV.0QXM5(8*,_LZT\Q%.,+.F[TI9^
MT@JE+=D\B+[1M/PUX99Y%>9'>8+ G#&61QGC),C37;KT%(C?*PWRXDT?DS[[
M;-V1L^+!8S$8;"/@\?)\[FQ4BK+)A2N:.%-5402RV(8 Z5Q7R@;/K3Q[JTHN
M6]&RLM64'I7@:T\3\*BFTXI*PX._N\VR]I[1D;81AEP^)FF#XCB"4RS/EBFE
M"2%& EFE7+II5(PU"=.-JB::U[RJJE*/I+,0V9Y9\*!'$LF(3-*ME,7#2(+/
MK8N9#*IRD"PO3O=T2>;=Q5LPLDP6$>!Y)_HVRRJ6 16CF:6)EF5&&1BD+R1]
M0;]K5D6TK(VG;(26,PH,C#YPLT1+1P-.TJRY0<N;%L5X<;K>W6P&E.(5'$)%
MJ^5Q";7P21XH*X5URY7<1#.@#EK(&(BGA=4N""=+7J3PU9;J<M24H-J(B-IX
M227AF-71'DG8R1MQ&+Q<DH4$JR*$(%BMM=+]:F*&)25F/:4FF)O%X5LQ6-<Z
MQ,QD2X%\BW=GS,H)0'J+WIY&LF\]1U3E;41.TL&&A(+D9B J1I=T9FF/TBZ<
MS*X(9?AZ3F!KJ$UR1-X2K]TN"&XVMLIN(6C.@7,4E&4D@:,-'?,"-!5SPF)A
M4C:^=BP8>NIQS>841Y<K/,T<4F7A_.6#.CM(>42!01<V]P[TYX7#VX+0Y@FL
M"C  %V0*ARHD6N0 +Q" C@#7K6[FI+D='DCPTBYD5B A1]&OG-FT>)'U)^RM
MF6;TT'I\#,3AH=]<!%B&<1LZ\JY5*H)/G)/E<#E\ZJ_2V$JFQZCCFK$=M:+>
M"GS-^^Y6)BC\/=6A!^98>2).)(6GC"V^:K)$)#G?VT'M.*\:[4A?'U7+]L9R
M'$)]9/O$+A-K0_.\1@\;$KL9'A"% IME#0+(#'R&1F&8=33"I1EN[T5ES&$H
MV6]P#%-IB>#+"'3$X1TADCQ$,CL 0\Q'+=3%PF!+=!?KVII*"4K\& =[A!C9
MD"_.L09#-"O%2*(GYNF4 DW"WD=@X+7.9+V%$C%;V6@)QX(87?HXF/"2RMAW
M=,7'PY(S)G>.1U^<1N+&Y;/R@"Z>M6/9,8NI&P2BEUB5[6=R'>^L['/FB&(+
M1Y6?F8&,(0(N#RA'1M">YKIVRJ;6[O:W+3@4N#L1[VU&Y!D9,T08W7*!(ECE
MSD,4.=+63K:N@X.5HVY%GPKM9#<[36)6RC#KG2)!>,"5IAEYL]F ZFK9A*EB
MR8;>W$WH)/%X;.8I 8W0IE4DW9+_ %"C&P56TTN14S"5UVDI%Y@.19 ;L<."
MPD5;HY57L#)>U\X))(S#I1%:P4+LN1B%)C(2RNIM),#J_#5>0 "]KVI8FWO.
M$A0*RL7EBDFS(I)CR%DX9!.@T50S'V23I66,TU%EN9AQC]L8=FBA"P6M(8\H
MCL;Q(K$J<H'>PT&M1FV*SH8&4EQ XBHJ=)R=M#:S\GW9,@^;8A)6RS! %U/$
MBXBH2!SW3.#8=QKTZ^<^EF(LY/BSC&V*\I8FI+[O,V22[2? ["P^"PT#-C &
MEDPT,;"&:)XK*HY+F73FZ"N8*2OGK<JKJ;L'%:L9W:>ROG?'Q<\,G$Q.)BD3
M#(5:*,.[&11D5SA' 734YK5D\32A:+R(JK4E&;;R>?Y]HGL7NNT8>9,-(X1%
MD@.60\UUO"[@Z21*UB3;44.6+IJZ4E:YJ&*ODWWBFV)LR/96.B<W@26+B(6A
M,C,TPT"%P"T=_9MU[4QKXB%1:WR_/\_S;2O5=:FUJTQ_MA[9BV?AC$.&"T?-
MB%"M(D@LZ1<)P2&UUMH-//6O5;RG=<B+3:XCEQ;6CQL$9U838=9L-B PB<SY
MLJA[<RJ^(#&P6P%-I2<?2R%WDEG[1$[S;2Q&,PV.@,?S:2.$83%- (1$))5E
M]@!F:5'*W7.0,Q/32ET$G4WD]7<+3DEJ\OS_ #R-5ORD<9$[8Z7YQ%F7#'*D
MF9))AQI )"J/(./E5<P!N*[-T+HN4HM+*Y?^C,'YJL[.1JHWJQ"#'&-)@^7%
MD.KL64*ZZ_3(+,+GSKU/L*DU@_8CMNS(/X-<)5,82.ZHRI&[Y1G94E0R6.8D
M$@Y%^W[)AQ=[$G*&]W@N.7#L6;7B1KGC<AQ"S,,X4*1H,Q-:W9:&]W/(&1S2
M2*LBJL<EFLTJE( BY3PU*ZNS,QL36;K37(RQ]"81/PYI"V9V+!E"R7S1A$CF
M6X$0"W[44V\E?@&*11*QXCB.!W*2S?PHRM94$;/ERKD!N!?H:T!;\YG>!!+A
ME(*N1&7C*OQ(PK*H9Y,V1@Q'2XTHL9)1L]1%C*J-H%OP4*%942.RJP]ECG)8
MM;2DRLY76@:'H@J-$!4.RI'+(K2+P6$@X)LH$FBV<.>]A:M<1?$,HGC#-%&8
M)H@\L<*3<L,B  <::W.C+H1;1NM;[A,DV\M QP<X?,.!PQ&)HT?#B\+7@=&;
M)(!F!93:QI<$[WX Q6X;#.1"2[R%G YDR3M9X@<A[H5 OZ]/0CX]PFWG7%;@
M\).JEGPTTCM*D=^&V0B^;*KGFY$',>@H:C)Z&[-Z:!I'@I+N8HT64&4!V#9F
MS2*(\/*[G*$S*2!;J;]Z+&+2SU-;LCZ1%C;YU"$62-F@X$F?@SM,,S!OXKJ6
MT(K;2-:.S,$BY8X\3))AXN ,26BE(E#&*"4L/HV8LD9=;-T%^NFFDC #B\*W
M$AD":F&5W#-&J11M):.?.<[%FP]K:^R!3C?AS-W1U$1?YW+#!-,<)D48<.BK
MQGO&6C)10T95P][_ +QRF[^:\K&7S"K$X0&[-*HG+&%8T.<WC 3/JKE054:D
MA?OH;;>;,N=@DTB61U"):'CN+!#(F1K@1 D7%K^?I6C+F'YI'8\2Z0PB-GE8
M*..8B$ ,FN8@N5N-++]NS87XB->>*&0"))6XD',H57O=S*;%D (%EO1X)I9F
MS!AX>+"XD,E\IC:.0HH=4<.L<;LI)20)U!N.GN(9X %XLTF157#A$<WD.=0<
M,\@"^R ;7R@]\M88!Y8X)5DEFQ D4PF&5I(2KQ,PLLL=T)"$:DZ:BM6N*3:R
M C<!6CDE>1CQ6CRL T)188$^D=55D4+8BUP<QZ6K+<.!M,6VXN^@W:VG%!B9
M<N%G:RK&[Q*A90%+YF_@A(Q&8#KZ4XHUI0>X\H\!%2G&HKO1&R7P\W^F*0I!
MBV,L<6$B0RLF40Y(3/S1 LLB 'AOKRAM#4FI;R2(2K>G.T=">NX.^JXF/#QX
MES!,<L3Q12.J2K<2\5G*@RVN;][WT&EQ5(QCEEF&ADM_BK&S#Y._BE-L4X/9
MV,Q 7 2/P,,[E62*9K/'9G<.G$(!YJ:3I-^<EYI9,'BH5H=7-YV2-NGAUOA'
MM*'#3*ZRY@'Y2N0\JA@#<C1O(ZFHFK3M-VT"R@H2MP)/;!VL9X0JH;C4)90P
M\R;=013=^:[\!,HW0[6S<2D\$/$,5\IRH21FL%!N+:E>QZ=:0VKLU"7#D&L:
M7L2EV&A=F:X0_5N-"#V[T.<K++B'IY]X=85(;$Y;M'H%!)51_%D)%BO?0FFT
MWP6A,8>+44&0D*HH5!SN04;V38, 4/95S4CBQUP.ASD:LK,,AY5OR^QE/G9O
M*LL:.[<V4 9K>TJ@+<="+C2P)%;MR,"6;,K.HRJ.)9_K'+E!"/FZ@=1:M:&!
M<!]+Q.JW93HJ(EM5?6S'RZ=ZV8&6%5%%F*$.P?GO9B+\PRW.A/>L,%%" 4,8
ML23S+H5 *WY3U!Z=:Q)[U^ 6.@1[6@C, 5E+7!" YE4<W707N-/MK=L\@<]6
M,+O=@G3BXD HIXB9!SIRVS9]3R$'4=33ZGZ(PJ>F,-O,,A)X#NI NA7.W#4!
M5 2X(5G>Y]R^1HT?1$-Y=@T>TA& (RN9HXU!Y>#."9"S>VPS\(#W:TM/(;O4
M*(9;3D9XUDE*MEL)!S-R*VH5&*J3H>WK6]==#+YCR[JXF1=7,2&-,CYEL#J@
M0@*6&F4CTI$[< T'970]. E=E2,,,ZY&=T(L$ZLIOF!S#WFFL_2'D6]W/4=S
M=F,6S75"0&8V8,-;:/8@72_:@5-4'I<UR$[O?B-0BBY)3(7[JH-@'%B<WE:B
MTG97>@#$-VSYC1R-(F+#KE;*[ODRZ9RPLNMF%[V\KTYWENVXC-R5K#V;D(L[
MR:LB,+D.== ,HC-].8^G2@U4U'M'&&6K'RP:HD"J68E OG9KGZIZ K>F=VWV
M$A'1 YG)T/+IR@6-SV)/3.3U/E6Q1\#PQE%RPMH>8:^U<"]ZU+..1CT"[&XC
MA@$VYQ[/U56Y&8@ZZ!0?.AJ+OGH(;2=F(3:>+(+\^=D#QV1E%B=;D-E%.(0W
MNX%*00P3!\FN8N2O,A#1ZV+=CRUN4$D^8F\I9(5^!A652ZBS'Z,$E;G):V53
MG8@DVZT+1#C.,.T5&#P:MPBX,>52=3;Z0= K"^6/SI#DK-"H)RS;31AQ^&PT
M9=9$5N(8T^JP:W-)=FN5 (ZUD)-JU\Q,X06JR$!M/9&$D=DPZI&X9F+J>)8,
MP"V=2H%B#VTIS"M.-H^E$;3HPEG%[K"F79^/V=)ASAIC+](6:*9,RNC\K$,7
MLFA/6U*E.G/56$NEB(-.#WD@:TD\301XW!!U)-Y<./I)"?9%A<KDOU/6U)W*
M;TEF*ZVKI4C9&7#C#.P1,6P0',T4N8.H RE0QRD/F'4 T-PDE=K()OT6[*68
M;_-N),C*\<SB-9"\4@4L?J^TRJ2HZTBZ%Q@Y^C8X,;1L2\<QE8V:94N6L+A+
MBXL.]JQ-,TXR6=@+*6DD:SQEE0OE4&^<BZ9E.HNWG2FFA.BN!9!8%U9-5)%@
MP)YY#II?HWE6C$[Z =HLF15SDB[BS,386*FU@;$L:PPXE>01/,H+2$#,LMB&
MXF==;7 !S 5A@%E8-<.C%R ]S8A%5[GA 7-@!6&&(*'97"JBY#(@12^557,;
M@CJ!VZ^E8892I0A4!M<KP^@X:@AB)!SD@ =16&'"1M(5"\H5)",EFD960*Q)
MU%[D=36[,P[X7(CD(F7() V4B37B.?I+Z,,BJ;@D5HP[K*ID$ES9FC+*"8@S
M!XKD6S*++;N+UA@-BX>1RB@)ID0L6DC<JC+)J+$96;0>588"@$C2/D(L1DT4
MV8]S9[FYK##OS*& 9"<SAT+$$%OF_772Y<=SUK##K"0#$98V;,%XBD@7DM?.
M;FV<"L,!*RHP?*3(4:YS'V%8\I*#47M6K(P#XM $NK7=GSYH^<1K*U[V-R0&
M/:MBF[V[@CQ)D*FTI!'+<-&S&XUXEB01?[*W%I.[$A',%?3-(TC-'&.'I<M)
MAT;4E@-)G\NE'$W0:P0]"2#GD;)S-FYV5KL1IE(;7UH,HN[? 4&3Q&+VK.Q1
M\I%N&1EGTD"W8D#04DS0(MH3E%(=E0F:0D1#-< [2A <GOQ(HP??]AE"+28C
M>8C\7,LAQ+L_+B$E@@B71%X\<L)G9EY@ZY@;#06I:5LD);OF!7<XF4,&*(DX
MF?AME5HW?#N"+!R>7&G-YWI5EQ>8F_8S+@I7FB9C"&Q$Y"LZN;0WACS$9K@A
M<A7V1K6FK=QM"GP/0,(4CB5^)PP5#,@Q$#QDR>=\,%L!T;WFDA%H'4,>1R9G
M#2+PTD=6+29;!(5&87*Q\!E.E^745AL'1*RHS1J+O%*CD 759(Y(1(%O>]I,
MVFMQ0)>DS89KR1,'C(9F&H&8J<V5@0MSHI)K1@+CS,K(0F4!@S@$,07T)N+W
MR"]NU88"XXE5AE)/+'S'-F8YG9@A4=!FUK##,K") "ZYP+*><KE.K"[C4WO\
M:PPZK)"0CY<S$$(NBZ@G-_?6 \Q6&&5I'B7+$<H9KHW-H&UL2PN4UZ5A@38I
MEB:12Z9F:Y<ALF8@:C2P&8V'E6C",/BCO V&BQ,"2Q(&2:+CEV42OGAE4*=
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M.P]F+C<04EQN/A$N(::_&DB8\3+.)(EX4Q8VT;2U*Q%;>=EE$U&+EKH25V7
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M/$ECPXUEOPP2@*LU\Q+'J!9NM*\Z-G?-,UNTW+>M=<S,FQL,JS*L;122 9)
M[98[&[95O8*UNM+5=I\T"="FW=-IA?-LG&X>)%P6T,5)-SLRL!PU:VBZZ9;=
M?2MNM3EZ4; ^IK134:C82XB3;.&,(?!X;:#2$O(,.J QN(KJI+@67,O4=*5N
M491<HRS2$N6*I/=E&,FSY-I8-7&$DPKP8EE$K!;YT0$%AT( !O\ "DJA.2WH
MRR%0K0G+=G%J0-6/"3S#@XM&7V_IHT#H;=,VEUH<E-*[06U/[\#R8>9/KAM7
M*B$"3B74L%6VAT4VK6\KV-RC*.J"J:2.[H<P:%AR!,IS$Y2DJFQS ^1(I:BW
MIF(WHK5I&(!E<%3(G$?/GMD"C(JM'>^CDR"Q[UIIK5,W=<&F"$?,R6"-_#A<
MJM])>XY#W)-:;L;,S0*J<,JP.;/&J\TH):',KLWLB_K6E*[LEF*:2S=[ 1G6
M.-)#'<-')G46:[F^EUMIZ4H2=L+GD<,4#Q*Y!O81MR,0<O8+E OYUIY&]UAK
M%9[R%,BHV0,@S*KO(R(!;N50^ZMFCJ&)%LC,V8%<POVO<VZ64UAAWE#+-)E8
MJ  1EYAG()-[>R,T8Z]:PPRQ*S<-NB*!F1N=LX'#L&_TWK6&&0%S(4 !!< Y
MB1&%!"H5RFX8.?=6&'$PC)61#R!KVOF)# %.4=1G[>588%&*0EA&N5,S#*>)
MP]3H W9+GSK:3>A@5I$7E-P^=983=4R6 5Y7S>8L5U/4T;19FA1X2%,AU2SR
M,H.70(EQ=6ZVT%K=:#*3>FALZ8TY,^4YBK9"%2W+]&,W:X(<ZUI)O):B9>B(
MC:,AE9AF6$<*+B,Q-D)79TS-D;0NQG?,.QOZTX622$":Q9"L0,H)  D6(#(L
M""9@%  4.T/NL32D[.[T,"YL051DPJ<P#QHUN&V6&/:4 5="6+2PP_@4K=;S
M6AH&X'BMF:. +"7F9F+9@I$TK: W&4Q.MK>=:D\DN*,%7@HB4@3(I:4QF^8+
ME>-%B$:H-!RXUV)\Q2!:TMQ%)! 9IV8EU>5[ E@X19!Q"S'4ALTWPK#:#@1*
MT@6.++'Q(5XF@1$65%9;^U8Y3[Z!+TF*!>&#29I&R*4$8*)H;.EQ=O-R"?2]
M:,!49UY$4J0 T;-8$]@AUL;#VN]88#>("6!C14!15>^A#*+ VZ&U[UAAPLD:
MJ49,P;*4##KF17)L>AN;V[]:PPZ !KL2K&)N4!<K&_4^\>588=,00MU)L6R%
M$ZD *H-_XNM88(?>C&C X.1LP1G65%4Z7<IG5B.PTZT2$=ZW(1)M/LL:X_'/
M?^/8V&VGM?YR)#@8C^;87%XL=BI)U3"JJG1BCXGK_>^E3^!P^_965V0=:M'.
M*U-<FS5EQ>.Q.T9\\^+VKC7QN(F9EEE'&)<302Z$I&Q*Y/J@:5-U.KIQW8Z+
MQXD94J7:2X#F8:)1@UC!S++&RQ'(I#8@!ESI*+.+/*+I?UIG="-Y)>=Q9*?P
M=W1DF,>-GCB$C")L,A5QQF=%:1@ANMWS*3]87TJ-Q<TVX)O(?X>#R=LB=>[N
M"?#8:,-'"JQJ! D=RR&-UF",SW,BG(0#UJ,FUHB7H+._"PN,.@C=HU59&94C
M4.6'*D0B((/*\H.4YNU_2ACH#XE1:1D!<YU*-DU!4YW!)&K ?;6& &57C#&1
M4SE3E# &Y$>*= 3<@ \-+^[TI+$L(L4Y>596R2F1Y<J !2^8SLMR?8X:_J^&
MXM)W>@.HG*-EK<1F)@DE</&1PLKR1RN;,UQ'B"K+US(^'8 GK14TU= ^KM'/
MTCA\-*0L+,L<B@EF<DMQUEF5XXWU!'"91E\JP0TXO,SX'Z5F5 S,Z*T*,.&P
M=R!(#V%LYK9IZ"P@BEC1\A,DG!^CXGM &!"1Y#++$2*U/5=QNGZ8H\)AUA"@
MR W0-(H&5BKM*C %N8VL.E(N.0X$2,BA"/HPB(HMF5C"P#,-2V8N+GL!6&+4
MP2VC4"0*.+)(I"-T7/F5$8=!8DDCSM6@ADP]BH9E!F:Y$Q&<\MU "CH573UK
M# ="IX.6R(78+=5U6U[/;J"Y.M"J1;:L8@3$KGD8YK\K,64+);0(S= EM?6@
MM.+S-@H)&@5-"^I"KE1#RGE!4 $+YTHP RL,/E1B0O":5"6N5#7RK[E*M6UF
M[<33=A*[2QX#9=%&5G1U&N4ZE6[BY%*<';M,=3<78-5O#M^.-Y70NKM$X5.(
M1&OF;W !<#X6IS3IR2263&\JSD[(CMOIOFB)#&)7C=S(2 [N.7*H$A%P<Q[G
MRIY1I-RS>0SJU8I//08W';?GFMB9]H([QD\?(K/]%F!"68V#1J#TMUI_&DKZ
M9$;*OO<6-_BMH I L,J%7A,C33C.MR@X@*6+$\2]FHZBAJVVPN@:01R.KH9)
M9%C5L^:U\ZRD*QN0L;]?45IQY"E+F"\% +1<<@2QA[JDA6X")E>0+EM)(V:X
M]!YZY)H4#Q$F*G@C7!AY.(.12R1K$$+*\JG17S4AM)-OD+B*@;,^;Q+&SK&6
MEXD_#9) >8!5*6O(2&T'I0D[JZT%V%#@\*V,:6,KPU7*+\)51S?*K1B, \52
M.8$]*3.3BC<8.3R%KL[9,DD^B,"D+%HW"Y SH5$D8U#&0C732U W[-KL#]4_
M8.7L/9:8811<)5?$!]<H8JQD:P! Y39@:0WE=O,<QRB.9L?9(@@",C,ZEI!G
MLN8L,H0/I:UB?A32J[I+M"TVZC:CJA:18;+)P<@:*,!EOEM9HP[#*1>4WCZ]
M:#?F/_ 4.#PBPASE5D8%VO;E?L+6NMCV.M)>;-A\,BJC%@'!0O(18OD20M:V
MH-A]FE;1MZ'=)(Y+@*HD9%DX+%K&S&[JWU1EM?X4HUJ%6*Q$B@D6CC4\-F#W
M_CL'8G3TO27NRR9EKB)VEM%TBDRL$F+E%!*L#RAUDO8A2V<6/D3181BU;B#F
MY)>;J-CMK:0"#%3JIX:.[1!QE^<+RDYM!8'4CN*W",9/+AS&LZDK6XD:-]-N
MS8B..1YI($E1FB2,@<60,>$4.8*JC(RGS#4_H)W\W-D76D[^<R,&V<;-B'Q6
M3$-&B3+$7!92N;Z0LM[DD$V.MCTJ2AZ.A'2DV\M DQ$\).(BADQ6*R*B@968
M1R I]*9"Q5QSL+$<H44M9,Q/F988GD(#8>%W7F14=#+Q$N&D4@<X(!NO:WK6
M-W5C=T=,4')>((8N 7!4KQ!+D02$!!K$42]CV-)L:RL!IT$$A@F5&1)>=A+G
MD?ARM>+/I9!&JZ'J-*V) N->+ X>:=HI8A,R1Q10_1JMS)G;AL2S1G0D="*S
M43.-XV0DS-.)<09(5RF-PC1HN0L8@<X)U+(S$V'>G4;;J:Y +6=GJ%<4\3*D
M>*BD2-1\XG:!2Y3$)'94##0F8@7[5NYI'5(,1,L;\ ,TZ%&1CQ%C,S%8Y^&&
M"(R@V?OFL>U);6AN3NK<0KVG!)AESPXAG240330JJWR$!"<UV) 5^9>HI5/2
M_"X&4E%=H A/#;$L61HQ,ISB6S1A$Y$"'ED5U.H-$2SR!.<GEP#W8NSOG>VL
M)AXTMQ65IE1#9E=B0QN<L+!%N3WZ4B4MR.][A="'65+<%J;._!?=+YG@HPV'
M(89&XQB5)(V0!F4]RP6WVU XNK>6[P+9@Z,=Q??$UMAX2.*"-HT"YU&MPK $
M*"@'7.26N.HJ'J/SF2]."44A42,T<(N3$L2)<,Q+&^:QR="*0E=Y!LM1-;=Q
M62*1C>[!55BY123<?Z70]C1*:NP=1J*N]"-'B!O''A<([<6T\1-\O+?0$(UK
M*USFN.MKFGM"-ZBB0V(JR5W%\R &]VU!MO;TDDL@,<&8($9FS1M(_#A"-?)>
MVOE4S%*$;$/.3D\PGB:.&!E=^%F>,1Q,I5Q(5N$:U[$O;K[ZUG<Q,(MY=K[/
MV9@))S(RRHDL+LZ*+A=0Q*@6RKT(UHD%O/=&]5V;;R1##Q'\2=H;/P>,^:XA
M,3BL3FC5(HPC<%4^@5U)X@C^D =QW(J;HX>,HI96XD7.;D[\ F\)=S8YI(MZ
MMOQ%]K8@RV?$HKO'(;RF]PRJD<>J*1H;&DU9*GYL0L)RE:/!$I<'LV$8GAKB
M+0/E?CH6C>WLE9"I"F[$:=#4?*3;SU'L8\]0\943$1J&8AX2TO$LD2<$1!P"
MALS/8:]\QH8L+,3B(5$KP&-D*,1*KL0[*^4H0+EBB]O2M<3!&$" O%Q&D1I>
M-]-)-<R/-''))"(US) !*-#H!6-W-G2;66-3+&6E&',AD =(;?PZ*D0LD>8V
M>M:@)2; BF(3$\H4RMGGC0J+FX4H" ZA2  #>XK9H$QX7#8MC.BP87#L5)GA
M2266!L0N25XGD9LL"+YWK+@NKEH#<+&G!.%BAGD8&+C2\3Z1I&+ @++F599(
MQ="-+ VK5@IP\<2J^&FC?%1J4$*)'"S9V:+,V(OJ\85#>QMI6TK]X:,4EGJ$
M^/Q*<7&0JB0)AI@A6#(L2"-1&[M!_!R1DL+$:&C1BH]YL#+*\W#CAX,D]T2'
M/9(FCCXTK$%Q[=HO9N*2W=@I.Y@D#YGF4M%(L,LLF%D.>.-S]7,M@KGH!YUH
M2%./>8QR9(TE98$>49QQSPC]->+JZ\,V5OLI1H+8^+*)$B4$2+=(Y6+QPK%!
M&50H^DC&:0YB=!H/J:88%V&.(G"RH]DXLD4CM(2<,LC$9H +MFP[#*3W6G+=
MFHO5FW))VXDW/DU^#K8O%X3>/'+'B49EEPV*G1C$J V:6-901'(C<MA:XU\J
MBL?5W%NP>3)'#4HKSN),#Q!VS%L3 183""..(.8E6%2N4%%96-K#)D(U]:C*
M--3DVV[#VK4W8I<2+^(DDVAM*7BM',& <O;/&CW)5TO=7< =3TIXO-0RS>NH
MO=GX:(0":- QB1)7FE2.^(CD@0E&C71) ;@>M-I.3R0GB",5.LL*.B\HD#Z+
MF(&6UV8G,UA[5^AK$N>I@D]HH7B8J9$4%M0RQNP))6ZK8:@Z7I5FW9:FD(+%
MPLL; %A#-E#NTB)*LF;,C%EL0UNH['2B4XM7OH*0E9)719$4F7AM]( ;2/[:
M@C-JSL9!I?F%_*B/(;U'YP0[2Q395F$7%A8,'<"-$C,48=,X^LK ZD=Z7!66
M8"3R;$]C#+(9(N!F2(H;1BRJLK*0[@V$:>8UTHL-0!LG_)01./E&;[R,ZL!X
M,;Q1CA*JX>QWZ\.Y%,0'DK"_:]ZA>D+^TXK_ %U?X,BP]&OET_HG_A1/_]:Y
M%O4MM\MZ'-LHVQM)NM]1B&%BIZG7X5)P=J4>XJN)^55/78"C86%CREFN%.MR
M+=/.];[>($RJI7,INI!8W;^*/7H0!6V:.5YR#956^6[$BXL;$=M36&K((]HR
MF/.P/(%(*74(67VC<]KBMK-V-C4[>QA9'0V37,+:"PT'-W!;O2DFLV+6G:-Q
MF#YF/-E7/E+,O,?JD6&:WI2Q058J2ZO(RA>90\8-QYYNA)%ZVD[V-=HC]I8F
M35^36,W&FKWM9%-AE"@=??1XI+(0Y6$-BI4<R?2OQ8K'D#,.=N0=+61/:'G]
MQ(JS?('>^9@=XW?A\RQQL%;.I9A<JS,4:XRGS%+S$W068F*-E)8QW=$8JX;K
M$PC  ;* I93WM2UIVB6^6AVR*5R%8]3QE96"K8'FLIT4 =JQ,2 F:)HY90[%
MF-DDYCSB1HU 4J!>$(38=0:VC ')(RD*%M%D$8U D.=LMPHN=&[T>.2[#3Y\
M3H.6-K2&(@-8<RW "J@7,NI<D^\TF2;=S$"L+*^0PJQ:X*92&$P8$W*LN?ER
MZ@D :TATY-Z9!%))9@^-TC15^D 5W"2</D!D6Q9ER@NQ;O;]R&FM3:=\T=@T
ML;L5DX@18Y6E$>9%PSY8CF)!#N);@@:Z7Z5AL'QLN97 6Q7,;.8F>-!RH"-2
M&!OJ-*T\LS YA(O#B#(970,,D9#*3U,<@4G1%[WN:PVN882-(0"55,N5#H2+
MH1'86'L@"WGYUF\M.(JZ,6+$0:XL,BKQ$L\AD !(:(J"H*@DM6^XT]0CQ7&0
MS,A>02,"R!0>74*% URC+;W@T19H$V8T)>+Z5PLO##LV2Q#$7R"VO,.M8TVQ
M2>1F@E)B @%I''-82!(U7/E !Y@SNNNM)MS-Y< ;&1 RJQ682AU3/+)=25NN
M4.S!5%P+:>ZD23>AM QF5XKRJ63,A,:7#%R[J,PTM8CWT/1FTCKCU41?1,C3
MK$RE6&2)5N"%;,ANP'>]J)32;NS4FK6XC:[161\W.3&[NN9BKQ*1JRHJA=3;
M0DWIZE99#9ZA"%FMB(R%5)$ C(;B.BH!S6]HJ2#H+BLYW- C#W0$NBE[1\*8
MW(3(NJHJ\RC6^HZFAR3UX6-@J6,XEN:1%24J8\3*K%8Y,K%6E7E81'*001J;
M&DZF68D=K;,C$C%P"\ZN)!+]&L^'+R"%H NBME(&;]]$ADC4DT(>7#F21HHE
MX!7AE>,[S(>"P2(W.55*,+V-[VHRT&M2^]?@$4@8MBF<+\Y$84/Q$6S\3BYL
MHY6NF9K G5K5F=Q%T%V8I*LS*C%P1Q7;,D;W#91E9G$EE(OT\Z<QEDC<GR#(
MR-BH9,1D *QL\<4LR$+&18",KRMRV-NNOI2TQ">=F#<(LCQ*DDV&,DK1V18P
M'5<@TDD! &8:>E8+L*/9"</%I)D3ER6RM&C+)%*B1@,%8OE5S?6]"J2LK+0-
M334L]+#_ &[D<$)0XJ4"-<+&W"5KB5E1K3/EBN CAO?:F%1^=;D/XY&/;4L1
MDE!,:Y%#+-'&UF3+GL6T)TK2T,EJ)Z..\CV9!*BYRP.5RY;Z1,H5RRY4Z^SI
M6(0='=F,D>>-HUSJ8CSNV9;E0P)LI%NFE^M;O[C04,512RJ6.1C'''*P4E.4
M+>UD:($]>M:5VQ#U"Z"/C"3,)88[,0US(' C5"I"@VC+KT(HS;5K:B0]V;$Q
MEPR<(QWBY'50R#*K9P48@JN:W;4TB3:](5%78Y>P,)>*8QJT+.X1B4"R28?Z
M)RT8))0 L+Z B_E>D)J3N.HJPZ.SX&120F>-V 11KR$6S*[%!D(ZC6@2=M0T
M5[A086+.; BS!E9% C52)>)JUK!"I;2^IM0!Q!9"FPT"MF$4BL;V?*X8Q!+6
MRY@$X9S<QOI2))WWGH+MQX!M$H#-FNX@52+ZFTET#HJYF9;$]!:DFSM(@R<-
MI&C9>$25US&Y)!RW9;*!U_FPP^R\$+]&.;-'G4EW)<YK6N5"LHU)Z5AA\1:,
MA^ZN%!)N74AN@ZK()&/^L]U;, $H70.6"0N0<XM<,;,L:FS$W%*=M307R2V;
M(7X0;,8^:R<-0H8]QGYB+=;7K5F\^ FU]-#!+,0BK%*SR,>&S %@5%F2U_:R
MF_2E133,2S,D+RQO+<'F52_L,78=  &O?S\J5-JUN)M@J,9+1L8UC8*R2#F+
M"&Y!99!F#L&-]>U"-&6-A("T:LYR6*Q@'.+7.5RQ.;+J .O2MWYFT<,9.&0.
M9&C;.LH4R*"QCR!;AE*V)[=*QM>TW=&2,,K@-"8U907+!64",6 OF*ZL1WK3
M:MJ;ND9PSB(F.-R-,SJ  Y$+<BJ19P&\B;UEU<RZ/BLD@,@R,';(M\H4)"%_
M@WOR.O:]M:U=&KHR1(O#XBZW9EC2,D31,>LES8%I/K#J?6LN9?EJ9!F<7D-V
MA^C%D=857,%9AH7:7ADW-K6K3O[#3OQ.N<LDCI LEKQQQD<K6.CL1S 6]*T:
M!"F.*(#G0W9BLA/+<:*K+F(%QH#UK3TYF?4:;ORO'Y-G9ORMO#7$>*_A;LB#
M!_*%\.=E38O9K0@X=-^-W(8FQ.T-T]I"-9"^-DUDP4I#,LI:/1,M2&&J*:="
MJT\O-?)\AK5HJ<'=9<%R[2DH\.)PNT<?LC:&!Q&S-H[+Q.)V5MC X^$QXS9^
MT-GN%Q&#Q>"RQR#%8.1&5LP%QJ:9U%.D]RH[2Y$)4I[DW?A^>0;X*0X+$18E
M0'R29L5F+\3AS#)DB<V949>R@Y::XNFL90E2G[.T;5*3JQW9>EP[R7WAQ%+O
M#N[!%!'")62=A(2TDK21S2!HI"KDE'9;: MWKB.W,(\+M*I3EDKY=IR[;M.6
M#VA.#63=^\#[1CDPV(.'*1P*QEN<K+BB$C9"1$ZH6B1S]GVU'J/F>;HQA!WB
MGVGS3L8P4D$T8XLZ.5:-IXVBCB5'G"_2A2#96ME_2-[T=3$VNQZ!/B%BF7+(
MOS<Q1HRRAS*P5&BSQL+7=I%0Y#:Q/2M72?>%@VM%D$KX< LQD,L@811339.&
MH27$ +$BZ#B81@Q8VR][$:&C5DGV#F%7=RM^?_"(C%82>=$PZ.W"$@$N26,\
M),0]G?.[/=8W U!UI]1J*,KM9$C2J9]H@ML8>*\J(78J[*6Y@%RS'.S-HJ"6
MX + FWUN]3^#K5)62M9CNG.38DMH8 R31M:.2#,,DRRHT>8#E4ZMG.86]]3=
M&LE+=3S)&E6:L(C;>SBD$DB-Q)!F$RAK9#G)9GR\H3*?.K9LNO)/=JY0)C!U
M9*IO<! 2 PE] PRH,.P%VD5DX@+^V8SE/L)<#T[3RM+/@3W> Y(V#1Q/F8A@
MS) #[,GLFQ#VE /?6B<@F\N(Y'AACTP'B!L*5F.$CCQRX9#;/"A5LCF>(V3*
M+]2>U072"G*KLFM#65OJ&N-I[^%G!>E8LC^%$F%Q6X]\(T4<$FR,)PHY697E
MX:L@RB+.LT<JV 2]EMUKQIME..TZB_=LY#B8[N)ESWF1[WDCQ?Y^Q<4<F&PD
M\>*Q#BY*K,@3.D:%<ZH8G%K-8W]::17'@1U2-KW"?#X2&.6-)7&+;$R28A%5
M&1(1',0 1+F$39 "%)!/E0Y.5[6S ,,\7+AECG>-CAUG&61R(OG,1C$;Y(R1
M&FBBY(Z4*G%N66H.6FF1';?2=<1%*SQ2,)N/&[EI B3!T>5)8@ $X88"_0]J
MMFSZ5FI7SY!*64^XC)O2%EC$=SB8G1Y$81'G.;+=\UBK*@TZ7M5[V?DUNY7)
M[")I[VDN\8K:L5SB 59E:</$"AD)7,$N +@78=/U5=<$Y;JW<\BP492RMR&Z
MVG"F5F<K&Q 1^$N9E522  =7S'2XN*M.#DG,L&"FTU'@)&9%,O$<<1F%S%%(
MXRH-"2 "HL@'QJS4VFK(GH--9:(!9<P4JTBQO"Q(S\P9&Y!&SC(9 C"XZL-*
M+<+<"%1B'*D/ V4A9.",I8<J M(5.9R>@OKVK#8!,;*P@5\\BR().(I#?2ZL
M%&H!#=KZ5JYG(V&?)LW;DP^"V=(^'AQ9E@/T+NZJI#9XIC)$&<.&-K6RZ5Q;
MISCZ=7$U:3=HPRN<YZ8XJ4Y2P].ZDDKOGD;2MV]C?,-AXJ293AY,2A.(C8Y%
M=. 9A('.'=BB-E%U8:Z&VMO/N-G*MB)3?!V7L.73NIJ#U&@VAC&PL\[\1Y\2
MS%E5@%2&%5 B(DDRR<24]A<TO>;CVFWR'%W>WV&S8\"B8N3+ H^=0X>182SX
MN,O&C<2(M(Z31*D_=LVFE0N,P<JSE*V9&XK#]9>2U:'(&]<NTXVCA!BB?:.(
MQ+#/H#(C##1MF4RF$0BX*Y0!Y5#2H]4U&7(B)T7#TL\D*B)"\,T6&ACCPY56
M7(TI1)S9&C1W,GT88Z G+3:4TEVC5Q;LWJ*6+9.(A@P?#699$S1'$QZ*SM/#
MB)),394C 'S<*JABQ5M!:@]=%Y/,UN-K)9O\\C-M+8F*PV&PJXG)''C96,@A
MM%G7#(.'&DN*OQ%+\MPP#>ZE0JTYMQ>2_$:=.2TS]@Q7B69H\%B9'D=)C&9#
MAE)#QK'&.540N,@"W:Q(;MZ3^R([]=1X7'VSU]E2LK7L:3/'3>:67;.TXT*,
M>+B+!;&,S,SQ3!E+"ZPB,D#KVKU3T(P*C1A?L=CO71;!7C"7)+W$3+K,5E S
MRLKB0,"L5@X*O;IS*- *[-:V7(Z#8'X2>%"Q!"H(X%,A12K%%#+Q#(05=3:P
M-C;TI29F7L#3#)QWF896)$LS.5?Z9DE8ME '*'4W&G0ULR^5UH#8Q&P!C+F<
M'/"5:]W>(WARG7A0K&;WZ?$7PUG[ 6G#5XXW<-B5@56<@LWTFJ\&\3!%"6/7
M4FL-/2_ %HW$4QR*2^<2HKHI Q T?B =([CN *3J"DI.60+@2/$0R\6%4R9W
MCNY56RLZOD5;@(9%;+<ZD>>E9:YK<9P$<&,&,NJL%83JH( &=3'J,UU.EZT9
MNRY!Y"I /(HC<2)$UR"D())+ _W['^;6M]X9@W9N'NQ9Q&B \11(K\-I(OHP
M%>.YN^4$D@"_>MIF,5^%PLG#$H.<F1X%<,HX<31J\F1P&DS<4@<P UHD+WOP
M!N<>8K8(HB6FUN;M.@*K*7+<H&H):1M3;O1)2:TXFD[YBKA?#?-BPPT!D@7*
ML1?*8V4@LTW=F .O6A=YLPX@XG$F5>!!))'$\D<4<S!YHI%)CDB;A.J+=SH2
M#ITK#9B>-3(U[(8TS7D>0AFF<NS1\.(]+VY@+6K<6DQNS#(YF62,Y7#+(7.6
M6(X8AH>&\9#1J\F6+46[BC)IZ:&'3$0JTCJ,[K&_&=FC56EXNH$2E]#>VATY
M?779@',328>0I(H,31*N<M&@;BYW+J#=\Y#,-"=;5HSB!LK8E,'$L32G#J&*
M=W:[ L.*@8)E5;#I]])>0EMIY'94S\8L?X*%FF1E4Q)?JN0!<\V8Z6!T[UK@
M:WF8,4C(8R(7DD7DBLRR1(0\B-$ZJ6#)R&WD36\]1:O;,QN4XHE,,EY1P^&L
M +1-DRB-6S*@CC89KV)U^S:E*.@K1 /@-"L8:/B-$JO)DD485US.)972P9B\
M;92IUN:-3;:=S:^H*SA&Q+!Y)U2*17>2-#D6"7.",D8OQ0QD 5A?+W\Z(F9?
MAQ.\F">5$/$RRX5F*.,L*J5C,@SEBH;.1ES=#?K6=IL+8<-PW5U+I9!$"0^4
M<&\<BWMD+9DS7)R\U8:;MJ \1AGDCG*($P\DR()EZRM[<BYEY$6Y&;IS5AB:
M>@#;#B*4/GC#I%'(LL<@"X>2 MD8'21Y!,UM+_MR]E>/I&^!*KP<\4)))XH<
M1C0<9@HD^@=,XQD;B-9Y/8),A4@D&QIYAYQ<?.?G#:M3<LXK(V?>&>_$LN&V
M<96DQ"<.3$17#QR)/$I0EC<AL.8W(MITIY4H*HDX:D99=8V]4R=&YFW\3@(]
MG[3C?@8F"96@Q"WR"$+A))(5=,RN/I%]WVTRE1E"6>@]I8F<6G%Z&U?Y/7C,
MVU\'L_ [1E1,<L<4<Y+*");Z2*4S,X;13V%-:]-:\2S8>HL51O\ =)&RW=#;
MQG@PY))N% 1 +%CYR7*D#L3YTQ<;9\!NUP'^V!M3-PD8R=19LP B*ZZF]F#W
MMIY4RK6O>.@ZPZ8XL<@:/B @\3J ';+ZDH#87]::S>;N3\?11T?0!&%@6L6%
MLI!U-S)E%QVMYTFYL[KD4*3]8$-]<7'LBT=P"!6:YF&4#*RM=+6N1W-U.8$=
MK>OE299Q[0BRB@OG1"&#!2<W*]C<(>90IM<$$F]*0, M$>*O(<BB_FW4 $D7
M!%88&,&')DSA3>/F-R4"K;H+CFZUE\NTP-HCF 8C/JO1>A]@#S.NG2MW%PU]
M@)GB,T1</&0G2,W !LZ\WH+&LNF]WB$R>0U>\^&48:9 ZW((4APTAS^U?L0O
M:BP3M[1K-9Y$9=[H)%8L@S1Y!&Z@ MQ+*;W[=#<]J>+A[!A).PQ&TE Q$PG*
M1KG;+=%87'13HV8M<V(%CVHZT&[=V)XPQPQGD(%G=A+)RB[W'!BX8O<#L?V4
MJPF3:5T*38TRI=0Q*.\I6&4%%;2P*@@,2"P[=Z&T]Z_ 7"7N'4W?D>7%PR<-
MI1&,@$3%LI+CAYAYN=!?6LD_-#2EP)9;&S1;,6XX:O"O6ROF S6%],V8?94;
M5:W_ &DI12C!<F-;OA.8\1-&\JV9E5BRYB@RW/8@D&GM).R? C:SO4=A/;O8
M;YQC0#?7FC,BVYKVL#H0@6Y\J))JUN()+,D[L#!M!AH97=;HN<6',Z@921'[
M9L&OTZ5'U6G*R>9+0I-0OV"UAE69 (Y$(0D7!S*S&UBQ6^6Y.E]":0TUKD@L
M'&R5U=@EYE4,W$RHA0EEM8!4+-<7N-016KIMI:H4_-UT DF+69%X$B',#=E;
MV<UK'EN WH>E8W;-F7$1MR5E5U4,YDSJO,M@[$&PU(8^G84K=N^&0&;28G8<
M&V,FN4+A)0P8$-II?EO<VM1+QC&R>8)>=.R%O@\*D0)R74L0@)X>9;<PM8D@
MCW4"3EJ.(Q:8J\)#$,/F?+96S",.<S%AJHO87#>9&E!;N[AXJR[0LVEC%5#$
MI'% ;+?4QI;V!]5C[C2E!@YRX_<H;K%223RO("RN^9W*BX!C%U#JVN0@:Y1T
MIS'=BG>V@WEYSRT%1L;9RK"9I@ 20U@<I#D75KO8%".U E-L+!6C8,<?BPC%
M5)1<B1W&5@?XQ)7I9@.M:2>IE[//424C//("F7ADLMF +,S: CN#?I18R:U0
M-MN78*_96'^;X96996!9RUM#H+&U[=QUH,GF$C=JP-:RAB7RLH8@L2732X R
M7N:RS9@7S8M8278K?0%I"I9O=<JW3O:L2;TT,;MF)M<6<7(7TX9D)U9<Q',"
MK$LAL4-$<-Q"=]RS>8?8?!0D/BE2.23AD*S(!ECRD$BP+-KYUJ4W]RQ5HI[R
M2N%;['V=-BQ++&K-+&$;5E1?[[(@O1.LJ0C:+N#GAZ<Y]8]>043;&EP6&Q$N
M%QDXQ2R$I$Q'S?(#(O"6Y#J90+7Z:]:)UL/O,@<J$X9PE)M+F%TQVCA(\/B-
MIX##XU#!<187Z67YT^BF2,Y?8O:]S6IJ-_L4MU>T1&=5*]6*:.F,P>&ADBA<
MR[+GE>*8++(64E,^5!FT+/E6XZTN+J1=LIF6A'S8WBV#L%L7%EXXDF@E$;$F
MTVL9!,0C8G3,Y4Z4*<E)66H?<=[70-VY&-W]GOM+;#Q082)LO%#=.:(V:$Z/
MRJ?9)M2*$)3J*$5YQNNU3I[\\HC?83>#9NT%,N"Q<,R7:5"DJ9#GBPKK&5)S
M D,=#:U.7A[/=>H!5HR5XM.XIMGR":!#8\P,C!M$RYU'#*C5=">MKT&I'==N
M(5.X:V;(S&-U0YFTY(SE>9QHQ'/D<&](-F-&X7LEF!#79N51[*IJUA?E-88=
M8RP+!9,Y<NQ #:E29(P6( &=6(OTTK# <%<1))F"D2 920.V9A8V)(;TK# ,
M[NO"*-JX#D-9A91(S'EN!8KYUAAT27(-696)()*\JA!E  .K $'I?I6&!?BY
M<H4*F;.C%F8AL\G1663V?:/2]Q2Z?%FF=MGQRB2S7-Y"K(W\(;&103TNO#C)
MT]U*G);K7$3N7%2(7C54RJC*B&RQM:Y52X.895*GKY4%9Z"[65A-;5E"<>QR
ML(&#<)@Q(59IVD(%P6M">G\Y(+SNX0VFAO<;(TV+E,B$*CS!BVJ\.-=H*L9"
MW^ED+J3Y%;480VDKO03T[,\LI0%4G#PNW&YRC)) !P^P^GTMKI2MV35T9=/,
M!P2KQ4,L A ,>*=@]KA&V=B5C1@2QS_/G!T%['X%T69@9[.#M+&B,Z1S"//&
M1RHBPB,NK-8G6$'S-Z"W=W-C@;+BN2Q):-C&]U R\1[RFS=4*I!K[J0Y):FU
MEF]!60QF-&8M'<#-&L:$%E4K&I! ).81GJ+FWNK-5<4G<S,$5TY&8YT2-<["
MS.K%1(IL2Q<C6WQH,O28H[JP3Z,9D+2:Y"I"\.*10KB]V&8C[:T8&\319V+$
M.4 Z J#9;7U  U/2L,.(P2QR:%0Y*,I95(4!0+7S%C?II6&&,!FN"&1LW(S!
MBRL .;*!FRY0+>0K##YU&=6S&RL"P890018GLQ%[Z=16&&&:0/(T8"74Z'.@
M'I8E@2=*PS17>@Q'BOMT;.P<YXJ<5%3AQ*<V:2 \=D#:\TRKD[ZZ>]UAH2=1
M#;$5MR'L-.'CMO/_ $P[PP;N8:1S@]BB6;'X;1)!MD99((%:]Q%A8HLS$\I+
M:=1>X82EU=/?XVR*O4DY3NQ [#@3!().#SB+)%%S%A"4L5D#69;-<"P%)KRB
M\D!5]6.QN;L,[<QN"PV1HH<-(F*9#9POL.RA5O<-#"W;M3.I/<B.L-3ZR=GH
M;%/#S=I<#AXT41)=84C+YS+$Z0Q$B-5!"A8DRWZ&WK4/6FY2<N)-4Z;3LEDA
M^\'A6P# E&9!'G5'((&2*11<FQ7.7Z'SIH/$K3;X6!N&B*JQ9?;8OG4DO'>2
M-BJWT!"L#6&V[&6>)5978$L%0LG*R$I]%;*IL2;7.O6M75]WB8FGH$N-5K2
M"-0H%U"Y"<Z0DG*223EE<?#[<9C7'@)[:&'#QK'$.G#D61"0R9@8SIHV4D&_
MG21 2'!G"X<J0TBV14B4W(?Z599>+["K9ARZ&BQDE',2Y13S,<EWEC$K?220
MR%@(SFF+<*=-2H5)#$USWL*6FGH!J--Y&3 P-<FS*JQ-$H4%<F4DA0[6.;-&
MVIZVK!&N0K(L.Q"%!&UD$21R,X)E<SA"Y%LI(==3I]](E)-I()"$E*[0I8OI
M(4:0!G&JQBP< $$(IZLEFOK2')1;N&!+1Y(Y#')9W7,NC!E-RO#(ZDV7UM6T
MT]#8&4B8KG#B)0KJ%L0'8E2,U[$EE-[5@M!E'$4=3'9C;-9Q;(IU^K=;&W6]
M8;/GQ+-(T8(N2@"JH%R+W(.A*UIFUH#,.K<,1D% 7:20G0D]K$VN2.P- FFV
MK<C#C$S<.PC2S)=KM<$*1U]!IWK2Y,P1^UMI+'$Q+'C9<B=P1<VL1=0IN>M%
MC3OZ0ERLKK@-!MO>J./-#(ZK*!<E7)RJMU"AE.4EB>E.E3XC.I4<M2/F]>^4
M3X@X=<0$DSHBZB4*ZEBX8*20I##6UJ=4J38RG6@L]2/&W=YFQ&,DFFDA3B9X
M&(?BB-(W8!D4$JDCN>AUT%2,*:7<1E2M=M"16?CPS0,YB$LK*'ERO).>\PX=
MP%?,.6X.G:C [@+$Q.T^'P\,*<;#PB#$J9.'')!8DB-""6E.E]*PV8<.A^CB
M$BY8\\DJ.$++S:)G=D<FR=1?V?=6&"KAPF(7#F20*%&:SR(I232,AHY+-D)1
MK:^5"U""DP.%6)HY&5S', P<M?15S9 4R9VR@Z7;W4*I)6MQ"13% N%^<9Y)
M"%B>42QQ1C^$YHUCXCV!!L=!<FY.E-^&02,=YV%ULK8K8/ K*8LP7$R))'&7
M;1N99')(RD$]-3Z4B;8]I4U%9ZB^V-LQ(\W$XB.Q@$9-GC18VXK@$+G+,HRV
MN18GUL+-#ATT.?L;9Q"JQY2R+.Q9=$9PS+$";:HA4Z?QO2ARFN(N%%25WH+/
M"PH\0;A,S1E<Q!=2Z,RH!TN"':_NIN\W<+&FH.ZU%)AE#F(9;R%)4+@L8Y%'
M*')M8*FH/>])DN09/GJ'B0N0 55Y%.L>4K$\;,Y4,=#ELMQWO2;,5?WG'SCE
M9E#,-&",H#6O&K)&#;2TP.NOWVWFC5TS#),F1W4MGB#AT(LZJC9,@L+M=CH!
M>]:DVE=Z&KI"7VWM##H&CBEC,Y,2HBYP@)S*\4BL#J V;SN*TX.5D8ZD8WOK
M8:K:NTEB$RS%HX^(PCD=K,> <RZ:D(T)4CIY=:>JFE#+48U:[6?W(PN\^]"L
MN(8S!(52<L;<15:(YFE*WL1*IL>XH]&DI:HCYUY-YD=-O8L[1XRQXI7X601Q
M2.J8>"8"::.2(.P;B,8RHZCFJ0ITXK,85:C=[#8[1Q"E7ZB+E0\4J&E=7S,8
MU%P6-_>*. C>WG:@&&.468PI#&$EF216<$HV1'$K+>]XY=/4^AK-38-'%)CB
MSJS&1KJA<,R)-B4M#($ S1 \QO8W%88<!HX7E$SH%3-"\B*\WT+M$I#$%09)
M(V*WOWK&8%S8F&1@B8=A+/%GC<1D  R1$1/(TN6.>0*VC$$KKZUA@5;1Q<C'
M#QRQK(TRR'*&#"%D*JV<7SGAH3T-CZUM)O0T$V-,' 7$QX?C*9I87X1=[/+&
M0LIA7Z2.,+<DD@"UO0N(Y12>H&:=V^ 6122C!KB,.B212JR3A('#02)8([9V
M-PT;=E-8V#ND%>)Q0DPUC)G5^#AF O&> LDJ9XLHB/%A,G)<@DWN#:LC'>=^
M B4EF^ 58N\D4C3DLSLV'5@W#9H8TP\ B0((XVX<@&=N:Y-&5K,!.2D[KD!"
MADB$9AA(>*-9,K)K)"UN'8Y;.P'?2M"!\?"/8S;6VPHFPLF?/%PQT$1C9F4J
M%S%URR(6O86)'70-L1/<IV>I)[.IJ4FV;8-QMAQ8/#X2-0I&1'D9Y#Q)#E 0
MVOEX@;K>UUJNXB=YW3\U%LI4W&R2R'_P<:QX81J%M&#(A8C65EM)8@DC,!IZ
MTPF[RN/8K@"-H8@0 LK9I4=18*2+A=%.;K[7NI/#/0W>Z:6J&?WMVZ,/A\1G
M(3AF26Z7LQ()9&+<H M3K#TO-<GJT KU%NYVR('^*>]N)Q.).#P[OE,C%Y4
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M(P6/(YYEY@8<IR J==2,W>L-"'QDIAR(J8@I,;A93[2@7 #>PA7I8_"B0])
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M1M+"WN2000(R/]*/2M2]$VI)NRU%;L_#?.)E=7=<K1N%/M\&)VQ*LW1;S+B
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MI4DVHZD;?*[U%[%@H"L491@(_P"MR%<*99(R"7!'U0!J=!36^8G4S31X=%+
M%(Y<Q8%6+)('X8*L=#F4B_O^S9L26T,1)%%&T;-R@B<D,$1)'8JPM8MHMK>M
M9<TA&8C$G$AFGFE$@4QF,KEB2:V:&10.@1!E(\Z)!9WX 'J(Z6:>622>54$<
M:<(!F(E5@+YKBX N>F6BI\3052N@>2-Y0K1#C,T:\15NJEFDSZ#."- 2!U]
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MS')%*%3.J$:RL7(Y5)&@OTM:M/M-> /4*3*BI(K2X<NDD+%LLB,!"I6Q"7+
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M-\LV,A>&T\(][*[T;MK9?G^67P_2NON*&(IPG+@T[9\"5.X/B]L'?_8V,VE
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M$L^((41D@C*&+6N+#IG%O;-OA6>T%O,PA@(Y5+1@R6R.MG*7^K[]*T9=@E0
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MKK(P85LV=+H2IC2P);-W7FC,C,22+L\B9O\ 76[5AASB#)PN'&@(/T1C0+T
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M1U[4.3RR#4H*63X"[P^'CN2T2W'$,9,*WR+ERL!U-T+>\TVNVQ\DD@QP6"8
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MH7C>3-'F*%F7AL)U&=>(8@C  DA=;_N39I._(T/EX1X8-M%@Q4YY(R"ZN-&
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M@4MT"DY$.<<O-(+ WZD#J0"I9J_ 2Z;@[2UOR]OY\@65%@_$"B11;N5?H1S
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MG=@-#8JK:9B0,Q4Z7O6&"?VMBX8X\Z QY%<Y@Y%PH+.Q'LZ6-8O27>#DW>W
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M 4M]$ZLHLU\MV %PA]:7"XB8F)))I;F6P<:71K@7="2JZJ00"23K1=!NPLD
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M##YI&5VGUM(RG*%8 %&1]"=,MUK##M)(7=&SA5)M$ZC-ED8W.G4K:^GK69&
MN.2%G5RQ3+%83%;!0&%N4Z9[]:T893(LJJO#1;(S&S9R9'LZY-+*LA))]166
M-6,<;AR  ADX920$$JJO_'%AH#6GD8G<RHZY4XKL1&JN![5F*V"VTL&)M6.[
M66IO5&-\78EA=F-D*E1]&C7&370 L 12DLC5CC#1K(\?$?,P;/(%8@LP-T"V
ML-+5N62,8.XC92#'&>%(K7.9&L4(-];.<QM0VLK"3I++*KR$1LK$@!4R@ZIR
MZ]=36E&)JQB5S)&T)FLTC74%%96-_KN]@C*;>ZLW59F[*UB+WRO/DG>&?RTO
M!?;W@_XFX*#/BH)\?N9O3#&K;2W+WICB)V=MG9&(89\.$F"\47L\5U:]'HXA
M4GN2LZ#5FN*[1KBJ#K1WH.TDBC!OQX7^)?R/?E$[7\(?%C9IV;O)NUM".#"X
MZ&$Q[%WIV )Y1L7>783M:+$X':B+F)76"=G5]*KG2K9*Q6 E!_<W<+<>/_"5
MW:^!_3# R5O.2;[K+\9+/>'9^ WEW:V=MS9N,%\1$L.*1T$C8&86X95OX(M&
MA)<:UP_=M5=&V2>O<<HMU565*?!V(\O!&NTY,(,45GSXE1+)(3&(<+QB&BE6
MP5YR,UCJ@/+3AP\U606T; 9FF:1,"93,50B8\=;W7$SZ)* ;$>NGG2=V3$NW
MI,Z21<Q2-?G"X9T<B2XS93EFD=5-XEUMG;E;M0VK"=<N(0XZ(JW".)C>.8QF
M)%=U5)65X\@$@S#.%T]114V^&IL1T^ BQ#ROQ.:1H)"51T:1%>17CXNJ'(X%
M[5(0KN"BN%AU3J."L]!O]I1B-3'/AW9UF>-8B2!*",QSD@$6&O6I[#SC*490
M:<26H2S3AH(_&8$F?@RD1\6<YF9RWT3,9 P(^LWLC^\%36%Q$7).SL2U"O:2
MMJ)/:Z!95D"/+(C/&R\1DBF538*NFD<:=35JPU;K*6[?,GZ,MY6"5XB[V=SA
M^$[ND1X>95)<,JR]RL<:D^A%.NL2T3L'4FLR87R8,=+#B/F&'+J1(R_\+#YY
M"ZEI/XTB]*Y/Y1J<7!UK7<XK+V%5Z448RI]=K)(V)[<CAQ.#PT\D9"RX%5<Q
MRYYVF+_-<AL>%F3#:#IS"N#4[)V>MSG23;>>8C\-BL.S0QM(S?-%BQ,D,6'_
M *Y25<,%BS"PXIQ3L2PUTI<DC35@QA3YQ@%^;Q2\.3B2S<=.$4LLC,KAB<DP
M,AYO*@3],UNJ^8UF]FR\L:RMB'@C>>9(R$1HXL,B\5F.3-9R.5_*IK9TY.5D
M@]--Y/)7(];=PLJ8F:%,BQXB60Q"4VQ"K;E) 8A5*]*N.%G%6C9W'5*2]J&=
MV[#''B'D20LF=!*ZW"C+<,0>I]D^^K7@I-I;I,X=MJW'@-AM:!;LTK,SM)QT
M4 "62Z( CVMRFUJL6%?FV9,X>2RL(?:AEAQ31QN0H3,8)64H^8YF-QKF0'I4
M]@IN2M'W$_AVG%;N;[!(8Z!GDGD6,L@DD:7Z-BNI)SV!!+I86%B*LM%_8TN2
M)JE*\16>&^P&V[O!ASP%D@5HXD?V,X8%6#]3[1^%0W2#'+";/E*#76-9=H'&
M8FGAJ3E+7=-YOR</#2&-<)')LV&V&=/X$M'FAC@$C( ?X5T1,S$>1KRCTHVK
M7K5I*^<FSC^U\7+$SE*]DW_P$F=_\7%#$\48BSX$M#AI)2Z1/PX+H#F-S;,0
M21WJETDHU2*C=TG*7$BUMW$QOFBO-)BC#/-PG<I!%G1L.H$YY6X4S@!0>]2-
M)9W62(VI)/3)'7=:-AM&,.D8@3B8=XU?G%\3PTE(TNDC#0T''-.C)I@)RO3=
M];$M=@QP/A?FZ19T8&%%SLI3%H[(7 4D.R3.H3LS-:J-7D]Z_:1<DO:A0KLZ
M$E,7C8)#$\H'#@<*C8B1](G.A7*UZ!OO@)W5HM0[PH2 XS.8\/*Y$(F5EDGB
MB'T4ZAH[GAS0'2W<4)R=]-1+CRT$MMC;@V1'(,0L>*2:6%YI8PP9?F:/&!$[
M6:-3&9+K;F++1Z5*59J*=D:W<F^2(0>.OB$\>S,7B)9725XI7@S 02JY9A!:
M)N;AF*UKC6NE]%-DRJ8F$.<D26Q\%+$8I2:OG]1IA\0-X,7M_&X@RL41<5/+
M(9" ]@6NHMJ5S+I[Z]>]&-F4\%22BL[+,[OL7#JA!1X60SY=U"F15'SBTK!+
MC*IE;4NW1>5;BW4U<+6R+(K<- PC4NI* $('8"UD,=M7:UNE;L*R1DDB)$82
M(L04O$K\SEB 'DC^J@N /.L- S#LR3%E"HF0 &)E(S'K&!*-3?IEK=LNPQWL
M&0C$Z-(QFB8R\V1!>58XU92&_P!#*L=1W K5["=.T'(+LF(25QE101D:/,UV
MXL?35<RAC[ZQM7S,S6@)B$:'B71R#>0!KD,#946]K\30"LOQX&)6T#&%!&I>
M7,97).1B Z(P;D-KJ&252MO[VM]QL'X22)V81X<-/)"57/.D9$:)]8MH[!A:
MPM6+(P4F!(CPZ.Q<K_HSEY!$LK.Q&;N)$ORCN?NQ:C9W>7$46'124,LA6%7%
MR]U8*W,TAM9A.XYB#YTI\^ E*V3U#V/,)'@2<.LR&=./*BL(5T57-KJ[ ="=
M 10.-^!FZ^0(>584C$:-%-IG4%2%SV590YZR.P*@?Q12)+.YB3N#XL5&1<L\
M@M+>)7CD,E[ Y0EB2EM=*2)DK73U!\&(0HF'"F12RN($#@2J_P!$J'3ED7,2
M#Y5H'X':*>&&.) $C=TG#&4+*JJP'*Y*7,N:XO?4BM9F] R08>/@33/PV=D.
M%3*&,[3<JK'8E;LJDV-K 42#9E@:RR8EXT6%Y(QH65E6.,@"2(V8#D>-U-^F
MM&4K]X2*LLS,\/#@C4EFQ#LZL@9%R2#/E!(TNU]-*7?*PH"B-5AP5YHW,BF-
MT /$%BYE2[  E"!<WK:5^\3*3CPR,T433 LT8CCX4JKP@ S:>VY#6#+6]SM$
M.;X 4Y\T:RL\@98XH<T A9E&126E&4NA9&L3WO6U!&G)LSN(;O+G:#YO.Q8J
MA,;(ZBS*Q%_*E[J6AK-@!HIT?%?UN&$EED<.P&5_X*8YM% 5NW6]:,,$^'BF
M$4$1:/YI-PL9B'=M2MUC:-.DS!UL5\@#WK:U]IFFH6R13QP1X69T#K.\\94*
MDKM&>*V9@+2JP'LGI3J]]&;,&(%U1IVX(B>[%8[/,D@DD+2O_HD,2R@,@YM=
M*)!I7N8 N BHUP\@?.J\!<Q*! D)DA<7X=CF'1E&G6B>)JX!& EC:!8V8,MH
MX&CC80M'(,N)(D>[1DPS'KU:UJ4*"R?#,(W#&5960NI"R29F#(JACT *!0?4
M&L78*B];&%Y(&PYP\\9GC1&*QM=$,LD<JH!*H!"<1AUZFMA%*W8PDQ?&A8(\
MB"6&)95.7F*F1[*LK:NJ:#3SK+\A2:EJQX?#W?&1Y,/AMH.<\;ATE$H5W@A/
M-'&I%C(& L+T]PM7>O"6667>,<30OYT381X9[=?$#"XME?%2?-9,/#E)>1YL
M5SHBH&RE462QZ68&G4HW35LT,I247:V9L!\*,?)AL?@<9&Y@G@Q8DDY6C>-\
M-)>.6*0GE +G-?2U,904[\QQ0Q57#5HU:;S7 WB> ?C)!M/"Q[/Q>):/:6'R
MX4)),K38BR(_%!N$*N2 !UUJ&KX:[;X'1*&*IXNC&::W^)LWW0WAAQF#PDD>
M(0\96:%ERDL20][@Z@K(*CY02CNA9[L79L>S9NTC*RJTF94=5.50!J-=>X7K
MY4'=48Y#>5X34GZ(M8Y5>%\C*60*>;59$;S/4@&U-=-=1TG=71WEEL02J=%+
M9AT%K67J I-[&L% 0XA<W(0C$'3-<,!K:VGU@*PPY7':]KA<K(FH.:UV]ZFL
M,.XQ<;+H+"Y6U[69=3?TO6&)[KN%N+VM'"5SNN<BRJNI+ V5;CK<7T]*VDY9
M(QU;JPV&\.*EQI+V"20R.0V?+F5O,:<H%.H)0=AG4DVW$:K'+&L[CAF)AG(D
M#W)^B>5+KKR\0&_J11;Y#4:K>]8B&Q,C%E?-";I;GE *.&&M@RFG5+1=QNIG
M378,4TEI\0LH:(O*(RV5@"%UB*WN+LUKT^AZ)'O4$'$JJ.).'&PC:\H]AE0&
MSZVU)'W5DU=&$C/ ^$OB,TT#2/!$)5G55,;!QHI()N0#II3#&-+5C[ 1WJC2
MS)+[=90C*(@.50O4ZL QT]*844[]A(8S))+0927-B,=+ >28M$JL'!RMF)!O
M]>Z:^@-.[NR(YOWCT1XI]F;I8[$E'5DPS@,MP6:./V1;^-J3Z4)4^NQ,*=^(
M[J57A=FU:T;Y09"W%[U;V>). ?<K9VR<5A\(N)#XW%HIR3Q&<J4+'SO<U?%L
MS![)W=HXJ<95FO-BGH[<C@DND^VND].?1S T&L-&J]^=M5?^0(?$'8GB-X5[
M^[)VEN!LC$RXF3=38^%0X3#EEQ,L8,4^#+D<*X%R+ZFG&QJFQ=I;/JX?:T]U
M*K*2?'A:WXQITOPW2OHEM_"XSHM3E*,\)"$DHMIO.Z?:2L\)/#_?;>#&X7?;
MQ1FDEVFL/$V?L9E5</LP3,A9YE0Y9,0"Y%NUK]JJNU]H8##IX+8Z^PYIR>K[
MO$Z7T1Z.;?Q^(CM_I=/>QK5XTEZ,%:RR^^#WQ#V3C=\=YMG;NJK?FO#8J+$8
MYBDC\<1.&$)/LQQN% ]*Y;M'9=?:.U:>^W\$HY]DF6[:M.KM''4\ LL+#-\L
MN ^N%PB8+ G#+$JJL(4&X A5!)PTTT"JK#F[Y;59MW))6LK*W8OSN6"G&,4J
M<,H*-B+GBQLW:&'QN*Q>SR@QT)@VGAGD!DAA.' (9%]IRP'2O+OE9PU?8?22
M.U<'?K':67&V95MJT7UJJ1]-.ZMV9H:W8GS[QJ\0]DX3;SC'[$W-CP6WMJ/&
MPB@Q.TY'"87"LINC##R+F*GH!4QY/,1B^F6U)[;V@G*AAX)13Y\;=PPI1J=)
M-ITZ>(\ZE0\Z:6CG]Q?LB]1=8S9?]43QFV?LM8Y9]W]T</A=H;50(R0R8_AM
M%L["9T^C+)9Y""/88'O5OV7A/T_Z:UMJM[VS\)3ZN*6:WU^/,>XJ+VGT@IX=
M*V&H4]^7WKO=)?C7<2#\1\)O4VXNWH-R?FYWD&RWPVR5Q$G!ACG<%1]*++$"
M#8-V-=HV:\/3Q=*>,5\/O+>6N7*Q+[;AM&>Q\1#8UH[0=*2A?3>MYOL*^GB%
MXM_+U\"][L7M7;>!WOW;W5P6+P\#[0Q4;[S[K.^$DQ#8>&:.%,1#'A]JQL,\
M@961F'?IWW#;*\GNW<+'#87JW5=/[Y*I?FED[+71GC#:72#RU="\0\=M2>+C
M1C.UG!3P\DW9+K/.BF\[+>C)IY6>DA?#S\JQM7"-@\!XG^'R;11GGEQ&V]RL
M>!-A52&)X#/L;:A,OSB8DAPC:6 %0&T_))>;GLC$K=M?<J9OV36E^;787#8'
MZ)>\8T>D^STI1=G5HMIV[(2NK<[3_DG3NI\OSY,.].#V?(?$+ [O3[4EBP;[
M-WIV=B=DXO#RRX<R&'%-(C86-3)8<0M[C5"Q?0;I/A9RZS"U)PAJX-/)?7H=
MGV5Y9/)SM2E3<<?"G7J/.%2+A*+X9M.*SXW:'WQ.T/!S";#F\6(X]S?F7YOF
MVLN]V$@V>B&#$#C/BHMJ1HA5<4%U);0FW>H>%#:]3$+9%IRJRGN[DKWO?=LU
MV-._*S+95Q71G#8*723[5C0C2ZQUU&%MU^C:>DMZ+O9:Z97-)F]^"^5+^4KW
MHW\V_P"#V^6%\)?D_P"[NT(=S=V=H;83$.=ZL;L7&"'>7:.R(,!>+%0J7*KB
M);PL00-0:ZS@L9T?\G]&GA<526(VY.._.5D]U.Z4%?):9?G?SACMF=+O+/BJ
MNTL%)T.C5)N-*E4J3IPFDKWJ*">_-OSY_>7C!9H0^V_R5'RF]A8S&ML[>O=+
M?C"XC$P-@,=%M+$[NXO#X7#0008PSX24+"\N/0MPHT;1AF)\IK"^5#H_B*:^
M%4ITI7>L$\N%]UYKGV%;VG^A\Z886?ZUU<+5I1WLU.46U?S7:<;WOJKNR5]!
MO][MQ?E\> &R<'MQL#XP;#@P"XF'9^-W)WFQ&]VSMF[-P=UP6(WGV7#+B<.N
M% 6Y!'..M/\ "X_R?;?E*E.&'=5N]I0ZMROEYLFD^[4KM?87ECZ&=7BYU,?'
M!J*EO1J2J0CNZQO3E-07)325M$;1OR9OREO&_P"4#N;OPGB]!AL>^Y.V]G;!
MP&^\>#CV;B]XYL5LQ\7BL+C-D8=5P>'Q>S(0BR21"S<1,UGC)/)NG_1W9>P-
MHTOTMDU"JF]QYV7!\;=_9?N])>1OIKMSI?LK$+;?V1X><5"MHY;RE>$M$W!6
M>]9.2DD[VN]I,D_/PFME901G.5HR!H;CI<BJ.=C"_$%F6SL PD0F_/?]U:8.
M;3:L PK&Q155FD91:V:[!3(UM-,T@]Q-9%.64<Q"SR#6.!5O8\QRJ9!J1?K<
M:@']%9V+4Q>=IF&$^.PVZ^S=I;Q;1N$P^&<88,1&DSQ"Y+6N- +GM6MQUYQI
M0XZBWN8>,JTVLM.TT3>+^\6T_&WQMVE+A?G&)BPLHV5LY'821$8>3^O,20I(
M#6E!7TM5I@J>$PULKE/JU)XW%-M.[X&R[P?W"PNZ&[6"P.$P_,(XF9I7NZO(
M4:2=C8&\LL/+ZU XJO*K+,L6%PZH4MR/I+B/C?A (,I?*$" @I9#&IYO1933
M4=F-D9BP5FSNCJC.UEA$BBS:?74#[*PP"SNHXAR,0PD9)\^LI/S[1O*QA%88
M9(03%(S6"%F09HRQRD!01Y NMJPP$H7"K<-S"1F@R=&>3 DF_6Z=3Y7K##"S
M97L\#L75+<ZG*O*=3V !^^LL[7X&'2=HF=45@2)(F![/:1- - AOI>^M888L
M299#!AH%9\7BAA!AT"YRDDL+KF<_65.""3ZTXBU9 VF+".-FVK!@A#(T&P<'
ME$LJ61L=*!\\D8=+M]3TH#?F77I2U[A>6\UP1GVEB$B0$C-(A.J>U(97$=BH
MZ*,PH<1;SLQM=J8R)I&5@5FM%Q&!*LB2))F _P"O&90+^M.*=TAM4E)9H0V/
MQ4DK1I$H)0<1BPRJ&B.&G (T#F\3>^U'@TGF-W&7)B=FB9_G.=8^(ZI&BPZ!
MF2/'82-)!TCB V>';R:BAXM6MQ2,^S\.9)^+$HC+96,QYI5C?B\5$7H>)Q_L
MI$Y<%J9N1>;2N+C9S++($&41*UB_U'9_F+,9";68KB78CT- G=Q?,5P%+@;X
ME5D58BVC7)L$'!46'N]U!W9<@B:20I,*N=4# Y6)5LR<S$)*#(&.J+F=1\:U
MH*6>@:H!'R$9C9U*@WM=RH)/6Q.E_.L,.XC6 -H3)<VT-K-95/-H3F/E:L,"
MG&2MERELR.EEY0[%P82!9=<FAUMV-8C<79H^P,=D4V ?,"<I)0=R!F[6^RL,
M;NVP]SJUU"!@QLJI8*YX8T-M 16&@#/($1U*,N7AY2VI0E;L".P';TK#!NMZ
M]H)@HGXCJT;9($<," DK 2'(/9-I*-3A%M-:C>JVLUIS-:WC[O\ Q;"V-M[:
M\$UL1B"VRMG0%;2G%XF/A1S(#J88IQ(S'J"U3^SZ'63\Y?8^+('%U&ZCBN1!
MG=")UPL,\S")B4GQ22DI,SA2\S64&616+>=2U>5O-6BT(R*>^VQT\!A3C)(X
MHLV(EQ<D#1L(V4I!)8$29-!&!;7K31M15],@D;REN\;D_O"?=X8# 85)H,MV
M02%06YB+LJM_>VU\J@,;*4[M/B63"PW87:X$J-GH(,$DB$F/..&S=5M=V+?6
MMF4**;J]L]1VFVLPV$DB(@8AQ([E&#%5 +L5%CJ++;WUAL[O(8420L,RL4"L
MP*D$9] #FN%4DZ=*PVM3H[(60+9I$RN73, NG$NOGG5Q]GOK#1\P+H5=F+2,
M9+ALO4Z CJMQ6&&)HXH[A&MJ Q8DK=2XN&Z:K&OW5AAT1@W$)!DU6259+ 0J
MPRVN+#JM_C26)9\[YI,CA@H"A1U7+U'GIK6C1](I=^75E,JJ$L05X:D,>^93
M?W5AH+,6(UC0O&9% 42 Y@.(6'-;^^M6&P&N*A9@L<09$D=7CRY'92QME?3E
M0]:S43O)Y)YF':&T!'$JH<CH+,T9!S+F;( 3KE4C4BL6>AL*(L6XB,@!D68/
MQU1M'E?KD&M]56B:+,QM)V;"J?'%) #(1(,EQ*;%$D%B&]S7UI48WS$RG;)6
M:.(,>K3\,K8Q@\0JUE8$BRMY*1WK)03CNWS-PG=-O)!-O=MZ/"X2202,(XX6
M<6;ZZ>R/(BYT]:RC#<\WBP->JHQ5M+D+]]=\I-H8R2 8PHP+"2,%;DE; -_%
ML.U2E&BE+/*-B-Q&)E-66A'?;NTI]H8IG#*%APPPV'^K'B9!*,S.>4!W-E1N
MQI]!)1LB+F[NX1[.69&$<:*TC!PB,W*8FO)D<MRO)&]R">M*-9-9BRV'L.3%
M_28DH+6X<2Q'1F#,6D8W2[%02 +BU#G44;<Q4*/6._!#X[%W.@&%2.[RXA^"
MZSHMHN&)HKJ<P,BHHE;WV--95T\AVJ"3L.7LG=<081T.&=Y7L'D'12254#/[
M0(U--I3MHQY3H)+SA2G9:X2-Y)2$$*D11VL)5R1J5C* %F8H0+]Q2'+>U=S;
MC8+)<0.(DP+B*)U2+.@41I&QC8*6-V>6)OL%:,2OH9,+AQ%+FC/&4"98_G%R
MSW&>*0=  0FAO6&;K.^S\(\TN=F,<J*K(L2EE#HZ-('OHFDGW&MH7!6?G:"]
MV9@4FG#(G$9 D<ID:R%]6(MK9BER-*%+S> XA!R?)"ZV=A"DDAB C"&T:E[\
M15L1Q.X):]J0IJ2?,)*#6[NZ)BEPV%/#C<Q&,<[ %>523F,E^X)H85.P>*B(
MD=HQG8HS-DL<I! NUS>]^E:%W1FQ$F41,  P8H%RY>@8(?,AK^G2L-VN=9>&
MHD>:S1J;E>IXA""P&I'.0/C6&68FL?CHE9PK,2%$Q3/92USD"KW/+:WI6]UF
MF[=XAML;0"/*(G C7-E(&EC9<I7L 3UHRM&R6HT=1[V]QY#'[W[=7"H593('
ML\CF2^KMPBB@: QR.K'R IQ"%W;@ JUW35UQ(^;S[XQ28:5IY8XYEDE9N$2Y
MBREH'S :6S =^_V/88:.K(FKC&G=C+8[;DDJ8IXTCD>*9#E5\A$B@,JKK<22
MJI6W<TY4$E;@-)5U+-L3[XK#XF=.(71E:,<2-BUP5SZGN@X]CZBEV =:[WX&
M"24''Q\7$\%(<.).# (F^=2$D+Q+Z@QL 2*P4JEWG9(,Y,1(PD5>7*@S*R</
MB-GC59%=%()036(_96A>]'FC+\YBXL^+ECC4!5A^;JY4 A D?%9U L["]JV:
ME-)75FSH<1,JQSXGZ,J))HCH5>6-&*KU*F-1H+Z9K5@-U');M@EQ,@+(T4:B
M29Y0C2Q%L\;JRYI47EX9"C+WUK!(%QTC1 0X<LD;B%Y!FSY6(6[)+H1&Q4Z=
M%L?*LUT-K,3Z8B>5<2C2 C*T*RPA45"2RE9#:Y8+&MW[WI:33S$MM9A9*G"$
MTLP60YU5D=&96"*@#(XUR6:X\_T*N)NSKC^$(5CA"GE?&.Y9@\<1CA4Q+?2Y
M )MUT^W$KNQ@72XV5)7C4*$B7(Q1LH$D48RE'L?IU5[$>M$4+.XEYJST"/%Q
M--#\T99$,P=0X;,UI2A :7HMF4BW6E@Y4TEEJ9\)A)\9B\/!AXUX;2%$XZDE
M%P["-)5#?2'/D8"][VK4G9=HBE!SFHFR#P$W4BP>!@=0B@"(I+ERYF"_PA%N
MH8V J$QLWO)7R9;MGQC1@U;56)Y;!A$$8DRHA9!(K)F+A&;)9AJ/9C^PU&5,
M[HDX5(Z/(R[?QD>"@<M(>8:B)@0HT-GOH$]:335U:6ES<YQ2;35R'/B=O4\T
MLL(Q#E$R21ASHI1Y\KV4@E5G5%]Y%25"C'=]A$8BI*^6A#[;^U%VMM&3$/),
M;A3$J_P3HXO*C,+M%PT[CO3^FE"-B,JM3DF%,2I'%.>,BX?#I-,A.:,@0H9(
MFDD;E9%(NU]+4KSI,%+<CYSMD5[/EJ>-F,VQXE[0V5LS'?/\5A./$L<2AH8I
MAB6PY*/'U#0H"-*D$HTW'=])H:QC"I3NKVWAT?D8>%<HV?C]^=NCB;6VI-Q,
M'(ZB41X90,DD9D4&"4,QRD:T6=3AD"J2=1[JRC#ZS:#LG#+AX.%)"PE*J+F6
M[),LT)@*'I(I$Q)/U1K3>4N+#**RYBHP&&,<D<C(,*[(PQ>*F<.@(-XU'6UR
M![Z'4<7H%44"OFLZ9EQ ,K!U5G ;A/([%H\DE^5BDN@I"L;!)CE@P0(@5P)U
M3@L!=%4<-F47O'Q<][]ZT]0D-&=H,,LV2Z.4<ZE&"ME&@>Q_T>,Z*.]:;5Q.
M[)+0!O"6D:/,LH9GS&2 QEUAELS3R#4N\ARZ<MZPS=?(YCC?!QH(4 *W=!%(
MI:1+_5',;92;4FXKJTCM/,PB1HT!B48CA/G$CF=\L<7'#ZBS2D>^LN9NQ,&*
MQ7TK(BH\;HY2<'BVR*8U1IFL<BJW;JQI2C*]["M]<P#'!!&DJ0+_  7$+%N#
M(KQE$DD41,>)G)!(]U.#+KFC!A#%AHHYC(CIAKP\>1<[,<0V4$1/IR-IS=ZV
M#WY'226 Y)(!&CH71D0%BHNT@"-_!Q<101;O:DMF3LV!9L5PG6/A1I)*#.),
MN<B(B%0ZJ"3Q2H-)L),$\J,%S1*T))=)Y,W$22=K@Q:"SJ.5T[5NPB:;>0"E
M7YN<SRI*8PZ /&<I5R-%B /" !.M^U9WB-U@"3-*9L.G!G$TA6&&+#AI)IG=
MXX\,789K!4%M.]:XVXFXI[ZBO2? V<?)<\&HMV=@P;P;<BXVU<<HQ.+<Q9$A
M5N9(%9AH8UM?W5$8RO+T8Z$[02HTNJ2\[BQWO%+>./"X/APR+PXUD.2%LA!,
M<EE8MUS <WE3&E3=26>G,))]73<ED[_40RF.+VMM"8\/C'YT)YI&7*T;CL;=
M%J8?F1LB/<FW<6F#@ :SH;E%GBE!S* 6NZ- -%!$!4'OFIK.5\A+T#*, *[!
M<F4D@-]A"KH;,Q! \J'P-K0^:6+))8,LK)'PD868Z\[ 'L.OI661K=0E]H3%
MV5&)?(3A^)(56$ %EXB,>H5HROPK=LLC):"!Q_#53+$6XCR.Z@N&X@4V4*@T
M$9/2QHT?12X@)R>@CY9&X\LA98&#J>.K,54&,2*@BOK<M8GTI>5NP&$V)*21
M3& Q$C$,!(%RH[+'RLO?*HZ^^LSR:-,(WQ5H,.G#>3$18F,L%49+LP65$/\
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MU""MED$+I<#,KB.X60+(F<*BZ9CF%P7&MKDT_' +1E:P LQ;+R$YT!'\&;
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M[97(*G^+JPK+9F<#!B8;L1PN)Q66262.[*2KJ$1%S%  2&-[$!:PP"8R&41
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MZ]J;^ Z<E9N^20#Q_P QP>"Q&*VA*L6#@@;$8R>:R1P82'^%SR.V58TL;DD
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MDJ_0!V474H %%U,>468A054FVH\Z0%,RI*(UE4HUV-D9>3*-+N#J6MT\A6&
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MD[!CP&SH<%@FP\$#PQ96$*Q@!(;.K1\X!%\NI ([TN2;S6A&T4\[ZCGQ)'%
MD**COF<D2*7:,*65CESW7HO34#[A3X#R+L[L4.SBLF$C>>2*&2:"4QV/#S<(
M$Y<KR@@D#N-:'8/J"X8\2Z8U."'*K$Q8M?+$ZQ9'#*0B\TH4E;E>O8UF1B3>
MASP8GLDN>*<I9^&V:-GB7BK*A*W'&5<I!L3>D-YY!HII9G>*.03%B)I.-?*5
M2/E@C7,2MB2N(#=#6N HP$LSNI18I#&I1<VL84-Q Q++&"5'0E=1\:VDK]@E
MLP#$CAR219@!PX^'*60\++F:1$!((L;Z$WI34.#,,&('$G=(3P0,,<3$S1HS
M&5EB&8LN5P@52UC8W'G2#625WS >)5H83+*(RCK&9"L9DC4O=B D*HJV*Z "
MX-'3OH RT"Z>92D+0@N6422HR@(RQ_P;9VPS..*QL;FZ][4OP,,$D2L(9WD<
MQ2PVB#.3")D&CN2<TA6(9#938ZUALYF=1*T;_-(PLD:RA1'SQE.5^5#&,[ >
MS<C)KU%), #2,J)RI!*%1(@%22&2,L(P97T<7;2RULPZ8/%JT:Q,%=DE6\T4
M(5LAC;D56:_$+*<UAK6:F '$,TS)AL/&52:4&4OE$2"$9@6<QJZ9R_W5IZ7X
M&GEKP)B?)<\%FWHVIAM\=KX838+"!X<)%+&@6:))+KBN$UU+ =+G-4=C<1U,
M=R+)/ 4'%=9-7EP-CV\6.PVPMDI#%PH\D3 1Q@*%5$U+#,$=@H[7M4+#>J2S
MU)1J-\UF0@W[WCEVUM%X(%-U811HTAOF;B?2#0J8Y%()%SUJ3P]/<2<M2.Q,
M^MJ9>BLA+[,V8\9CE6.V'>0R*BY1/,+:F9C&"5OV-%G4[<QJ+?@. G!E,8X;
M63A#BO9)"JN$-EC5VRWT)&ON V:;5C%/FR2<3,'1FG=A9E;BL;\-2<S1!F%B
M2"!:W>VC$T%^,DX.%G9EO*LJG,/:&=,HBC"A&"D#SM6> H1F+EBD@>SS9XH&
MD-@UQG2565(K$MDN"">M_LQ7D\@<I65^0B=HXR$X57D8\:6$+D"1KB(^#](J
MR+F"CB0L!;344=)@)O>?;824^)7%0F-5@4ED=RS!0[%)"!)REN&>$W*38,+>
M5]ZY+4&] IDYX;*[8<HI0ELH<RJUR0>( N8\MR!?]*UDK&@LGQ2JT>%@%Q''
MB'DE$9*-:-6).6\D2\0@"]]=:TD[ODS3=LV$4*1I+/-$&9.+\WRF=FE;-Q3D
MCR@JZJ8QUN1WHVZK9B;JU^ !D81F10BS,B2O#Q0Y=GF>V0@YR!Y *+>E*X9&
MG+D;,OR3Y9OE*;YR,A4/X';Q6(9F06WZ\->4$Y;D$]U!%OM@^D'R./TJ_P &
M1.=&_ET_HG_A1/_4N);Y*6WTWH(!TVYM&Y#=SB)+"W7I4A!>9'N15L3\IJ>N
M_$+(CD6P:Z@$E38$,JW[Z$!K]*( "O'SLBM(7RW# = H\KVTU[Z5J^=D;62&
M<WCQ^52H  *MH#8DDMS%AU&AL/2B*]@>O<-3BY2\V8\]RX!C-B]K9M/3,;T2
MV0M9,+99##I>RL0I)YFN#=0&%P<I.OI6"C* JALR#.SW7([#AZG-8 VL1]U:
M,"[%J&4NC+=@W*O,%%[$LQM<6I:N:81XELDYLP*H2]U!R*!T"=SF4W\[TMW!
MO4!3 -?+)Q7.15MRQ(6%E+GJS$=Z6G9&C Z,]P6"Y6#.T:W16')D,9L60A>M
MJW<T=KCB$9<WLQ !;95*%R2IL!&Q4V]U:U1H"O(W-RE3E<Q9"$,QN%X;,1TC
M';2MW]YLX1H1E69WB+-.D4Q**Q;*IR%5%RER/*]Z5DS#&C.5;))F= \BLK<,
M!>A=5-@3E'QK9AS'P[1,[M,%1@#E4&.[,QL!8$F]S[ZW<V!0[9I!"R$N"T;(
MYXJ,K$60*;9F4?96TN1JZ1V.)>4A45I>6%9I3&[LK 'EL1I(3W]*4A#5\UH9
M9;1H XE1E?)+E=0)6+!C>_,+R/?W'[%)W-9\0//.)552+%68,RG5@-%9'OJH
M'G\*QF+("I)+&"J<&UE+-(]XYA*)48@G42$6OY916\WIH);SR Z8D* ,O$+,
MZJH1VCU*(0^8A!D*FMJ+YFKL&3!45 I;#M,.'((^&PO(PREOKQKI<>^EK)6X
M&79B^NA#\%R)8Y+N6#11M<-FT-V9M*V:O?4$8>0G#OF=2ZH674YHX<UE9AT&
M@^-8;NS*$B64/>[LO,^A5F>-M)%&@4 77WFLN8\P*ZB+#@QPLP5 W#+V8)9@
M7S$D(I;MY5AH*F^C,;\.,NO#54#-:,2$V:2Q*$.#U[UM/D8=&)=4!5(K*5=R
MS6R+(Q" *" P+7S>1%;MR, <^CNR6$87(N9W;,][DJS7O=P+5EGPT- &=V5E
MB<E3<_21I?,  6 )[$R7!\JTTS8(@X5B9WFR1'@WB.=@"N7CD'R/4]JQ<S 2
MCDJ[ *\1R QNW5">&6)/M.0H.G2]#W9,W<#'.H>[+GCO("EU"PN/X,= 7?/8
M'TI<,LGJ+NN85XH_-^"%RE%95<9[W!-[%K 9Q?7W4JU]-!$FN F,3+$)&&)C
MXIC5T0*H]F\I4E_:* /J1;M18Z=H,;/;^'BDB;YP'$ D621B%T:V592%*S9\
MO6]Z<0:M;B!GK;L&\Q4,T;J2$M%*)>9>)&%4$1N$_A X# ];=*7<#)WT%'A<
M1>6 \7BY0'C+( D:HQ7(4-G65@,U];J12H9L0/;NS"D^'@20@)$HFF=>3BI(
MID1V*$,PL#?30>^F]96EWCZ"ND..F'D>-,\9,;"3ALN9>>V2-I";W16-O0G[
M6T6DW<+N^\,MG;$DEE)Q"ME$ZH,N5P+LO(MK-?-KY6K)R30J,,QQ=F;& G;,
MJQB./,KM<B2X0!PHT)+HP4>8--IU%!99L=QIML6^#V<L"&91ED(RK&,H8QL-
M93':P)Z=;T!S;'$:20=10\-QESF1%41%X^@(NX8@Y2 !26[K/0TWGNI!BT>9
MF(!R,W#8H?9T#*H'0-K[J2@RTMV&=<T0 C9BI(C4N.CLXNK>EOA6S1FXS$O$
MMHF%XV96R+G8/H&%[DY1IZUJULS#D,CEF,3,XN%.7*N8D W;0FX%9H;5F9I&
M=5-II$6Y1GMHEVE;(M^OLTE9RN;LP.'#I$5526)A:4$A^8Z%E(T&GE2[&K,P
MS2P6CC90<V=I[ DK]12!H"<QO6TF:OR"N?% E58AG2,!W*F/-FSQJA%[$ J
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M)<ERO2Q":,H[LS5-8.JG34;JW,/3FFK<1';2PLX:0(T14HTL3!KLI*:Y6L!
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M8G:,'B5N?M'<[:N PB\*63##&;,_-D<V*=7DA5T!+"%2UQ>\;7\F_1K:+ZW
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MKBQUT-]=:PRQFOPI@ZZEW?4=0N>5[IVN58'W6K#+'*EF"E2JM&K+P],ZDGG
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M>47",0FI:]Z;XBKNQU'^"PRJ5//MN1^NYN6W8W;V;N%NGAL-!&F%X>&$Z3*
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M9!?76MI6U$FR_P#)*XB2;Y2&^J&2Z1>">\RA7RB5O\WGAKSL 20!J#YFH3I
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M.JS28=V>/,Q=3,R(6R31^S)8YA9C:XK>INZ.)<3?AB4LR@,+J5D)DSH0#U)
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M5L]N-$(LY#ETN!'(&!(/46IPDF-GEH!\%.HEB7H\N(;#J6>Y:=EZ-?6-%"Z
M"]+22S$:DA]R'CD0P<D<B8>,A[&16++'&R*P#-D/KT'W-\1JO:/J+320_NS\
M)G0.55VX$1,R\4H$FLY5 R*MT(J/D[-WSS'RBM1<8'"QBR@<\+H4)0$RZ9R
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M)%R");=2"35DI5='JA"BUKH,_O&DC2SQS,HS(O##BYD:,L8XHB_M*H4YC<V
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M#,+FGT8J*R(NO5;\UZB9S8<7;$<229,HC,4C6!8/&Q]E@5C=(V<]%7[UVN-
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M(/"RY"XS2LG#YX8P5URD^GI6-<&;?,-5=G4PQH., J@GEDRNRYBN<Y080I[
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M*L)"S1Y"!FR*+CC6 RCN#6[\C#DR(Z*')42<R1QGF6,64<('IERW;R+5G8;
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M3<ZZ5K<1K>8J=E8XOE82JO#E8N2"CGAQQ @1D6L7%O>/L')65KAHNZS%Q@W
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MDEK">)2PR:7%SVT68 YX<2,-@<9 5@#_ $4C  ,5FED#KEYC(L3%KFVA)K#
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M]_G?@6O =*Y.T<1D^:'OW7\1,'.4,N.9XH2<^(*Y&=6]F,J+A%U_UU=2Z/\
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MJ00H0V.8KQ!;(#W370&M*:T83=E[  ZQ,9#*.'==!:ZJ0;@^H-*O?0#---W
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MB$O$B&*(@BQRR8B16R@<1!TMTK#? V?_ ))5W7Y2F_<(M)$/!;>5^*19E?\
MI\\. 8Q8Y2C7+=.M0>W_ )''Z5?X,B?Z-_+IK_6G_A1/_]"W]X@R%=\=Z[$D
MG;F/ L+BW'>P-LHT]_6GM-/<7<5?%/[9GZS&BVOC4L09;6'-Z&Y5[#N0B@CU
MIQ :3&;VSC!++E!9U(()L07(Z@*0$5[=2=:6W<W!9!%Q%'$8/D(1'RLQ!*Z
M$L=+&L"&0,2Q9B$4<I7-;*K=2#U9C;1>M:R,.6<+S6#9%;J%NJ]  ;V(\Q66
M, <A #W*R A<P?15!$BLP_BJ/7I2D:80,4$A;)8@V*H;+=>C)?V@?*EWR$@2
M7(+D(S+,+=0[ DFRD$C*0;GW4J-Q#UN$>(E?.[*X2VME"GBA$ 6^8W)('I14
M_<)?:% D8&1A+DD(C"IJ!<9I&*\UM<H^-*$O.("D/SEAPU($8Z!S?,QRME +
M$"ZZWHD7D(\ *Q$@L1EL;DG4?Q ,IYC&3K>MW-G=0[,&&56R&-\I(#R(BN7&
M?EL<VGK2D:\#Y8BZJQE^D$BA2[J&1%%K*0K+G>U^M;,R,3HK.Z"X)2;.2CMD
M)T:1B+ ,2-3I6&'>(\+F:;.0$52.5 @N,RC.+J=+GSK+FS-Q(F:[K(I(X?#%
MU,V752J&]E/GWK2=S- ),8BS,8V9\JKF092"JJ,S,+AL@ 'J*W<WH<HP6RMF
M"/E1N&5,C%=+E);!=>XZUM&F"N&"4D$J'15*MS,5),8C==&%E+%CTM]V[B0"
MP=66S12J>%I&S'A(+Y0%-QJMKGSK+FC*9D<1QR!\I/##60 "['AW!S'+67,/
MI%O$["3/PY%)7ANQ)=7B"M?4K<:CITK=S+''!B01QQB$/(P*E2S/*A>X+,/X
M,$=NU*3R-<3(@8$"7.Q24C(&#",%CE?EYBQO]U;N:!<-\KR--E:X6)FMF(4E
M@K"Y*@EC8'4UALYF@$@))$BQ(&*\4+G.:-"[9\I906Z 7%*1BN%V+52&:&&9
M4AELLB:K"3*L61;:Y)6C.8=K7I2U%& LYR+&-2I&(9SK8$BT0T')T'F*VNTT
M<G$"\B@*&0(B)(N:\C+F(N/9CS1@4B2S,S.EK1B%E15022$9?KGKE=B++&QN
M//\ 2AF@CQGT>',29F.82F5ECM(YD=6RK>Y9UD&@UTK+\#&(;&/,\D@C#M>4
M*RH$4A60,#FO9 I!T.M+&TMYR=@',0%B>(<.T;J%(6S$@QCC$6C*I(?,$=JV
MDWH)X9&)Y264!#)(THCU^B S*)H46]HT6)>6U[TJ,7+7(RP7R9LTZOF"N7&5
M$62:<D%\F;,H01MIH#2MVTEQ-IM:!!M-#.8H8R$ PY0"4Y73(K.[A\JJR%R
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MJET9F]E5)Z^=8K\ 3>858C'?0R79'CO=<0F:RDNC,KW)#7<V!U&M;W>9F\]
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M 2;*OVCSU4&N@WBS.0[9AF-A=E;.#,8Q+RZH"HZ=[>^L-F3*55PJK<YUSJX
M61D4J3F) MQ+5AARO",@L1&B9W]L-F)SG3772 5AAR$:1>=%L&$S@-8WT;.P
MO=2"_LZ7K1JZ.DC&/B< LX!R*=3SVFU;RL3:MV9L[1,T<#$6#*SJ0T2"R+,8
ME5>;4LL.GG6[/D:NC!(3'98\KF=+N@(+A<DLFBCFN"HOIU-:,NC"T68M$60A
MVD6-V%R(U8*C91JP1)NG>U89= 20LL2EHD6PXF9&_A+C,8Y%TX98?&B4U9L%
MQ B0F02R,JKDC=D4\V3(966,91<Y#@U%%-F6/#R2E$**I# K)8@CYNPC([>T
MII-U?5&[^:'$<21$HJK#$Y99&25@_#0LY<BVCEHOA6[KFA(;1X5L[JQDT =6
M#"XMHJOT-K>ZLNN:%)YAQ$C1A5NMCPU*Z'56CNP[%@.M EZ3"&<.R,T5DN0I
M0@,2H21LQ.>R V4GRTK1A@XN8,5.4Y,A#* 68#7*!=6 ]*PP#+*2)%Y!P^97
M()(:P LM^8O<BWX.&&";(D0NA)=AF.H*N21:QL57,I K# ++*ZL]@"S(C'FN
M%+'*0/, "M&KHQB7AF2S&R@@(HC.5_JLMSFL2IK=FS=T)/>#&Q)!,9$#K+GD
M620,&1!IPB5Y8T![G2C45GVW 5'YK(:^(FUWVA*R1XD0Q\;/.0JRL8XAPYX3
MGL$4Q1*1;K:I*A&[9$XAYV-<VWL<-Y][MN;:C$4T6$Q2X&!VRR-BX,)&N&Y6
M9KM&Y1G! MF;O4ZKQIV>K(R<OK%?L+8^+VMB\!L[@.F%F=%ADR$I+A\G%$DI
M51D'%3+JW46IM4FH0;8*%)5)J*S:-BGA;N''LS#8944%G0<5PI"#*8%%@^G*
MK&YOK8_"$J3WFY<2>H8=+):6).;,P*X5(PKA5@4LP;+F9R@"95'+RFYTII.3
MX#^&4;<0Y:5&41AU+)H7*D%FSP![V[!1IYFLB\LWF*.D$0C0<,N6Y[ED)ME4
M9;@@E6)/QH53TC3/F!CENC'(5 LQOE8QKG>WM %B?*BT_1-G+("BK& 1H<@!
MS.<H+'+[1YK_  I9LQL^9B0JL% 7+>]P1K8>8K# NG89\V5PI&;+8@!M0!;R
MLHM6F:?,)L5B#GMPTMEL69Q>.W0L>P/P%)$A=$5>6Y"H\87*R7>^9M<UKJ!8
MZ5AH46%@M*RR<Q94"&ZF1X3<DBQS:/FOY?&L,%)-)%@=F2R/*N:1#%"&YWM;
MMFR@Z'IV%;NO:9>[W7I82,C)AL+QC&K.1E"\D7-(2.+H3F-Q8B_:MJZR9BE?
MV9"0Q>)EA#33B1I"66-%6XR^R>)UL0 +=+TXR8A_&)]@6"2!(%Q,K,'DO8-_
M#<-3?D3ZW,3?304D!= N3'0IA8YBP='&3(,@4GZI=A[)/<$UAB68C(6&+Q1D
M8+99F6-8R0L; VUZ!@+:VHDO1"/0<?9^'=<LJH.(54&RHP8_QC?4'M;TH$K;
MHN#M'VB@Q3?-,.SE5#6S@M=+LOU5R7#:_&A&W))7&KW@VI$DJP@*6LY-\Y"Y
MPO-S"Y.=B+=S3F*N-YMMW8EA/&50F0AP4NRK8E>HLG74Z'S%%C&R$!EA\0TR
M3A6C%[NC965A8 .E_P"*P(UZ"M.Y@)3$,L3-*1)ER190%;34&Q##0 ZFL,.C
MP(7$C6"B9>'86R#L'77-<GK6C##'A+3.T3LV'DE83$(+AVLF6UKA!G.O;6MF
M&/%8-1#R92^2PY5( +&UB3SG7J+UM-IW1@3# Y!92[L %#9M')(( #  Y;]N
MU&4[B4FM0XP6&>)@QXEF#<JR=,JZ-H&%@: W<4"WEG>/* P4!@S% 9+@'+(@
M.DBC6_XMJRY&!8=K2P01H91%.B.S.Y)8$FZL8]$B.4:ZTM04M%D)<MT+(-N'
M$XA4 *EC%9A(KAG+CF\U5VU]U$<;1N@<:N]*W 6>S<06!@E(T:V=UNK.8T.5
M>@(9K@&_;TIO/S= Z>1QB8H"\B"-7C6-^)%+SQ!G%G-UYD!'3UK(.^IC;$GM
M/=K9F-Y^$8>(D212.V8QJA!Y%74>E^PI3;6@EMC!;Z>%V-EX,V"F?,4D<+*X
M8.1$@$I47)"J- "*=4*RC&TM1G63<KD8]YMP]Y\)&9Y<.S_-H90L^'#HTO*S
M!A$PDE+7L",WL]J>QK0>7$83HRUCF,_C,+M#!9/HCA79Y89,D,T/#=>'+RF5
MV;)/8EKJ+D=:.I)K=6HQJ0J1?G+(PM(L$2(YXK.8&D15-W5N*KYIES"ZF0'6
MUC6 S'$XPB2RF")<5PQE#K&ZH&$)ALK$"69N&!8]ZPS70#(65LD>&4XAFREB
M%D=T4ZLZZC,?J".X\ZPRV>88J7-\L;1.4)=<P EOR,V5A9'7H!>]S6&[ M,/
MAIFA)M8QA!(SHRJ41BNK9E#Y;YNXOZUAH .X@=)I3(,&\CQ2/AR[R97C,:%5
M20*X1B"UA>PK#1P5X8);A8CZ%RZR.ZL2G!19L.N7O]878@UAAB^D!8+$JJ_#
M?,I0-:Q*QAN&"5D!U%P#I6UDS: F*C:2\CER%5<L9_T%K\&&R"ZAGSD-8FYM
M6[IJR69ON D8ED3$RAX8>%-%(C2D-E8\P>,'5CB%8$902 +BB+1&T<(0WS@N
MT6)=)(VN7721IHQ(B21W,D>4]' RFM/419@&217'SA71)3 &1)'XS 2I)(4R
M#E6)V8J2=!?TK<?21@GR)VAFB>="&:*0)$5>T,3D_1QZB3(RY;#H-:,:,4<C
M2-+FA)6;$J[XB0JHC:=<3"H!7FR9""0.AZULT&^R]D,V+AQ!Q+SF>)XL2>=L
ML.(LZQ\$HYXD1O<VT[TENRN;M=[O$V'>"6PTCV4L<<;*,D*G$!<RRQPJIN<N
M6[$RA>AZ>^H7&2NRP82"5GV$H,+,<+A#(LD4D@NZ=5LJ\ELPN18$U&M7DEP'
M[U(\^)6WY(X)WO*(P[CD>/V^K Y[,H ZT]HT=YI\!GB:UENHAEB]IIM*?$JS
MDK)/*ED3*<P:7))G7,X%@+FUF&G>I*UE8C+N3;!6>6+"K(5SND:A9L@C<L3E
MR*@T=.FCV/>DFK6S(^^,V_D6ZN[&*Q>+CGFQLYQ$.S#'*,-BH\7#&3(N&;12
MD#6SDW$G0:FG=*-E>P&4MZ>X1[\%MES'9^.W@Q2<+%;4QQF6;EF:+#F-^$[
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M@\@4@H;ES)G (C:/D87US!A:@[]G;B%C!H<C9^%X(0I%G?*&+&QT*:]+!2I
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MN&2.W/F/OM26\NTVD[WX!KGB0PI'(ZK(P&6)0SH"PS?2&V3(3?UH4KVMQ%I
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MAAB25FD54A!LGTBY]%"E18GL^9A]M:-25U8"N59A)JCE[EPV;(@XDB1E3?\
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MF9\I0J@5;\I(!(9%0 #6EP34LS87S&0*DDKKFRYC=@A4LD_1.N6[6^-):=S
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MG"R-&N:VJ@H3;H-*W<P$#6)Y!9+M;+(2<I(8 ACH'Y186N;TJYADBD>>"-)
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M5[F9!]F4&)C9&X*M  "),4\7*75?XDI)Y@->M G'@:N"<B207>)F=I,-%99
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M=,K'V1UTK9ES"[E>&KPB0922D3$&QUXBGH;*P![:5M(U<[VS1EHD(4!5C>Y
M:0:$@GL3H*PT827$ADBS?1L%=,FBKEU() ).8G2E)&=ID+F2,*KDL.9R67F+
MNP"E66Z@91Y"LM8S-Z'5!Q&%T+H 2T013&95!-BXM92R^7>M/0<!GA)(DD )
MC,<4-C<,";.Y]D][K8>@I:%)(-8D1Y%D0")+YW3,UT%KKE8= Q.HO6-V1E@+
MCT=%$B$95EED%RP!;4.J7 SY;GIVK.&9IZ9"?GF#*((BERJ,3S,_$MK'D/*4
M91>L$&)B60"]PZR+&R$=<G0HP'#R7(TZW]*U?B9D-7MW#\(,YDE!9FD@,)N3
MD8IPPY&2/1.Y ^-*OF)EG%VY"$Q$D8E(%[!&D;#,+ 2E#=BX9>(]NH'7M6T@
M#R"QIN=EC49&R<3(ATDC6,I&O$8\TG$Z 7'V5LUKW&5V<LJ%6^<11R292V56
M/^A-TMR 6T-C1*;X=IM/W@N2030/(9."\G.BJ9$*$HJ/8\P;*2RL-",XI=S:
M $Q>.%88U14X30)F15C)DR@NPE%[H ;6L38FM.69CNEID)R5H%6:5V:\*\68
MQKRO'$L<<?!S,5S$^UJ"+]#6)-LTI9BNW<QK8?%X.(8I2K,LSV>2=66=2T0:
M0@(R"Q51>P+&DS@Y9,'+TG;F2^W'VPC1Q1,"%=2!D?(JSA"!9!H2@%NNM,:D
M$LB4HRNDN%A[XYFDC D1+E%,0-T"91]=TO(2Q;I]M-6K#JP38Z< 280.[9]6
M4OPWSBS*4R7 CCOU-B:Q+W&M.\0^.Q=V9,X9M#S-IG0$:,,K*K:"_0FG,;*/
M:!G+,3<N(C0E69N6/,JA7E"EE+%B[YF*G-IH*WFP%U< 2XB3FD$C-'''$2%#
M#.'NN4YN5<K$'MTI<;I^PT\S'FNC2.8(I0V1E9$"V"G+D;, Y4L+V\Z')-W[
MQ/#C:X FC.=(V13&J%U51SGZZQYO)?OZ4NG>[[C%I?B!,4RH>(D2/-*5CR:Q
M*.&A>UQJ-"?>11;FP)'*7#E(WDZ-G!+1\1E= 2["P$9Z#J2/L5>R-]P;89&C
M>+-FYRS*$XL@DD ZD\J*N1D U/<=M$3=[&T**"%1DE,+K/'<SE2 O,<J*EY&
M]H$GI;2M+059H44#9462 JSF%LSR6" 7RE3&+<UM :QZ"HZAIG5FN?J! O$-
M@&(L"+*00&-K?@I%Y -\4JF3*"Y L0JG(C \S"7, PU M;]REF8[ C#S9QE6
M%H[JX8AD57Y@RM9QF S"_76U::LM3$[Y&58L\BIRS-):\<68<7*,Y![Q@9KD
MV[6K35U9Z&'$DL4F9)F=%D98^7*%8J0BR(UF(RW.EOW:W#=^>@$;$\*18UDX
M:R1L+NZO?E;+)_!KS@J#IY5J4%_9&KA@DXDCS B.Q5V4R.W%=08R!'K=)+7M
MT%"<6NXWD97F8K'()0&XD0E>-'"EB"N=0 0F53D/OO6L]#8*BQ2#^$LLI5/;
M<ZQC3/E86!+&U9H8?*TK_3655ADLRLR%'%[R%LJJ;(MRH[D5FC-:F-N,>')*
M^<?2 HH"(SYPT8 -O9C%_6U;[30(:3@L[ 1B5TO&3I$Y!RJ41?9E%[\UKTHP
M$%B<JM.$D5 [,$!3)E5GC.:R%I)9"P%]"+>E8;[ /QE1F1V!C:,R6*A6M[.:
MXS=R-*WXFD^>AUE,5X%600R1NI470JZJE[?1KF%R+=1:M*YAD&+CM#%DNY+2
M(T;:1Q$VS-,;LK<VOV5F9F]97XGTCVQ2MQ9&1E6,J69LJCJZL0N8K6^!K?NS
MO(_$*.)&5<N>**.V>?(;A]-0K$?&]):0N]] 5>[H!'&$X;*)&N6<@Z=-%8'H
M:$FWD9>R#;#/D!AD-UDS+Q$(!=RP-VMJJD?;6.-N\4I<. /3(@8$6;AB[%<^
M2^J$YK$7 ^ZDBKHY65\V>,AGC4.S B,2BUWM&>6]ATZ_JPRX.0L09'RE1<*N
M6[2NG(  - 4)^-8:;1EBE SQNJ1,655 ;,&'LDLO\%'8>HK8D%XG#)CL,<'(
MPX,\.1UZ$AA.(V9^EE+!J1.$:RE3EHTU]0.<=^&YV&B+Y:6XTNXN^<6TX<&<
M)L;:F*QCXW&0QY4.(D;-AH[:R !1J0+5YZZ:;$GL['.M;['-E%VW@G"6\G=$
M!=F[:FGQ3X3$218B&.>55*QZF"7G2$NP'M$CFO935-G3:CF0&Y)9Y[H_6ZT@
MQ4QB4Y)0N%1&,2%L@>596FOJ+JAOI?\ 77<<MUON%4TFVUH2CW&P4<^*PR1Q
M)<XC#I*87L&CS9595>*YOYU#TVX/+5#VCF[(F3N?A(X5C@960Q9+@L\CG@1A
MT:)5D) ,7*+]:F,+Y[ST)>C)IA/XRE(=@/*24'"G++J">(6$364'JO37K6\=
ME[A&+T-)_B9CXY=I;1BGCQ4CI)BC&T@:.'$9FO@R<HE0B $9@+TG!TY)1E;.
MQ7ZDM1ASB'SR/A0F=WY)Y1FS MPYV17N&25?9?J.PJ2M?+@-&\C%)-AOHY C
MM+-G@SJ D2N)@XNFD=VDDL#?13VI:BUQ5Q+9V D5 9#/!.&^GC@DR(TE_HGD
M>S!HYX$ %M+$6I-HB0=&8C%-,$O'.LWT3":2;!E1Q)<GT@C6S#E!(N:0^1MN
MVFAEPV*>!X\2+J$0Q1S+'=6,TV:192$;@2 DNH/LA;#M<<HW5C:S!ZXAEQF+
MC>&196*KAQAS&(YGDCXQF8$YD0#0Z  T/=7+(VT@?#B7>##%@8(I9+<"-U5Y
M<1;,HC<&41Q #F! Z&A]7VB;+V!7M.?&O#/&LZ98IYI,5E*H(X(I$$BQXA\L
MF:+B$*P&4 5NR!3? 1HP4AG8PEI)+32R)+([QM"T;".5G66,.VHLZG+<]:)O
M16N@+(7^ZVS'>43$J)(YHY(WN'/#CC+/'*S%@BF0-8DV-CJ:AMHUG%67H#+$
M2W>XD;NAA)9YEBQ#M!#(KJG"LBQXCJYEF4%P5*V4@:@Z53<;*]WVC)O>S'XV
M#AI^/"TJ)R8=6!SJ%S,S 78Q_P 'E.I-M:KV(M9M<Q,8JXZFS<''+AL.JM*%
M2-$D!8N'C'$.8A74\LMU&GL6J,FL\AQ%"8WHE7#C&021H<JE;Y/HX8X+SAU.
M8NK986  O;-]IL/&\T^%S;CDS5;\HQ\:XQ<;8MYKAG3A-DC586D',2"X)5"=
M1<@>FG9.A^ZK.VE@U&-N]6-7>\F%.+DQ,?#RJ6?/+S.[,#<W9O9O\*]$;(J=
M7"+["YX&>Y%2?(;?'[),T6&=<I'TL2J+,S,A(+GZ,_2+:W6]6_#8UP98J&(L
MDUJ(_:&SS'&J6M(&U9'#"V064QFP%SWM:K+AL9&K%+C8F:=935ONK!1P"S.K
M1Q\2,B/(Q) )4$,6OPUN3Y]:?WOJ%LN\-MF[+DQ1B1HBT;E8V*EUXA24QE9+
M#*%2VEJ;8G%0PT')M7L-L3B:>%A>1(?<C<^7$<-(H!*1(RO&2[2C(RB12,MB
M8P01:N9[<VO))ROI>Q5]I;=IQI+=;WY:$UMPMS,/A\K0*4GPP#B4EL^&RW<W
M=W4*X9B5(!"L6S6KD6U-H3Q%3>EFRFU*M6<]Z3;NR4F[FR9,-@(VE)1IN(8V
M#VD502YX!&8"-KDV))U^RI5JSG4?.YD(NWG:BTV3ASB,CY,1+\VF2/#QRMPU
MS1$Y(_X(ED8LQ8W/4>E@RE^]"J*';W>P:1&)@799N5F#-EA5H\ML/=0(\8A[
MD!2MJ#4>0Y2MDAR,+AL5!%)AXH3B8(X8!A\5-S/-*JQ\;AGB <5"0MF NP-N
MQIK:+S;S9NS>8KMG87$M$3C!AU@1[LP0IB)'GRYTE="Q<L3<@GO2)6OD(FK"
M^P6 R2?.HLL<?'C(%HPV0V58U5=660]#>A.-]1O:_$/C$\4;P##I)C$E1VXU
MSE1)@JX>'-?E*WS$G2PI5K::FFLKA*R08:,XO$&%$%T7$(%CG@X(X:Q2F5;F
M1186ZUN,7-;B3WT(T[B.GBCOZF%P\F"A8L$AX;9B@:\LR@3(&C7Z1P,H/34^
MM7/96Q[1C+^B-78JG0=1Z&MSQ7W\GQN,Q46"F?#REYBT#-!G$*CC,697%U4D
M7TO79NC6Q:-.FJM6%XM977O+ULS"]714I+@,%A9%QV(M-/B&;*V)=@U\/*L9
MS!&!U4 G1;YJNZCN1W5:Q*--:Y [$00 <641QH&>97C$D9G8)&W$:2(,> G'
MRE3J&!O6XZ&@+&QNB$0+DCD!=1(I@BS7;$0."N>][ D7/6E*X:'HF51+(S7
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MN%#)]#;FX36&EE5Q>47[]S5AP>)ZN1/X?%*X1KL*3$331)Q+.V>5F"1Q31@
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MNMEH,&B9R%D<Z1CF!+YLP3+KRE!]M(4MY7X#C0PXG%B0A06 ,K/Q7-V^A1P
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M<E;<2T.2Q-CV.M2;E&$;K0A0QDFAX/\ !E8VB5\S &5%5CT"V4.2.^MJ3=&
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MOI%"[LD?@MO,F5TU^CW]\.50\0V9@JFVO45#;<^21?\ KB\)$[T>^6R^B?\
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MV"T@?/$(RH1E8(F6-9N>+,7D+$$7,993H.](N*\ OC-I&:(6 < %W7E5EL6
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M(F@([G36M"F#<$[!50R9HY9EX_#O(1D#\-BDF2^1<O(5.B7M0JM\A<;6L&F
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MWUK#%S DAUN<S@ )JH M:]KB_P *2S9@R ,PR98W(4Z9BUP.5#]5FO\ ?6O
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M .J&0%5!C0+FRFQ3,3S7_O01:MF&-K9 UI#+G+F[VS"31#;^*K @#RK:9IZ
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M[3[Z'X"]U,S1;-<2JD-RH0!9 UK-T C Z7K+K0S<,\.SWNT;91D1R0YT9D<
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MIS/"TD4I7D9+"U_3[?2/1'8E+9N#59K>Q%2-UV?G8Z1LVA*CAXRGE6:_&QF
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M63AJCG-*C_268 ."%@PQ!!K69CS5C&6DE"R(JOR!"(Y5):4&X5G&J<->PK+
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M@/=6& :>8NSA0PR2*$5EX:3*HL,J]'*@:&L, 43YW($9)9V<H;*3($R#,6!
M:P[5AAV"A)I Z \*%PRJUT1R!:]K:WK# 1E96+.0F>RDBUGO\XNP\\U88!F
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MUNOG'E47K&[:ZFUF9BD:QWRJW$DS19] QL1KV6,=0*W<S0^C1G*!F0L@$K9
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MS1(ZN\8#D68$6X3HMD?,H</')F[_ +MV7#4P&PX@!3'(6+R*ZQL%R1W)C1Y
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MB;'D/$D*@C.K:*I(Z!QJ?(UOL,L!GCR'.%RF/,CMF.EUD!(/2X4WTK.)GB<
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MI(/=;8LC3X3#QQY+,9)8S]++D(M$ZD')*YDL>&MR!416G>_>#=7>[R0.R-F
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MH98T;DA50"!F('.X^^BMFC)+*BK&I95*1A2D951&0+*1ZRC4T$V$Z(JDAIG
M5,Q:^96+C)G8G7H/LK#:U7>&ER)DC!A!C@6XUUD.J2C2Q)%JP=AHJK'PD+@N
MPS9V8K;ESVN-!_7,]Z28"HD+!)4<%%C&4 %RRN2&)*Z=":UWF!G"D;\3*K&,
MESF)L>6(L/(=(16C#)$1D4LYS&_+& 'O_I@1WK##*6Y3&!F%\S'HH7S,ELUP
M036[FS@&SR9D:1T4QQ.2.&\CCV[=!%KTK+F&4N'*OEX9#M?7-]=K=;@?96[F
M I4*1Y2EV;AJ.46?BZY23UY>U;,>ECM#F$N9F51DLN=E.;+Y\M[Z5AECNT@
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M&->8_5T\S67%;MT!9)FCB8)-*YDDEXF= K%8H\T<)4= X()'2B*#>9O<[CC
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M&0*&9;,[1F,6$A "%[!UX)/_ &M0FS)>CGJ!95BC5@7CS10D*;9%4ENLATS
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M3E13V(/4T*]AZ-QM:0?.LY#*$=U(RYB=)5+"\A!4C7OI67S0SJNTV<;.F)5
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MN-3DN+>E.Z.-E&I&W%CBEB6I;M^*R&FV[N:LL:&-(;B(2L[DE6O=9'TNQYV
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MZ_2!QJH.MB!U];UG$%;B87)=N$L:\,I?B#)=4'73ZXS>=;N8SJZ*%56'%,A
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MHV7,%8(P4*(\WI<^=9[,C##&4DG9T"F..4L<-*U@ %Y'C/5DS"[7&@K.\PY
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M:>.AC"X9VSS8C,99N(5B591-PE'4 B_6BQC96!59QN)*?'Q<.?-&)$@LDZ1
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M PWTW"%U'4]._G41MQOX)%<.L7^#(G.C]_ATWPZI_P"%$__6L1>.KY?&7Q/
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M$V 4&2Y+R(" [:65N>P(%E\_W;2--A?8MJ0 &>P!-QS$M;ZS6YJV:.-6478
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MBW<+>UE)OE.57)/<5AKB=.$+"2=B>4F++E;AM(LC%4:Y+&YO?UK9CS,/#6,
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M8GAG2HC5]H 16T9IY%*B*-EL1=YR;LK2\13&FO&C'862C4U;0V]!E-Z\,IQ
M2#%3@6A<B#.7&9M5C.H!D(N:EL+?<T$Z2&QVO"9(X8UP:1S$0/)BXFS+)P^T
MLACOP?I?;J1II??9&N(GFO+D$<TUA*G%6-[J6CT.(Y?I$-M ![5'ZM<1-I/2
MP9B2=&(3*L0DACPK2E$AF7-SL2W,K 6XD9H4H1OVF69B$ZJ9&FAUERR%F8K'
MFOD9I0!J7"V'I2-Q6-K45VP,;=7Q"8:&*0N(X0I:4QH0"<JJ?I 5C^%ZB]H0
M\WL-O3L'-V#B$C581B4S2'$17/*L,@F25P&D'*ZL,P7O>]5;&4I.[[/Q *L=
MY9CDIC&@PZG)*SS-#)#* Z8K(K#YP3&.@8:D^50,Z4M]\QI;,5\;3<%IV6.5
MC-B9W=II4@YX4RQ+F[/FO3?-9,P[Q/H\.(CC<2/F@PX*#G'-Q8IU 889%;J>
M_+6LA.ZGP 6/57>*0\-(L-:.+@)<JXT9K_561L03;RK7=H(DN04/#+QYX"B(
MIA0\AXA4/)G(E4L!)96XF4C2]8)T.(X[Y,-##<(\:KB%Y3&DS$,62]BKB[CK
MH@K36;-:F1\%/Q)(VQ**'"3JHB5##$7GMQ,PS,"OE1EZ/8+5K(QML]"H$;HB
MA&8\=R(@B7+%B4,R\63F"@E;_>YINR6>5A5P&V%G9HLLQ02Q8B&/AYW&) 0'
MC2E8\H"L.W04XC.-K!(OS0#_ $NK,AQ<CVQ6?A""+.$C<R:6E:P^=GM:U*E6
MM9<!<9/V6'.W:W5Q&(EBFA2,*5CXK2 !3-',@EC8V%Y\@U/G3:K64LF$C3WE
MO<&/_L#8H5(Y/FJ"%&626>)M4B_@B5&@#$C77I]Z=Z4HN*8=>9D/!LS8ZSQQ
MOF;A,R+DC4@NL>O%0]1=1S^=-;I.SUT'$&YJPN]F83.)%:%HX2[M$SHSS.Q^
MA#,8Q=(F$7+>M/FM!Q&FT^P6<.%A,47LPXF-&2%E5I9UXJ -G!^B:0]B1F!K
M2C]8ZC2OJ'.%AEED;*L<EHY4#_P<I555F&O.9+WO>E=7?O"QIH,Y<.LN&4Q&
M-6#9"8PH:,QC.RB-E!DS%N8D];UM4WJ@FY'EF)W'[,^<12R'- <ZYY<I1 C@
MDK:$.&+6TN-*UU5KF*DKW6@Q^^>POG4#B.,QNT0<3S"S-&4M=46%0X(]/?1<
M+/JYI\;FU349W9"OQ%\/XI[RK$TKM&\22+FX<3I=DF&BF)D?TJ^;)VM*B[I^
M;Q"TJLL/.\'D^ T&[OBQXL^&F/$&P]I_.MF8%9(OF6TT23"@*DC&,,\;8@-F
M)O8V*V]U=.V9TCQ5#==*IE;)/2WYYD[AX8>?G22WFKY:DH-@_E Y,&7P&^.Y
M/&E,&:?:6RWPRX;,N4$KA1+!*46/0>T3:^M7?!]-<1;[/3BUV:#^GA,%-[TI
M3AX#V8/Y>O@A-AL/-C-F[7PQX;QQ\/9.*T"8?,5RC#MD24D\_P!:W72IBETS
MP=26[.FTK!JFR\&U>CB(]S0&VI\JCY.NU.*$V]BME\-T9IL3L[$/$2&)"L6A
M#,B9LITT(K<NDFSIY*32?-7^L;2V;)2<G5IM=Y'3Q \2_!3>##XB'8V^>#D9
MYFC$9V4X,IQ)LQBXJK&8F)Z@76F.*VGL_$))RRX>:-*]&5K1W+]Y ??=M@8G
M&XL;'QL.(>%Y5:6%7D6*\,DN50MQ:;I[].U1]/%14FXO*_YY#6%Z;^R6WNS/
M(CYMS8C8X/B4B?$, TN(,1/$A1R3&44Z@EOA4M1VQU,5G=CB6+W8I)"$_J=X
MG$&;A9954&5Y$(AE52C,$=FY<[R,U^^E//T_3S>MC2Q:OGJ$.-W$Q$*< O/(
M\9C9'=O9*1K( A>Y)0/8$::46GMV+R;6O$/'%Q;L% W9Q<>)'#PV*D9 '&:P
MBD!!&=F73,QDU]*=+:E&>4FEW#AUJ2XV.(=B8Z!UPW!20M=>%&QD6 AVOGLK
M$9UUM?ZG2B1Q-%Y[QG64I9I@]=D[1SSIAHN+@TEC$V*@+JLKQH&0Y9 C,S-K
MI<6I7PBDI7WE[3'.*T>9V"%97B:/$. Z_.(N'(! LS2B#$F0\M@5"_&G,:M-
MO)KV Y><[ZH[30F1'PLK3MB8X4XRF.(1I'(Y10K!E)$*V'32U'C*+]%W8FUC
MF 0X=7PC*JAN&T4R9F<2K(L2M*I9[Q"QN/.WP=0E<S-AX$A:*/#L,TDB1B6Z
M,V:5!E,ZM'](SY18^1%NU/Z;;B">H/@PF&ACCQJ3-D,<ZSF1ENY1KH)6=@X7
M,.FO[5IQ2SS!Y9W!6S<?.LW$S()5ARI8VR9"8P>*N3D8 6Z].W<&)H1Q%+<S
M]OY]@&I",X6'/V#M]H4CS8@!))HVXBRWF37AM':PXL4\P/GE&M4W:NQ^KBU!
M>;Q[RO8_ R;E*.G$>'8VU!$!(<8^9LV7,]HYN&L@E6)[\X*2%<WULOIISK:&
M#@DXRCYN=RKUL.DVGJ.?@]HX>%N(0K2/G8PF4M)#PW8K))8-:**.46Z=?LY]
MC=GI2WJ:M$C*M+=TU%'%BHRX5>(<,V'>><8)@T&=4TD"Y!(%L";CE!.M0LJ<
MKN+T0R;YAC@L6DT,:Q".0.9)X7.)$K2E>"&574-'Q%%A8:C-K3>5)K0%*3OF
M"Y8<JJQ)F56)=GD,DK\Y/!RH@=C"QRV':A3@U9L#-W8VV\FSDQD\T8PYE0*Z
M\$1R6BR3PKR+"LJQB'-;,0I&;7T)",EFM1K)N[8Q^\.ZV&BE<P<2)A&V'<LP
MX$?"F,S0 S,CF0Z$LNI^RG'6NUGJA+KQMNO41;;OXY\1)BHH!&JRB)I[S'YW
M*8C)&921*Q:-18: 5OX1?+2PB=5-)>X%P[!>23$2E>*'15E0H26DDR3,MR5D
MSH[N;*->_:@RKQBKZW!.HM #-NS/Q),/#AI3,IDDDEC'TT^'5?G ;51%&8XE
M]FY(K2Q,=U&U5?'T5]03X[92F-XH#,Z%GRM*#\YRE <LCQ@QW!8Z6Z"B0JQ:
MO$5"M:5W8*7V(DB*DTT/&PV:;#-&2LJ)+'>6%A(BR%G%]=4\J<JJ[<!PJ[7H
MKS7J<8? 1QP.QPY>/"R1XIL_.TAB^DC"IKF;$6(Z=JVJLD[II(S>DY73UR,.
M)W;Q9 ^;%@LV,4O+&O$FBCC8L<J!E(SABF7IRT>EC%&5I2RL'C*V>JL)O%[N
MLN*>>8202O$V:.8.I!XQ6-&S#Z1I%"Z7T!M3^GC).-H/*X15FH[G:)G:^ZT>
M(C,ICPT1$29VL\3F'$0H\65396X;LXM_?5*X;:E2G%+B.*6+<'NYO/P&VVKN
M!Q(XYECAFCA"QKE7*2RFZA!U)'?SJQ8/;-5-.3LNTDJ6T=UM7:;&WVEN4D@E
MX<+760GA21*; #B(K(P R"1";^=6[";>E'=O9P[-2:PNUJE*RNMVPCMH;K2A
M)1)><QXAH=5$9'T7TAC^F-\A<:93>_2K9LS;D*DFO.MVZ%GP&UZ<[Q5\U?L.
MN[[8W=?:6!Q%^+AS,%ERZE5+1\0.2L9C81(;64W:K9AL7%6Q$+;Q+RKT\12M
M+33\ALF\*MN2G9V$G,C!)YD=VCFFA9E6$1QAIUY(E3$(>(?XMQWJUX>O\*I*
MLM'XD!4I*-1TI:(V';@[9P8P<<L>(+X^%8+1++#,LD<JY9B)UZ(&-T)N2*5*
MUFC=-JG/+G]7$FI\GKQ#?<K>5,$':+9>V9(!\WCF,DF$Q8X@D!)98UX@>^ON
MJ)Q]&T%)\B^=&ZL:T*F"ENW:O'Q?U&Z#<N7#[=P$.(CR22Y%*LUA9,Q*_11B
M[$?QKFU0<O.E9\!Y4I=5/=XCM[+V1)C(3&^4%+RYLJ@A@+*1FNWM6II-1C+S
M5F)4.(T7B!N%#CL-)$^&$Y F23ECU=7M;V3W?RJ!VOLNAC,.TX^=89XO#QG3
M\]7CQ7,UX[V;DXC=7;N)5<.XPKRDM89.$JS(^=6S(MXSJ!;7IWKBFV]BRP=5
M[L?-9RW:^SO@]9RCG3?'D'6QY(W011F.3.JEI (XVXF(E7G9 Y'$X8(O;455
M^IDI;K5KD4H[J%YLL!R7,DCKF)C)55563FN\:<RJ+]:R5/=R'%-65Q:;-ABB
MD$8*O)9L[+H#GLX !)<H .G<TJ,.#60YIZ"HP8 %IA%9HQP[PWD+<*/_ $'3
M)8#0W%.*=.*TU'BT,\\#&%.(A6..+BJY5D15,NMAQ&M-;V=#K19PO&W"PMZ+
MN$MM*%L2XCG()9HLK,5"1%QF9!GY0QDLAO\ \+J#QU'D!E%:#9[6V<&22"0J
MSJS]67A%\V@5EY5:_>JUCJ%U<95:5WVC:;=V68\$,&D.'FD+.ZJ-1PX 9HP[
M#D"\0:WTM54Q-#SFK#+$4K9C)[R;)6.5>+%"QD(M&F=$#2EWS9XP0V1C;H>E
M0.(P^[4OQ(VJY+49/;.SL7QY)D)4D&6$I(\*9H>*L2O-$4(4'B7+ @#K0)3Z
MOL:$QFQ1;B>*^T]V,6<'B<;+/@<-B\/&\T]WDP\.'3B'$ MJUFD(6+IWJU;"
MZ78[95:,:DM[#_R_D+'L_;5;#R5.M+>I??<B>&X/C!@]N8:.7#[6,D)S1F:&
M<QRN';G9C>YRWU'U>E>@NB_36CC*#G&7FW9T? ;6C4HK=EO=I)S=_?A,8\>)
M2<R,R(J*AZD_3")H[V8JDT)O76L#MVC7A'/5$]2Q*G*_8.ULC>R QAP[RS\*
M)5$B,,TDC9FB)8D6OI5CI5W*&6@^I5>;'!V=*N(OB6G3)-<R1"1,R.XXI"@<
M^13&([KR 24ZA.\;<!PFT&V'7+&3(-6P^4N'SY59B%>XM;+>_OK:U-G>%X8%
M2("3+&V4N'OQ\WUKC/UO1S05I)\X9RHYI'X:YK\-1%:-D_YJ0->]88&&%B;#
M/=7>8*]@K(X4Y1Q1*9-#]&=*QF&$R*S9%#D.WTG#OR2R_0\:+[:'U?:/+AOA
M,S,7DX6=DS11R&/-&!Y=3KU]:&;!29I27*,F2T@"WC,EP?QUK# T5SPU:0)G
M,>=EEY!IIK\!2>[0PY#<0CBA9++G"+9' X0 MZ "LT,!3",9")+ GGY9#P]1
M_P +MI6D8=ED:P:ZV.CR1'.[OVXW4D$5A@+5LW.[/<:9 -.36_8]ZT8!R3+(
MP <+8_Z_]=88=%PSNMRG*"6*$9 HOES:][5AAD"21H5B,8*L537J!H GFVFO
MK6S9TEC;YOS')(R@+&XYBU^TLDIMK6& =Q-$J*R!1:S2%P>8$76]R.H-:,,,
MS*\RI<-SDD.18*2#;3J.32L,!44,BNS1%AJ' (S+8^T.)KE'D.U;-K7(,5PX
M5C[64?1@(_,/<>\9'3TK9L'10$%+(M@#>4$,-.N;OFK9JUP:L5HD!?-S#*R^
MT/I7UMV3]59<RPE=OXT8/#N)Y (XHW?-V=R#J/($TBV]YO:"JY4V:I_E*[>7
M&20X!\0(Y-H8J6127= ^%A'#RYQ[7.#IVJQX*"A&W&Q7\1)N=N"&$V/@PX"(
M.(&$;,\9:1BY41,K7_@S>+IV-'MG8;OZR??R>]R&V=LW\X2898Y,9E#7;-+P
M@2P#=^)Y]-*A<?53JJGR1*;/I76\^),J%61(UT C^E .A8<HMY76WWTP;)K0
M$*Q59&4H&SFSC.Q<)K?H0":!4U1ILY!L4D8%E5@6"W )(N2$T(I<HQ;N]3#A
MI25?AFYD) TR-;R)\@:Q9*R-]Q@>0!(U>Y,0L%)N1<VMZZUH2=3,TBE!PXR
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M@JVF9)$!:1S?AH)4/+F\[>^MK4P+PV0GBF5QG63)RYBBM?A1R+9& -O:U%*
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M!8&1"@D*&UXV E47UN:KFT%:LUS.C[!FYX:+[";R8B9MGAT=\G"5[9K%W/\
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M8K9BW#YR+NHX=HUTX9].]:-'$LUXRS7$N&*1H@8@AF.=P2I4%RIU%^U;-:Y
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M4+08@QKA\K2,W!"(KF!HRG"5ERL]KD]=#6X8M75KBZFQKQM<AAO?N+C-D[T
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MPP[@JP SFQ)R (.R2 'XVZUALRLKPMJ%4,RDNK ,;=FMI<CUM67%\#*EXP"
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MB!<R$@7F;Z< Y3>R7&G>VE9OWU;!R=@&=G)';^#XJP":8%!>82%FT"G*QX9
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M=[A4A B9))FPYM&4N%/5SH%70*Z] W2MN#X@CB4!F#1)'&ZZOG6S2)>YC/\
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M*P73NV^XX1;O)&$M$.?(9"K-D5\D/4$,M[_"L%STRY@F%EQ(+N C.OUQ9\Z
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M> O[@"&1HAPV$:\&%8U=3G8<1&5%C+=3$8S?U-:MV PAGQ99,0O$F/"R,Y8
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MBC9K!/:+9LUQG', %',S$'IT!HB&N\%\N))N#>X#,2S7)!ZJ"+C0TM(0Y6S
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M""*1!_":@D@FPT'2MJBWF-92OH)]L892Y,@-SE 16+*' -T]FP4G[*WNVTU
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M"B7!<+B9Y"%F"&&+E9BN7DC8D*3QF-NNE+WD\T(>]J!7#K&XS.A$9 1;@DL
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MG*U$$SD[V,44:126ED"R<>4&$IF0YW&1F;H "WL^59P$WN#2BJC2P1JS9LJ
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M!WY44J<AULQ:R@$)VJS.2?$>1C84K<JJ6YF;+DC<7^D)S/<@6!"*;>ZDYW[
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M#J0189 /J];5.06>0A*S")XGEGBB9TC3,\EGB"M&^>Y&7^^)\J)]SF:L 1F
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M8,)M[$4+4Y/>@B;G@UX\X3:V&P1;$QMB\5+P5A8B=[R6)CD;E$.4',;B]Z]
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MUFP<F!XRLBRJ!FPS!S( I!AQ*JP15;OAS?J-;VK.X%4T.@XA9^0LZYR;JTJ
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M1<-U!<NV;0UKQ$[Z[0BFF5)<5-K"I!>./.)HQE:*S#VVUMR@&ZTIQ>IF]'0
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MLW:M& ^)S&\?SARTLF'7$Q9;3KAKZW-\P$K$:CL*V;1P,,V%CPDASRK*O$F
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MA020P6Z26'L<L1%^Y-/:<+::"] ZP&$=I+E>(T@X;HNC2N5(1HHR1RH.MB-
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MW&C$XO'' 67#A5*R2"2UHV4:Y5 )%:-=I@4.9 L@9HE0^SH6S#V;BQ%F()]
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M"1E12,P+*-5-],XZ$GJ*V89\*[B?AEU8!%R@( 26N%.8^=::5KFUJA20XE7
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M9Q,(U>+^U#$?FD)<H]R2KB/VR1?,=&5!]7M3_#0NAGC'9>PU@>(FU9,;O;M
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M_%!),20%L%)1R7O:-0Y] >?M_,6,;O(2LQ%XZ1\A+%G=>&Z%<WTA*VX88ZV
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MK7CC#2%['^$"@=:PP$J&=7GT9%=@2JA.(&CB,:*HUT+'TUH=0VCNR-$#(5+
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M#QF,BCDAU"&YACD$:3(O-HAS$<F4W!\ZUW&P.%6)V6'*[9FD7B6@612.2$,
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MTE,1O8=ZG]D[4C!?!\2MZF\HR^]Y#:M1C+/[D0NQ<9/%,AC8PF.9%Q&%D%R
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M&\D<:R'86%WKWF>-P;M(IQ^S-U5+QC10"!?6]2E+H!CG\?6HI=BE+Q421I]
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MADFFC&(?%OEYW@)!7$?0'AE8%#$*.8L!ZT^PV(4=3%ID,QO/N]B<,^'E3!+
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M<QCNI>+-<,5]HD@=#Z^5+4(IIK4TUD%6+@24#("BE0K+>_,.8D]\HIM6AGV
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M*V9X@!K 2+Q'A:3*4)(RR2$^QG%\A%NEM:UXF ,$@N"!F0<1CG+',_*5RC0
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M]('=C)+=,A!%C;*!&0S$GVF[="*V;".=F+ETZA''"=190_,S$WRL2'%JU8P
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M"\0B,&\@#&WK:L>ANQQPCPFD!:1RHE%M54J<C #0-%Y#J+4*2N:L8FE9^'R
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M90!HH4:M>]NE(?9H:L?,A8R0B)6RM&T9918KES W_B96+$GN*2::\Y'9DO(
MC0Z!\R%0$,;C/?..AR].Y%(5]VZYF[+@/SX=_)F^4!XFI!)N5X1;X[8P,S0B
M#:Z[#Q>R-A8A6(RN=O[<&S=A-:)M;XC0:G2I7";"VSCK/"X>M*+XVM']]*T?
MK)##;(VEC,\/0J2B]':R_?.R^LF;N)^23^4#O"</B=]=X]Q?#[#9[SX9\?B]
MY]MQJZ '^LMAQ#8LC)<]-I#7IIJ+/@_)_M>K9XJ5&E'E=RDO9'S?[XG</T*V
ME55\1*G27>Y/W++^^)P[A_DC_D^;OIAI]^=X]^?$/&Q<-L1ASB\#NKN_B)%
MSL,!LO"XC;<88WL/SFUE/GK5LPG0'9-%)XFI5JR[U"/N2WO[XL.&Z$[,IV>)
MG5JR[U&/N2O_ 'Q+K=3Y&?R5-RXDBV+X">&D[(BB/$[Q[O8;?/'QY3=3'M+?
M'\^[0C<'N)03YU9,-L'8^#5J&'I>U;S]\KOZR;I=']BT5:.&HOUHJ;]\]YCW
M["W(W+W6"KNSN?NMNX$%E&P=W]D[' 'D!L_"8< 6J3A2I4U:G&,5V)(DJ6&P
MU!6H4X07[F*7@A440.?5AA]6&'U88?5AA]6&'U88?5AA]6&'U88?5AA]6&'6
M_4 V/Z/6U:$W.M["V8$^[N>@-9X&N%C@L/LO\#Z]M:PQLQDZWK:1HY4D]]!Y
M^O[Z2S#OFL;'3]%8;61WI:,/JPT<5AAW%:%K0ZD5AI\P._+?N*TT:.EP1H:2
M:>AA8]NWW5B$WL=+UHRY]6=AHXK1AS66,.*PP^K-'F8<UAA]6&' O^G].GW5
MES9]26S#ZM&'U9>^9A]6TS#D:]3I^C]UZR]C#O=1T[WO8=OP:288I4BF1HY(
MXY8W #1R(KQG7HR."K?96.*DG&5FNTTTFK/00VUO"KPSV\)_SSX>[E;3DF#*
M\V+W8V+-B6OHS#$M@CB$<CZP8-ZU&U]C;(Q-_A&%P\V^+IP;]]KC2KL_ 5OC
M:-*3[8QO[[#*[Q?(S\"-OK(V#W?VCNMB92S-B=V]LXN/+*00LB8/:_YWV=$4
MTLJ0HOI5=QG0#HWBLZ=*=&3XTYM?5+>C[DB)K]%MD5\XPE3ESC)^#WE]0P6W
M_D SP7EW.\0X9BJ%4P6\^R'AS$2+('FVGLJ>96+6(:V"'6_I5:Q?DR:O+ 8I
M-\JD;?WT6_\  (6MT,:SPM>_9)?C5_\ !&.V[\F7QHW3?%KC-T'V]A%9VP^-
MW5,6V(<0M]0,'AB-K(B$YESX5#;M52QG0SI#@6VZ#JTUQIM3O[%Y_OBB!Q/1
MS:V';;I.<5QAYU_8O.]Z&LFV)B=FXB39VT]G3[.Q<"9IL+C8),!/$1E4%XYD
MCF.>0$\P[D5"3PM2DW3KQE"JM5)-->PB94I0>[5C*,UP=TP=!A8LZQI 8VSE
M6D.0!'RR"Q.I"'+I2E2M;D*4;*Z'%W)V0V(Q\67#Q,V'1EFDS_2-S=6+CZ06
ML1Y"NE]#=EPE4C5DF_\ A)K9U'SMY\256SU2'!Q1D*T:B-6!RK8_54#0 W0D
M5V>$-V*BN"+12R@ YD@V>^T-L;2Q$V,#NHP.$=>)'ARPR(L*@7>9FI:T5A]&
M6]'=63,L<N'@A7&[7?YQM/%.LN&V<Q,C1*'2*+#1X=KVQ"B0$WO8FE=QMN4E
MNP]% '%X/%XB-,;M+%IL7#F1I(AA0D.)@%[11XC+99&8#4 Z4N$KY:LQ3MYL
M5<';#VK!M3$+AIYU)A7B+*\;1_.8UY0V=AE;,%.E*E&RR](1+):9W,VU3@A=
MH8%4$Z2A08W 8@MH;YQ;XT-99/4U=+TGF <*\3NZ(W,VJME*H H[*>AUUK::
MX&)IL%FQ&9@ 4Z,!HUN7*&.H)M]E+T%71U90(P2 N<76UKBW0,="+UF1F5LP
M[V#MJ39DJI<G"L0DT.;E4_QD!T7]=:4DN\U92[QR&Q<<ZM(A1LP6Q)%]=;@#
MEZ6%+4E;(#*#B%G#N>&%XCN25YKE;-=FR]+4I20.ST#3#8:P!N&8#E8 #+UY
MC?KUM6/FAU1I9WEJ9I.'&"S]2!89[6(.I"]+?"L2;'5XK(+9MKX>(F,*%<YC
MF>V4J";$$:6K&F;ZR$4 %WD0@!6C+VU/4V\EM;ETK-T1UZ>:/OZ9([K< !K6
M(O<Z@',"-+5FZ9UYU;>1@I='(N 1<+;]NMJWN^XSKN\!R[VK&EPRL<RYLO;U
M MH:S=Y"E6[#(=[48 !A9@JA2>3,03F/0LVF@K:AG8Q5KO.]A";6VW%B9I+2
M<0$HP;-ER'-S$*=5%QTHJIMZ 92BY9NPC<3CX<C7=G;,P9G=0K*'T70@: _"
MEQIR,3B^(08C:H#$?.2J*Y9(^*0%?*+L#?4D6]]*W.>HB;BE>X3R[Q+A@ 99
M560 LZC+<!M2THL1=K7%+ZGVL"JF[Q,Z[U*"P+OS*9%(-@K,%N%?3,0 -.E:
MZJW 5UO<9H][CPUO*>49Y YLQ!-@6RFX(/6LZJ2X.XI5;ZV#2+;Y?.6;B(P)
M(N3923'RZ@E4RZ&@V:=F"E.ZT$9O/E> #D8M>RV+"56&@;,#>UZ+36\W"V30
MSKKS+HU>?*@W$3:FS=JRK@<TYAG/$AAB+J8092!)E!#L@L#?TKGO2C9LDI58
MI:E-VSA56HR=EIED:L@@CF3!O''.N'$A)F1.,K12E),.B2717<1AF.A8$:US
M&<+-WU.;N.[)P>JR!1PI5[0N8E#,Y25$FC)D&95BD.8 (.Q.AIO45UI=B):7
MXBAP>'"P&5D9[OPUS)#)F+K)%#(94'$"M'PW.NIL=33.4>.J-K-Y!A@,/-B9
M93DBCRR1Q-$J,DDPC(5G#(!:RK<7TMTK2R:N%44.!!L]IH8Y,RQARRMF7.6-
M[01V>YS%E%V/07]**K-BMR]K@Q]D(KQ1-A6EC?B2F3*RPY(T.8PW%^&) 03W
M\Z+3]+(W*F(+%;OR/+B1%#%&\O!$*!(U211(<^K@%)=>^A%3N&JMTTKYC64/
M.[0H&[!(GC3#2+DDD6<QJY:%\Z *V4%9([,;7-K4]A52UT,W7Q,>"W=*-(TA
MEBDBX9@8AL/<Q(6S(-0/[ZVM/Z;C-7B$C%V\W45>S#B,.53$1M-#PVQ#RQ9G
M4B!99B,A .(D:*1P2;$$^E'7[K0/333'JV1M%L/A_G*L))/G#85,-#$3::49
MXI59K,52%ES VM:E=7">0[W4\LAW-V-H8M(X^(7EX2\I:,1F.8L,V5UOFYCF
M OV[4!X*G/4VJ2M8>W8.,D58FCDXD97,,P.1Q,6D#DZ961;6[:GX15?9#C4R
M7FFHTI>P7NQ)$>/AG$QF665RL(*E@>N63-U#]F[4*6#=.25LAQ&FT[O0</9:
M$21NS.RM'RQ,(V;,KA=66V8@G0=EUHL:<4K67N'$8Y]HX&#C-RG!2[&(V)LT
MN;6XC]GRO[J)".78.X:=HH\&9$ULT3*XB"JP"^T-).ARD::]J=1A]\/(*XHX
M3[$:QIE,<5VRDEE+?2EG-PI47MYT6--7RN.$G;L%!AD=[.,JK[.5(_8X;7)O
MTNR ?;3F*5K<!<8VSX7#J**T2<A^D<E'-E;5K7(TL!?TIQ&*U#QM<-(49"&;
M,RHP0 A1)*S>7=5UH].%V%AJWV!BT31ME9#>Q7*@!-FM;/>PL+TYA3L]0K#&
M-9";Q$"0(#8!44@6S YB%Z?;3N$7J*CIEJ"4BD=)2@(95)9E0:9A8"YN+>ZC
M[KT>@O> +(#(3PWE+HPS-8!&!U8^5@#6.' VFGF%&(0<1V*W<(8U1;G,O>[:
M7U[]J'5INU^)DKY!-C8BD9D!3(Q<QEK6&53F ]5M3=PDUF)L[9H3\V$C9)$L
M5<(73C$K%H;DE[^W<Z#RII5HVN^%@$U=B.VC':(N;K'9U^D!"LP[&W,8K]ZC
MJD5+S6-*D+/L$9B,,&B=D.4L2RA2TBQE;GF#<P!MWJ-Q-'=TT&THWRXB2Q.
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M^;GZ-( =7@L2L<B!N:_E[JC90>G$"\@GQ:O)),BXGCY4O@RJ\-B\D-C'-(+
M"X[=Z;32N#F\A%X^"?#Q$69XBRIS@D13<8PRQ()+W*&8<_32LC[@$H7XA(^!
M?,6E1S!,<H.<'*\0!7B'0LH;0VU9M11XU.'$&X20!D@SS/*SR!^0?P^EN+"L
MB*IYVA;HQ)TIQ&7FFKL+I(Y LN)F25"9XE6.-5C6)0AR(6_T8Y4BN![-]+4:
M,EHGF%R K!)$,A:0R*S?1)D%V58K$R$6,?TG6_6GF'GYV6@J*S"'_/<F(XK'
M"IQV17@3*B&;FC:)26))GT8]5MVJ;PU3<GVAH2L^T(XX&C",7$[J\TQ<F^=&
M?Z613KD(U.70DU+1Q$=]-9#A5/.L!,3O;B=B2S<':6,P"LLR85^(\:*^3)A;
M+J%$TLA:_6WQJ=P./Q-!J5*<O>R3PV+JTFE!DH/ +Y0N/VAMB;96.Q#Q/')A
M6CQ#R-&7A0Y'2%2>(S-WS=:ZQT-Z2UXXA4ZL\N\O>Q-HSQ47";^R(W ^'F^4
M6+P\,C3!@I#6M<DL!8@KJ2 ?A7H_9V+AB<,G?-\2WT*F\\A]<'M*1<LJAK/:
M2$):P1I&S7;1EY+'+K:I/)+(?JM99BXV+M(RS(BY5,@*C*S,Y\]=3:]9<.GQ
M'&PLR.BIG'*=7E C.9="H(]H@BUZ'*'%:#J%2^4@>,N9P!8DD @:\,^V+]=6
M!(H>@7M,\0R ,R!D:^52/8\B&S"[#0^^L,M[QM]]]H)@\'BI)I>$BJZ6D"@R
M9P2N2QN&6G-"*EEV@ZSW8&K[QSVRD^U-G[*6=69A)M%X7+GYP0[1QQYOJY"@
M*DZVJPX&GN1?85W$SO(9B%#'% [88I)(ZV<%7:Z)E9; WR9N]&D[OL&O;Q,K
MQ"25HW1XYPPD=LWT81V&>3AMR!6/2MIY,QJ[1/GP;PBX+8&!+1CB2NY *@%E
M?+E<E=%Y=0;]ZAL9G,F\%&U*RUN2DV?DBPSJP*NIR@9K%D$TPS,XL.(0.E1]
M3@25)6NNT-)9E,D<2RLP +96"!A(%!0&ZD@L=*0H2M<(!8EXLC.2.^I+<LPT
MD)((47:X'NHJ5EH:"K%,'F-D0,F8 1MET9R.=2;LU* U=4$LA,J!7S,#E5=<
MI)0 GKKV(K0'P ^'A996B8R+F.<@M<#.V;*=+7(%Q6&"^@,&#P@8(.<!X[ !
M[G4!V N:%*,G*_ <1J144GJ)S>3;T,6'D*L !&ER7R"%R 20;_QCT]:)3A9Y
MZB:E6+C9$#O%3>W$8W:,^%BE?("F9E);BB/(7MVL0I(]#4EAZ2E>3T(G$U7O
M;J8SL.,(VKLW#*&G.(VGAX4=L2T6LCL75QI956_J2+>8ITX+=:XC:-[DM<7-
M\]VGL>+B*8L+@H+?2N&#@W4 &URPZCI>F4K*%N-QU!YCA8W:<4R(JF545+R+
M')?,2  3EL!JE)=AQ)B5Q..SR=2 7!L<IC2-QE!MKK=J3KIH!<K,ZOC3-%(L
M<=N<(&CN,HZ!VMUS%=+:UC-IW0'Q$*$\SR1EHPP,FB6O9[#JJB^G>Y/G6*]Q
M,WE[1+8L91)PLMHY"JRE+AB%%R#Y"^E.M.\2KL"00J9$(LY+NS]EN.)<N-+*
MH RUAC>78"5&7)8 B1D^FL+@'*"2?4J1:DV0D.H92)$C694,E@I-B0 2VM[K
MSA;"DU+)&K"N@@$D?$+M"3F:S:F50%'+_% XG0=*;.26H=(&P0+.X,-G5E6]
MU L=6)4]%TM\:3UBX&'3%Q1VEL6E+HH)5KLIS,MPWF<NO>MIIJZ-2M83&)PH
M 5Q=;HQX2.KG,&*.01J#E&HO1$P4M1 ;05.&Q8.5+<-3(R-RMQ0HN;GM1J;!
M3T$DT4<2B!X;%HM)'+! C$BX(O9F9#KZ4L;_ '1C.:0R-(8V4P%F6X9UC095
M(>PN%I DX>0B4!K(JYS$P4O?G:QL <U@+6.E:N:;!B+*[01WX4:,&F>1% 8R
M E9&0>Q$%TRCJ=:6*!31)&%D0D"2SW=\_$L@0E+6"AV)(^MH?CMY&'"RWF@P
MY/T42KQ0@_A&7,ZGR8,21\*U?/L,,KY0DC\*XO(5TL;.Z9D'GK;[*S@88)60
MJ\,2@RALS.$(&<(K+(EAY(0?=6UVF!<!([@,"UPS2ELQ#,^J<O15-M+:5NYA
MU*9U*RA^,<S%%&4<.-ELQ-PP%C\:R[, <H5)65LLC./HHD4JRJHN64C1B1UO
M2X/-W-,#8N411(TP@%[95OES1NQ6,E5!>24!;ENVGG2S0E\2H5I$XDLBL"%A
M=4(8..AE/4 *+#\!<;&[@#$!8XHF2)";@R1L@OD70*+7NJMJ?2E&&3#)(.*0
M\:R1A; %00@*LT?\8<0..EKCX5AM!I!+)-D @16R&3.,[9E4GZ,$'*"HUH<C
M7$$,4D*LJBX4YLA&9;Z%U!U.6_0GH/2DFC*8G2%7D417 $;9TD+@DWD$>H59
M!W]*V8<L3#+"L81BY3(S>P0+$@BUF8J+6UTK9AU.49GE9EF19%55<D%QGC#-
M8GE C/7SI+?O$5,HF 1B27)'E9C?.MN)Q6S%WMF[D"U* YVS,LS"=K*,Q&56
MLH!7L([ BY0 @CRK#$C!,7X<'TI"LI0(K:(58@<55ME %89H88(IAG3AJ\<<
M8!(T4J0Y)0&S9E+BW8CW5AK,Q3O(L8*1QNY>15S74NL<S7L>@"C\>67]YEV=
MFAB"VRCC*Z!B\Q$/TIO93T81@W M6&>)](\<;&9FCR0LJ7"L5U<\D>3ZSLMQ
MIV-:N;R LID2/14<.'Q$^5LP3(WT86-[ N?C:L-!+C75S#B,[R*Z)(\;\H1.
M(JO;+<E;=;=JRY@C=IR0S0GB"-E9>)AUCCR1/&&:^9C]*&+6[VH\%>*1N]DG
MVC);U[7BAFD%N4(H*2EBPE)ROS+=E"1 D=#>E[LK^;J96J-0RU-<'RH-_6P.
MZV/2*?(^T/G4>"6&.9)YT S*&YDX=I)!UL&%/([L:=WZ0PG5G5W81]!O,U9;
MHX:3'B3$SX8-)/*^)"RLW.5:Q:19+JT4F4YAWM6L/YWGAZ[TCPL3!W'P-HHY
M9)\-AFR()3"RK(8Y"D+QK'$4!7D/J#J>E'=AOP[24.YF'PN%41$1S)-&D8-P
M#APRID=H^KN;]18:_;IVM8U3DKY:CZ[/P2<&*&$LDD9X9/#5KF4.6!%K-(D<
M*M>] DKNU[!M%ED2/\&O!O&^(>VH,7CXIH=A1!<3F@1?G&-+'*L3DA3$@:,'
M0ZJ+=Z8XK$QHY<24PV%C);]71Z+E_(;2]VMUMB;A[)AAV;@\%AI!#8E,.L=@
MJCG-AFXNG6H656=>3OZ(^46GO)>9:R$+OEO*\TDRIB3+G# A" HS,T("W/*5
M9;]M13FA24?.8.K4W4T,GB,6TT\[!#B65 S2OE"GZP 8=&%^MJ?03W2)D]Z3
M8%3%!F4<1'D,;</,1F9EUE63H%R^=M*6)NP+).%62\Y@;*3K9G2[6RH!K*23
MW[5ILS3O"&3%0PO)&,TCR*><Y2L4L8/LQ@Y</&X]IP;BL6AB"QMH*'='D9WE
M(55"F[ M-$9 &MQ%B$1O;J!6+5&!+)*LP9ED,,<TJ,7$:LD<:W.7(?8"AKGT
MHV@.>J"N7$!D3BK##PX4 EDD+LFL^0BW,K2)(&(M8. *P3=Z<0HDQP:0L9 N
M;I';E57^D$I<6RDAJS0(H/F%38IUQ&+,D29(CE"*I+,"C\*PT&8R-FN.4:5@
MH#228>'#A2R87B.[P3Q$"9<JEG$B]@EB;=R*T8 &>&=4,,;OB^&9(7,T@:/A
M&_S@A#8YQZ6%888Y%8*1+"JJT(CC"Y&^DSQ9)=?::4Z%M +5LV89V;-#,"(G
MA4Y[@E5ED%K*(]-5^ZM&&##P NQ6-C%?AA\CQ&?C6>1B3[4.4#^^L .PMAHR
M(/FV;#M'.,0DBPN&UB7C$94E[RA0G*?A6,RW@99(RD_!R"."!EC0.>& DFO$
M95%S](;"]:! H'"F4C#&1T99(VF =988XQ:-F0DD$@#4];5AC.> ^(P\><1Q
M-PEB"SEPS2@E3):XO=>GK6&M,SE,*KW:-6*HJX:)P3:?-[2]G9U[,;J+5AES
MO%#/DE^<$10"00K& 'F27CR-&<..T<I<"2UM*V%RX:@_(RA8?HG<%U=8SE54
M1""8\]P)%>4#X5LV9XX1.C<7.;98D<758TR<1&X78L3J>IH&INQG.&4AU,<!
M6-LT4CW5Y5! C $M[@ZZ5H'OOD"9(0BG@JL>9Y 9)65C)"3J!:^5BBR!;>5:
MOS$ZF,)%PT5)9D;+:82,DJM(2>&(EN,S/W7M1[+7B:S BK+&LD4I&0QF2(RL
MB\)@]V4JINO\$;>GWY9&@<$>609I5,<R"9EREG41G(RC/<+G5%:UNIH3U?(,
MM%?D8?FA25'!#D7$#$F6ZDYLHMR:#2UJRPHS28HD&/A-&2RAUX1''.@ 4@E,
MJGMY5IHP,8,.6GC1E8B;(,0#$%.BDJ;W"A0K EAJ:!4MF9P#,R61K<R31Z!P
M6"ER$:..6X9+L+BW:AA.!V+K"Y;A)-*5"HT)&9"D8^L2Q_T0<U889(H8P0[Q
MKQ\04B92_P Y.I52B$WRR$?6-88=GFC$J@X5@I1@(I#8MEB%S);3H.O2M/F8
M!@%FC,<63/'=((5$B @=0T@959M=?=6S#8C^3.4?U==ZV7D4>$6W%,:G3-_3
MEN*&9_XSAE(!["HC:_R9?2+PD36P/EL_HG_A1/_2LK^-(3^JOXBDYK_TX;9L
MS'E &,EN%'4T]IOS%W%1QGRJIZS\1M)&"@ @N3J+]?@W304M#8ZL"A4$"QU.
M6PNMM";:"_<]#6&'5LMCE>VF8YB38J.51RCVC?3I6UI<T![E0]B+.PC!&I'*
M"20=0"12K\]30$=R' )';2Q'M, #KH18UMB6\KF-KVTU',,H-B.@S7.EKBLS
M$>)@9T.92/XALVJ9;6Y; #K2D:>8#D*W)0^R<N7*;"Q_B^RI\J4:.G3+J#<W
M;LP/]Z>I(M2TS#K;,42,HK,IS&2^47)RN/0 >^L;L\F:OF=&#*"QLN5AE&C9
MP1&+ZC33SI#>8JYQ[*@BX89""%N"+Z@ZC0#O2DS+^\Y;* "$^E93<YA;(S&Q
ML?*_V4AYNYHX#B)\KR90,HSL#('OH<UM;773RK3RR-QUL=(U#%B641YR,A5D
MN5.95&MRI#"DWR[17B9B,I>]KA0<B$@<QZ:BX(/?RI.\8=)6)(=M-0"2U[FX
M&49A>M-FL]$=P [9CJ3R7)Y QLVG8BPZ4A_69;F91=A9<@):QT !;L=-"+5I
MYYF^!SD+ W !0%U(!):]PZ];&UOOK2?N-6OIP,)!+$V4MDN+$C*<B+FD.8 $
MGTK-XTCCH;E 6*B0AI 54)H2O,1S7TZUI,48+H%O&"6<97=A=56Y-U%@186!
M(&@Z5C-IY' .7)8LQZ%.QLOL^9%N]Z2V8?,!D7JN4Z'+:RD950]-!EM?TI*8
MD#Y+</NS$E6#Y$N38Z:,;>?G677$PS0QR3,GT;2!#:Y&@.896L;J8]?C6I2B
MD8T#1AH8DD:90CN7*YF(RLA+,5(ND8(.@[T)SE-K2R,L@&V+PXS:!1EMEMHQ
M(N&'34$:V&E1^(QU"@FYR67!"7.,4)?%XR.;$! ->A<$%5L[V4Y@ S#-?0=Z
MH>T,=/&U7+/<X=PTG+>=P-+J2K'+'&G%5W&4AKV!*GJOGK49P$]H5\4'-&KE
MESA  7;*2SM>QNQU!]PH#R9EN 72?1*W&.5Q]$Q/U0H[VN;7%"?(2%$\EVSO
M$1'P]%#%XY)7Y2%:X.8BUAJ!6@#U8WFV42XD%U>,-E3.0J +<NP"<T@*5CU&
MM1#6;0R<IDC$@4L 0Y5F<=04M]4GK;6D6\X%9B8G*JS:-P^9X[H,S*EP#IE4
M7"?COI)\#%V@29$>(JMUZZR',"7?4$ N3E [Z5O/CF8?:*($$)*QL+NH5Q?Z
MK"SW"L+$@]+TAZFP-PR$<17DM+E$")=PTA-@.8WC4BY/8FD2RL9H=9(U4YKA
MV(7Z-D 1R2%9#TLRD=.E)\0,LED!@W!!LV25R["55TB[:+DYY#WM]44@$WP/
MFPUX%=B'23GE%K %>@>0%K!^JWK1G><,)'5E4(JJ$ (RELI]E;BRE1WO;4=:
M0]337,QSX2'A*[DD%0'(*KED8@E@ 64WT[FU";:>0EH+U@.%C)6-M9$>4YNF
MIO:UR>@/2DRO)Z"6LLC)&Z.JF_#=Y"(01RY '[E;*6M\32&K/M$I9YF1XX^8
M @HY8.6SET8BZ@#(%(7WFU"5WDQ-N 5<-P[7CRB(KIRF[1L"A Z@%0;]C2N_
M01>TL@3AG"AE9E,TEB@R.)DF#G7-<)D'D>M)DKB&PSCP^ VMBL#C)<V&VILJ
M61\)B%98TQ.'DA48C"RZW9"AN ?K+0]ZI1IRI+.E)9_R?GH#ZN+=V(C:#3'>
M";"OA&P^:3BPAKEY0F6R1+_!JHR:D]SZT[IQBL.I739K-9<!P4V;'AQ$V*E,
M94*P@FLA/$7G*Q*Q<VOUOK4?.<FWNH7<7FYGAKOKXB8T;-W!W-WFWSV@"F?#
M;L["VAMOYN)%*B;$G 0X@8)&C!S&7(BC4D5NA@\9C)[F%I5*D^48N7OMI[0U
M##XG%2W,-3G4E^Y3?AH3?\/?R7ORE=\Q#B=X\'NUX:[.DDBES;T[:AQFTOFN
M0+]#L7=F/;++B+:\+%2X1AK>QZVC!=!=N8EJ5=4Z%-_?.[]T;^YM%BPO1':V
M(\ZLH48?NG=^Z-_<[$Y?#K\D7X1[",>)\1O$'?#?G$_1M+@-AX? [E[$E*=(
M)T#;>VS-%&"0&BQ>&+=2!T%KP?D]V?2M+&UJE67**4(_XS]S18L+T)P5-[V*
MJSJ2Y*T5^-_6C8#X>?)O\!_"J/#?T@^%&Y.P,5A!$L.UTV)A=H;P_1*JQM)O
M'M1<=MZ5@%O=L03>YZFK;@]C;*P"7P3#TH27'=3E^^=Y?667"[*V;@TO@U&G
M&2XV3E^^=W]8]GQ[=+_IJ3) XL?]+[M?YJPPZ'RMT'GY=ZPPZULV?5AAV8=/
MLK2-(ZULV?5AA]6&'U88?5AA]6&'U88?5AAQ6&CX^8[7^/I6C.TXOW[];>GG
M;T%89V\3&6'EKKKWZV%ZSP$W.I(T/?[O=\*W;W&CKV]>GPK'J8<5GB:.PZ'I
M?[_A\:2T;."2:PPR(=+>7X^ZL3LS#O2S#ZL,.16&T<UALQ.+CM\?Q:M-&@*+
MWMY4AB7S.C"L1IYHZ5LT?5JQA]667M,/JU8P^K9A]67]QAQ?IY'OTMY:==32
M68?:6_;I?]&M:9LXOU-Q^RM=QAQ?]?V^7G6L^)AS?U TZ'K6=QAS6M3#ZE72
M[S#Z_P"//WTF]S#Z][?96UJ8<CK\:V8=Q:W72]@?QTO6C#L"--;]K^OE\:T8
M?7/;KU-_+R'772M&'-:OR,"K:VP]B;>P_P TVYL?9>V<*;CYMM7 87:$%F]K
MZ+%Q31ZV\NU!KX;#XF'5XFG"I3Y2BI+W-,%5HT:\=VM",X\I)-?6,CO)\F3P
MDW@+S0;&Q>[F+E-SB-W<?+A$)TM_6.+&.V6BBW1(4T-5[$]#M@XMWC2=*?.$
MFE^]=X_40V(Z-[*K^C!TY<XNWU.Z^H0F!^3%BMVY9'V)MK";5PY=WCCQ\#X'
M&A3<I$\L9Q.&G9>F;Z%2.PZ5/;)V71V935.+O%*R=K,!3V!+#_$S4H]N3_)X
M!?M7<[>78]VVCL7'QQ1@*TL$/SO!JJD$2-B<)QH4N!]9@14_OJ6FHIX6O1OU
MD7;WKWH)0O%71$=HBLV&N<RF3+R.0;#,IZ'L:Q,2G82ZS8; 8AMN;9='VK--
M+AL!A9<T9A!F+H(VUSXB1K-F[7M?2G-KWMH.'*6[N4]+?RAK)&DA3:>\:H;%
M'AV:TG)'&Z9.)(BFS2DB_2Y-)C%IY?G^?Y]B=_<\R"S?$3V.Q&T]IX-HMDX9
M,+"#B$P6*F'"5UB#%$8BSJAS:>?>C66C-M13\YW8=XA7EV5@\L8.*2-H\2T)
M8QG%)97 ZA4$BG+TTU[UJR!2S7M"N"219V:1 7<:9B18!;,.M@0>GF*1)V7:
M#3S%$A5@G$>-GRQ\XZ'D8W"VM<#[Q6KWU#7OJ98A&ZY2V=+6+L><>7+TM;I6
M)KB;37'0#N<C9;J024!.56"C4'UN#6F;0J-C[058EPLLHC0D""5V4F++_""0
M=6S Z7-*5N JZ]HJ(OHV1ASJS.4D&89U*L+Q^IRZZVI5K"'!J5UH#8L6@4(6
M,=U 8$:^S<9^UR3T\JV%3.DP,ZM]-'>Q N5L 3901I6S>ZI9L*FV%%(Q:6<"
MX8LK'E5LH%U\LWW?&L-]6GQ.OYDP$!3(RJ2,M[J<NO12-2K7OUK$S.JBM LQ
M6$@S,J1Y.$V8C->RC0F_?/>_I:L;S1O<BN(G9Y8UDD10Q07#*PZ#IH3ZTL3D
MGD8>%AG6/AL^4FS!M2+]0-#I?O6[VT%.W#D87V3\Y:R3&-;FWE#_ !6!Z$OK
M[K>M;4TLWJ)ZO?"':&ZF,R2M!(68M[=R6>X)/8BY.O6C1JQY9_4!>';>6HB\
M7N[CU"@YHPHC#EAQ#'G"@E>9@S2-Y^^B];%\_P ^PQ4JD+[RR$GM3!XW"KEQ
M$)$7$:;E0G*CL^5,VIN +^EZ+%QEH G&4=>(E5D7B//FO$<RN)%=^&"  <H8
M*<SV'32]Z7P--+=0)BPQ 5# 24 8HKYC'/JJ 9[LRJ) 3KW]--J5N1J+MP.)
M,(TC2H$D$B*2TJH45LPS#II)8Z=*4JB6J5C'*^B">?:>+V=PE8&58T*EV+@N
M[RRGA@?Q1W\J-U<*D;L%*33!3[S)B\$8)E9<25RYFL4C6.[Z-:Z7!Z]Z"\*E
M/>BW8'*=XYZ$=_$_#8/:VS<6SJ+M#)$8E;,)\VC&->C/8WU[ U#;3PD:]&5.
M>C(/&0C)--Y6-.^_V[R[#WCVI%!&.#),TGTJA0B/)(+QL06LL::=-3]G#=HX
M6=#%U(-62>7<<NVA0=#%SCPN))<A<PP%<0O!$SAR\<6JY2"I5L\L$1+$=3:H
MN4+C&23L&NSYX4DF2&)L5%'PV=('LDD,LKN"$+@!R'6PRBRIIY4"K35KF]W.
M[%?L.&2%H(3AD+3R-)&S6;AIF8J,21K_  9 '76F<HN+#0638X6S B\?#PPK
MIRE'S-(LBQR.Y9F)*]BOU;#W4NGG[@T4VLM12IA)VP[3?PP!9+JV9DC9$&7(
M>5$0OHH%C<T>*S".%XV"K$[)BFP:K+"&DD:(O%9(8W6*12'7$2LI&L>MR;GI
MITD*$MU)<P,J7( G8PPS(B+)%'-!&<1%'+>,*)G+RD-=9I)%(N1T ^QY&5[\
MK@^J<<V!6V0CSQ0X2 2IA\4A)*NQB2($*Y%T$@<G5;@FGU&HHA(QL[L,8-WL
M4P3$0?-9"K\&=8RD#2,A>X0.7!81ME91;UO3V-12R#15V&>SMG21RB1%>1<C
ML^3$97CDF<L.([E4<E&L-;@"WI1XROKJ$%WL:25'FCCD<6X9<LS+&J1Z! !:
M$2(W5NI%.XR6KR#060\^PL29H4&'G4 J[0Q&5)(IB#%F49;YT3-U&BT^<5*-
M\@E+)CH[%Q&0N\F'B0*5C$L)1GFE^M&,Q51'YF_2F-;!]9I<<M9KN')V<2B+
M=Y@Q>-C+86 <1<RIK&I .2UQUO[X_P"!M745YQN%.3S0Z>RCF(RR(_T,!7F<
MME**2IT8JP-[D>=)C0E"5GH.81:U%CA0)&'$@C!)RH"P;-_&=^8/<)>VE$C"
M2>:':5M [B!9N)(K\)A'#'960(%A1;V4@-:_>_6G,87RLAY'T13X,V496L?9
M8 6 !$.20]+@9=?2CPII9F[-AU#&$"!6DDU+!K!D5B#?A@]1H?=[Q18Q3D*4
M7[0S$3MPVCL&9=55E^C_ +Y^)<GW"G<8V60=+S;<; Z(.T>6[!6LUW'4AARL
M>I:XN*-&%PD8Y!E'!K;(IRH"0URXU7,67IE4>5/84[*X6,?<"UCL1E&;Z7,E
ME>."1-+\1A["J1Y:4:,+K(79<@+B(69I%55"YB='#*&<7 CME=@"!VK-U\C=
MD$\NN6,AE=<V8<(KQ,XRK9^H6_P%#E&[,<5KP"":.YL%"H(V+ V=6N=0!J 6
M&E!G%^P2UD$F)BFS%G7/ !E*,19KQJ0>?E!';6F52*>3U RC[Q,XY&"1NS@8
M8/RV4RLK9&-KJ' L1YU'U(>=;*XWE!L26/P4,8+()7#IE90Q#\0',8KWNP U
MOWZ5'XF#:&LZ;3[!*8N)X<0N:4R1*F7$!0 SA #PFRB0*A4A;@]15>QM)9\[
M#.K',(=H8>)VDDBCCE!1Y(P,[/&H6\A35") J^7:J[BJ2<6UJT-7%ZB2Q6!B
M0OBFY8E%^&([DDKK=>MV)ZU5,5AK-W60-P]PDL?A0$=QF4_1LDIY_P"'"95*
M&_,EC?3457,;AX[KRX#2I!KSA*3X:9UCB$AB9LYF5%]L%C)P;BUBXD]OSJJX
MB@U=O495-1O=IX**?"2QKQH&AQ!CG3,F(FQ!42%,,(B,PL1[7>JYBJ+NY</J
M(^I&UWJ(.>&:-9XL*%RLV6/B.D$*(K1.QL>:0.HU6_32H*<$EN?=#9V$X A7
M$(V3$96SF%(W6=H(Y@\@DMF18U^JPUM3&4+L&^ 3;2C;YW\VR"6%S+*S*]Q
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MAU&:^F>QK=FEE>PF56VBN@I9N+(7=Y'8\,1 DJX0=GMRY[]:P!)[SN8)'#3
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M*=I"HQ>T!B;LLPC,4@23F( M+$H#*.5LW47\Z"H-O/44YIY( 1-+($C4!.4
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M!<\(C@\*V4!FXF<2GT -;N:-CGY,V')X[[V.IC,8\(MNHA21V8AM\=P7NR%
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MM,S231!5S(SYF+Y[*<PY;(@Z\U_NK5F9=A3-A\--SSI&C,Y!X=KG*!S#0W#
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M,4H<2+QE4F8".Z'2R@Y"%MH2>M,:\;0OV&T$F)P@E0,T3DF-APP4X 8R!05
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M4FG#U&P$X:Y<L8,WT:Y@$ 55!L<VN52"?+6M&6.'PKJ[*X7#HJ9F+YLSQA'
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M#6GL+;B[BFXU_;51+[]^(U+RV7Z,HURS!&(M8Z/ZVMTHG<-;^\QR2,PRCF!
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ML2(0_#@F)U*GO<$6,%965B W<[:,&83"S0,P41EF!R(+R%F(L)3F ES:$MU
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MUX!^D8T0NH "( ;N<R_2  BXO9;4BWO"1N@0G'=5Q"C*;%F/$!L2K^V.JJI
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M@YU5]\MQ3&6[:@$_ZZHK:_R:/KKPD3FP?E<OHW_A1/_7L*>/6,:/QE\40,Q
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M8=3E/UNGF?O]];,N=D;,+?Q3;\>^M,VC(*VM#&<]/L_36S2./LK1L^O[JV8
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ML[-B"0J8EEE6.,62#COF:,YN8.";6'0:5Z#V-!TL'"6E\_J.A[.ANQ2LD_\
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MVD:01JG\8! /(7H[LM %7TO8%3QR%3(1)$V8R ,5?*)3F:%.O+F.GE;RI'>
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MF'SL_*6C3Z@D*\,-KT) (%_6M6%ACAIF<NA9YG:-&11 [+) -1&H)RQKIY:
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M#2*H-S8'*5TTO)[0L.]P-?.M&P!B(\S995*J!>YYN=2"08^XRZUIOAP$M7U
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MG6A21QQ498^+AT4RH_&9@"^8FPB<D'4V!K$:9\R1A3%)I+&JD16#2%K@J@<
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MB(6#!,IME-Q9K795TOZ5L"@*^()R-AV20H[)E)R*EA[9'7.P5N5=#\:U<RW
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MM9)O,%.^1A<% ARD@KR%+@N1U#=O:^RHRLDFK S%+E>P4%,MV(<$WN@S7;N
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M+6#6+$'H/MDZ%HQLL@,G?02KEPC#AQQMPX^*$LT3LJ*JE@#;7)<:WUUIRA#
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MMJTS$O<80+1DM)P6C&4F_4A7;AK87R$J-+:WI B1S8/&<O.7?+"S$<_(DC@
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MNAL!2TS9U<,&5N4M>[#,3E )"Z:Z'TUK-1/>8'8Y'MJ#J=2&N&UZZD 5F2%
M EVS!;V(LU]1JU[@C06K.PT\W8XX36S 938A@23U];^5JTI(49#$<JDD7U!
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MH7R#VV*D G(&%R=%*G7H-*:-75@$OK"N:+*KL$1F<!5LPSWOJQ]PIG6@TLM
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MHUY0&)ZLAMVTJS;,P,KK=6=R'=2=6KU<?2N0NW5V1B=^=_#*\&(GP\<HD)B
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MXUZ:!;]Z<X=6S!UX[SW4,MNYLQH(\+'%AT5A%QU<CBX@Q%E20DG3CQ@\JFX
M-[:4[OE89[MI6>@\&R(VPZRPP.N41L!-RW E;Z-WF%E $>52 IN1K0I/.W /
M'0-V8(MI()'E21KNSF1655&614T#@-J!W/PK0JQE3A12&#$3&)PT1C9<X,><
M7RO"<Y3,"268FYMZ6SL,?:"(E102K,8HPY%N,Y*&Y*Y6RW!"]+VUK+F=H&<B
M:+B*H"EW42.L@#DZ\)KN0H4J#H-+:5B859YG:#-) AFGO)'R1-!& 5DD124D
M)!9X66]^];-G6=ED811E8G**LTP=F*J6'LAKL0".8 Z"L,.R,84!CD:4,J!
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M#S1,XYF.2PNY]*:5(V=AK)6$_/ATD!S$J,[,#&PU0BSAC_%/>FE6'&QIYJW
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M2"Q]DY]54:?PA'>M6-F$LL8 >-AQ$8$M=W0*>A'U1;O6K6, I:-E>(-]'PP
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M+_>'OZTJXR>O8%+7@>7E&8F0*<I?.HD.4A2"%+ GX"MF([(44M-(2%4,,QS
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MB0*69?/*+DK>E32L^=C ?B8B452<\Q95@96SE6G90X8"Q(1+M;II3>YMJ_<
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M2HI<J8&1D;I:1UM%F&A)=SS>58;!;\4JJQA%:\L89E8. '+*5<$>T._>]8:
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M+9^7*!8V )\SWZFM.[[C>BMQ,C1* +=3<&QRBQ%AIJ&UI&NIG@<)$Q-^6PT
M(%S8(+6-^@.E:-MGP(7,+ BUE]2>K=*RYEV8&%[V!(O]H/QZ"E6NS+G %@ !
M:R@YKW73M;4Z5LU?@<WTR@Z$6M;H="0;]KUIFKV.I12;M8D].HMJ#KUMI2#7
M$X"DW^!ZZ6'4ZVU -:OF:O[P+9 ^7,>@OI9+E@2&/7W5ES=N1@D"W!O<]2 P
M! /GWO6:HTG99@*=05?,025OEN6L1J![[VI$LV)D[C![V9OGV@S!LUR?9 4D
M<MM1K\*A\2O/&4K-L!8.)HD1B N;*,JV%@3?."UM;#RM4/7SD)[@=G+W8*/K
MHYDMJ1:[$*;: ?:::VS- ,HYS,;(+W4$&UO,#3RI-K9<3+ 2;4Y",RR6!#%>
M'_&%P3IH/O\ L3N97XB69P&$2I,J\P 7*5T!UN5&N53>AN+NK&A9;B^'&^WB
M7MJ#=W<?=W';>V@3$\GS94CPN!PSOE^<[2VA,R8+9V#0Z<29T#'E&9B 2T<-
M6Q$^KHQ<I>'?R#T,-7Q53JZ$7*7U+O>B-K_@=\AK<S<;YGO!XEM@]^]Z8\LT
M.R6B9]T-CRW#!5PN)C27;\\1!^DQ2+!KI!F4.;/@=BTJ%JF)\^KR^Y7Y?;EV
M%MP&PJ-"U3%6J5>7W*_+[<NPG>B)$B11(D<<:*D<:*$1$0!41$4!515   %@
M*G-,EH3Z5LEH=ZPP^K##ZL,/JPP^K##ZL,/JPP^K##ZL,/JPP^K##ZL,/JPP
M^K##ZL,/JPPX/X]?2L,."="?@.M[^5O?6&'0$?=WZGT!["L,.E88?5AA]6&#
M=>(/B[X8^%6"&/\ $3?G=O=*%T,F'@VMM*"+:.-5;YALW9$9EVKM-P%/+AX9
M6L#IH;!JXBA05ZTXQ[WG[M1KB<=A,''>Q52$%VO-]RU?L1KX\4_RIOA=NRLF
M$\-MT]N;\XY@PP^TMLR#=78;K<A,7#!)#C]NXJ$6OPY<-@F;IF'40-;I%3NX
MX.G*;7W3\V/XV_<BJXOIGA8WC@:4ZK7W4O-C^-OW(A'MWY9GCYXKPXQ]M;XX
MK=79&(+M%L3<S-N[A5@?/?#'&820;:QD+J0",1BI00+=S>B[7V[M6M4=/KI1
MI_>P\U>]9M=[93\3TCVOCG)5*KIT_O8>:K=Z\Y^UL8J6>::21\1.TTDCF626
M6<R23/(<YD=SF<O?VB;DDU66G*[>KXD1)MO>><F&$4F;+$"$!L46Y-[CGRL;
MW+GKY4*4&9O7U!HS)&)"2Q/)DOKRL"07Z ^9H>XV8&*EG$4D+#*MY6S6LK+U
M%R=66^AMK6;ELGJ;6@=X,ER%U4WS74_69$NA5M,K7U\J&XA(Z7%[L2=#/DS9
M'721@++=AF8)YZ=[TN/!*UPR>5AS<$T9 550!C8=+GD'-:QMIZ'2I*BKQW0R
M=D1+\1]W8]@;YXG%X7#HN'VFWSN(IKF$A^E#)87()O:GM*#J4NKODB"Q%%4L
M1O)9LR[!W=QF(DXV)B812H@1G)41\0E5R@6)N6!/I4M@=@5<5YTKJ!(X7 5J
MK4M(CH;.V?A\(JPHJLSH,UDR!;FUC>^8 C7I5UP>R<-@LX9R+#0PU.@DE9MA
MLD#%A?E++EN<M[#0A3U*OVM4HDV\QSD98PELN6/B+< \K$6N5"WLU@>GK14C
M3,H"-S+I9""1<$L=#?O>_7RK:1I+W!IAXE(6S* M@6=KG,!E( &O*":4*2N^
MP46%A4H.4>RI /0.NA#-H0KBUJP<+0.T1S8D918D @ #T%NMK:5H4CNX4J<^
MA(RCH +WUTL>AK9NP63+<$#F"OFREL@NI/LL+>7G2D)>H"=F,JA+LI@!8/TS
M$R!KGN0?*Q\J7'3,U8'1IF5;,K7>]QI<$DG36QLWIK2=YF!E%"M@#?H0!F!7
MA]@2;\UP:6M+&T"54V4FPBN H6YL0[ C+UL0/=6V;X]AW?16:Q"W('<GW :V
M-8EG<RP7SKF*J"4RY2 .:^NBGH0H/M:]J7%&T )5LC L6-^8*&NJ@FXS&Q(N
M?.B0>=WH( $JD DZYUY2;$$6LH) .6Q%;;9K4P<,7!Z-E=0;]%)U-B+7(^RL
MO;O,,X3*([YB>4Y[7 0FP))Y>3MI2T[&&=,IYG47.BYK"RW]NXL<I^ZE7"72
M,JJ&4-EO&5N+$%CY!@>I/2M,P$1HSD, %R ^6<CH%-NEJU>^7 6&4*OH"YL"
M;A3ERG->Y[,3;2DIF+/+B',8N@LP4+F90<H8NQU!4G-6-97"< ?"Z13%I,IR
ME@K*6R$62P.6P[UM9.XNZ!&UB3"N.PDRIB2O R.6*LK$"252I)60(2/*B0R6
M6AIL[1XL9'D:-3@-GV@PD (XV(E1N&TM[*KWE%E)OI\:VU;UI&N/88=H89,7
ME3%1J<7.;HB "3"X8#,H))N2?/6U$C)VOQ$N*DK/00V*V<8I<I7V@]I"C6X8
M#%3FL06S"_D:=0DI1N,)T[,X39XAE,Q!&<AQHS$$6%M$O:RBM[W 3N<10K )
M&  R7501>P)M=6%[&PK5\NPS=#[!X09([.W)( 2G0E90;B][AA)?332A-L6E
ME84>&B)XH9@%?V$ Y@!WN;<J_&](SN*63#..(& @D!L^4VM;(&S!CY?"M&]0
M>H7*AZKH,Y[G*+FY\ZW="K X)RL "3E6Q4&XR<VO]ZP-JV8T"03PF74&[ $D
MY2+7!&I(&M;\#1G4-D9A8$9&) )S"PO]4CI2.+-K3M!"LB6 4DN-#ENJ?M_5
M6(7W:&9"Y;+?+<$FQ!N/*Q-K5N^8M'8G73E(Z];I_%]-32KF^QG=-8VS&TER
M+E@;JS92//1@369O4RWN.X%N:^8*=3VUTZ?"D2U-//)([M<&["S9DRFX(T!M
M93?2S&DYZF(YCR\15M89@;AK#*-+6]PK,T*>]8$#-&+$J8R2U@5U;6YOVNIK
M.-S:O:YTNK!@G+;F)(+  'H''+TI68H^XD853< Y2PX;:@7-P1UM>L,#C9.W
M-L;&8R;*VGB\-&$+\.*9^$[:-=L,Y;#R$,QOF4UC49922"4Z]6D_L<FOSY:#
MCX#QDVGA,L>U-GX;:2C1I,,QPF+Z7+,@62!B!K8*@/F*#+#Q?HNS']/:M6/Q
MD5)<UD_R> Y>Q/$3=3;H18=I18'&2?[X[29<'.')L$1W;YO.Q/01NYMV'2A3
MHSAPNNPDZ..PU992M+D\OY!;^XCIH1K_ #BA#LZE@+AM 1]OH*PP#W+L==.@
M)Z:GR\Z48#8DL+_92689:T8?5AAQW'N/ZJPPZ%M-/B;:'S^V]*R,,=:N8<@V
M-_Q\:S4P^O>YZ:6T_'2U88=>_P"BL,/K?"L,/M!WZ5AAP"+ GRO]NE9;@88)
M  ;]0>H\C^C2E*YATS>GIZ_;ZUEC#Y^91Z>?3W?;6=AAB#=+BY-_=Y_$5G@8
M8WY3>W4^MM3WK9H[JUP!W_9YUG@;.S=+_8?V5IF&'OU]]_/UZULT([>O<3=O
M?* 1[8P*_.XURX;:N&"P[2PMC=52?*PEA#:\.0/'K?+>Q!*=6I2?F/+EP UJ
M%.NK36?/B11WQ\*]YMTGEQ42C:VPENQVAA(F4P*NBG:.%!=\*533,I:+I=@3
M:I&CB(U';27(B*^%J4,_2I\_RB,P[++S,ZE"F0YQ<@*"ME&5@5UT)%_UG<>5
MQM=6L"1 \2B1+,H9A8YK+<,V<#AY3<):DIIY,4K<0LVKA(,;$V5"9 BR\UB%
MNNH4KJ+'36ET[QRX":F[)#:O&(9V*Q\*PR%0""4OT(/]_8WIUO#/1BLV7CE7
MAPJQ,B6TO?,+<USULBTB23>7 *IV[Q9QL,3$&>-%"J1F 4M*!S$$&^HM0'YK
MMQ"IIH)=H8'.LD7"DR,S#KF(N[Z9;D 9;?91J;2L">3STL,%M;!OL#;<^3,,
M+BI&9H\@&5F56+ D$,Q=!3V,(R3RO8@,33=.K;5!K@-C1[2Q,3)D99 21)8
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MK+-B;M<05B,T,9BBA$C1F.R(X:5%LBW9R"'0*K:CK>M[LC6\[:F2)(572)9
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M#_='PUW>PF[.YNQ<)L?9>%2,/P(T^=X_$)&L;X_:F+RB?:&/F"\\LA+'H+*
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MTX*QA)I3G+, E\N3B ):YYOC67,.V&D59#% TG&D692)&"V5"O#,*A6CXKY
M+'IUZUES R2$PRN'0(T@(<)JQY.LCH0,U_A6&SK JJT>&*!UQ6AE=N#()D99
M1E="Z1N5S$'ZPZ6(K5S1AP\2N!F>7AJ'BQ$?\(T<V=^90/:63.1\?MS@:<8@
MN5<ZKPDL51D23.5+*^C1NF@46K0((YA9I5DP^8@O:2_$"<R Y%# AC8J=1F_
M1ANX28V-9) P2Y*J>*,XA1A&H'$C4F0./.]KUM/@9V &5 YS/'E%A$8I'*QS
MJ<N<OF<@DD"WG6&!O!!%& IPYF:1(Q&D<N4O_"7)Z9(V4HPO;VJ#/41*RR0#
MVC$Y18>"88XEX<JJP+2,\B+&MVT4+?6QUI D)F)CGX>=6RR%9(XHV,HXTJY8
MP]_9&0=ZV:.N-PL*S)$$X;$&5<H:(BS9I4!))LBFU[ZWK#9AC0Q-(2$!1GD"
MJ+E5DX"B,Y3>/.K/F MFO6C3R!S?1J%DDQ$4<K1$XEK/AY9!A@ <VL@ %UL3
M8UAL"85(N&Y*$8=[RV=6,N:"]BJ WYF9;#H;>^M;J,,X(,)$;G@QM&P15X;6
M8Z%U""S'R[TG<9LRS1Y(S'(<^2(RHS,Z',4Y4S(0!"'(Z>UT-:W&9D )>&;R
M2Q1&*S\RLP5E@D7+D1=5*6-P>O>BK3M-'*\)7*Q+*T8$<S.<K9%*?29;WZGR
M&E:W8F'8K(RHP:[&\J1267.[K:(WZ$B/4EM?*AM,V"9I)%(5> 8^$<[P]5#R
M."%4 #+$%'QI:A'7B(LM0.P+VX<KR1,,DTTKR(7CA(:1"3>^==*58UNOED!E
M>:%BT<F<H<KB,YBJ$,JD'V2MF/*0<OPK=N!O=0(6,9EDY/I0_,O,C32/RJ@C
MRQJ?,* :TTGDS=K::@I(X3+*V,D9)%/T,"B9FC:.'$I'(]@+JS$&USY&M;J-
MH$1"6261)K-$K22PB*#,(M>5B=55XSH;=:0U8V'L<1CO.(9 LBA8U8H(V-UA
M)COHA;BEB.FE(%(,DX$^'CMF%SQG>X^I?.,A'\'F(M<:"AVS$N+N=XE28.Y%
MTS#)*;A"W^A@QIE$E_K=0*T+6B1L1_)P1*OC7O8\<3*G]2[;2Y[C(9#O7N/Q
M BYV8*9$)%QT%1NUG]K1]=>$B;V#\LE]$_\ "B?_T+1WBV+^)V_=A_W4^U[M
M>VOSN70]"12N!4<9\IJ7^_?B-LZ.= $%R3F(U%M?< 321FP/(A ME )8]-.8
M@=QJ0?NK=^>AI'RQW5C< V4+<7%@;&Q]+UAKN.2(TMJ2,IU/U@-#Z6\JWG[#
M'<"R2@.,@RC.+&^O;IZ>=*2, 3R:%3?5;,1WOFU4ZZ&MI&-LQ(MRH)N!I<"X
M^^UQ6.R-7N#P%!RVL= 1H+F]R0>^E)9O,!8@MJ!<$Z#6P9;FU@;6M>DFKG6.
M-[VLME7N;:^[J;$UC=S+OV'=B+@W4V%K@C-UOT'F:Q)M7,;.A!8'-8@BXYK?
M=W(M6]#.!V"V!#B^8 J0 "PS'3OEN+#X&M&_ Y-K',2?+7KU-O0"M.QE^!QR
MG0#0VM<:WTL?@:1V<#1R2%-K+< Y3TTMKKKKH:SM,N[@9RV4Y2MB+Z%NM[ZG
M2^EZ3VFM *Q[$V%CT'72_>XM>]JS@)[0$;* -2SD:DZ@#N@Z"_?2DW$&,@,0
M;DW!OFL+>=K#T-N]:,8VV^&!8KQ05L 2WD#<$>5RJZ5'8V%UO )K.XA\)H&'
M(+,0 2<I9>9-3TN%M4146=P5_<#)+NJJ,IRM:7O;*>8(.^;7[_@WLS3=QS/"
MOP2\0/&C;(V;N;LHG X61(=K[QXX2838.QT8 CYYC>')Q,24(9,/"LN(<:A,
MH+!QAL+5Q,K067%O1?GR'>#P.(QD]VDO-6K>B[WS[%F;?O!3Y)WAGX08.'%3
M[/PV^6^#JCXO>?;^!P^(X$R\V78.S9OG&&V-"C7LZE\2UR&E*V5;%AL!0PZN
MTI5.;7@N'B7'!;)PN#6\TIUOOFO!</'M)14^)0^K##ZL,/JPP^K##ZL,/JPP
M^K##ZL,/JPP^K##ZL,/JPP^K##ZL,/JPP^K##ZL,.-*PPX(Z&POU]Y\KUAAU
M!N2;#V23H-3^FU881I\4_E9>"/A-\YPFVMZX=N[?PV9&W8W16+;NV$F0<T&,
M:&:/9>RIETNN+Q$#V-PIJ*QFV<!@KJI/>J+[F.;]O!>UHBL9MK9^"\VI-2J_
M>QS?MX+VM&M?Q%^7CXP[]/BL#N<,%X;[!F9TA.RT3'[ROAY+\/YWMS'(T>'F
M(L;X+#X9T.G$8:FD[2Z4;0K)QPS5&GV9RMZST]B14<7TDQV(;CA[4J?9G+WO
M\21%_:NW=Y]YY!B=Y-X=O;?Q(*'YSMW:VT-K8EVO9FXN/Q$\E[OTO<B]4VMB
M,1B'O5ZDYR_=-OQN052M6K.]6<IR[6WX@.'#K$A)L0>A<@@E;@G4W"D>=Z;-
M.]@5@PCC0A5<#(.8,+<Y()*D6MKU^%:MS$VSR!0V9',69D52#:]@RF.RDYC8
M:G*;=ZWFM#3@GWA1C]T&D7B1QHX(D%CE+,+V"C,#I8VHL*LD G1366;&HVWN
M+PFDGPJ?,I1S.4%D=KJ?8Z*AUY@.OOJ9P^+G9*IYT!E*FTK/1<&(@38G9,WS
M;:$+IG5&CD!(BD%[ YE#=1:_2GZHT\1'K*-NYB.HWX-T_2Y"YV3M'CQ@*T*A
M6S!2%Y\QM=G/6,VT_OK5%8C#.$W:]P5-R]&65A8X%FR\@S<,7+-<6Y0,H/6_
M<>5,90MGQ'%K9L-L.,RYB2"I9@&"N2;] .EKF_I0[-BE;VAU@\I58R^N5B5<
M,S."2"H-C8H0+:TF2]PN_#B*+ %W("WM'<WO<!LNALW,5!^RA227M%7:60M=
ME"6/(QD)NH!L I9K!M";EA&%O2H-)A(W6?$-MK.'@BC.0Y-"H-R]NC%3J.M7
M7HE%RKRGP2)7"NZNA/H$#(+69R5)"Z  7 UN%)MVJ_H?ZHR97)U50!H<O1E&
MF4'J&)-ZVK&TC+EYB3&Q-@!8'D"]=0IL;=Z(GF*L@6BJQT&4)<M8V):ZDC,=
M&'Z:4:X&?(Q*1A06/*H+$=>:X87 ;TTK%?V&*S#C#0<-!IF+$MF#=QRZ'0VU
M.IK82 >PP\HN+GZM@+: '3K;W=:QAH@W*1[6IS!<A&DA87#"PL+=.U8N1OCD
M8'1EN%0%K'0V*K>VMN[* :4K"6%\C(K%CE%S?FLV4D\AL-02:5GH)9A( =LM
MUO=5TS7+$,6 T%F K$V;!\0N6%Q&JE"XZLQ'<$VR M2C SC SL"' %[Z::@K
M=3IY&MV5LM120*0*![( !9G;6RJG37K<FDW,,<BAC=0A1=6L"& 8:>0Z]:4K
M\3,P X)S!PM@&YK7U*G06O[1Z$4:R]ABM[0M*@$*$!-KDMH #?IU!-:RM80!
M54LYSV9$9>I522W4*-; 4KM-'(C)N&*K(;9;:QY@UM1H;BE&'=8F=@K*JG^]
ML"<I[=3=ATO69ON-Z=X)-C=LI90&Y;D,+.+9BI.<95-*T,NS)&MR2;YE!8A>
M5K-KD/0D FMMF78(17F74,K(%9,NKFQM8DGF:LNO:;NP7'$00;, ,O4G,6_B
MWZ "DBHMZAS&$.3E/-IT-@0.A-[A;WK6:=@L6P4(QD8L '9QD9;Z)UL +B];
M%7!#*9H6!#9B,T!4',77VLR_Q7\^@K:LF:N^  +R8Z)EF$<!@#!E[JT=P0=;
ML"]B#KT%&T5UQ-.^G 3T&,DXF*=U9,1G7"8>)\W*KC5HB=0!KT_F,TE%):\3
M5PU+J)2L;WCP&&DXB@ *\I52[  VS6?[30U>]^)J3\T0>)B*8IY.EU1I+(&N
M;\NE[+(!WIW%Y9C44.%V@T*%0"&#+9>C /\ 68 6L._E6G&_>8*O9FT)96)8
M 1G((UN2K'Z3,1UM<+0Y1X&7%CA<6C1ABX (N!U902;94ZZBU(MD*2[@UC?.
MFO2X((RD BPU&MCI]M)MR,!@GO8Y5)#7SD:Y?XJ]A?O6G$P%K8!G5@P%]#TL
M!I:POH36*Z8M:]AW7(59<N8'+JW53>RD'KPWM>E"^WB"4>,HO6]LH;VK6/7J
M#:L3$M._89$;G+ C,O*Z%=#;HX'7-84K4RUC/GNJR#2-@1K];_2CI?SK5D^\
MR[1E#D :C+UY0&N;6'P%;LK&U)\S(ALH#!@"IMH+^C#O6K<@BO9'UR+"QL+L
M&Z>Z_<5NR-G90P +'1NK7N"?AZUIVN;[SDWLHY<MCU7VCYD]]:UXF_ [!<RB
MZAAT ]GIJ2&/D:W<S7N.P0(>87S 903<D&V9EMJ"I^%9=\#2=M3M*1:RLQ()
M4'3OW'F03]M;LA0'C*M=;Y6R2!6*W9K:7[@:UF2-79RZ*V2.6Q.551\H4*2+
ML.Q)OUK:L9H$^U]I8?9L1.+LZ@.8"&50'8 !BQU5@!IY]:4HN3RT$MV7:-S(
MF/V]BUXTDWYM8A4=[\26,6RKY%0>^EZ-YL5V@U%OSKB^V-LB+#<)%@"$+9K#
MF<+?*#Y@7UH4FY/7S0R2MGJ+*%OFELA:-KY<RAE93S LA4 @ D5II/7,4LM,
MA3[+WYWFV,0,/M*7%1 FT./=\9 P!]D+,YDB6_\ PMD/K0Y4J;6GN'%+&8BD
M_-DVN3S_ #]@Z.Q/%_9N(RP[=PK;.F&4-BL*7Q6$)8D!FBR_.802#H!+TZTW
MGAI+T'=$I2VI3EE63B^:S7Y?$=K!X[";1PT6+P.(AQ6&E%TG@<.C>8N.C*="
M#J#UILTT[/4DHSC..]!IQ!-:%'%_3[-:V8==;Z$^S>WZ!]M;RL8<J+=K?M_
MK'F8<D];:_=^.M:,/K@7]/T_KK+&'7,!^[U_76[&'!*GIIT.@U_FK%<PQWM6
M&'U^FO7I6[LPZ.._PK$S#'^!^\5LPZR)G4^:C3]'3O>LT- =&(/3I\/+3TZU
MEC#&VC&QZWZZ:'SK##*A[WO^WK]@-JPP[6-@>W3M_/6&S&1Y:ZW(TM6&CGJ.
MX[6O]OPK=S#N" ===.E:[C KVIL;9.W(&PVUL!A\=$5*@RQ@RQ7^O!.+38>0
M$Z,C*12HRE!WB[")TX5%::31'O>SPNVEL0R[1V 9MJ[-&9Y<,09-HX.._4QI
M88V-!W0!P.JV!:GE.O&;M/*7U$97P<X>=3\Z'+BORC!;=PD6(P[,H;E)X>4D
M%QE?,P)]D @ CUI_1E9[KT(JJM]#<+&%D8"ULPS=RJ*H+M?J%?I[Z=VL[H9<
M;"HP$JAXF0G*2ERNH7*&!%KV[TF5V[+D.(M7]@N<+*LR>TP89A<@=&Z=- !K
MVZ4W<&I7X!4WQ"['X2.TB'3F07S6"KH+E3?E/3XT6#S7(1)73!NY&Q85VO+*
M$R%HU/.B647(&706T\JS$3\Q):W!T*45/>'CQNSH'CB!19&*$92!E*CJQ-KE
M@.],T^ YJ1NA$8_8<;-(H1/X]\HL#H .FB@=O.E#:<%)6EH)'&[N@D-&.$6(
M2ZH"6))(*@ ^7PH,Z4)<%<8U<-=W2 46"EP\HDD1'6.1<Y9; Y2/.]CYT!T7
M%]@V=*T@VP:.I"J8VY,QN R@%LH%LMA84AIK(59)=H<PQ\-@MEL2JD#V0.IL
M>H I5KQOQ-J_$4&'B2S/E8JY&6P%B0!=[=0+*/2LD[*W$U%<P[PR$D*$S'2Q
MLHN6%K#0>SWK<%;74<JUA08: :HQ;B#4BUPMM=+:=J=^ 6*O'M%%AH#PT+%+
M,PL IS-8WZ]NE(NPB4N&@I(8U)T 2Q'5!8V )\AK:M*[U%I67-F<KRC.@#$D
M9E-K:ZFVOU12N_45W:'7,JA>R+S VN6TT'G6KF68$92<S%1?0@#0 7';KK6A
M2^H"OUS6RC/H%%RIM:X!O<FDMW%&(QE038$D$D,6.EKD@:"]8F88RBJYU)6Q
M*]S=A?*+ZV'OH<KLTS'P[*P*&1@H9;@:W[==;TUJ<3'EWF0*N1%ZLP5<BA I
M!0D1G2X8GIKUIA+2_$1G<"2$$S+S*2VC$ KI8\,DZW!H?>9+T0.R,5,S:JKN
MV7VE-E)4&]] P[4B32 @"7*X.8DO=4"\@S%C87U!TS>MJ0[:<30%=& <LA&6
MZ@ WU M[SI0)+.ST$M *6/0\WLC3*%<G,\A%UT("JOV4TFDV#8%E06+N P#*
M) +#(0.4@>\T&2=[&6RS">7#AN,R%F9 RERW-GMFL+6[6TH60VGI=A/B$SY2
MI:^@<Z^T.XZJ"?=09I6[0<E?0*I85(6,,TCR%R04"A=3[37 N?2F<J?!B9)A
M'B<.I#* ).%;$6R@N6"-KF8#*4S:BFE1 9QOF)C&",QLL2HDC(3F5 1#?5F-
MK\Y\ZC:T&QNTK]@C,0G$CR+ENZL[.]U(C4<COT!9K\E1>(C= JB7L$;MG#'.
M)!&D@XA#H^550..6PR] 3<6JO8ND[WXC*K'+M&WVY 8EF8J,[(4?+%&^96%F
ML6Z CRM4+B*46KV&559#$;XK)@]F,\KM&2O"8G+F:*0<6-V+VY5.A[U"8S#[
M\DDLB'K/S6N9J@^4GMHX%IU0)&0Y<\)R>?$J0#)$/J$Z@W/704[V5@98JO:W
MF,K&+PO758M<\R&>X^ZF*WMWFCF>"65EQ**SNDA2)$;A.QO&YX8!+6M:NM;&
MV9'JMVG%*C'/M9*X>+BXTHKS3>?\G;PG@V5A\"T>!B(MAC+,(T9U4H "+A01
M\-?T=@Z-[/ING9JV[V%PP5&S6ZD;4=S=AQ87#0Q10QA%1/\ 0PEU "AF7E&8
M,#ITTJXVZJ'FNZN6G!T]UYZCM82!&6/AQA5 L AZ:1Z  =\QIM-2OF24(JX<
M(M@UE)L<I0"P/GY&XI40MSE@40&0 A;V TN!PNH ]K+?[:4FS -)<L5!7,1E
M8! H &N;X_"MO/+B880Q+=%RD$9;:$#I<G6VE:N_88<_PC %HT*JS+VT5KL-
M 1>W2M7YV-F QEE)XD:%CRM;,&%R; "UFMUK3>1H#22*+*5D*LY!RME4E3:Q
M4@D"XZ=JTV8!'90V4G-9F)ZV\_: \K=Z3WF,P2PED-\A[YLW, !(WIIFM^.N
MXNS,"2?ALQ*Q-PV4BY R-Y,"-+9@;#M1UDK<300RPBYX;N7!^D)1<I$C%%*Q
M$YNG8=+7K:[0<]0EEX9)BD4IJ<FES)*&)NQ/,#;X4M+BA)U55#0Y@S(Y;.9&
M8E7&I*ZD@4EZ&S/&.)K%:$![JA 4D V8LULI##6W4WK3RRXBD&R*DIL08FXF
M92JV&(4=&1%L8VRGII:AS?O"!M#"56, <LA9E=R591<VN/:4@Z=>U)N9;@#7
M6ZE5<$E M]2"P ZANMEN*7?WF">VE".5)(RR HRE0"HL&SH2;,4(MZZ4EMW,
M0VFURV4JN5C>T2!F16<:N-.K!3?J12HM7%)VRX"0FQ*X<'-)*YXD05574 V/
M"RZZEB03W%&<8F;U@QCQUI &42HZN1'ES"*3J2 ;Y6 I,H(6I9YBXV#CL%')
M')(G4(%$63*IR_2.S 7+:][T*2DL]0U-INS>0[&Q=H8-HTCB2&1TXK%FM<QL
M 5NS"Y/ZZ XR;N.E9*PLH<= 53Z.-E5V9CRM;D L<M@0#>UZ&U9V=[F*%WKD
M&\>.@OD2(E+V+(O*I(OI>XO>MZO45N'8[5944*K$*Q4A^0O8GGS=#<6%O3W4
MFSU%*+T.Z;9P\AX;9<^?*!8C4C7I9; ][UI]QEGV ''8B)TRH0_"SB4%4L02
M"MK7!R&^O7[JS=>O$VE=W&KV_'ASB<IDYF1M= KE^8EF7J01THL+I68B=D(C
M$9@JH(U=#&<V8:YM1D&6PMF )[T5*SS MY)H3>*C:(V<K'.X49@;(F9CF6)0
M%>[%==3K1\EH%AZ)AC7B2R7(#%5)$R!FDRE@&!TMJ*Q&P?&A-@Q*A<N8!@M\
MY(+9>K 6ZFM^(B=K7XAQ@9$C9V7.$$R:_4-ERD2#KE:U^M:X@HWND@V**$=R
MKE@AS9B!SMS!UMU4"UJ$I2<[7"I\!,XM5LW*EW) 8ISLYYF('36CW$36?L"=
M0PT:$R*K '/=0-?86X.=38G6_2DWY@+!'M*&ZDQ98F<F1NK%BKL I)4D 6Z=
MZTGF::5NT2A?%\<Q1D*V8RELV90B#I9PP%R:5P!V,XQ(5+*BE55&E+(P8YY
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M#RB3A1XB:,9TC1#$8E:%SF8V(T"EC;4 7K# .I5AE?E(06U;*[O*69#&JE0
M#UT K5S CEQC'.HX8NG#<M(G*)$C*,.KC+J0:+%72YB'*TL]!+[4V@[)$L$Z
M0L"YL@#@P(U@[)ELQ=A<YK@=:,HY7>0&52W:,!O1C_SSOGL+")P\3'AQ+*T3
MW6-V,DKQ+(18Y F'8#+87 HT8I*]LP,9SWF[L>+"X>9(,*8R'(NH4N)@55BI
M+EB2,W4$]*;7?$W8ZRYH&:)DS<.8\1@JDY KO<DNJ-E5A:UJPV?2H9+K')%+
M&J.>(54)*5B4H) I89G9STM>DF (1RB:96A618X PASY69F@!9(9'.411'4]
M_C6C1VX,1AC+*098UXK\C*'AYLGD'NH]_>LTT-Y6"R8RW<#A*I)D2,0YI.&!
M](=-,XZ];"E1;?O$L#,486("RV?)E;)F4QD1AH[ %\ZK?70"EIF C#!HQ*67
MB-$"R. >&]P.+P;] AT/GVI5\S<%YQT,[Q^V1:;*R=!](3PXTDD>X4$M8>_S
MK08$J83$Q:$HR9(DM999'U725% #,"6)ZC*.E88",%'/QHFE"QQN&BA#J@<\
M,>R' ?,7/7-6=ANV5@Q1'X<N8BZ\"Y5B9))5"JL<>0V:RW+=!8WH4FT\C%%'
M>""..00R D%UFDR.5X<O$(X87V3= !< #]>E-WS>1NR!2B*.0'.[KGDCR. S
M2-Q<QB8+8,8D)MZ4MS5K&DLT=W41A;,[M*R@QQQY;RNN8R'3*JQ1D6;K?O0U
M-WST#F=\/D>(7,A%E=@K$,&UD12O)F,6NIL&HCJ*V6IHS21Q$2"/,S-GF8R1
MHF1$0R1Q!;!\LRJ<UN];IMO4P #AS+&P9RTA0$QV#(QS&1D8:)ETTHB,.%BE
M5XTD(A3-E!=SQ>&4:2/4:EW49R3<YAY=<,#F+$-'A8\0?I.!*JR(/I$E4KRL
MLALH:XUTU[5AAUD*HY),9!$>)$4(574.75"  0&)E)R]R-:V8!$+!YLD-BT8
M2ZJ TDU[W!S^S$-;^E)$3=CG).\,"$\22RB?$ \N8.20;?Z(5ZFL8, B",I-
M(S9GCF>7)&PR2QLQ06<V+L@:Y'>L-F)L/&UEC(:[QR+TRH,FJ,.AN  :PPZ2
MPO)()"D;(702*R<I=K&*  V"'*AY^U]*V:[ (TL;,&CB,)+*K!\S<0,MM;C3
M,ZW4:V M09*6K-2,;N?I8^690%C7,H,#*'#O?-?ARH1I0[B0'*O"25RH65KA
M953@PI&2QN ,UWNZZZUES0&-V:-^)$EHTD.=,TL<C229@0R$&.0&X'2_W;N8
M<2+'FE7"19"849VFCCAD=HPPC8VT*G,OGTK=S#%,L/S7#21F&\A8NC.['/Q;
MI"5;*,L9)ZZ_"M&NTX=F9F,9CX[,I"($5V*:D_\ 7M0UJW<V@,J.\S.%A1SP
M\_#6)UOAEP[->.X+C$\<A1]3+K6[F<05&@E"&)EC9)94'%C,L807+(!?VF/D
M+"M7,"[-$-'O&RIQ%59GS&1YF6\I#&R!9!H?/6MFD9Y8B!&JAHWNQ;( 0R%
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MQD/"528R'+&2(Y59&R90;XE".G0"A/45<%QHLQCX,KOE$8A91&EI(P6(/,"
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M+W #$+8J,IZ#F!-O2D--]QJP/AE70.;%S8@BRY6Z,S7&MQV%9:VA@H8.&<J
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MP=:T9J8IIHL,^(D8QO HC1PI*M*C$953B, F7B ,="16)M:&<0NG021M%*_
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M_*+!@EDC;IKG&I[U%XB(FRT$CM*+F+Y97,;*Y+LAAD?*#8L+$ZL?=455@M>
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M8I)(@(.H"Y;>^MK)9C:4FWV&2" O(GUT5E5C95RMY+;2VHM[ZR4MU/2YN,N
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MO>^;JMZS<B9NH#"-5$:AQ.T:,BOE!8@N[<1!<6!#@5BBEH)DDD87*QLJ-%(
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M2:M<W=/)F(@91JM@W6UO>"?=2+&_8=6B!1>]B ;7S&U[V.I[BL;LKFM7V'
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M-((Q&K +>W(>E@P.F@]];2L)LP:JY0%MS#O^FX\JW="XIK(XU!/?34G2RWU
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M/6D63U!S25K("-'H 0MPHT/M"^EQY:T.2X*P,"2JV4#-Q,P*@ ]R;EM=1D%
M<6GGH; 4@L!$Y+\/G.0'-;J;G-:WG29+B9V!8Z(5G*FY*$JK$BX)((]>3[*;
MRBKV!2XI:!9+$1S%AGS,$14((!U8N5T%NU!FE>P'3N"N4:Z:Y27(ZL01RZCE
MO?[: [F^\+'1F1NSD,1F9K!KMU L0%O3>:S$R5^\(YXN(_L26)5#DNHS("2%
M'3A'OI8TTJJSRUN-IW;[1.XF,B,.;L@$F5?KK[.6+0G0<4_;3*:OH <5>PV>
M\6)>-6BC"Y5L&X[!"8P66YMEMF96('04/J.L5WJ-YQ3NEH,?M/"MC\665@R2
M.8XU2-RR!CR\;+<Y5 ZBI/#;/=24;+SF(6'BY;R7G"PW3W.;%99&BD8C^$5K
MA% M&%C4Z6S*#;H173-C[-IX:FI2LJG<2%&DE&\B1>[N[<6%PT>J6"Y"H4K)
M>ZWMT(!N?2IZ4OJ'5.-LK9"U&%RD&1"JV5C8#4*F8QD]";]J0GR'48[IF9$"
M%8P5CTY!?3T]U8;5]#KU0DA &R(0#E+,%)X5VO86 U%::Y:BN)CR$,B!2C.U
MQ)<$DE;OQ/XJ#ZOG2'9^EF%,# "0"SJH>Q!LH(MH2!<FYI6JX&'4.>9 69K@
MITU(+$YF(NZZBP/2LMQ>AAT 509.('=F/(X%KC46%CJ2.U;6>1AB9C,@T*$,
M,UU4*01T';L*5:W<: LV(?*'B578&PS:M90!(P"],I%AYTI17$2VS#(V:S/9
MY&4Y% (;GU;/WZ?9666AF\SI(5:^JQM>,% JV!9)&5KZY=%%QWM6[&KL(YF4
MR*]U42,R@QJ0ME 6^7L2*5ID)<K20#D:PLUW)! )Z'AG./,*UB!>M-B>&9AD
MNN10D09BRMT"AEZW(M<]:T99/4!X@EH\F212S$JJ"X5E NW-H,Q%*3L[FTK/
MM [1HEW-VN6!(4\0!K:76U@-=:RYLPE2LC+R,"!JS.SJGUB">Y]^E9<QZ'93
M&A52>3/[-KYF*6+VL;WTUK#$#H4*P@*P&:10CL3,4)U) 4 HQ/GK27K[#8:*
M9%(:X$:L$OT7B-H6 &H!!I%A5V!=I29$:.\;+:X.MV+ =&.A*C2MI9F7CQU&
MSV[C%$,J,MF8\)+$DW<K_P!CA0/=2U'/+0UYJ5QG-IRQHTD;9V"RW,EP;-G)
M5'!^HZ$&W0T6UG=:6-[WFW8C<=*OTH@09T8&($A@J6O8EB1HQ)&E+2]P/5W"
MF2;5P2Q9BL29[9"PC1P6-@$M(PZ#6EQ5\D:;S8!6;+(X8JP@9T,48)+(H75#
M:\EFN20;#O2]R(FX+BQ/#9H%#RB3Z170*64E0+2/K>P';3]2EDK(S*^8:X;$
MLI02.1_PR2,:21J,BQIRW$BL-;5IW:[3%:^0XFR\?+%##E).'#Q\4Y03&0;'
M.A'*Q#>5"<>#U#QFFK/442;:P\DK%V;/#F,:#NMRF6PT!"V/N%(<;*PIL.HM
MH-)#&QF1HP<[11D,\JIJ&7^*Q;M?6@M6T60K?;/L1M%9E$4I,1<J\847<.U[
M@#.,P9+7\C2K6C=ZF;UPTPF:2P8(YE')F0$11CF9R4);VCIY4";3=NPQ/@./
M@(V,<(<AUX2,F=; C7F1%TRO:P+>5!BE:SYF.6[J9=I[13"1,P=,/+%[8?0%
M&&@"ZYF)Z6ZTF4$] D)-R[!(8#?F./&?-Y)26#$GB.%#*,QSHE_9!%K>E:=*
M5KC^,Z>BU'EV1O N-B4J5:\:2*<Q%V8 '-WZ=.M-G#/,+O)Y!CC9XYS(0QLL
M1(4]"+#,NO*&)O:MI*W:;DUNOF--M:0MB"<N12YER='6Q*JP4CG-K_<:<QT3
M[!D^P+[R$.J1QA4N^?BW+#AQAE(!NTF6U*,"'&12(DD@<B]F5BHRQ:ZYP>8@
M^FE:7I(P)8R\S&21 "K6+QIG1U0>UH1R7-Z*:=@IQL1$BEE(BE$EQDU6T?ML
MC,+9SJ--!6A#0BMH*J!F+<61K"-'-A%F&0G2Q&=6-O=1H13R>AD7S.,,TR1.
M[.L#3M LQU-P[RABBIRA\J#6M5(I>CI8WEPT##B('9&$;.1]" N8W7I+(@MS
M +HW6LIZ/D98.,.TA6(-</.IE5Y<S11OE*@&Q#6=;YK^GE2VK,2!P]YA&6#-
M&I 0Q?1.2KA\@>Y8"XMY5@H 3</AL\ZNBEB)2020;942[$@)(HU-M+5B^LQF
M)E51AV-U*A!D4M8%ER269;9K$7]*UW&KF?(06:15,0O;*P0,BO'HZG5F8C2W
MD:VF;N%ZF8K(Q0%YK-&>@4Y;DL>@ #Z7%OU[[ 3U/N$"D1L8BS19900'EEC7
M6Y6R,"EP!W-9<P#+#+%(26D,8>4E8T5F/$55CS-<. BH0;=#?WUHV!YE#EKL
MJ)(R1VC1\EUZY;L;M:USU_5FAABRA?I(CF9D9&L;7<))E+#0\.ZBY[FU9<UN
MKB I>%F D;,QFCB:5$8F.-@[$1K?F0 K?WTI.S[1+LM-  $9E:1@653)PBRG
M,  R)8]U=B#;TK-YF9@2:.22=A8KG<EX\F54OJL@)NI-G&GJ:6FWF9P"P)RR
MA6>)"&;$G/=H@9; Q+;4O(I) Z"M-V[KF@CD:2-FD,V9<0\RE[E0PXG$5%1K
MMD,@N5&AM6F\A$E?,),:P81F$K=<H(.969O9955[\I4=NE%6E@3=GGH-EO-M
M-,+"^?B1W67)(8R>%PP[M(KA@%"E%ZBQK:UR%.2C&_$B5OIMI%PLTKO/),,0
M%,ACRLZ%&/#=F?._S:9,A86O;6I&%K %)S=D:\O&?;\7]?1P3HP6*-9%CXT1
M,^;BLQESV!RZ&^GG2IV<6N WG)QJ)P5\T/\ _DS999=N>*F,GPS9(OS9"9C'
M<1XAHW>\3I:)A)_?=>W2H^GE1DOW0\Q-W*GW,W!312<-HE*A;!)4E7*5<L2+
M!+9F0:W[5CS:$M6=@"4PXCS-#QQ()(M+!C)D1@A30@226 ;L:R]D).J8)FFE
M:S)R9\@"LB<0EAFU -M%T^-:;25V;N"H,/ER*49I R/=658S'G!DS '0H0!?
MKK6;\6LC7>"EPD89Y(T#LSR2E4-VO8B)486?0VZT-S?#(7&%U=Z&5L(5BB$F
M82<R*@D$?T=LS!Y0&!"LQ&NH)TI+F_8*W%Q,)V:\\D<A6&-F9)<4ZYG,<@90
M&A=&&C-ES"W2YK6_(QTT]-3MBME+Q(%!MS%G=$24.RW89=+*0/.LZR2UT$]6
MS VRX])PN>1U?-&I*![HR'*1;G(.O;2E=:C6Y)&!MGE8Y4:3^NIIBTBL@58F
MC50S\H"V<$#0Z'6MNHK9:FU%WST,T<+F*021HZRF"3*]GG41.!RE0,L=AUZT
M-R;05(&&,J796+LY)0.;L#:0\S'ZJAM//I6M=121D:TB")5CB,6B !;2J0MW
M<@ ALQ/>];R%.*T1T: 1&6*0\9EE4-F#YAGL%558E\F0D!@0 #VK6C$VYF08
M8RV*AT2P158B)K1*65U"L04F4 V]*7O.^9C1]!<+)*QSHD3'(S960'JY8\PR
MGRZTI21I+/L.ZX)9G"OQ'O:5.'S"\F5 ESS6%A>U+R%;IAEP\K,K$F$LH,NL
M@-T8Y,M[D*;:@=*3VY&;H.2&1R(A'&LDH.1F "S2DCBE'ZJ534:C6MW0EK,+
M0@;@$+((PTB\<\,)D+!7S*+%?I+Z]Z7&=N"L: C81[.'X$L9FX9XE[*'SC.(
MN\4BW4_;1.L@:M<[O%"N9L.R(JYEC+J(UDR,JIE4@ELH\^IZUO?CS!N/+0PR
MX1H8EE98)!#*CG*[EHI#U0@W(S@]NE;NC6Y+L .'5<0S&>583!%]' 2KQ2$$
ML(VR *691R]JPUNO5@7::L( L14/F#.MB@0Y;ER!E1E-[6K8EZ /!$##@/F*
M2R+&TA4H$E(3)%I9FC<@V)K$8L@XAEDC<Q@2%"N9>,<K(JYLHS,Q) )Z5EQ1
ME+ED=[V:10KLR/9LH(%K/8'7KI6S5O>8PD3O=D#G##1FC9'+!8N'>YR:NQ_C
M4'??,+N1.#A3%$Q7/(8E61<H5)%RDA49-%)-S<6YN](S-[L48GB;%9H9(XXO
MZWD9F2.TQ!&:QM92^?M6 WF$LD#!&A2:,$9'DD$:B4<PC/$D;Z(%0+W%S<D^
M=;0C=BPGQ3LF)8QLDD+RY1F< -D%BKMU="PZ7M6@;,ZQ&3.1D+32([,K$/FD
M2_T:GD4'S%9<TLS'!"4G&2,6F1C([-E+$@@F100";_;29.RNC$"\/"H$*)&H
MFL[7C!"-)(05N@Y5-S[/0TI,Q:G >5(U!(D668QJ;APDJV_A >8(12=Y&\_8
M#8%<N9\J,BNRRHO(H9<S+%'W0EM;CK6VDUF8 9I7<B1792)5ED#+J,^9 TI^
MO""Y-O=0V\[<#8&GB>2\N9G9 SF)K$RE2+%7/-&@47"BP(K1ASAHTQ$CQECA
MX7 4X?+HMN*^=F;0-(X!.NE9XFK^<8PQ4QY6(7BLKMQ,ZH44@D&S'BNOM6-M
M**HHS0^GDFD'!1LL"&/A#*>*0[=26%F!%M32EH9H"(8R$BB=G8S<(RJSEKS(
MH*QD"X*,.EM*V8*: 3Q-(8H.#.55>,C$Y$ *2LK:E0PD /N]U!>N8KQ%!@(Q
M,D;3D1@)(5=%9RY3G5T:^A=S?T!M[DO3(QZ!HJWCXO,C#4YFTT-N$0W0!^_6
MAMMK,3<GS^3S>%O&_>?ADACX6[>;(;L2O]-FXN8YSU"N;#TJ,VK\G7KKP9.]
M'_EDOHG_ (43_]6S7XQ)_N5/$*P%SO;MDZ]P<;+H-:4LT4;'?+*OKOQ&Y"D.
M+ WUZ6N;:@"W8$]*QY,: P*; :+;3SO?ROWUI3R-G>UPI%B2 I8:'->XTU&A
MK.XW<XZM:S7L;]M1V)OH+UJ^1M&9$O<'J"W4>HN/2])N_8;[08BC0,NJCROU
ML<H/H*2^P*E8[#F"J%M>Q8-UO?H.FH'V4G0P^"D]/9['] OTZD"M-FGEH=@A
M* 6'4=#8C3EOU\ZRZ0BX = CFXO<:7U&O[*7?(39@9TRA;DL"P-M.F@ ^!7[
MZUJ;YF '*&RB_P!NAOW]XK;>8ENYR+\]P 58!A?-:Q\AY_=27J98^$>I;0DG
M6]\MNH;M<'M6KFK&)^(&T-[6'4::]!T.A:MJUC (T>=S8D',2,PO;2_-VUK.
M&9HRX#9FT-JXW#;+V7A,1C\?CYE@PF"P<#SXG$S2&T<<,,89V=CV T K6IN,
M)3DHP5Y/@;._!+Y.>PO#R' [Q;Q1Q;:WV:&.99)E23 ;NR2(&?#[+B.9)<9$
MQRMBFNVEHP@+%U1C;74MN V73PR56K:5?ZH]W;V^[MD[2B6/JPP^K##ZL,/J
MPP^K##ZL,/JPP^K##ZL,/JPP^K##ZL,/JPP^K##ZL,/JPPX9E52S$*J@LS,0
M%50+DDG0 "L,(>>+_P LGP]\/_G>Q]TFAW\WIB#QE=GXD)NWL^=24(QVV8Q*
MN,EB;4PX027(*O)$U0N-VUA\->%'[)5[-%WO\GO1 X_;^%PMZ=#[+6[/17>^
M/<O>C5]XJ>,?B7XK8Q<=OGMN;&[,28RX+8&S@^#W=V=RFQPVS(Y&2:>-6MQI
MS-B,IL7(Z5/%8_$8V?V>62TCHE[/QO,IF,VAB\=*]>=X\(K**[E^-W?:--&F
M;.T!:&R_7L5U-A=200I\Z82CST&!UE>)F48K!I(0S 2P$Q!K&X8D:D7^VM[D
MFLG[#+AE#%A617CXC%AEX=LRFW8DFY]?.F\E+1F\C*NQ<,J.9 W!Q"$2QBRJ
M2>AN-1:_QI#K-RRLY+0W;+L,L&SL/@U*82$H#E4Y0JKIUS7&HRCK3RC@<9C)
M9Y1[3=.DI9+(,%PJJJ9E!4FXN!9+!R0+=;BXJ?P^Q\/1FIU&YSMIP',:"CF\
MSO'$ ,H!ZL-38E; GMIUJ85DK6R"^ (CA!L,BMR@E6&8*;\I[\I[UK7+@9WA
M=M+8.%VAA,3!PX\++.#EQ,"A&SYKBYL"0<UK4VJ4*=5-62;X@Y4HRT68C=G[
M._,S3X&6&7BQB[3JIX,B, 4RN+B]^]ZK.TL)64M+I#*M&2=F@0DA4\@-^C<U
ME-^UM2 -"?=4?U#>N0&P+3$\J\6,1E54\9.A5V(!8 C.?LH<J&?F^XQYAAP+
MQHV8V<:$6)TN"$/<7/OH#C9FU>X80L0+V"E3PF.MV"@$VL3J+TEQL:<.8*C9
M0HY2Y#W86+:$]1W/6DV-6Y: I6R$"Y:Z@@'^,%(RD'MUMY&M./(2SN)&'$.?
M,I-U9K:'H!UTRG[:UNFK\PVP 7E(DR752X! +,3JQZYB672M./$5KQ%IAYFX
M>FBJ$U ) .6X.AS '[JWO65PEE[1OM^L(,9CL%B5@ >6$))9;!F'1V:V:^@]
M]2.$6^FEH,\1!NHDM;'38FPFC4/(MLJL1H.4AAS?8OXO5CP&RE/[+5TY#["8
M1[N_4T%JL>50J@,%"%4',JL>M^_76U62UH[I**-E;B=PF:]QZD:BX%@ +:CI
M]E:0I1S,^6Y%[C46 TL3T]0,H[4M.XM':*)@ %N;-?H.5;VZ=+"EK(6E9&=(
M\P;,&LIU]HYST_?I67-V,L:#EO<,<HNI/(POE(#=2?LI5^!H&*'/M+>QLEBI
M!/77I<9AK2UF*7(%88>U<:$W+6-@P%B-%L.M:EV"D&D,98$L%&7-8C4Z$:@F
MU[4G05HC."5O?II>Q R@V!T]HM;J:58W9'22]M-"IU S"Z=;W&H!%*61JU@&
M\:W+,N?4LMV.H?V18:BU;-<3" ;J6L#F8<KG4G4!1K86TK9EE8%1HHOFMFL,
MPU4GJ0=.R,?C^C$:\ >BA0"&S*'TOH1?^*NMSF-;U,LSN38')E4@L;VT%N@&
M@&8FM&['S)8\X&8=+ !"&%R+^\?"MHW[S&&%[9+6T\^U^O6MW]QIOW -E!)<
M,P:^9@;E5S![:] P4? ULRQC"KJ"<P4@7 T+/W/N!ZTI*^;T-V.!8@AV-^C6
MYLP&NGEH!2LC:TS/ECYCD((#$93I<B_P%KUJW(U9G<)<J -=0U[Z>=B*59<#
M9W46(RCSLHN;WZG3E!'GWI1N_([IS+T(ZBRZB]K-J>EFK+LRYG2-C=<QTNV;
M3DY=-%T)K&S+@F./E!;*3E(OFY1E.I4  #04FXI(%0IF:,9@;Z@WL ?/6MIW
M,T#:,Y"-;@$\N4$-;078F^MJW:Z-+0'HI)T(RY0X 4D*NHL2UM0:0V89 H%\
MS91GRZ:JRE@5-NF4E/LK1OCV 29&4R*UK%N3+I:WGW.E$C9Q-ZH*6%G(!*W(
MYAJ0>FG8+1$L@3=G8'2[,^>10NH!D1<B] 5(N0I.G72LC4W<N MP;60728K$
MX892C A^'*'L%<)U8 ]5/3M15%260&3:>>H)EP^$QT>%QD.2.2*[<._M J5(
M/]]>UJQ.4+IVL;E9KM,$<_S(;3FVFO 9XI> Q,A1@8P(R&&E_.EVNDH\!.MD
M@?%P_P V8%LP8-BL& H:Q)*WTM<C1]+WK&VY>PS.^8<2X4KB, P(RM%*4]1'
M*K,H&A\S25+)W-< =' S_G*,J )&Q97*0"JNF8$7MS,=;5O>OIQ-W>3[#$A>
M;9L;$C/ ^"E+,,I8CEFZZ W'G6VVI61B>?:&,B%7P.))LG$?#R!",V5Q>.[V
MN.:M\XBEFK&1 L>-D69 YQ X\6N52%'"G73J6*WZ5JYM6L"\/"BM/@V;,!(4
M4VUR.;QY/]+^JDIMY<$+=^&AGAB,D,F%D+),C<-F0C1KWB;,Q-LUK&PK:=W;
MB;!:1\6$.VDT.=@1[5T_A5-[ *#<5E_.L)>62 6+VK@CAN+%.))D%X@EG=G7
MVH@%N!FZ7HB3OI8W9MVT03S;8QV/PO APQP;E1:=G :!;C5!UN"O3O6[6=WH
M*<5'7,Q1[/Q&)6$[0E;&NJJ5:36-FZB0+892;TK>3=Q&>JRB'F&V:MLKQ@*Q
MNUK$#2P%C8@6%:DW>[-I\LV&L6#B7HH!5AE9"Q (Z7 M8VT)[UJ]^X7NKF#C
MD4900+#+R_?<BY/2D6[S?9P.CRG4"QY<Q-[656L0 >NE99F/L [S$,P:[$D%
M%%@!'IS ];@4M1R-7 LDKY6-\RC-R@Y5Z);L3]2B1LE9F7 TCW5]<K #7S4]
MQ:^H4?;2D\^P2U=]@73R$GJI!RBY!#$+H,O=;WUI7 2?1IG)=22;]">R:][V
M-[^^MV2-\0\PX)90@S"RL?\ 2*.@'F">M"F[BHJQVQ<N5F !!47.6VE[9;7O
MTUO6XQWLV* #9W&0Y;6.6^4CF&8&Y ['47THJ20ENQBC92N1<EE0A[6 8&X4
M$"P)!+5OP,=V8@H6]T<A;L"+C,-;6(-^_2]9<U<Y5^6,V*K9B2X(%KV"EEN2
M1ZUF9IZG8M:P8$!FL/7M<=[&E7,X'#E4&4$9M3E()!UZGN /.M6%I6.O%.9%
M)(*(S(F4#-8FY)Z$_JK+&P-,X"NP*_2@@!M%=@,U@#R]ZVE9F'"3S(RR0L\6
M(C,9AEC=HYD8V),<B$,A4BX(L16[>U"%K=.S'MW2\8Y\(L6S=YHGQL486,;3
M@;B8Q%!R@XJ)V'SH#NZE7MU#-32KA4_.IY/D2N&VE*"4*ZO'GQ]O,D!LW;&S
MML85,;LO%PXW#/TDA;V#8')*AM)#( 1=756'<4RE"47NS5F3%.K"I'>IM.(.
M+V'IWOK^-*387F=2QM>]NOH-?OZUNQES S7M_/6S+F13H23K?]E:=S9\==!Y
M>7W^^M&^%SL"+^I_'WULQ&52+&QZ]"/3O6F;N<J3KIZW_=YFL-G8GI8^77I_
M/6C5S&?/0ZTJWN,.*PQ&2P_=\*Q/,T?:$:7]=.AOV%8^9AUL+?K_ %5J_$R_
M,#L.87-KBQ'[/2E"&=E]/=]E99&D9U/7OK^K]%:%F':6RMG[9PIPF/PZRQ]8
MWT$T$A4@2X>6Q,<B_8>A!%P50FX/>CJ)J4H5H[LUD,OMK=7:&PILY+8K9[.%
M@QB)[&ND>)0$\*4^?LMV[@/J=6-16TD0N(PTZ#OK#G^4$8!18*M[W;4MIEM<
M7.NMZS@(C]0<Y;JHR^T1SZ6!'6YTNIK+L7X&15!!6^E[@VN.(.P'\4UM<Q&\
MSNB'/;JY(['E;R[DBQ^%*$OF#84#9VL0HLI%QS6\SU(O6F(8.CA5U!$=B.@)
ML+'O6KM/L-,$Q81AH%.7*<V@*GO<==16W.*[Q.[G<S?-U]H?7[+T4CI<=[UF
M\*L8WNK,&TRD@L>N70 V^-;3]PEW]AU 7Z]C>X"MJI"BX9O0G3WTJ]^XUIWG
M14*WRZ@:G30WY1J>F6])GZ+-:GSA196Z$$L1T'EE'8T"W(Q<^)B.N8DWM:UO
M:!) M?RM6"EV'Q&5KV)L,H Z:Z:^NM(D;U/FYM;DA.5C:^I%K$?Q;'6D";6R
M,.4,C'+FSEKL+ C0^S<Z:M2):FP%E;5F.11?F;,>NE]-#:D2O[#6IARL^B'D
M5V ! Y>_0:W;M:D6-6Y&-];H-00'Y>4V&C WZFA2]*XAZ@<= ;&^8V8="M[F
MP[D6ZTG4TM +DUD;*W3-J+V\[]#;6AR5M!#BGJ F5@S=%9EU/95N"!\;"AM<
M4">3L!&"N#896NQ4MKEL-;C2^:U"DC0$8R1W#&RE>H"ZYM+FPO2=U2S-A?,B
MB+-IR 1DMRR.MM2OF=:!.'$&UF L0OUF4C1BK,#=E/LWL;7RFF\T[[ST!6MH
M%;Q'+9AIEY/0 W&8#K>@269B606S(H60$$* .FI*MH5Z@DDCXTWG'.XEY!+-
MPW(81,T; HLB7$G%710$N JBU-*L7>P&=K^P1^U)LB9 2S27SR V(D#Y;#+R
M!N5>_P"FF]*DI2L[@6L\M!IMMP'%3,"B2<P#J07^BC10I<@_4*\WK4S@<%ON
MTO0$TZ%Y>=<P[+W5,^+BDF1HT:$MQH4LQ4KI8+[*@_6(-7+ ;,5&<:CMNCZ%
M&VFH].[F[HP]E,:LG"C*L6U!"7O8 =]??5C=K+)60>,4\K(<#"X'AQH[(6=;
M78G4$^0L 5LHMY4&<[IYNP;=2T1E:%,B1J56\?35VN19GRWU>QZT/>>IN2OK
MH I84C=;-HW, 2+&/H"/[X'MWHZ=S6ZM0$S(KHJJ1G#A<P7*Q/#'<\@)8TI7
M=S1UYE='LLB$#49VU0!463L56V@TK35\N(0"27:7G!99+K&+'2W4]1H*6E96
M,,,B"-+-:Z/R\%;LP.4O=B18Y;6'8UN-V\N*,,!SRY.6P^E8@]4*FT8;S!'4
MTNRCGP$;S/C(7RIE5G#% 1?*'3S&EUL*RR6=\C-Y@4O9\T42H<N52NA#<HS-
MF(4@WO6]WF),<S6 4#,5:1DD=]<P X@8BP(S7MY5JW$V$\I8YLKD)<@+?,S:
MM]8=;*WV5ES5O<8)02,L9/*0]AE&5=!G%[Z&VH[VK&Q+S DBLY!5\ZDM91KE
MRM<LX'7-^BM:F6Y 4R1\-Y"R)9VLI0L<Y-W!4?6![WK'J98ZYE+FP*YA=N>[
MG,H49!TL0.E9J;0''ML'LC@L'N2&&5F"Z:6ZZBU;S-^!V82K>-HXW*%PQ#%N
M1K93ETL+'IYUIOW&6]YT='!OP_8(;,IM96U&7T! K=[FM#,K6&1([F0JB,P*
MIF[D@-:_KK6N\Q/@"3F2-HP$.A)8O_';AW"]BK ]JUVF[V02[1Q#A"))%#JI
MMT:PANK ^KY;BBP2MH(=[70T^W,>JV7$2L#F9@R)K9A[9 %F(!L-!J*7NWT6
M0AW>NHV>TL4Z )&I99%L3(P+E%%HYY&(!YHP-/.EI<14=,^ C7),D[&$N-,Q
M#7MU!O:UR+:>5*[.0L*)&,D<69VX(D^DLKB1<V6Q<'VB#&+"_LTN%K ^TQ0Q
M29'),BQIQ)E+<J(SZ:1^W]+U(O:]&5K&CNLZPRL[O<9%L$*JP=NI( -E%^EA
M6P,O2#3"8B962212"N3E+,R(\@TE"J#H!J??6G9ZFXN*S=[BFPNTDBC(YF9X
MV?$'.RAG!N06;JRV!^-#E%7OGH+WT&&'QD983Y"JLK%"YMF5ULQ/4MS$Z^0H
M;C=76@N,KJXIX6:*"(QN5D4%D5+JIC9+JQO<,P%!:SR%JZ!\<N>2+*]S+&I&
M@;A->QRMT!=!J/P$M76ZQ47P%MLLI$PL656 0290_*Q(RDYK"^77WTV;XA$Q
MU\!#P(N+[&>%8U56O&P.O%?-<QI'WL:;*362T-L;C?3:S10REI>(2K@J%ME2
M Z-&]CGS-FU]*/35YH6M"-.!VE(=JS8PB;B<8LKM(>1'9QK;,IY+>ZGDHIPL
M:WVG<D!NCO-,T<*S,2(EA$A,@17(N"!>Q-O=I>F-:FG*XYC-37:.]A]M+.HC
MD#V9CRO8*6URNO-=E"&U[VIONLUUCCYKT$]M/$"9R4)!4E ]A=+?50FY%]*4
MKK)F;R>=\@-"\<<H9F6);-HXT/%BR/+_ '\A,0T[4KM-.2O8!8\<!)%D D,A
ML6;ED164,!DOS*Q T'2MPM<6M!.DR9;07+"PEBL4"<P+96O9U%AIWOZ48SO"
M_''.<I95='99;D%TSIS9GMS1H.4#2DIB6(3%94XDET=1*8A(V9G;7E)3HL:D
M:]-*<P[0?$!1Y\/<1YR""[7*V+:LI0\V5 S:::UN4%+7@+B#E,F5F ;FC"
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M1$9GCFECP?.C=0[KP@6U&4^\TUI7>'WK:R^H+B91>)C%YJ-/Z[FUQL3$2F8
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M2EP4#R%F8("(P1J/,TI27::W4%XACC"S8I])(3(&"9V*\T:#3LN8FWG1-Z/
MUN@<X6=9SQ%ADX6>)5*@"**V97;4B[1_&LS$V9TQ.1YE"H;-&V0QC(LX5?I&
M"Z@!.@)K5LS0%PZQIJ\)RLN2SQ@B*/F4!=!H%.C415&W[3+!1CL,2 &=W4(\
M,:V5"6S9P647+ 6T-% 2BUW -$=02\EPH#@GFO*4+Q( N@*.Q!-O*MWL:#01
MDQ06SRQ3A8Y9G"MDD!/1B 2C76L-H$Q0$%8II!PP'#'AR900W*!E1A8B_>M-
MY&K'TT<%L.RAHXS'FF!<O&9(&8@)ES%%)A'3M0-1P89'4LQ'$D4NCE6N'EG9
M;G/?41II:M7,,PV?)BGDGG"A3(R@YR@#%LQE 2Q9"1TI7:!:2=@DQ^#60RK-
M<0L)D5LZQ^UK>).0.6/LJ36LQ,LE="7:.+)&C1*BIFX,<QR!S'8*\DCA0,QO
MF/GI6P)G6,RH.'&I"QH45)"JO"@RH>?)=;>1)K#9D*%9Q)D:-$2)'+DA6D8@
M(([9BS(#?UH<V].!G>9A'P)VN%&:5EB:Y5GM*$BFE6_T89K\WK>M;[M8RQP>
M"YENN<B-5;*"&+C0.EK!\W\:U*W5P-@@19<.@BY4>/B!%<M+G1LI#A@IS!M"
M?*D[[OP$78'Q,;%IXY%*2H'$Z 72(!V5&6PUS)9@+FE))ZFMYW 4PC!;,T<:
M-=U<.7<JL/+&P;+9G91KVH@N_N/D:1%D+! SB[12LKD-F=0N:]C'PGZ]!2-Q
M,SMX@0\/#S*I*@HMUX0)C)< NSZZ<I%]-:6K(P$*+NJ<8W8Q%@D@*NJ7Y%9A
MRAEL1KTK# W@66&2/)&D\@^C@!LHC81A2S-<B;*GLVK&[*YO44BNRX13')&2
M\90_0MQ >(CR"1=;HS+;-I:@O-W9NV8,@*AXU/*&@+B-6R\-<P5S&OULB@#M
MFZTF6C-> <":*2>:)%?+)&4&<.L?$#*^4KELO-WO0C1.W\G;(I\==Z$4 %?"
MC;N9;ZQ,N]VX:D#N8YFN1IID-1^U7]K17[M>$B=Z/_+)?1/_  HG_]:SYXP1
M ^*._P 2O3>O;!T47(;%R]3;441:%&QWRVKRWWXC9NBQLO*+:G0=@!8$ZEA?
MSK'?@-;&918EF L+]!_V+IUYAUK3S[S$9T72]NM[W%]6-Q<=+!=*3?D*.^4=
M !<^EN8"]CU&E)N;5F944\V@!N3YK;O;W&M-Y=AM9>XR*@LSDKIT[YN50/0=
M*TW<+<X5-5LW0Y@;$]3>P.IUO26S#-D L#>_2U[=#<DGOK6M=!+.,^MU !&C
M:?Y5Q8UMH&SK*@:[67,1_%N?AZUB?#@:>2 4D-[76Q UU/\ >V[V!UI5Q(":
M,$FUP+7!_OK]P.P%8Y,P^$84,- ;:Z^1 \K&](S?<8?*@47)%CT/7IV)\AUK
M'FS+F QLY'3+UT4:7(!]2-?._>E7L8.9X;^$F\_BCM;YEL6 8394#I^=]O8F
M-SL_9R-S%1[)Q>.91>/#H<S7!8HEW&*\AUA,%6QD]VGE!:RX+\K[/^$V=>'?
MA7N?X:;,AP6P-G1/CN';';>Q<44NV-HR$#B--B\@>'#DCE@CRQ(.Q8LS+22+
M?A<'0PD-VFO.XOB_SY:#D5L='U88?5AA]6&'U88?5AA]6&'U88?5AA]6&'U8
M8?5AA]6&'U88?5AA]6&'U881R\8/E.>'7A(F)V=+BOZ9][HE8)NOL6:-Y,--
M:ZKMO:-I<+L9-1F5A)B<I!6%E-Q'8S:6'PGFM[U7DOQOAX]A%8[:^%P5XM[]
M?[U?C?#Q[#4OXC^-_B7XJ8_$XG>C>+'1;-Q$C_-MV]GXF;!;O8'#LY,4";/@
MD2+%/$IL9I^+.X]ISH!4L7CL3BIMU)/<^]6GY]Y2L7M#%XV3=6;W']RLHI=W
MXW=C3G"E2&*9@+YC>ZF_0#2Y/J:8/DM2/<; F-<BD(;*;=.H]XRVH;CSU$Y6
M,V3B?4CY5"GZ-;DD^W:VI!I#B^ BW,RB!= 8X]19392&O<$$$74\OWTBW%&'
M9,&&X;* EI!RY1RFW06%CIWK:BV]U:LVKMABF$6,(S#B V)D:[6OZ:6MVM5I
MPN"H4()J,74MK;P'\::2NT"#&I(%CR\R918D6YBW6RGWZT][%H;[#G*"&SBX
MZ!2I'0:L.@-R:W:QAUX>A8K_ !1TL#<6Z]FMY5O@;1E6+0,$L; V.MO)@!VL
M*T89N';)H->PM_%/U=.6Q_';+7-&0QJR*F0.&-F!%P-.A]-?.MVRLS+7.C[%
MV;B!>;"0YC;GB0(1?2X*V[D4&I0HU'><(W[A,J,)YM+V!)C=SE+/+@)W#Q(Q
MCPCGEF8#,$S$ YF'2],:FS(23<'8;SPF>]!B&7%8Q95,T+X,(X1EFS1AK7#H
M ; D$=+U$5<'&$7O7OW?C&J37I)H5&%Q^$ER(63.S9&*E;!RJ@EO4ZW\JBI8
M:I#.SL:G9?G^?Y_6:B'(PS"X"$*1?+UN&Y1<D??0-V^8B_(X9BO*Q)S$Y2;D
M6REK'KE)^ZL4!#N<C*P*1W#76P&7OK8L;J0?*U8X&@\P"C,1]8Y.JZBQ!TM8
M4B:]QB[-1023Y7P\(2Q)5?: !L!K>Q)-Q0U'WB\[VXL.]H86*6'"R/&ID"-]
M6]P!<$DZDDBKAL3#0W92J*Z5A]AZ,7+>EK8 I'&(ST6^IOT_TJY;$7-69)+3
M0?*/([@+F&5#<J+C70GN;FU@:VKV,L[W>AF6,^\  M[+=CKR]!2DLA21SE/D
M #H+B[#L"+=3[[ULWX @(Q465Q:RBYL#F-[GL5 &M;%1U,XC"BX4%C?0D96*
MCJ!:XZ5NPO(S*HLK,+L]@^7DRZ7(5<H[=ZT:[C,([!0@-\NI 6S$Z',+"QL?
MMHB^LWD&$4=K+H3U-NP:UAYDUG$VLP?$!E>P!^%QHPZ$D'-TK.(O+@<G+:Q!
MN=+OI;3H;+?K?O2D:S]IC81@ @#73N1Z\I]:V9F!G&0-I&+D6.F@_C"VF77I
M6S$C&F5B%) 4LAMW4!=+-U8FVHK9FFFH,"J#I>SK?-V(L-0>JD*=*PT"HDN%
M) -TOZ@D:MY]:UJ*TU%!@=VMX-HA&V=L+;./#"R'!;*QN*5A8^R</!(3<^5;
M%QHU9>C&3[DQ4X;PH\1,4+0[G;?4,;@8O /@F!/\;Y\<.MO?6TGVA5@L5+2G
M+W6\0^A\ ?%'%$,=W(\,A(L9]J[$3EM]=%VA)* #_>WK>ZPJV9C9?<)>U?E#
M6+Y,GB+.1FFW:P2D@VQ.TL2Q4@WM_6FS<7I\32U%\0L=D8IZ[B??^1,,HODK
M[W,?ZZWBW;0V76$[3Q ! YA:3 X;,+]-12[<@BV+B'GOP7O_ "!A%\E+:A(,
M^^&SD-K-PME8F4&Q&HS8R#RI(I;%J<:D?<&47R454 R[]78$D\/=L="=>=]N
MF^GI67L$6QN=3^]_[$"8_DL8!&);?+%/V &PX5RF_:^TW%K5O+4W^DT?VQ^[
M^4S'Y+FR^7+O?CQE%M=E8<W[B_\ 7H) /K6-V-_I/#A-^[^4Z'Y+VR\V;^F_
M:-[@DG9<&I!UN/GEB":Q,S])X??OW?RGS?)BV>-5WNQE^Y?9$+^7ECTL+BL;
M$O8T/VQ^[^4QGY,T(N(M\G6Y/M[ 1QKVL-LQCK6KFEL?E4_O?Y0(WR;L5&3P
MMZ\-)U S[(DAT],N/G O6[Y&/94OOU[OY3$?D^[>C_@MO;(E(-QQ8L9%?TTB
MG(O\:UO<A+V546DH_6 W\"M\80QBQVP9\W3)BL8";=CQ=G1J/@:RX)[+Q"T<
M?K_(%TW@_OS!F$6S\-B=#K%M# @:>SD7$30VK7$0]GXI:13]J_&)K'>&V_$
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M!N=;5NYM/F=5)$84J4+@*GLJ;W/-EL38K;7K697N;R>AU8MER\A#%E9F!9%
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M92TXK\GY_P B94%KWL"3TT  RCKTZ4XT&$I<$<B^N6X%PK:V%SITZ"E9+O$
MI=&(ZVL!?S"]K:@_IK.SB)#*.,@ D9!D4=-.MSI8F]^]ZU=>T2PRC1E&AL+7
MMW^WK2+WR,2>H+1"%+'S&@Z^H!Z@'TI-U?((HMG?)8@H#J>A ZWZF]R:VFN)
MOJWV&.2('1EN"!JO46Z>_K6][D(<;Y<0-PF :QT%NVIOU!] #\*S?8AP:.G#
MU-P<H'<6OIIK[ZQS;5N FQC"K9>4 E@=1:Y7RMT^%JT:.&427^KS78Y;$'+H
MK=!8 ?&LN;.B+RO:QUL2=?=E'0:TF2OGV"D?-9+@E;E3=B K'R!(&B_>*$)>
MIC*EQRJH&:VASY@>Y:X(ZT.7I& !XP"Z=,IZ:78?WJGVC\:TU==I@'<Y;7"$
M D9<AS:_6;O:WKI2'<TS'(/:1<I%U]GN2!W]HCTI#BGF#:,$@5R^4(H(4%@N
MAR]2%%@G3M:]"<6C3U C@*+W8'+EN>F>_LG+J HU!K32>IJP%9  - QRY2W1
M22-"!VM2&L^P1**M?B!Y+7 8A0 5/*,VFHOT%@>](E%,%:P <*EI(^;B$KS=
MK=P>IH4DT; &6\A!%\V74H+:Z95!N!?OY4B7 TP'*K2$<3*4(R#L$*BRW;K<
M"FLUF"<<\PME1<J<W,+@OS74C12?, ?;3:4+OM$V:"Z<(;FP4*>C*J@KD*YB
M-!;IY7H,ED(=A,XR54LQ!6SO=8Q82*!RFQN *%&%Y6X K7;N(#:(=GF7590P
M"I<%0&8%#(,M@TA47/45)4,!O/>^Y%TZ2 ^#V'\Z<M)"9)"P8DJ&>SV)0#J5
MS5;,#A84Z5Y+SKCG<2U7 <C9&[R01 C*Y/2\9Y #=K:Z&-K^^I:\5PT-6DG9
M7%M%@TA50JIJNF51<6T%S:^@I"3]@XIP<5;B=B@6UNH)R@A3T[]Q6=PNS ,J
MA6.@YD)!S,&"GJ<MP-#:M6MW&@OG*E6RYT9B)6S$7<_WU]2GD#1H7>IJW, 2
MJI( US,  /J^R>?^]S 6]**NTRR 9=A?(Y6[W8,+K<@=+#4%@U*M<V!6)(2Q
M6Z,QS! 56YU+2"X^T:5NV>>AF0%<LEC'=E4L00<V9U,=LJZ KF)[:@UFJN)=
MUH<H))(PV4 HIC:Q%RR\S$=#D(Z]:6GPXB;&-BK9.;AF6X"-S@#J0IZ"]K"L
M[]30'8\RC, C$WLJDH%  '2Q"@#[*SP,7U@/B*Q9;%LS,>I8@=&:U[#-Y=JT
MW[C=T%\I4DY6"V]E<C+E)ZD.,NI\KV%:4698"8ALK@'F7+E)*VS/U.HNP/EK
M8UF>AJ7U 3, "HSF0L+ B]B.D;Y,IU&I\J79 =Z2=C@975"JY93<A59@&LUB
M2'LMK'S-;48F;TC$ZHI5",ILV9F:^8\Q'2X%AZTBV;Y!HZ(#1..1W921F8?1
MYVN=1?2PC_C$W(K/ Q,S*JR_2D1Y6;*@N7)<#1+G,0H)[ "M>)O([A)'NF9.
M(KL3JQ(RE2JYCS$ +TZ5G:8<%E8.X-BC 2@(Q49?JBYNQ#>5;--( SXIH^=U
MB</EN4:S&W9@[@BP[ :4J,;K(QI,2>U\<SQ/$BE7E)U6^0*H 4EFY<UAYTKT
M5;B(O9OD-#MW$,<^82AXF1XVX@3BLA[+&S9!IT UHL;6$)MR:X""VG-(Y"KE
MSL<\KY;V$S%N'F(!+@'06L*WYU[(7IJ$\Q819%=+NRR\,9.)E496+FUUME[>
M=+2C:QC?O"Y06C5&:7A.RL@C8,]D+N'<E6Y#?L;UN-EDM!*=]3$ UR5X2+.I
M56.8.$&5F9I+*W("6'30V[4=6 ;\CI'&Q$86-)PSS*)"H)D(<G,SZF11$ 1Z
M5JZ--WS>H-0--*K1L5CX9*)$>(I=&NUPMB58DZ=+:=!IFG::!@QN7BQE7$)#
MYBB%3<!;D78.7N=!T:LS,!FRU(:Q=@E@Q<$*%B(-AE+,I!8^^Y-)E=Z:"X2W
M7GH+G"2(B*&S%@%,;JJ "PUNA4DLO0ZZT"47]SH'NM0SPI6\A4YFXBB0&W$B
MX:&UBP9%6QO:W?[!2R[S<7YR'/W?0-%&&-U8(@)13(0RZY570@GH:9-Y!^(X
M6)G&$V:A5BLBQ,J7S"ZVU5E8L+D]:;I7DT;XW(Y>(.U)#"ZL"TDDB(HXF80Q
MDL3;.#E4ECH-*?T5%>=;,W%MZZ#3[,,8>-.=TO9RR+9;R2?2LHRC(#ITO1V\
MLC)#E;+DDB?)E3-)Q).*0IC&JYECS9@%<6R]P;VH32-+)VXCC;)Q\D2*KL3)
M)GRQN[%XHPQ4!2=;V'OM3:<4W;B*4@[DQ1D"ERS1P('9F]HJ&&8.+#5LQ \Z
M'8([(-L)P&7(7DT+AP1E>-'&:.UR%(NUK]32-'F8],M3)C(KHL[1MFC1RQ4@
ME6 M')K=1TUL!>LC)IA5:W8$9CCM(U^(S.BZ*5RE@/8&F6QN=+6N;49OW&.X
M Q*(BYU2$_26"A'>144Y3F4ME*'U&E:-=XB=HQ96ED3(%$A8!C&<T9%GX8?V
M65R.G2C1;RL#>3"-&(BDC/,I1<[Y4=@;W+#KJUM2PTM1;FXZV!F'*22+$^4A
MLI66,Y0%)L0!H!(WGT%;N+.ZMF 8YF4,N3(;$L5(D,IZN1F]16,W;(SAB<OT
MI5$;*4C^C,I%N24@6R6MW&M:W6S:T \LT,K\*-;Y9E5%:;*RY0EX_:.9>4@'
M2U_=92BXFT@&LD@5'7A(LKIFY&^BS>U&68E6(.I8ZUMI&I(RX;.H",>(8V=W
MS+Q4DY\UE86" V%CUN*0TKB#EW$UQRWZCE%K\[.HY&(>,D6/47I.;-@=XI#E
M $+)97:P^D5A>Y1 ;2.>^8=*SC8P!8B-S'#=2,JGB !D=$#<Q96+$B^7IH3\
M*P1)F-0[FRM&SWY!*>8.5Y@VH%\NH/6L[!)@8B&\2HT<BHQNUE7BDC,%868L
MR$ZWI:65V8 UDD^< V0(LA20%\JK&%T_TU^AO\:W:Y@$G9,KY>)8$92[\10S
MF]D.5F4J ?(6-99&PNGE 6T:J[M'Q$YRV6,-*;E)0%L4(!\^ONUYN@F^8G)G
MNX)CR+*B$1H[HO$YPS%E?5LIUZ$5M,3((9L8@6:.6)5 :4DE]"M@%8L2O$C5
M4+7-^8"MNPG@(K&X[AK))(94!$F742 9(PP!YF.=A8AK7-Z6N0.5[JVI'G?;
M:_%B#3))EE11(1)8%GD^;EDXEP;F8:#M<]J=02B\M?Q :D7NYD _$_;4? FP
MYB!"0B)"<@8M&H3(=2,R!!K:Y^VG2LD-[JV[QN:\M\]HRXF>:##R12/*[P$N
MMCF<WB1E8J,R/T\_6HG$SE*=N(^P\%'-<#?/\AW<(>'O@)L6.;!A,1M_%8G;
M&.DYA-+)P</PVNW#-@L+CO[7E3F4%"$8*]DM.\'-WFYJUF3"DD)E$PA4P9Y0
M9G4*D9*W4!,M[E3;0VH3RU-J5WV&6&:5QB!%PR5PPAB/#8F-S$I^CZ*7RW/J
M:UJ$,^#>0<:,.<K<KJ6-V=2S([YNH"VMKUO6FKFS)$I7BF9HXBSJP":L)'4Q
MQLG8$-8@=S0=# 7#.595S,H+EV+!#98RS,6S Y3)(.E*1M!BDS2OE61B++9\
MP6[.QLCE>:Y705MJ^1OP#_ 8WC(K-E(CR1NN569"KA70'1CGOUMT-)<$8L@V
MA>#$M"$A="ZJQ9ELJ\/*71KF_/?4]>U#::%K0/8</#(+00P.R3"602(20/I,
MPA(MRL;?9:M7? )%97XG,.S4RLK+PXF >2R&/I#$+,5UL7)]]ZQ+W"@'/LE)
M"PCBB3)=KALL95A;F.A#^0\ZQ6T-22]H%39<06*-X/9X:NC"\G24<C!RI)R*
M;6NV76MY";'PV?Q8\W#2,1D!9)6U*VU!8:@D];=/=6D99@9MG&_!$,;2OQ$9
M!EL9 B,06"@EBA.7+87K=^XRW ZB$Q,1+&(PN:-[BZ)(1PE (ULYU'F=.G73
MR$N*M<QC!F*9+EBT85U+QIECC%C=.:Q#6(<!22NE98UNL[3"/-( ,J,A^E"V
M>0'4K8Y>5"+C0VM6=QI1=S-*@7#-_!*>#%(ZL-&8II=8],T:ZWM?6M\ GB8A
MA284 "N")8@YY7XMB653>ZMPF8KZVK# #-A\/&Q<((S&1&8&8-G+.P+V'*6(
M/<4J[$G1L)''B1(S*0&+-&VK94AS9%X66-;=#VN]_<I2L:L86V?AGSYA&BE;
MHS.V9D Z &X,PU!!-[4O??,RP5RX:.,9.&C8=[NS1QE6$A0\K"]PAL+KTI49
M)ZZB;>X"8Z(MDNK*&"QL%ED52C 64AUOPRPY16TUJ(:L%D&%2,LS!3(#D6XS
M&-#H!<:VL==:VYRYFO X&$X<W$EC5X <C"-F661,UY55%ME8#V-;^M:-F1<#
M)BI2J*6"I)(<I"NBMER1*38<HC)L-32]^7 1N(X3#J7$;<1Q$A:-UB4DMJ.'
M(-%+ 'KUK6_(S<1B9;IBDX41X0OG:\D\K"^1R3J@NQOEL#2>X6=,+AI P5@J
MYX2SK(VD()(*Q*R$9%%M0+UOQ-!Y''DBC4K)%SY<I59LVGU,P;AB3ZMK6[UN
MX/=E>XC-IQO-*V3*<K*5 C(5P^A66%;2%E_C7S#MZ8)DDW;@))LO&=6#BVA0
M/DE++* V0L2&8I?4WTZZU@&^9GAA)EY)YN&2)#$MUSJHY!,QYC)FK#5@0?HU
M"HS&0JO&$_*5%R;M*;Y6\O.M-)F'$$BNL;.Q9H\^0J43B!@H*M< R@Y!8W]U
M:<48<8B2$$2%)%9E* *JKF8>R<HO< ]&ZBL5T(4FC,#D6'-B<LA0<9GDXCY'
M:YU.8L+,%()L*U9& >7Z)@[2JAS/AF!MPIF&5!&AZCD31CT.G3JO2R0D+II7
MCY8\*P9I26^<*B-)"1E)A(&2RCSZUBN]!<6V^P$.L((FM%<QNC<UBX*+R"/J
M@%]1I>MBCXA5D0LD0)+1QLZ$JI.@S*V9B(UZ WK#.PQ.>$K0!CFX;%219G0F
MV=&'1V Y?[TULSL!N!E*'.\9:1G(429I(T=!PR%-\R@ 6&2M2]$VA58(WEX>
M1Y&D&0YE#,7D!L['E(5& MKK0135S/(<+&D4R2LLZ2RK.KR*7D#+"<J1K=HR
MA<B_:LM?(U<$X7$XAEGEF>.2)L\:YNJKENH=%CRY@]LOF:1))/(TR=/Y-MED
M\?-[I(M4_J2[>69BY-YFWSW$<*%(&4!"=.BDFW6F&U]WX)&VO6+PD3FP/ELO
MHW_A1/_7M#>+BG^J;O\ $W.?>O; 4#ZI7&2@,W][2E+@4?&_+:GKOQ&SRE[@
MDD^UWN //3H;UL:G1.5@V<,H4AB=+'TOJ;UIYKM- Y!Y]U]UK^A\Z1>PJWN,
MF7II8VU_'H16FS=D9  1<$$B_>]B>HL>M_NI(LZLHLRV (-QUN!KVZ "QK1N
M_ [ %,H&JZ'-UUOFZ=16:ZF^P[A<QZMVM?K\#Y5EA#.X4&PZZ=/+U\ZQNV9I
MF<Q@H= & ^SUUI(AA<ZJ"0Q(M>V4WS6Z7[7)&E+1IZ@)@0.F6]R=.@UZ^72M
M6N8!R1FOKETT\[6/+Y]*W8PY',=;9=";D:@=!;L1\+UEK&$A?!OP$VQXCSP;
M9VN)]C;FPR#-C,N7&[8X397PNR%=2HB!7*^)8&-#<*'8,%Q1OGP)/ ;-J8MJ
MI.\:'/B^[\ILFV#L#8VZ^RL)L38.S\/LS9>"CX>'PN&6RCN\DCL6DGGE;F>1
MRSNQ)8DF]+2MDBV4J5.C!4Z22@@XK80^K##ZL,/JPP^K##ZL,/JPP^K##ZL,
M/JPP^K##ZL,/JPP^K##ZL,/JPP16_7B)N;X;;&?;N^>W<'L;!#.N'29C)C=H
M3HN;YKLW 1!\7C\001=8T;*#F8JH) JM:G1CO5'9?GH Q&)H86'65Y)1^M]R
MXFKGQG^67OKOQ\[V'X?KB=Q]UY3) V/CE5=Z]K0DE;RXV%F38D,JZ\/"L9A8
MWG925$#BMIU*MX4?-I_6_P GL]Y4<?MROB+T\->G2Y_=/V\/9[R%L,KB5C*7
MD=R2\C$L7+L2SN2268DW)ZDU"U8;WK(@&O>&HPT4H"D$#EU%^WE8=C3)W7>(
M,R0,IL;'730CZNGI84A_6)?(R")"3E4W(MF'1O[[MI>DVOJ9F9X\-EM<'.VE
MQH00>_:_3[:TUR$6L9#%GLH706'2UCU*@] 21K6E'>=EZ3-6!<4 *E2N5E-P
MK==.PL=;GSJ:P. E%]=6M?@AW3I;OG2,@5[!5RVRCE#"Y8%>E]1H3UJ827L#
MO0X"E65A;*Q-QH=1UZ:]:4M!*,BACEL;Y5:V@%P;^8TL6M6<3:1V6,W!L=--
M;6OW/6XM]U(MQXFVN1W1=1IT4VZAM.O+VN:4S#((B;%KY0RV9N4@ "R_Z6PK
M!-@3&BA+@!C:]KD D::$Z@VK'<WE?L!"IE&6P\EL>C?<.@%:S3R%+(SK$PLP
M-B1EL=2FGM7Z]*PSO VT]C8+:N$DP6+0-&]F,RC+-%*%NK1FU]+:^=9*,9Y2
M67@#E!36>@@8]QL3LV>66)QBL."2& .?,--5Z@W!Z"HG&;/J35Z.:&-7"U$K
MQLT!8=L3PXLX:3#L(5.5W8E'C/U;(0"UJAJF M&^DT-U&RSU#&1^(%(RB(DD
MGHQM:V5>H)4#X&FJI66?I"'K;\_S_/N$0J'YE15RV!M:XTTN?.]:E3S[3+7[
MA3[,2]F8*-;,"/JD&UR==1]]-:L?.[!2CG<'*IDQ\>C/PW&2_0=P<W0&]$HX
M>I7DJ=)7DQ:AO2RU%%)FD*J[&RBVNO,>H%NPJ\X'#2PU%0EZ?$E:<-V-N)C,
M0 (R]P";][ ]/.GZ"JYSD.IMJHL%"_57HUN]ZV;NDK([IT9+7(L6)Y6&G4#3
ML:4N7 VE=]AD"6M8YK"YN+?#7J;"E+)V-V!$::@6#*I))5N501=1;H-3;XUM
MY+M-: A8^4:C,E\Q[&QU \QK6KB]5<R6Y[GVA'E46UN?9!\S8UO)FK&6) N7
M4"XUOFRE@+BWIR^?:EH4#8>8_6TZ$V)4C6Q_O36/F;L&$4;,52.-G:4@<.)"
M6=B= B@$LW3I6^X6L]-1P-D^%?B+MPY\#NAMO+( T4V,PIV9 P8@@IB-IG!P
ME2">8,12E&3S28XIX+%5,XTY>ZR^NPX&S?DR>(>.L<<^P=CH=6&+VC)BIU]
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MI4$,+@@CV;BVHN;^ZMHUIKH!I&4+J;D 6 U()'LCS%^]*OR,<E[3&LP)*E=
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MF9'5 J92CL& D.:Q*YM!YE@1;U K$8LS"V5VDR 1L0;+:SW[WOH0;5LRS6;
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M :@W L#KUZ@V!ZZFE)MM&-7[SI8  D7<MU[^7Z*)?W"7%7[#H8@+AK-<ZWT
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MD;2 ;)('!4O$F5A$MLQ+#ZS Z"XMI^!BS?8:D[(P$*$8YT>Q$;:/FS1C--[
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M\TTGD!<NLAF8%64J)$0K+F475E0&S$/U]*U=\#-U *<MRDR\3JI$BIQ";>T
M"61;M]M*B^ /Q,,DD<C&*:)5:5,BY2H9K^U(P/3F3WTK,Q ":<K9XHS%$C$H
MDB765E4YG)70IF46!Z5CO[3+A3BI8PS!9%$A1 %%B3$#(&4$Z] *QK,2WR$Y
MBL5&Z/H&NQ>-5M9@!J1:Q2P6Q%ZVE81?F)7;4L2X<Q%$421+8F3+]&S9@J9^
M8K:X:_6EJS[S38WNV\4ZX0KA0\393>0Y&)-N1U^J5* @GK:E<,S1&S?_ !TD
M,$BM-&&A@B,<ACS1&4SJ2%B.BE<*SV(T5M:-3DW-)\!$TG%IFMSQ=VU%GQ4I
MD#%$9KP2WR2 6SL%Z I$;MV)]:>RLHMO091C:IEI8B[N5LE=^O%+=/=MC(R;
M4VYAUG=4.=,,)$>[ BQ4H2,W6HBFI5<2OO<V/K]72;XO\999W9P*;O; V-L+
M"D)AMF86.(JP9 CQP\,LJ-K:92>FEQ4A4:E)R[D C'S15)C9!P'EECE&?BE4
M#.TB2<HCRKJ-/2A]XN*:=S-/)'(JXB*5H8KY1=2!&_*@9] S.C$6^RL:378$
M!.'Q"F$M(TS*V1VA2/AA>&MHV:5K.P(.8D6L6H"=F[&P>)4C43CV7"M](A8E
MSR*8\UFM'>X(Z=:39/)Z&T!RT95GE7/,QD:_LI)PG#*N0=\@.O<TI00KN,^$
M.<3QB9.(SNJ',5R+J0V;IRA#;N+UF[$T*;9Q9#)%"BE26EED$H)8@QW )U#9
M;G\:BN*2YBNPHO( KJTB F1F4A1$J .++=0Q6P!\Z3+3,6LA2[-5S'E0DAP6
M%\S,D8F2RJ2 5(*WMW%!DW&]@D;;HHI8G6(G)<9 1(%/%8V/$55ZZ#M0W-M6
M,.4B$D687?V,RC* 5M<-*KCE93UK2UNM3 .V'XI4,H759L_\1PRA7Y;#/9VK
M>]+5LW<+FP/$#+&KGAYT-XSERN 'F-[*23W-:<I/(W<[C#99QR\P**I+#Z.Z
MB)F&74W3KWK6]),RX"DB12MX;E386^D27*^DT@/-=;#XUM5)7[#&8U@+R :.
M2[O'&V4@\(%F!#6,9<GSIQ%IJX-Y,Q?-\LQ:3-GEXB\.RE(T"&S@K<*I/8&L
M$@?@R95(>%D(RB9HPTL8!LK ]V4:6MS5ES#%B(0#(+&Q +E@59U*9,_*='8'
MK6<38$&';*K.B%S''-)=!JQ&8F_90&)-;O9&(Q/!$6*,RHC$9GD!"M'FNQU%
MSQ%\M6L/+7+OVF&%X@8R(Y74K83,ZYHFD 7(RDC,XO>X&MA:LOPX&'1L*O%D
ME/#9$B!*C4QR9LBR!=%8%"=&MK67,?, 3P12,H"DHZ ?3$#+)#E75>@16-P-
M+"BIM: G<R_,\/EF:%$+\-7&6V1"IUS,]D(8UO>9JR 4^$E53E3Z$R/))!&5
M*&5TR@Z\^53[(OI2KQ-6 DN#6&(3+Q8_I5DR*^;*)0S*_+8VCBD&GF+UN\4;
MR,2X9#D'$*(I4%G#7D9LV:5GY;WTTK+Q>9EN!AAAXBIGB6QAX7-S8E%5H@DZ
M/IK)G.E8W'GD98SP8*$%(\LO#]E KL)S$ ;7E/-:YU6MZ&60/EPIPT#S1O-(
M8DD10&"JD<HRL1F!D<K*;L>X/:DIMZFFA'[2PCRX9YL.2TN8NL\=\LL\FB1O
M8YE4'2C?8P4T]> @\5AS#-%%F@$A"EXC)[,1&;$@2F[!2RG7J#2$ :>];(%Q
MNRY2S,LDK*YLWM9WS1,P(%BYK7@:,B9&:7YP2B*%XR1J)8IC>VK'46)M6=QA
MB:,(Q$J6A,D9CA(C<"-!D! 74#-S=>AM6N[4PP1P$R-Q"(#=6PQ0YFE23G4A
M!=4 7MWK-.X')6.4.1)Y6+*&GD"AH@T@BR^R"W\9M3Y5KL-'$S+*PXD2O<R(
MH#"2T\A#$67S)+ _5K>7,T 8DSQ2$E@>9)5&=E3*?HYHR018D6(I5S<=3M(B
M\Z%D<312<8RBRS.L:Y%-M(RK#SUK AVES-%'( 5MPPQSV0R!)7)S&X:R]?.M
M)MMF,"$F3.D;G)["YB5E1 +\8YK *@TT/2E&!SL^/Z##AT4<$$+/&UV *C/8
MGHQ?J0#6FEHS \BECA6%H(94MG8.03E5661LY-LUQ&<OE>AO)M(4M ,^)PL
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M7I8W[D6O0][B&AJ=N7+8G2X)RG7KVO?RK2;84[E0;MY+IFU \K]+TI/M,/B
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MY8@Z94&A+&^8$"C)W RRSXBXB0(73.<PPZV0,08R[JL)8D A2@U&ES0W9@M
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MK&89@@T-NQ_TMS?3T(I)O*^9D5.F:UKWL=/2UNZWK:5V8=N$!R6MERYK'6Q
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M(!^M>W7H2>MNEK&D.][< T(KZ@Z9 L>46!!92_3ETM8C6^GV4F^=N MY!7*
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M#JR6-O6U/%96L%NWF]0YP"JI90UI&4,&L557C1FRL+Y2'5=!6^P0\Q98=\,
MH6.-O8266[2<=VNRAOJV5& )^K:_>M,%))/(/4"@+&P0 6##AVO<DV!'06-K
MFD-F[L!HH,K",98U>3BH&MEM9D0*/]"8)JHZTIZ&MYAULAN;,UXQ(R9=;J 2
MY)6-KLA-P->@H4DD\A;S#7:F&,N&$:QAI67+)%PU-ED;FDLNA)07]#0MY6S$
M0D[V8RVU,(L<[QX@$O=V"*6+2E6X=F8@G,L0'QI<6M%H'9ECF*&ZL41[*->'
M:_*(R5LMT O8]:QJ^IN[%9LS>>3#<!,SA0512;F5E!Y&%N4H2AZ=!09K/+0)
M"JEYLE^?Y_GR=K8.]*8B%&D9B$<@H'#$+?F8@W/W:4*4;9!X._G+T1RL)M=,
M2C RH(B"4)8(2- !VN1ZT@<*I'1'?$XM51LDB$D "V1B"OLD:7(U-ZS)FG-"
M%VKM$<0Z@#(V< @<UK<1;6))/8:"MI6&]2>\[(3<438G(TA.19'D5D<IF8Y2
M2QN&NN<@#I8_8L:N6=F -JPPQX=W"P$)F1DR6-CK:,CVLVNEM*SM,3N[H;S'
M1P6E-A+F4&)226"KT92W)="Q%VU%M*=4IM)7T#!%&[8@J!*85RNI8D&.2Q(L
MYU"D #44YR]@K0,L.JF)DG"K(IB,+L2R-?0E47EU Z^7W:?-"0#B<-FDD56$
M65V:)HUT<+H0_0M& W3UK+&P!*ZQQQQPMQ567(6EY@^9>?+GN752?A6DA,FU
MH%DK@(((Q8CB#BDW81JA8V[Y0P('E>B)6$7;U"F9,O$O=64PR0M[&9+>P ='
MS:WO6,RX48HADDU1 7,I7+=AE< (P "Y3?6_:MB&)V>09BJHN5K*"N8YV5&;
M(1T5%DO9O+2E[N5P;?(3.+=HH2%+2 FS%64Y@6=@(V%P60D=KV^[=E82(S&S
M(RR-))Q0 A0R7"<<\?*21[# 9>FE:LA28T^V\<TT>*D$CLR%RW"TC;AG*L*(
MUA)(X U([42&M^*8E^E;@11\4\=PITE=)XY6C9Y8[,RNYLMU"\J  K<BW,/2
MC4HK?N]05:]K&M?Q5Q"OC)PJPJQQ!"0YFU2S,HL3YW) ZFAXW+,UAS8/\@S=
MB'=_<C&[:GB3YYM?'!HL2%,9CB4-E4,X+*S2$ @:6HM)*GA8J/',U5M.OO<4
M;&-G8@PY$*Y8^*A6Y"PH6XK"0ZZ#.M@>Y:D!8:7X@V+'\3@/+'%%)DCL@B3G
MLSQ/&Y%K%B+ENIK4FTLM1:5P4T>JH[,&)B(,K7"(5B$@-FNX"N]B>@]U#<FT
M;:5K@N-@DW$'.$OE2,Y4Q"291E(\B/T4,38[03WX[<*)A'QHG%FSC,X(:$"Y
MT46)[=:S3W& J&6)HW3#G*QE)#.<Y60->QC2S,ULNIU^VL3L9</L,N<QOQ64
M##@(TC29I)F8J8\KDD!&0%?*MR]$6F]1181HUA&'02-,54.RQJ560F!R%#'(
M6D8L"W7*?2AWL8*79ZNH25ADA=62;,6+1MFM90;BUNX-:D[!8+,6^QXB  MU
M"SH\C,R,I4:H530Y1E%@.]!85(.$XV1+H9XY%RQ9CD*1":2TI-M7RL*2[:O@
M*,HPW\"S,G$4+&$*<TN9[.04T)R^8K3DFC5F*#!84"V6.-\AO(HN0X! +*-,
MO.1>WD:0C230:%2@>/(%D#B)N12JYDS76]U (^MVK8H*<4V'PPGXQ%KHVA!)
MR$68@#GM'?3O26K+6YJR$SM#:N&BD<!H>0XA>&#F0,&*"8Y;"-N2]S6XQDQ+
M<;Y:">?;460%9+!I54MF":IS<LAMDS>=%BI++@)>ZN(";;@O&7CA*L)5XU@M
MI$/$O(PTL(U-O.E:B;H!?GK"XA#*H1D54!09D>_,UQT+V%*W6:;5NTP_/(^-
MF)68-JQUXA:,S.$N.QXH%NAK+/B8FCM+M.*-L..&&C>P'0M9KL;6Y@5<UHWH
M<G'QSRZ.5A5&+%5"%0@3Z)@;L6NX:_6VE:1O(!XK&N$D=<RBZ*.G#:=RS+*"
M+E203I6&K@8/R'* UF(E8CZ0@V<YFZA PTK+\#3,C3NJJ8@C#(%4]6DYN'<*
M]S&[7S"EV6ICS,V"=)9#&2RSQ1DOHZ*6S9LV37.M^XTO6C _PZ(BJ[K(+/F0
M HTLH9,C&30 %![/GUK# R 7Z58BB-(5="NB,I:[YR!HMOXNEJ2%L"1%&RB7
MZ,QQ1O)<GERQG0-(G,T1;IYUHQ&2*"$Q\,QLXS,,I4W+3"++9;6R(8SIT%9O
M=IF1ADV488YPPC:S%I';EXN;H HN!D\O.E*HS6Y'@!%V-Q@IXB+'R*ZE#=5?
M(8[+T8J ;GO2M\3U?,*\9@(4$K.D=X"JYH='S+&@!5U%E-S2HR8.60PV^<T@
MQ0RJ[<%1E,:AF7+(64,Q4E6+@"_4YJ/!WU&DWY]@MA6-8^)*B):58_FJ(C2A
MAJK'J41K<W0-6V ;NS@@L(R_&#N;@,BQN^&<92S26N/( 5AA])+*Y+@1 %TA
M.<(K2,Y'"0V4'*&CL3V6LR-F%6D0HTV',L1EY^''QE"J.:T376*,'NM:;27:
M9F!,6AS\0RL%)"*'3AE (Y7C"Z ,I(7_ %HM2-^7L,L8XY"Y*LRV"AQ/G)Y\
M]YS(,NCQEUM;VK&EK0PQ/S/-&O$+1F,+(SV55<FXC92&;B:7!\ZWX&C&CNKN
MDB&UG9(Y4"&/,/I(U*Z2*%M(+] ;5EP>\[VX'23$Y8HIH96,BHR&*PDR@ J,
MK&_+F8:=[5HTWQX@C .[QI)+DPP"M$R*H9YSAV5YV"1\B.\8(O:X-9D:/L3$
MLD:8E&X9$Q9C#-9^"HR\\2V4%S]3V5K=Q=V9HI95N>*/I@RS(9/91U 5F5#<
M*S6  Z$5IMI7%1=W9BBV/&L;+QE,A<YFC500%25K%PUP'\O*A3E=7%L$[<9,
MT818VF0YH4DRF1BZ=,POS*W:LI).YI$[_P F?PQX\;WH+B7^I+MMY+^;[W;@
MNW+]0*[$6IAM=WPD;_?KPD3NP/EDOHG_ (43_]*TQXL*/ZIF_0'M-O/M6_;E
M^=RFX/F#2&4;'?+*OKOQ&XR"Y&9;C-F-R,MR#85J_$:G!!&O7F/,>EP.Q[7K
M)&'0J+@V)<K<:\NG8'H#WUI-Q1@9%((T93IITO;RT/QK:U,N8#&1<= 2;+W.
M4]!Y$"E-Y=IEU8Z-=0,H/ETTN-3\:PQ9 F%R2+G46'E?TMW-(OQ9@91FX!O<
M::@Z=?.L?,Q<@1H0+D]0/MOUZ6'QK#5SJ5OI<D<H .G-?7+UM84DT9X(Y))(
MXHXWEDE<1HD:EY&=FRHBHJDLSL0  "2;5ANU\EJ;"O!?P1P&Y6'PV\F\$4>-
MWMQ,"2Q1N@;#[O)-&"</AT86?:>5LLT_U=4CLN9G+&-LWJ6O9VS8X>*K5<Z[
M7[W^7M]W;(JEDN?5AA]6&'U88?5AA]6&'U88?5AA]6&'U88?5AA]6&'U88?5
MAA]6&'U881G\5_E&;#W-^<[$W4&&WBWE7-%+,'XFQ=CRCE(Q4T3 X[%QM_H$
M3!5(.=U*Y"WJ5XQRCG(AL=M>EA[TJ%IUOJ7Y7V+W\#7KM;:&U-O;2QFV-L8W
M$;1VECYFQ&+Q6)D+RR2/V%]$C3V510$10%4   ,)/>>\V[E4J2J59NI-WF]6
MP"82;=1:U\O4V.@-KZ&M-B'3YG7YOT;+<ZW#: "VEA;7O6F[=PEQ.DD$>7,R
M@=K :WO<&]O.M?6:W?>!6PT)%\BDDW'+U]_I663U2-;J.T>%C!]E1KITL .H
M8'2YK322T0M(')&N6P5;+?ZI! M?MZ^5#;8M*S[0NQ<JJ#:_G<G7KKZUM<S&
MKYNUQ+SD.QLI/?J3[K#LM;N[=@-HP<"[6L+*OP)/;4CJ1UK5S>AUX))ME %Q
MF M=3;H1TMI6K^\S-O(R<*W07(/0]#?S^VMIFL^)U,6JKJ 3?4WO9;^@'33W
MULV^P^$2@VZVL<NI:W\6W3RK1EO>=60F^90A:UU].EO0VM66OF8_J.RIS=>E
M@;]@!K?WUM&&98"2+9F+ 6!(-Q?OULNE$T1EEP!$:6LI.7+K?VLP;2W46L0?
MLK5V8\^\SQ@"PL"0>IUUMU'6M,QW]AG"MET%AJ>:]_,GRZ4EF>!F6(@ 'IHX
M%QU/F!KT-:MP-69]ES'E-R+68]!>VE^Y%;60L["+SZV%NX!%N^ESI2KFM-#N
M$RG0 GL1>WF7(U! M6[W,URX'=(]+%; ,-;$W)^M[R*VKMYFM3($*^AN3<]^
MNG3RK+)&[(SA5T;,3;0FVIN.E^X)M6M,C,@9L[9N-VKBXL)LS XS:.-ENL6$
MP.&FQ6)>QRGAX?#I)*]F\E/6LLWYJ-QA*I+<BFY/@LQ^]U_DT^)&\'#FVCA<
M%NO@I,K-)MB?-CFC.A*;,P:SSI(/XLS0?M<1P]1ZY(DZ&Q\75SFE"/;K[E^.
MQ(S=?Y+&X6R.'-O!BMI[TXI<K,DLAV5LPLNH*X3 R?/+!NS8EU(ZCK=Q'#P7
MI9DQ1V+AJ>=5N<O<O<L_K)$[*V+LC86$3 [%V9@-E8.,*%PVS\+#A(N46!9(
M40.]NK&[$]31TDE9:$I"G3I1W:<5&/8K!E6"SZL,/JPP^K##@FWE\:VC:1T]
M?T_H^%*[#=_<?7M?0]OM\JPTV?$Z:#3]/H:RQG:SI67-'&M:N:S.*PT<5@DY
MK#9Q6&'4D?;V]U;-I'4ZUIBCBU:,L<:5@G(Q/\.GZ_LK7$T8JV8<&W?[ZTS#
M"YL;]0?N'?MYUN*,,/4G0'XD6MYTI\C1UN22 >OV>X][6I/@)>IC8W)T&@U/
M73TMY7K? 48":3?@A)T;MVU^TW^.M;3-&*]C[OQ]E9<PY+'[>U:\33.EC8][
M=?W>^M\!(';KIT[>MOLK=KF 8]=:U>YHX]U:,.IN;@]/N!_?6)O5B;9G6]@>
MA'E?N;7O\!2M1,E<QEB;^70@=+??6:=YG ZLW,/XJWUL>OI6)9=IC,3$-92-
M+:WZ>?O%8LA#6062X=E)9"2M[V'8]2#YBM^(-H#G4#3N+^FG?6^E9>QHZ$6O
MUMYCOZ>5KUB,./?^!KIZ5OC<P[9=#>UQ?4=_?ZBMWX&CLMA8WN!U'J=*Q\D8
M]#AR!>Q L=1U/6W;M6D( S2$FW6QZWO?XD=JW8UNV,$H5P5=593RLK ,""+:
MBQ!'Z:WH9KEP$OM#<_8V/SNF&.%E<MFDPC"&Y\S"P>"Q/6R@FMJ;6N@UG0I2
M?)]@C,9N'C\/<X'%18I%NP5@N&E.8:J+EXFL.Y9?=2E-<1K/#33O!IH3>)V=
MB<$P3%X:;"O<!6D0JC^>607CDMZ$TM2NLAM*,H^FK 16&9U6XL>6XT(#6(%]
M;7K:=Q+W3$\EQKTU)N/9)/IZ"E+-=@F3N%^)E0=;E&NI4$ @V]LZWZ4N-]$9
MVA6PRA;@E07O(!J^@5=>G4?;2UGRN:3M*W '1)F  7+G!+/KH>H%^FH%(DS;
M%#@U"\O*2RZ:9LIM<7Z=*U)NU^P/%67:9Y6+:7N.AO89AU)/8ZDZTF/-ZBM4
M 9'CM9$'LG.&-@Q!]D=2#2DQ#U,.53>RV&CF^@%E.@^)&M$4G8UJ?*5RFY"D
MW+*NINW06TM:E)\C/$Q$.0<MQ8@D^8_OM.MZVF8^S4#2#H"2 QN<I["RCX'O
M2E+CP--^P+)0%D.4,N4,>747'1B>PT!]X^Q:>60*6H#!;0%%?7ZMP,VIL-0&
MR@^=:N:[C(J "P"K89A<ZDWO:X-R:4GE8UGQ.KZV!#:@$93?E#:@FQL>GPI6
M3-J37<9>&&4K=3<&S%;&X?52;Z D&MH)%MZG,0OU7.02%2U@/JF[7'0=*TQ7
M?F8IK69B1?.$S#VCF8Z@BY N;5LU<*\0<HL00S\E\^@YO:!(YF('OM6(V@MQ
M2C4%U5>QS @E>UC<V"D_;2E?AJ"N 5*R<,7M>V0BP0*HZ!= A-^O>EYK0T]<
MM 7AE8&(V!RG4Y;*NNI(%P6)/4^5:;XL59:ACC788)XQJ5<,TF8:#70 7!!O
MY=JTK7"2]$2I4.P1%%[Y[9A[3<Q )YE5NM$T0/Q.=5;*P!"K=;,<I)!YFOYV
MM\*RYNU]1X-P?%3;.ZQCP..$FUMA+9?FK2E\1@5T%\!,U[1*NO";Z,VT*7)+
M>KAXU?.CE,?87&3H>9+SJ7AW?D)?[%VQ@-O;/PVT]F8@8C"XE<R-[+QN#9X9
MH]3%-&VC*>A]+&HZ<7![LM2>I5(U8J<'DP\!\A^+T@)<S!M+Z6]_2M&[G?0B
MYL/?KK67,R/BO>W6WZ.M8GP-'&73S%B?VW]QK=S#FP%S[[ _BU8). 2/37W
M^=8;,@<@BX]?37IIUK+&TV"(VOV)U]1;2DM&^()4Z?&M&,R+UZ>ZLR-@E3[A
M>P\[?J[5HV9QI6(4C,I/P'Z:QHVW;O!"]*QFF=)H(\1&8Y1=3\"I[,I[$5BD
MXNZ$3IPJQW9Z"<Q&$?"N%(S(2<CCHWO\F"WN*+O;ZOQ(VK1E1=GZ/!F CKT(
MN+ W\N]M+"MJPF.AV53SL;=OTV^RM.V20HYU[EF].I^ TK##X="2.N@!4C]>
MMKUAAR& N"+_ ([4EJ[$^)P==">O0^7H=/2E:.YBNNXX%KW-[7M;W:Z?$5O0
MVWYIWL".N8$DM?4 >1\A6EKRL([&8LHU  &M[@:V'GZ6I=[9\;"=U/)F%D4
M@6U!%CJ>OO'<>5$6;[0<HV>0'>.Y*D9@!RYA;7N;^E+[A+ $D LPR\V0BX!.
M7OFOTTO6,2XW 4\-B1:\;$G0:Y0.8 Z  M>AO//B(<0O>&RD :VNJK?15UU(
MN.U(W;]XEQ Q5LI%K:WTT9#W(\OOH;C9Y"=WF!F-B6(L;D!A?0$6-Q:ZWM6G
M$28I%#<]D7IZZ+V ))!/G0*D,MY&FD!6 &8'2_M$7L1V ]H4!YY-&L] NG)
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M!M7"J8D!V7*X9@0IL38KE*]K!1U]:,XV7:#>06F1F4HV4.K* ;9$<=!D!N;
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M,RP@1@JL:Y@C,KOF635XM"#9C<:UIP3=V;O8^+MBI1PP#8NUI9,_"X0* V)
M,85; =K5K<1F87QQMB&3.ULL9;+8YF )(!RY0SJK=>]J0Y-9&[ 2=85XK,X:
M[H'*!GR"/4_..$Q6-B#8:TJ+;5S0&,Q0AH9)"O";,["ZHK<,"Q;.3(5S*?0
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M*Y:'5C8FY();,RDVZK8:CZHI=T8\M0+/);.%(O>Q87-E.OI[))[:VK?@:;?
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M3H#IV/73H=>E*BW>PE\^*,+7Z$#KI[5]?NHBU!/-W,3*&T;I8GKT]VFM;,T
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M2QPEFF9[RE=)<]VRN]V"ESJV4$$:]#2$VV&=DE82.,Q&L<+$ R+F5AJ@"GF
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M@T@>2,?2AF S$1CE* L3:WL(U[WLU;T%JR,$6)<2".2$,6,AC8<-ELKZ(&N
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M:NC$RVU-_4@?C6MW-6,1)&A)(\ATL?V7K+\1-[9'0M;M^K[ZQ.XDZ\46\B=
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MB7=&-LS,Q4*%LBW&L<B:6%C?4UJ5VK&W+D*B+$!XHUA&'$LC1 -)F?,W5V
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MW"D7((/;O6&6L<&.]B0%O>]O(=SU[FE)<#>ID2+X:=^A-_+0]O.L>9JW(S!
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M+9K@#32X77IYTJ_N-.SS,<9)<#0@@D,VG,6]G-<WL?/6LO8UQ#7"YP0F<A0
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M6'$Z+&4>5].C*T29A<PR*&N<C-8ZZ$5NXF3W17X;9KX7(Q"HK+E8Y4)(*7(
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MOIJ;.P-AK8ZZ#\>5:9KB9P[%; V'0C34=?4ZBL2SN;.[,%S>S>W0W[BQ)/<
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M91F&IL &)4CKJIIC)^<:E9NXWF].JJQ!7-<)IU+9CIF_C=*TM?8.8?%C6R1
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MN]E8W>YCDL"=0<QT(/?RMTL:Q/F)>1C+"Y%["P+:7-AY'L/2E)FK9=AB.8D
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MEEEG8C5I7=[&UQ?.6UMZZTEROQ$-R>;,5K"PZ'J+=/6_J![ZR[]IF9\5\K:
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M76P]!;I6VS7$Y9$/7+;N" =/(WO24^0EYA5/L^-[F/D:]P!87-^FGH*6IB'
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M.+$ $$:AO[X'N"*6I7S&$XN,MUZG06OI8<O< :]O7K6-\Q-F8[DDY22>G?\
MGM6]>XT8VTL+7![7/6^@/72LR3,L=".H) 4"Q'OZ7Z"VM:,7UG46-B;J+$7]
M;#07O86-*-VRMJ=6 /0\P%_,,/(V_?6C1B*COIR^0ZG4]<O:L=M>)AP-!8@V
MY1F%@?[XZ"UPM9<S=.RG+H%L!U/G<W!OZUE[&SXZMF (/GIH.X'36LN9;(Q%
M>IMI<FV@/70D+8=*U<R[,1 M8VT[#4G7KKK]]888'%H@#H3<67H>OM WUN:6
MLWV&<+(!E2#9CT%OCYWZ]:(I&\S$R@ GH0.OEYD WUK:DS#&X7O<$D<PO]XU
M&@ZTONT, S]+C3L+]2+=_6E&& @GK:P4D:];]NYO6Q%K]P&=%)Z#I9!WDOT]
M!UK3MQ,M[@HQ6&NIR@* P;*%M>PZ=K@WK:8&4;/L$_B\$K+=D"D@$.-!F';3
M6WZ:)&>8-P3$MB< R&\:ADNURV77EZ'0"VM%C4U66HB4> G<0HCSAQ8>S;VK
M@ 7'0C6^E+5F^T TT$>+B(=[C+:Q1@Y%\N6P ZWYM:)%Y?G^?Y^[37 *L1&R
M,<B@]<^4AV$;#V@^B%\W:EQ>=A(0XP(9),J&X;F)M=K *04Z:D$W[7M14\P<
M^T3^+C*.2 #F"\@ "QMV9BO,5%;3N":35@I-Q;*4$JG/F!)6097)T-^7ET]]
M+1KSM#*L[ LR%$9;.4MH_*%9#;*2 1T\ZPWPS QV@IL<QS*QT%@EK-8 '0%3
M:M.+$7 DNT[ V:0*,V9@!F:3ZAOE )(^T5FZ^)F\)['[64)(,PS(R$ZZVMS*
M0;$LX.NMJ)"/+06I1MJ)#'[7+K)FD+'."(SE "DG_1!S1L".Q-_2B*.0B<D(
M+%[4E=IV)U"NQ4-PT)SD!"K9ESK'S7Z4O.RY#;.^6@E,3BA/FE60HX=% C>Q
ME3,H!1M.H)-P;W^-+7/L%78%9WQ$F60/HS%6;, 68?68J<R#-TO85ES7:=1"
M@XAEDR"1C9DU+"PR FU\K$:VM^BL,[SNK945R%>0H 2<WLD*O""FX^B*:>^M
M7L[&XWN9F(X:A1=UD;B2N";!ND8RV! )Z^=8I:"CXQL#)F-E7(R Y;/(HS/?
M7,!D;3O>MWN9W'"JJ,9+7C:,KQ"V3+FRY2R]&!]W6]8\T8"(T!24RMF 4,@"
M(3DS6*CH6%SH:U:YK4%"-8]).7A\-Q$3& 68741DQD%,I%QKK27%/-ZFP,^B
MMB'"QL4=%8WY&&MLBE5*FWE[J7:R:6AJ]A.;1Q4LQ?#Q*'N &*94F5@ZD7RB
MZ@K)T'46K=T#;OFP!@,.64HT2DS75P1E*KF97,<AS2HQZFUM:SCV&)9BTP.!
M7"HH*JD:H01F)-E5<EU.7.I)-V-R2/C6F[Y<#+,-DF01#,YDS ME89A'EU1[
M^SD;ITN*28\@RBX:Y $"/+*LKL6NB*Z,.'F  ((U(U(I,LUVFXK,46RXTXY]
MJ0!I(BELP,F<Y67K>,+;O>@5,D'I).1(K=#!+E5K A@MU-ER%5 ^CRG-J?6H
MVN[R'T7G9#HO$!"0P DR,RW#EE0*[)S7L"UM10?>+L-3O0MY0I1#ESR!2YN2
M+FX74D$VN+5N.1M^B-DT4A(:=T62UTB106 9M0"0!EL>AN:-%Y@WDL@)(!Q.
MAX9S+J 43)&+AEZYF51<#36E7Y"-(]IA))162)FS'V"50Y3>Q (L0!2KW$-*
M2L=@C*ZJUB6R*20I4 K*$L5T+Y^OPK/ P"&0"3AL Y,LA64V 6-7(L3D]BX/
M>MNZ-I(ZB$,T@9\BV!Z@1RJ&NQ-K@  FPI&\S$P=AXPDP*GBK9)-&9@4L5*
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M&C2Q < +$0=18*OQOYUM,W8&M''$<G\(\:Q32!$:1@W-F0OIR-W&@TK+FLC
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MDC;B/FR9F7-:06 CC%K@>R392;=:PW&^8/S1L"X;J2BDJ00I"GKI?,*TTK!
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MJ!<^58E=F;S%3@L895$A=A)' 4D(&8V)6-V:YT)*UK1BT[Y!RF.R F.18W0
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M+$L@9#E*BW4AKCN+,*7=-V$[J8F,=LYH7::$(R%B2G/F4 68!5T?4:>^LTT
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M35D<91Y=;"_X\JWD8?9!H?2WO_ K>1KP.0G46 &OK?WW\JS>]YESDH21V]+
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M#67->!DR  "UK '33MWMWUK5S;1R!6&D9%6^HZC6WF/UUCL*5S.%N+V%R+
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MIZUM-OO!.+67 [Q17(4KK:Y-[@V\_P#2]JR^9B#"&/07U(-[Z:CTOV.E;WN
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MT0=.HI68&2S"/"8/60% 6>5B7N#H3J+:7 !Z4J[,W;=XH!A(0@!CA9@+!05
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MG30TT%.( 600@D,UB9%%HAF!/,BW#&XZUNYJS!F (AT/TBI(=1=1);)KE4]
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M(.4:$V^VQ(-:OEVA(V:#=1TMI:VE[@==*'QS%/0SAE %K ][?H-;U$YG=7U
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MO&R2 . $NXSPRY4Q#*JDIQ%%CJQN:#W"07BLKJ[F,AFF4F._/:-+L" 50E)
M1KH0+@UAABG,>57GD2-I$)/ 8AEE9LL8B *\12+F]B*P7%\!6;(C; X!@">)
M- TZQOE(G$?(XC.90);ZL#:U!F_.<O8$M[A,8R5VF34.KXDRR1E,TB*>6\3
MH.$.Y-Z&HW6HJ.>098:-9I,DJR+]#=&093(P!RQ9E7F=%NW>])GE%AJ<?/\
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MJH4US"1PU+E</8=B;)B50FR]GC3J<) S?%VC+$^\T14X+-)!53IK2*]R#&/
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M(Q\2@ZR?-WD@ 'M7GB#PWU_C4*5.I'TDQO.C6AZ46O8% 1A<$>>G>WEZ4-M
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MR88<1 -6N=3U_1W-C6.:-WXG0SJ!>_X_12'4-.;1A;%]; YNGI\:2ZR7$2Y
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M,UCU_1:MFTK7[C#(6)86Z=K^R3UO[ZWH!;9@)*@L%UTO>QMV%CH>M9>YM.[
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MKF8]!,SI&KMF(4!BYL.JE2,OD-2/C1=>P0VD$V("Z1J@;-8ANK,/,WZ'3UK
M<@DF%C]*4CO(Q:^4DHH'(JFUV8FMK(1?6_ *(I<LS$%48L!D938+<W7, I4C
M3TUI6N3-.RSX"HPDCQAK1E[K<J3?2Q-E(OVU]QH;06#R,&T(?HUNI3(I RV;
M.6;0@]<IU%O2M:FY//(0^)P8;$%22+/;,P6Q!%P +62U;S$\0=A8E6)K*;L;
M*%Z'*]C<G0]:PWFQ00."H?+D$:L#'?,%8'*S?5("+\.;TK1IA+M!Y%5ECRDC
M*]]2K@D 7[VRD^^E)>\T\EEJ-[M?$CBSLP (Z=G9H2%NEK%!9J+'D 4FA'G$
M0M+%D>=R$8"P;,62[',"1<&EY6N9O9YA]LO%'(K,K*\@0@N [C,_,L8OE&5!
M?S(H3^H+"2>68XVS,0MK%EO)(JA51K,5!R@$Z"][L-#\*;55Q#K0-W&BYE/\
M&RB-5%HW+ #S0*2=>]"N; [PP70.'R% 'NJJ"UGS")NI (%R=:V;$_M&%4RF
M,#(,H*11ZDL2%+V 'T8%[TN/8):6;$3M&&P"Y Y1LCJ@ S GED87ZZW/F0+T
M9, ],Q)8O#R9K,J2H"" Z!@@5<SOF-B'6]K"EVRRT$]H48C#L6*C4%06RW]H
MQMK8W504D[]" :)%Y9FM  (E*RI<WC&9[697#RN5"LK!7)7VB;6O2KB9:'>^
M<*X.5D.=+'B-&%'*MAH$0&YK.T1=:I'9"_-Q3=T1T0ME5F4QLP8 :FYO?O:P
MK=S+W#6(MRR8=E6R!,BAHU9@2Q.2X%R.II#2>;T,4FF*+!8N1(TD62,W1+#,
M<\)&89B.;F) L.FM":0:,VM!60;1!PSB329K<)G895!+:%NA"*= ;'2AO+M'
M,:EUV@'YU+)(N5E92P5LQS9D!"ED#:L">H.E8UQ>IN]\SC&819<.V49R/I(R
MN2Z1ZYHR2;W+_5UTK$[&66HSNT(5P^-90+YP5')>/,6<BPL%"#-S&XN12T\A
MO/*7> AJZ)+& 66-50MRW625C=58&Q$EM.PN:WX&C.F9$:22ZN ,HRM)(SOH
MP0GD,5S:U[Z5HP[S8>-1G8/_  ,;.&)3BO&ZL0[+H%((%N]8)ES$UBTDDFC
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MRT"J:#9;;BS.R6N 0+$V&O6^FESI?N11(NV8-Z#8[6PJ\0@1L%OF!S<BVTL
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M=FX&*)S)(YB&9),I5"3F%V8!=+] ;5J2WLQ";DV$*J>*D@D5D;/))AU-XY0
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MH(T&@)%_:>VB-RFL[S'F!F0%=,UK=+WO;33O:L-'2,,I%@ %7,1YV.H-[ZD
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M@9.5;CS)[]:;R5@JO;/D& C#1:@I+E4H!>Q/.& 8V!N1I2%&QFJ[0HQ$><H
MK %&N[Z%20;@,-%-AWI5LC:R68C\=&HSD$NKHYC8939'C8%'!.K!@/MHD,\Q
M$M!(8H<S#*RE5"!2R@#2ZQAE'6QZCRHJT!M70EL3A[^U](!E)9FO=2UBDB@7
M8(3>_72E1=@=F%F(B4@I&061U0DDHK129N9";VL5HE[KL$26=S%(TN651F"9
MA&8\R:,+9'%[$LA6^FAK.T29T(0H\1C"(<UVC(-XQH=;$:YA<:7:L?8:T!,8
MXJ.\QOD#C*5Y\P:^9=0KD7TO6"7EF#HY$++EC S!,Q-U)>-;YQ&-;W4DUCS,
M#J&=\Y%U:89;%$(S*"<K"^F:_04EQ%QSR#[#2<25"7#NV7.R&TA5;70*-$5+
M7/J*$UQ"IA\KK,C+>[.6A4Y1TX8!-B;YB0?MI'8+U&AWHPV&XI0JX  B%E*G
M,_,44'S-KWHD<T(GJ)H0H(LP0<1F7.05X2JCJ^5E]H,J+U[FMB+6.JE3&>&H
M9&1LY%BZEKY5(["W>UZPQ.QW;AS0LK0,<L,"*)+\UOI";WNKW&E]+UAIN[N?
M'*Y"S7(N&XQ]E;(L2N;<H,K'IZUHP+I8(P7&9891$PS6"B5=0R ^9ZZ:ULP*
M<3AA-$(K1!E =7!;.1'Q&*&U[!E-[VTMK67-W$EC8&(<1CG(<*<Y!#DD K;5
MT%N^AHBE96%IY!%,)8YV,;,%&1))76\CRF-0J*K&P7,PL;7O14TLN*-I-]P?
M;'QP# IB'AMF4%&SWD+JJB0:(J@9KW[&LOO*V@IQRN.'',KQ,L?#+(S\21+@
MAT3,2;Z93]])4+-,"%\G#B"2+E,V:34LRJ3(%)DS,;%#:W32]$,L'&RI X=I
M.'F9U5!(@5"S!EDC[%5=5%CUO0):FUR&%\8=WEBE?$+9E$F2P&16L-0?KE<N
MBZZFDWXAZ$[+=8V&ZF\+Q<'!W"*K,F$#_P +B64*7CF'DMB%O6T\K,744> ^
M>R]L+CX<T>18EDCY>&!9E-FOS-F57Z^5&@G:W%#22MWBHCQ1L;Y3GR#E!YA[
M05EN6!!'M=*RX-Z MUXT$JK<!!G8QLQ&N@(5R  A OUK;DEWFE-/F-7O9#/$
M[Q)"',D8ES.Y9(RH 9P[=;OF('8:T>F[ROR!3U[!J9I2JQH7600L<JR.1ED5
MC?(^I9B?.G"C?0%>P9;O[55\7PVM(Q42O$S@!!F:X!MUL?NK>XT)D[H>K8VU
MWFPS!U/">1$ZH!KF:RI8DY=-=!0IQ4GO15C2=\@NV]NW#E.(5%"8@O);(.LG
M,KH%)*A674TJC)2=FLS-%<2L>SXX945Y%#EDD>2P"A84!'$XGTG,8?:&O-1D
MHM: [L*9#\WE40.2"$B+*!\Y,TER636PLM]3V-+N:;8<8''+)F6(SB:TA($:
M!N+"&9&+FX("D$_QK:4.:7#04G<-I@-H85L-+DDZ2(2+*DL@+'*=",K,>7L
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M_ JP67'8PK=(EZE(4]J1[$(@[L54AKUHT*>_+7@N;&V*Q,,+2=26O!<W^>I
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MY;J[P)Q=>ZS +*I]0P-(E3IS]))@ITJ4_2BF^X1&TO#K R@OLS$R81Q<K!B
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ME)<GH:25PW@P2HI>RV$C @J3[0N,MAE UZTAL(DK!A#@@;JRFV0L;HQS%=%
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MNJ.";=6%JPRP*BR,T8,=RB%"BD2Y#&5E>0#35K==;6M6&CZ3#MD"1L$C82*
ML9+*PNT18F^BGO;]VNTV )(1,569<[(BELF9&-]&<@C(#?S-JPT WPZ Y!97
MFN>+J5)XR+(; 67B*!;4 V(O6&!%M+9;$#$DHR.2F4J,\8,ALJ*K-FN/MI5S
M:=A!;1P5L4K :HWTM_HQ:-BP:_\ "9;V!L+@=-:+&5[Y!5*P$BEBP@X312/)
M(%$4L@!SJI&8J7.;AG,"O\;7RK:%7WD*O9^TII(L@/#(*CZ)@'F90ZL.&XD1
ME MH;6I:=P>2#=YG?Z)8\.X/$5BG+E=4S-&A-K!5U).8'T[*U$M,[X>:,-&I
M)/#*G*I*M>YM&C+=1>_QI+2>3U$]P*WCV;#M39TT7 66?AYLTD8=[.MK,S,%
MA^%@>]!M9FXO=9"#;6R9=F;:QBK*T#QJ[*(W>.1563.(W(RA9"&L6!]D5M08
M9U;JUA?;L;>D.2 ME92MKLSV+Y<YBD!8\.VI.A-J+#++BP%25\^(ZNSMJ+(
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MCK[!7;,QN>*3B1Q,K+DDX?TO#S"XF)=>)Q'Z$T&2W786C#M?#I/&BJ!)97<
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MBV3NX$/M'%VOAZ3S^Z?XOR^[F0>U,<X_:U%Y_=->'Y?=SM&4*#;3[OQTJ%(
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MU#;L;.3:PZ JRYNX-]  .I-#;OFT*1A=&!/)8] 2 JZGVK\Q!L=-*Q*QK0Q
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M=QJ-OQ2KBU53<*,EU)&8F][J.EE^WOII1T#"F*/A?1L44.@*AKY]9&&095
M '8@G].^!@,5E'#8-:Q<E@;LRFP(*D 6N1:]R+>NB-##O+'*\:",QC,6O<:E
M0Z'1%) LER;@W-9W&&(QA>>-LP.7.DP+<Z:&U[%3WT%:3X& 5HR&CCRQK&
M-#G=LP-CFN6# '4]/6E,T=I1+=7C0-D3F12!>PN &R@+8'T!K2S?:8!Y8^*
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MG2_:UQ^-/C6:F-'0M:_?[/:UO[JQ19F1B+<I[D@].VOZQ>E;MS+Y =V)^L0
M/MU^-M*4H(3?@!6.I[VTK5FNX2_K,16^A\[7]P!ZUJPFQ@*ZE;#XG[[UHT8F
M4W[#4V-K@W]=-!6TN*,."IU].O?K^JE9&'.6_P!E]1]M:9HZVZ=;$B]AK\/@
M*RS]AA\5'EW!!/EY@:^598PY"WL!WN0#[M->]::MH895C)U M?5[]+DZ>H8
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M4F^OPI0*2"SB9 8\XCBG8<+/<ROUS*U]0O;TI5TQ/B"'@R(KLH891(N0CD5
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M;:BW#OFZ:T=.Z"!CLN<O+)#FE!4F,QQA5#DKF2 /U9>I-J3)75S+V%0<3)E
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M 55ZVK=C!3;-Q,D#YE>6[-DXLW*D2H<UW[L'4<HMI67 H76S\>@CC^BED=7
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M-=X<8;%AP%<E2JA01J"@US'4G5CY5IK,2'4,X$9-WD+WL+Z<W>W?F^-):S-
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MM(<;A#-H6$,"(5) 1FS'*HN7+LPL,L;?;I2<XY<3#/%#GC,,>9[N6+BXRA2
M2MP!E(K##+P<S%;9,P$48!YD",S%H6<7(:^NEZ4LS KQ^%.2;,L49:)6C8#F
M)7F9N50!(5Z@&Q%J7'ZA,DN(U>\D4$QF,<=F*L"T0R#^#+)(8K,6D##6BPU
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MIWF:'8 @^[\6Z]#2C,M69 /2WGW'QMYUEDS?89$%QU[:>9]_OK=K"EDC,@U
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MV,"C$$E)&9 L0(10Q)9E)900H ))"&YOK2T\A,M!!;;PBF*9@A<MY'*V0"Q
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M?'X"G$<U=!,C);70BW3W>E:-G<*?3I]ON%*,61WRD:=OMK#;[=3D6Z:7'P[
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M!F>,*_!2$(BYGY2,N3.<XE/H#Y4M9B.TRA"9R)%,L4S+%(I-D#CF9>(BEE(
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MX /O.M:ND)[0_BPXA0LA6UP7L;L7MDT'4FXZ4ENYAGGS1JLS<M\P:X/4+JQ
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M"20D<5Y$E4L1F9E"AK9;*"H!'G6Y:,UQ'P\&XS-O+AY%4JN'1YN(;9CEE"
M,NBR$B_E3.O:WL'U/SJ,B<^+FNF&7JR*"RJ;D$VMZ#[J8JZ;8A*QCBG0L&;1
MSJUUS#,HLY-NQ8:>=+36ALY^<*\8<HEV+<P7J1[)]!\:W?B8/A\GYW;?3:68
M6ONMC#;+:UMJ[$7[3;I37&_$I\-[\3)SH]\ME]$_\*)__]2_Q6&'U88?5AAB
MFFBP\,N(GD6*""-YII7.5(XHU+R.['0*B@DUJ4HPBY2=HI79IM13E+)(A_OK
MO-B-ZML2XHNZ[.@8P[,PQ)M'AU)^F:/V1/B3S.>HT6Y"BJ5CL8\76<\^K645
MV<^]Z_45;%XEXFJY?T-:+\^+$B$]W7R_'2F6\-6SN  !I]VOQI+=C5['(UTM
M232\XYM8^HZ^G>M7%=QF"C[A]IU]U9<V\CFPMTI;GP0DY 'H/W_=0VV:9UM2
MA-CD"M"DCGX4EY9FSM;0=/LK5Q-\S@+KT'>M;S-G 4>\V[]/LZUO>N).Q /E
M]E(<N1ED? #I;3\=?.L5V[F6.U*,'L\-=R5F$>\6U\.KQ==E869 RR'_ (NE
MC8$%!_H0/4\_92;)L;9JE;&5UYOW*?\ A/\ %[^1-;-P2E]L5EYOW*?C^3W\
MA]JM!/'U88?5AA]6&'U88?5AA]6&'U88?5AA]6&'U88<5HT=?LI(D#XK%8?
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MF2YL1<LH_@PUO?2T\@3R=F!I)XUS#HPN6*L,O/)8,MC?AJ-#<5AOP <LSYB
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MTN#S2$L:+'X!HS8*UD-V4DYC>X&2W7J>_:C< =FWF)W$0E6>ZMD4"Z,6.MP
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M62-%ZDG] ZDZ"AU)PIP<YM*"6;!SG&$=Z3M%$:-]-\I]YL3\VPY>#8^'DO!
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MO>MW,9WX(^T6.GZ^MJU<T=C$-+6[=OMK=S9QPE![DVMT![6^&NM;4C#DQ7T
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M\U(-'I5ZE+T7YO+@%IU9T_1TY"]V=MC"[110K"+$6N^'8\P(ZE"0!(OJ-1W
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M?ZWH\5F;1W*DGMTIS%V69L^5;'\:_LK=T:,@K:T-G-JV;L?6I:-6/K5LU8Y
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MSKK<#H021K0'=9"E?@9Y""NH(+,,Q##*RB_Z!2$;UUT"?%JCJ^MB!=3;HHT
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MS&T89(WB<!B[!0515.9>I -S?44I-FGE[@%B('!62$*RQB[Q!@3):Z. #9$
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MQL[2,0Z1DJ@&H&;N2-&44JE&R&DY-+=0C\5*UFC< V3(/9.<G4:Z^Q>_PHK
MRBW%<Q.8_$Z94D)2-@-%R@*"$O)?4@F]A1%FK+D :SS$IB<7ESC1;&RCF8YL
M^C]S8CMVHB2MF(>]?L)?_(-Q:S^,^\B #_K6>VI+J&5;#>K<RW*W0E9!?UJ-
MVLOM:/+?7A(M'1"_Z9U$_P!H?^' _]*\KXF[P->/=_"2$:+B-I%#:]QFP^%:
MW8@\1AWNGK54Z0X[-8&F^V?XE^-^PA]IXC3#Q?:_Q+\?N&<RCR_;T\O?56(:
MR/LG2W?K6A-CKDMUUT'N]UNNE;$G 4GJ +$6U^WX5AB.2GD!^.E:S-IH^$?G
MT]-/W5NXFYR$%]?A]O7RZ5IF'Q0'T]?/X=!>LO9&'.0=@.VMA_-6FVS#FVEK
M"WEVK5V8=;JO0:^GP_92D^9EFS&?</Q^JLO8W9GP%S26_<9:QDRBUOQ^ZLN)
M:.;#R%O=67,2=SND;2.D<:%Y'941$7,[NQRJJJ+DLQ-@.];2E)J,;ML4DV[+
M4DMN?NW%N]LQ$D1#M'% 2XZ4!2P8BZX97&IB@&G6Q:Y[BW0ME;/C@<.E)+X1
M+.3_ !=R\<RTX+"K#4L_C7K^3V"MJ4'A]6&'U88?5AA]6&'U88?5AA]6&'U8
M8?5AA]6&'U88--XA;XM@E?8>RIBN+=0,?BHFLV%C?IAHF75<1(IYB-44V&IY
M:UMK:O4WP>&?V5^DUP[%VOCR[](7:>/ZO[7HOS^+7#L[_#P8W4ZFY)U).OVU
M4+W().YRHYAV_?V]YK#9GMY5AH^M6T[,P^MVM2M3:666IVM;MTHT4K&K.YU:
M54&MBQZ*.OQ/05DG&(3):@-Y6?J;#R'3]YH,I[W<(N< C0#OI[O7UI-N(FQV
M /?KITM]EZPW:Q]6"6=E6_H*PT9"HM:W0:5LTC&5MTUO^/*L%6.+>ZM7-V/K
M5JYM*Q]8>5*2;[C3=CBPI=T).<H-9O&T<VU_5V^'E67%'P4=+?MI=[&C[)Z:
M^1OY5O>]QAU*V^/3]EZ4I&'Q4CR_72E,PZV-;U-')%JWDS9Q6[&CZU8HF[7.
M;5EK&[9'V4VO670DXK>IA]:E)&CGI6S#[KU )_'QK#:OP.0OZ/MK5S=N9S:M
MI7U-]QS2S.\^K##LJWU]:T9F9@NH[UF2,L=POW'R[CM6U(W8[A/3\ _NK=S+
M':WX]]:-'U88=A6F+6AS6U8V<TK(P[+Y:6ZZ^GZ*V9F9!>Q)'X^Z]9H*L=JQ
M9F6.P%;2MJ;2.;5LW9G-J596-V.?A]E9DC+F1%OVOZ^5:;--OAJ=\@\_QI^R
MD[PG>.<FE;WLS+MYG%J5858YM6K6S-V,B@6N+"WKH/V7K6AECJ??K2C9];W=
M*VLS#D Z$&Q%B"--;Z:]C<5NUC8?[.V]B\&5CE+8J Z978F1+=XY#=K#R-QI
MVZT>CBJE-VEG'EQ#T\1.&3SB+;!X_#8Z/B8>0-879&Y9([]G3J/?J#V-2=.M
M3JJ\/Y1Y&I&HKQ8+H@HZGW5ES?><=+:=.I_76F^W,PX%CUU]>E^OV=:2\C#X
MVZ'I:_3IKV]:Q7U,,=;US,.OZ;]O+4]/6M=QAQ;R O;R&GN[W!K1AQ;N+#3O
MV'G[[][UILPQ$CL*U<P^K5LS#BDF'%JRYJQ]67,L<?96=YJ_N .,P4.-C9)5
M&:Q"2 #,C=B#U*DG47L?O ITXU(VEKP!SA&HL]1"8K!RX25HI18CHP]EU[,I
M\B*CYJ5-[K68QG!P>[(P6'X'PUI%N0DX"^G8^[\7'PI>1H^M\/=TOYV]+5II
M&'UK:V'7])]/3\>>DC9VMITMZ?CTK+6T,.+?J'Z.Y%*UU-'.G\VGN&FM;:Y&
M'('I:M69AS:L:8JQVRC37X?C2L[3+&0 "_X%9KJ:.XI2T,M<^(K#&CD6U_3^
M/2L-KL,H%@+#KK[NE:R,L=JV:LSD5@I'U8;/JPPY^%88=QI8_@_JTK9O=N=A
MKY?LK!+B?6N;7T[_ +ZT:LSM;OIY5@JV69V&GF?QUI47?N-I6,V0Z6\M3V^%
M+3]XH[Y1;H+_ *?B0*7;*_$PZ\/]'W_=I23#[(=!IVOU_!Z5EEKQ,,H'X_?2
MDN>AIF6-+]OM_&M+T1I @1]=#]M_V5BUR%6.H0 G2YOY4X@K9F6.<H\A]GE3
ME&'!3RM6"EIF?6UM;44LVLSZW;3]?[*P5;W'.4?"_P!GXO2T:W>!\5^RMW,<
M3ZW[?A6&[<#CS^VL$GU88?5AJUSBPUTK9O0ZY1<Z#R'>_O[BLN;N8RO0BVGI
M?\6I2-HQD#MTI0JQQ;\?']U;-6N="H-QI?SK:N:[.)U*7Z?#]=;\33S."+"V
M6X\]/YZTUP-=Y\!Z6\O3])I*NNXW?@? &VI%SU[_ (TK=S5S-%(8I X'HPZ
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M#FL0V8FS*4M<::$^M$N#>F6A,'\GUB7G\;MYE:0MP_"W;?$3*% =MZMQ64@
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MNW5Y)&+NQ]69B:YS*4JDW.3O-N[]I3Y7E)R;O)NYURG]=98VD=K6[5LW=(R
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M2XQYBFH^T9K?O;N(GV1M(H$B9(7(!B $:E/:=KZAS3FG!7L-9-FGGQ3PL_\
M3'C9II3(_$N[+G*F:,J0X$G,%9K]J)->;D'4L\^0WFR<.\F-PX4AAGB-P-7(
M^JY]M5S&LI753M!UI.,&35W/A$>S\$)H[A/IXF:P<*;9Q?12K9N4=14BKK+B
M1_"_$=/9[AT582) 2S!>&O#!(YED5M<T1]:1-^<;[1;[#4PXF)I9#GD$?TN9
M18MG5@,H(L+#W7H4LLPD$WH.9LB,M(6BU1HS$S* ;Q#G,K)H6);0$=:!*5GV
MAW&(HUPR(JS$!F%HBRYLB(P-F.4];]^QI/6/@997M;( 31M" &)5'A;*SGB'
M1;I8"[6!!-_.DWYZF]#I'B"V4@VSIDD2-4 :,: 3%K74-UK9NX)@SJ K%&'$
M<Y8L[JC*N82KEZ*K6&7O6)V%+D#S"[$B$AW31B;-D=0H8G-890RF_E2DD*N'
M6&V=)B1&)$8I&EBZE@\C&_\ !C6PN1\*'-)&XW>2)'^''AMA\5/%CMHH3@E8
M<&)@ TL@R$\;-TCCD:U-:DK1=M;!Y5%1ANKTF/;MI\+A8X\#@%0)&65VA7+&
MHRA5CC\PAOK2:6]Z3>H&4M[VB-Q"98>6ZN Q+,",Z#0  ]-*<1MP /1H3N()
M6(9@P7)= #<E6Z"_:P^RC1U!,3TZ !A9LK@"Y]L'VF(_UH/OHB68EZ"3VBH%
MD3-Q8RSNV06;/KG:WM&Y^VEP?G6 2$=M.-)H3='EECS%SHN=;_Q;@VOWHEUP
MU$Z+,EO^3WBX7C?O82K*6\,-LC+]4+'O5N5EMW+$L1\*C]K.^%CRWUX2+-T0
M5MIU/H'_ (4#_]2ZYO.O^:';1[G:.* _Z6M]YKFVTOG"M])+Q*IBW]M37[IA
M"0+BW8:7U^VF=@%SJ1;IYD_:+5KMX"6[:'P2]]/+IK\36GKVFK^\[<,:=^A'
MN^X"XK+\S=S[AC6V@/6_EZ&M7N);;[SK8'J!II^JEI&'! \A]GXZUHPX(N?>
M-?6DYMY&'.73IY?:/7K6],C#BU:2L[F''6M-K@)5[G%AY5C?!&9GUJW'F:.;
M5LT&VP]D3[<VGAMG077BMFGDM<08=+&:9ATY5Z VNQ [TXP>$GC<3'#T^.KY
M):O\]79#C#T98BLJ4>.O8N+)08/"08#"P8/"H(\/AHDBB0=E06N3U9F.I/4D
MWKI=*E"A2C1IJU.*LBWTX1IP5.&44K FB"SZL,/JPP^K##ZL,/JPP^K##ZL,
M/JPP^K##ZL, N.QN&V=A)\;BY!%A\/&9)'/D- JCJSNQ 4#4D@4*M6IX>E*M
M5=J<5=_GSY"*E2%*#J5':"1&'>/;N*WAVE)CI[I$/H\)A\UUP^'!Y4'8R,=7
M;NQ\@ .=8_'3QV(=:64=$N2_/7M^JH8G%2Q55U):<%R01@=*8IYC5L[Y?T?@
M?92[A5H?6.G\WVVUK+HQI:\3.EK=+6 U\_U=JVQ!RQ"B_P!@^_2L7U&TO<!7
M=F]!Y?MK'<SP,6M:T$N_ QV)/G?R_'G2C:S.RBY K00S>ZL-.YUK8@[6K0JR
M1V  ZG6WXM6TQ+5SXD>6M9<S</@#VT'X_;6S35F<Y?._OK!.?L."H_'XUUK=
MV9<QE/W'S^%:N[A(NY]DZ=/=TUI0HX*?CSZ_9>L,.RI^[I\??679K([6/;]U
M;7;J:=UH<6(K!)R*VK"TCZM7>ILZ%+W/?[K>5+4F^XT=!ZT16-H^I=Q)W"'O
M2;V[C3[#N!:M&9GUN_X^&M;%'#+?ST_7U^-8C#IDO?S]Q^&O0:4O3,RY]P[=
M>A'V'O\ HK=\S:=S[)T_'I^FE*7(W)G 7S)-NQZ'T/K>L$G:VGI67-G:P)_7
M]U:NT8_K.X7[?\FW0=M/Q[MVYF*WM,E@.P_'[JPV?5AAW5;V)Z5HP[Y=?3R_
M'K2D[*QN[.;:^E;69K/F<9/M_'Z*5D9H<A?M[]#8?I[4JXM9G?+[AV-N_OMV
MT-8*2.]A^!YF^MZVF]#9W O6[F'UNW>L,.0OG67-7.P6LN:NV=P/3\#]E8*3
M=K'< GI]WXTK9AV [Z@_SZUIO@;L<A?/\:?#] K-=#7>=P+=/=T^[W5EN9O7
M0XRZFXOW^WTZTJ_(V<$#0@6O^#]];1LX O[^WK6S#FS*?U]JPV91J!WTU]_\
M])O8PYT^VLWC#D:_C\=Z2WD8=LH/4=_QZUI2:9A\% N+=1WZ^OW4IMO,3<[!
M0.U9=F^\4.SMMR8?+#BBTT'0.=98A[S_  B#RZCMY4ZHXN4/-GG#P'-*NXY2
MSB*^*6.>-9(G62-M0RFX/H>X/F#TJ2C*,DI1=T/4U)76:.Y M;\?"MWL;.N4
M7I.\:S."GE67-F.E&'U:NC#ZDF'6L$LXK#5CZDO(V=2;5B39B5S&=?WUNS%'
M4UH2S@UG@:.-:Q&L]0'C<%'C(\K<LBW,<EM5/D?-#W%"J4U45ONN BI34UVB
M+DB>&1XI!9T8JP]1Y>8/:F.YNMIZC!IIV>ITK+&CBM6-G-8D8<90?+SK9ASE
MT&FG6MF9ZGUJQ&6/AITZ5AB;U.P Z#[*P5J9%'3SK7>:N[G>P/E6&T=<NOIU
M]W[JV:=]#M:DV%'-8DS#D 7O]]OQV%;T-,^RF^@K#%F?$$:?CWULV=PAT]U_
M+KV^%8C>AV"=>P_2*R]C:L=PMM1U_%ZS7(V9 /QWI:669AV5;_;:E*UC1D"@
M:^8K-39E -KV^[]-*-/,[HAZ]+D:]>^OD!:U:R3L98$JHMKUT]UQW'?6EZBD
MDS):E)71L[93Y5O=L8<Y3U.@\_YM:W;,P^M;N-12DDC&<GO[_L_1;6MJ-S5C
MD $=KDV[C7R]UJ6LG8PZD+<W['S('ZSI1DV8=;:7%AKH"03\:7;,4?9?QY?J
MI2-I-G('PI5A1S;^?]E99F'%;M8PXR^7[OLK:9JUSIE))T-O=Y>7G6&_$^/8
MZ="/3\:UAESC*?2MHPXM2D8??96:&'Q'NZ$?NK$^)F1T(Z=+_@?II1M'4KU!
MK-<S>J.ENU8)S,94CU_'Z:5=&7MKJ=<OG?\ 'WUM-,S(ZVUMY];GM^JL-:.Q
MVR]>_0"W2L,.I4^6H_3Y>^M,Q,^5WC=7&A4]+? CW$5B0M-)W0?(X=0Z]& /
M[O>#2@]^*.WZ/VUF9N_N.N7RTO>]]1^!2D\K&L]3G)?X6^X?&E7-Y'V6UK]O
MW>G2MW--G'3I:UO=6A.O>=,QO6/ZA5D<7K>][C9SIIZ]:VF8??H_'ZJRQG$Y
MU[DV('V5@H^(#*8V *LI#7_BV-_46!K3S$N-U9B6D4QRO&U\R&P*GVE[$=>H
MM6W'+(;2BUD82QO87(MKF-CK^^LMSU,[]3J->IU'2VN@^RMY&F=#K<]SWZV^
M-;N(=TS$^@N2- />?TUCOP-:G5==>HU]?P*3=W[333TX@)R2Q/J>OEV^RBVR
M-YF!B;D"W<GSTUM21-[@=C<E@+$^?0W\^XI1NP&<*#>UF[6[]!IVI2S$MM!?
M+W(%];$$$7MWM;M2D;>@%?-VU50+V&A6VHOTL32E;V@^(63"Y%BUAY6Z6%C]
ME$N]#&%TBA221=B1?TO<AB/?6-65Q(!<*&;-KE&N7H;ZW-JPP*YA>UUL &M<
MW)/:Y^-+1H+3>S:&UR5)O9?6U^][^XTNYH S)>U\I-C>U]+_ *!:E10EA1BA
MD-@MUN&MK8Z!;$Z:BEK00T$DP/$))#@6&H[6ZV'6EHS5!?*HO>Q-AE)L-+L.
MFH:]JSB)MR C+HUKY22 >YTM\/T4K@)\3 P4-RZ]V#::#N.W2L,U,3(&.M[&
MQ&MK MT"G+?7U'G6&NXQF-1T)8Z6/0 C5D(UOH?.L-'"Q@L&-\H!-P>HL6MK
M;32MW,XG1PH)LH 5RQRV.8E>AOT)S5AAAR@MF LH4 :\PM?7R(MI6&CD"4#.
MO3M>R_6T\B0=:PP%QXMHQ:4@7L1;J2NFE[=JT;#K#XU1E!O;HIL-#<,?,#-;
MIZ5AK0-H\4"@NP &KWL26(74GNI/OK0G>!RS-;0@I8:GS]2"#<5JU^\VLP?#
M,6%];*0#;1KD]1<V&@K3Y&6S#&*3,6!Z7TN-?/2_7]%)[#$P0& %B.92#T%]
M+DBQT!UK0H[WL 0 VA-R=>8=[V  M6F_<:,;RK:]RW7*H&A'F2P!%JTK<3+!
M?))8\PT.HU[CII:];U,8$=G8EKKIIERGV?>212M%D)>IU8*RY;6N" P-@0=2
M+=SI6&P,\"RV#$*2+]+C*#8:GSZVK>]9Y"'&X$;!ELRV"D7'3L+6)/2YS4K>
M$;EF)W'8%;$! "!IKIFUM<"QUI:8.<;::6$1M##.%!(6ZEBRO=AIRW-A<@ ]
M*4F#"6%$!R2:%6.4DFY<J2#IVT%;\3 =$,C@$G* V;J@:Q.HOU '?M6=IE[A
M[@YA=5)-@T2BQ/U@+C[;^E)-B[V1B"X!%U(8#*203<@B[>1H$U;N'$+:=@M\
M)*&5N:S-=6'UK9KZ=^O?3I3=VNK!U9: J2Q4V8DV(U'6S:L-;=!K[JU<S-B7
MQ<;9ERE2HZYN70'J//6L1DLPIE RAA;E!).@.8E5!MJ#8@C3I2T_<(M8#$$7
M!()8Z@&W34] 1K>E9,3H!R ;Y0+ ]3II?0&_EK2K^XU<ZV<O=B"=>@87\@3T
MZ>M9<W9/74SQJ&4(55#<G+HP+]1:YN0 +UG@)E%+(ZRW)RJ#>]P#E4$@C*;G
M2QN:3D([$ )4.8N="@RG7-IWTZ"[>^MZB6FW?@!21=KM8A>8G0#J0=;$A;'I
M6TS+VU.L;2*P7,K!>>_J-!H=+5MF)^\-H Y +*V<!B6!%B"-;J+Z9=*'J\A8
M8"RHJJ0QY;%1?+YKZE;^5J4C=T@-B">9$!1K6 )-R=<UK7\_A2A$G?03^*0,
MN8-E>,/H+7.8A>:_=B=*S5=H-B/Q:<-64&XM95R\J,>MB3<E@>]&B^'$'/)"
M;Q2!;Z *M\IT)YURW)U&4%=?*]Z7W#9\@J94S%+7:W#!L+=' M?ZHRZ5E[&M
M'<+9DD3G .>PRLMS9OA?6L[S=T94:.,"YN[%6-G-P229;W NSE5(] :PUO6.
MP:68,UV0@W#1V4@(YR^A(7K?K6S>]<ZC,&92@:-1F+-J9+CE()U!'<$=*V;R
MX:@E$5QSCB6;,6&G;-E#!018/UZ4EZF-^:94AXF< !0ESFUS %;VU!$A('6U
MQ2=#:? PS1@',K-PF.>10<DFEL\9M;R':VM9H; 4X+#B* 1K>PL5.F0 G+=E
MO[C670M>B RF@#"S:YLHU*JXYF("K&X%NNAK+K05F&$*%TLJLQDZPC1;_P 9
MI+EE>]^UC:A2U$AYA)1$P0\P@RQW9C8&_-VUMF%K]>U!ES"1? -);$9N90S%
MLIU6XU#=NMNE:NKYZ"Q [PX>YERHH#+(1S!>=AS7O?0W\Q6[YY:"%>[OH--B
MA*95XC(KJZ'6^01QFP"E&ZY%L;]<U'3R!M^\46#B658V<LHU:)2JA(['3( 6
M(!MUO>L@[NW$3(-FC8Z(4NJAE?74G,&TN38 ^0-+S$-F+#%BZCJR1L"'NN7-
M(5(U49N85J6C-<128=;Q!I$SE$-V%ENA!)# Z@6!H4@O (L;)(TDI7*4MSZ9
M= +#ET!MYUB4C041NS, Z!DL[LRW"VZJQM<<II367 UF#'P44B$,@0E<ZD7+
M."A"O8#ZI[G0BDI<48 FV8+-GN2T,;%^8!AH0 M@+Z_MK>IEV=UP(:(%@RYU
M:&R@J<K#3,%S$DZZ@5F>JU,OST$!M7"M'BI,@!"R3!RJ!%;A\,<0R7#,+ CR
M)IQ%MQN!DUO6X@/!X-VLL8%CFU).H+ DECF'*3W-*3L:'%V#LUH>'Q I="$*
M67*0%)Y2#< O>PZ^S\ SM=/@%@TU8<S!0JA7C:*$L;Y3(,VNFCFWX]P9W;R,
M6F07[2VD(V>V<R*KVNP%TZ*.PZ?;6XQ-/3(0>,M/([!7<=;$<J E@;W<(!KY
MWHROKQ$#<;XWCV7C$98E P[%\P6S(+WXAS$&RC07N:+3O=-C>=S4YXH7Q.\V
M-Q$95T#N@1FA57"=&4'63-;M>C2S'"X+L$GNY@EQ6U(R46/)+ERQ)Q!&3F)D
M7+>Z );S!I=!+?[!%3SHLEYL*",87!D$.!%"48,%8*N47*R* ,V0]:>:YC"S
M%_@E,<<21$0EY<S .IY ANB$HX#DC6]K^M)FKOV&7'%V,R.S+)&PC*@.;Y2K
M95S! H)!86H%0-1'3V5'(7LJ*I/T8Y;&.)O9!Z6"92;TUDU<<-"B;#S*P O+
M$'4,HA#$"X" M'R,,VM)3-!3C4,3%U7,))7#W2S- TEB(Q<%2;'J!:U;[35[
M 7"1R7Q A $<CL4>4 ZMKP0HNQ;+Z4I"D^/ 'X3#RJUXR  6MFN ^49K!;%@
M"VFM;61M.^@I,)@QFC'"5FE5HV.4,ZM,%8R6RW*G6U]=/0UMNVHIW'U\/MS/
MSA+#/+"8H8V56(0N\@4C-E4BPC-M3VH%2=]= D5U4;RU)#XJ2/ X5<)@H8X\
MT65N'H $)!17)878JI)TO?[ )7[@/I/>>H0NA=DN@98Q?/F]JXL0^@)UZZ4J
M]M#+^\),9F*E3E:1LR6.:R!3:UVS \HI<&S3R3? (L4'13F&=1]*P3E"JUKJ
MH75BN8"VE'B!R$]C(HPY5![5I)!HI ?0*EBINHN3K18ZFFE[!(8Y>"0"C,P5
MUD(MF<2',.K6LGJ;UM92 2OJ(W'KFC;+&W$7.3=,I<$Z+FN$  ]:6M6^%Q$B
M7WY/YC_5NWG2X(_J6[98L&# M_37N3[(%\BJ&L1W(IAM7Y-'UUX,L_1!WVE/
MZ!_X<#__U;L.\RC\_P"V2?\ CCBOY5NGQKG&T?E];Z27B5/%_*:GK,(<EK]#
M<&P];7%J970WN=63X'K:M70DY70?LZ4F3-G-)61H^(OH16T[&'3*/W^59O7?
M88=2NIUT[5CEP$W/LO>^E;3LC:S.M9>YL^M27F8<6I)L^M>L6IIV.;4LUD=[
M6[#\??2'(2[,D1N5L&/8VR(9'1?GV/1,3BI,O.BR*&APU[ A84.H_CEO2W0]
MBX".#PBE)?9ZB3;[]%[%]=RU;/PJP]!-_&2S?XE[/$6-3 _/JPP^K##ZL,/J
MPP^K##ZL,/JPP^K##ZL,/JPPZLRHK.[*B(I9W8A555%V9F-@% &I[5IM16]+
M)(TVDKO0CEOGO-)M_'M'AY'&RL(Q3"QW*K.PT;%R)I=I#[%Q=4\B6OS_ &OM
M*6.K[L&_@T=%S_=/OX<EVWO4]H8N6*JVC\1'3M[?R<E[1'*M[_94(R.=^!W
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M S/V!?,H!4,26//YJ!TRC+<]JVGP, A-B/98*1=&+6O?*+FUQ;RI3;OV"&C
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MUKYE"92KD6-\X).O2E19L1^*1YYA=)2X>-V8+8.&>Q#>1%8G9YF@+.$A@ED
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M Z6(OW\@3:E)WT%1S#A  1F  56-K9K_ ,4GL*Q2,XYF.5200K#,+&QL3KT
M.G0UO7/@(XA%C([DNTC7-@Q76VALIMYFU*MRU$B=Q,49-O:93<7%C<Z 'M8F
MMJZ$-)Y!#BL(75@X'0%HUZJ0>4K8@ZBB)@FFG<)L3A\V9&!1" ,W,SL?($W
ML?A2DQ%K"?Q.#M;*5(O9@_>W< J0+TI/@S5^83R0R7*+&X5"4UN.559@U@H/
M<VTK8EYZ 8B7*RY] JA@=2%)TUZVM6S+\SNK'B(X)"@\.4H;:$7>^;*0':WN
M K#>8,,J,T647)"%B""!:]@QO;E4CWW]*T:! ='<7TCT((S* R,,P8@ \P)[
MZUAK,$BS751=<MI MAF8EC(RCK<D =>U)?8:,\396N"UP,JN![(!L0>X5[@=
M.U:NF;5^ *$N9,K7,C:*&Z7O9;$-=4#$&DM7=Q>]==IAED;*""S+RJ0K, H;
M1M"0Q!(]]:L9F%KS$9% ;A\H)OS6SW#*22>4*?C2K(WO,[I<%&:SN+H,ZV"6
MN-;:,;'7U-:M?(W>^7$%B!9%5+(IL)"W7UYNQ.G8TB2:SXFG<[C *H'(&( 5
M;<I&;*UFTUZ&_F/=0[F[MG5L"F8L5NIL5&;V2-&!%KD:FU;RXZ&[>X[1;/0K
M;*A #&.Y"E3>P\KD$7K%H;45P8'Q>$C51&I4*J!I"5UNHLK VMIK>MIMO(T\
MM'F$LL:L; G)>)2S956POFROEM<@T2*YZB+MZ@B+"YG4HS+J@9P+<]\Y(7ZR
MD#J#26[7OJ8GP8=/''AX"0B+<%%(%] +D$7U9B3>D1NVA;LAL-L2ETE:*21(
MR[-HG.+>R57H&N1<TZB@3Y!1A1, 6:5,Z#5)'[=+6 &:07O6VDS$[!OAL.I;
MB2 2G, !(#H1?./B *&^6AEP1A\#QFN8R&L'8BQ:,:CAYA< ,#TU_36M#=Q4
M;/P4421%F,=BIR%2YRD\YY<F@'6@R7%F]Z7 /LR1Y4B-K"P<D93S,25UMJ90
M?A6D_<:838PJX?*&=6[@YO\ 3*-"5/?RI:=A(7RQ<-18@E@1K?,3ENI'-8L4
MT]_VE>O>8-SOKM8[#V+B\6R*HACF8*S@C(R6!8.26<$:V[BBTU=WDN(&K++<
M7I,U,[V[4GWEVSB\89.23$3B%&6^4++EYF()!8$V]*=1LGV@HK<20F#L]S*\
MD@00+.BZ7"Q1@1H97.NN8'*-12[^\V.GX?0Q852_":4-B(Y,P%R3(RACPB!9
M5L?*E4VK9@YI.P]\$&'$F3(G'#ZL!F7F.>1%6]O9Z7I5V\@?:*[9F!69X00;
M2NC,P.21Y,EUN-5S >M:F[9]AN*=G8>7=W"QPR@EI)FDD5+R!18M8!.XRW6]
M_.@5'?-:!8+,<S"X>\19HV+7RJ;V5I/HP'%C>UU--^/8'BM04B,ZE0S.$='7
M,;V(T)U%E8]M>U:8LS?,90KDO)(Q;*K1W)$>8EF/<W%LVAUK:-#E;F[E3[?Q
M<9#-'A<D?%<+< +;-FTOF)Z6K4I6=N(N*4'FKDJ-G[,PNQ,)#@\*A!6'F=\A
M)?*_4Z &Q!H5[ZZ&//N/G#/(V8L&S.I<=20Q4>F4@7TTK6@DP," (^&  ;77
MU'M:V\ZW<QH"E;*^<F]B3RBX[E4&MF9M367XHU?CP ,EWNW4H,Q[6&GLY= :
MVLY9">(7R%@H8!LC!SF)%P;D=.^E$T-2O;((<3'R$7SMFD)91ED O?KJ+6-+
MB!>3$GBT,O(49,JZLS%M +@#,2"">X HL7F:>0EL6M@QA4*JE@S:$9=<Q5O,
MD:^=*U>6@&0D]HHPA%GR("<Q$0+!"#ELVMU)[TM:@6[HEG\@0!?&G>0(2(_Z
ME^V,JA2BFV]6Y8+LIMSDW[=#3#:GQ"]=>#+/T.^=*GT$O\.!_]"[5O&/[/[7
M/GM#%>[^$:N:;2^<:U_VR7B5'&?*:GK,)<OH//I3)Z#8ZY>A\A]OE]E);RL)
M6M^!]:M)LW<^ UMUI6IMO(X(^'X[5IWTX&;R,1U\NE8U;N-7NSX+;MWL;^7F
M+^0K+L4=2OV??2G*_>:N?9?.D9HU<^RZ5O>9ESJ!UT_ _::Q"&[LY5!:^A_5
M6I/.W$VLQR_#W80Q>+DVOB8PT&"/#PH=05?&$ F07N#\VC((\F8$:BK)T<P'
M75GC*BO3AE'MES]B^MKD3&RL*JE1XB:\V.G?_(/15W+$?5AA]6&'U88?5AA]
M6&'U88?5AA]6&'U88?5AATDD2*-Y9'6..-&DD=B J(@+,S$Z!547)K4I1A%R
MD[12NV:;44Y/)(C=O7O!+O!M*256<8& M%@822 (P=9V3H)ISJ=+@67M7.MJ
M8^>/Q+DK]3'**[.?>_Y.!3\=BGBZS?\ 0EHOQ][$TJCK^!47)C!H[TBYA]26
M8?5B5S#D4LQ*YR3Y5FHIO@="?MK:3?<:U.M%R2%+,^(I-V]#;1Q:E\!.9];T
MK3,NSMDL-*TM;LU<^M]MM:W<W?D<@?KK%F*5O8?5O-"CZLNS1]669L^M6[HU
M8ZE0?VTHU:Q\!:L,5^)VK#9]6&S(JWZUK/@;>2[3OEOV _'PK23-)G!7N +C
MMV/Z*4:XG0J>P_'K]M9<SB?>E:%Z+L/A]GXZTM&DT^\Z%>NMS^/MI29O0Z4H
MPY N?MK:,,H4#W^=:EF8<VK21IW.+5EWP,2/LH_'ZSUI2;%7MH=2M*3%*1QE
MZ'T^S]]ZW>^1F]<X*CRHBR-JW$^"D] -.Y_'EZ&MWMJ);L=@+:5N_(U;B=@O
M?R]_Z1I67]YJWN.P4>1T/<7T_FK3;%6.X TT_5^BM7;T-H[Z4JS%7/K7K9JQ
M]E'X[5M6XBE9'-O2MW;S,.:V:.RB];669M+F=K>[^:MW%9':VGE6KFKG:P\A
M]E:-'8#RI1AV"^>E:N9D90H%);%)<SM6TN9LYM2KF['-KUABL?&W87_'Z;5B
M-LQZ?@4K,S,^ ZWZ??IY5M*YL[9;6M8WU['IUI61AV5;] 3;0]//[[BM-V,,
M@5A?3W#2PI+:9AR!?T\_6LN:.]AY5JYKQ.;>6GNK:^H4<A?C\ >OV5COP,.V
M7IH.G4_@CM6(P[*.]NE@/MU)]12DKF'S+VT'7UMKVZ4M)<3:1UMY5NUC7B?5
MF9L[#S'7M6C>1W*@^GP^/2LO82'>SMI&#+!.;P]$?O%Z'SC^\>[HXHU]WS9^
MB.:5;=>[+T? 4PL0""""+@CH0=00?(T_O?-:#RW$^K#5\SBPK#+>\QDW]U8;
M2L=:RQGB<5AK0XK#1S;\>=)LS>FIU\OQZ?I-;2YFCXC3]?7]E9DC#CT_1I^#
M2;&^TX-8A#9UMY_C](I7<:N=" ;@CKH>XL>Q'NI.;%JW$2V/PI@E8J+1N2T>
M4<O]\O\ >Y3]U,JD7&78QK4@XOL %O3J?+R\M-:1D#L<A2>@T_%^OD:RZ,L<
MB,V_;UK+HRQ]DMUZD$_#M:U;U,LD=<A\JS(2?!3?X?9[_?66-I\3OE-_2MHW
M?+M,P7OH?3[/VUEK&)&55!':U_C]U:\39SEN1]XK:L:O8R"( &W72QO]M9<V
M9%07&FOG;MYUG8;,N3UK1F1W"V &A^%:SN8=@+Z"MFCM;S^^E9&T=P!]GN^Z
MMF&0 >5*4>9B.;4KQ,M[CM6TKBM#L!?\>GGT'2E&'/2QU([]A[NG2L-'UAZV
ML-1K]NHUK<;F'(4_CH;'6E7,.X ';X^?[JTV8<^77S%OQZTI(PY"ZWL/2WW4
M:*RN9?@CN:4S3U." >WV5LRY]E'E6\S+LZD5M&TSK8=_Q^JEJPHX !T^_P#=
MVI6F8KQ.IT.E*,SXGU8;7U'UO3\6_::T+2.;=]*PT=<MNPK8EG'2MB=#@].U
M8)/B-/A6&++N."OD.WWUH*F<,FF@!/P%;R,NC$PMI87O?W>E*7U"E]1U(^W]
MU;UT-LXK-TT="I[?S#R\S6].XPQVK=S3.P6W[^E:;-,X*]?Q^-:U<U?F8F Z
M=^MA6TQ21\MT*N/:&MNGXTK$\Q5^*#=2'4,O0BXU\Q2[A#DBE9:F,ZD>FO;U
MK1K@?$>0U&O:EQEST,7(^O8>\:6T[=_?6]=#:YG ;3KU!'NT_76[&-W/K^?;
M6]8S37(QL+GL-?WUAM-'7I[JSQ-.ST.N:M[O,RQUZ?C2LM8V!L7%Q8&L.9>=
M;=;CJ/<16-70B<;Q[1/VT.MK^5M"/3M>M)@4!7.I_'7[Z(]#9B'KW/ET]*2[
M>PUEQ,&)<7C6_6Y\A]E+2N#TU C::V&AO;0 ^_WFLSN9J87M<==#J.GQMY&L
M1B7%Z 9CURVZFWX]U*MS,8#<DFW8?@Z>AI5K"+YF'74=B=1U!K0FYA:P4DZW
M!Z=_*LSOVF7 ,O0]=-?YZ)D)X@5]-0+Z:V[$=;THP#L!ET ))L!?KK;J;6-A
M6(T%LJ:$G2VJZ@=.G72UQY6I2, <B@D&_5;&WV-[[$4M&@%+;J03;5@;'IH/
M0WI5C KF4$DZVN!?I:]]<O\ >^7>L7;H(862*221:V4WN-3V(\[^5*31IA:Z
M#*23Y<Q&NG1>_P :((: C:2,P L >P%S^H6I7 2!62^4=03<^9\]3I:XK9C1
M@8"_0]["PL??T M6[B7V:&%EM=F*C[]>ES?4 "WVUAH",CD&3*-,YUUTZ: @
M&U9?F88\C:7'<W()U':WEK6:F'QB[V(Z$YB";@:>=QK6+(PX"@V)(S%00+V
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M9U!60YPV:T0.4@+89>MK:GX&LB\Q$[/-"=QD06RD9I&(0*VH70\_>UOL%$3
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M!)#@("B9<@M;(2S:!@1T[ULRP80+:SE9 5.9BHNK$Q!6.FEL_P!])-=YD7,
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M)8K9M18 =2;Z:G+]]*- &2X/4$'R]#;3XUMZF!?,&-R;#F \OVW( I2?O$,
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MUKZV(TK9AT<%@RQJ  A)([7TN0.PS Z>5;T,."2U@!S6;-ET%E6QU/>LTU,
MLBJN=@ $(S'-JP U-K>K&L- 8E&0Z$@D WZ6)ZDZV !K9AAD0*M@.4&UP>7*
M+YK#KKIZUALQ R76Q95)L#U'LV"@=;W'>M>)@9P;3EB8(YM?+J;*_2W*/XM8
MT):RMP%#A-L(2N=URD%1_>Y?=?O6G$0I-9"BCQL4@'0"^6^8^SUS CM>AVL+
MC*^NH(XJD=;@=;GR_;6LS+HZ%@2+-8=0+:CW>8(K#-3%*0<N70B^:Q\AH2>E
MP#2HVXB)( R\VN7.200"/)=0I%O/[JWX" MF16TS EP Q'4?WH&M[GO2DQ#0
M18F&]KA1F&7*%M:QM?[ZRYI:"6Q>""NTA9P<K6ZD'L+=@<M;-Y!'PU!-WO;_
M $-VL2P!M9K9KZ_&MB.P^@Q!@(%R-+D]]6ME(U) !-JQYZ&)V8Y&[VUPR+<V
M0677EZ'K;J-#0I1XL+OMV:U'(PN+$B)J"H1[>H(T\[6IK.%M!S&6\NTXQ"Y@
M;"Q)T/D/=TU!I,3;T"&3"L'S+=5+$V;7TT]Y[4NZ2S$7X'/S,J<X30+<VZ"]
M]!YCK6KY&C.F$OELO-IVT )ZGXZ>^MW2,[T#4P:+<*"-038$:FX&8][^5)O?
M-&F_<"(\.0MNI U([J3J?-1;X5I78G4[E(PI7ZR@F_>]NYT^SUI3M[3:9@D*
MWS $ V)MUUTU]Y%:,=V<C3.+'*1:YT8&PZ=+C6L\1(&EL%M<FXRVL.I[^>E;
M0F5K!;)_>K;0\VMQ;OY LM;$O,"3ABS,>I];V'8?Q;$ :^E;6@E@"490<J]3
MJ>O4>8M:MB'?AJ%,H4,3:Q8$7[77MYVUI0FZ"K$ D2*5?ES$.; /GS%=>NAM
M2M'V WGD]0MD0!2#[0-CW%],VO1JVKWN:MQX!9(JJ6L0MQ?.+77J!RF]^G2B
M7?$T],PL9&#7S$DJ;C+8:=Q8:WOT-Z2LGVB5J$F+!)&;*3E#$*2+D@BQ'16&
M:_K1(L2W8(GO$MW)X9&K9CJEV'3L03\:7J( 7SX!&"!F4:7 U)0YEOW !'7O
M6&79W7'7*G+&[A@<]LQ#&Q(N+$&X\JU8W>YFAF1KBWTC,7='N"NO0%>A/:M9
MHP,HY+ABO$M8 @V(!!S="038V^VL;L8#@K%+9[@6S2*0VAYK>0(%)N893<,-
M+*"+ @%M;'J-03H:QM:,PZ,K\RH;+(/;8J0#<'138DD ]*U=6,/N5E+!55>Z
MAF)M[&HZ $ZUI9FTS"RDNJJ0ILK*<NA*VC.OU05%[]Z59<&8=T9PQ"&R"]Y"
M,RD_>+4-W-WS!BSS%$Y;@H<I# W8@W8BULMNWE6K&S!-FD5U:Y+!5)RV ;,7
M6UM3H+^M98S4")A0H)8<1W#-9NF8:J%O8DZ>E;B\S#JK-'KQ.A<*5]D6Z6/F
M%-_A2[YV-'60R8F,YV,N6Q%FUR]R2+7)/2DNVIAC7 A0"69@&(8HMP%(T+-?
MJO;34UBDF8"$PZQLJD!\S%@$U(*C4GV0M@:S>5NTT#(,B%ELKW9C'8VSYA=E
M8]->GQH<[IW-YAK$#9ES$E&86**A92;Y54:"P[WU_0)N2?Y_G^?OW8[L<JYR
M&.09; 9LP/LV'2XI%VQ685XF0L'9!:P5%!)S W^M8:.5/VT2*:$L*9W0AGU$
MF41V !87/.[E@0%N+4OM-,:/Q-V\=F;%D6-D3C(Z7:^8RG54&4"S>O>CTHI/
M(%4SM'@S6IO#;%[7Q.*8YF=[L 2Q:TC!FN]P)6-OA3I9 EEH$C1I&QLCL&0L
MV6UU4=+$Z9PWI2F:8;[OP2-BX71)W2^55+7-CS:YA[ 52U_XWW[C]0.HU&/8
M//@H_F\/$,A98\I#Q(%8*1E^C4Z!E;4TH%'07FRL.D[K*Y46:P20LQE7/'=G
M/LO9CF/][6W*PL>3=[ F$*>$H!L 6S6)Y$!%NW6F[=V%NEZ(]VP-FLP;(I9L
MQL1J2+*18>18BU-YMICF";60_&Y^YTN/ECDQ"R)AS8!\@M(@X?T9)[:&@.6=
MV.&E"/:/MAL)AMFP\#"1+%9=0-#>]KZ =+5K>WM03;>IE8,"J7#9386_C/S&
MY[V-;5C1TRLP1+W %TS #*I[G[/LK=[9F'1EZJ03Y,PL".UO2MWR[3 .XSG4
M6-U491=<OU;][J*VFK&& K>X+% 3:][$6-K&WG:MLTSH%)LA5R&=QF'8=02?
M+UI-^*$78"90&#%@S&ZW]G3IS=;JP&AK#4DV@NF)7,UP+J!9=47,<G6VN4=Z
M*G<%+@$LT8&@ D%^K^Q<>T5-CT-+35\S01XM5R92Q!-\K!+,,AU"WZELWW5O
M+ZQ,M!/8F/*"KW8!<P#"Y:[7N"-+:TL")7&0,2ZR'(R*1#R!F!)O8]F!%%BP
M4N1*;Y#L67QCWF<*,I\.MJ@$$:$[R;GDC*!>S$$TRVD_L$?6_$RT]$/G*:X]
M0_\ #@?_T[N&\0'Y]VOZX_$_RAKFVTE?'UOI'XE,QCMBZGKOQ"8 >0^S]/QI
MC9:#='#*/TUNRUXF.7 ZE0>A\JTTC$\LSJ5L= /U_LK1IR2U.F76W74]OQI6
M<16\SDC0VI6ANYBRF_O-:M83O7[SXK^/.DZF.5CIE]W:MI(0G<X(L/Q^.U;9
MET"((9)I(H8D+S3.D4:*.9WD8*B#U9F%(C&52:A#.3:2[V*C&4I*,5>3=D2=
MV?@X\!@<)@HU55PV'BBY0 &9$ =S:UVD>[$]R:ZGAJ,</0A0C:T8I?E?M>9>
M*--4J4::TBD@91PA]6&'U88?5AA]6&'U88?5AA]6&'U88?5AA]6&$>]\MMOM
MC:TR(Y^98%WPV&2_*S1L5FQ%@;%IG!L?X@7UKG6VL=+&XN44WU%-M17#+5^W
MPL4S:>+>)Q+BG]B@[+\;]O@)*H4CCFE-7T,.*T8<]:T8<U@0^TK##X@>5+O9
M&KM'3*.X%:WFS&WP/LENE*33,N^)U-;R0K>N<6K5LC25SL*Q:"SFMF'(K9M'
M-:2N*/M#1%D:R9Q6Q+.MJVLQ%CM6W84?"D-7%([5JPH^K9BS.0._P/QK%]1C
M=E8^RBP]?Q]U+-7N<D6K+W-)6.*PW<^K#>NI]6S#ZM&'(%88E<^M6)YF]W+(
MXK;;9JQS8=ZVEQ,31S8?KI68JZ.N47^SW:Z6'E<T1/@8<Y=!IJ!?R_%JW<VK
M' %^E8*T."//\?JK? UJ[GUJWD9:YR!YUM(Q+(XM2[FMT[ >E:-H^I21A]2C
M#D"MHVD=P!^.WO\ 4V\ZR_(58[Y=3;3K?]@T_'Z<N;>1STM;3W]^WD:Q9ZFK
MMGUKD#XZ?@'0TI669B7,RA!IT'F+7/I>QL*U<5?D9 H\A2;LP[5F9H["MWSL
M+2LCFL-GU+MQ1HY%8GS-VN=@*RXI([6\]/Q^TUJYLYL/3H?7MZ7Z5M?68=@+
M>5_,7_:*WEP--V.;5EQ.;.U:%(^K#9S6TKLP^HEK&CFMI(PY ^ZMZ&TKG-O3
MKTK0JR.X4>7X_=[_ +JVF:LCD*-.ECK^-!>L>IJQWRBLN;W3FP%8;2L?5HV<
MTK59&CD#\?CK6[9&':W<CX=+>OZ?QTU9(5=ZG<#S!]_P^&OPI1ESM:_:M&['
MV7R ^/3[.];N:L=<HZ=_T=.I%K5AH-MGXW@VAE/T))",?]#-^A/\0G[/MH]&
MKNO=EZ/@.*53=\U^CX"AIZK:\!T=:P2T<5INYH^K1NUSZU898X/2L1K4QG6E
M6%61Q6S1Q:]:9EKYGUJT9NGUJRQKN/K5LU<[ 4AFFPHVAA #\X11;02*!H/)
M_CWIK6A;SE[0,X_=(*LHO?[J!=V!G-AY"L\3#[+IT]+VK:>>9FAS:E63,.V5
MO*M71AD"@=A\=:TS#O2K)&'<+<#M^O\ 4*S-&'?*/(?961NS1V \@/A2K&'-
MJVA5CX"MVN:1WI25D*/JV8=U6_7R_=6(PR6%8:M<YK=KFSFE6Y:F'U88<@:7
MI2U,.;4HVT<@7I23>AB7,RA+=?Q^RE9<-12R.^4>5*-7/LIM?[@*VLF*69C-
M+-,XK9H^K#1]6[F'-O=6]=#=CXBMVX&:'!'[?QVK:,T.A%P?77\>0I1M,Z9;
M:6\B*P)&2XG6U:%Y'=1TT'ZZPTTCO:MB;(ZVK5K"3J0/+KY>5;S$LZD?C\>@
MK#2S=CZP/;0?;6Q=K'4@FP\_Q^JL1N_N.C+;M^S\"MIBH\SK:MZF['%JS30U
M9ZG0@'M6A+.,H/:MI,3Q.K :BVOITM;]M*OP%'4BLL;.N6YOV'GJ+>_M2>PW
MXG!L;Z>E^VM9F8&&&-XK'JI(]PZCX4N#R%+T3.:(8SIE.O2_8_=8TJYAT86&
MFI/VW]/36MIW,6IC86![$]>X-NOV&LNC:S,1I5^!HX)MV[5G$Q'2^M*L;L=L
MU_3W_K]*38RS.IM;MU^-JV8CYN@Z 6T /3]%)T[S:SU,4B+(C(W1@5/Q\O=6
M[Y&FDQ'3QE)'0C56*MIY&VA[TI#;1M'$8.I\OQ:L=F:>N06RVSM<7YO>0+?H
MO2D;,+#S'EZ_'SI29I]A@8#RZ6]_KZ5N^8-YZ 9UM8]OU^1-;R$Z@9SJ=!>_
MW=;>8K?:C;9A(ZWK7@(T SV(/<?H)[:V'3[*W%/CJ8 9GL;#VK=^@![F_:E*
M.=S0"<F]LH-K#7WWOIZ4K0PPG*%-Q<A4O;4&QTS?$UN]S (XNQ]]R+>E_L%;
M1HP-:Y.FMM=;:9A<^=@:VC7>!'((-^M@+]3I?IUMH:4GS-7 ;@%N< CJ!TOY
M:]M:4LT:?U *<* "-18"UB>OZ;6K8D 2QC6PZ];]K#ZO84I72, ,R"S$ V!'
MZ+GW4I/,3W@,( P(TL#86 &I\ZW<TUP,,L8S9B/+L+M;2VOGT]+UOP$VY@1U
M)<DJ=#H-5NH'6Y]*W=&6,<BBV4:"ZC70D%N@M[ZV98QL 3U-_A8#H"3TK9EF
MNXQJH+6)L>WE<VU'87K3R-6.CI>Y)"@YA>U[C3H--+5M/EJ:,#IF7*<X":DV
MT\['FL18UF7 T 9$SWT:]^4#,+=!<=.A^VL3,.LN5;9EOJ+,;9E]2?(FL[C1
MB6*^<W7J=!J1KKJ>A(&EJRY@&,;%@%N0"3:U^HY,UM.6VOE6[F')C &9LP)-
M@% RBYN>NHL:RYAA(4V'*;DC6_M7\_9%B*RZT-&)XQ])<=%L0!IKY:=+GK?O
M]FS ,T9*A2" HTL"0YZ'S!(%9<V!3'E+93=F&AZ!;@:D=B!IVK## UD-LO4'
MK8\P[J1>VIK##JHMYGZ2Y%S:U\V8>C7L*P3H^T'PXF= 3Q'""QRWL3KTUU(U
MK#=T&^&VJP!S-J3TO?E"%0-!J20*2T(>6@=1;35@ <I('N+'77KT/6M6MDA.
M>H/2>-UN2""-!T]H?&XI/:;4E]U^?Y_GV<-UT%QH#VOIK[KTI&FN $= #8A7
M :PL-2>P!-;U-!9.+KJ  3<776U_9^VL!.Z"/&09AK9".K6N+6&OK?I6TS6\
M[B7GPZ"2X.;J3=>46ZV%QJ18]*W>YKM"N:"VHC#*""&(U+:DN.@&4 ^M8G[C
M1WP&(F@D8HQM8)E]D%LY!*]5M:MNPJ,G$='8^TR%"ESID!-QJY L;&W**!.-
MT$C*3S%M!B0V4L00U@Q;H6MVMI8BF[5APFWDP7EC:Y 4&X&I707%S[ZT8UQ,
MG"07&C<Q50+&VOM'SK3N)[C[AK<@"Q!53I?-F/6X)M85AAD"ABUK+WMYC3+Z
M#0]ZSN-/L.AL0= .7J !T[7\ZWXFNP"R:D93<7-P+6)([@];$5J_N$W,5\MR
MX)/4W/2W2_H#67MJ*O[CYK&Q/,39@I'3R(/3F-;?UB<] /-W8CZK'J;7^L--
M+@UB8A_4%\I&MK78:'6X'33WVK8GL LA4V.FEP;'IE N1VZ]:4F::Y .9 !H
M6O[5R-->G30UOQ--!5,@+ D: 6O?J6/4=B016-\@;^H*YHLQ()M<BY#92M@;
M6.H8:=*6LQ#Y\ M9-&+ @Y@.502U@;9OJBY'E679G"P7SX<WTL3E%S;1B.8%
MNXTT^'NI2=Q-E[0NFC!-[*V07Y>VGN!.GD32NQ"7<(9P.&H4 WD]LH2Q OI8
MZBVE*T=Q+5Q,8I 9K$94"GS+<NI!.@6]Q2@812V9I.&$  YB#<@]="VG6EF
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M6VGP-OU_96+/,&CJ1;I:EW%/3,Y"WT\NFOI?[ZR]A*NSME-@=?9U[]!V'O\
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M##NQ&BV&I)N <SGN)!J  W0CK6=IAAMFUS%2I?L#H6MRL;9E K;=LD8 RG4
M+8G1B.H'IU[4M9FFKF(Q@6NP.6YL-,Q;4+YY//UK.P39@:2,:Y;L"58DK=ER
MBY!U%P6/E6DTGV"6G< RB-0X"FY)SV)(%R%7(.PN3<44$VKZY@#$1D@-F72[
M,HOE9QH#[@ +UNXEM/0(\3"@8GA%2$S@!;AI"-!U]@7/QI<&(?U!/-'=F4*
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MP>OE6E<PPLH8*;W-CF([%N@%NMA6-MB& 94N0 2 =&N-6L+@Z^;4K>RL":R
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M\A\?QUK=\C;T,=8)L?5AE^!T;X4I"C'K2P>9]^/Q\:TVC+7.C=/Q^+4E&+M
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MK!)BD468F]_==;?K_56T_<8 I1IVO?L.GI6S360&9;Z6MT(\QW!^(K-'83W
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M/37[JW?WFCN(8V-\NNO2_+VOY6UK3N89(HY$N$.BD@^>H)!(UTT-)9L.8)7
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M=QB#C"PA;,X=95D35"+(2ML@4]%73FI+:NC:0HL/$6 &4V0@!V(_TIN!;+<
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MT]*S>-'*BW>LO=]ALYI1H^K##ZM61L^K9H^K##D=16& ["3<%RC'Z-^O]Z=
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MY9A<]7FP4R'4L3<L<K:%?8Z%.MJTL]31T "#+J;:#WGS\JT;R/@Q -E!+6)
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MCVKG-F'\705BST-6L[F C0'* 2-3EZ BX%N@M]];,O[SH&( LE[D+=O:]_\
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MQA6##)968V!)0@@W!N US2# /*HD((3F L0=1[5LMCW)I.2T, 4JKGZJ <S
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M/<:T:/E6S,0+9A8ZZ&_?T]:W<SL..K!18D6L.S7(&I]U8^1IW>IA>,92",I
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MHM^!IGQ5192"3J']"/+T&6MIF79P5&EK%;'2Q%B>H\P!VI2,X9G1E'-<-FT
M/9@.@(.@)%8:M8^95LMAEZ&W7AGH/(92?6U:-'0C_2WTL1[.G-H3IUK#1B4
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MQY"7J!'77UZ7Z?=T(K:LQ(%9%))OU/;\=+UO+@8 Y5OKIUZ??KY5M&@(ZC0
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M\]]2"-!9NE[&DWOKJ;6H;A;7>P%E [#VK@D$7L;GUH3;OV!.)T=8W&A .8!
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M 'I?J?06I<5Q,,H&O7X=M1]XM^BE&)7.UOLU^-_/X5H7H9%%:NKB6=ZWH:.
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M8): <HL2?/3OU].W2MZHT!Y%S"UM?T:?L-8LC #(ENI(MW6W>U]?(:4O70T
MR+"][7O8]=1VI? PP!;&]M1V!ZW\KVZVO[ZUD:,3!>MM;][CN3T'6MYK,SQ,
M$B&^ER"2;:G7]-;\!*[3!;J.]^^EA6S3.C:W_0/LMI6> EHPL"5(53;KU[WU
M&NIK%D[LQ&/+8B_G:VAYNF7S_96VS9Q)&0#EZ6N1IH!UU[WK%+@:N!F N22+
MZC3K]HMT)K9C,+ @ZVL3J/7U-*N8=6_4+]OL]+UC,,3*+=+6U\OW#6LS]I@"
MD2[$]#?7L0+@Z>I/V?I4M!+7(#Y6N;:7\K:=B#ZTKA=FN)C=2200 +&U[:^_
MSK$S&82HN/U7U!OIZ7O6-V-=@'D4#W&X%^U^YZ5K,U<"2 6MT!(L"+:C2Y!\
MJ6C0&="J$6O?H5MY]>O6LN:U F5E(URV/GTN+GIH20!6/7L,,I-O9LS:!LWI
MIT]"*S7N-'4-E(7*220"5L/>1_>V%:DKY\##EA;4'4@>EA:UK=1TUUI*-,PL
MG,0=2;Z'O^GI6^\U;W@8K<V(U/NZ'2YZ]Q6M3;"][K<6N6L+ 7*FVMO*YZ5O
M42V!Y!H3T(UZ#VCYZ]JQ"0&1J6N02+<IM<'SOV-;M;0T8KZ<H4$ ]-38FUKF
MW45LQW]AV0&^8 A1JHO]P^/WUKB:.ZDY1?K:^HL.MA<VN2/U5M:7,M='S+T8
M&YM=AH;^J].QK'F:T,=M%YLM[D6-[W%[$: VM2'F:=CAE*IR#,6-QK8ZC4D=
M*U=7S- =@0V:Q)R@WL#:]C:YU.H^%*3-]P'8:ZBYL=?CT]3:MK,3)&,I;V1H
M/+3N;'77K6N\3X 8K<ZCH;ZFP!';UK#1@8D.2!F !)-K7]"?3L:PT898Q938
MG30D9M"I*CT.9=#TK%?3@8%Q4.3<7S,5U'0CJ#;0@5N]C MDP]PY)U#$ZV R
MWT%A< 4I/W"7]042(?9R\@UZDGT([W^ZEZ9\35GIP [PL06&@)'MD#IYZZW%
M9?AQ$M9&!D"O=A<!,PL2 &8DA6MU\[5INXFQW-K$BWM*S#S.EQ8GJ"*S1&GD
M&4;*;#V+I86T )!LX'6X\J1S%'=+B0@: +]4@WUU+]QTK+7,1G0ZBX/-?1?:
ML038GJ!>WV4EHQL,8,4\9<F2UFLH6]KC4@:@WYO744EH&[W%OLZ=<0L18L"J
MV.9BQ) ]JY]#K06K/L#+-7X K&B2'*R@,CH6 Z7%R"+UJ_N,:Y ,XRP:ZL %
ML 3S9K]!W L/C6FT9N]I\N(1KEB2![(S: E>E^^IM6[Y]HEIHQF4'3K8@VOJ
M1V!N&[4N\6)T[CH7N>;*07L&Z,HN+] #8K6/+0TK\3$Z*"2F9@<PS9A<,G4C
MME I)O(+L0D;FQ!"Y5!)MH1>Y'8H?QZ*0EZB2QT7M7[C2Z(0Q)-@U^@O2[@[
M<A'XB/B29;V)S%2+MR]&&ME"W%&UR$2M>X$0+&X##H19M,Q'UB !KF! K5[&
MA485@0!<, ;*Q )RGF&K  D =J')YBU;@*7"(SQKF.:ZDV;*I5?, =2!0V]3
M?$-P+K<Z$D-:][6&EO.YH3%(ZS$7-U*$ $ :K[SW-;3S,"Z=0Y8J2 +7L;9@
M=7-R3J*(K+O$L+91<R%4 %\XO8ABKG0$]/?T-):R-<,P++$TI<K9=+&XT)M[
M1Z  6TTK$^)G9Q K@0Y1EN3Y] W4'MK>E=QK0X$Q47  N2HOKRWL7];]JQ<S
M+JUPXPV0,"9 [$K8:J1KH0!IH5%:;9M/,4F'2ZL]P]V&9B ;Y1WNMSI26\[(
M4$6\>)R!<B%+$:W8KKEUZ7M>M13?<;&AVC!+-),SLX5 ]@I*AAFZ@&REU^VC
M)V0-IWOP"U-V]I;4E$."P6(Q3.4"11HTDH?ZCY5!8K?L; $TI.Z[#4*,Y9QT
M).^&?R>),0$VEO=$8HKPR1;.8ZL H).)/U0?(=*%5KPIIJ+O4#QC&&:M*1,;
M96Q]G[&PD6#P&&B@AA14144 !0+"QZ_MJ/E4G-W9MYN[U#$@=20Q];G]/K6&
MSL%ZWN3;K<6]Y/H:S(4T=E(U*@D <Q'<^EZP3VG:]B!H1EOTMKY?"MW,9\2#
M<D=KFW;U]!6\N(DX%O?H*Q6N;1S8BX&G;SZ?LK.\S,^*ECU)Y!Y>8.E[5M(R
MY\5NP!T)O<#4];<OQK37O-'07 T36Y L ,H/?7KI678I'W#(U)N+YB>^A36W
M][?XTG0V<Y0%6ZE0222"WOZV[BE+00<&X6_49;]+7\A;M<=Z+?*YIG4@E39>
M@S6746O?+?RI29HX*E1S:EAF-Q8>G2]B!]M;,.A2P9@]P5M8CK<W/D36=AHQ
M'2Y(REB6S 7L0+9 HZ,+]>E888N'RC4D:W'>_F;7OK6F(DS$4M>YZ&X/F#J1
M;6U_OK60EZ9: &4 .38"XMIW[C3J,MZ(EE8UPR S+YLV6Y +*3F!ZMK8 $U@
MCM9@*WLUNF4G4!;'H!;I6[F7'R^3XJC??:K*+7W7QOG;3:NQ.FO:D56]U+M+
M%T7^<)_0O_"@?__6NX[P_P!O=K?X?B?Y5JYGM3YPK?2/Q*+C_EE7UWXA-3$:
MG!]_G^/A67R,.IO9N_37STU^ZDY>TP^["_D/Q]M(D\\C#ZXL3Y?#\:UD5GVF
M&*ER? P6^X>S_G>VUQ+*.%L^!\0>X,TGT,*^A&<N/5*F^CE#K]H=8UYE*+?M
M>2_&_82VQJ/68O??HP5_;HOR^P?&N@EN/JPP^K##ZL,/JPP^K##ZL,/JPP^K
M##ZL,.DLB0QR32,$CB1Y)'/1412SL?0*#29RC"+G)VBE=]R-2DHQ<I912NR,
M>U<>^TL?C<>]PV*G>103JD9-HHQU_@H@%]PKDN+Q#Q>*J8F6LY-]RX+V*R*#
M7JO$5Y5I:R=_R>Y9!939@S(.U(OGF(.16Y/(W'4^-)1N3/J((/J2VV^TV<$V
MI21NUSHQO2DC-#J*V;6AS27H;.R=2?3\?HI#=C9DO2;LU<YK:Y&'U*;9AP1<
M??6T[/,PX ^_W=/A?6B;W 5VG%+1L^I1HX-)9E['W6M&7OW'8#M2]$89*2(.
M16&UJ=JVL\Q9R*VV;BN)VK0HX.NGI]]*3,XG4"_NHC8INQD%($ZLYM2DKFVC
MZEFE;B=JT+/JWW&'U;CS,.XK8I9'U8;.Q(TZG]7PK#69DL,OW^73[>U;XFT=
M+=-/CUZ>0I:5\S1WR]M/U_@5HV=:W:V;%G8*3>UC^/*M.1HRY;6MT_'ZZU>Y
MBS9]6=YLYMW/3\:^M+WE[1+.0IT'WC]-Q<Z7K+\3(ZG#"UK??^-*5%L.CBU_
M?1+F2T,RJ%]3Z>[M_-6:B;HR =/M'[]#6C#M8"M&'!/8?CW4N*XL4D="+].O
MW_#[*(F;[M3L%TZ]?N_1WK:8LR*I/I67,OR,M)L;T.:VM>PP^I1HY _'X]]*
M4>9AW 'Q)(N?,>G?4]ZW:QAV"]3UOYB_?4F_E2DKF&0#T'\_EY4O0T9 M)N*
MR1V"BDW9ESFMI&CFE&'-JS,58Y I27,Q*QS6TD;."+VI2-HXRFWXO670HYRD
M=/+\:=Q673U,.X'X_%ZRQAS6K,V?5NR,.:V:/@+_  %ZPPY"D^[]7F*TV;,@
M6PMYBQ/X]*3<PY"@7MWK&[F'-:,.;4I+B8<BMFXG-8*/JPP^K##ZL,.:VD8?
M5EN1A]2C1R1:MF(XK##N&.@/2LSMD99!E@Y>L9/7F7W_ %A^NCT*B]!^P)3=
MO-!]. I]6S#K6";NYQ8Z?'\>M8KW%JUCK:_3O^/*]+N98^M:L%)'(_'X]]:9
MAQ6&SZL,/JW8P^K$KF 7$IT<>X_J-"K0RWD JK[H"4.* 'U;,.P%ZQLW;B<B
ML68H[V_'X]36:/L$GUOQY4JYESL*T:\#N-:Q?4*R9]6(V<THP^K$8<@4M6-I
M71]6S5CZL,MF=JT+.:W;W&'U;O;0PXZGW5K,WP.U+-'U8;[#@5AFG<<]0:S0
M5%GUN]NU;3LS>1U*ZT1,S+4^ )K'D;OS/NE8;/JPP^K9A]6[7T,.+5M:]HFQ
M]2A+/JV8?5AM&-A8G[_P*Q*XHZUHP^K1A]6T8?5MF'%JT::.+5@FQP:V8CH1
MY=.M;%>)UK9LZE![JVI6-'1A;U'G6[Y79ACMU_'PI%C3.U*%&)K=>GZ?L)\Z
MWV&&.M& Z,YD4^EC[QI2EF89*V8=2-+C\#II6UR8HPG2L:L)9TM^/CU^-;N;
MN8V%_A2DS? PL!U]/=Z6^%+7(R+.HK'$W([@'\=C;0TG0&V!V&IHF5C;7$Z-
MT/NK5LQ(1XY?I ;:%1K[M+?9:MV$2686N/?;II]M_NK6G<(:,! ]_E2C0&E7
M4VMYWMZ5N_$0\@&_2VMSY$]O*MJUS5K -OYQ?T^ZMO4V G&IZ=0?QYVI2$@5
MA]Y_!%:--9=H'9>O0V);U /7X5M"6!'%B1;S%OW'TK9H"/>][W76YMKS=B/*
M]*- 9TY0=.NGQZV'2U;4C "VF8Z:-;7R&FGK6]688";V-NIM;KYV^%*-&-@+
M FX-R=/?]]8:U,)73-W!/Z-+GXUM,2TT8&ZW)ZZFW;[:5FQ/>==+#OIIZ]-?
MC27F8S$U@<U^AZ >S<:W]]ZSL,.)&'3K<$'7L=->YZ^^L2YF("N+DV"CR'H+
MZ#N:6F;,3+?0BUM3Y^\W]]*-<3$P/EW(OU^'?SK9LZ'N"/A^K6M>)H"2#Z0#
M+H=+C0 A-+#OJ:4).A6Q87Z=+]?7W7K=S+@=@ <]P00!;R)&@]Q%8S3YF,I[
M[#N=-#TMWK:9H!3:,!K8Z=- ._K6DS']8&E5 +Y1J W77W^AK=Q.; [9@ILJ
MKRCZVF47((]3>MWOJ:[0+8MVOV%NIL/3N*W:QAV$9))L00" 6N  3UMIV%9=
M&CH .;N"-?4#[P*TS#L?94@'STZ>\^8I%LS#H1=0;=3<YNNHZ#J>M;-:=X&?
MVNEAE4:>MS\1ZTEF]0O<!"2!I>Q;TN;,.^HI=KB=6 60L7)! MU/E_&^%981
M;,"NH'K;0^1O_-67YF7,)C'*5OS7)!Y0+Z*0?*MW,/E!4 7]-+]>4@:] 3WK
M+FC+8NM]3=50'H,P!O;W5O@:,;(I!4$AE(70==+G3O8TDP[NMU7N5TN.Q)\]
M!T'>M7L).+#+9AEM86U\_(:'2D-VT-VRN8&L;VMS#06M9;"Q/ET.E;O8RWO
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M,Z5NYHPLI/D+7&HMIT^ZMW1A@*:W Z"U_0V(\[:BM7$V,3(1YG^-T /D==2
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MK+F':M&'U88?5AAS:MV-Z'U;2-':MBD_>?5AL^K##ZL,.:W;*YAV47!OWK.
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M^*!W%_>:SMX&'1@Q7WE18:=+W4 ^M9>S,,;@*1;72VNG3RT'2M&&$K<.2;7
M%^G?K<^58:9@9 =!J#W%M3J"7TTN!26S+@2==<I/4:@]@>]]1VK:O8T%KH#?
MS%[#S8:7)Z@ ?IK>;$6,.5@+G0'6YN1?^]]#6&[>XQ7O:QN1KIITTN/6]8[B
M3%8YB0Q^WR'UO.Y&M88SNEPV6[$^UIY]['W5I]@GM,CDFYU)L,Q!L2#VUTU
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M"66X(#'5NA[&W6EJ_M$LQ@7Y;7+$J//3V1J-;V\Z5=VST-VX\#)$MPV@#6S
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M]B=#J+>?H*WP$F)P+J2.W0"P'7OW%:N;5M&=2K'7KIH!K;TMWK;,:,#KFR@
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M;O8(CFMK,V?5LT9P-!Z"DK-FV<THU8^K##FE7LNTV?4HT?6K#=CFEK0T^9V
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M;I6(TM )(+ZVUZ?;;]?Z:(C2 I_'[ZT[F,#NFA]D:?9Y?;2E;01H@*Z+8D:
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M8)>1S:P%^A-KULRRL=R++?N=/L[>\5HQ?68V4 ZB]M-/7UK=Q-D?6OH=._\
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MHSI7_4[%_P!SE^0JZ\H70?\ JM@/[M#\IV'Y2+Y O_)?_)]_[29NU_W'5O\
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M)U9JG33E4DTDEJV\DEVM@:]>CAJ$\3B)1AAZ<'*4F[*,8J\FWP22;;Y$+_\
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M?\F1\G?_ +2?NQ_W'5K]372#^D\1^\E^0S^:1T!_JQL_^[0_*??[<P_)]?\
M)D?)W_[2?NQ_W'5GZFND'])XC]Y+\AG\TCH#_5C9_P#=H?E.#^4P_)]?\F1\
MGCM_W<_=C_N.%;71K;_])XC]Y+\AG\TCH#_5C9_]VA^4>7P<^5#\G7Y0^*V]
M@_ OQJ\-_%G%;K0;/Q.\>'W"WJV5O'+L3#[5?%1;-FVE'L[$3'"1XZ7 S+$7
ML',36Z&S+&;,VCL]1>.HU*497MO1:O;6U^5T3&Q^DW1[I!*I#8F-PV+G22<U
M2G&>ZI7M>S=KV=NXD ANH]UOLTIFBP+0[5AEDSK:L$M6,;4M&C'2KHT?4F_(
MPQOVK$88ZVG<PZ-_,?U4I9JQAB-(DLS#$UA]M;1@2S+:1QY,WV=O+L:4(D!&
MUT\ZU?@(X&!E/45LU?BP,PL3Z$BMHW+/,#2+^[[/LI:^L2F!V'7W?SUIZ]IC
M1@8:^A_%M?*E)FK6 DJ\W;7]0[UM:=IK0#-<Z"U;$NV@%9-?C2DS3TN!I!UT
M['7733[+VZ5E\Q+ ["X%NUR3^L_&MK(TP.P![:7U-^A^RYO2]30%91KH+^NE
MB1>_K>U)X]AH"%?(6-_?>EW1HPL+=K'6WNZULPQ$:'30Z=A\:R]\S (P(.G>
M_K[ZRZM=&9F(]?L^\5H2S$5MT_'[;4K4PZ>1[ZZ^A_1:M&CKKYZ??;R^)K=S
M5N1]86Z>1^(Z?HI)O1'4CH1I8^5_3WVK+)">XP%1J2#EU8,3U\A]M$,N8&':
MPZ6U.H[W^ I29G8!F&NM]+FVEOP*QFNSB89+DV[6M[R!<:^\UB$M@-S<WL;]
M1Z>9K=N' V!7ZE; WU[]/W]JU;WB- -( ?9^!\K'0>F@K:N;1B9>QU%M+_I'
ME6=IIF-AJ!\1?7U/:Y%:->)B8',#V'1?<//L :WE;,WXG&H)TRC46%K^1:W;
MK6&CX $ F^@]KM[CVUI+5LC#HR!K=SF]^FF7[*3>QAA9<F70$D"_:UOV_JK+
MFF Y4(N2"23<6Z$D7S>ZM"0&W>XUL>FFEM>EJWVFFN0!90#U-B#:]CIKH/CT
MK>H@P, <I.H'4E0+ =R;V.:MFG=:&(BUP0" H%K=?,>O->MI^\UJ F*JW+S+
MH>XL2=0!>E:F:'S'-8B^IZ"XT%P#KY7I-A+/@+VO8Z? ?H%:-');H3E  L >
MI(T^!-[_  K;T%+,[IE!).I)M9NM^Q'Z:2S3?,[C0-FN;"RL.IU[]P*3?W&K
MG0@GF([>0.7N/3J*Q,TSH!UT/*.NELUNOVUC-9G4K<:)?S^/77KJ16KY]AO4
M#O<: @+8W/36^E_+K6S1@D.7J"U]0%Z*.Y)]36O TP,5[:];DBY [Z^5[5HU
MJ Y$+'4ZG-U[GR\[::UES&@&R,IL +7.6QM:Y-PWIY5O/B:MD I%**+LN9KZ
MB]V%[B_VZUM//L$K7L ,B=6RY;^SY&YZ7Z6N*4;O8PLHR\R6+:@ ZDD@Z>@O
M6LC3S."G8* 1H!?K;KKYD5K42SZ/ESJ;]B0<NO70#\=*WP-W!43]R%(N1>VO
M,.A\K5IWL)ED&4;YAEL- .A^J19;@ZYFU-"?UB>T,89?XU@.4'H18_;K<4-H
M)&7,4.#Q!4K<6'2P(T)]+T.UPJ? 5V%E$T9A:^H(\R0=0-;4B2MW"KA5C\-P
MI&4"RD ^EKV!N;W-_6E)W5A+S"UA<=1H;7/KU_36GE[#3R,)4&XZ "^ITT\A
M_?5M&=YURD:6L0._U?7RK1M+D="2+\Y46N;?6MYV[ULU)9&7,6&8*1<@7]+6
M/EI2>X \CJ8PRM<BRC-8VU]!Z@FMWL8!,@U 7VK!B;D+Y:C0$UES3.<E\VMA
MRG0 @D]Q<BPK&S'R.KD!FRWTT7H%RD7^^_G6[FC&K,>:^JZDL;:J-+=0:PS4
MPMQ#9,UK$G6Q-K%CS#H+,?@16U8Q+@!GLP)U:R@'K;-[Q[0M]U*1EN)@<9!E
M6)F !;F&9>A76^K+8_\ 8I![5E\[/0T[W P4@JMB!ED%R 3H>;4DVZV-+9O@
M9$.<J2#=!8]+@ &P)ZV9?O I.@E@M"O,K =$,9(!)N<H# = -!?L:1>R-"UV
M+/PRBYM%RCFS6+W]ECKV[TB6H2+L*/>1PV(P,R$ 2X!03TL(9I;J3Z(X^%(A
MQ7:;J:H4.[F-M>)A=6C%[ZY;=[ZW%^E)FN(NF^0[NQ9\\9B8V! "VO?I<<IT
MIO*ZD'5I1W0X%[VZD:Z?CRI>0W:7 RC7M[[^GNI*-GVNGZM;T9&FKHR+?MK;
M^+6[B4K @ ?JN#67-I<SL-;7L-/QZUHRQW TT(N"#>XK+F'>U[=+=_\ 34I&
M_ ^M>]^4@6]/2MBCH5U Z>OG6Q#.+7NA  Z=^5NM_MK9K0^["]V-S<WS=^IK
M3-]Y\NA8@BP'?J/0^72L,L<$7%]/+37^:MHT[/O/K$7'?IWO;II6[B+'1A:Q
ML/XM_=6&FCK;74 VZ>_O[JWW&';R]PZ5O@:,17J<I)%QIUMH;VZ-6[Y&&$V5
MBIO;MF%NGIV_56K&&,:$G3J>FM_[XC7E6WE6KFGVCL^#((WJQX[?TOXJQ]/S
MCLK7MU.M+6I/=&[_  ^?+JG_ (43_]>[5O(;;=VO;_CABOY5JY5M;YRK_2R\
M2BXY7QM7UWXA%>H\;:'!-9J)N?=C6&+0ZGJ*0\C38\GAKA>'L_:.+(UQ&+C@
M!\UPT6>_N+8D_95[Z)4K86K7^^FE^]7_ &(L^P*=J$ZOWTK>Y?RCE5;2?/JP
MP^K##ZL,/JPP^K##ZL,/JPP^K##ZL,&4\3<7Q=J8#! W7"X-IF'E)BI2"#Z\
M/#J?C7/^EU?>Q=/#K2$+^V3_ "115]N5-[$0I<(QO[_Y$ALR>U5*Q N65CN@
ML/?6V(.:08<,;5BU-I&,T2YC.*3>[-'U;,.U8M19P:QO,TT?"MHTCNM;9MG>
MDB#[2D/44K':]*-WNSFM7%'(K#:U.U;N*.*T8=J*M3#I6]09W'2E"HG-;X&S
MZMMV5N)A]6XY9\3#FE=IHH7_ )=3_>D?B_\ \ZOA)_L9[M5ZZ\DW[",-])6_
MA9'BGRT?SP,5]%0_@8&H&ND'*CZL,/JPP^K##ZL,/JPP^K##ZL,!FS]H8_9.
M-P^T=EX[&;-VAA)!-A,?L_$S8/&X64 @2X?%8=XYX9 ">96!UI,X0J1<*B4H
M/5-73]@NG4J4IJI2DXU%HT[-=S69L.\ _P K%\O3Y/.-V>=VO'O>C?C=W O&
M)-RO%_$3^)N[>+PD90KLU9=X\1/O-L3 CA@ ;*VCL^11<*X#,#3]K>3_ *)[
M8C+K\)3I5G]W17523Y^;YLGZ\9%]V'Y4.F^P9Q^#XZI6PZ_H==]=!KEY[<XK
MU)Q?;J66_D0_EZ/ /Y0>/V+X=_*%V5A/D\>)^T>!@\'O#B]J#%^#N\FTW:.)
M(8-Y,>T./W'Q6,D<F.#:PDP2*N4[1>1D1N)=)_)/M;8\98S8\GC,"LW%*U:*
M]5932XN'G?N$KM>A^AOENV)MVI# ;>BL!M&62DW>A-]DWG3;X*=X\.L;LGOO
M4JZJZ%65@&5E(*LI%U92-"I!Z]ZY0\G9G<+^X[6_'[-:VC5SM^/W5LT12^7A
M_NCORR_]2E\HC_8AWPJ?Z*_LHV;^'X?^%@5CIK^PW:_];,5_ 3/-$KVJ?/$^
MK##ZL,/3!^0=_NCGR,_]2C\G?_8AW/KQ7TJ_91M+\/Q'\+,^BG0C]A>R/ZUX
M7^ IDLDOT[>=0)9[\.)DK:5V;.0*48D=JT+.:(M##D"];2N8E<[4H6<UM:F'
M84H4D<UM*YLY I6B,,H '2D-W,.U*6AA]6S#ZL,*&/\ 1!G^]&-Y?^@F\+?^
MV7CJ].^2S]B</IZGBCQ!Y>/YX%3\%H_X+-(==&.,GU88989I</+%/!+)!/!(
MDT,T+M'+#+&P>.6*1"KQR1NH*L"""+BL:35GH;3<6I1=I(]"_P#)!?+MC^6[
M\ES94^]FTX\3XY>#PV7N)XNP22YL=MJ9,&XW6\19$.ICW[V;@97Q# *HVMA,
M:J(L2QW\L].^C7ZG=LM45;9N(O.ER6?G4_[!M6_<N/&Y[W\D_39=,^C,7BI)
M[:PF[2KKC++S*O\ MJ3;_=QG96M?:W5-1T\^K##L*QBH\SFM"CFB&C2'_1"#
M7_)R[R#O_59\+/\ MJ8ZN@^3!6Z5P^@J>".,>7K^=]4_"J/^$RA17I0\.'U8
M8?5AAZ=GR!%M\A3Y%AOU^27\G+W?]:>W-KR#TF_9'M#\.K_PLSZ0]!OV$['_
M *U83^ IC3_E9/\ ><?RN_\ H)=H_P#;4V53[H3^RO _3KP9%^5'^=]M7\%?
M^%$\VNO6!\\CZL,/JPP^K##ZL,/JPP^K##ZL,/JPP^K##ZL,/JPP^K##?C_0
MXO\ O07;/^IW\1_^WG\/*YOY4_V,Q_"H?X,SN?Z'S]GD_P"M]7_#I%[6O.R7
M,]M'-*2L8?5B5C#ZMFCZL-F0+]X_72&S#N!:L[]3#KEI9M,[6%9<RYP1>L3,
M3#'#&\0'\4E?ON/N-.Z;O$<P=XF>BI7%'-;?,P^K:S,/JPPXI#9A]6UJ8<TK
MB8?5AA]6&'U8889ENH-NA^X_OM0ZJR3$3T M"$'-88>7_P#+^_W>_P"6O_JM
M_E'_ .S'OE7JWH[^Q_ ?@='^#B?-?IW^S?;/]=<7_&*A$BI@JA]6&%Y?^AF/
M]T/\6O\ 5<;^?[#G@+7 _*G^R&C^!0_A:Q[4_0X_L(Q7]=:O\7PQ8HKFQW\^
MK##ZL-K4[5M9BNP^M2C31]:L--'-8*T1UK8@^K#1]6UJ8<6_'[.U$,N=#\/A
M6Q2/JP4LSZMW,MF<UEQ2-#WR_P#\O'\GCY)^/VUX9>"N!P?RC/&W9KS8#:<.
MQMLIA/"S<;:4?%BFPV\^^."3&2[?VUL[$!>+LO9*. RR0XC&X*=2E7[H_P!
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M[?P#6C&!'4]"+?;8VZ#U%:O[S7:!9(QU L._I]]S>]8F^(EZ!?(O5K6R]-+
MCO;SI8FW P$$^UWMIYCS MTL:V(,<BD68Y=1ZB]_3SUUK9K0+)-,V@Z]KFP\
M_*]JR]K&SBWO -Q>]A8ZVL;\M;8EG*GK<6(TZ::]+'[*T:1QHK$-:Q.6_7H;
MW'G?O6N\5<[H21<"US<=[V&I';R%)>60F1D%[@VY;'TU';T(K&)SN?=B 3J.
M][Z^=^XN:1H9P.E@,QZ^>MB/7XUNYC.I%A<G4C[OWBMLQ+@!I  QO?+?E"V!
M!-NO;2M)^\QF(Q@W+#,W1;@$$:6!/<WK&[Z"3&R@#4: :]-;:CK?K?KVK1@#
ME0L@[ BZWZ]>G4:WK5S ,Z#*ZMJ"NO8]+#F^)K29E@$\:WZ7.F:_6S?56_4V
MZUNXEKD 98\K,3<@, 5'3H+7]PI2=Q+7N KBS \4C(FAM<6)Z?"MFK&,J+L2
M<HRDW-[BPOI;IF.M:SX&&/4D6%[C+[P.PO<\UJVF:T[C.F57;0&_0&P%NA.G
MF?.M.XF0,C*J!T!8A5U.OG<>8'3UI#U-7!\!RW/6]@ W7OVZDW%(EF;3MF&T
M+GOZ6/F!U/GH30[9A>%Q48#$D!5S>S;7S)-QIVL6^RD2-QY<0^FC^<0JP.9U
M&MO?<@>0I&@KL""1 KW":=AWTZC70DE:4W<TT!V )OWUT8!3>_2P\J2:,# C
M0D7MK?FOKT!U(UK9M71AR]M+ ,2+V]XK$S&D98S>X!Y18 $]/LK3!L[@@@6
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MQ]_MIO\ *.?\B)XM?]D[9?\ XE:S]6O17^GJ'O?Y#/YEWE!_J5BO='_./O\
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M+"5L5"BTIN"3W7*^[>[6MG;N'_\ ]M-?E'?^1#\6O^R=LO\ \2M1OZM.BO\
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MH+D@=_+0UFII+/(QZ'6_11;S;7K;OI6KFT=P=6%[:=?33II:L7:::.RD%O0
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MD=^M*%&51TK8E9L[UN)L^I1AV%:8M:':E)61L["E)"EH<THV?5AAV%*2-H[
M7-JV*,P%A:L,.:PPYI=C#ZL,/JPPYI:1HH8?T09_O1C>7_H)O"W_ +9>.KTW
MY+?V)P^GJ>*/$/EX_G@5/P6C_@LTAUT4XR?5AA]6&'U88.QX%^-&_7R=O%_P
M\\;O#7:1V5OMX;;S8'>38DY:48;%'#EH=H;&VG'#)%)B=B;P;*GGP&/@S*,1
M@L3+$39C3+:6S\-M7 5=G8M;V'K0<7V<FNV+M*+X-)DKL3;&-V!M;#[9V=+=
MQF'J*<7P=M8OG&46XR7&+:XGI>_):^49N)\K+P$\-_'SP[Q&;=_?[8$./Q&R
MY94DVANSO#AF? ;S[I[6R6 VINUMW#3X25@.'-PA+$6BDC=O(NV=E8G8>TZV
MS,4OLM*5K\)1UC)=DHV?9H\TTOHMT9Z0X+I1L/#[=V>_L%>";7&$EE.$NV$D
MXO@[7633;_&F$="?.1H;GI6,PR@W%Z2U8V:0/Z(2_P!YR[R?]"UX6?\ ;3QU
M=#\E_P"RN'T%3P1QCR]?SOJGX51_PF4):]*GAL^K##ZL,/3O^0+_ +HG\BO_
M %)?R<?]A[<VO(O27]D>T/PVO_"R/I#T&_83L?\ K5A/X"F2TJ$+2?5AA]6&
M'-JU<58YK!1]6&'DM5[6/EB?5AA]6&%P#^A??[A/EA_\]O@U_P!L?Q$KA_E>
M^4X'U*OC ]8_H:_D6U_I</\ X-4M35QT].'U88?5AAS2^XP^K$K&'U;,.XZ@
MTEBM5?B9*2)/JT8?6%[VUI:O[##ZMF'U88?5AAVK!2:M9GW>LN;MF<VI5C+!
ME&<R*?2WV:'[Q3Z#O!/L'$7>)WI9L^K##ZL,/JU>S,/JVC#ZL,/JPP^I43#F
ME&CZM-7-@.06D/;H?N_;36HK2:!OTCL#?M033/+Z^7__ +OA\MC_ %7'RD/]
MF/?.O6'1S]CV _ J'\%$^:W3O]F^V?ZZXO\ C%0B/4R50^K#"\O_ $,O_NA_
MBU_JN-_/]AOP$K@GE3_9!1_ X?PE4]J?H<?V$8K^NM7^+X8L45S4[_J<]*T*
MT/J4DK"6SX5NQM/,[5@H^K##BE)7--YGU98TV<:?C\>=;5[F6N[(YN+>=*,T
MR.N;\?JK=A:.M;%'UJPU9%*'^B:_&#$;Q?*:\"_!+#8LR;(\,/"'%[Z8R".0
M\.+>?Q/WEQN#Q<.(A%@9X-WMPMFRHQO9,40+7:_;_)A@U2V77QS7GU:RC_8P
MC^6;]QXV_1([6EB.DF!V-%_8L-A'4:_=UIM._:H4H/\ LBM!733S@?5A@YG@
MQX3[W>._BSX<>#.X>%CQ>^'B?OEN_N3N_'.YCPD6T-X-HP;/CQF/F"M\VV9L
M]9CB,3+8B+#QNYT4TVQN+HX#"5,;B':C2@Y/N2O9=KT7:26Q]E8O;FU</L?
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MD>*/+/\ SP,5]%0_@H&H&NDG*CZL,-JWY$G_ 'IY\F7_ *3/_P!0^>*]<_\
M*G^P/'_[3_&*1TSR/?SQMG?VQ_%:QZ 8KQ\>Y5J=JW%"KG-*,1SUK<3-7V':
MMBSOT ^^L[!.K/,+^4QNULG<OY2'R@=SM@_-_P Q;I^-WBMNUL7YIG^:?FG8
M6_FWME[.^:\6#"R?-_F>%3)FBC;+:ZJ=![IV)7J8G8N#Q-6_6U,+2D[ZWE3B
MW?7.[YL^<G2+#TL'T@QV$H6ZFEC*T(VTW8U))6R65ER7<,C4F0Q]6&%I'^AE
ML)B7WN^6#CEA=L)A]W/!7"3SBW#CQ.-VGXF386%CUSSQ8"9E](S7#/+;**P^
MSH_=.=9^Q*E?Q1Z3_0[1D\5M6:7F*GATWVMUK>#]Q;7KS\>H1 >+/B3L+P:\
M*O$WQ?WGPNUL?NUX5>'V^?B3O#@=@P8/%;<QFP]QMW-I;S[6PFQL-M#';+P&
M(VMB,!LN1,,D^)P\+S,H>6-27#O9^"J[2Q]#9U!Q5;$5H4XN5U%2G)13;2;M
M=YV3=N#T&>T]H4-D;,Q.U<2IRP^%H5*LE&SDXTX.<E%-Q3DU%V3:5]6M5HY_
MZN1/D._]<K^5;_V8_A#_ -STKJ'\QCI1^WX#]_5_T!QK_5!]#/Z5VG_<Z'_)
M)V']$B_(<_ZY5\J[_LQO"'_N>E*_F,]*/V_ ?OZO^@%+]$)T+7_17:G]SH?\
MDG(_HD?Y#@-_ZE7RKO\ LQO"'_N>E9_,:Z4?M^ _?U?] 8_T0G0Q_P#17:G]
MSH?\DF\[PC\2=A^,OA3X9>,&[&$VM@-VO%;P^W,\2=W<#MZ#!X7;N#V%OSNW
MLW>C9.$VUAMGX[:F P^UL/@-J1IB4@Q6(A296"2R* YY?M#!U=G8^OLZNXNO
MAZTZ<G&[BY0DXMQNDVFUE=)VU2T.S[)VA1VMLO#;6PRE'#XJA3JP4DE)1J0C
M.*DDY)22DKI-J^C>K<.FZ'YR*V;2N=JT+ >T=H[/V1@,;M7:V/P6R]E[.PL^
M-VAM+:.*@P6 P&"PT;38G%XW&8EXL/A<+AXD+/([*B*"20!1:<959*G33<V[
M)+-MO1)(14J4Z4'5JR4:<4VVW9)+5MO))<6S3%\IC\O)\A_P%Q./W>W&VQM[
MY1F^6">;#O@_"F'"'<K"XV%G7AX_Q&VU-A-B8S"29-)]BQ[:2[#3KEZ1L;R7
M])=J157$QAA,.^-6^^UV4U>2?9/<.0](O+=T,V'*6'P4Y[0Q:RM1MU:?;5E:
M+7;353\FEGQ4_HDCY6&\LT\'A1X1>#/A9LJ5W,,NVX]Y?$G>?#)IPD7:T^T]
MU-W9+"^<OL8EC:V2Q#='P/D>V%12>/Q&(KU/W.[3C[K2E_?_ ,G(-I_HANE&
M);CLO"8/#4OW6_6FO[+>A#_C?NXQ$VG^7/\ RGF/Q1Q&%^41L_8L10+\RV9X
M->!TN%!#,3('VSX<[7QN<A@-9BME&E[DS\/)ET+A&TL(Y/FZU:_U5$OJ*I4\
MM7E(G+>CM",%R6'PUO[ZE)_6<[,_+H?E/,!BAB,5\HC9^VH@A4X+:?@UX'18
M4DLI$A?8WASLC&YP%(%I@MF.E[$9/R9]"YQM'".+YJM6O]=1KZC=+RU>4FG+
M>EM",UR>'PUO[VE%_62^\*_Z),^5ANS/AX?%?P@\&/%'941BXTFPDWG\-MY\
M2H%I@^UHMJ[V[O1M)8%2FQAD8M<,"H6 QWD?V%63>!Q&(H3_ '6[4BO9:$O[
M_P#EMFS/T0_2C#R2VIA,'B:2^]WZ,W_9;TX?\;_DW5?)E_+T?(=\>\5L_=[?
MG;.WODY;Y8UX<.F#\5H<(-R<5C9F0</ >(VQ9L7L3!X2//KB-M1[%2ZG3IFY
MUMGR7])=EQ=7#1CB\.N-*^^EVTW9M]D-\[#T;\N'0O;DHX?&SGL_&.RM7MU;
M?95C>*7;45,W2;.VCL[;& P6U=DX_!;4V7M'"P8[9VTMG8J#&X#'X/$QK-AL
M7@L9AI)</BL+B(G#)(C,CJ002#7/)0E3DX5$XU$[--6::X-<SL%.I3K4U5I2
MC*E)733333T::R:?- RD9L6<TLP^I2L8<THT4,/Z(,_WHQO+_P!!-X6_]LO'
M5Z:\EO[$X?3U/%'B'R\?SP*GX+1_P6:0ZZ*<9/JPP^K##ZL,/JPPL,?D ?EX
M?U"/'3%?)9\1-M_-O"CY06U,/_2;/C7M@MT_&L0PX'8V60R*,-@?$; 0Q[)G
MY9"VTH=FVX4?SASR[RG=&OTSV<MLX6-\;A5Y]M94M7[:;\Y:>:YZNR.]^0KI
MO^DFVGT9VA.VR\?)=6WI#$:1[E57F/7SU3T6\R[\1>O/)[-3.//S_'3I6S?@
M=A]U:9KB:0?Z(1_WG)O+_P!"UX6?]M3'UT/R7_LJC]!4\$<:\O/\[ZI^%4?\
M)E":O2AX</JPP^K##T[_ ) O^Z)_(K_U)?R<?]A[<VO(O27]D>T/PVO_  LC
MZ0]!OV$['_K5A/X"F2TJ$+2?5AAR*T+2L<UAL^K##ZL,/):KVL?+$^K##ZL,
M+@']"^_W"?+#_P">WP:_[8_B)7#_ "O?*<#ZE7Q@>L?T-?R+:_TN'_P:I:FK
MCIZ</JPP^K:5S#D4I:&9<3FL-V3 >T=H[.V/L_&[6VOC\%LO9>S<+/CMH[2V
MCBH,#@,!@L+&TV)QF-QF)DBP^%PN'B0L\CLJ(H)) %*C&522A!-S;LDLVWR2
M-3G3HTW5JRC&G%-MMI)):MMY)+FS1M\J?^B!?D5^ N(VCN[X5/MSY3N^^"XD
M8C\.\1A=C^&L.,B< X?'>)^UH,3AL;#*AS1XG8FSMN89K6+J:Z#L?R:[>VBE
M5QF[A,._O\ZENRFM.Z<H,XKTG\N_0[8;EA]E[^TL:OVIJ-&_)UI73['3A47:
M:2/%C^B2OEK;WXG&0>%VXG@MX/[%DXHP$B["VSO_ +W802!U0XG;>\>V(-V,
M:\"E2I78, +@E@RD(+_@_)7L"C%/&5*]>?'-0C[HK>7[]G&-J?HANF.+E*.S
M*&#PE%Z>;*K-=\IR4';Z)?B42MK?ERORHVUGDS?*=DV? V*7%1879/A'X&8!
M,.8WXD>'CQ,?AF=HRX53H4EGD$BZ/F[S4/)[T0A_T4N[6SJ5G_E+7[D5:KY:
M?*75?SDXQO>T:&&5NR_4WMV-N_&XI-WOR]7Y3_8N,.)VEX\[ WNAY?['[P^#
M7@YAL&++(#9]U-Q]V,?S%P3]/U06L,P857R<]$9QM##2@^<:M6_]].2^H<4/
M+AY2:,]ZICJ=5<I8?#I?WE.#^O\ EG[X*?T3AXQ[)Q6%P?RA/DZ^'N^VRV>*
M'$[;\*-M[>W VWA8,R"3'-L;>C$[^;*VUBQ&&/!3$[+B=B+/&!8UO'^2; SB
MY;,Q56G/E42FNZ\=QI=MI>TO.Q_T1^UZ4E#;VS\/6I\94)2I22Y[LW5C)]EX
M+M187^2#^5*^1K\M7YILGPJ\2X]@>(F(C1W\)/$J'"[G>(F<QB62+96SY<=C
M-C;VF!;\0[%QVTA$%O)D!%^9[;Z(;=V#>>,I;V%7]$I^=#VNR<?[)1OP.]]%
M/*9T1Z8VI;,Q/5[0?] K6IU?[%7<9]O5RG;C8V(5647X[6Z5L78YK9A]6& O
M#'E9?(W^W^:G-!Y.(6F\K FCA#!BL5AL#AL3C<;B8,'@\'!-BL7B\5-'A\-A
M<-AXVEGQ.)GE9(H(((D+.[$*J@DD 5M)R:C%7DQ,I1A%SFTH)7;>226K;X)&
MD[Y5/Y?+Y"_R=,7M'=K<K;VV?E)[]8"27"R[,\(/F&(W*P6,BS\FTO$W:D^'
MW;Q.%8QY>+L5=ME68!D',5N^R>@&WMI)5:\8X:@^-2^\UV07G?OMTXUTG\NG
M0GH_*6&P=2>T<='*U"SII]M:34&NVGUG=RT:>+7]$Q_*\WJQ$T'A%X1>"WA+
ML=Y,\,FV8-Y/$W>N!5)RPG;6+VGNKNU+&RGG)V&') *L@N#>L)Y,=CTE?&5J
M]:?9NPC[K2E_?'%-J_HC^EF*DX[)PF#PE'AO*=::_LG*$/\ C?N(<[2_+Q?E
M3L?B)9L/\I7";)AE14&"V;X*^ C8>*R!&:*7:7ACM''AY""Q)F-F/+E%@)J/
M0'HI%6>&;?-U*OXII?45&IY</*=.3<=HJ$7P6'PMOKHM_69=F?EYORIN Q:8
MG%?*0V?MJ%0P; ;3\%/ :+"2$VLSOL;PSV3C@5MIEF4:Z@]M3Z ]%9*RPSB^
M:JU?QS:^HW3\N/E.ISWI;1C-<GA\-;^]HQ?UDS/"+^B:/E8[L8O#0^,G@SX,
M>*^Q(C%\XDW:_IF\,-[,0HLLY;; VEOINTI=5NH38B97)N2I 6%QGDQV353>
M"KUJ4_W6[./NM&7]\7#9/Z)#I3AI*.U\'@\516NYOT9O^RO4A_QM?DWH_)2_
M+Q_(4^4IB]F;L;S[S[6^3IX@[1DAPD.P/&-,%L[=7:&.EO\ 1[&\2MFXG%[I
MKA\Q5$.UWV-/-*V6.%M":)M;H#M[9B=6E%8G#KC3NY)=L'YW[W>7:=LZ+^7'
MH1TCG'#8FI/9^/EENXBR@W^YK)N%OI.K;>2BS=+')'-&DL3I+%*BR1RQLKQR
M1NH9'1U)5T=2""#8BJ9FG9ZG8DTU=9IG>MFP-.-5/F"/L_GIO66:8B1C!M0&
M8T>7[\O_ /W?#Y;'^JW^4A_LQ[YUZNZ.?L>P'X%0_@HGS4Z=_LWVS_77%_QB
MH1'J9*H?5AA>8_H9?_=#_%K_ %7&_G^PWX"5P3RI_L@H_@</X2J>U/T./[",
M5_76K_%\,;J/E'_*B\"/DE^'F+\3_'[Q$V+N!NM"[X;9XQS38O;F\FTU3B)L
M7=3=S9\6)VWO)M>12&,.$@D,4=Y93'"KR+1MF;)VAMC$K";.I2J5N-M(KG*3
MRBNUOL5W9'8ND/278G17 /:6W<1"AAEDKYRF_O805Y3EV13LLW9)M5=OE(?T
M3AOAC,;M#8WR3O 386P]DQS2PX/?OQQQ>+VYMK'84F1$Q4&X&YVU=D[,V%C%
M&5TXVV]JQW-GB-K'J^S/)70C%3VQB)2GQA2R2_LY)MKNC'O/-72']$ABYSE1
MZ+8&$*5\JF);E)KFJ5.45%]]2:YHUE[R_EX_RHF\&(Q4F$^4-LW=7!8N"7#M
MLO=KP?\ !I,/ LQFS/A<?MO<+;>WL/.L<H1)%Q@= BLI#W<VJEY/^BE))/#.
M<EQE4J^"FE]1S?$>6_RE5Y-PQ\:4&K;L*&'LNYRI2DGV[W#GF9-UOR\_Y4'=
MS$X23&_* V1OA@L)## NRMZ?"#P?;#3I"$53B\?N_N/N_M_$3.B6>1L;Q'N6
M+%CFK*OD_P"BM5-1P[A)\8U*G@Y-?4;POEP\I6'DG/'PJP2MNSH4+/O<:<)/
MOWK^TVA_)K_HG';T>.V=L3Y6W@'LC&;-E>*#&>('@5B\9L['8&,.D8Q.*\.M
M\]J[4P^U':)C).^'V]@PK*>%AR&")5-J>2RFXNIL?$24N$*J33_LXI6[+P?:
M^?3.COZ)&NIQH]*L#!TWDZN&;37:Z524E+FVJL>R.=E9[^3G\J+P&^5EN#A_
M$KP \2-@^(>[#F*':'YMEEPVV]W-H2QF0;(WKW;VA%A=N[L[6"*2(,9AX6D0
M<2//&5<\KVELK:&Q\0\+M&E*G5X7TDN<9+*2[4^_/(])]'^DVP^E.!6T=@XB
MGB,-H[92@_O9P=I0EV22OJKK,?RF%\B;/J4F:./@-?=6S+Y'70W/O]/WTHW<
MZBMBU9G:M"CBL,//G_H@#%8C$?E-_%R*::26+!;E>#^%P:.Y9<-AW\-]W\:T
M,(.B1MB\7+(0-,\C'J37H?R?12Z,4;<9U/\ #9X)\O$I2\I.+4G=1HT$NQ=3
M!V][;]II:JZG'#ZL,-G/Y&C;N[V[OY3;Y)>T-YAACLW$;[[Q["PWSK$R82+^
MF'>CPZWSW9W2*RQ([/B1O7M?!<&(C+--EC8A6)%8Z9TZE3HQBXTK[VXG[(SC
M*7]ZG?D=*\D%?#X?RD[*J8FW5NM.*N[>?.E4A3]N_*-EQ=EQ/2%KS<?0XYK:
MU,/J48?5K5&'U8EEF8)[>[=78._6ZF\^Y&]6SH-K[L;X[O;:W5WDV3BD$F&V
MIL'>'9N)V1MC9V(1@5>#&[/QDD3@@@JQHM&M4H58UZ3M5A)23Y-.Z?L8WQ>%
MH8["U<%BHJ>&K4Y0G%Z2C-.,D^QIM'EJ>,'@%X@>%/BUXH^%TVZV]>TIO#;Q
M%WVW!EVC'N[M1H\?)N=O+M/=Y\:C0862%DQ3;.+@HS*0VA(L:]28/'X?%X2E
MBE*"52G&=KK+>BG^,^96UMA8_9>U<3LQTJLGAL14I7W'GU<Y0OIQM<;K^D#?
MS_O2=[?^S;VQ_P!P5..OH??P]Z(_X#C?VFK^\E^0^_I W\_[TG>W_LV]L?\
M<%6=?0^_A[T9\!QO[35_>2_(7,?Z&8VUO1A/D\?*/\-MX-D;;V3A=V?&/8&^
M6S%VOLW%8!)&WZW+PNQ\>F#;%B.241MX?1-(H0(C2 @DNP'&O*9"D]H8;$P<
M6Y47%V=_1E=?X9Z__0WUL3'8&T=G5X3C&GC(U%O)KXVFHNU_HE?O[7:S!7,N
MT]'$=/E@?[J5\J/_ %.OC9_L:[S5(;'^=\+^$4_\.)7^EO[%-I_UOQ/\#,\L
MNO4Y\QSZL,/JPPO)_P!#-?[HAXL_ZK??O_8<\!:X?Y2_GVE^"1_A*I[7_0W_
M +!\5_76K_%\*6):YV>@#ZMFSZM&C@_ ^GOK:,,1T]U+1AQ6&'U:U,,;+I8#
MO[M*TGF88Z48=#H1;T_[5UK(Y/,PST<6=;4AB;7.I%OA2+>XWHSI6UJ$U1Q1
M1!T8CXTAJ[,M<P$5@EJQUK!)C;J=-/YJ5P,.E:, \JW5@=25/WBEIY&!*PZ^
MGZO*L!RYH#FE&GH8VZ&M<>P2M; 9[7T[ZTN-Q1A<="+7]W[-=!6=II_68OQZ
M5HQ/("R $DCKK]W4_ 4K0U>[[ *PMK\/W 5G$3),PMKTI:$R5T!VMKY_=27J
M(6@'=?2_V5M.YB,##]/E]VGI^//=DT8V!V%_TZ#]?OK,T),+#W4F6>AH"R)8
MZ#U_'3J:6FK6>I@'8:=+VK;5C1B8>G3L/QTK#5C"WGIU/X/?M2UR- 9QK[]?
M0?SD5OO-&(]/U'T\^Y_=6N)A@8 WZ:_C[!6:,RX'8:] #I\/=>U*5C# QM?W
MUHT U8\8"PM>^@&AUT)&FE;N9P#-@"HUL2!?3[O2U8:,!%K:Z]_QT-ZVS+6
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MSZW<^1N>_73[JU=\#1\0 ;,!8WMUNQ/<^=ZW=F'!'\877L/+]%;3, [#4,+
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M'0Z$"QU%A<=>X-9P,08@AK7-Q<Z_?T%JT*R/F6YT%QENPU 9CI[AI]E;1O@
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MF'!"VS',0+'7ZRWZZ=18Z"MW-&1;D]>ES8$!=?+K=/T7K&\S!1[%G(G2^@D
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MZUNXEF%E&N@MI^#;2UZW<TF8& N?P!Z:=@*VC&@,PZ_'R[Z=-;#33\6TGF:
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M=*T8GQ SLN:V4&XN ;\H.AL16(2T!F#:6Z6UMW/0>HT^VE7]PEOW'56R7 (
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M/MI4#3,=+>AHZ-0A43%2C-3@ZUAJ^9@I5L\C1\:4C MQ7\(?<OZ/T4F7XC3
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M6>N/T.4I?I'M&-WNK%P=N%W3S]]E[D69ZX\>C44,/Z(-_P!Z,;R_]!-X6_\
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M88>1_7L$^5A]6&'U88>B=^0I_P!Y6?):_P"DW?\ 41OB]\;6KSET\_99B_\
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MR _WH'V4I:& -A2&@<EF8#2C3T [C4^GZZQ<C<0,:WH)9A>UZPUP,3=*VA+
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MVQ!!T-4S^:%T/_IS_C5?_1G4_P"8KY3'FMFY?A&$_P!.=O\ ;%OY5#_D6_\
MPMOR=/\ N;M9_-"Z'_TY_P :K_Z,W_,4\IO]3/\ ?&$_TY]_MBW\JA_R+?\
MX6WY.G_<W*U_-#Z'_P!.?\:K_P"C,_F*>4W^IG^^,)_IS[_;%OY5#_D6_P#P
MMOR=/^YNUG\T/H?_ $Y_QJO_ *,S^8IY35_TF?[XPG^G.?\ ;%GY5#_D6_\
MPMOR<_\ N;E9_-#Z'_TY_P :K_Z(W_,3\IW]3/\ ?&$_TY]_MBS\JC_R+?\
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M;JHIU1%##^B#?]Z,;R_]!-X6?]LO'5Z:\EO[$X?3U/%'B'R\_P \"I^"T?\
M!9I#KHIQD^K##;+^0V_WJ5\E[_I-?_4._BW5)\HW[#<9_M7\/2.I^17^>9LW
M^V/XI7/0RKRT>]3ZL,.PI2%(CE\K3Y,VX7ROOD_^(G@#XAPJFQ]]MCM'LO;<
M>'3$;1W0WKP#C';K[W[(#M&PQ^P-L0Q3% Z+BH.+AI"89I%:6V)M?$["VI2V
MGA?C*<LUPE%Y2B^R2R['9K-*U?Z4]',#TLV%B-A;07V*M#S96NZ<UG"I'MC*
MSME=7B\FT_-&\;?!S?SY/GBSO]X*^)NR3L7?GPXWCQN[>W\$&,F'>;#%9<)M
M+9V(*H,9L?;6SIH<9@L0 %Q&$Q$<BZ,*];[.Q^&VI@:6T,'+>PU6"E%^*?)I
MW37!IH^=&V=D8[8.U:^Q]I1W,;AZCA)<,M&GQC)6E%\8M/B-93PC#ZL,/JPP
M^K##ZL,/3O\ D"?[HI\BO_4E?)Q_V'MS:\B=)OV1[0_#:_\ "R/I%T$_85L?
M^M6$_@*9+:H0MA]6&'U88?5AA]6&'U*321AY+5>U#Y8GU88?5AA<$_H7G^X3
MY8G_ #V^#/\ VQ_$2N'>5_Y1@?4J^,#UC^AK^1;7^EP_^#5+55<=6AZ=/JPT
M1X^5QX4R^.?R7/E#>#^%PRXK:7B-X->(NZFPXF%\N\>U=U=IP;M8A18@R83;
MYPTJ:'F05*;$QBV=MC"XYNT*5>$GZJDM[ZKD!TJV6]M=&<?LF*O4Q&#JPCZ\
MH2W'[)6?L/+:961BK JRDJRL"&5@;$$&Q!!%>OSYI:9/4ZUAH^K##TW?R=GC
MGA/E'?(C^37XLQ8LXS:6V/"[=_86]4LCYY?Z>-QH6W'WW,@+R2HLV]6[V+EB
MSDNT$B,;Y@3Y.Z3[/>R]OXO!-6A&M)Q]2?GP_O9*_:?1WH!MJ/2'H;L[:B=Z
MD\-&,_I*?V.I_?PDUV-$TJ@2X+)G:M!#CN*PTUF<UAL^K:9AS2KFCZMF'U88
M(7Q1W%V?XH^&?B+X9[6(&RO$3<7>[<7:9;-E&S][MW]H; QI;)9\HPVT&O;6
MG&$Q$L)BZ6+AZ=*I&:[XM-> RVE@:>T]G8C9M7XK$4)TGW5(N+^IGE0[Q[O[
M6W3WAV]NKM["O@=N;M;9VIN_MG R?PF#VML;'3[.VCA7Z<^'QF&=#ZK7L&E5
MA6I1K4W>G.*DGS35U]1\PL10JX7$3PM=;M>G.49+E*+::]C02TL"?5AA?$_H
M<;QRP7B+\A/:'A'-C86W@^3YXG;S[!;9O'$F*BW/\0L5/XA;N[5EB]J'#;0W
MBVOM["Q Z$[/>WD."^4C 2PVWEC$OL>(I1=_W4/,:]B47[3W#^AZVW#:'0B6
MR6UU^ Q,XVOGU=5NK"7<YRJI>JRP%7/3O!]6&'U;,/J5:VAAK;^7M^5+^3M^
M3LVKX9[$\:=W/%C>S:OBEL_>C:NQ<#X5;!W/VW-LG9^ZV)V'A)L5O#_3=OYN
M,F%CVMB=M%,'\V.++G"8CB"++'Q+-L'HMM'I%"K/!2HPA2<4W4<E=ROINPEI
M;.]M5:^=N=]./*;T?\GU7#4=LT\55JXJ,Y15"-.6ZH.*O/K*M.V\Y>;;>ONR
MO;*^OO\ ZN;/D&_]<E^5S_V8?@W_ -S[J?\ YF.WOV[!_OJG^B*)_JDN@W]*
M;6_N6'_Y*/O^KFSY!O\ UR7Y7/\ V8?@W_W/RL_F8[>_;L'^^J?Z(S_5(]!O
MZ4VM_<L/_P E$N/D4_EG?DQ_+P\:/ZAG@]X=_*!V%O6NZ6WM])]J^(>Z_AQL
M?=K"[&W?EV=A\7Q\7NYXK[V;5.*GQ6UH(X43!.K,_,RJ"1$;;Z&;3V#@OA^,
MJ8>5+?4;0E-RN[\Z<5P?$M?0WRQ=&NG&V/TDV1A\?#%=5*HY5848P48V3NX5
MYRO>22M%^PVV8@>S;7K^JJ36X'5),\O7Y?W^[X?+8_U6_P I#_9CWSKU3T<_
M8]@/P.A_!Q/FCT[_ &<;9_KKB_XQ4(CU,%4/JPPO+_T,Q_NA_BS_ *KC?S_8
M;\!*X)Y4_P!D%'\#A_"53VI^AR_81BG_ +*U?XOA2Q1Y5S4] '-+U-:'%^WK
M]WZAI6["M=3ZX^S]M98U8\D"O8)\JSZL,/JPP]$W\A3_ +RL^2U_TF[_ *B,
M\7:\Y]//V5XO_:OX&F?0#R)?SL-F?VS_ !NN;<*IYUA:'U8;/JPP^K#"'7Y0
MO<.;Q,^0M\K?<O"POB=H;3^3]XHXO9.&C2>23%;;V#NGM+>'8>%C3#2PS,^)
MVOLJ&,6+"[:I(+HTWT<Q"PNW<)6;\U8B%^YR2?U-_GF5#I_@9;2Z$[5P<%>I
M+ 5G%9YRC!SBLN<HI?B>C\P>O4)\U3ZL,/JPPNT?T-%\H+9V]WR9O%?Y.FT-
MH1G>GP=\1I=\MC8"201RR>'WB7@L.\1P<+C-B5V9OKL+:CXJ1"1%^<<.KJI=
M#)Q/RE[/E1VG2VE%?8JU+=;_ '<'^.+C;N?L]F?H<MO4\7T;Q71^I)?"<)B.
MLBO]:K):<[5(SWFM-^-[75[*]<TL>C#ZLM8P^K:>1A]6C#ZL,.*T848/Z)<V
MWL7:?R[O#?9NSWAGVINY\F'<C9NWYHIY'?#8K&>)'BWMO [*Q&&91%#-A]F;
M4BQ0=23)'C5!ME%=T\F<)QV#5E+T)8J37[RFF_>K>P\3?HC:U&ITXP].G9U:
M>S*:EGHW6KR46NR,E+M4NPKP5T0X ?5AA-+\G%L+';Q?+^^1=L_9Z9\1A_E/
M>"6W9!ED>V!W7\0M@;S;3>T:NPX>S=D3->V5;78A02(7I)4C3Z/XV4M'A:J]
MLH.*^MEQ\GE">(Z=['IT_26TL/+V0JQG+ZHL].S[O6O,=SZ3D<_E@$_[29\J
M,:6_VG7QL_V--Y_TU)['L]K87\(I?X<2O=+?V*[3_K?B?X&9Y9M>HSYD'U88
M?5AA>5_H9G_=$/%G_5;[^?[#G@+7$/*5\^TOP2/\)5/;/Z&[]@^*_KM5_B^%
M+$MJYZ>@6KG6U)L)L?5HT?5AA]6&&(^?G?3XTM&SK6S1R/*L%)Y6.#26:.*2
M:.EN9=!;7RZV[]J6C:R9V\Z)$-P.E8#/JPPZ/TI4=3&KHQ4H2=3WI+U-:F C
M4UAC1UK1HQO\/7SK##$PMKI67" +$?5T\_U4I-L&]0&1Z5IY"&C"UOLZUB,M
M:.9A(K'J# []?Q_/2UH*0'(/;]'GW\^]:8G4PG\?C2L,,$BB_P ;Z#J?(_=2
MM581F@,=+^E)0K4#MUHBT$2O[#H:QB683\*PPP/J?QT\JVC0'8#MT_'GWK9C
M5@,R_#]/OK9K4P,.MO>?3R^XULT]3"1Z7\_M\O/4UFN3U-&$B_6W7\:5K0PP
MY=3;RZ:W]/C6G;4QF)^MK#TM6&KF(C\?=8^E;1L"2_6U\NFES6<1-SC#@YG/
M86%NQ[Z^=*5M#1]*+D^6OGI_.*Q&UF!6%M+Z:G].OK]M*[31T;J1I\.WI2;F
MC&PT]WX-;1EC%WUUZ?CUI7<),;'MYBYK#%S,9_'I6&S#(NM]+>@\_P!E:T$O
M(P,MM/QTOZ#M67XFKW,)'XO]_P :V)L8)/+X_N]U:$@4^_0:>6GNT.EJS4V8
M' 8&W7O?3[?6M:.W PQL"!U%["]^E[F_VVK+B;(QL;6T%S8=;=?T5AECYM+:
MFP&MKZ6U]:Q,SQ SBYN->OOTZ'7744JZMGJ:9C"DWT\K>^_:M;PFV=SXW"]?
MQZ?;2#'D=+];>\>8I-LC3=^XYTZ]3UOVN?V$UI7X"68'U!)Z_C[C6Q.H&8?J
MOU-8:,9U';U]]888F%Q:QOTOII^K45B$I ,_CXUC;1LQL.I\^HZ=/+0]!6)F
MF?&]M/2VATN/M[UG$S4X8'RN?,:CO<CRK,N)CL!FMJ#IIIIH/3SUM6GJ:,1&
MA%QK>W6X/8]KG2M7,.N6VF@OS#S\^^MQ>M/,T=+6]-.I%_QUK5S9B?M;3]O2
MQ_FK+F&,C6U@?*YOT_5\*QFCLNEQ8>@OJ=;$_;Z5HT<B]P1[SWOZ?9Z5IF'8
M];F]]-+#W7]!6&C$RW/7H!J.A([>E)N);MW&$_KO6&-9&*VNOV]_YQ:L,3R.
MUM01Z?9Y=;UAC^LX<$ 6'737R_;<5G$WP,#K?T/2_6WPK5S3[#$18CKT/IIZ
M^9K:?O$9HY4G4W-^Y[_??O6/M-\#(E^FE^I(/ZO+W=Z0\^X3KF"HR<H[:6/K
MTO27KV&'8^?V>^D\3#BY)^%K#IWUMH#6&DP3$;@<HO8>@%[B^@%B+5CT-O2X
M*7KYCI?X:>NE(-')L ;&V;*#:YZ7OZVU%:U-KF81J6Z, =-=?0:CI6]-##K:
MZG2W;SZ=[^M8WEF8\P1 ;$$W(%OO/2W>M+,Q:BG3FPY!['0Z:CK?TH?W0O@%
MD@LWN-[>?;TI8EA?C$#)*?[U&'E?,5'E?K6GF)D)N2(ZN ,ZDJ=3J+C4=@;5
MM/@(,,2V(  9B'TO:UCH&&H! K&89@X<6*C3E'?KH;$=_P!%9X&M#*C75 U@
M5Z?'I;R]?6E*QL'X49SPV<$.'4KZGJ6['KY:=:TV8#,&JQR9 ;#/J6T.GNTU
MI+=U<V.OL4?UBI)Y2+*-;7OKUN;$4&?I=H2 986W&('=PVI\AIEO8 &D/0Q/
M-A]AWRRH=-1;3]9K%]9IZBB#$CU_=VI/ (\SL#8UM9O,TF"HR/M_%ZQY";F9
M>OZ+UN^789KD9>MM:Q&F^9D YM==>_X\J49?(R ] "/73[AII6^W@*6G:9=+
M]+Z>[XUBN:>6IV6W>W?WWT^/2MW-6,G3KT[6\Z4FO:(T,@Z ^GQ^W4UES9P1
M<CK;3MT_;^JMF/L.1]NMO7XGT%9F:.-3:QZ]3W/K6[M&'#: ?'UZ^^MJ7,PX
M(T]XTM]_WUNYHX&4@WZ:6M2K\C3',\*%MO'C3I_:7$Z_^5VS?ATH^&=Y]MOQ
MHGNCORV7T3_PHG__U+K.\Y_S1;;U_P""6*_E&_;7)-L?.=?Z67B4/&_+JOKO
MQ"(G4=.I_=48[>T;/3([7I(AM:&? #-CL&NEFQ>'6WOF06U]]%PR3Q%-<YQ\
M491SK1]9>*)9UVLZ0?5AA]6&'U88?5AA]6&'U88?5AA]6&'U88)W>ULF[6VC
MYX&5?^Q[)_YM47MIVV3B'_K;&.TW; 5?49&"N07.>G(I-Q2/KUAC9Q6"3ZE(
MP^K&8=K5D1;7 XK;R$'(ZUJ]V*B<UL4?+U'OK8BYFI,M31]6^!A]6+0PZMVK
M!43X4H*?5AAD7I6F)>IV%8C$<UL4<BL-K4[5BU%G0F]%%)6,R]/?J??YULV<
MTE9NYA]2C#FEK0PH8?ET_P#>D?B]_P ZOA+_ +&F[5>OO))^P?#?25OX61XG
M\L_\\#%?14/X*!J"KI1RH^K##:K^1*_WIW\F7_I,W_4/OBO7/_*G^P/'_P"T
M_P 8I'3?([_/'V=_;'\5K'H!CI7CX]Q75SFL-G:E<!9R.M;T-K4"[5VMLK8.
MS,;MG;FT]G[%V/LW#28O:.U=K8W#;.V;L_"Q#-+BL;CL9+#A<+AXEU9Y&55'
M4UNE3J5JJITHN523LDE=M\DEFP=:K2H4Y5JTHPI15W*3227-MY)=YH8_*"?E
MSO!#P-W:WA\//DK;P;%\:O'#&08O9>'WOV-PMK^%/AUB&$D$FV<3MWFV;OYM
MK"$A\'@MG'$[.:09L5B0(_FV(ZYT/\E.U-JUX8S;\)8792:>Y+*K4_<J.M.+
MXRE:7WL<]Z/$^G/EGV-L7#5,!T9J0QFV6FE./G4:7#><M*LE]S&%X7]*66[*
ME=O'O%MW>_>#;F]>]&UL?M[>7>;:^T=O[P;<VIB),7M+;&VMKXR;'[3VGM#%
M2EI<1C,=C<0\LCL26=B:].T:-+#488>A%0H4XJ,8I62BE9)+@DLD>0<1B*^+
MKSQ6)E*>(J3<I2D[N4I.[;?%MN[82T0"?5AA+#Y"W@UC?E ?+!^3KX383"RX
MO#;S>*FZT^\"0QO+)#N=NYCEWIWWQ@5$?_..Z.Q<;-=K("G,56Y$!TJVE'9'
M1W&;0DTG##RW?7DMV"]LY11:.A>R)[=Z5X#9<5>-3$P<OHX/?J/V0C)GI<5X
MJ/H814^7A_NCGRR_]2C\HC_8AWPJ>Z*_LHV;^'X?^&@5SIK^PO:_]:\5_ 3/
M-"KVL?.X^K##ZL,/3'^09_NC?R,O]2A\G;_8AW/KQ9TJ_9/M+\/Q'\+,^B?0
M?]ANR/ZUX7^ IDC-\=T]A;_;H;U;B[TX)-I[L;Z;M[<W3WCV;(;1[0V#O'LS
M%;'VO@G.I"8O9^,DC/HU0V&Q%7"8BGBJ#W:].<9Q?*46FG[&BPXO"T,=A:N"
MQ,=[#5J<H37.,TXR7M3:/,<^4KX';R?)J\>_%CP(WK64[8\,M]-K[MC%S0_-
MSMC9$4HQ6[>\4,-R8\)O-NYBL)M" ?\ "<2M>V=B[3H[:V5A]J4/BZ])2MR>
MDH]\9)Q?:CYR](MBXCH[MS%;$Q5^MPU:4+Z;T=83[IP<9+L:&/J3(4^K#"SK
M_0^?R_-C>'F\.V/D4^*NW</LO=_Q"V]+O1X';9VI.(,%@M_L=AX</O!X?38W
M$2\'#)OE#@H<3LF(\*-MJQ8B%3)B=H0H>+^5?HK4Q=*/23 Q<JM*&[62U<%Z
M-2W'<NU)Y^:T\HQ;/2'D'Z<T<!B)]#MIS4:&(GOX:4G9*JU:5*[R7663@LEO
MJ2SE-)W":\_'K(R+TK>B$/4[BL3-H[4K44LF4YOZ(1^7SL;Q*WJV)\B[PKVZ
MFTMW/#+;W],WC;M;9F)$NS]I>(F%P\N$V#N)'B(&R8I-QL-B\1/M),TD0VIB
M(H6"8C9[@>@?)3T6J8.A+I%CHVK5H[M%-9JF\Y3[-^R4>.ZF])(\F>7GIS1V
MCBH=#]F3WL/AI[^(E%Y.JE:-*ZUZM-N>JWVEE*#*R-=E/.!]6&#Y?)H\#-Y/
ME+^/OA-X#[IK,-L>)V^NR-VSC(8?G!V-L>64XK>7>.:&Z\3";L[MX7%[0G%_
MX'#-4;MC:5'8^RZ^TZ_Q=&FY6YO2,>^4FHKM9-='-BXCI'MW"[#PM^NQ-:,+
MZ[L=9S[H04I/L3/3UW-W2V#N#NANIN)NK@4V9NQN5NWL/=+=S9L9O'L_8.[F
MR\+L?8^!0Z73";/P<<8]%KQQB*]7%5YXFN[UJDW*3YRDVV_>SZ183"T,#A*6
M"PL=W#4:<807*,$HQ7L22%*!0DKCE(H8?T0;_O1C>7_H)O"W_MEXZO3/DM_8
MI#Z>IXH\0>7G^>#4_!:/^"S2%713C)]6&&V;\AK_ +U*^2]_TFO_ *AV\6ZI
M'E&_89C/]I_AZ1U+R+?SS-F_VQ_%:YZ&->6CWJ<TI&_$Y%*-J[9S6(45G_Z(
M2^0&/$OPYPGRU/#+8G%WZ\)]EP['\9L%L^%>/O'X6QRG\W;WRQ1VDQ.T?#W&
M8@KB7"L[;'Q#R2,L.ST Z[Y+^DOP/%/H_BY?:U=WI-_<U.,>Z:T_=*RSD><_
M+UT%_3+9ZZ8[-A]O86.[B$EG.CPJ=KI-YO7JVV\J:*8M=[/(!]6&'U88?5AA
M]6&'IX?($_W1/Y%?^I+^3C_L/;FUY$Z2_LCVA^&U_P"%D?2/H*[="=C_ -:L
M)_ 4R6M0A:D[GU8;/JPP^K##X:D#SK##L1;X?B_I>L,/)8KVL?+$^K##ZL,+
M@G]"\_W"?+$_Y[?!G_MC^(E</\KWRG ^I5\8'K']#7\BVO\ 2X?_  :I:JKC
MAZ</JPP^K##S<?RLOR9<7\E?Y=OC?N3#L^3!;G;Y[PXCQ<\.).%PL'/N9XCX
MO%[<CP6S;0P*V"W7W@?:&Q18&S;--V;VF]5="]K1VQT=P^(;O7IQZN?/>@DK
MOME'=E_9'ST\J71R71CIMC<&HVPE:HZ]+DZ=5N5EV0EO4_[#VO6_5I.>GU88
M68_Z'K_*"[#\'-]]O?(X\7-X8=C[D>+NWX=X?!W;6U<0(=F[#\5<5!AMF;3W
M0Q&+Q#B' X3Q"P.#POS$%DB7:V$$2JTVT+CE/E,Z-5,=AX[<P4=[$4([M5+5
MT]5+M<&W?]R[Z1/1GD%Z>4=D8V?1+:M10P6+GOT)2>4:[23IMO154ENZ+?C;
M6H72ZX,>P3D5AM.QVK0L^K? PJ:_E2_RY7C9X%_*FV[X(_)%V]N!/NMX7[+P
MV[OB#M_;6[.!WO3:GB>,1B<1O%LO96+DQ4<6'PFZ4$F'V=B56[#:<.+1OX-;
M]FZ(>3[ ;0V1':&VXU.NK/>@E)QM3^Y;[99R7[EQYGEKRF^6K;.Q.DT]C=%*
ME!X7#14*LI053>K7;G&+ODH*T'^[4EP-;_\ U<-?E'_^]F\)/^T5[*_[CJM/
M\S/HM]Y6_NC_ "'//YOGE"_;,)_<(_E/O^KAK\I!_P![-X2?]HJV5_W'5O\
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MX<2O=+?V*;3_ *WXC^!F>6=7J,^9!]6&'U887E?Z&9_W1#Q9_P!5OOY_L.>
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M=?\ 'Z*U<V=SUUMT!%AI_-6KB7<Z-KT':Y[7]_45EQ+T [>T>G\_\]9VFT<
M"]].GIWZ>ZL,X]A]ITZ=>@Z?@UAL^[=;WU(\B/*]:=C .XZVTZ6T^[XUK@)9
MA=?/3U[C3I6<1/@<"P Y;F]^X-[#0GI8"L-7.\=@-1:[:6/GIT\@16F;!RA2
M.O0'7T!I!HZW&4$B]R;'OZ#[*S)=YIG2X!M\1TN+Z6]PK'?4UX N"P UOW/O
M[@#M>D2U%9VSU!I72X&OEY#OZ&]Z2F889".F7J/O_9K669E[,Q*=;GI^_K\*
MV;N=;BY OUTZ^\? 4DQZ&> YF!OUM:W:W:L0E"GPI'#.EP5)\A>US<=;BAO4
M6M#!*O-V[].@]]M=*VF:DK ":-7(!T!1TOU&HT/K<BLN(;R$Y)%<Y3J ;:="
M;=_6E9K)"0.T0S J"IU RVRZ#RZ"]JQ-V-G*Q@7#$WZW[7 U()T%9?W"3LJ#
ME/76P&HU/F>XMTI5S 9AKI,IL.M[@WRY>FG:Y'P-)EH;#14(Q;J+6+9A<:<P
MS7/GTK7 VF.CLQ<N AS,=1[A<GL/=0):A8Z!I@P&DF-@0B9[]#R]!YBDZ+,3
MI<'8,YI <Q Y;@ZZL;Z? BMFA6Q$V7KTUK5PB?FWXF;UK+W,L9X^][#ROT]W
MEI6^ FV>8)%:^Y,\#(.@]U8N8EZG?I[P=/QTK?;P,,B7/4]_(?STJYO0SZ G
M3XGR_367N8N9W6Q%K"W;\=>E8\C:T.U;3$6,@)';0 _?K\*WKWF'*^_7KKUM
M6._ P[#OTZ]OU^M;,/OY_??]];NM31UL+C2U[^^E&'3R-NGIWMW\ZW8T? :^
M??2LN^)CT'.\*==X\<;Z'8N(T_\ *W9M.<-Z?]C^-$]T=^6S^B?^%$__U;JV
M]!_S1[;T_P""6*_E6KDFUW^N>(^EEXE"QWRVK](_$(;U%#:YWOI\/U5H'(&[
M,%]I;/'GCL(/_!\6GQH^$^54OI(^*%T/CX>O'Q1+"NU'1SZL,/JPP^K##ZL,
M/JPP^K##ZL,/JPP^K#!,[Y&V[&V/\% ^V6(?KJ(V\[;'K^I^-##:GS?5]7\9
M&2N0G/CFM<1:T.*Q"3ZL>1A]2D[&CZM&'-+6ANYQ6F:.16EJ;1S2S&SE?:'V
MUAHRT,P^OI<4KLXFUJ<9AI6=QECIWZ_96T+1V[4H7P/A6&(RCH*2Q+U.PK:,
M1S6Q1R*PVM3D]#61U%HZ446903;]'NK5Q+9W%:CJ*/J68<TN.AHH8?ET_P#>
MD?B]_P ZOA+_ +&F[5>OO))^P?#?25OX61XH\M'\\#%?14/X*!J"KI1RH^K#
M!0;K;V;U;C;=P.].Y6\N\&Y^\^R_G7YLWCW6VSM'=_;NSOGN#Q&SL9\QVOLG
M$X3:&$^=[/Q<L$O#D7B0RNC75B"'$8?#XNB\/BJ<*M"5KQG%2B[.ZNFFG9I-
M=JN'PV*Q."KQQ.#J3I8B-[3A)QDKIIVE%IJZ;3L\TVM!X/\ :L?E3_\ )+?*
M _[3)XB_^+'4;^IWH_\ TC@_[C3_ ,TEOU3])?ZHX[^[U?\ //O]JR^5/_R2
M_P H#_M,OB+_ .+'6?J=Z/\ ](X/^XT_\TS]4_27^J.._N]7_/.?]JR^51_R
M2_R@/^TR^(W_ (L=9^I[8'](X/\ N-/_ #3/U4=)OZHX[_=%7_//O]JR^51_
MR2_R@/\ M,OB-_XL=9^I[8'](X/^XT_\TS]5'2;^J.._W15_SQO-\_%;Q1\1
MVB;Q#\2=_M_&@?B0MOGOCO#O0T,G#2+/$=N;1QQC?A1JMQ8Y5 Z 6>X79^ P
M7R*A1HW^\A&'^"D,,7M/:6T+?#\17KVTZRI*?^$V(&G8Q/JPP^K##ZL,+;']
M#S?(>VKNYL_>3Y;?B'LDX.3>O9&T=P? _ ;0PJC$ON])CL/_ $Y>(<"RJSX:
M/:N+V<-D;.E7)*^'CQY(,$\3OY^\K_2BG6J0Z,8.5U3DJE=K3>MYE/V)[\EI
M=PXII>H_(/T-JX>G4Z8X^-G5@Z6'36>[==957+>:W(/)M*?W,DW:0KAAZ1(J
M?+P_W1SY9?\ J4?E$?[$.^%3W17]E&S?P_#_ ,- KG37]A>U_P"M>*_@)GFA
M5[6/G<?5AA]6&'IC_(,_W1OY&7^I0^3M_L0[GUXLZ5?LGVE^'XC^%F?1/H/^
MPS9'];,+_ 0)85 %I*SO]$#_ "!,5XB[FX#Y:OA=L4XG>SPSV+'L'QNV5LW"
M9\5MOPXPDCR;'W\X6%BXN(QFX4N(DAVC*X=CL:5)6>.#9I#=L\D_2N.#Q+Z-
MXZ5J%>6]1;>4:CUAGPJ:Q67GIJS<\O.OETZ#3VA@X],-FPOBL-#=Q$4LY4EZ
M-3+5TKM3;O\ 8VG=1IYTZJ]#'DT^K##+#-+AY8IX)9()X)$FAFA=HY898V#Q
MRQ2(5>.2-U!5@001<5C2:L\TS:;BU*+M)%G+Y!?]$);<\.MW=B>%ORTMW=Y/
M$;9&QL/A=E;$\;-SEP>-W]BV?AT7#X6+Q!W>VGC-G8;>^7#IEXFU\-BH-HO%
M'FFPV.Q+O,W%^E'DGI8NM+'=')PHU)-MT9W4+\>KDD]SU&G&[R<8I)>D.@_E
MYK;/P\-F=,*=3$4H)1CB*=G5LLEUL&TJEN,U)3LLXSDVW8!\/ORKGY.WQ)P.
M%QNPOE9>%&QQB3$GS7Q VKB_"_&X>:4Y3'BL-XBX'=AXA$]P\NL(MF#E2&/*
M<9T&Z78.3A5P%>5N--*HGW.FY>[7L.Y8'RG] =HQ4Z&U,+"_"K)T6N]55#WZ
M=MCOX@?E7?R=GAK@<3C=N_*R\*-L##&5/FOA]M7%^*&-Q$L1RB/"X;PZP.]#
MRK*Y 272$@YBX4%AO"=!>EV,DHTL!7C?]L2IKV]8X^[45CO*?T!V=3<Z^U,+
M.W"E)UF^Y4E/WZ=I7W^7M_1">\OB1L';?A;\BW8.\/AIL+:^'Q.S-M>->]B8
M/"^(6)P,YFPV+@W!V!@<3M'";F_.L,!P]K3XB?:B)*3!#@,3&DXZOT6\E%'!
MU(XWI%.%:K%W5&-^KOPWY.SG;[U)1RS<DVCA/3CR\XC:%">S.A].IAJ$TU+$
M3LJK3R?513:IW7W;;G9^:H22D5D9II<1++//+)///(\TTTSM)+-+(Q>2661R
MSR22.Q+,222;FNS))*RR2/.+;DW*3O)F*L-'U887'_Z'Q^0#B_#G<W:'RU_%
M+8IPN]OB;L638/@ALK:6$R8O8?AQBY4DVSOYPL5%Q</C-_I</%#LZ5 C#8T3
MRJ\D&T@%X!Y5.E$<9B5T<P4KT*,MZLT\G46D,N$-9+[]I9.&?K?R#]!9;/P<
MNF.TX6Q6)ANX:+6<:3]*KGHZMDH-6^QIN[C4RLV5Q\]&G84I"D4+_P"B#?\
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M'R?^63;_ $)IQV;B(K&[!3RI3DXSIWUZJI:6ZN.Y*,HW]'<;;=E/PQ_HB/\
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M[0VUB*N)QC5MZI)R:7WL5I&*X1BE%<$-33HBCZL,.RJSL%4%F8A5502S,38
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MI)??U81^IRNWV+,F<%T<Z0[1:6 P.,K7^\HU)+6V;46DNUY9/D;)_ [\@_\
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MV**25EDC)2X_6;/JV:(J?+P_W1SY9?\ J4?E$?[$.^%3W17]E&S?P_#_ ,-
MKG37]A>U_P"M>*_@)GFA5[6/G<?5AA]6&'IC_(,_W1OY&7^I0^3M_L0[GUXL
MZ5?LGVE^'XC^%F?1/H/^PS9'];,+_ 0)85 Q+2=A2F;B!L;@L%M+!8O9VT<)
MA=H;/VAA9\%C\!C8(L5@L;@L5$\&*PF+PLZ208G"XF"1DDC=61T8@@@D5N,I
M0DIP;4T[IK)IK1I\S)PA4@Z=1*5.2:::NFGDTT\FFM45J/E[_P!#Z;F>)&.V
MOXG?(LVGL+PNWJQDF)VAM;P6WB?$87PUVOB96DQ,TFX^V,-#C,5N'BI9"5CV
M;)#/L@ET6)MG0QD-VGHKY6,3@X1P722,J]!62K1^,7KIV4U^ZNI\]]O+SMTX
M\A.#VC.>TNA\H8;%.[EAY75&3U^QR5W2?*#3IYJW5I9U7_'CY+_R@ODQ[R2[
MJ^//A)OIX:;37$/AL)B=O[(F&[^VFCXEYMVMZ\'\ZW8WGPAX+VFV?B\3%=&&
M:ZL!W'9>V]D[:H]?LO$4ZT+7:B_.7K1=I1?9))GF?;?1K;W1O$/"[<PM;#U+
MV3E'S9>I-7A-=L9-##5*$&?5AA]6&'U88/SX#_)?^4%\IS>2+=7P&\)-]?$O
M:;8A,-B\3L#9$QW?V(TG#RS;R[UXSYKNQNQA!QDO-M#%X:*[J,UV4&,VGMK9
M6QJ/7[3KTZ,+9*3\Y^K%7E)]D4V3FP^C6WNDF(6%V'A:V)J7LW&/FQ]>;M""
M[922+5'R!/Z'PW+\-\=LCQ0^6KM387BEO5@Y,-M#9/@INZ^(Q7AILC$Q-'B8
M9-^=L8F'!XK?W$Q2 +)LV."#8X*.LK;1AD 7B72CRJXC&1E@NCJE0H/)UI95
M&OW"SW%^ZNY<MQK/TYT&\@V#V=.&TNF,H8G%*SCAX7=&+U^R2=G5?."2IY-/
MK$\K+^"P6"V9@L)LW9N$PNS]G;/PN'P6 P&"P\6$P6"P6$B2#"X3"86!(X,-
MA<-!&J1QHJHB*    *X]*4IR<YMN;=VWFVWJV^9Z+A"%."ITTHTXI))*R262
M22R22T0*K(FSFE&'85@J.A0N_H@W_>C&\O\ T$WA;_VR\=7IGR6?L3A]/4\4
M>(/+S_/!J?@M'_!9I#KHQQ@^K##;-^0U_P!ZE?)>_P"DV?\ 4.WBW5(\HW[#
M,9_M/\/2.I>1;^>7LW^V/XK7/0QKRV>]3ZEK0PYK##D5H6CFE1,.:484S?Z(
M5^0"OAMX@8+Y;7ACL98=R/%;:N&V#XT[.V?!E@W>\4I()?S7OF88 $PVS?$+
M 8,QXQ\BHNV\.TLLCS;211WGR7])OA>&?1[&2^V*,=ZDW]U3XP[X-Y?N'9*T
M#R'Y>N@OZ78]=,MFPM@L5)1Q"6D:UO-J6X*JE:3_ &Q7;;J(K+5UP\XGU88?
M5AAZ=_R!?]T3^17_ *DOY./^P[N;7D7I+^R/:'X;7_A9'TAZ#?L)V/\ UKPG
M\!3);5!EM/JPP^K##ZL,,ZZ*/=^FL,/K=#Y5HP\E.O:Y\L3ZL,/JPPN!?T+T
MUMQ/EAZ7OO;X-?\ ;'\1*XAY75?$X'U*OC ]8_H:_D6UOI</_@U2U4&!KCK5
MCTX=J28?5LP^I:T,,<T,.(AEP^(BCG@GC>&>"9%EAFAE4I)%+&X9)(Y$8AE(
M((-C6UEFLFC32DG&23BUF5L/RA']#Y>'7C1M#;WBQ\CG:>P?!OQ%VA)B-J;8
M\)]LIB,/X2;TX^61I\3-NWBL!!C,;X;[2Q1=R,/%A\3L>23(B0X!,\QZIT9\
MI>*P$8X+;BE7PJR51?&17[J]E-=MU+MEDCSQT\\@^S]L5)[4Z)2IX3:$KN5"
M5U0F]7N-)NDWR2=-NR2@KLJ8_*%^2/\ *3^2IO"^[GC_ .#N^GAOB3BIL)@-
MK;6V6V)W2V[+!_"-NUOILML=NGO)&JZEL#C)\H/-8Z5V;9FVME;8I=;LVO3J
MJUVD_.7K1=I1]J1Y:V]T5Z1=&*_P?;N$K8>5[*4E>$O4J1O"?]C)D<JE"OGU
M88?5AA]6&#H^$?@EXO>/>]N$W$\%_#;?+Q.WMQA3)L3<W8./VWB</"Y(.-VE
M)A(7PVR-F1!2TN*Q3PX:)%+.ZJ"0TQNT,%LV@\1CZM.C07&32]BOJ^Q7;)/9
M6QMK;<Q2P.Q\/6Q.*?W-.+DUVNV45SE)I+BRT_\ D]OZ';CV-C]@>+'R\<=L
M[:F(PCP;4V9\G/=;:2X[9:XE.')AT\5-\MG2_-MJ)AY<QDV1L:23"2E8S+M"
M:%IL(W(>DOE-ZR,L'T=32>3KR5G_ +7%Z>M+/6T4[27IOH%Y 51J4]J=.)1E
M)6<<)!WC?AUU192MQITVXO*]1J\':RV5LG9>P=F;/V)L/9NS]C;&V1@L-LW9
M6R-E8/#;.V9LS9V"A3#X/ ;/P&#BAPN"P6$P\:I%%&BI&BA5   ''ISG4FZE
M1N523NVW=MO5MO5GI^E2I4*<:-&,84812C&*222R22622622R084D6?5AAR*
M5VFT9$]M/],/TUM>DA:U1H&_*-?D%O![Y56T=N^+OR=-I;%\!O'7:DV(VGMO
M94V!F'A)XC;4Q#&3$8S;FS=DP38[<K>#&3,9)MI[,P^)AQ#YFGP,LTK8E>G]
M&^GV,V3&.#VDI8C +)._V2"[&\I+]S)JW"22L^%^4+R&[(Z3U)[6Z/2A@=MR
M;E*-OL%63U<E%-TY/5S@FF[[T')N2I[_ "H?D+_*I^1SMV79'C]X/;T;H;-;
M&-@]E;\8?"-MSPXWB<DF'\Q;][(^=[N8S$S0@2'"//'CX4=>-!$QRCL>RMO;
M)VS3W]GUH3E;..DUWP>?MM9\&SR5TEZ$])^B-=TMO82K1IWM&HEO49^K5C>#
M=L]VZDONHIY$2:ERJ'U88?5AA]6&#S^"/R=O'/Y26]<>Y/@1X5;Z^*6\C&'Y
MQ@]TMB8K:&%V3#.Y2+&[P;8RQ[&W:V87%CBMH8C#893H7%,\=M' [-I=?CZL
M*5/G)VOV):M]B39,;%Z/[;Z18I8+8>%K8K$\5"+:C?C*7HP7[J32[2VW^3C_
M *'FW5\,-H;O^,7RY)=W_$C?/ O@]K;#\!=D3+M?PWW?QJ9,3 WB-M1XHX?$
M#:."FRB39D"_F+B1NDLFT\/( .1])/*'5Q498/86]2HNZ=5Y3:_<+[A/[Y^=
MRW6CU9Y/?(#A=FSI[7Z:NGB,9&THX:/G48/5==+^BM<8+[%=--U8O*T/!%#A
MX8L/AXHX(((TAA@A18HH8HE"1Q11(%2.*-% 50  !85RQW;N]3THHJ*48I**
M61DT%8*U,<WL?$4.I;=N(EH>7=\O_P#W?#Y;'^JX^4A_LR;YUZGZ._L?P'X'
M1_@XGS3Z=_LWVS_77%_QBH1'J8*H?5AA>8_H9?\ W0_Q:_U7&_G^PWX"5P/R
MI_L@H_@</X6J>UOT.'[!\5_76K_%\*6**YQ%G?F<ULR^>1P=>WX_GK:R-W,=
MK=+_ !'V^8I1L\D.O7Y\J3ZL,/JPP]$[\A1_O*SY+7_2;O\ J(WQ=KSET\_9
M9B_]J_@:9] _(C_.OV9_;/\ &ZYMOJH'5CZL,/JPPYK##ZL>N1A]6<.TPZ21
MQS1O%*B2Q2HT<D<BJ\<D;J5='1@5='4D$$6(K$[9K4TTFK/-,KX_+K_H?;Y/
M/RB<;MGQ$^3?M/ _)L\4L?Q\9B]W<#LGYUX+[S[1<M)FGW7V>(<9N%B,5(0K
MS['#X*-06_-LDC,YZ)L'RA[1V;&.&VDGB<(LKM_9(KUGE/NEG^Z2."=-_(+L
M#I!.>T.CLH[.VG*[<%&^'F^V"SI-\Z=XK]K;S*L?RF?R57RZ?DIXK'R^(G@7
MO+O#NC@IIEC\2/"[#8GQ%W$Q.%B9E7:.(VCN_A9MJ;M8.?+]&-M8/9DYN+Q@
MD ]6V7TLV#M9)8:O&-9_<3\R?=9Y2_L7)=IYBZ2>2_IOT7E)[0P-2IA$_CJ*
M=6DUS;BMZ"?#K(P?8:[JL1S\^K##ZL,/JPP^K##ZL,-@OR6_R7/RW?E=XC9N
M)\+?!3>#96Y>T'A)\4?$>'$;A>',.#E=$;:&$VYMK#)C-Y\-ARX,B;$PNU,2
M!>T1L;5_:G2G8>R$UBJ\777W$//GW664?[)Q7:7WHSY,^FG2R49;,P52.#E_
M1JMZ5*W-2DKS2XJG&;["VU^3^_(0?)W^2;C]A^)WC-C<+\HGQQV5)AMH[,QF
MV-DC!^%^XNU86$T&*W3W.Q;XJ3;FV=G3GZ+:FUWE*O''/AL'@9EO7(^D'3S:
M.UHRPN"7P; O)I/SY+]U+@G]['N<I(]5] _(?T?Z*SAM+;#6T-MQ:<7*-J-*
M2T<*;OO23TG4OFE*,(,WNFWQ^P_?;RJB*YW XT]/7]WG2D8=2==*5<W=D=?E
M?G_K$OY47^IU\;/]C7>:I#9&>UL+^$4_\.)7NEK?ZE-I_P!;\3_ S/+0KU&?
M,<^K##ZL,/JPP^K##ZL,/JPP^K##ZL,/JPP^K##ZL,+)_P#0R/\ NV?CY_J=
MI_\ 9*W$KF_E,^:</^$?XDCT9^AM_95C_P"M_P#EJ1=AKBKS/99UMJ"?,>MM
M?>">M8C#-2]$+6AB<5B,[#'6F;.K=*7 PQT0T=2+BA,TS U;1JV1UI2U$F-A
M<Z#I^/N%8U8PZ5H4!Y_9&G<?KM[NM9PS$RR07N*2)1A;\?CWUB,,)I9J1A:L
M0A&)NE8V:MP ;C7\=J4M#/$Q->VE;5C# ?A]M8S3T,#^[7^:L7:#6H'/E^BE
M"GFC PUZ>E)>N8CB8SW\_P ?=6T:=C"R]K=-?4@5MNQM.QA(Z^?N'E>WEVM2
M;F/L,)'V>>GIYTH28F%CVM^SM?KVK>J[31B87\OCY]OMK1@'<>5NGV].GVUN
M+-<3&0+=.O;\=K5J6I@$86-JP2P)*-=+?H/N]VM+O=6- A@ BBVMON)[>5C^
M/))NP'L;6O\ M'X_'IMO,T8I.Y[>9^PV\R!6U?CJ98PFW3]73WFM7L:S,+CR
M[_CTZ5M,QF(@&X[=J5?WFM3&1;H>YZ]KC2WNK3-/(Z==>G;3O?S]QK&);,;K
M_/\ CM6D*3,36[6[UF9IF)AWOH.H[?9[S6+D:: [:_BUOMZ:4H2S"X%M/:![
M]--+UF?L-& @BY/Z+W_!UK'V& 9A]EON[7T'6U:DS#&0/VT,TS&5-[C[3TZ]
M+5NZ>IH#N+V! [#IY:>\ZBL,,!!TZ?"_2];$6S[#@&_D>_7IY"L-9F.0=[=
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MZL,/JPP^K##ZL,/JPP^K##ZL,$WO@,V[.V0/^(V/_8KHQ^X5$[=5]D8CZ/\
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MA-FX<B,.(V4K9,K6MY1.DE56A*C3]6"_Q]\E<'Y /)WAFG6IXO$+E4KR2?\
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MVF8?4HT.9X5?W0XS_$V(_P"G[9U.\'\:_5_&B>Z/?+9?1/\ PHG_T[J6]/\
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M\*)__]>ZAO5_='MO_&>+_EFKCNV?G3$?2R\3G^T/EU7Z1^(G[U%^(QOF=@X
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M^[6L-&![ZV/4=.^G[:VGP-:,Q$5NYLZ&DM\M#&8'6W>_XZ>ZL0EG0Z ^@O\
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M#;>(P>(W5PNQ\7M!]LIO9OUN1'AX9H]MQ"$P/B&9E?,$ !:P[ Z-8[I'.K#
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M^E=J_P!RP_\ R4??]7+WR$_^N3_*U_[,3P=_[GS6_P"9KMW]MPG[ZI_HC/\
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MB);,)/;\?OI2,NCH:1)&C RVOWMY]/,6'2]JRYAB-[D ^?34?KZUC%<#JQT
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MO_"][JJDZ>];X-;>W6KVN[7TN[:LWA_DYMN[<WG^0A\DG>+>7;.U=X=X-L^
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MQ:+9Y(L70P'DJP6-Q3:PU&GBIS:C*348XFO*348J4I-)/**<GHDWD2X^3/\
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M_KI)?64JG^B'Z#3J]7*CM*$+^DZ5+=[_ #:\I?WM^PVC_)C^7K\DKY84$@\
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M?'QC_P"V)X?5UCR6?*,;ZE/QF>7OT3/R#9'TV(_P:1M!_(3?[RJ^2S_TF_\
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M5727#Q;5DFP[QLLRQME#1.SNA'2':--5HTE2I/1U'N7[=VSE;MW<^%RU[?\
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MR;8W1W6VW& JGYQ@<;B<*V<!920X4V!Z!](<7!5)4X48O]LE9^V*4I+N:3[
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M;'[\^',&-P6&6Y FG_J<[Q^(&+$)L/8B=@#J!K9SB/)YTAHQ;I]15?*$[/\
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M_P"W /D'?\FS\D;_ ,"1\&__ !<ZJWZGMO\ ](XS^XU/\TZ7^KSH/_5G9/\
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MV<NTMG;H[,Q,KP@G\W;,P2"[ * Q!Y7C.GG2C&5'-8ETH7NHTXQBEV7LY/\
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M--33LT]4UJCVO3J0JTXU:34J<DFFLTTU=-/BFLT4^_Z*-_ZV!\CO_G.\8_\
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ML;)'!!LK=CQ"W7VCM[YQ* 8L+/N['M(;=PF*D# K%+ATD(/LU5L7LC:F!O\
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MP[X;CRXK>W$;:X<CLY8[R3[R2;Q&<%C:4XKBJ+ ,  !17TPZ2.?6?"ZF]?\
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M25H\B?E.Q/2>A+HSMZ;GMK#T]ZG5>M:DFDU+G5IW5WK.'G2O*,Y2EQ^7(/\
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MQ=E8?9&#WO@N&HQIQ<K.34$E>322<I6O)I)7;LDLDZ*G]U,GS)!KB1C^4_\
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MM7J65?RY_P#O+'Y4?_2$O^HBO".N3^3K]F.#_P!M_@*IZ)\M?\[+:?\ :_\
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M+[/7[1:]:NS"I#_13'_>"W_MSG_U/==A\D__ $?_ -H_RQY4_1-_](G]N?\
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M3B6 V15*ME!'.>FG2Y=+\71Q?P;X.Z5-PMO]9O7E>]]R%K7TLSK_ )..@3Z
M8#$8#X9\+C7K*I?JNJW6HJ+5NLJ7O99W6EBL?^40_P![V3_ZH#Y&/^Q]X!5V
MSHA_.K7X)C/X2N><.G_\_!_A^S_X+"EYP&O,A[23X':EI6%%<+^B6O\ =5O
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ML!06[]QLZ%A<@FQ _;H>U;2=NPPZW^-K"WX\[UE[F'!K.PTSBM"4<$_;_/\
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MT%&IPG5G&G33=23226K;R27:V#JU:="E*O6DHT81<I2;LDDKMM\$EFV:+?D
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MBT\VME'WT5#W^UUP?R8&^^,_)N_E8MX? SQAQGYBV-M_;&]_R9MZ]K[2"X7
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MS%A7>_)Q@*FSNC;Q.*\SKZDJN>5H;L8IOL:BY7Y-'A7R[[9I;=Z>K ;/?6?
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M#^6E_L>^/]=WZ1_L ?X/AO\ #I'A[R>_S^%_7#:/\%BB]=7"3W$4.][\7/\
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MYJZR^0/\IW?'Y8/R<=W_ ![WP\.<!X7_ --VWMYL+NUL# ;;QFWX\9NYN_M
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M/2^CN-Z.=%MN8/H+T=:KXJM.I+%5KIN\*-22BVLM[>BO-65.-T[SE)G+.DV
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MK+GNIW6DD57I5^B*P[PLL%T,PU7X7-6Z^NHI1;XTZ47/??WKFXI-9PDL@/\
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MS[)\)ZO>ZRK4J^A\'G:V_N^D[VOE>RES_P!73O\ WXI_X<[_ ..]5#_S*O\
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MY+\9T=<NE?2.#AMFK!QI4I>E2A+TIU.56:RW=80;4O.DXQE5^7Y_WF3XP_\
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M6T=J;LNDF*@E.SNJ-.Z:I1>CDVDZDEDY)1C>,=Z2V_+AG-^2\^4^?,^"Q_\
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M[]3^-*V)N=2==>GIZ5FB%6.I'H?V5NYIV,FMO?KYVK1AQZ5@,[C\>1_G%:%
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MNDFB!&\_Y'W\F[O=C/GVU?DN;L82;.TF3=C>_P 3MR,)=U12/S?N9OOL# !
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M^V-Y=K2<?:^\6P5VUN!M[;&)9\[8W:^V?#W:^ZNTMJ;0>P#8C$2R3,H"EBH
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MU@I,1^_WAUX>^*N[.,W+\4-Q-S?$C<W:$V#Q&/W2W^W8V)OANSCL1L_$Q8W
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M,P>$V=LW9V$P^ V?L_ 8>'!X' 8'!PIA\)@\'A,.D<&%PF%@C5(XT541%
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M ,4RE?JAV_\ T]C/[M4_SC/U!]!_ZC;)_P!R8?\ T9]_MO\ ^0=_R$WR1O\
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MF!K5*4GKNR:OWK1]SN0NV-@;$Z045A]M83#XJDM.LA&3C?C%M7B^V+3((O\
MD4/R84NU6VRWR6=E#&-,)S#'XG>-L6RLX3)E&P8O$I-AK#8?P8PXC)URWUJ>
M_5OTH4-SX4[>I2O[]R_UE'_F,>3.57KGLN._>_QV)W?WO7;OLM8G!X,_)L\
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M&7.A[@VZ?CX?&D-HT86L.A)_':M7-F)F]WW_ +JRW$TU<PL?T_:>U;$M7[C
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MGX6U_'K6F[F'0ZB_I^/NK$Q.AB/VUMNPG4ZDTEW,;.A(L;]/T?MI)K>,#WU
M%_4=-:W=&7,)\R=?+W>=:8EO,PL/(=3UZ$=[_C^;!#=S$5(_'O\ .W85J1HZ
M$FDFGV&!KWUI-[,V=+UIW-;QB?37MYF_Z>E;3$F$D:Z]>FI_;YBMWOP-&,Z"
M^F@Z W/[.U;N88;WO<#TZ:#O;2DRR-G4C70?L%)OE<U<QG]-)OQ-O0PL/T>?
MXZGUI4>;!LQ&_H!^G[JVV8FD8V3R/7\?HK3ED:;SN87TT]+G[?7L:1>^9BYF
M$^_[^U9D8[6R,9I-P?>86_'[JW?WFF[LZ=/NZTEN^IET8V I"?N-7X& C\>^
ML9HZ&_[/T>^L,N@*W7I;\?"U+N:;N8S]P%[>?OI.9HQ,;VT_;6/)&&,COTM?
M[_AYUHV8R3IWT\[WU[_96F:.IT%]/Q^FDW,9T/[ZQ9,2\T8V'4C7O2][AQ,3
M. 0+W_GI+-G6Y^'3\=:T:O9W1QWMW[?@:]:Q"9/B<=/??KY6^ZMB<]3LIO:_
M\_P[VI+,[M#X_JUM_-;K6NTVKM6.+6N?Q]_E6[Y&U]9P387K5[NQLZ93^K3U
M/05ES&U:W$^ [G7[OP*W:XALRC07N+^OO/Z:U;,S4QTON,.Z_C^;WBD2T,M8
M[C^;]GPI*,WD<C3\?=6VS#(OZOVWI+,,B]:Q&P0IM\!^/?85ET:9G4_IK-4)
M! !(\[G[*299^PS6-S\#]G[0*R^9ET=U%K$6_&GZ*1)JYI/WAM$/HQ^/*D/4
MVO1!*"Y /3\?LK$Q:%"@T'3V%'PM^BD[V8MZ N GB#W?JK.!J.O:&BWL/QVK
M5Q:O<&Q^R/QV%)?I&&>_L^EAU]VMO6L,3,RZ:?CI2DV9>QE7[#Y5MF];,%@U
MHVF"%UK$UJ:1G06^T5F]R-/0$+V]]8U<U$S ?CW_ ,]:1C3O<[4JYL[KU^%*
M;$L[]*TF):L=Z4$/K]?*MF<#ZL1HXI:$-69R*48AS_"?^Z+&_P")<3_T_;-J
M2V3\IDOW#\8D_P!'OELOHG_A1/_0N<[X?W4[?_QKC/Y9JXKMKYVQ/TTO$YGM
M/YPK?22\1/J=+5$25L^ R.U)?U&'U),\#J:V(>I\*QFXZG:M"CJ:V)9+'<7:
MOYWW8V9.S9I\-%\PQ.MVXV#M$&8_QI8 CG_35VCHYC?AVR*-1N]2"W)=\<OK
M5G[3I&R,3\*V?3F_3BMU]\<OK5G[175.$F?5AA]6&'U88?5AA]6&'U88?5AA
M]6&'U88-]XD[&_.F[TF*C3-B=DN<:EAS'#VR8Q/]*(K2'_F8JK]+<!\,V6ZT
M%]FH/?7JZ27N\[^Q(/;^$^$8%U(K[)2\Y=WW7U9^PC2.M<@>90%J=JVM!9\:
MV:;L<UM&SBM&'8=:VC:U.U;%'843@*B^!S6"CD5ES:U.;TI9FV['U:>1BL<U
MB9L^K9AR#;TI>J,,](,.:(C1]2HF'84HVF=J4G<4=A6["DSM2EVFSZL,.5-C
M[ZQFFC**TC2.:V*.:PP[5H6CL*6A29VI:=Q1S2N!A]6T^!AF3I^/C]E9?,P[
M5LT<BMHW<[ T2(J]SFE&'-8S9V%*0I.YWK B=SD'7U%+3N:OP,JFX%ZV:O9V
MX':]98Q/,[4I9HV?5N+L8?40T=A6"H_4<UH4<BL%1.U;3%'U*,,J'2V@_76&
M[,[UAHYI431R*V*2.U9=BEJ=Z4+O<YI:=S#L&MZUEC31D!K>1K-'-ZPVG<YK
M#9]6UJ8<TLR]CL#6M!2=SFE)W-GU;,/JW>QAS2D[FCZMF'(-;N;3L<BLT%+,
MYI1AS2T[F'(K9M,[5H7H?5AAVS?H^_\ 96+(38Y#7TK9C5CN#6&D[':M"EF<
MTI,PY4VOYVTK;S[C#D,>^NFGXTK+<C#N&N-2+]Z2T8=@:VG;+@8<THP^K##Z
ML,.;U@I/F<UH4=KFP [W[^M8)RU.PO[O=K^VMFF98T,CJH[]3Y#N?LI4(N<E
M%&XQWI60;    : "P]PI^LE9:#Y))66AS1%H8?5AH^K##ZL,/JPP^K##ZL,/
MJPPYHBS,/JRR,,4KY$)[]![S^R@U'NQ?,3*6[&X7"F0W3.U+-GU88?5AA]6U
MJ8=A2S:9R*T*6A]6&'U88?5AAS2HF'(I1M'(Z5H4M#FM&SZMHP^K=V8<THT?
M5AA]6&'U;1A]2[V-'U:D^!M:'-;1AQ^K\&MF)G2WXZ>A%:%'PT/[?=6F8SM^
M/?21#.#6T:..HI9JUF??CO2C#K2A1Q_/6F;6I\2/=_-23&U>QT)_'X]:RPAY
MF,MITU\O.E6-I9]AT;7X=NGO\P!>MK(6LD=*4;/JPP^K+F'4_P ^E9QN:9QY
MTG.YK0^M?R_;^L4J]FEP-HZ'X:_CMIK2KHV=:U<TSBE;QJQQ6)Y"3J3^.OEJ
M*W<W8XS'T-;N;LCI?X>[3X7I-C31UZG2L-&>M&'U[5AAT)^W7\6[7O2D9GH=
M/2MF\]#@UEA+9TI+R$(QOKTM[K7M^RDIYBTSIV^)Z4KB:>IQ6"3J2*VD;S Y
M)%[=+'7I8=K]C:L8FWO A!Z^=S2KFSJ:U(PZ,>U8M <I9V,#'RZ?LU^'3[JV
MD8L]3$;>?X]_2LOF+1U-;$LPDCR_96N%Q%FS@7^!K3>1CL?$?CK]U#NC1@?I
M:W4:>_R\ZUQ, YTZTI9F'6_7W_C[:W8U+D86))L5OY=_3W]_6L?8:1B)%[@W
M^[\?96KFSH=:PTSH?Q^/,4FYHZ,-.P T%_TWT'3]%9?WF@*UB3;\?@4M7MF8
M=:QF 9P"3J;?;;SMUM<TI6M8T!VZG\?HTK!+U.+TAF7RL=2+BWX^':M(T87_
M !V)[Z@^GVULT^0&8_?2M#3R5CI6KB3&1KTOZ'7O]HTK1A@D[#W_ (^ZL1LQ
M5J788=3I^G]=(,,9/2UQT_'K6)-,2T8R:4[B-#H:2S3.A(U'ZJU9V-&-M ;$
M=_U7'7J:08@*Q/>E&I9(Z5J[$&(Z=/C[^]NU_P >[&[B;V,1ZFDM\#1A8Z_"
MM-"M%VF.M"3HXN#I?0_@CRK5\S *?T_'[Z4WP,.AZ'W?C[JSB883UT_'XM6/
MM,.-;'ITH<K7-9&,UAC2,;$W_'7S[]JQFK97,)_'G6[^\'8Z,=*2WF:2N8&U
MK3[!5S$P%A8?CO\ 96KW>9HQ-?\ ;6KB)&,_HT^/W5EP>AB?IIW^[]]:NN)N
M_!F%OC]WVBDW-HQFM&,Z-TMY]*V) C#[+Z>ER?A:MW1HZ5E[F'1P+7\OV_MI
M)LPG6M,PZ$=0#VO;[O+I67,,?2]P#VU_5W%ZUX&F=6^%O3\#6L$OD=:V(9T8
M7'X_&M:9BN8^E:%L^)%NG:M*]^P0T^9U/;TT]^M+$O(^!U%^G3X?S&L:-IF4
M_?\ C]%#;,3YZG1NWO\ U>?2L,5KW.O7R^/Z?A66%W.1UOUO^/N-9Q-/F??K
MT_!\ZVA#/NGQ'W?OM6WF*B=:TOK-,S#0?J]*3)J_::X'U]:TG83=\3X?C\>^
MM,6C,!^!;O\ S5ES5S(O6MK0V9UTT]+?JI+,?89T/X^[6M7R$@C,3T/X]:TC
M;M8S@W+>8)MJ>FO3M66!F1>H\J0^9B#:/^#'3I^K]U)"+2P(CZGX?#K67-\0
M_C.@_P!**0^P5=V!T/MWM\:V*XAG'8CW6I$G;(4I6>8+3I;R_=6KYF-F86]Y
MO]E+$@A?/33SK2? S@9U[>ZMW%Q! ()M6UVFT@2MOLK5K+(3P,RFY'O%:1J^
M0)'7[*5P,7895/7WUI7O[#'([WI3T,OF=UZZ5IL4TFLC)[ZWH):RS.;VI:S-
MHX7O6V;9VK0D^TI29IV9\.]$CF:60Z'A/_=%C?\ $N(_Z?MFU)[*7VS+U'XQ
M)[H]\ME]$_\ "B?_T;G&^']U.W_\:XS^6:N*[:^=\3]-+Q.9[3^<*WTDO$3R
M'6W8U$NS0R,E#O=&'4UB$O4XK!)]26;.:R+-LXK&_<:'D\(=K\+&[1V+(UEQ
M<2X[# G3CX>T<ZJ.[2P,K>Z*KWT&QVYB*NSYO*:WX]\<G[TT_P"Q+5T9Q.[5
MGA9:26\N]:^]> _E=++D?5AA]6&'U88?5AA]6&'U88?5AA]6&'U88=)$25'C
MD57CD1D=&%U='!5E8="K*;&DRC&<7"2O%JS7-,TTI)QEG%HB)O#LE]B;9VAL
MQ@<N'G;@,W5\-):7#/?H2T+K?R:X[5PK:N!EL[:%7"2TC++MB\XOW->TY?CL
M,\'BYX=Z1>7<\U]04"H^/( ?&E(U+0^!K>ABS.I;RK+7%6.,QOU^S\:UNQNQ
MF&H!]*PV=J6G<P[5L7X'-8LS9S6:,4M+'%;9JYVI*=A9]2S1]6XO@894-[W[
M5MV3,,E*-'U*3,.:6E<T=ZQ)IA-3FE&':MW5Q9 ;Y-7Y3+Y(?RMO$6;PK\#]
M^MN[Q[Z0;N;3WKDV?M+<7>[=S#C8NR,3L["8[$#:&V]DX+!&2.?:L($>?.P8
MD @&UTV]T!Z3=&L"MH[7HPIX1U%"ZJ0D]Z2;2M&3?!YE)Z/>4/HMTHQ[V;L:
MO.IBU3<[.G."W8M)N\HI:R61/JJ878TS_EKOE8^/_P D?P&\)]]/D];_ ']3
M[>;>7Q<7=?;>TOZ5MR]Z_GNPCN;O-M7YC\SWWW<WEV?AK[0V?#)Q88HYN3+G
MRE@>I^2?HWL7I+MG$X7;='K\/3PN_%;]2%I;\%>].4&\FU9MKL.2>5[I+MSH
MML7#8S85?J,14Q6Y)[E.=X]7.5K5(32S2=TD^TE'^2[\;/$[Y17R%? WQD\9
M-YOZ<?$C?'^J9_3'O'^9MW]W_P X_P!+_C#X@;K;(_L1NMLK8FP<)\TV#L3"
MP?086+B<+.^:1G=H#RA;)V?L/I?C-E[+I]5@*75;L=Z4K;U"G.7G3E*3O*3>
M;=KV65DK)Y.-L;1V]T,P>UMK5.MVA5Z[?GNQC?=KU81\V$8Q5HQ2R2O:[SNW
M/RJ67<["L8J)W'WUM:"TD^\Y%*61M/AQ.U$X6-G%:,,B'7K^P^^E/-&&6L3N
M8?5LT<BB)^\S0[@TM9BTSFL-I7.16&XG84L4G8YK<>0KC<[ VI1LRC47K8BQ
MW%;0JYS6S#ZMIV,.:68LCM6"UF?5HPY!K!:? [5M/@;.;ULW<RJU^I%_QU[5
MLT=ZVG8PY%*O<Q':M"SFB+0P["MK(7J<THPJV_EN?RC?RS/DA?*L\/\ PU^3
MOXQ_U/=RMM_)[W4WXVIL7^I[X5[V?.MZ=I>)'BQL'&[4_.._&X^\VUH>-LG=
MK Q<".=,.O S+&'>1G[;Y-NB'1W;^PZN-VMA^MQ,<7*"?658VBJ=*25H3BM9
M2=VKYZVM;S1Y9?*!TNZ*=**&SM@8OJ,'/ 0J2CU5&=YNK7BW>I3G+T815D[9
M7M=MNSIN;M#%[5W1W5VICYOG&.VENYL/'XV?)%%QL7C-F87$8F7A0I'#'Q)I
M&.5%51>P %@.+UXJ&(G3CE%3DEW)L]&82<ZF%I5:F<Y4XM]K:38I;T(=)W.:
MPV?5M&'-+,3L=A6M&*3N?5O>-E<G\NQ\O+Y5_P C7>[Y.6R_DW>*O]3C [^;
MN>)&/WL@_I&\-][_ ,ZXO8&T]T,/LF7B[^;G[T38'YI#M2<9<,T*R9[N&*J1
MUWR9]&=A](:&+GM>AUTJ4Z:CY]2%E)3OZ$XWO9:W//OELZ;]*.B.+V?3Z/8K
MX/"O3JN:ZNC4WG%TU'XVG.UMYZ6O?/A;=E\D??G>GQ/^2C\F/Q*WYVI^?-]O
M$/Y/7@OOSOAMKYEL[9OYXWIWM\-]VMO[P;4_-VR,)L_9.S_SAM;:$TO PL$&
M&BSY8XT0*HYUMW#4<%MS&8/#+=P]+%UH05V[1C4E&*NVV[))7;;?%G8^BN-Q
M.TNB^S=HXV6_C,1@,/4J2LEO3G2A*4K12BKR;=HI):))9$A:B[LGSFE(T<WK
M9N[/KZUES+YG:EBCFLNS#ZEF'85IBUH<UAL^K##L#85L2U=G8-\/V5AF:61R
M#>L-:'>M"SFB&CZL,,JFXM?6DM&':M7,.:6G<P^K##ZL,/JPVW<Y!M6&([ V
MT[5H58-,+'9,Y&K]!Y+V_P"QC3VA3M'?>K#TH[JWGJP71FK!C79XH?E4?D8>
M#GRDV^27O[X@[P;,\;EWFW!W0.[N&\/]\]I[.&W?$O9F[6U]T<-_3%@-CS[$
MX6.P.]N!:23C9(#(PD*E& LV#Z)[;QNR_P!-\/3B\!NSEO;\4[0<E+S6[Y.+
MX9G/]I^4_H?LCI'^I7'8BI';764J>XJ51K>K*$J:WU%QS52-W>ROGH[;$ZKA
M?R*'RZ_$O?;P;^1M\IGQ6\-]M?TN;_>'W@SOUO7NAM[\W;)VQ^:-O[&V)BL7
MLW'_ )KV]@-J;%Q_S;$1AN%BL//"]K,C#2I?8.%H8W;6%PF)CO8>I7A&2NU=
M-YJZ::]C3*OTWVCC=D=$-I;4V=/J\=A\'5G3E:,MV48MI[LE*+L^$DUS1J$_
M($_+L^55\M;_ &K#_:FO%/\ JE_U-/ZA/])/^8?PXW-_,O\ 3E_5D_ID_P"M
M?[H;J_G+\Y?TJX#_ #W\XX/S?Z+)GDSW'R@[ V3L/X)^E=+JNMZW>\Z<K[O5
M[OIRE:V\]+7OGPMR;R%=-^E'3+]-?U28KX3\&^#=7]CHT]WK/A&_\53A>^Y'
MTKVME:[O8JKFYZ!/JPP^K##ZL,/JW<PYI29@!Q+W8(.BC7WG]@II7E>6ZM$
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M,DVJTVS?DG[BX38AF+)L_'>*&\&T-JKA^(Y6)ML0;I[,PC3"(JI<8%5+ MD
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MI[NU8WD)OS.%(Z?&D2S1I@;'X_!;+P6,VEM+&879^S]GX7$8['X_'8B+"8+
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MY!C$1K[Z2U=FV#(SVK=E>XG@9E[?#W?SUMZF^'L,ZG7WFL7$TF"!TK$+6@(
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MAX[U>I-1BN;;LOSX'H/:./PNR\#6VECI*&#H4Y3G)\(Q5W[;+)<7DLRDEL+
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MP,=MO=+ ;S; W<PV[\>Z^[NUTGQ\&\F]>^NT\?MO%;3VR</AX<(_$Q3M%##
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ML_0/;^,Z4=%,)MW'QI0Q=?K=Y4U)06Y6J4U92E.6:@F[R>;?#)1[_*!_E9_
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M''3^B?0CHQTJV,\11KXJGM6FG&I#>IN,9M/=EN]5O.G+5><GE*.]=7.*=/\
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MO^AM:L<GCK_1,N\C1[X;+\.][-A;$L<1_2J_@[\GG9*O&Y?%+#)L7>_94OB
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MM-S'Y+%MJ/\ D^ODMMMG_/@\.Y$AYH6_L5'O)MV/87\ S(/[")A]#SCHX#7
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MVO6LA.H'<W/X\SJ:5?(Q9'2DZF'4VK3T--H#MWOUO^V_KK6KKV"#H>E9>^7
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ME3II7;^U\4H>:]=[=I5EKFY13=GFK_\ 7G=:GN\H9_E'?_1@:?\ U1'R)O\
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MXR3R::>33633R91K_+3?()Q'R!]\=I^(/R=L1M7=KY,GRM,-)N;OMN-@7?\
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M:?\ J3/E&_[#V^-2W1[Y^P/X71_A(E2Z=_L(VS_6K%_Q>H5M?Z&#_N^^5_\
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M[OTUIN^0M6>?8&2&_3RO6GDS:=EV @  ']1MZ5M/B8WF9TZ>?K?[NW2MWX&
MI>@K&C>K! K.!I:F5#^/Q[JUQ-O)@A/V5LQZH$#S\Z2S3,PZCWTH4P6O2M-O
MVB6LSO?T_'Z*VC=SFLU-GU88<TM:&[F4'05BU8F3/JVA!]6S#L*4C:'0\)O[
MH\;_ (EQ/_3]LVI?8_RF7T;\8D_T>^6S^B?^%$__UKFN^/\ =5O!_C;&_P L
MU<-V[\\8GZ:7B<QVG\X5OI)>(FZBAD?7K-3+LR+J/=2&8^9\6 ]:Q)F'0M?W
M4OL-'PI+%H^K+V-V.M:OD(/JT8/MX/[=NN.W>G?5+[0P()^J<L>,B6_96R.
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M3V/_ #K)_P!;<3X53Q/TC_G]T_Z]8'_"PY>IKS<>USZMFRH3_1/']WWR0O\
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M]4UO9IBJ?0KH91FJM+9&RXU8M.+6%H)IIW335.Z:>::T(>?ETO\ >5WRI/\
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MB[1+,9'X-*N:N8S6-W-&-S8$CW?CW5I9.QA@+7.OK;OT\OMI+U-G4V&OQO\
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M>&VQ7I]$=CS57"X2IUF)G'./6KS(4[K)JGO/?U6_*,?2@TIQ?T,?_NJ/C_\
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M;=Q,L)L;'8;$XJ,'-QIU(RDHIQBY-)Z)RBK\VB0C: DGIIZ7]?/4B]1R?(L
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MM?OK5C+&(L3UM^RM,W9&,UIYB6=#K^/P:%>S,,++8G3R]?Q>PI:=S3=C&U@
M!2D:RN=*3=BCHXN+>?H+?'RZUJ]C#$1\3]U]>_G>LO[A#,+'K67OD(XF!FZ_
M9H*5H*TS>AT;M6/(TG?4QG3WGI^OW:T/4UKW&%CK^.WF.G6L8I:69U.OO'GW
M_!K+^X3+)G6QU/E\?V5K>2!MMG4Z]O3\'K6KB=#$0+_9^.W:M[V1EWQ.I%O=
MZ6OVI,I7>1B,9K<6:E]1C)[_  U[FMO,TLS'<G]^O7]%;U-]IP?AT_?]FE:;
M%1T.0"?=J#WU].](N;T[SNH^WS_'K67$R.WG;K;]NOQ K++CH9?B<W/X\OP:
MVK-&KGU8:.1U%8C%J=^WZ_4?NK4F+MQ.X_'7]'NI"S-+4R+K_-VK#? SIH>O
M7]GZ[5E[HU?(S#7W_NK2US-&= ">OV6Z^GGJ*WH8"!^/C6C#NO0_C[?@:Q"E
M;VF9/TVI+=Q47S!"=CIVI(K4-(^GW]_*M9(0"HNM_5?TUE_>;#>/0GO_ #TE
ML5>P*BZFE/)&)@^/6_PK.1M.X,4ZCW7_ $5K44S.IO?WUCRR- B/I6)BN*!*
MFXI5T)>IG7M[JSB)6H(BZTF>@IO@9R.XI,7P8I/@91U'PK=S? %(=#^/*E)W
M$<3)>YT.EOV>ZE*UA3.;_9YTB2YF)G:MIFSZE(PRKTK:>8AZG-*-'U;,/JVL
MC!T?";^Z/&_XDQ/_ $_[-J7V._MF7T;\8D]T=^6R^B?^%$__T+F&^/\ =7O#
M_C;&_P L]<.VZ[;8Q/TTO$YIM)?KA6^DEXB=4Z>ZHB]Q@T=JP2?5ETC9]6D[
MF'U;-'U9=(V?7H9N_ XK#1S6[Y6,/JT82*\*-Y$QNS6W?Q#GYYLT/+A<W^B[
M/=P2H;4EL--(1;LC+;H;=4Z%;5CB,(]F57]GI7<>V#?^*W;N:Y%VZ.XY5:#P
M<W]EIYKMC_(W[FAWJO!93ZL,/JPP^K##ZL,/JPP^K##ZL,/JPP^K##BM&AE_
M%/=9Y@-Y,%&"88EBVJB^TT:E4P^+"_6X8.1^X4*>@)'/^F6QI3_7;#*[BDJB
M[%DI>S1]B3T395ND&SW/[>I+-*T^[A+V:/LMR8Q=<[6943ZM-V-:G5NE;B[B
MD<J?MMW\Z5H9H9PUA6-&VCK>];61B5CL*6\Q<3ZDKD;9R#6V;C+/,[W[5M/W
MBSN"*VQ+.P?4"W\_[*Q*PH[UIW]AA]6)\#9V4V(K;T-&:L3N8?4M/@8<THT5
M+?E2?D7_ )7WA7\HO;WCU\@W;^'QNS-I;U;7WTW0V7L#?O!>&GB3X<;0VYB<
M7B=H[N8':6W]I;$V#M+=V!<=+AL-+^<TDGP+G#XF @-)/Z9Z.>5CHOM+84-B
M],X.-2-.-.;E3=6E544DI-14I*3LFUN64O.C+1+S'TC\DO2G9NWI[:Z%S3IR
MJ2J04:BI5:3DVW!.3C%QS:3W[N+W91XRV$_DR_"/\JENSXZ;T;]_+PWQWJQG
MAU)X0;?W7W<W2V[XI;H;UP1[\8W?;<;:>S-M'=G<#;&UMW!BX-W]D;3B7:$K
M'$Q18G@J0LKJ*3Y0-J>3C$;'IX/H92IK'?"HSE.-&<'U:IU$X[]2,9V<I0>Z
MLFU?@B\^3S9?E)PVV:F,Z:5:KP'P64(0E6A-=8ZE-J6Y2E*%U&,UO/-)VT;0
MLORUGR4?'[Y6_@/X4;F?)[W"_J@;R[M>+@WGVWLW^FG<O=3YEL,;F[R[*^??
M/-]]X]V\!B?Z_P!H0Q\**62;GS9,H8AKY)NDFQ>C.V<3B]N5NHP]3"[D7N5)
MWEOP=K4XS:R3=VDNT=^5SHUMOI/L7#8385#K\13Q6_);].%H]7-7O4G!/-I6
M3;["4'Y+[P5\3?D[?(7\#O!SQCW9_I/\1]S_ .J7_3%NY^>=W]X/S=_3!XP>
M(&].R/[+[K;5VWL'%_.]@[;PL_T&*EX?%R/ED5T6 \H6U]G[=Z88S:FRJG6X
M"KU6[+=E&^[0IPEYLXQDK2BUFEI=96;L?DZV3M#8/0W![)VM3ZK:%+K=Z.]&
M5MZO5G'SH2E%WC)/)NU[/--*?=4PO"=SN.U*X"UH5;/!'\G)\LS='\KWMGY4
M>\/@W^;_  *Q?RG_ )0'B)A]^?ZH7A5B^)N=OOC_ !)FW8VQ_2S@=^,3O@GY
MSBV_A#\W;9XQ4/%^EBC*N%]#;7Z==%<5Y,8='J&*WML+9^&I.GU59>?35+?C
MONFH9;LL]ZSMDW=7\V['Z!=+,+Y4I](\1A-W8SVCB:JJ=;1?V.HZNY+<51SS
MWHY;MU?-*SMN>_*A^"?B;\HKY"OCEX-^#>[/]./B1OC_ %,_Z7-W/SSN_N_^
M<?Z7_&'P_P!Z=L?V8WIVKL38.$^9[!V)BI_I\5%Q.%D3-(R(W+/)[M;9^P^E
M^#VIM2IU6 I=;O2W92MO4*D(^;",I.\I)9)VO=Y7:ZUY1MD;1V]T,QFR=DT^
MMVA5ZK=CO1C?=KTIR\Z<HQ5HQ;SDKVLL[)Q?_(G?)/\ '_Y(_@-XL;E_*%W!
M_J?;R[S>+IWHV)LW^FG<K>OY[L([F[L[*^??/-R-X]Y<!AOZ_P!GS1\*:6.;
MDS9,I4FP^5?I)L7I-MC#8O8E;K\/3PVY)[E2%I;\W:U2,&\FG=)KM*[Y(>C.
MW.B^Q<5A-NT.HQ%3%;\5OTYWCU<(WO3G-+--6;3[#<^*Y6SKD3FL3L*-"_Y2
M7\BEN?\ *IV_MSQO^3[M?8GA=XY;8DFVCO=L+;$4T/AWXF[297>7:V-DV;A<
M3C=T]\=H2D-B<?%!B<-CY!GQ$"SR2XMNR]!/*MBNCM&&R=M1GB-D1RA*/QM)
M<E=I3@N$6TXK)-I**XGY0/)#A.DM>>V-A3AAMLSSG&7Q59_?.R;A4?&234GG
M**DW-ZU=WM]/Z(!^1OA4W%3<?Q=\4]U=AI^;MD8>7<?9'RD]GC X=8L-@)-E
M;T;J1;S;ZQ;.CPTL7S?"SXV)</&N1H(S'(B7VMA?(STHE\,ZW#8?$3S;ZR6%
M=]7>$]R%[WNU%W>>\[IOGU#&>7+HG'X$J.*Q.&AE%=7'%JVBW9PWZEK6LG)6
M63BK-(3M_P 3/Z(#^5W@5W!@\/?%KPHW>VSGV=M=L'X=;-^3G%-AYTF@Q,^T
MM\M](=W][L-@4PK2<2+!8Y$G4@<*60Q ZHX#R,]&I_#'7PV(KQS5ZKQ/=:$-
MZ#=[6<HY<TKBJ^T?+ETJA\!5#%86A/*5J2PN3U;J5-V:5KW49*_)NQLQ_)B_
MD:=@?))VW@/'7Q^VIL/Q&\?H(3+NMLK9(GQFY7A9+C,/DQ6.P.*Q^'P^(WEW
MVX<KQ?G!H8L-@@SC#([Y<4:)T]\I];I)2>R=CQG0V,WY[EE.K9Y)I-[M/CNW
M;E]TTO-.B>3KR2T.B]:.VMN2AB-N)>9&-W3HW6;3:3G4X;UDHY[J;M(WP*;'
MWZ5R5YK([21&^6?\B;P6^7+X6'PW\7-FXG#8[94N*VEN)O[L08:'>[<';N)A
MCBFQVQL5B(9HL1L[:*8>*/:&SYE;#8Z*-,P6:+#S0V+HOTJVIT3VA\.V;).$
MDE4IRON5(KA)+BL]V2SBV]4VG5>EW0_9'3+9OZ7[4BU.+;IU(VWZ4GQBWJG9
M*47E)):-1:K(C\G]^6"_)P[T;<VE\D?>O;GB%N#M#'/C,3B_"C';$VSLS;WS
M: #!XK>WP,WZ;'&7;\F"B:(283 [6X 7A)C+O'G[S^K+R:=-\/"GTCIPHXR*
MLE64HN-]5"O3MYM\[.4+ZN.3MYW_ %#>57H!B9U.B]6=? R=VZ+C)2LLG/#U
M+^=;*\8SMHIYJZT_VN3^B MXDDW5V9\GCQ/V%M>5#@DWE'R1=J[->#$1$0-C
M8]K;V[MXC<?/))SYY(6PS YE7)T;?J4\CE'[8GC</.GKN_#$\N5H253Z[^T>
M+IEY<JZ^"TL!B857EO\ P%JSY[TX.G[U;V _P,_(S_+2^5YXL;.\:ORC7B#M
M_8&P9/F$^U]C[8WOP6]OBWO+LC#R3RX7=?9B[(Q&U-V/#C8175UXG&PBS%8\
M"DK.\6MJ^4WHOT<V=+9?0JC"=7.S4'"C%\9N]I5)>RSMG.UDU[&\DO2_I5M.
M.V.GU><*.3E&4U.O.*T@MUN%*/MO&]E!.[5L;</<7<_PPW-W9\/?#_=[9FZ>
MY6YVQL%L#=G=S8\'S?9VR=D[/A6'#86!"6D<A1FDDD9Y9I&:21F=F8^>,9B\
M3C\54QF,G*IBJLG*4I:MO5_R+)+)9'IO X/"[-PE/ 8*G&E@Z4%&$(JRC%:)
M?C;S;S=W=BOH*=QV$V\.P=C;U;"VWNOO'LS";:W>WDV1M+8&WMC[0A7$8#:V
MQ=L8.;9^U-F8Z!^6?"8_ XAXI4.C(Y'>C4*U7#U8UZ,G&M"2E%K523NFNU-7
M0BK1I8FA/#8B*G0J0<91>:E&2M)-<FFTRHG\H'\C5\L[Y(?C1+X[?DZ]Y]O;
MR;O[/VAB]I[L8#=[>K ; \6MQMGXI@^*W9VGAMO8O ;'\1MVRA^;E%?$3;0P
MWT>*P+@.\GHS8_E+Z,](]F+9/3.G"%9I*3E!RHU&M))Q3=.7'@HO.,EDEY:V
M[Y).EW17;#VUT!J3J4(R<H*,U&O33U@U)J-6'#5N2RE!YMJ'97Y0'\OEL'A;
MK[3^25OGO1M:)XL,^\6U?DD>(;?.)9H8LDTNU]TAL3<D("V9I(XTA1RP:P7*
MHJG1#R25OL\-HTJ=/7=6+I^$]Z?X_P ;FETZ\N%"V&J;+K5:JRWY8&KG_90W
M:?M227U)1Q?)(_+._E'L;@]B_*[\1<9\GOP Q>,PDVW-V9OZ7-W!M'9V&Q1>
M3"X+PJW#Q";7WDVC!,.)"-[,5AX48+(DK9$6@OI%Y,^A<'5Z.T5C-KI/=EYT
MK-K5U:F45SZI-\&LVPZZ+>5WR@35'I5B'@-AMK>@]R%TGHJ--[TVM5U[2T:;
MLD2(_*-_D<-G3_(Q\'/#SY%FY;[4WG^3SO+O3O%B=@8[&;-_IT\5L)X@[*V!
M@M_-Y=H;=Q)V3@MK[]2XG<O9$J09((7P>&^:X1(UAPV&:&Z&>4F:Z2XG&=)J
MN[0QE.,5))[E)TW)TXJ*NU3M.:OF]Y[TF[RDI[I_Y)J;Z(X3 =$*.]B<!4G)
MQ;765E5C%59N3W5*I>G!VR6ZMV"5HQ8G\E)XV_E2X]^?"'Y-7RA?D\;Q[F_)
MV\,=SMM;LXOQ)WW\(][]T-ZEV;NON6V#\/\ 8$F]>VMJ8/=_;6#P6+PN$PT4
MV#V=)B9EN)9W*L5SI]LSH'\&Q&V]CXR%7;->K&2IPK0G&\YWJ2W(IRBVFVTY
M67!+BKR8[8\I2QF%Z/;>P%2CL##4I0=6I0G3G:%.U*._*2C))J*3C!M\9/@Q
MGRR?R;?RTO%;\K9+\IO<'P9_/W@>WB_\F;>E=]_ZHOA1LN^PO#[<_P (]E[W
MX[^EK;6_6SM[A^:,?NOCH^%\PXV(X&:%)%>,O+=&^FG1G9_D^6P\7B=S:GP?
M$QW.KJOSJDZK@MZ,'#-2CGO65\[6=H7I;Y/NE^T_*B^D>!PF_L;X7A)]9UM%
M>;2IT%-[DJBGYKA)6W;NV2=U>U77!DSTP<THPC]\K3<C>CQ-^2K\IGPVW(V9
M^>]]/$'Y/OC-N/NAL;Y[L[9OYWWHWL\.=Y-@[O[+_..U\7@-DX#Y_M;'PQ<?
M%3P8>+/FDD1 6$OT?Q5# [>P6-Q4MW#4<71G-V;M&%2,I.R3;LDW9)M\$V0?
M2C"8G:/1G:.SL''?QE? 8BG3C=+>G.E.,5>345>32NVDN+2S6E?\AC\A+Y5?
MR.M[OE%;4^4=X6?U.L#OWNYX<X#=2?\ IX\.-[OSKB]@[3WMQ&U8N%N)O?O/
M-@?FL.TX#FQ*PJ^>R%BK =+\J/2K8/2+#X.&QJ_73I3J.7F5(64E!+TX1O>S
MTN<B\B_0KI-T3Q6T*G2##?!X5Z=)0?64I[SBYN7Q<YVM=:VO?+C:P5O=NCNQ
MO_NKO'N/OKL/9N\VZ.]VQ=I;N[R[O;7PZ8O9FVMB;8PDN!VELW'89^67#8O"
M3,C#0V-P0;$<EPV)KX6O#%8:3AB*<E*,D[-23NFNU,[MB<)AL=A:F"QD(U,)
M5@X3C)74HR5FFN314T^4C^1"^55\F/Q1E\=?R<6_^V]K[.P&-Q.T]A[IX+>Y
M-SO&#<>&=^+/L/9NW,?B]G[!\0-VTC0H5Q&)P^-G@*8>7"XQ@\\G?=B^4[86
MV\#^E?3&E&,VDI3<-^C/]TXI.5.7<G%/-2CDEY>Z0^1KI-T<VD]M^3ZO.=.+
M;C!3ZNO3OK%2;4:L.]J35HN,\Y,AP7RX/Z(/W5BCW-VE\G[Q8WFVNA& 3>?&
M_)&VAM24R36PL,\FWMTMU\%N1(,/(,_'=#%]>5F36C2Z,^22N_A,,7AX4]=U
M8M+M]&<G/V:\AO'ICY=\,O@E3 8JI5TWW@6^R^]""IY<].+R#C<[\FS^5)_*
M/;][O[T_E"/$S>WPV\)-C;0@Q[;%W@Q^[6&V_+AP[+BH?#[PBW/B3=#=';F*
MP<\N&;:NUL'AIXD8.T.-5>$P\1TSZ#=#L+.AT1H4ZVT)*V]%2W;\.LJS\^<4
M[/=BVGSCJBX/R>^4GR@8VGB>G>)JX?9<))[LG!2MQ5*A3^QPDTVM^<4URG:S
M4/Y5+\D/\HC?[Q<\#-C_ ")/D^87;?@=X4?)CW.\+<))A=__  IW2;"[R;+\
M2O%O>;;28_";[;Z[K;8VKMG:<6]F'VCCMHC#O'C,9C9',K3<4*'H+Y0=CX39
M^*J=)L6X[4Q&.G5=Z=6=XNG2C&SA"226XXQC?)12M:UW/E,\E6W\=M7!4NAV
M 4]C879M.BK5:,+3C6KSE=5*D)2D]]3E*S4I2;O>]K76YV Q>RMT=UMEX^+@
M8[9N[FP\!C8,\4O!Q>#V9A</B8N+"\D,G#FC89D9E-K@D:UPG$5(U,1.<,XN
M<FNYMGIW"4Y4L+3IS5IQIQ37:DDQ2 VH0X3L-]XL>%.X/CCX;[X^$OBAN[@]
MZ]P=_-BXC8.\NPL;G6/%X*<I+%-!B(6CQ.!VEL[&0Q8G"8J%DQ&$Q4,<T3+(
MBL'6 QV+V9C:>/P,W3Q=*6]&2X/P::R:>33:>3&6U-F8';6SJVR]I4U5P->#
MC.+XI\GJFG9Q:LXR2:LTF5*/&;\BG\NGY''BA/XP_D]?$K>#?;9&"FQ<NQ1L
M#>_9NX?C-L'8Q9,5-L/>3![0Q.PMT/$'93I&L<B8:4_G,I9]EH"J'ONSO*3T
M8Z0X);/Z6T84JC2OO0<Z,G]]%I2G3??Z/W[U/+>U_(]TUZ);2>UN@6(J5J2;
MW=VHJ6(C'7=FFXTZL>#L_/MG26C$0_+E_H@_<*&+=O;OR=_%;?+:&"5E?;TW
MR0]L;R38E8Y'PH$NUO#G=O"[LXDA\,S!HTSR*PD)971CCZ,^2;%OKJ6+H4X/
M[GX6HVXZ5).2U_%S-KIIY>,"EAZV Q5::^Z^ RG?AZ5*"@].&NNC0C-Z?DR_
MES/RDV.V;NI\H'^FG<#PL^?X?$XS">([;M^$'AWLQ\+BAP,9C_#?=+!X7>K>
M_:.#DB>7"2XG9>/DB;V9X4=&+FAMKR9=#HNOLGJZN.MDZ>]5J.ZT52;<8)Z-
M*4;\G8:8GHYY:/*'..%V[UM#9F\FU5W*%)6>KI02G4:UBW"37WR319 _)W_D
M\/"S\GYX68K=;=;%G?'Q+WQ. Q_BAXHX[ 18''[RX_ Q.N"V/L?!*^(?8FY^
MQ'Q$QP>#,TTADFDFFD>1^3D'2WI;CNE>.5>NNKP=.ZITT[J*>K;XS>5W9:))
M)+/T)T!Z [,Z";,>&PKZ[:-:SK5FK.;6D8K/=IQN]V-V[MMMMY:UORZGR#_E
M6_+(WN^3GM3Y-_A7_5&P.X>[GB/@-ZY_Z>/#?=#\U8O;VT]T<1LF+A;^;X;K
MS8[YW#LN<YL,LRQY+.5+*#<O)CTHV%T>P^+AMBOU,ZLZ;CYE2=U%3OZ$)6M=
M:V.=^6OH1THZ78O9]3H]A?A$*%.JIOK*5/=<G!Q^-J0O?=>E[6SX7W1?);W1
MWR\(?D@?)UW$WLW8Q@\0?##Y-OA'NEO+N9L[:>[V+QXWRW*\,-W]C;9W8P.V
M!ME-T\3C/SWLV3"18G\X#9SO9_G A/$KGFV\1A]H;?Q>*H37P2OC*LHS:DEN
M3J2:DU;>2L[VW=[A:^1V'HSA,7LGHG@,#BJ;^'X;9U"$Z:E%OK*=&,904M[<
M;WDXI[^X]=ZV96WQGY,OY?7R^_R@$'C;\O7PL/A3X#R;3;&8O9&$\5/#/>G\
MT^'&Z\[S;I^#6[&'W!WUWAVS!/MIIPNT=I?-\&CM-CL:'CQ,D,3=?CTRZ+=%
MNBKV;T6K]?M3=LFZ52-ZDO2K2WX167W,;O2,;.*;7GB?DXZ==.>G2VSTXPOP
M78F]=Q5:C/=I0?F8>"I5)R3E?SIVBLYSNI-)VT-D;)V7L#96S-A;#V=@MD;%
MV+L_!;)V/LG9N&AP6SME[+V=AHL'L_9VS\'ATCP^$P6"PD*1111JJ1QJ%4
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MW9+SH-MK>5XNOUN;X?\ Y?C\FO'+X>>&&[7B)XD^%NQYW_-&QMRMW]F?*/\
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M*/R+?B5A_!3Y&O@I\@GP=F\1MF^%#^.FU/%S>;:>^_AMNEO'O#O;OWA_!:'
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M;Z>=^M9?F*2 Y'70WMZDG[0*VF8WP,?NK&Q*.*28=2P\_LU/P/:LL_88,O\
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M[HPZDD_C\"AM9FSH36")&-C<5B8A.Y@N>G7I_-W[5EA6IT)Z:#3\?HK5C;R
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M,TS'8=1]Y/V#72]9?F(9A9;:C[/+WTI.YM.YTI+O<4<5AAU.M8T)WCJ/+O\
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M 8C%D9%*Q$ZS,+(+=;7]LCR'?R[.:.&JUW>*\SGP"TZ4YZ>CS%?A<)#@TR1
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M"+\#NO7X5C9IZ&:M7RL*.#6(TV?5C,1]2DS3/J(F):'2\(O[I,=_B/$_]/\
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ML23K8??^!67Y&F[G2M&C&SVTK35^XPQLUQ8_I_?^/TXDM3#J; VTN-.YL/U
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M=M*5O,P)=H;17# Q1$-.=#W6+U;L6\A]OD6>+Q:I+JZ?QGA_*-ZU;<\V/I^
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MOPZ"AMW%+,Q,??\ C]%)OP-2?(Z$]NWX^-JT(?88V'[?Q;M6*1AC(M^/+O\
M&LO<T87.OI;\&D2R-HPG\?S:4BYAC>POKK?7XB^AK+O@88&:_3]YK:7,T=;?
MC]'Z:3*7N!MY]AT(]U(N8CH?Q>MHU(Q-^BL8%\C&3VU/E^KXBDLQ,Z&LL*.I
M.E;L;2YF)M*V[&I76AC/X]*T# SVN;?&US[KWZ5M"UH=+ZV)ZZ C\7L:QY9B
M7]1\1;\=O.DZF[F,TEB3J>_?]WEY]*T88S?4ZWZ]_LOTT-88<:6\O/\ 'I6&
M'0FWQ&GOK#5S[L+];??^CK6&71A;J=!K^/=6"'*YC-;U,.I%)8EG6]K_ *>U
M:,.AO8:=?O\ P*P4M0,3S WZ?'3]]8)E:YUR]/T^_0>?I6[W-*1Q:WX^-89V
MGW6L,.O3T^.O:^O?K67%96.O4?J.OP].E:;!Z,Z'KZ=?6W6Q];5BT,?(^(U\
M_P!A[V K.!K1GW4>[[/UUACYG5NEOC;UZ5M/,PZCR\Z4S-3L!I:D]HJV5CNO
M6L%+0R CH?+^>MLQLY_F\ZU>YINR,BGI^/6L$&5>HK&9P,RFWPZ4AFUJ"D8V
M\[@>5;1N]LS.M;OD*B[L$IT_'XZ5H5Q!$?0ULV#D['M;])_4!27J:X]H)3I6
MN)G$&Q'OT '4=-?YJWV&T9X_J^5]/QZTHQ@Y.@_'XUK3U-< 4AM>U:%VY@E3
M<"L% L=1[ZW'3(P&)T/OK+F @ @BLNFC=S.AYOQYUDM#+F8==/?_ #UM&(SJ
M=![JV;3S,ZDV^-8C<F[F5=#6C?!@A#U_'XZ5MZ9 CO6+,V<$V%;,6;.RZJ*T
M+.U+3N8<7U]WXTK%J)XG:]ZV;.P-KTK4TT.MX0_W2X[_ !'B?^G_ &94WL'Y
M9+Z)_P"%$G^C?RZ?T3_PHG__T;T&UF VECO\)E^W.:J.+7VU4]=^) 8CX^7K
M,2>W]E)MK9LV$:PE XN%D/\ H>(0'(2>N5P2K?WK>ZHG:6"ACL+*CDJFL7R:
MT]CT?8R/QF&6*H.F_2U3Y/\ /(C]+$\$DD4JF.2)VCD1A9D="592/,,*YK*,
MH3<)JTT[-=J*;.,HR:EE)9,ZCS[6Z4E,4G=':])L9='%ZS0U=G%ZU?F9<R W
MK>\#9R#:MW3,,_K0FK&'U),/J(C#ZL,.,WE6[!(K(^N;WK+"K'>M"#FL1AR#
M6-\C:=CZ]*WLC+G-ZUJC=_><#K6EDS+YASL/;>.W?VEA]IX"3)/ W,C7X<\+
M$<7#S*+9HI5%CW!L18@$2&SMH8C9F+CB\,[5(OV-<8OL?\JS2:=X7%U<'6C7
MHOSU[FN*?8_SS)A;N[?P.\FRX-IX%N609)X&(,N%Q*@<7#RVMS(3<&P#*0PT
M-=TV7M+#[5P<<7AWD\FN,9<8ON^M6?$Z3@L92QV'5>EH]5Q3XI_GGJ'E2 [/
MJPP^K##ZL,/JPP^K##ZL,/JT8?5G PXI+Y\##K:L$M'U8:.*PP1.]^YN%WDA
MX\.3#;6A2T&)M9)U'3#XNP):/^*UBR>HN#7MN;!H[6I];3M#&Q64N#_<R[.3
MU7:LG%[1V;3QL-Z-HXA+)\^Q_EX?4X[8O!XK9^)FP6-A?#XK#MDEBD%F!ZA@
M1RLC W5@2&!N#8URROAZV%K2H5XN-6+LT_STY/1E+J4JE&;I54U-:HP"DQ>0
MCB"!VI:9KB9*(F+,BF];N%B9%HD1:U,J>T*)P%&85N.1AUDP\,P^D16/9NC#
MW,+&U*=*G57GHR4(RU072[*.I@D!\DDT/P8:'X@4WE@G;[&_8P,L.]8,+Y(9
MH3:6-D[7(Y3[F%U/VTRE"I3=IJR_/B#<91])69T#6ZTEJ^@-G<&DZ&KY]IWI
M2%G-$-'U9>QAS2T[F'U;,.0:4GD8=JP6<UAA]6&(R!OC\:RXJR9E!_'OUUI2
M9O3N.U;-G:M"\FCBY'>MB&K&53<7]:PT<UAAV!K:-IV.X-+N+3]QVO>MW%7N
M9 :UHQ+.X-*69M.Q\0"/?6+(5J8B+&U$3XFCFEZF:'-ZRPJZ.:4D;,BM:E)/
M@;5CO<5EC+'<&M79M-'-Z4LS;=CZ];-;R.;UN[-I\4=A6Q:.P-OQ]U98RQV#
M#OI6Q+0:8/96T,<0</AG*'_17'#AMY\1[*UO(7-.Z&"Q.)^*@W'F\E[W^(-2
MP]:J_L<7;GP%=@MTHDL^/G,K:$PP72/W-*1Q'!] AJ=PVPH1\[$RWGR62]^O
M@2=+9T5G6=WR6GOU\!5P8>#"QK#AXDBC7HJ"P]Y/5F/<FY-3E.C3HPZNDE&*
M)&$(4X[L$E$S5L4<5AA]6&'U88<6K,F):Y'%)[S1Q6C#ZL,/JPPX(O67-IG
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MENU8)?(P/J>OQ_72EH8E8QDZV_ ]WF*T[&,X/Z?OI+8ENQB-[&X\R2.]CY:
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M "S52Q;^V:GKOQ(#$?'S]9A=>FH&XU>_>Q>'(NV<.G)*5BQJJ-%E]F*?3H)
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MWKM3U3[@-?#T<33=.M%./UKN? CEO!NYCMW<48<0A?"NS?-,8HO%/&"<H)
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M?#L/OO6TS;9UK+B3J>GX^^M-\C-#&>O8ZZCJ?4_&M";F-CIV]._H+]]:T*3
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M[M/T>=;L9VG2YUUZ]:48<5LP^K39A]6)W9AS1#1P1W_'XUK9AP;:] >FHO\
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M;0(%*X"UJ"0>GV'WUN(K@"H^OPI2X P7'TK?$WR!L?;\=-*3="T#$[UIYF^
M*2DL5Q!2]*WQ,0*4VM^OIK_/6C%H"5U(^%*3]YO0&)T^-:?I&&3\?C[:6M3#
M(G>MLS@9U.H]U8V;OD9@:RYM&93>U)8EF1AWK4'G8S@=E-_?^-:7:S[#1D!M
M6V*6AV?MZBM1-'2E&CZL,.1WK<3:=AU_!_\ NFQW^(L5_P!/^S*GM@?+)?1/
M_"B6#HW\NG]$_P#"@?_5O)[9/]E=H_X7/_EFJ;C/E=3UV5W$+[//UF%=-F[
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M:4FC1UN!2M4:T9QF!&OV'K27>YLQ4HPXK##XUG@:9Q>LR-7]YQ>M2L9=G1I
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M!:=JW)YV,Y@M.U)X"ON08G>D\$+X@I.G;\#]U;XF I>@]U+3S-L%KU^RL1M
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M+D^ZD"3&;#7\'T'KK6&@*QN3]GPZG36_7WTI.QAB.FHMTUM;]NH)K+FG8^#
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M9,2@0G>EO4PSIW^%)>;-F=.];1IZ&0403'4$+T'WTE!&=KULU<Y7J/QWK:?
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M/W4EO,P$IW^%;;S,!2FX%8GFS8-C]D>HU]_8>ZU);U,!48M]OO\ V7O67NC
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MFVE_?TM^NMOT;<1.AB9NNH]Q]QZ]S2;&/,QEAWZD>_W=@*2S3UR Y.MR?/\
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MW_%ZTT;NF<%A]GE^KW4AO@#DKNYC!\]?+\=Z0\S3B8F)]_[?/X5M6$WLS$Q
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M9A]239Q6&'U)N8<7]:U=Z&9'%ZT:N?7K&S2?,YO6+,W<QR(DJ-'(JO&XLR,
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M[LT8*&:.P-J4C1V#]:W8V=2;F];TT,.*PT94Z=/WTEFSN*5%YFCDD"B7Y&'
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M;7L3:DIYF/0ZDV]QT^P:]+]K5N0)G4GF!L;#J>WX'Z:2M#1\["W7R]UC6KF
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M6(T=#;L>W3[?7M6^\PZ&D-FCI^FD)FCJ;=ZVF9<QG4>_^>M7%IY&)]+7TZZ
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M8S=S*/=?0V_&M:-WL95_56";YLSQ_C\?&L%)\ 2EK]?A6Q39G3K^//\ 56S
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M3\?V=:7O&CBDOF8=;@]*%+D;.@U:_EKITZ6]>QK6FF@IZ&%F-_4&Y-@.GKW
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M4ZDJ<MZ(N\#M&#'1YHSED4?21,>9/4?QDOWJPX?$PQ,;QREQ7(DZ5:-177I
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M:/\ TPXG_JE6? \8_P"A5/WLOR"O@U?A"=_59D_-&UO^-FT/^F+$_P#5*M?
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MY_>OW,X^:8L_[ZXC_I1+_P!2UOJZWWDO<Q+IU']R_<SCYIC/^)<3_P!*)?\
MJ6LZJM][+W,UU=3[U^YG(PF+_P")<3_THD_ZEK?55?O9>YFU3J+[F7N/OFN,
MM;YKB+?\PE^WV:SJJOWDO<S75U/O9>YG'S/%_P#$N)_Z42_]2UG5U?O9>YF=
M54^]E[F??,\7_P 2XG_I1+_U+6=74^]E[F9U53[V7N9P<'B_^)<3_P!*)?\
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M>T>W^^6)^[Z(WTK%1K_>3]S$]56UW)7[F8CLG:__ !KVCU_XAQ-OY*LZBO\
M>3]S_(9U-7[R7N9\=D[6_P"->T1_Y18G_JEY5I8?$6]"?N9KJ*OWDO<S@;(V
ML/\ @7M&QZWP6)\O^96K7P?$?M<_WK_(:ZFM]Y+W,ZMLC:Y/]J]H$?X#BO\
MJG;[JW\'KW]"?N?Y#74U?O9>YF)MC[7)']B]I?\ 3#BC;_P5UO6NHKK+<G^]
M?Y#.IK?>2]S.@V1M@7'YJVE_TPXG_JE6/#U_O)^YF=55^]E[F<?F;:]_[5;2
M_P"F'%?]4J'.A7?W$_<S?4UOO9>YG'YGVQ:PV5M+_IAQ7_5*D?!Z_P!Y/W/\
MAIT:OWDK]S.&V/MC_C5M*YL/\XXJ_P ?HM=*4L/B/O)_O7^00Z-;[V5NY_D.
MOYFVP1KLK:-_+YEBM/MBO6?!ZZ?H3_>O\ACH5K>A+W,Q'8^V#_P)VD-?^(<5
M_P!4A6G0KO[B?N?Y ?55_O)>Y_D,9V+MC_C5M/O_ +X8KR_YD>XK7P?$?>3_
M 'K-]36^\E[F8CL7; )_L5M+II; 8F_Q^BT%:^#XC]KG^]?Y#?4UN,)>YG4[
M&VP?^!6TNG_$&*]__"JW\'Q'WD_WK_(9\'K)>A+7DSC\S[9!7^Q6TR>G^<,5
MW\_HJW\'Q'WD_P!ZP;H5_O)>Y_D,;[&VS;^U.U.YTP&+Z^OT/3]-:6'Q'WD_
M<Q/45^,)>Y@<[%VU?^U&U/\ LGXK_JE6_@^(^\G^]?Y#?4UK64)W[F8_S'MH
MD_V'VI?_ !?B_N^BN=:SX/B/O)_O7^0UU%?[R?N9P-B[:'_ C:G_ $P8O_JE
M27AL1]Y/]Z_R"G0KV]"?N9\VQ=LD?VHVI_TP8O\ ZHUKX-B->KG^]?Y!/P>N
MON)^YF([#VT?^!&U+>F Q?\ U1Z:5M8?$?M<[^J_R&NHK_>2]S.AV%MH_P#
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MV_\ \8]L?'9F-_ZHUOX/B+?%S]S_ "&O@]?[R?[UF8;O;P6']@]L?]DW&_\
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72]4U]U L71BE4ACYN<9)=2]4U]U _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>fsridynmyoja6mda5mdg4zmfky.gif
<TEXT>
begin 644 fsridynmyoja6mda5mdg4zmfky.gif
M1TE&.#EA*P . /       +;5R"'Y! $     +      K  X 0 A-  $('$BP
MH,$ !A,J)(APH<.' AL^E A1(<6*&#-JC!C@HL6.&P%X#%EP9$22&DTZ[,BR
<94N4)56NE&D1)L.*-%'FM)F2)T:).WV># @ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>fsridynmyoja6mzkwzmyyzjzkz.gif
<TEXT>
begin 644 fsridynmyoja6mzkwzmyyzjzkz.gif
M1TE&.#EA*P . /       +;5R"'Y! $     +      K  X 0 A1  $$ $"P
MH,&#"!,J+#A08<.%$ T^7#@QHD6$%2\2#,"QH\>,%D%J'"DP(4>2%T525.F0
@)4.4,#<>=!ESIL.:$6G2'+F384^3/X&Z[(BSZ,6  #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
